MiR	O
221	O
/	O
222	O
as	O
new	O
players	O
in	O
tamoxifen	O
resistance	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequent	O
cancer	O
in	O
women	O
.	O

Despite	O
advances	O
in	O
early	B-P
detection	I-P
and	O
treatment	O
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	O
rate	O
after	O
lung	O
cancer	O
.	O

Around	O
85	O
%	O
of	O
breast	O
carcinomas	O
are	O
ER+	O
;	O
thus	O
,	O
antiestrogens	O
like	O
tamoxifen	O
are	O
beneficial	O
.	O

Although	O
,	O
tamoxifen	O
is	O
useful	O
for	O
many	O
patients	O
,	O
plenty	O
of	O
patients	O
respond	O
poorly	O
to	O
initial	O
therapy	O
or	O
recurrence	O
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	O
resistance	O
happens	O
.	O

Drug	O
resistance	O
remains	O
a	O
major	O
clinical	O
obstacle	O
to	O
successful	O
treatment	O
of	O
breast	O
cancer	O
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	O
treatments	O
are	O
because	O
of	O
acquired	O
resistance	O
and	O
MultiDrug	O
Resistance	O
(	O
MDR	O
)	O
is	O
a	O
major	O
contributor	O
.	O

MicroRNAs	O
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	O
RNAs	O
.	O

Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	O
expression	O
,	O
miRNAs	O
are	O
considered	O
as	O
important	O
cancer	O
therapeutic	O
targets	O
and	O
biomarkers	O
.	O

Since	O
2005	O
,	O
when	O
miRNA	O
deregulation	O
was	O
first	O
reported	O
in	O
breast	O
cancer	O
,	O
more	O
than	O
1000	O
reports	O
have	O
been	O
published	O
about	O
miRNAs	O
.	O

Increasing	O
number	O
of	O
studies	O
showed	O
the	O
importance	O
of	O
miRNAs	O
in	O
antiestrogen	O
therapy	O
,	O
especially	O
on	O
tamoxifen	O
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	O
are	O
involved	O
in	O
drug	O
resistance	O
.	O

Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	O
molecules	O
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	O
as	O
a	O
new	O
player	O
in	O
breast	O
cancer	O
pathogenesis	O
.	O

We	O
have	O
also	O
focused	O
on	O
cancer	O
drug	O
resistance	O
mechanisms	O
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	O
,	O
miR	O
221	O
/	O
222	O
,	O
involved	O
in	O
cell	O
cycle	O
deregulation	O
in	O
breast	O
cancer	O
.	O

The	O
relationship	O
between	O
these	O
oncomiRs	O
with	O
resistance	O
to	O
tamoxifen	O
is	O
also	O
emphasized	O
.	O

Spectrum	O
and	O
prevalence	O
of	O
thyroid	O
diseases	O
seen	O
at	O
a	O
tertiary	O
health	O
facility	O
in	O
Sagamu	O
,	O
South-West	O
Nigeria	O
.	O

The	O
prevalence	O
of	O
goitrous	O
swelling	O
has	O
reduced	O
in	O
Nigeria	O
since	O
the	O
introduction	O
of	O
salt	O
iodisation	O
programme	O
.	O

Thyroid	O
disorders	O
are	O
the	O
second	O
most	O
common	O
endocrine	O
disorder	O
after	O
diabetes	O
mellitus	O
worldwide	O
.	O

They	O
present	O
to	O
general	O
outpatient	O
,	O
medical	O
and	O
surgical	O
clinics	O
accompanied	O
by	O
great	O
anxiety	O
and	O
poor	O
health-related	O
quality	O
of	O
life	O
.	O

The	O
study	O
aimed	O
to	O
determine	O
and	O
describe	O
the	O
spectrum	O
of	O
thyroid	O
disorders	O
seen	O
at	O
Olabisi	O
Onabanjo	O
University	O
Teaching	O
Hospital	O
over	O
a	O
10-	O
year	O
period	O
.	O

This	O
was	O
a	O
retrospective	O
analysis	O
of	O
records	O
of	O
patients	O
who	O
presented	O
to	O
the	O
hospital	O
with	O
thyroid	O
swellings	O
over	O
a	O
10-	O
year	O
period	O
(	O
June	O
2004	O
to	O
June	O
2014	O
)	O
.	O

Clinicopathological	O
and	O
demographic	O
data	O
obtained	O
from	O
hospital	O
records	O
in	O
175	O
patients	O
diagnosed	O
by	O
clinical	O
examination	O
,	O
thyroid	B-P
ultrasound	I-P
,	O
hormone	O
profile	O
and	O
histological	O
confirmation	O
in	O
cases	O
that	O
had	O
surgery	O
were	O
analysed	O
for	O
this	O
study	O
.	O

The	O
records	O
of	O
175	O
patients	O
were	O
obtained	O
comprising	O
151	O
(	O
86.3	O
%	O
)	O
females	O
and	O
24	O
(	O
13.7	O
%	O
)	O
males	O
(	O
female	O
to	O
male	O
ratio	O
of	O
6.3:1	O
)	O
with	O
age	O
range	O
from	O
18	O
to	O
76	O
years	O
and	O
mean	O
age	O
of	O
42.3	O
years	O
,	O
standard	O
deviation	O
13.5	O
.	O

With	O
clinical	B-P
diagnosis	I-P
,	O
distribution	O
of	O
thyroid	O
diseases	O
was	O
simple	O
goitre	O
103	O
(	O
58.9	O
%	O
)	O
,	O
toxic	O
goitre	O
64	O
(	O
36.6	O
%	O
)	O
,	O
hypothyroidism	O
3	O
(	O
1.7	O
%	O
)	O
,	O
malignant	O
goitre	O
4	O
(	O
2.3	O
%	O
)	O
and	O
thyroiditis	O
1	O
(	O
0.6	O
%	O
)	O
.	O

The	O
age	O
group	O
of	O
30-49	O
years	O
had	O
the	O
highest	O
prevalence	O
of	O
the	O
thyroid	O
diseases	O
100	O
(	O
57.2	O
%	O
)	O
while	O
the	O
extremes	O
of	O
age	O
,	O
below	O
20	O
and	O
over	O
70	O
years	O
had	O
the	O
least	O
(	O
5.1	O
and	O
2.9	O
%	O
,	O
respectively	O
)	O
.	O

The	O
prevalent	O
form	O
of	O
thyroid	O
diseases	O
seen	O
at	O
Olabisi	O
Onabanjo	O
University	O
Teaching	O
Hospital	O
was	O
simple	O
goitre	O
and	O
most	O
common	O
in	O
females	O
.	O

Studies	O
on	O
autoimmunity	O
and	O
other	O
goitrogens	O
are	O
required	O
to	O
further	O
elucidate	O
the	O
cause	O
of	O
this	O
high	O
prevalence	O
.	O

Women	O
's	O
perspectives	O
on	O
human	O
papillomavirus	O
self-sampling	B-P
in	O
the	O
context	O
of	O
the	O
UK	O
cervical	O
screening	O
programme	O
.	O

Testing	O
for	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	O
screening	O
programme	O
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	O
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	O
self-sampling	B-P
.	O

In	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	O
and	O
practice	O
by	O
identifying	O
potential	O
barriers	O
to	O
HPV	O
self-sampling	B-P
.	O

A	O
cross-sectional	O
survey	O
of	O
194	O
women	O
aged	O
20-64	O
years	O
was	O
conducted	O
.	O

Logistic	O
regression	O
analysis	O
was	O
used	O
to	O
identify	O
determinants	O
of	O
self-sampling	B-P
intentions	O
.	O

A	O
purposive	O
subsample	O
of	O
19	O
women	O
who	O
reported	O
low	O
self-sampling	B-P
intentions	O
were	O
interviewed	O
.	O

Interviews	O
were	O
framework-analysed	O
.	O

Most	O
survey	O
participants	O
(	O
N=133	O
,	O
69.3	O
%	O
)	O
intended	O
to	O
HPV	O
self-sample	O
.	O

Lower	O
intention	O
was	O
associated	O
with	O
lower	O
self-efficacy	O
(	O
OR=24.96	O
,	O
P≤.001	O
)	O
,	O
lower	O
education	O
(	O
OR=6.06	O
,	O
P≤.05	O
)	O
and	O
lower	O
perceived	O
importance	O
of	O
HPV	O
as	O
a	O
cause	O
of	O
cervical	O
cancer	O
(	O
OR=2.33	O
,	O
P≤.05	O
)	O
.	O

Interviews	O
revealed	O
personal	O
and	O
system-related	O
barriers	O
.	O

Personal	O
barriers	O
included	O
a	O
lack	O
of	O
knowledge	O
about	O
HPV	O
self-sampling	B-P
,	O
women	O
's	O
low	O
confidence	O
in	O
their	O
ability	O
to	O
self-sample	O
correctly	O
and	O
low	O
confidence	O
in	O
the	O
subsequent	O
results	O
.	O

System-related	O
factors	O
included	O
a	O
lack	O
of	O
confidence	O
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	O
screening	O
programme	O
,	O
and	O
concerns	O
about	O
sample	O
contamination	O
and	O
identity	O
theft	O
.	O

Insights	O
gained	O
from	O
this	O
research	O
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	O
self-sampling	B-P
and	O
to	O
help	O
inform	O
future	O
policy	O
and	O
practice	O
.	O

Personal	O
and	O
system-related	O
barriers	O
including	O
low	O
confidence	O
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	O
screening	O
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
HPV	O
self-sampling	B-P
be	O
incorporated	O
into	O
the	O
cervical	O
screening	O
programme	O
.	O

Correlation	O
of	O
Technetium-99m	O
Macroaggregated	O
Albumin	O
and	O
Yttrium-90	O
Glass	O
Microsphere	O
Biodistribution	O
in	O
Hepatocellular	O
Carcinoma	O
:	O
A	O
Retrospective	O
Review	O
of	O
Pretreatment	B-P
Single	I-P
Photon	I-P
Emission	I-P
CT	I-P
and	O
Posttreatment	B-P
Positron	I-P
Emission	I-P
Tomography/CT	I-P
.	O

To	O
evaluate	O
whether	O
technetium-99	O
(	O
(	O
99m	O
)	O
Tc	O
)	O
-labeled	O
macroaggregated	O
albumin	O
(	O
MAA	O
)	O
can	O
predict	O
subsequent	O
yttrium-90	O
(	O
(	O
90	O
)	O
Y	O
)	O
distribution	O
and	O
imaging	B-P
response	O
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

Retrospective	O
review	O
was	O
performed	O
of	O
records	O
of	O
83	O
patients	O
with	O
HCC	O
who	O
underwent	O
(	O
90	O
)	O
Y	O
glass	O
microsphere	O
radioembolization	O
with	O
(	O
99m	O
)	O
Tc-MAA	O
single	B-P
photon	I-P
emission	I-P
computed	I-P
tomography	I-P
(	O
SPECT	B-P
)	O
and	O
(	O
90	O
)	O
Y	O
positron	B-P
emission	I-P
tomography	I-P
(	B-P
PET	I-P
)	I-P
/CT	I-P
between	O
January	O
2013	O
and	O
December	O
2014	O
.	O

Images	O
were	O
fused	O
to	O
segment	O
the	O
whole	O
liver	O
normal	O
tissue	O
(	O
WLNT	O
)	O
and	O
the	O
largest	O
tumors	O
.	O

Fused	O
images	O
were	O
reviewed	O
and	O
analyzed	O
for	O
comparison	O
of	O
absorbed	O
dose	O
(	O
AD	O
)	O
to	O
tumors	O
and	O
WLNT	O
as	O
calculated	O
from	O
(	O
99m	O
)	O
Tc-MAA	O
SPECT	B-P
and	O
from	O
(	O
90	O
)	O
Y	O
PET/CT	B-P
,	O
subjective	O
imaging	B-P
comparison	O
of	O
(	O
99m	O
)	O
Tc-MAA	O
SPECT	B-P
and	O
(	O
90	O
)	O
Y	O
PET	B-P
for	O
tumors	O
and	O
WLNT	O
,	O
and	O
correlation	O
of	O
tumoral	O
AD	O
with	O
response	O
on	O
follow-up	O
CT	B-P
.	O

Final	O
analysis	O
included	O
73	O
and	O
63	O
patients	O
for	O
WLNT	O
and	O
tumor	O
(	O
99m	O
)	O
Tc-MAA	O
/	O
(	O
90	O
)	O
Y	O
correlation	O
,	O
respectively	O
,	O
and	O
62	O
patients	O
for	O
AD	O
vs	O
response	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
/	O
(	O
90	O
)	O
Y	O
limit	O
of	O
agreement	O
for	O
each	O
reviewer	O
was	O
viewed	O
as	O
clinically	O
acceptable	O
only	O
for	O
WLNT	O
(	O
-15	O
to	O
15	O
Gy	O
)	O
.	O

AD	O
interreviewer	O
variability	O
was	O
clinically	O
acceptable	O
for	O
WLNT	O
but	O
was	O
too	O
broad	O
for	O
tumor	O
.	O

Mean	O
tumor	O
AD	O
for	O
objective	O
response	O
(	O
78	O
%	O
)	O
was	O
313	O
Gy	O
vs	O
234	O
Gy	O
for	O
nonresponders	O
.	O

No	O
threshold	O
was	O
found	O
between	O
tumor	O
AD	O
and	O
response	O
(	O
P	O
>	O
.1	O
)	O
.	O

Catheter	O
mismatch	O
between	O
(	O
99m	O
)	O
Tc-MAA	O
and	O
(	O
90	O
)	O
Y	O
had	O
a	O
direct	O
impact	O
on	O
AD	O
mismatch	O
between	O
the	O
2	O
image	O
sets	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
was	O
found	O
to	O
be	O
a	O
poor	O
surrogate	O
to	O
quantitatively	O
predict	O
subsequent	O
(	O
90	O
)	O
Y	O
AD	O
to	O
hepatocellular	O
tumors	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
distribution	O
correlated	O
with	O
(	O
90	O
)	O
Y	O
distribution	O
in	O
the	O
normal	O
hepatic	O
parenchyma	O
.	O

Diagnosing	O
neonatal	O
transphyseal	O
fractures	O
of	O
the	O
distal	O
humerus	O
.	O

A	O
traumatic	O
birth	O
can	O
cause	O
significant	O
upper	O
limb	O
injury	O
;	O
the	O
presenting	O
features	O
are	O
non-specific	O
and	O
the	O
differential	O
diagnosis	O
long	O
.	O

Transphyseal	O
fractures	O
of	O
the	O
distal	O
humerus	O
are	O
a	O
rare	O
but	O
clinically	O
important	O
birth	O
injury	O
.	O

This	O
injury	O
has	O
typical	O
radiographic	O
findings	O
,	O
which	O
due	O
to	O
the	O
un-ossified	O
nature	O
of	O
the	O
distal	O
humeral	O
epiphysis	O
can	O
easily	O
be	O
misinterpreted	O
.	O

This	O
article	O
presents	O
the	O
radiographic	O
appearance	O
correlated	O
with	O
arthrography	B-P
,	O
ultrasound	B-P
and	O
MRI	B-P
obtained	O
from	O
four	O
cases	O
of	O
neonatal	O
transphyseal	O
fracture	O
of	O
the	O
distal	O
humerus	O
.	O

We	O
hope	O
that	O
by	O
demonstrating	O
the	O
appearances	O
for	O
each	O
of	O
these	O
imaging	B-P
techniques	I-P
in	O
relation	O
to	O
the	O
underlying	O
pathology	O
will	O
reduce	O
errors	O
of	O
interpretation	O
that	O
may	O
lead	O
to	O
inappropriate	O
diagnosis	O
and	O
management	O
of	O
these	O
children	O
.	O

Perfusion	O
Angiography	B-P
in	O
Acute	O
Ischemic	O
Stroke	O
.	O

Visualization	O
and	O
quantification	O
of	O
blood	O
flow	O
are	O
essential	O
for	O
the	O
diagnosis	O
and	O
treatment	O
evaluation	O
of	O
cerebrovascular	O
diseases	O
.	O

For	O
rapid	O
imaging	B-P
of	O
the	O
cerebrovasculature	O
,	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
remains	O
the	O
gold	O
standard	O
as	O
it	O
offers	O
high	O
spatial	O
resolution	O
.	O

This	O
paper	O
lays	O
out	O
a	O
methodological	O
framework	O
,	O
named	O
perfusion	O
angiography	B-P
,	O
for	O
the	O
quantitative	O
analysis	O
and	O
visualization	O
of	O
blood	O
flow	O
parameters	O
from	O
DSA	B-P
images	O
.	O

The	O
parameters	O
,	O
including	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
cerebral	O
blood	O
volume	O
(	O
CBV	O
)	O
,	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
,	O
time-to-peak	O
(	O
TTP	O
)	O
,	O
and	O
T	O
max	O
,	O
are	O
computed	O
using	O
a	O
bolus	O
tracking	O
method	O
based	O
on	O
the	O
deconvolution	O
of	O
the	O
time-density	O
curve	O
on	O
a	O
pixel-by-pixel	O
basis	O
.	O

The	O
method	O
is	O
tested	O
on	O
66	O
acute	O
ischemic	O
stroke	O
patients	O
treated	O
with	O
thrombectomy	O
and/or	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
and	O
also	O
evaluated	O
on	O
an	O
estimation	O
task	O
with	O
known	O
ground	O
truth	O
.	O

This	O
novel	O
imaging	O
tool	O
provides	O
unique	O
insights	O
into	O
flow	O
mechanisms	O
that	O
can	O
not	O
be	O
observed	O
directly	O
in	O
DSA	B-P
sequences	O
and	O
might	O
be	O
used	O
to	O
evaluate	O
the	O
impact	O
of	O
endovascular	O
interventions	O
more	O
precisely	O
.	O

Discordance	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
:	O
Implications	O
for	O
breast	O
cancer	O
adjuvant	O
treatment	O
.	O

Pathological	O
predictive	O
factors	O
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	O
cancer	O
adjuvant	O
therapy	O
.	O

In	O
randomized	O
clinical	O
trials	O
the	O
variability	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
is	O
noteworthy	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	O
and	O
central	O
histopathological	O
report	O
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

A	O
retrospective	O
analysis	O
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	O
tumors	O
diagnosed	O
by	O
local	O
pathologists	O
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	O
of	O
European	O
Institute	O
of	O
Oncology	O
.	O

The	O
inter-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	O
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	O
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2/neu	O
.	O

The	O
Bland-Altman	O
plots	O
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR	O
.	O

DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	O
specimens	O
from	O
10	O
Cancer	O
Centers	O
were	O
reviewed	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538-0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580-0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Moderate	O
agreement	O
was	O
found	O
for	O
HER2	O
(	O
k0.546	O
;	O
95	O
%	O
CI	O
,	O
0444-0.649	O
)	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

In	O
our	O
retrospective	O
analysis	O
,	O
central	B-P
pathological	I-P
review	I-P
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making	O
process	O
in	O
early	O
breast	O
cancer	O
,	O
as	O
shown	O
in	O
clinical	O
trials	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O

High	O
fidelity	B-P
visualization	I-P
of	O
cell	O
-to-	O
cell	O
variation	O
and	O
temporal	O
dynamics	O
in	O
nascent	O
extracellular	O
matrix	O
formation	O
.	O

Extracellular	O
matrix	O
dynamics	O
are	O
key	O
to	O
tissue	O
morphogenesis	O
,	O
homeostasis	O
,	O
injury	O
,	O
and	O
repair	O
.	O

The	O
spatiotemporal	O
organization	O
of	O
this	O
matrix	O
has	O
profound	O
biological	O
implications	O
,	O
but	O
is	O
challenging	O
to	O
monitor	O
using	O
standard	O
techniques	O
.	O

Here	O
,	O
we	O
address	O
these	O
challenges	O
by	O
using	O
noncanonical	O
amino	O
acid	O
tagging	O
to	O
fluorescently	O
label	O
extracellular	O
matrix	O
synthesized	O
in	O
the	O
presence	O
of	O
bio-orthogonal	O
methionine	O
analogs	O
.	O

This	O
strategy	O
labels	O
matrix	O
proteins	O
with	O
high	O
resolution	O
,	O
without	O
compromising	O
their	O
distribution	O
or	O
mechanical	O
function	O
.	O

We	O
demonstrate	O
that	O
the	O
organization	O
and	O
temporal	O
dynamics	O
of	O
the	O
proteinaceous	O
matrix	O
depend	O
on	O
the	O
biophysical	O
features	O
of	O
the	O
microenvironment	O
,	O
including	O
the	O
biomaterial	O
scaffold	O
and	O
the	O
niche	O
constructed	O
by	O
cells	O
themselves	O
.	O

Pulse	O
labeling	O
experiments	O
reveal	O
that	O
,	O
in	O
immature	O
constructs	O
,	O
nascent	O
matrix	O
is	O
highly	O
fibrous	O
and	O
interdigitates	O
with	O
pre-existing	O
matrix	O
,	O
while	O
in	O
more	O
developed	O
constructs	O
,	O
nascent	O
matrix	O
lacks	O
fibrous	O
organization	O
and	O
is	O
retained	O
in	O
the	O
immediate	O
pericellular	O
space	O
.	O

Inhibition	O
of	O
collagen	O
crosslinking	O
increases	O
matrix	O
synthesis	O
,	O
but	O
compromises	O
matrix	O
organization	O
.	O

Finally	O
,	O
these	O
data	O
demonstrate	O
marked	O
cell	O
-to-	O
cell	O
heterogeneity	O
amongst	O
both	O
chondrocytes	O
and	O
mesenchymal	O
stem	O
cells	O
undergoing	O
chondrogenesis	O
.	O

Collectively	O
,	O
these	O
results	O
introduce	O
fluorescent	O
noncanonical	O
amino	O
acid	O
tagging	O
as	O
a	O
strategy	O
to	O
investigate	O
spatiotemporal	O
matrix	O
organization	O
,	O
and	O
demonstrate	O
its	O
ability	O
to	O
identify	O
differences	O
in	O
phenotype	O
,	O
microenvironment	O
,	O
and	O
matrix	O
assembly	O
at	O
the	O
single	O
cell	O
level	O
.	O

Structural	O
properties	O
and	O
psychometric	B-P
improvements	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
in	O
a	O
Slovak	O
population	O
.	O

Health	O
literacy	O
is	O
an	O
important	O
determinant	O
of	O
health	O
and	O
health	O
equity	O
and	O
therefore	O
requires	O
robust	O
measurement	O
.	O

The	O
aim	O
was	O
to	O
examine	O
the	O
psychometric	B-P
properties	O
of	O
the	O
Slovak	O
version	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
(	O
HLQ	O
)	O
including	O
revised	O
wording	O
of	O
response	O
categories	O
.	O

A	O
cross-sectional	O
survey	O
of	O
the	O
general	O
Slovak	O
adult	O
population	O
(	O
N	O
=	O
360	O
,	O
mean	O
age	O
39	O
)	O
was	O
conducted	O
with	O
the	O
HLQ	O
following	O
its	O
translation	O
and	O
cultural	O
adaptation	O
.	O

Psychometric	B-P
tests	O
(	O
confirmatory	O
factor	O
analysis	O
,	O
Cronbach	O
's	O
alpha	O
,	O
composite	O
reliability	O
)	O
and	O
association	O
(	O
linear	O
regression	O
,	O
ANOVA	O
)	O
with	O
sociodemographic	O
variables	O
were	O
undertaken	O
.	O

The	O
performance	O
of	O
alternative	O
version	O
of	O
response	O
options	O
were	O
explored	O
with	O
the	O
Mann-Whittney	O
U	O
test	O
and	O
item	O
response	O
theory	O
.	O

A	O
highly	O
restrictive	O
nine-factor	O
confirmatory	O
factor	O
analysis	O
showed	O
acceptable	O
fit	O
[	O
χ	O
(	O
2	O
)	O
WLSMV	O
=	O
1684	O
(	O
df	O
=	O
866	O
)	O
,	O
p	O
<	O
0.0001	O
;	O
CFI	O
=	O
0.943	O
,	O
TLI	O
=	O
0.938	O
,	O
RMSEA	O
=	O
0.051	O
,	O
WRMR	O
=	O
1.297	O
]	O
and	O
reliability	O
was	O
acceptable	O
(	O
range	O
0.73-0.84	O
)	O
.	O

The	O
revised	O
response	O
categories	O
had	O
a	O
better	O
distribution	O
with	O
lower	O
average	O
scores	O
in	O
three	O
domains	O
,	O
compared	O
with	O
the	O
original	O
,	O
and	O
improved	O
item	O
information	O
curves	O
.	O

The	O
nine	O
HLQ	O
scales	O
are	O
robust	O
,	O
providing	O
a	O
fine-grained	O
assessment	O
of	O
health	O
literacy	O
.	O

The	O
revised	O
response	O
options	O
improve	O
psychometric	B-P
properties	O
and	O
are	O
recommended	O
for	O
future	O
studies	O
.	O

Association	O
of	O
Fat	O
Mass	O
and	O
Obesity	O
-	O
associated	O
Gene	O
Variant	O
with	O
Lifestyle	O
Factors	O
and	O
Body	O
Fat	O
in	O
Indian	O
Children	O
.	O

Common	O
intronic	O
variants	O
of	O
the	O
fat	O
mass	O
and	O
obesity	O
-	O
associated	O
(	O
FTO	O
)	O
gene	O
have	O
been	O
associated	O
with	O
obesity	O
-related	O
traits	O
in	O
humans	O
.	O

(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
study	O
the	O
distribution	O
of	O
FTO	O
gene	O
variants	O
across	O
different	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	O
between	O
FTO	O
gene	O
variants	O
and	O
lifestyle	O
factors	O
in	O
obese	O
and	O
normal	O
weight	O
Indian	O
children	O
.	O

Fifty-six	O
children	O
(	O
26	O
boys	O
,	O
mean	O
age	O
10.3	O
±	O
2.2	O
years	O
)	O
were	O
studied	O
.	O

Height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumference	O
were	O
measured	O
.	O

Physical	O
activity	O
(	O
questionnaire	O
)	O
and	O
food	O
intake	O
(	O
food	O
frequency	O
questionnaire	O
)	O
were	O
assessed	O
.	O

Body	O
fat	O
percentage	O
(	O
%	O
BF	O
)	O
was	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

FTO	O
allelic	O
variants	O
at	O
rs9939609	O
site	O
were	O
detected	O
by	O
SYBR	O
Green	O
Amplification	O
Refractory	O
Mutation	O
System	O
real-time	O
polymerase	O
chain	O
reaction	O
using	O
allele	O
-	O
specific	O
primers	O
.	O

Generalized	O
linear	O
model	O
was	O
used	O
to	O
investigate	O
the	O
simultaneous	O
influence	O
of	O
genetic	O
and	O
lifestyle	O
factors	O
on	O
%	O
BF	O
.	O

Mean	O
height	O
,	O
weight	O
,	O
and	O
BMI	O
of	O
normal	O
and	O
obese	O
children	O
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6	O
,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8	O
,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2	O
,	O
respectively	O
.	O

The	O
frequency	O
of	O
AA	O
allele	O
was	O
57	O
%	O
among	O
obese	O
children	O
and	O
35	O
%	O
in	O
normal	O
weight	O
children	O
.	O

Children	O
with	O
the	O
AA	O
allele	O
who	O
were	O
obese	O
had	O
least	O
physical	O
activity	O
,	O
whereas	O
children	O
with	O
AT	O
allele	O
and	O
obesity	O
had	O
the	O
highest	O
intake	O
of	O
calories	O
when	O
compared	O
to	O
children	O
who	O
had	O
AT	O
allele	O
and	O
were	O
normal	O
.	O

%	O
BF	O
was	O
positively	O
associated	O
with	O
AA	O
alleles	O
and	O
junk	O
food	O
intake	O
and	O
negatively	O
with	O
healthy	O
food	O
intake	O
and	O
moderate	O
physical	O
activity	O
.	O

Healthy	O
lifestyle	O
with	O
high	O
physical	O
activity	O
and	O
diet	O
low	O
in	O
calories	O
and	O
fat	O
may	O
help	O
in	O
modifying	O
the	O
risk	O
imposed	O
by	O
FTO	O
variants	O
in	O
children	O
.	O

Identifying	O
the	O
presence	O
of	O
Parkinson	O
's	O
disease	O
using	O
low-frequency	O
fluctuations	O
in	O
BOLD	B-P
signals	I-P
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
and	O
degenerative	O
neurological	O
disorder	O
that	O
is	O
characterized	O
by	O
the	O
degeneration	O
of	O
dopamine	O
neurons	O
in	O
the	O
substantia	O
nigra	O
and	O
the	O
formation	O
of	O
intracellular	O
Lewy	O
inclusion	O
bodies	O
.	O

Resting-state	B-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
RS-fMRI	B-P
)	O
has	O
demonstrated	O
evidence	O
of	O
changes	O
in	O
metabolic	O
patterns	O
in	O
individuals	O
with	O
PD	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
presence	O
of	O
PD	O
could	O
be	O
``	O
predicted	O
``	O
based	O
on	O
resting	O
fluctuations	O
in	O
the	O
blood	O
oxygenation	O
level	O
dependent	O
signal	O
.	O

We	O
utilized	O
RS-fMRI	B-P
to	O
measure	O
the	O
amplitude	O
of	O
low-frequency	O
fluctuation	O
(	O
ALFF	O
)	O
and	O
the	O
fractional	O
ALFF	O
(	O
fALFF	O
)	O
in	O
51	O
patients	O
with	O
PD	O
and	O
50	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
the	O
individuals	O
with	O
PD	O
exhibited	O
altered	O
ALFFs	O
in	O
the	O
bilateral	O
lingual	O
gyrus	O
and	O
left	O
putamen	O
and	O
an	O
altered	O
fALFF	O
in	O
the	O
right	O
cerebellum	O
posterior	O
lobe	O
.	O

Support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	O
recognition	O
method	O
that	O
enables	O
predictions	O
at	O
the	O
individual	O
level	O
,	O
were	O
trained	O
to	O
separate	O
individuals	O
with	O
PD	O
from	O
healthy	O
controls	O
based	O
on	O
the	O
ALFF	O
and	O
fALFF	O
.	O

Using	O
the	O
leave-one-out	O
cross-validation	O
method	O
to	O
analyze	O
our	O
sample	O
,	O
we	O
reliably	O
distinguished	O
the	O
participants	O
with	O
PD	O
from	O
the	O
controls	O
with	O
92	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
SVM	O
-	O
neuroimaging	B-P
approach	O
may	O
be	O
of	O
particular	O
clinical	O
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	O
at	O
the	O
individual	O
level	O
.	O

RS-fMRI	B-P
should	O
be	O
considered	O
for	O
development	O
as	O
a	O
biomarker	O
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	O
of	O
PD	O
.	O

Effects	O
of	O
diacetyl-liensinine	O
on	O
electrophysiology	B-P
in	O
rabbit	O
ventricular	O
myocytes	O
.	O

Diacetyl-liensinine	O
is	O
a	O
chemosynthetic	O
derivative	O
of	O
liensinine	O
,	O
extracted	O
from	O
the	O
seed	O
embryo	O
of	O
Nelumbo	O
nucifera	O
Gaertn	O
,	O
in	O
China	O
.	O

It	O
has	O
been	O
found	O
to	O
have	O
extensive	O
anti-	O
arrhythmic	O
actions	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effects	O
of	O
diacetyl-liensinine	O
on	O
electro-	B-P
physiology	I-P
of	O
myocytes	O
.	O

We	O
exposed	O
rabbit	O
ventricular	O
myocytes	O
to	O
diacetyl-liensinine	O
using	O
standard	O
whole-cell	O
patch-clamp	O
technique	O
and	O
measured	O
the	O
action	O
potential	O
,	O
L-type	O
calcium	O
current	O
(	O
I	O
Ca-L	O
)	O
,	O
delayed	O
rectifier	O
potassium	O
current	O
(	O
I	O
K	O
)	O
,	O
transient	O
outward	O
potassium	O
current	O
(	O
I	O
to	O
)	O
and	O
inward	O
rectifier	O
potassium	O
current	O
(	O
I	O
K1	O
)	O
.	O

Our	O
results	O
showed	O
that	O
diacetyl-liensinine	O
significantly	O
prolonged	O
action	O
potential	O
duration	O
at	O
50	O
and	O
90	O
%	O
repolarization	O
(	O
APD50	O
,	O
APD90	O
)	O
,	O
at	O
10	O
and	O
30	O
μM	O
,	O
while	O
shortened	O
APD50	O
and	O
APD90	O
at	O
100	O
μM	O
.	O

In	O
addition	O
,	O
diacetyl-liensinine	O
inhibited	O
the	O
ICa-L	O
,	O
IK	O
,	O
I	O
to	O
and	O
IK1	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
suggest	O
that	O
diacetyl-liensinine	O
might	O
be	O
a	O
potential	O
anti-arrhythmic	O
agent	O
.	O

A	O
new	O
approach	O
to	O
nasomaxillary	O
complex	O
type	O
of	O
nasal	O
bone	O
fracture	O
:	O
Clip	O
operation	O
.	O

Nasal	O
bone	O
fractures	O
comprise	O
almost	O
40	O
%	O
of	O
all	O
facial	O
injuries	O
.	O

Most	O
are	O
initially	O
reduced	O
using	O
closed	O
reduction	O
.	O

This	O
study	O
introduces	O
a	O
newly	O
developed	O
method	O
,	O
the	O
clip	O
operation	O
via	O
endonasal	O
approach	O
.	O

The	O
operation	O
was	O
performed	O
in	O
these	O
patients	O
by	O
a	O
single	O
surgeon	O
extensively	O
experienced	O
in	O
facial	O
bone	O
fractures	O
.	O

An	O
absorbable	O
mesh	O
plate	O
made	O
into	O
a	O
clip	O
was	O
used	O
for	O
fixation	O
after	O
open	O
reduction	O
via	O
the	O
endonasal	O
approach	O
.	O

No	O
screws	O
were	O
used	O
for	O
fixation	O
.	O

Nasal	O
packing	O
was	O
removed	O
the	O
first	O
day	O
after	O
surgery	O
;	O
aluminum	O
splinting	O
was	O
removed	O
the	O
third	O
week	O
after	O
surgery	O
.	O

Three-dimensional	O
facial	B-P
computed	I-P
tomography	I-P
and	O
cephalolateral	B-P
radiography	I-P
were	O
performed	O
preoperatively	O
and	O
postoperatively	O
.	O

Plastic	O
surgeon	O
satisfaction	O
and	O
postoperative	O
complications	O
were	O
assessed	O
.	O

Fracture	O
relapse	O
was	O
not	O
observed	O
.	O

Reduction	O
status	O
was	O
well	O
maintained	O
.	O

Postoperative	O
complications	O
occurred	O
,	O
with	O
a	O
low	O
final	O
incidence	O
of	O
1.8	O
%	O
in	O
the	O
third	O
postoperative	O
month	O
.	O

Plastic	O
surgeon	O
satisfaction	O
was	O
very	O
high	O
at	O
4.58	O
.	O

This	O
operation	O
takes	O
5-10	O
min	O
,	O
and	O
is	O
simple	O
to	O
perform	O
.	O

It	O
entails	O
a	O
short	O
hospitalization	O
,	O
and	O
the	O
duration	O
during	O
which	O
nasal	O
packing	O
and	O
aluminum	O
splint	O
are	O
maintained	O
is	O
comparable	O
.	O

Undesirable	O
functional	O
,	O
aesthetic	O
complications	O
and	O
secondary	O
surgery	O
resulting	O
from	O
inaccurate	O
relapse	O
were	O
reduced	O
.	O

The	O
clip	O
operation	O
is	O
a	O
useful	O
technique	O
for	O
correcting	O
nasal	O
bone	O
fractures	O
,	O
especially	O
nasomaxillary	O
complex	O
type	O
.	O

Transforming	O
Growth	O
Factor	O
Beta	O
1	O
(	O
TGF-β1	O
)	O
in	O
Thyroid	O
Cancer	O
Patients	O
:	O
a	O
View	O
from	O
the	O
Peripheral	O
Blood	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGF-β	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	O
.	O

The	O
level	O
of	O
TGF-β	O
in	O
patients	O
with	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
has	O
not	O
been	O
examined	O
so	O
far	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
TGF-β	O
concentration	O
in	O
serum	O
samples	O
and	O
in	O
PHA	O
-	O
stimulated	O
whole	O
blood	O
culture	O
in	O
vitro	O
and	O
to	O
analyze	O
possible	O
associations	O
of	O
TGF-β1	O
levels	O
with	O
leukocyte	O
,	O
lymphocyte	O
and	O
platelets	O
counts	O
,	O
the	O
histological	O
type	O
of	O
thyroid	O
cancer	O
,	O
and	O
stage	B-P
of	I-P
disease	I-P
.	O

TGF-β1	O
was	O
measured	O
in	O
22	O
DTC	O
patients	O
and	O
20	O
healthy	O
controls	O
using	O
the	O
duoSet	O
ELISA	O
Development	O
kit	O
for	O
human	O
TGF-β1	O
.	O

The	O
concentration	O
of	O
TGF-β1	O
in	O
serum	O
samples	O
from	O
both	O
groups	O
correlated	O
positively	O
with	O
the	O
platelet	O
counts	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF-β1	O
between	O
DTC	O
patients	O
and	O
control	O
subjects	O
,	O
but	O
PHA	O
stimulated	O
whole	O
blood	O
cultures	O
of	O
DTC	O
patients	O
produced	O
less	O
TGF-β1	O
than	O
those	O
from	O
controls	O
.	O

Additional	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	O
.	O

Cost-effectiveness	O
of	O
diabetes	B-P
screening	I-P
initiated	O
through	O
a	O
dental	O
visit	O
.	O

To	O
analyse	O
the	O
cost-effectiveness	O
of	O
a	O
screening	B-P
programme	O
and	O
follow-up	O
interventions	O
for	O
persons	O
with	O
dysglycemia	O
who	O
are	O
identified	O
during	O
a	O
dental	O
visit	O
.	O

This	O
study	O
is	O
a	O
secondary	O
analysis	O
utilizing	O
data	O
from	O
two	O
relevant	O
publications	O
.	O

Those	O
studies	O
identified	O
persons	O
with	O
dysglycemia	O
who	O
were	O
seen	O
in	O
a	O
dental	O
school	O
clinic	O
for	O
routine	O
dental	O
care	O
and	O
determined	O
compliance	O
with	O
a	O
recommendation	O
to	O
seek	O
medical	O
care	O
.	O

The	O
response	O
site	O
was	O
59.4	O
%	O
.	O

The	O
Archimedes	O
disease	O
simulation	O
model	O
was	O
utilized	O
to	O
simulate	O
the	O
effect	O
of	O
a	O
weight	O
loss	O
programme	O
for	O
identified	O
subjects	O
on	O
several	O
outcomes	O
.	O

Two	O
scenarios	O
for	O
weight	O
loss	O
programmes	O
were	O
considered	O
:	O
a	O
10	O
%	O
permanent	O
loss	O
in	O
body	O
weight	O
and	O
a	O
10	O
%	O
loss	O
that	O
decays	O
over	O
time	O
.	O

Both	O
diabetes	O
and	O
prediabetes	O
were	O
analysed	O
.	O

The	O
decay	O
path	O
costs	O
$	O
21	O
243	O
per	O
quality	O
adjusted	O
life	O
year	O
(	O
QALY	O
)	O
with	O
3	O
years	O
required	O
to	O
achieve	O
the	O
weight	O
reduction	O
.	O

This	O
cost	O
decreases	O
to	O
$	O
6655	O
if	O
only	O
1	O
year	O
is	O
needed	O
to	O
achieve	O
the	O
weight	O
goal	O
.	O

Without	O
decay	O
,	O
the	O
cost	O
per	O
QALY	O
is	O
$	O
15	O
873	O
with	O
20	O
years	O
of	O
intervention	O
,	O
vs	O
$	O
647	O
per	O
QALY	O
with	O
10	O
years	O
of	O
intervention	O
.	O

For	O
individuals	O
with	O
type	O
2	O
diabetes	O
mellitus	O
,	O
the	O
cost	O
per	O
QALY	O
is	O
$	O
48	O
604	O
to	O
$	O
56	O
207	O
depending	O
on	O
adherence	O
.	O

With	O
the	O
addition	O
of	O
oral	O
medication	O
(	O
a	O
sulfonylurea	O
)	O
,	O
the	O
cost	O
is	O
three	O
times	O
higher	O
.	O

Under	O
the	O
conditions	O
described	O
here	O
,	O
identification	O
of	O
persons	O
with	O
dysglycemia	O
in	O
the	O
dental	O
office	O
for	O
initiating	O
prediabetic	O
care	O
is	O
a	O
cost-effective	O
means	O
of	O
identifying	O
and	O
treating	O
affected	O
individuals	O
.	O

Hybrid	O
automata	O
models	O
of	O
cardiac	O
ventricular	O
electrophysiology	B-P
for	O
real-time	O
computational	O
applications	O
.	O

Virtual	O
heart	O
models	O
have	O
been	O
proposed	O
for	O
closed	O
loop	O
validation	O
of	O
safety	O
-	O
critical	O
embedded	O
medical	O
devices	O
,	O
such	O
as	O
pacemakers	O
.	O

These	O
models	O
must	O
react	O
in	O
real-time	O
to	O
off-the-shelf	O
medical	O
devices	O
.	O

Real-time	O
performance	O
can	O
be	O
obtained	O
by	O
implementing	O
models	O
in	O
computer	O
hardware	O
,	O
and	O
methods	O
of	O
compiling	O
classes	O
of	O
Hybrid	O
Automata	O
(	O
HA	O
)	O
onto	O
FPGA	O
have	O
been	O
developed	O
.	O

Models	O
of	O
ventricular	O
cardiac	O
cell	O
electrophysiology	B-P
have	O
been	O
described	O
using	O
HA	O
which	O
capture	O
the	O
complex	O
nonlinear	O
behavior	O
of	O
biological	O
systems	O
.	O

However	O
,	O
many	O
models	O
that	O
have	O
been	O
used	O
for	O
closed-loop	O
validation	O
of	O
pacemakers	O
are	O
highly	O
abstract	O
and	O
do	O
not	O
capture	O
important	O
characteristics	O
of	O
the	O
dynamic	O
rate	O
response	O
.	O

We	O
developed	O
a	O
new	O
HA	O
model	O
of	O
cardiac	O
cells	O
which	O
captures	O
dynamic	O
behavior	O
and	O
we	O
implemented	O
the	O
model	O
in	O
hardware	O
.	O

This	O
potentially	O
enables	O
modeling	O
the	O
heart	O
with	O
over	O
1	O
million	O
dynamic	O
cells	O
,	O
making	O
the	O
approach	O
ideal	O
for	O
closed	O
loop	O
testing	O
of	O
medical	O
devices	O
.	O

Clinical	O
course	O
and	O
therapeutic	O
outcomes	O
of	O
operatively	O
and	O
non-operatively	O
managed	O
patients	O
with	O
denosumab	O
-related	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
DRONJ	O
)	O
.	O

Details	O
regarding	O
risk	O
factors	O
,	O
onset	O
,	O
and	O
outcomes	O
for	O
denosumab	O
-related	O
osteonecrosis	O
(	O
DRONJ	O
)	O
are	O
sparse	O
.	O

This	O
study	O
examines	O
the	O
clinical	O
characteristics	O
and	O
operative	O
and	O
non-operative	O
therapeutic	O
outcomes	O
in	O
patients	O
with	O
DRONJ	O
not	O
previously	O
exposed	O
to	O
other	O
antiresorptives	O
.	O

A	O
retrospective	O
medical	O
record	O
review	O
was	O
conducted	O
,	O
and	O
data	O
were	O
collected	O
,	O
including	O
clinical	O
findings	O
,	O
management	O
,	O
healing	O
outcomes	O
,	O
and	O
radiologic	O
,	O
histologic	O
,	O
and	O
micro-computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
analyses	O
.	O

Seventeen	O
patients	O
were	O
treated	O
with	O
denosumab	O
,	O
with	O
14.1	O
±	O
8.3	O
doses	O
before	O
DRONJ	O
onset	O
.	O

The	O
majority	O
of	O
lesions	O
were	O
observed	O
at	O
sites	O
of	O
dental	O
prostheses	O
(	O
41	O
%	O
)	O
and	O
dental	O
extractions	O
(	O
35	O
%	O
)	O
.	O

Sixteen	O
patients	O
were	O
managed	O
non-operatively	O
(	O
10/16	O
)	O
or	O
operatively	O
(	O
6/16	O
)	O
with	O
either	O
major	O
(	O
5/6	O
)	O
or	O
minor	O
surgery	O
(	O
1/6	O
)	O
and	O
included	O
in	O
the	O
follow-up	O
analysis	O
.	O

Complete	O
healing	O
was	O
significant	O
in	O
patients	O
treated	O
with	O
major	O
surgery	O
(	O
80	O
%	O
)	O
compared	O
to	O
the	O
non-operative	O
group	O
(	O
20	O
%	O
;	O
p	O
<	O
0.035	O
)	O
.	O

Denosumab	O
was	O
discontinued	O
in	O
60	O
%	O
of	O
non-operative	O
patients	O
and	O
major	O
surgery	O
patients	O
with	O
no	O
effect	O
on	O
healing	O
.	O

Histologic	O
findings	O
of	O
4	O
patients	O
analyzed	O
exhibited	O
a	O
decreased	O
number	O
of	O
osteocyte	O
lacunae	O
,	O
and	O
micro-CT	B-P
of	O
3	O
patients	O
scanned	B-P
revealed	O
trabecular	O
thickening	O
.	O

DRONJ	O
lesions	O
occurred	O
mostly	O
at	O
sites	O
of	O
prostheses	O
sores	O
after	O
a	O
mean	O
of	O
14	O
doses	O
of	O
denosumab	O
.	O

Major	O
surgery	O
demonstrated	O
more	O
complete	O
healing	O
than	O
non-operative	O
management	O
,	O
and	O
denosumab	O
cessation	O
did	O
not	O
improve	O
healing	O
outcomes	O
.	O

Biogeography	O
and	O
taxonomy	O
of	O
racket-tail	O
hummingbirds	O
(	O
Aves	O
:	O
Trochilidae	O
:	O
<	O
i	O
>	O
Ocreatus	O
<	O
/i	O
>	O
)	O
:	O
evidence	O
for	O
species	O
delimitation	O
from	O
morphology	O
and	O
display	O
behavior	O
.	O

We	O
analyzed	O
geographic	O
variation	O
,	O
biogeography	O
,	O
and	O
intrageneric	O
relationships	O
of	O
racket-tail	O
hummingbirds	O
Ocreatus	O
(	O
Aves	O
,	O
Trochilidae	O
)	O
.	O

Presently	O
,	O
the	O
genus	O
is	O
usually	O
considered	O
monospecific	O
,	O
with	O
O.	O
underwoodii	O
including	O
eight	O
subspecies	O
(	O
polystictus	O
,	O
discifer	O
,	O
underwoodii	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
peruanus	O
,	O
annae	O
,	O
addae	O
)	O
,	O
although	O
up	O
to	O
three	O
species	O
have	O
been	O
recognized	O
by	O
some	O
authors	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
current	O
taxonomy	O
we	O
studied	O
geographic	O
variation	O
in	O
coloration	O
,	O
mensural	O
characters	O
,	O
and	O
behavioral	O
data	O
of	O
all	O
Ocreatus	O
taxa	O
.	O

We	O
briefly	O
review	O
the	O
taxonomic	O
history	O
of	O
the	O
genus	O
.	O

Applying	O
the	O
Biological	O
Species	O
Concept	O
,	O
species	O
delimitation	O
was	O
based	O
on	O
a	O
qualitative	O
-	O
quantitative	O
criteria	O
analysis	O
including	O
an	O
evaluation	O
of	O
character	O
states	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
genus	O
should	O
be	O
considered	O
a	O
superspecies	O
with	O
four	O
species	O
,	O
the	O
monotypic	O
Ocreatus	O
addae	O
,	O
O.	O
annae	O
,	O
and	O
O.	O
peruanus	O
,	O
and	O
the	O
polytypic	O
O.	O
underwoodii	O
(	O
including	O
the	O
subspecies	O
underwoodii	O
,	O
discifer	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
polystictus	O
)	O
.	O

In	O
this	O
taxonomic	O
treatment	O
,	O
O.	O
annae	O
becomes	O
an	O
endemic	O
species	O
to	O
Peru	O
and	O
O.	O
addae	O
is	O
endemic	O
to	O
Bolivia	O
.	O

We	O
recommend	O
additional	O
sampling	B-P
of	O
distributional	O
,	O
ethological	O
,	O
and	O
molecular	O
data	O
for	O
an	O
improved	O
resolution	O
of	O
the	O
evolutionary	O
history	O
of	O
Ocreatus	O
.	O

Association	O
Between	O
Early	O
Lactate	O
Levels	O
and	O
30-	O
Day	O
Mortality	O
in	O
Clinically	O
Suspected	O
Sepsis	O
in	O
Children	O
.	O

Improving	O
emergency	O
care	O
of	O
pediatric	O
sepsis	O
is	O
a	O
public	O
health	O
priority	O
,	O
but	O
optimal	O
early	O
diagnostic	B-P
approaches	I-P
are	O
unclear	O
.	O

Measurement	O
of	O
lactate	O
levels	O
is	O
associated	O
with	O
improved	O
outcomes	O
in	O
adult	O
septic	O
shock	O
,	O
but	O
pediatric	O
guidelines	O
do	O
not	O
endorse	O
its	O
use	O
,	O
in	O
part	O
because	O
the	O
association	O
between	O
early	O
lactate	O
levels	O
and	O
mortality	O
is	O
unknown	O
in	O
pediatric	O
sepsis	O
.	O

To	O
determine	O
whether	O
the	O
initial	O
serum	O
lactate	O
level	O
is	O
associated	O
with	O
30-	O
day	O
mortality	O
in	O
children	O
with	O
suspected	O
sepsis	O
.	O

This	O
observational	O
cohort	O
study	O
of	O
a	O
clinical	O
registry	O
of	O
pediatric	O
patients	O
with	O
suspected	O
sepsis	O
in	O
the	O
emergency	O
department	O
of	O
a	O
tertiary	O
children	O
's	O
hospital	O
from	O
April	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2015	O
,	O
tested	O
the	O
hypothesis	O
that	O
a	O
serum	O
lactate	O
level	O
of	O
greater	O
than	O
36	O
mg/dL	O
is	O
associated	O
with	O
increased	O
mortality	O
compared	O
with	O
a	O
serum	O
lactate	O
level	O
of	O
36	O
mg/dL	O
or	O
less	O
.	O

Consecutive	O
patients	O
with	O
sepsis	O
were	O
identified	O
and	O
included	O
in	O
the	O
registry	O
following	O
consensus	O
guidelines	O
for	O
clinical	O
recognition	O
(	O
infection	O
and	O
decreased	O
mental	O
status	O
or	O
perfusion	O
)	O
.	O

Among	O
2520	O
registry	O
visits	O
,	O
1221	O
were	O
excluded	O
for	O
transfer	O
from	O
another	O
medical	O
center	O
,	O
no	O
measurement	O
of	O
lactate	O
levels	O
,	O
and	O
patients	O
younger	O
than	O
61	O
days	O
or	O
18	O
years	O
or	O
older	O
,	O
leaving	O
1299	O
visits	O
available	O
for	O
analysis	O
.	O

Lactate	O
testing	O
is	O
prepopulated	O
in	O
the	O
institutional	O
sepsis	O
order	O
set	O
but	O
may	O
be	O
canceled	O
at	O
clinical	O
discretion	O
.	O

Venous	O
lactate	O
leve	O
l	O
of	O
greater	O
than	O
36	O
mg/dL	O
on	O
the	O
first	O
measurement	O
within	O
the	O
first	O
8	O
hours	O
after	O
arrival	O
.	O

Thirty-	O
day	O
in-	O
hospital	O
mortality	O
was	O
the	O
primary	O
outcome	O
.	O

Odds	O
ratios	O
were	O
calculated	O
using	O
logistic	O
regression	O
to	O
account	O
for	O
potential	O
confounders	O
.	O

Of	O
the	O
1299	O
patients	O
included	O
in	O
the	O
analysis	O
(	O
753	O
boys	O
[	O
58.0	O
%	O
]	O
and	O
546	O
girls	O
[	O
42.0	O
%	O
]	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
7.3	O
[	O
5.3	O
]	O
years	O
)	O
,	O
899	O
(	O
69.2	O
%	O
)	O
had	O
chronic	O
medical	O
conditions	O
and	O
367	O
(	O
28.3	O
%	O
)	O
had	O
acute	O
organ	O
dysfunction	O
.	O

Thirty-	O
day	O
mortality	O
occurred	O
in	O
5	O
of	O
103	O
patients	O
(	O
4.8	O
%	O
)	O
with	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
and	O
20	O
of	O
1196	O
patients	O
(	O
1.7	O
%	O
)	O
with	O
lactate	O
levels	O
of	O
36	O
mg/dL	O
or	O
less	O
.	O

Initial	O
lactate	O
levels	O
of	O
greater	O
than	O
36	O
mg/dL	O
were	O
significantly	O
associated	O
with	O
30-	O
day	O
mortality	O
in	O
unadjusted	O
(	O
odds	O
ratio	O
,	O
3.00	O
;	O
95	O
%	O
CI	O
,	O
1.10-8.17	O
)	O
and	O
adjusted	O
(	O
odds	O
ratio	O
,	O
3.26	O
;	O
95	O
%	O
CI	O
,	O
1.16-	O
9.16	O
)	O
analyses	O
.	O

The	O
sensitivity	O
of	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
for	O
30-	O
day	O
mortality	O
was	O
20.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
8.9	O
%	O
-39.1	O
%	O
)	O
,	O
and	O
specificity	O
was	O
92.3	O
%	O
(	O
90.7	O
%	O
-93.7	O
%	O
)	O
.	O

In	O
children	O
treated	O
for	O
sepsis	O
in	O
the	O
emergency	O
department	O
,	O
lactate	O
levels	O
greater	O
than	O
36	O
mg/dL	O
were	O
associated	O
with	O
mortality	O
but	O
had	O
a	O
low	O
sensitivity	O
.	O

Measurement	O
of	O
lactate	O
levels	O
may	O
have	O
utility	O
in	O
early	O
risk	O
stratification	O
of	O
pediatric	O
sepsis	O
.	O

Unilateral	O
Laryngeal	O
Pacing	O
System	O
and	O
Its	O
Functional	O
Evaluation	O
.	O

Goal	O
.	O

To	O
establish	O
a	O
reliable	O
instrumental	O
system	O
for	O
synchronized	O
reactivation	O
of	O
a	O
unilaterally	O
paralyzed	O
vocal	O
fold	O
and	O
evaluate	O
its	O
functional	O
feasibility	O
.	O

Methods	O
.	O

Unilateral	O
vocal	O
fold	O
paralysis	O
model	O
was	O
induced	O
by	O
destruction	O
of	O
the	O
left	O
recurrent	O
laryngeal	O
nerve	O
(	O
RLN	O
)	O
in	O
anesthetized	O
dogs	O
.	O

With	O
a	O
micro	O
controller-based	O
electronic	O
system	O
,	O
electromyography	B-P
(	O
EMG	B-P
)	O
signals	O
from	O
cricothyroid	O
(	O
CT	O
)	O
muscle	O
on	O
the	O
ipsilateral	O
side	O
were	O
recorded	O
and	O
used	O
to	O
trigger	O
pacing	O
of	O
paralyzed	O
vocalis	O
muscles	O
.	O

The	O
dynamic	O
movement	O
of	O
vocal	O
folds	O
was	O
continuously	O
monitored	O
using	O
an	O
endoscope	O
,	O
and	O
the	O
opening	O
and	O
closing	O
of	O
the	O
glottis	O
were	O
quantified	O
with	O
customized	O
imaging	O
processing	O
software	O
.	O

Results	O
.	O

The	O
recorded	O
video	O
images	O
showed	O
that	O
left	O
side	O
vocal	O
fold	O
was	O
obviously	O
paralyzed	O
after	O
destructing	O
the	O
RLN	O
.	O

Using	O
the	O
pacing	O
system	O
with	O
feedback	O
triggering	O
EMG	B-P
signals	O
from	O
the	O
ipsilateral	O
CT	O
muscle	O
,	O
the	O
paralyzed	O
vocal	O
fold	O
was	O
successfully	O
reactivated	O
,	O
and	O
its	O
movement	O
was	O
shown	O
to	O
be	O
synchronized	O
with	O
the	O
healthy	O
side	O
.	O

Significance	O
.	O

The	O
developed	O
unilateral	O
laryngeal	O
pacing	O
system	O
triggered	O
by	O
EMG	B-P
from	O
the	O
ipsilateral	O
side	O
CT	O
muscle	O
could	O
be	O
successfully	O
used	O
in	O
unilateral	O
vocal	O
fold	O
paralysis	O
with	O
the	O
advantage	O
of	O
avoiding	O
disturbance	O
to	O
the	O
healthy	O
side	O
muscles	O
.	O

Comparison	O
between	O
magnetic	B-P
resonance	I-P
imaging	I-P
and	O
B-mode	B-P
ultrasound	I-P
in	O
detecting	O
and	O
estimating	O
the	O
extent	O
of	O
human	O
carotid	O
atherosclerosis	O
.	O

In	O
MRI	B-P
studies	I-P
of	O
carotid	O
plaques	O
,	O
ultrasound	B-P
is	O
used	O
to	O
find	O
plaques	O
,	O
which	O
are	O
later	O
imaged	O
using	O
MRI	B-P
.	O

The	O
performance	O
in	O
plaque	O
detection	O
has	O
not	O
been	O
compared	O
between	O
the	O
modalities	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
compare	O
the	O
performance	O
of	O
MRI	B-P
and	O
ultrasound	B-P
in	O
detecting	O
carotid	O
artery	O
plaques	O
and	O
measuring	O
extent	O
of	O
atherosclerosis	O
.	O

Subjects	O
with	O
at	O
least	O
one	O
plaque	O
(	O
height	O
≥2·5	O
mm	O
)	O
on	O
ultrasound	B-P
were	O
imaged	O
using	O
MRI	B-P
.	O

The	O
number	O
of	O
plaques	O
and	O
their	O
height	O
was	O
measured	O
in	O
both	O
modalities	O
;	O
plaque	O
area	O
and	O
volume	O
were	O
analysed	O
on	O
ultrasound	B-P
and	O
MRI	B-P
,	O
respectively	O
.	O

Thirty-eight	O
subjects	O
were	O
included	O
.	O

MRI	B-P
detected	O
plaques	O
in	O
95	O
%	O
of	O
carotid	O
arteries	O
with	O
a	O
plaque	O
height	O
of	O
≥2·5	O
mm	O
on	O
ultrasound	B-P
and	O
in	O
all	O
carotid	O
arteries	O
with	O
a	O
plaque	O
exceeding	O
2·5	O
mm	O
.	O

MRI	B-P
detected	O
53	O
%	O
of	O
the	O
plaques	O
with	O
a	O
height	O
below	O
2·5	O
mm	O
.	O

The	O
plaque	O
height	O
measured	O
with	O
both	O
techniques	O
correlated	O
significantly	O
,	O
0·59	O
,	O
P	O
<	O
0·0001	O
.	O

Ultrasound	B-P
-derived	O
plaque	O
height	O
and	O
plaque	O
area	O
correlated	O
similarly	O
to	O
MRI	B-P
-derived	O
plaque	O
volume	O
,	O
r	O
=	O
0·52	O
;	O
P	O
<	O
0·0001	O
and	O
r	O
=	O
0·47	O
;	O
P	O
=	O
0·001	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
MRI	B-P
has	O
a	O
similar	O
sensitivity	O
to	O
ultrasound	B-P
in	O
finding	O
carotid	O
artery	O
plaques	O
that	O
are	O
2·5	O
mm	O
or	O
higher	O
.	O

In	O
smaller	O
plaques	O
,	O
MRI	B-P
detects	O
fewer	O
plaques	O
.	O

Multiple	O
carotid	O
plaques	O
seen	O
on	O
ultrasound	B-P
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	O
and	O
correspond	O
to	O
a	O
single	O
plaque	O
.	O

Plaque	O
height	O
on	O
ultrasound	B-P
is	O
comparable	O
to	O
plaque	O
height	O
on	O
MRI	B-P
and	O
correlates	O
fairly	O
well	O
with	O
plaque	O
volume	O
on	O
MRI	B-P
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	O
burden	O
.	O

The	O
E3	O
Ligase	O
CHIP	O
Mediates	O
p21	O
Degradation	O
to	O
Maintain	O
Radioresistance	O
.	O

Lung	O
cancer	O
resists	O
radiotherapy	B-P
,	O
making	O
it	O
one	O
of	O
the	O
deadliest	O
forms	O
of	O
cancer	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
lung	O
cancer	O
cell	O
lines	O
can	O
be	O
rendered	O
sensitive	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
by	O
RNAi	O
knockdown	O
of	O
C-terminus	O
of	O
Hsc70-interacting	O
protein	O
(	O
CHIP	O
/	O
STUB1	O
)	O
,	O
a	O
U-box-type	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
a	O
number	O
of	O
stress-induced	O
proteins	O
.	O

Mechanistically	O
,	O
ubiquitin-dependent	O
degradation	O
of	O
the	O
cyclin-dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitor	O
,	O
p21	O
protein	O
,	O
is	O
reduced	O
by	O
CHIP	O
knockdown	O
,	O
leading	O
to	O
enhanced	O
senescence	O
of	O
cells	O
in	O
response	O
to	O
exposure	O
to	O
IR	O
.	O

Cellular	O
senescence	O
and	O
sensitivity	O
to	O
IR	O
is	O
prevented	O
by	O
CRISPR	O
/	O
Cas9	O
-mediated	O
deletion	O
of	O
the	O
p21	O
gene	O
(	O
CDKN1A	O
)	O
in	O
CHIP	O
knockdown	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
CHIP	O
potentiates	O
p21	O
degradation	O
and	O
promotes	O
greater	O
radioresistance	O
of	O
lung	O
cancer	O
cells	O
.	O

In	O
vitro	O
and	O
cell	O
-based	O
assays	O
demonstrate	O
that	O
p21	O
is	O
a	O
novel	O
and	O
direct	O
ubiquitylation	O
substrate	O
of	O
CHIP	O
that	O
also	O
requires	O
the	O
CHIP	O
-	O
associated	O
chaperone	O
HSP70	O
.	O

These	O
data	O
reveal	O
that	O
the	O
inhibition	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
CHIP	O
promotes	O
radiosensitivity	O
,	O
thus	O
suggesting	O
a	O
novel	O
strategy	O
for	O
the	O
treatment	O
of	O
lung	O
cancer	O
.	O

Implications	O
:	O
The	O
CHIP	O
-	O
HSP70	O
-	O
p21	O
ubiquitylation	O
/	O
degradation	O
axis	O
identified	O
here	O
could	O
be	O
exploited	O
to	O
enhance	O
the	O
efficacy	O
of	O
radiotherapy	O
in	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Mol	O
Cancer	O
Res	O
;	O
1-9	O
.	O

©2017	O
AACR	O
.	O

Critical	O
Aspects	O
for	O
Detection	O
of	O
Coxiella	O
burnetii	O
.	O

Coxiella	O
burnetii	O
is	O
a	O
globally	O
distributed	O
zoonotic	O
γ-proteobacterium	O
with	O
an	O
obligatory	O
intracellular	O
lifestyle	O
.	O

It	O
is	O
the	O
causative	O
agent	O
of	O
Q	O
fever	O
in	O
humans	O
and	O
of	O
coxiellosis	O
among	O
ruminants	O
,	O
although	O
the	O
agent	O
is	O
also	O
detected	O
in	O
ticks	O
,	O
birds	O
,	O
and	O
various	O
other	O
mammalian	O
species	O
.	O

Requirements	O
for	O
intracellular	O
multiplication	O
together	O
with	O
the	O
necessity	O
for	O
biosafety	O
level	O
3	O
facilities	O
restrict	O
the	O
cultivation	O
of	O
C.	O
burnetii	O
to	O
specialized	O
laboratories	O
.	O

Development	O
of	O
a	O
novel	O
medium	O
formulation	O
enabling	O
axenic	O
growth	O
of	O
C.	O
burnetii	O
has	O
facilitated	O
fundamental	O
genetic	O
studies	O
.	O

This	O
review	O
provides	O
critical	O
insights	O
into	O
direct	O
diagnostic	B-P
methods	I-P
currently	O
available	O
for	O
C.	O
burnetii	O
.	O

It	O
encompasses	O
molecular	O
detection	O
methods	O
,	O
isolation	O
,	O
and	O
propagation	O
of	O
the	O
bacteria	O
and	O
its	O
genetic	O
characterization	O
.	O

Differentiation	O
of	O
C.	O
burnetii	O
from	O
Coxiella-like	O
organisms	O
is	O
an	O
essential	O
diagnostic	O
prerequisite	O
,	O
particularly	O
when	O
handling	O
and	O
analyzing	O
ticks	O
.	O

Rinsing	O
paired-agent	O
model	O
(	O
RPAM	O
)	O
to	O
quantify	O
cell-surface	O
receptor	O
concentrations	O
in	O
topical	O
staining	O
applications	O
of	O
thick	O
tissues	O
.	O

Conventional	O
molecular	O
assessment	O
of	O
tissue	O
through	O
histology	O
,	O
if	O
adapted	O
to	O
fresh	O
thicker	O
samples	O
,	O
has	O
the	O
potential	O
to	O
enhance	O
cancer	O
detection	O
in	O
surgical	O
margins	O
and	O
monitoring	O
of	O
3D	O
cell	O
culture	O
molecular	O
environments	O
.	O

However	O
,	O
in	O
thicker	O
samples	O
,	O
substantial	O
background	O
staining	O
is	O
common	O
despite	O
repeated	O
rinsing	O
,	O
which	O
can	O
significantly	O
reduce	O
image	O
contrast	O
.	O

Recently	O
,	O
'	O
paired-agent	O
'	O
methods	O
-which	O
employ	O
co-administration	O
of	O
a	O
control	O
(	O
untargeted	O
)	O
imaging	O
agent	O
-have	O
been	O
applied	O
to	O
thick	O
-	O
sample	O
staining	O
applications	O
to	O
account	O
for	O
background	O
staining	O
.	O

To	O
date	O
,	O
these	O
methods	B-P
have	O
included	O
(	O
1	O
)	O
a	O
simple	O
ratiometric	O
method	O
that	O
is	O
relatively	O
insensitive	O
to	O
noise	O
in	O
the	O
data	O
but	O
has	O
accuracy	O
that	O
is	O
dependent	O
on	O
the	O
staining	O
protocol	O
and	O
the	O
characteristics	O
of	O
the	O
sample	O
;	O
and	O
(	O
2	O
)	O
a	O
complex	O
paired-agent	O
kinetic	O
modeling	O
method	O
that	O
is	O
more	O
accurate	O
but	O
is	O
more	O
noise-sensitive	O
and	O
requires	O
a	O
precise	O
serial	O
rinsing	O
protocol	O
.	O

Here	O
,	O
a	O
new	O
simplified	O
mathematical	O
model-the	O
rinsing	O
paired-agent	O
model	O
(	O
RPAM	O
)	O
-is	O
derived	O
and	O
tested	O
that	O
offers	O
a	O
good	O
balance	O
between	O
the	O
previous	O
models	O
,	O
is	O
adaptable	O
to	O
arbitrary	O
rinsing-imaging	B-P
protocols	I-P
,	O
and	O
does	O
not	O
require	O
calibration	O
of	O
the	O
imaging	O
system	O
.	O

RPAM	O
is	O
evaluated	O
against	O
previous	O
models	O
and	O
is	O
validated	O
by	O
comparison	O
to	O
estimated	O
concentrations	O
of	O
targeted	O
biomarkers	O
on	O
the	O
surface	O
of	O
3D	O
cell	O
culture	O
and	O
tumor	O
xenograft	O
models	O
.	O

This	O
work	O
supports	O
the	O
use	O
of	O
RPAM	O
as	O
a	O
preferable	O
model	O
to	O
quantitatively	O
analyze	O
targeted	O
biomarker	O
concentrations	O
in	O
topically	O
stained	O
thick	O
tissues	O
,	O
as	O
it	O
was	O
found	O
to	O
match	O
the	O
accuracy	O
of	O
the	O
complex	O
paired-agent	O
kinetic	O
model	O
while	O
retaining	O
the	O
low	O
noise-sensitivity	O
characteristics	O
of	O
the	O
ratiometric	O
method	O
.	O

Bone	O
Degeneration	O
and	O
Its	O
Recovery	O
in	O
SMP30/GNL	O
-	O
Knockout	O
Mice	O
.	O

Senescence	O
marker	O
protein-30	O
(	O
SMP30	O
)	O
decreases	O
androgen	O
-independently	O
with	O
aging	O
and	O
is	O
a	O
lactone	O
-	O
hydrolyzing	O
enzyme	O
gluconolactonase	O
(	O
GNL	O
)	O
that	O
is	O
involved	O
in	O
vitamin	O
C	O
biosynthesis	O
.	O

In	O
the	O
present	O
study	O
,	O
bone	O
properties	O
of	O
SMP30/GNL	O
knockout	O
(	O
KO	O
)	O
mice	O
with	O
deficiency	O
in	O
vitamin	O
C	O
synthesis	O
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30/GNL	O
and	O
exogenous	O
vitamin	O
C	O
supplementation	O
on	O
bone	O
formation	O
.	O

Mineral	O
content	O
(	O
BMC	O
)	O
and	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
the	O
mandible	O
and	O
femur	O
of	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
2	O
and	O
3	O
months	O
of	O
age	O
with	O
or	O
without	O
vitamin	O
C	O
supplementation	O
were	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

Body	O
and	O
bone	O
weight	O
of	O
both	O
age	O
groups	O
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild-type	O
mice	O
.	O

The	O
bones	O
of	O
SMP30/GNL	O
KO	O
mice	O
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	O
and	O
BMD	O
significantly	O
below	O
wild-type	O
.	O

Oral	O
supplementation	O
with	O
vitamin	O
C	O
eliminated	O
differences	O
in	O
body	O
weight	O
,	O
bone	O
weight	O
,	O
BMC	O
,	O
and	O
BMD	O
between	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
each	O
age	O
.	O

These	O
results	O
indicate	O
that	O
bone	O
degeneration	O
in	O
SMP30/GNL	O
KO	O
mice	O
was	O
caused	O
by	O
lack	O
of	O
vitamin	O
C	O
,	O
and	O
that	O
this	O
mouse	O
strain	O
is	O
an	O
appropriate	O
model	O
for	O
bone	O
metabolism	O
in	O
humans	O
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	O
vitamin	O
C	O
.	O

In	O
vitro	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
functional	O
properties	O
of	O
a	O
novel	O
Lactobacillus	O
paraplantarum	O
isolated	O
from	O
fermented	O
dates	O
in	O
Saudi	O
Arabia	O
.	O

Fermented	O
foods	O
produced	O
using	O
dates	O
are	O
used	O
in	O
Gulf	O
countries	O
as	O
beneficial	O
and	O
healthful	O
foods	O
.	O

The	O
beneficial	O
microbial	O
flora	O
in	O
fermented	O
dates	O
contributes	O
to	O
maintaining	O
the	O
nutritional	O
properties	O
of	O
dates	O
by	O
preventing	O
the	O
growth	O
of	O
spoilage	O
fungi	O
.	O

Here	O
,	O
we	O
examined	O
the	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
properties	O
of	O
the	O
novel	O
Lactobacillus	O
strain	O
D-3	O
isolated	O
from	O
fermented	O
dates	O
.	O

Analyzing	O
the	O
morphological	O
,	O
physiological	O
,	O
and	O
biochemical	O
characteristics	O
of	O
this	O
strain	O
demonstrated	O
that	O
it	O
was	O
similar	O
to	O
Lactobacillus	O
species	O
,	O
and	O
molecular	O
level	O
amplification	O
of	O
the	O
16S	O
rRNA	O
gene	O
showed	O
that	O
it	O
belonged	O
to	O
Lactobacillus	O
paraplantarum	O
.	O

Under	O
shake	O
flask	O
cultivation	O
using	O
date	O
juice	O
,	O
the	O
strain	O
produced	O
significant	O
amounts	O
of	O
ethanol	O
and	O
lactic	O
,	O
succinic	O
,	O
and	O
acetic	O
acids	O
.	O

Purification	O
of	O
benzoic	O
acid	O
extracted	O
from	O
the	O
extracellular	O
fermentation	O
medium	O
was	O
confirmed	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
(	O
NMR	B-P
)	O
,	O
and	O
infrared	O
and	O
mass	O
spectral	O
data	O
revealed	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
values	O
of	O
10	O
,	O
20	O
,	O
10	O
,	O
5	O
,	O
and	O
10	O
mg	O
mL	O
(	O
-1	O
)	O
for	O
Aspergillus	O
fumigates	O
,	O
Curvularia	O
lunata	O
,	O
Fusarium	O
oxysporum	O
,	O
Gibberella	O
moniliformis	O
,	O
and	O
Penicillium	O
chrysogenum	O
,	O
respectively	O
.	O

The	O
strain	O
showed	O
several	O
advantages	O
,	O
including	O
the	O
ability	O
to	O
survive	O
under	O
conditions	O
similar	O
to	O
the	O
gastrointestinal	O
tract	O
(	O
low	O
pH	O
,	O
bile	O
salts	O
,	O
and	O
antimicrobial	O
susceptibility	O
)	O
and	O
high	O
levels	O
of	O
extracellular	O
enzyme	O
activities	O
.	O

The	O
strain	O
's	O
growth	O
patterns	O
under	O
various	O
concentrations	O
of	O
H2	O
O2	O
and	O
its	O
scavenging	O
properties	O
towards	O
hydroxyl	O
radical	O
(	O
64.85	O
%	O
)	O
and	O
DPPH	O
(	O
84.97	O
%	O
)	O
were	O
also	O
interesting	O
properties	O
.	O

The	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
properties	O
of	O
L.	O
paraplantarum	O
D3	O
may	O
provide	O
health	O
benefits	O
to	O
consumers	O
.	O

Seated	O
maximum	O
flexion	O
:	O
An	O
alternative	O
to	O
standing	O
maximum	O
flexion	O
for	O
determining	O
presence	O
of	O
flexion	O
-	O
relaxation	O
?	O
.	O

The	O
flexion	O
-	O
relaxation	O
phenomenon	O
(	O
FRP	O
)	O
in	O
standing	O
is	O
a	O
specific	O
and	O
sensitive	O
diagnostic	B-P
tool	I-P
for	O
low	O
back	O
pain	O
.	O

Seated	O
flexion	O
as	O
an	O
alternative	O
could	O
be	O
beneficial	O
for	O
certain	O
populations	O
,	O
yet	O
the	O
behavior	O
of	O
the	O
trunk	O
extensors	O
during	O
seated	O
maximum	O
flexion	O
compared	O
to	O
standing	O
flexion	O
remains	O
unclear	O
.	O

Compare	O
FRP	O
occurrences	O
and	O
spine	O
angles	O
between	O
seated	O
and	O
standing	O
flexion	O
postures	O
in	O
three	O
levels	O
of	O
the	O
erector	O
spinae	O
muscles	O
.	O

Thirty-one	O
participants	O
free	O
of	O
back	O
pain	O
performed	O
seated	O
and	O
standing	O
maximum	O
trunk	O
flexion	O
.	O

Electromyographical	O
signals	O
were	O
recorded	O
from	O
the	O
bilateral	O
lumbar	O
(	O
L3	O
)	O
,	O
lower-thoracic	O
(	O
T9	O
)	O
,	O
and	O
upper-thoracic	O
(	O
T4	O
)	O
erector	O
spinae	O
and	O
assessed	O
for	O
the	O
occurrence	O
of	O
FRP	O
.	O

Spine	O
angles	O
corresponding	O
to	O
FRP	O
onset	O
and	O
cessation	O
were	O
determined	O
,	O
and	O
FRP	O
occurrences	O
and	O
angles	O
were	O
compared	O
between	O
posture	O
and	O
muscle	O
.	O

FRP	O
occurrence	O
was	O
similar	O
in	O
standing	O
and	O
seated	O
maximum	O
flexion	O
across	O
all	O
muscles	O
,	O
with	O
the	O
lumbar	O
muscles	O
showing	O
the	O
greatest	O
consistency	O
.	O

Standing	O
FRP	O
onset	O
and	O
cessation	O
angles	O
were	O
consistently	O
greater	O
than	O
the	O
corresponding	O
seated	O
FRP	O
angles	O
.	O

Considering	O
the	O
similar	O
number	O
of	O
FRP	O
occurrences	O
,	O
seated	O
maximum	O
flexion	O
may	O
constitute	O
an	O
objective	O
criterion	O
for	O
low	O
back	O
pain	O
diagnosis	O
.	O

Future	O
work	O
should	O
seek	O
to	O
confirm	O
the	O
utility	O
of	O
this	O
test	O
in	O
individuals	O
with	O
low	O
back	O
pain	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
for	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
Diagnosis	O
of	O
Prostate	O
Cancer	O
in	O
Patients	O
with	O
Prostate-specific	O
Antigen	O
<	O
20	O
ng/ml	O
.	O

The	O
European	O
Society	O
of	O
Urogenital	O
Radiology	O
has	O
built	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
(	O
PI-RADS	O
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

This	O
study	O
evaluated	O
the	O
PI-RADS	O
diagnosis	B-P
method	I-P
in	O
patients	O
with	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
<	O
20	O
ng/ml	O
.	O

A	O
total	O
of	O
133	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
were	O
prospectively	O
recruited	O
.	O

T2-weighted	B-P
(	O
T2WI	B-P
)	O
and	O
diffusion-weighted	B-P
(	I-P
DWI	I-P
)	I-P
magnetic	I-P
resonance	I-P
images	I-P
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12-core	B-P
transrectal	I-P
prostate	I-P
biopsy	I-P
.	O

Each	O
patient	O
's	O
peripheral	O
zone	O
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	O
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	B-P
cores	I-P
.	O

T2WI	B-P
,	O
DWI	B-P
,	O
and	O
T2WI	B-P
+	O
DWI	B-P
scores	O
were	O
computed	O
according	O
to	O
PI-RADS	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
PI-RADS	O
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	B-P
biopsies	I-P
as	O
the	O
reference	O
standard	O
.	O

PCa	O
was	O
histologically	O
diagnosed	O
in	O
169	O
(	O
21.2	O
%	O
)	O
regions	O
.	O

Increased	O
PI-RADS	O
score	O
correlated	O
positively	O
with	O
increased	O
cancer	O
detection	O
rate	O
.	O

The	O
cancer	O
detection	O
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2WI	B-P
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
DWI	B-P
.	O

For	O
T2WI	B-P
+	O
DWI	B-P
,	O
the	O
cancer	O
detection	O
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3-4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5-6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7-8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9-10	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	O
was	O
0.700	O
(	O
T2WI	B-P
)	O
,	O
0.735	O
(	O
DWI	B-P
)	O
and	O
0.749	O
(	O
T2WI	B-P
+	O
DWI	B-P
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53.8	O
%	O
and	O
89.2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5-6	O
as	O
the	O
cutoff	O
value	O
for	O
T2WI	B-P
+	O
DWI	B-P
.	O

The	O
PI-RADS	O
score	O
correlates	O
with	O
the	O
PCa	O
detection	O
rate	O
in	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
.	O

The	O
summed	O
score	O
of	O
T2WI	B-P
+	O
DWI	B-P
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
PCa	O
.	O

However	O
,	O
the	O
sensitivity	O
should	O
be	O
further	O
improved	O
.	O

Spinal	O
load	O
in	O
nurses	O
during	O
emergency	O
lifting	O
of	O
obese	O
patients	O
:	O
preliminary	O
results	O
.	O

Nurses	O
are	O
exposed	O
to	O
the	O
risk	O
of	O
injury	O
while	O
handling	O
patients	O
.	O

This	O
is	O
particularly	O
true	O
for	O
obese	O
patients	O
.	O

The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
estimate	O
the	O
spinal	O
loads	O
and	O
the	O
related	O
risk	O
of	O
injury	O
to	O
nurses	O
while	O
lifting	O
obese	O
patients	O
from	O
the	O
floor	O
with	O
a	O
bariatric	O
sheet	O
during	O
a	O
hospital	O
emergency	O
.	O

Six	O
male	O
nurses	O
participated	O
in	O
this	O
study	O
.	O

The	O
biomechanical	B-P
analysis	I-P
focused	O
on	O
the	O
lifting	O
strategy	O
.	O

Thirty	O
obese	O
in-patients	O
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	O
study	O
and	O
divided	O
into	O
three	O
groups	O
according	O
to	O
their	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

Three-dimensional	B-P
motion	I-P
analysis	I-P
was	O
conducted	O
using	O
an	O
optoelectronic	O
system	O
.	O

The	O
trunk	O
kinematics	O
and	O
the	O
loading	O
on	O
the	O
spines	O
of	O
the	O
operating	O
nurses	O
were	O
computed	O
.	O

Our	O
data	O
showed	O
that	O
when	O
the	O
nurse	O
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	O
was	O
more	O
flexed	O
at	O
the	O
end	O
of	O
the	O
lift	O
with	O
a	O
reduced	O
range	O
of	O
motion	O
.	O

The	O
values	O
were	O
higher	O
when	O
the	O
nurse	O
lifted	O
patients	O
with	O
higher	O
BMIs	O
.	O

All	O
kinetic	O
parameters	O
and	O
tension	O
in	O
the	O
lumbar	O
muscles	O
at	O
the	O
end	O
of	O
the	O
movement	O
were	O
characterised	O
by	O
lower	O
values	O
for	O
the	O
nurse	O
placed	O
beside	O
the	O
patient	O
's	O
head	O
or	O
feet	O
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	O
groups	O
.	O

Our	O
preliminary	O
data	O
suggest	O
that	O
only	O
the	O
reaction	O
load	O
on	O
the	O
spine	O
of	O
the	O
nurse	O
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	O
's	O
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	O
safety	O
limits	O
.	O

The	O
Effect	O
of	O
Image	O
Review	O
before	O
Patient	O
Discharge	O
on	O
Study	O
Completeness	O
and	O
Sonographer	O
Job	O
Satisfaction	O
in	O
a	O
Pediatric	B-P
Echocardiographic	I-P
Laboratory	O
.	O

Incomplete	O
echocardiographic	B-P
assessment	O
accounts	O
for	O
approximately	O
10	O
%	O
of	O
preventable	O
diagnostic	O
errors	O
and	O
may	O
place	O
children	O
at	O
risk	O
for	O
adverse	O
outcomes	O
or	O
increased	O
testing	B-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
physician	O
review	O
of	O
images	O
improves	O
study	O
completeness	O
.	O

A	O
prospective	O
quality	O
improvement	O
(	O
QI	O
)	O
study	O
initiated	O
physician	O
review	O
of	O
first-time	O
echocardiographic	B-P
studies	O
for	O
completeness	O
before	O
patient	O
discharge	O
.	O

Studies	O
were	O
incomplete	O
if	O
not	O
all	O
anatomic	O
structures	O
were	O
diagnostically	O
demonstrated	O
.	O

QI	O
examinations	O
were	O
compared	O
with	O
controls	O
obtained	O
before	O
study	O
initiation	O
.	O

Demographic	O
and	O
clinical	O
information	O
and	O
duration	O
of	O
scan	B-P
were	O
collected	O
during	O
the	O
control	O
and	O
QI	O
periods	O
.	O

An	O
anonymous	O
survey	O
was	O
administered	O
to	O
the	O
sonographers	O
to	O
assess	O
perceptions	O
of	O
the	O
intervention	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
QI	O
(	O
n	O
=	O
63	O
)	O
and	O
control	O
(	O
n	O
=	O
63	O
)	O
groups	O
in	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
technical	O
barriers	O
.	O

After	O
study	O
completion	O
,	O
35	O
%	O
of	O
control	O
scans	B-P
versus	O
5	O
%	O
of	O
QI	O
scans	B-P
were	O
incomplete	O
(	O
P	O
<	O
.001	O
)	O
.	O

In	O
the	O
QI	O
group	O
,	O
the	O
sonographer	O
,	O
physician	O
,	O
or	O
both	O
returned	O
to	O
scan	B-P
in	O
12	O
(	O
19	O
%	O
)	O
,	O
nine	O
(	O
14	O
%	O
)	O
,	O
and	O
two	O
(	O
3	O
%	O
)	O
studies	O
,	O
respectively	O
.	O

QI	O
studies	O
were	O
longer	O
than	O
control	O
studies	O
(	O
44	O
vs	O
36	O
min	O
,	O
P	O
=	O
.003	O
)	O
before	O
review	O
.	O

Physician	O
review	O
added	O
a	O
median	O
of	O
6	O
min	O
(	O
range	O
,	O
1-28	O
min	O
)	O
.	O

The	O
majority	O
of	O
sonographers	O
believed	O
that	O
immediate	O
review	O
improved	O
communication	O
,	O
and	O
50	O
%	O
believed	O
that	O
it	O
improved	O
their	O
job	O
satisfaction	O
.	O

Review	O
of	O
initial	O
outpatient	O
echocardiographic	B-P
examinations	O
before	O
patient	O
discharge	O
significantly	O
improves	O
study	O
completeness	O
.	O

Review	O
adds	O
a	O
nominal	O
amount	O
of	O
time	O
to	O
total	O
study	O
duration	O
,	O
improves	O
sonographer	O
-	O
physician	O
communication	O
,	O
and	O
may	O
prevent	O
unnecessary	O
testing	B-P
,	O
potentially	O
reducing	O
the	O
cost	O
of	O
care	O
.	O

A	O
Revised	O
Approach	O
for	O
the	O
Detection	O
of	O
Sight-Threatening	O
Diabetic	O
Macular	O
Edema	O
.	O

Diabetic	O
macular	O
edema	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
vision	O
loss	O
among	O
working-age	O
adults	O
in	O
the	O
United	O
States	O
.	O

Telemedicine	O
screening	O
programs	O
and	O
epidemiological	O
studies	O
rely	O
on	O
monoscopic	B-P
fundus	I-P
photography	I-P
for	O
the	O
detection	O
of	O
clinically	O
significant	O
macular	O
edema	O
(	O
CSME	O
)	O
.	O

Improving	O
the	O
accuracy	O
of	O
detecting	O
CSME	O
from	O
monoscopic	O
images	O
could	O
be	O
valuable	O
while	O
recognizing	O
the	O
limitations	O
of	O
such	O
detection	O
in	O
an	O
era	O
of	O
optical	B-P
coherence	I-P
tomography	I-P
detection	O
of	O
diabetic	O
macular	O
edema	O
.	O

To	O
evaluate	O
the	O
screening	B-P
test	I-P
accuracy	O
of	O
radially	O
arranged	O
sectors	O
affected	O
by	O
hard	O
exudates	O
in	O
the	O
detection	O
of	O
CSME	O
.	O

This	O
investigation	O
was	O
a	O
cross-sectional	O
study	O
of	O
CSME	O
grading	O
in	O
monoscopic	O
images	O
using	O
a	O
sectors	O
approach	O
.	O

The	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
criteria	O
were	O
used	O
to	O
confirm	O
the	O
presence	O
of	O
CSME	O
by	O
the	O
following	O
2	O
methods	B-P
:	O
stereoscopic	B-P
fundus	I-P
photography	I-P
(	O
method	B-P
1	I-P
)	O
and	O
dilated	O
biomicroscopy	B-P
in	O
combination	O
with	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
method	B-P
2	I-P
)	O
.	O

Participants	O
were	O
recruited	O
at	O
a	O
university	O
-	O
based	O
practice	O
between	O
June	O
14	O
,	O
2014	O
,	O
and	O
December	O
28	O
,	O
2015	O
.	O

Area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
,	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
.	O

A	O
total	O
of	O
207	O
eyes	O
from	O
an	O
ethnically/racially	O
diverse	O
group	O
of	O
207	O
patients	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
53.6	O
[	O
10.8	O
]	O
years	O
;	O
58.9	O
%	O
[	O
122	O
of	O
207	O
]	O
female	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Twelve	O
eyes	O
(	O
5.8	O
%	O
)	O
were	O
diagnosed	B-P
as	O
having	O
CSME	O
based	O
on	O
method	B-P
1	I-P
.	O

The	O
intermethod	O
and	O
intergrader	O
agreement	O
for	O
CSME	O
diagnosis	B-P
and	O
sector	O
count	O
was	O
substantial	O
(	O
κ	O
range	O
,	O
0.66	O
[	O
95	O
%	O
CI	O
,	O
0.47-0.85	O
]	O
to	O
0.75	O
[	O
95	O
%	O
CI	O
,	O
0.53-0.97	O
]	O
;	O
P	O
<	O
.001	O
for	O
all	O
)	O
.	O

Area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
was	O
93.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
84.2	O
%	O
-100	O
%	O
)	O
when	O
evaluating	O
a	O
sectors	O
approach	O
against	O
method	B-P
1	I-P
as	O
a	O
reference	O
test	O
and	O
offered	O
up	O
to	O
an	O
8.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
3.0	O
%	O
-14.3	O
%	O
)	O
increase	O
in	O
specificity	O
compared	O
with	O
the	O
existing	O
methods	B-P
of	O
detection	O
.	O

The	O
positive	O
predictive	O
value	O
was	O
33.3	O
%	O
(	O
95	O
%	O
CI	O
,	O
25.6	O
%	O
-45.5	O
%	O
)	O
,	O
and	O
the	O
negative	O
predictive	O
value	O
was	O
98.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
96.9	O
%	O
-100	O
%	O
)	O
.	O

The	O
results	O
were	O
similar	O
when	O
comparing	O
a	O
sectors	O
approach	O
with	O
method	B-P
2	I-P
as	O
a	O
reference	O
test	O
.	O

A	O
sectors	O
approach	O
shows	O
good	O
screening	B-P
test	I-P
characteristics	O
for	O
the	O
detection	O
of	O
CSME	O
.	O

Its	O
implementation	O
in	O
the	O
existing	O
telemedicine	O
programs	O
would	O
require	O
minimal	O
resources	O
.	O

This	O
approach	O
will	O
have	O
the	O
greatest	O
effect	O
in	O
a	O
setting	O
where	O
implementation	O
of	O
optical	B-P
coherence	I-P
tomography	I-P
,	O
a	O
more	O
objective	O
and	O
sensitive	O
way	O
to	O
detect	O
retinal	O
thickening	O
,	O
is	O
not	O
feasible	O
.	O

The	O
proposed	O
method	B-P
also	O
may	O
be	O
easily	O
incorporated	O
in	O
the	O
automated	O
diabetic	O
retinopathy	O
detection	O
algorithms	O
.	O

Spectral	O
fingerprints	O
of	O
large-scale	O
cortical	O
dynamics	O
during	O
ambiguous	O
motion	O
perception	O
.	O

Ambiguous	O
stimuli	O
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	O
correlates	O
of	O
consciousness	O
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	O
perception	O
might	O
arise	O
from	O
the	O
dynamic	O
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	O
areas	O
.	O

While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	O
coupling	O
as	O
a	O
correlate	O
of	O
cortical	O
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	O
modes	O
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	O
functions	O
.	O

Here	O
,	O
we	O
studied	O
two	O
coupling	O
modes	O
,	O
namely	O
phase	O
and	O
envelope	O
coupling	O
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	O
.	O

Therefore	O
,	O
we	O
recorded	O
128-channel	O
EEG	B-P
while	O
participants	O
performed	O
a	O
bistable	B-P
motion	I-P
task	I-P
and	O
utilized	O
state-of-the-art	O
source-space	O
connectivity	O
analysis	O
techniques	O
to	O
study	O
the	O
functional	O
relevance	O
of	O
different	O
coupling	O
modes	O
for	O
cortical	O
communication	O
.	O

Our	O
results	O
indicate	O
that	O
gamma-band	O
phase	O
coupling	O
in	O
extrastriate	O
visual	O
cortex	O
might	O
mediate	O
the	O
integration	O
of	O
visual	B-P
tokens	I-P
into	O
a	O
moving	O
stimulus	O
during	O
ambiguous	O
visual	B-P
stimulation	I-P
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long-range	O
fronto-occipital	O
gamma-band	O
envelope	O
coupling	O
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	O
motion	O
perception	O
.	O

Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	O
parieto-occipital	O
alpha-band	O
phase	O
coupling	O
controls	O
the	O
inter-	O
hemispheric	O
information	O
transfer	O
.	O

These	O
findings	O
provide	O
correlative	O
evidence	O
for	O
the	O
notion	O
that	O
synchronized	O
oscillatory	O
brain	O
activity	O
reflects	O
the	O
processing	O
of	O
sensory	O
input	O
as	O
well	O
as	O
the	O
information	O
integration	O
across	O
several	O
spatiotemporal	O
scales	O
.	O

The	O
results	O
indicate	O
that	O
distinct	O
coupling	O
modes	O
are	O
involved	O
in	O
different	O
cortical	O
computations	O
and	O
that	O
the	O
rich	O
spatiotemporal	O
correlation	O
structure	O
of	O
the	O
brain	O
might	O
constitute	O
the	O
functional	O
architecture	O
for	O
cortical	O
processing	O
and	O
specific	O
multi-site	O
communication	O
.	O

Hum	O
Brain	O
Mapp	O
37:4099-4111	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Common	O
Laboratory	O
Parameters	O
for	O
Differentiating	O
Between	O
Community-Acquired	O
and	O
Healthcare-Associated	O
Pneumonia	O
.	O

The	O
correct	O
diagnosis	O
of	O
healthcare-associated	O
pneumonia	O
(	O
HCAP	O
)	O
as	O
opposed	O
to	O
community-acquired	O
pneumonia	O
is	O
essential	O
for	O
the	O
selection	O
of	O
a	O
correct	O
empirical	O
antimicrobial	O
approach	O
,	O
reserving	O
the	O
broad-spectrum	O
or	O
highly	O
potent	O
antimicrobial	O
therapies	O
for	O
resistant	O
strains	O
most	O
commonly	O
present	O
in	O
HCAP	O
,	O
whereas	O
treating	O
the	O
less	O
resistant	O
strains	O
,	O
most	O
commonly	O
associated	O
with	O
community	O
and	O
long-term	O
care	O
facility	O
-	O
acquired	O
infections	O
,	O
with	O
a	O
more	O
targeted	O
empirical	O
approach	O
.	O

The	O
standard	O
approach	O
today	O
is	O
to	O
differentiate	O
between	O
the	O
two	O
based	O
on	O
the	O
medical	O
history	O
of	O
the	O
past	O
90	O
days	O
prior	O
to	O
admission	O
.	O

Measurable	O
,	O
quantitative	O
assessment	O
may	O
be	O
able	O
to	O
assist	O
in	O
this	O
decision	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	O
method	O
of	O
differentiating	O
between	O
community-acquired	O
and	O
healthcare-associated	O
pneumonias	O
.	O

The	O
records	O
of	O
126	O
patients	O
admitted	O
with	O
a	O
diagnosis	O
of	O
pneumonia	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
probable	O
cause	O
of	O
their	O
disease	O
,	O
in	O
accordance	O
with	O
common	O
practice	O
.	O

The	O
routine	O
laboratory	O
work	O
taken	O
upon	O
admittance	O
was	O
analyzed	O
using	O
logistical	O
regression	O
and	O
Student	O
's	O
t-test	O
.	O

We	O
have	O
found	O
that	O
the	O
red	O
blood	O
cell	O
distribution	O
width	O
and	O
the	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
,	O
both	O
routine	O
parameters	O
obtained	O
in	O
a	O
simple	O
blood	O
count	O
,	O
can	O
each	O
assist	O
in	O
differentiating	O
between	O
community-acquired	O
and	O
healthcare-associated	O
pneumonias	O
.	O

We	O
have	O
found	O
two	O
statistically	O
significant	O
parameters	O
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	O
history	O
,	O
chest	B-P
radiography	I-P
and	O
other	O
parameters	O
in	O
forming	O
an	O
immediate	O
clinical	O
impression	O
of	O
a	O
patient	O
presenting	O
with	O
pneumonia	O
.	O

Role	O
of	O
breast	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
in	O
predicting	O
residual	O
lobular	O
carcinoma	O
in	O
situ	O
after	O
initial	O
excision	O
.	O

Breast	B-P
magnetic	I-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
is	O
a	O
useful	O
screening	B-P
modality	O
in	O
detecting	O
suspicious	O
lesions	O
in	O
patients	O
with	O
a	O
history	O
of	O
lobular	O
carcinoma	O
in	O
situ	O
(	O
LCIS	O
)	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
breast	B-P
MR	I-P
imaging	I-P
in	O
detecting	O
remnant	O
LCIS	O
lesions	O
after	O
initial	O
excision	O
.	O

Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	O
with	O
LCIS	O
who	O
underwent	O
initial	O
excision	O
were	O
enrolled	O
.	O

Breast	B-P
ultrasonography	I-P
and	O
breast	B-P
MR	I-P
imaging	I-P
was	O
conducted	O
after	O
initial	O
excision	O
.	O

Imaging	O
findings	O
were	O
compared	O
with	O
pathologic	O
results	O
.	O

There	O
were	O
nine	O
(	O
31.0	O
%	O
)	O
cases	O
with	O
positive	O
margins	O
after	O
initial	O
excision	O
;	O
they	O
were	O
LCIS	O
(	O
n=8	O
)	O
and	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
)	O
.	O

Residual	O
lesions	O
were	O
identified	O
in	O
12	O
cases	O
;	O
they	O
were	O
invasive	O
lobular	O
carcinoma	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
LCIS	O
(	O
n=9	O
;	O
31.0	O
%	O
)	O
,	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
and	O
papillary	O
carcinoma	O
in	O
situ	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
.	O

Prior	O
to	O
the	O
second	O
operation	O
,	O
these	O
lesions	O
could	O
be	O
detected	O
in	O
seven	O
cases	O
using	O
ultrasonography	B-P
(	O
sensitivity	O
,	O
53.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	O
using	O
breast	B-P
MR	I-P
imaging	I-P
(	O
sensitivity	O
,	O
83.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
.	O

Breast	B-P
MR	I-P
imaging	I-P
showed	O
higher	O
sensitivity	O
than	O
breast	B-P
ultrasonography	I-P
in	O
detecting	O
remnant	O
LCIS	O
lesions	O
.	O

If	O
a	O
suspicious	O
lesion	O
was	O
found	O
using	O
breast	B-P
MR	I-P
imaging	I-P
,	O
a	O
second	O
operation	O
should	O
be	O
considered	O
because	O
of	O
the	O
possibility	O
of	O
multifocality	O
,	O
even	O
if	O
LCIS	O
was	O
confirmed	O
at	O
the	O
initial	O
operation	O
.	O

Quality	O
Improvement	O
of	O
Liver	O
Ultrasound	B-P
Images	O
Using	O
Fuzzy	O
Techniques	O
.	O

Liver	O
ultrasound	B-P
images	O
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	O
diffuse	O
liver	O
diseases	O
like	O
fatty	O
liver	O
.	O

However	O
,	O
the	O
low	O
quality	O
of	O
such	O
images	O
makes	O
it	O
difficult	O
to	O
analyze	O
them	O
and	O
diagnose	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	O
and	O
quality	O
of	O
liver	O
ultrasound	B-P
images	O
.	O

In	O
this	O
study	O
,	O
a	O
number	O
of	O
image	O
contrast	O
enhancement	O
algorithms	O
which	O
are	O
based	O
on	O
fuzzy	O
logic	O
were	O
applied	O
to	O
liver	O
ultrasound	B-P
images	O
-	O
in	O
which	O
the	O
view	O
of	O
kidney	O
is	O
observable	O
-	O
using	O
Matlab2013b	O
to	O
improve	O
the	O
image	O
contrast	O
and	O
quality	O
which	O
has	O
a	O
fuzzy	O
definition	O
;	O
just	O
like	O
image	O
contrast	O
improvement	O
algorithms	O
using	O
a	O
fuzzy	O
intensification	O
operator	O
,	O
contrast	O
improvement	O
algorithms	O
applying	O
fuzzy	O
image	O
histogram	O
hyperbolization	O
,	O
and	O
contrast	O
improvement	O
algorithms	O
by	O
fuzzy	O
IF-THEN	O
rules	O
.	O

With	O
the	O
measurement	O
of	O
Mean	O
Squared	O
Error	O
and	O
Peak	O
Signal	O
to	O
Noise	O
Ratio	O
obtained	O
from	O
different	O
images	O
,	O
fuzzy	O
methods	O
provided	O
better	O
results	O
,	O
and	O
their	O
implementation	O
-	O
compared	O
with	O
histogram	O
equalization	O
method	O
-	O
led	O
both	O
to	O
the	O
improvement	O
of	O
contrast	O
and	O
visual	O
quality	O
of	O
images	O
and	O
to	O
the	O
improvement	O
of	O
liver	O
segmentation	O
algorithms	O
results	O
in	O
images	O
.	O

Comparison	O
of	O
the	O
four	O
algorithms	O
revealed	O
the	O
power	O
of	O
fuzzy	O
logic	O
in	O
improving	O
image	O
contrast	O
compared	O
with	O
traditional	O
image	O
processing	O
algorithms	O
.	O

Moreover	O
,	O
contrast	O
improvement	O
algorithm	O
based	O
on	O
a	O
fuzzy	O
intensification	O
operator	O
was	O
selected	O
as	O
the	O
strongest	O
algorithm	O
considering	O
the	O
measured	O
indicators	O
.	O

This	O
method	O
can	O
also	O
be	O
used	O
in	O
future	O
studies	O
on	O
other	O
ultrasound	B-P
images	O
for	O
quality	O
improvement	O
and	O
other	O
image	O
processing	O
and	O
analysis	O
applications	O
.	O

Can	O
diaphragmatic	B-P
ultrasonography	I-P
performed	O
during	O
the	O
T-tube	O
trial	O
predict	O
weaning	O
failure	O
?	O

The	O
role	O
of	O
diaphragmatic	O
rapid	O
shallow	O
breathing	O
index	O
.	O

The	O
rapid	O
shallow	O
breathing	O
index	O
(	O
RSBI	O
)	O
,	O
which	O
is	O
the	O
ratio	O
between	O
respiratory	O
rate	O
(	O
RR	O
)	O
and	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
indices	O
to	O
predict	O
weaning	O
outcome	O
.	O

Whereas	O
the	O
diaphragm	O
plays	O
a	O
fundamental	O
role	O
in	O
generating	O
VT	O
,	O
in	O
the	O
case	O
of	O
diaphragmatic	O
dysfunction	O
the	O
inspiratory	O
accessory	O
muscles	O
may	O
contribute	O
.	O

If	O
this	O
occurs	O
during	O
a	O
weaning	O
trial	O
,	O
delayed	O
weaning	O
failure	O
is	O
likely	O
since	O
the	O
accessory	O
muscles	O
are	O
more	O
fatigable	O
than	O
the	O
diaphragm	O
.	O

Hence	O
,	O
we	O
hypothesised	O
that	O
the	O
traditional	O
RSBI	O
could	O
be	O
implemented	O
by	O
substituting	O
VT	O
with	O
the	O
ultrasonographic	B-P
evaluation	I-P
of	O
diaphragmatic	O
displacement	O
(	O
DD	O
)	O
.	O

We	O
named	O
the	O
new	O
index	O
the	O
diaphragmatic	O
-	O
RSBI	O
(	O
D	O
-	O
RSBI	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
ability	O
of	O
the	O
traditional	O
RSBI	O
and	O
D	O
-	O
RSBI	O
to	O
predict	O
weaning	O
failure	O
in	O
ready-to-wean	O
patients	O
.	O

We	O
performed	O
a	O
prospective	O
observational	O
study	O
.	O

During	O
a	O
T-tube	O
spontaneous	O
breathing	O
trial	O
(	O
SBT	O
)	O
we	O
simultaneously	O
evaluated	O
right	O
hemidiaphragm	O
displacement	O
(	O
i.e.	O
,	O
DD	O
)	O
by	O
using	O
M-mode	B-P
ultrasonography	I-P
as	O
well	O
as	O
the	O
RSBI	O
.	O

Outcome	O
of	O
the	O
weaning	O
attempt	O
,	O
length	O
of	O
mechanical	O
ventilation	O
,	O
length	O
of	O
intensive	O
care	O
unit	O
and	O
hospital	O
stay	O
,	O
and	O
hospital	O
mortality	O
were	O
recorded	O
.	O

Receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
curves	O
were	O
used	O
to	O
evaluate	O
the	O
diagnostic	O
accuracy	O
of	O
D	O
-	O
RSBI	O
and	O
RSBI	O
.	O

We	O
enrolled	O
51	O
patients	O
requiring	O
mechanical	O
ventilation	O
for	O
more	O
than	O
48	O
h	O
who	O
were	O
ready	O
to	O
perform	O
a	O
SBT	O
.	O

Most	O
of	O
the	O
patients	O
,	O
34	O
(	O
66	O
%	O
)	O
,	O
were	O
successfully	O
weaned	O
from	O
mechanical	O
ventilation	O
.	O

When	O
considering	O
the	O
17	O
patients	O
that	O
failed	O
the	O
weaning	O
attempt	O
,	O
11	O
(	O
64	O
%	O
)	O
had	O
to	O
be	O
reconnected	O
to	O
the	O
ventilator	O
during	O
the	O
SBT	O
,	O
three	O
(	O
18	O
%	O
)	O
had	O
to	O
be	O
re-intubated	O
within	O
48	O
h	O
of	O
extubation	O
,	O
and	O
three	O
(	O
18	O
%	O
)	O
required	O
non-invasive	O
ventilation	O
support	O
within	O
48	O
h	O
of	O
extubation	O
.	O

The	O
areas	O
under	O
the	O
ROC	O
curves	O
for	O
D	O
-	O
RSBI	O
and	O
RSBI	O
were	O
0.89	O
and	O
0.72	O
,	O
respectively	O
(	O
P	O
=	O
0.006	O
)	O
.	O

D	O
-	O
RSBI	O
(	O
RR	O
/	O
DD	O
)	O
was	O
more	O
accurate	O
than	O
traditional	O
RSBI	O
(	O
RR	O
/	O
VT	O
)	O
in	O
predicting	O
the	O
weaning	O
outcome	O
.	O

Our	O
clinical	O
trial	O
was	O
retrospectively	O
registered	O
with	O
ClinicalTrials.gov	O
(	O
identifier	O
:	O
NCT02696018	O
)	O
.	O

ClinicalTrials.gov	O
processed	O
our	O
record	O
on	O
25	O
February	O
2016	O
.	O

Adenoviral	O
Delivery	O
of	O
Tumor	O
Necrosis	O
Factor-α	O
and	O
Interleukin-2	O
Enables	O
Successful	O
Adoptive	O
Cell	O
Therapy	O
of	O
Immunosuppressive	O
Melanoma	O
.	O

Adoptive	O
T-cell	O
transfer	O
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	O
cancer	O
,	O
but	O
efficacy	O
in	O
solid	O
tumors	O
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre-	O
and	O
postconditioning	O
regimens	O
.	O

Thus	O
,	O
adoptive	O
T-cell	O
therapies	O
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O

We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	O
T-cell	O
transfer	O
by	O
using	O
adenoviral	O
vectors	O
for	O
direct	O
delivery	O
of	O
immunomodulatory	O
murine	O
cytokines	O
into	O
B16.OVA	O
melanoma	O
tumors	O
with	O
concomitant	O
T-cell	O
receptor	O
transgenic	O
OT-I	O
T-cell	O
transfer	O
.	O

Armed	O
adenoviruses	O
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	O
when	O
injected	O
into	O
B16.OVA	O
tumors	O
,	O
suggesting	O
safety	O
of	O
virus-mediated	O
cytokine	O
delivery	O
.	O

Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	O
coding	O
for	O
murine	O
interleukin-2	O
(	O
mIL-2	O
)	O
and	O
tumor	O
necrosis	O
factor-α	O
(	O
mTNFα	O
)	O
when	O
compared	O
with	O
T-cell	O
transfer	O
alone	O
or	O
viruses	O
alone	O
.	O

Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL-2	O
,	O
mTNFα	O
,	O
and	O
OT-I	O
T-cells	O
.	O

Mechanistic	O
studies	O
suggest	O
that	O
mIL-2	O
has	O
an	O
important	O
role	O
in	O
activating	O
T-cells	O
at	O
the	O
tumor	O
,	O
while	O
mTNFα	O
induces	O
chemokine	O
expression	O
.	O

Furthermore	O
,	O
adenovirus	O
treatments	O
enhanced	O
tumor	O
-	O
infiltration	O
of	O
OT-I	O
T-cells	O
as	O
demonstrated	O
by	O
SPECT/CT	B-P
imaging	I-P
of	O
(	O
111	O
)	O
In-labeled	O
cells	O
.	O

Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine-coding	O
adenoviruses	O
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	O
T-cell	O
therapies	O
.	O

Anatomic	O
variations	O
of	O
levator	O
scapulae	O
in	O
a	O
normal	O
cohort	O
:	O
an	O
MRI	B-P
study	I-P
.	O

Accessory	O
attachments	O
of	O
the	O
levator	O
scapulae	O
(	O
LS	O
)	O
muscle	O
have	O
been	O
described	O
in	O
the	O
literature	O
in	O
previous	O
cadaveric	O
studies	O
,	O
but	O
there	O
is	O
little	O
knowledge	O
about	O
the	O
incidence	O
and	O
distribution	O
.	O

Knowledge	O
of	O
LS	O
accessory	O
attachments	O
is	O
relevant	O
to	O
clinicians	O
working	O
in	O
the	O
fields	O
of	O
radiology	O
,	O
surgery	O
,	O
neurology	O
,	O
and	O
musculoskeletal	O
medicine	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
incidence	O
and	O
spectrum	O
of	O
LS	O
caudal	O
accessory	O
attachments	O
in	O
vivo	O
using	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
in	O
a	O
young	O
cohort	O
.	O

MR	B-P
images	O
of	O
the	O
cervical	O
spine	O
were	O
obtained	O
from	O
37	O
subjects	O
(	O
13	O
males	O
and	O
24	O
females	O
)	O
aged	O
18-36	O
years	O
using	O
an	O
axial	O
T1-weighted	O
spin	O
echo	O
sequence	O
acquired	O
from	O
a	O
3-Tesla	B-P
MR	I-P
scanner	I-P
.	O

The	O
LS	O
muscle	O
was	O
identified	O
,	O
and	O
the	O
presence	O
of	O
caudal	O
accessory	O
attachments	O
was	O
recorded	O
and	O
described	O
.	O

LS	O
caudal	O
accessory	O
attachments	O
were	O
identified	O
in	O
16	O
subjects	O
(	O
4	O
right	O
,	O
6	O
left	O
,	O
and	O
6	O
bilateral	O
;	O
12	O
female	O
)	O
.	O

Ten	O
had	O
unilateral	O
accessory	O
attachments	O
to	O
the	O
serratus	O
anterior	O
,	O
serratus	O
posterior	O
superior	O
or	O
the	O
first/second	O
rib	O
.	O

Four	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
posterior	O
superior	O
and	O
unilateral	O
accessory	O
attachment	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
attachments	O
to	O
both	O
muscles	O
.	O

Both	O
unilateral	O
and	O
bilateral	O
LS	O
caudal	O
accessory	O
attachments	O
were	O
present	O
in	O
nearly	O
half	O
of	O
the	O
subjects	O
examined	O
.	O

They	O
were	O
relatively	O
more	O
frequent	O
in	O
females	O
than	O
males	O
.	O

The	O
findings	O
indicate	O
that	O
these	O
accessory	O
attachments	O
are	O
common	O
,	O
and	O
in	O
some	O
cases	O
,	O
those	O
accessory	O
attachments	O
can	O
occur	O
bilaterally	O
and	O
to	O
more	O
than	O
one	O
site	O
.	O

Extremely	O
Giant	O
Liver	O
Hemangioma	O
(	O
50	O
cm	O
)	O
with	O
Kasabach-Merritt	O
Syndrome	O
.	O

A	O
33-	O
year	O
-	O
old	O
male	O
has	O
been	O
found	O
with	O
a	O
giant	O
liver	O
hemangioma	O
of	O
initial	O
size	O
29	O
cm	O
for	O
5	O
years	O
.	O

He	O
received	O
arterial	O
embolization	O
twice	O
in	O
order	O
to	O
shrink	O
the	O
tumor	O
;	O
however	O
,	O
no	O
effect	O
was	O
obtained	O
.	O

The	O
tumor	O
had	O
rapidly	O
grown	O
to	O
50	O
cm	O
and	O
caused	O
abnormalities	O
in	O
the	O
hematological	O
and	O
coagulative	O
systems	O
.	O

Preoperative	O
computed	B-P
tomography	I-P
revealed	O
that	O
the	O
right	O
hepatic	O
vein	O
,	O
right	O
hepatic	O
artery	O
,	O
and	O
right	O
portal	O
vein	O
were	O
not	O
involved	O
by	O
the	O
hemangioma	O
.	O

Resection	O
of	O
the	O
giant	O
liver	O
hemangioma	O
was	O
successfully	O
performed	O
after	O
intraoperative	O
intentional	O
bloodletting	O
with	O
concurrent	O
blood	O
salvage	O
.	O

All	O
hematological	O
and	O
coagulative	O
abnormalities	O
had	O
returned	O
to	O
normal	O
after	O
the	O
procedure	O
.	O

Incident	O
fracture	O
associated	O
with	O
increased	O
risk	O
of	O
mortality	O
even	O
after	O
adjusting	O
for	O
frailty	O
status	O
in	O
elderly	O
Japanese	O
men	O
:	O
the	O
Fujiwara-kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
(	O
FORMEN	O
)	O
Cohort	O
Study	O
.	O

Frail	O
elderly	O
individuals	O
have	O
elevated	O
risks	O
of	O
both	O
fracture	O
and	O
mortality	O
.	O

We	O
found	O
that	O
incident	O
fractures	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
even	O
after	O
adjusting	O
for	O
pre-fracture	O
frailty	O
status	O
as	O
represented	O
by	O
physical	B-P
performance	I-P
tests	I-P
and	O
laboratory	O
tests	O
for	O
common	O
geriatric	O
diseases	O
in	O
community-dwelling	O
elderly	O
Japanese	O
men	O
.	O

While	O
fractures	O
reportedly	O
increase	O
the	O
risk	O
of	O
mortality	O
,	O
frailty	O
may	O
complicate	O
this	O
association	O
,	O
generating	O
a	O
false-positive	O
result	O
.	O

We	O
evaluated	O
this	O
association	O
after	O
adjusting	O
for	O
pre-fracture	O
levels	O
of	O
frailty	O
.	O

We	O
examined	O
1998	O
community-dwelling	O
ambulatory	O
men	O
aged	O
≥65	O
years	O
at	O
baseline	O
in	O
the	O
Fujiwara-kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
Study	O
for	O
frailty	O
status	O
as	O
represented	O
by	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
,	O
physical	B-P
performance	I-P
tests	I-P
(	O
grip	O
strength	O
,	O
one-foot	O
standing	O
balance	O
with	O
eyes	O
open	O
,	O
timed	B-P
10-m	I-P
walk	I-P
)	O
,	O
and	O
laboratory	O
sera	O
tests	O
.	O

Participants	O
were	O
then	O
followed	O
for	O
5	O
years	O
for	O
incident	O
clinical	O
fractures	O
and	O
death	O
.	O

Effects	O
of	O
incident	O
fracture	O
on	O
death	O
were	O
determined	O
by	O
Cox	O
proportional	O
hazards	O
model	O
with	O
the	O
first	O
fracture	O
during	O
follow-up	O
as	O
a	O
time-dependent	O
predictor	O
and	O
with	O
frailty	O
status	O
indices	O
as	O
covariates	O
.	O

We	O
identified	O
111	O
fractures	O
in	O
99	O
men	O
and	O
138	O
deaths	O
during	O
the	O
follow-up	O
period	O
(	O
median	O
follow-up	O
,	O
4.5	O
years	O
)	O
.	O

Participants	O
with	O
incident	O
fractures	O
did	O
not	O
have	O
significantly	O
worse	O
frailty	O
statuses	O
,	O
but	O
did	O
show	O
a	O
significantly	O
higher	O
cumulative	O
mortality	O
rate	O
than	O
those	O
without	O
fractures	O
(	O
p	O
=	O
0.0047	O
)	O
.	O

Age-adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
death	O
for	O
incident	O
fracture	O
was	O
3.57	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2.05	O
,	O
6.24	O
)	O
.	O

When	O
adjusted	O
for	O
physical	O
performance	O
,	O
this	O
decreased	O
to	O
2.77	O
(	O
1.51	O
,	O
5.06	O
)	O
,	O
but	O
remained	O
significant	O
.	O

The	O
HR	O
showed	O
no	O
significant	O
change	O
when	O
adjusted	O
for	O
laboratory	O
test	O
results	O
(	O
3.96	O
(	O
2.26	O
,	O
6.94	O
)	O
)	O
.	O

Exclusion	O
of	O
deaths	O
within	O
the	O
first	O
24	O
months	O
of	O
follow-up	O
did	O
not	O
alter	O
these	O
results	O
.	O

Incident	O
clinical	O
fracture	O
was	O
associated	O
with	O
an	O
elevated	O
risk	O
of	O
death	O
independently	O
of	O
pre-fracture	O
levels	O
of	O
frailty	O
in	O
community-dwelling	O
elderly	O
men	O
.	O

Two-stage	O
reconstructive	O
overlapping	O
stent	O
LEO+	O
and	O
SILK	O
for	O
treatment	O
of	O
intracranial	O
circumferential	O
fusiform	O
aneurysms	O
in	O
the	O
posterior	O
circulation	O
.	O

Intracranial	O
circumferential	O
fusiform	O
aneurysms	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
are	O
difficult	O
to	O
treat	O
.	O

This	O
article	O
shows	O
an	O
endovascular	O
reconstruction	O
technique	O
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	O
self-expandable	O
stent	O
(	O
LEO+	O
)	O
and	O
flow-diverter	O
device	O
(	O
SILK	O
)	O
at	O
different	O
surgical	O
times	O
.	O

Two	O
patients	O
with	O
circumferential	O
fusiform	O
aneurysm	O
,	O
one	O
being	O
an	O
aneurysm	O
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	O
cerebral	O
artery	O
,	O
diagnosed	O
after	O
a	O
headache	O
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	O
aneurysm	O
of	O
the	O
lower	O
basilar	O
artery	O
,	O
diagnosed	O
following	O
ischemia	O
of	O
the	O
brain	O
stem	O
.	O

Endovascular	O
treatment	O
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	O
reconstruction	O
technique	O
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	O
;	O
a	O
telescoped	O
self-expandable	O
stent	O
,	O
LEO+	O
;	O
and	O
a	O
flow-diverter	O
device	O
,	O
SILK	O
.	O

Angiographic	B-P
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	O
branches	O
and	O
perforating	O
vessels	O
,	O
and	O
thrombosis	O
of	O
the	O
aneurysm	O
.	O

The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self-expandable	O
stent	O
and	O
flow-diverter	O
device	O
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O

There	O
were	O
no	O
complications	O
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long-term	O
follow-up	O
with	O
full	O
arterial	O
vascular	O
reconstruction	O
,	O
maintenance	O
of	O
cerebral	O
perfusion	O
and	O
complete	O
aneurysm	O
occlusion	O
at	O
the	O
6-	O
and	O
12-	O
month	O
angiographic	B-P
follow-up	O
.	O

There	O
was	O
no	O
aneurysm	O
recanalization	O
nor	O
intra-stent	O
stenosis	O
.	O

Circumferential	O
fusiform	O
aneurysm	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
to	O
the	O
brain	O
stem	O
may	O
be	O
treated	O
with	O
this	O
arterial	O
reconstruction	O
technique	O
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self-expandable	O
stent	O
called	O
LEO+	O
and	O
the	O
flow-diverter	O
device	O
SILK	O
,	O
minimizing	O
the	O
risk	O
of	O
complications	O
and	O
failure	O
of	O
the	O
endovascular	O
technique	O
,	O
with	O
the	O
potential	O
for	O
arterial	O
reconstruction	O
with	O
thrombosis	O
of	O
the	O
aneurysmatic	O
sac	O
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	O
arteries	O
,	O
in	O
this	O
type	O
of	O
cerebral	O
aneurysm	O
.	O

Striatal	O
dopamine	O
modulates	O
timing	O
of	O
self-initiated	O
saccades	O
.	O

The	O
ability	O
to	O
adjust	O
movement	O
timing	O
is	O
essential	O
in	O
daily	O
life	O
.	O

Explorations	O
of	O
the	O
underlying	O
neural	O
mechanisms	O
have	O
reported	O
a	O
gradual	O
increase	O
or	O
decrease	O
in	O
neuronal	O
activity	O
prior	O
to	O
self-timed	O
movements	O
within	O
the	O
cortico	O
-	O
basal	O
ganglia	O
loop	O
.	O

Previous	O
studies	O
in	O
both	O
humans	O
and	O
animals	O
have	O
shown	O
that	O
endogenous	O
dopamine	O
(	O
DA	O
)	O
plays	O
a	O
modulatory	O
role	O
in	O
self-timing	O
.	O

However	O
,	O
the	O
specific	O
site	O
of	O
dopaminergic	O
regulation	O
remains	O
elusive	O
because	O
the	O
systemic	O
application	O
of	O
DA	O
-	O
related	O
substances	O
can	O
directly	O
alter	O
both	O
cortical	O
and	O
subcortical	O
neuronal	O
activities	O
.	O

To	O
investigate	O
the	O
role	O
of	O
striatal	O
DA	O
in	O
self-timing	O
,	O
we	O
locally	O
injected	O
DA	O
receptor	O
agonists	O
or	O
antagonists	O
into	O
the	O
striatum	O
of	O
two	O
female	O
monkeys	O
(	O
Macaca	O
fuscata	O
)	O
while	O
they	O
performed	O
two	O
versions	O
of	O
the	O
memory-guided	B-P
saccade	I-P
(	I-P
MS	I-P
)	I-P
task	I-P
.	O

In	O
the	O
conventional	O
,	O
triggered	O
MS	B-P
task	I-P
,	O
animals	O
made	O
a	O
saccade	O
to	O
the	O
location	O
of	O
a	O
previously	O
flashed	O
visual	O
cue	O
in	O
response	O
to	O
the	O
fixation	O
point	O
offset	O
.	O

In	O
the	O
self-timed	O
MS	B-P
task	I-P
,	O
monkeys	O
were	O
rewarded	O
for	O
making	O
a	O
self-initiated	O
saccade	O
within	O
a	O
predetermined	O
time	O
interval	O
following	O
the	O
cue	O
.	O

Infusion	O
of	O
a	O
small	O
amount	O
of	O
a	O
D1	O
or	O
D2	O
antagonist	O
led	O
to	O
early	O
saccades	O
in	O
the	O
self-timed	O
,	O
but	O
not	O
the	O
triggered	O
MS	B-P
tasks	I-P
,	O
while	O
infusion	O
of	O
DA	O
agonists	O
produced	O
no	O
consistent	O
effect	O
.	O

We	O
also	O
found	O
that	O
local	O
administration	O
of	O
nicotinic	O
but	O
not	O
muscarinic	O
acetylcholine	O
receptor	O
agonists	O
and	O
antagonists	O
altered	O
the	O
timing	O
of	O
self-initiated	O
saccades	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
timing	O
of	O
self-initiated	O
movements	O
may	O
be	O
regulated	O
by	O
the	O
balance	O
of	O
signals	O
in	O
the	O
direct	O
and	O
indirect	O
basal	O
ganglia	O
pathways	O
,	O
as	O
well	O
as	O
that	O
between	O
both	O
hemispheres	O
of	O
the	O
brain	O
.	O

Developmental	O
Regression	O
,	O
Depression	O
,	O
and	O
Psychosocial	O
Stress	O
in	O
an	O
Adolescent	O
with	O
Down	O
Syndrome	O
.	O

Kristen	O
is	O
a	O
13-	O
year	O
-old	O
girl	O
with	O
Down	O
syndrome	O
(	O
DS	O
)	O
who	O
was	O
seen	O
urgently	O
with	O
concerns	O
of	O
cognitive	O
and	O
developmental	O
regression	O
including	O
loss	O
of	O
language	O
,	O
social	O
,	O
and	O
toileting	O
skills	O
.	O

The	O
evaluation	O
in	O
the	O
DS	O
clinic	O
focused	O
on	O
potential	O
medical	B-P
diagnoses	I-P
including	O
atlantoaxial	O
joint	O
instability	O
,	O
vitamin	O
deficiency	O
,	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
,	O
and	O
seizures	O
.	O

A	O
comprehensive	O
medical	O
evaluation	O
yielded	O
only	O
a	O
finding	O
of	O
moderate	O
OSA	O
.	O

A	O
reactive	O
depression	O
was	O
considered	O
in	O
association	O
with	O
several	O
psychosocial	O
factors	O
including	O
moving	O
homes	O
,	O
entering	O
puberty	O
/	O
onset	O
of	O
menses	O
,	O
and	O
classroom	O
change	O
from	O
an	O
integrated	O
setting	O
to	O
a	O
self-	O
contained	O
classroom	O
comprising	O
unfamiliar	O
peers	O
with	O
behavior	O
challenges	O
.	O

Urgent	O
referrals	O
for	O
psychological	O
and	O
psychiatric	B-P
evaluations	I-P
were	O
initiated	O
.	O

Neuropsychological	B-P
testing	I-P
did	O
not	O
suggest	O
true	O
regression	O
in	O
cognitive	O
,	O
language	O
,	O
and	O
academic	O
skills	O
,	O
although	O
decreases	O
in	O
motivation	O
and	O
performance	O
were	O
noted	O
with	O
a	O
reaction	O
to	O
stress	O
and	O
multiple	O
environmental	O
changes	O
as	O
a	O
potential	O
causative	O
factor	O
.	O

Psychiatry	O
consultation	O
supported	O
this	O
finding	O
in	O
that	O
psychosocial	O
stress	O
temporally	O
correlated	O
with	O
Kristen	O
's	O
regression	O
in	O
skills	O
.Working	O
collaboratively	O
,	O
the	O
team	O
determined	O
that	O
Kristen	O
's	O
presentation	O
was	O
consistent	O
with	O
a	O
reactive	O
form	O
of	O
depression	O
(	O
DSM-IV-TR	O
:	O
depressive	O
disorder	O
,	O
not	O
otherwise	O
specified	O
)	O
.	O

Kristen	O
's	O
presentation	O
was	O
exacerbated	O
by	O
salient	O
environmental	O
stress	O
and	O
sleep	O
apnea	O
,	O
rather	O
than	O
a	O
cognitive	O
regression	O
associated	O
with	O
a	O
medical	O
cause	O
.	O

Treatment	O
consisted	O
of	O
an	O
antidepressant	O
medication	O
,	O
continuous	O
positive	O
airway	O
pressure	O
for	O
OSA	O
,	O
and	O
increased	O
psychosocial	O
supports	O
.	O

Her	O
school	O
initiated	O
a	O
change	O
in	O
classroom	O
placement	O
.	O

With	O
this	O
multimodal	O
approach	O
to	O
evaluation	O
and	O
intervention	O
,	O
Kristen	O
steadily	O
improved	O
and	O
she	O
returned	O
to	O
her	O
baseline	O
function	O
.	O

Pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
1-	O
year	O
follow	O
up	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	O
surgery	O
,	O
and	O
impairments	O
have	O
been	O
described	O
up	O
to	O
4-6	O
months	O
after	O
surgery	O
.	O

Evaluation	O
of	O
pulmonary	O
function	O
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O

In	O
this	O
prospective	O
study	O
pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
measurements	O
,	O
health-related	O
quality	O
of	O
life	O
(	O
SF-36	O
)	O
,	O
dyspnoea	O
,	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
and	O
pain	O
were	O
evaluated	O
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
valve	O
surgery	O
or	O
combined	O
surgery	O
.	O

One	O
year	O
after	O
surgery	O
the	O
forced	O
vital	O
capacity	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4-5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Saturation	O
of	O
peripheral	O
oxygen	O
was	O
unchanged	O
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O

A	O
significantly	O
improved	O
health-related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF-36	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Sternotomy	O
-related	O
pain	O
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min-max	O
;	O
0-7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	O
breath	O
(	O
0	O
[	O
0-4	O
]	O
)	O
and	O
while	O
coughing	O
(	O
0	O
[	O
0-8	O
]	O
)	O
.	O

A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	O
function	O
was	O
associated	O
with	O
dyspnoea	O
limitations	O
and	O
impaired	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
.	O

One	O
year	O
after	O
cardiac	O
surgery	O
static	O
and	O
dynamic	O
lung	B-P
function	I-P
measurements	I-P
were	O
slightly	O
decreased	O
,	O
while	O
health-related	O
quality	O
of	O
life	O
was	O
improved	O
in	O
comparison	O
to	O
preoperative	O
values	O
.	O

Measured	O
levels	O
of	O
pain	O
were	O
low	O
and	O
saturation	O
of	O
peripheral	O
oxygen	O
was	O
same	O
as	O
preoperatively	O
.	O

Outcomes	O
of	O
Subaortic	O
Obstruction	O
Resection	O
in	O
Children	O
.	O

Studies	O
of	O
long-term	O
outcomes	O
of	O
discrete	O
subaortic	O
stenosis	O
are	O
rare	O
.	O

Therefore	O
,	O
we	O
reviewed	O
the	O
long-term	O
outcomes	O
of	O
fibromuscular	O
resection	O
in	O
children	O
with	O
subaortic	O
stenosis	O
over	O
26	O
years	O
from	O
a	O
single	O
institution	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
all	O
children	O
(	O
n=72	O
)	O
who	O
underwent	O
resection	O
of	O
subaortic	O
obstruction	O
for	O
discrete	O
subaortic	O
stenosis	O
between	O
1989	O
and	O
2015	O
.	O

Median	O
age	O
at	O
surgery	O
was	O
5.0	O
years	O
(	O
2.7-7.6	O
years	O
)	O
.	O

There	O
were	O
no	O
operative	O
deaths	O
but	O
three	O
late	O
deaths	O
(	O
4.2	O
%	O
,	O
3/72	O
)	O
.	O

Overall	O
Kaplan-Meier	O
survival	O
at	O
10	O
years	O
was	O
93.0	O
±	O
3.9	O
%	O
(	O
95	O
%	O
CI	O
:	O
79.6	O
,	O
97.7	O
)	O
.	O

Peak	O
instantaneous	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
74.2±36.7mmHg	O
(	O
16.0-242.0mmHg	O
)	O
preoperatively	O
to	O
12.8±7.4mmHg	O
(	O
2.6-36.0mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
42.4±17.2mmHg	O
(	O
12.0-98.0	O
)	O
preoperatively	O
to	O
7.5±2.7mmHg	O
(	O
1.4-19.3mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

However	O
,	O
over	O
the	O
mean	O
follow-up	O
period	O
of	O
7.8±6.1	O
years	O
(	O
0.1-25.2	O
years	O
)	O
,	O
29.0	O
%	O
(	O
20/69	O
)	O
of	O
patients	O
had	O
recurrence	O
and	O
18.8	O
%	O
(	O
13/69	O
)	O
required	O
reoperation	O
at	O
median	O
time	O
of	O
4.8	O
years	O
(	O
3.1-9.1	O
years	O
)	O
after	O
the	O
initial	O
repair	O
.	O

Freedom	O
from	O
reoperation	O
at	O
10	O
years	O
was	O
71.1±7.1	O
%	O
(	O
95	O
%	O
CI	O
:	O
54.6	O
,	O
82.3	O
)	O
.	O

Risk	O
factors	O
for	O
reoperation	O
were	O
age	O
less	O
than	O
five	O
years	O
at	O
initial	O
repair	O
(	O
p=0.036	O
)	O
and	O
extension	O
of	O
the	O
membrane	O
to	O
the	O
aortic	O
valve	O
(	O
p=0.001	O
)	O
.	O

Aortic	O
insufficiency	O
was	O
present	O
in	O
54.2	O
%	O
(	O
39/72	O
)	O
of	O
patients	O
preoperatively	O
.	O

Progression	O
of	O
aortic	O
insufficiency	O
occurred	O
in	O
38.9	O
%	O
(	O
28/72	O
)	O
.	O

Involvement	O
of	O
the	O
aortic	O
valve	O
at	O
initial	O
repair	O
was	O
associated	O
with	O
need	O
for	O
subsequent	O
aortic	O
valve	O
repair	O
or	O
replacement	O
(	O
p=0.01	O
)	O
.	O

Resection	O
of	O
subaortic	O
obstruction	O
is	O
associated	O
with	O
low	O
mortality	O
and	O
morbidity	O
.	O

Recurrence	O
and	O
reoperation	O
rates	O
are	O
high	O
and	O
progression	O
of	O
aortic	O
insufficiency	O
following	O
subaortic	O
resection	O
is	O
common	O
.	O

Therefore	O
,	O
these	O
patients	O
warrant	O
close	O
follow-up	O
into	O
adult	O
life	O
.	O

The	O
Role	O
of	O
Rehabilitation	O
in	O
the	O
Management	O
of	O
Patients	O
with	O
Charcot-Marie-Tooth	O
Disease	O
:	O
Report	O
of	O
Two	O
Cases	O
.	O

Charcot-Marie-Tooth	O
(	O
CMT	O
)	O
disease	O
is	O
a	O
hereditary	O
disease	O
with	O
signs	O
of	O
chronic	O
non-progressive	O
motor-sensory	O
neuropathy	O
which	O
is	O
characterised	O
by	O
symmetric	O
muscle	O
atrophy	O
and	O
weakness	O
of	O
the	O
distal	O
portion	O
of	O
lower	O
extremities	O
.	O

The	O
aim	O
is	O
to	O
present	O
two	O
cases	O
with	O
peroneal	O
muscular	O
atrophy	O
,	O
applied	O
rehabilitation	O
procedures	O
and	O
rehabilitation	O
outcome	O
.	O

Patient	O
DR	O
,	O
aged	O
51	O
,	O
and	O
patient	O
KH	O
,	O
aged	O
78	O
.	O

Both	O
patients	O
had	O
weakness	O
and	O
pronounced	O
atrophy	O
of	O
the	O
distal	O
portion	O
of	O
lower	O
extremities	O
,	O
numbness	O
down	O
the	O
legs	O
,	O
contractures	O
in	O
the	O
ankles	O
and	O
walking	O
difficulties	O
.	O

Evaluation	O
of	O
patients	O
included	O
a	O
clinical	O
examination	O
,	O
Barthel	O
Index	O
,	O
Time	B-P
Up	I-P
and	I-P
Go	I-P
test	I-P
,	O
measurement	O
of	O
the	O
ankle	O
range	O
of	O
motion	O
,	O
and	O
a	O
manual	B-P
muscle	I-P
test	I-P
.	O

On	O
admission	O
,	O
the	O
Barthel	O
Index	O
score	O
was	O
60	O
in	O
the	O
first	O
case	O
,	O
and	O
80	O
in	O
the	O
second	O
.	O

The	O
rehabilitation	O
program	O
included	O
exercise	O
therapy	O
with	O
for	O
lower	O
extremity	O
,	O
occupational	O
therapy	O
,	O
stationary	O
bicycle	O
riding	O
,	O
galvanic	O
current	O
,	O
water	O
exercises	O
,	O
and	O
ankle-foot	O
orthoses	O
for	O
both	O
legs	O
.	O

The	O
therapy	O
applied	O
had	O
no	O
significant	O
changes	O
in	O
the	O
clinical	O
neurological	O
status	O
of	O
the	O
patients	O
,	O
but	O
yet	O
it	O
provided	O
some	O
improvement	O
in	O
ankle	O
contractures	O
,	O
better	O
mobility	O
,	O
and	O
a	O
more	O
stable	O
gait	O
.	O

The	O
application	O
of	O
rehabilitation	O
procedures	O
in	O
patients	O
with	O
Charcot-Marie-Tooth	O
disease	O
can	O
improve	O
their	O
functional	O
status	O
and	O
walking	O
stability	O
.	O

Endpoints	O
for	O
screening	B-P
thyroid	O
cancer	O
in	O
the	O
Republic	O
of	O
Korea	O
:	O
thyroid	O
specialists	O
'	O
perspectives	O
.	O

Cancer	B-P
screening	I-P
is	O
aimed	O
primarily	O
at	O
reducing	O
deaths	O
from	O
the	O
specific	O
cancer	O
.	O

Thyroid-specific	O
cancer	O
mortality	O
may	O
be	O
the	O
most	O
ambitious	O
endpoint	O
for	O
obtaining	O
estimates	O
of	O
screening	O
effect	O
.	O

Numerous	O
observations	B-P
have	O
accumulated	O
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	O
cancer	O
mortality	O
endpoint	O
has	O
been	O
difficult	O
to	O
study	O
and	O
is	O
confounded	O
by	O
population	O
heterogeneity	O
,	O
provision	O
of	O
randomization	O
,	O
and	O
requirement	O
of	O
large	O
cohorts	O
with	O
sufficiently	O
long	O
follow-up	O
due	O
to	O
the	O
excellent	O
prognosis	O
of	O
the	O
cancer	O
.	O

Accordingly	O
,	O
it	O
may	O
be	O
important	O
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	O
cancer	O
screening	B-P
efficacy	O
.	O

Recommendations	O
against	O
thyroid	O
cancer	O
screening	B-P
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	O
not	O
only	O
in	O
significant	O
reduction	O
in	O
cancer	O
mortality	O
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	O
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	O
that	O
can	O
reliably	O
predict	O
reductions	O
in	O
mortality	O
.	O

The	O
term	O
``	O
derivative	O
''	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	O
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	O
.	O

Derivative	O
endpoints	O
may	O
include	O
thyroid	O
cancer	O
incidence	O
,	O
the	O
proportion	O
of	O
early-stage	O
tumors	O
detected	O
,	O
more	O
treatable	O
stage	O
,	O
the	O
identification	O
of	O
small	O
tumors	O
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	O
in	O
the	O
number	O
of	O
people	O
who	O
develop	O
metastatic	O
disease	O
,	O
the	O
increased	O
chance	O
of	O
lesser	O
extent	O
surgery	O
,	O
and	O
the	O
application	O
of	O
minimally	O
invasive	O
approaches	O
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	O
thyroid	O
replacement	O
therapy	O
,	O
a	O
consistent	O
follow-up	O
,	O
low-dose	O
or	O
no	O
RAI	B-P
administration	I-P
and	O
risk	O
factor	O
assessments	O
where	O
case	O
findings	O
should	O
be	O
continuous	O
.	O

The	O
Korean	O
guidelines	O
for	O
thyroid	O
cancer	O
national-level	O
screening	O
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-P
thyroid	I-P
experts	I-P
.	O

It	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	O
cancer	O
screening	B-P
.	O

However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	O
and	O
demand	O
a	O
complete	O
analysis	O
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	O
participants	O
with	O
complete	O
information	O
necessary	O
to	O
make	O
decisions	O
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	O
cancer	O
is	O
screen-	O
identified	O
.	O

HoLEP	O
learning	O
curve	O
:	O
Toward	O
a	O
standardised	O
formation	O
and	O
a	O
team	O
strategy	O
.	O

Holmium	O
laser	O
enucleation	O
of	O
prostate	O
(	O
HoLEP	O
)	O
is	O
renowned	O
for	O
the	O
difficulty	O
of	O
its	O
learning	O
curve	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
interest	O
of	O
a	O
three-step	O
tutorial	O
in	O
the	O
HoLEP	O
learning	O
curve	O
,	O
in	O
a	O
university	O
center	O
.	O

It	O
is	O
a	O
retrospective	O
,	O
monocentric	O
study	O
of	O
the	O
82	O
first	O
procedures	O
done	O
consecutively	O
by	O
the	O
same	O
operator	O
with	O
a	O
proctoring	O
in	O
early	O
experience	O
and	O
after	O
40	O
procedures	O
.	O

For	O
all	O
patients	O
were	O
noted	O
:	O
enucleation	O
efficiency	O
(	O
g/min	O
)	O
,	O
morcellation	O
efficiency	O
(	O
g/min	O
)	O
,	O
percentage	O
of	O
enucleated	O
tissue	O
(	O
enucleated	O
tissue	O
/	O
adenome	O
weigth	O
evaluated	O
by	O
ultrasonography	B-P
.	O

g/g	O
)	O
,	O
perioperative	O
morbidity	O
(	O
Clavien	O
)	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
length	O
of	O
urinary	O
drainage	O
,	O
functional	O
outcomes	O
at	O
short	O
and	O
middle	O
term	O
(	O
Qmax	O
,	O
post-void	O
residual	O
volume	O
[	O
PVR	O
]	O
,	O
QOL	O
scores	O
and	O
IPSS	O
at	O
3	O
and	O
6	O
months	O
)	O
.	O

Enucleation	O
and	O
morcellation	O
efficiency	O
were	O
significantly	O
higher	O
after	O
the	O
second	O
proctoring	O
(	O
0.87	O
vs	O
0.44g/min	O
;	O
P	O
<	O
0.0001	O
and	O
4.2	O
vs	O
3.37g/min	O
,	O
P=0.038	O
,	O
respectively	O
)	O
so	O
as	O
the	O
prostatic	O
volume	O
(	O
43.5	O
vs	O
68.1mL	O
,	O
P=0.0001	O
)	O
.	O

Percentage	O
of	O
enucleated	O
tissue	O
was	O
higher	O
in	O
the	O
second	O
group	O
,	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
69.5	O
%	O
vs	O
80.4	O
%	O
,	O
P=0.03	O
)	O
.	O

Per-	O
and	O
postoperative	O
complications	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
urinary	O
drainage	O
length	O
and	O
functional	O
results	O
at	O
3	O
and	O
6	O
months	O
were	O
not	O
significantly	O
different	O
.	O

The	O
learning	O
curve	O
did	O
not	O
interfere	O
with	O
functional	O
results	O
.	O

The	O
second	O
proctoring	O
was	O
essential	O
to	O
us	O
in	O
order	O
to	O
grasp	O
the	O
technique	O
.	O

These	O
data	O
underlined	O
the	O
necessity	O
of	O
a	O
pedagogic	O
reflexion	O
in	O
order	O
to	O
built	O
a	O
standardized	O
formation	O
technique	O
to	O
the	O
HoLEP	O
.	O

4	O
.	O

Impact	O
of	O
femoral	O
artery	O
puncture	O
using	O
digital	B-P
subtraction	I-P
angiography	I-P
and	O
road	O
mapping	O
on	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	O
aortic	O
valve	O
implantation	O
.	O

The	O
use	O
of	O
large	O
-	O
diameter	O
sheaths	O
carries	O
the	O
risk	O
of	O
significant	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	O
aortic	O
valve	O
implantation	O
(	O
TAVI	O
)	O
.	O

In	O
this	O
analysis	O
,	O
we	O
sought	O
to	O
assess	O
the	O
impact	O
of	O
a	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
and	O
road	O
mapping	O
during	O
transfemoral	O
TAVI	O
on	O
periprocedural	O
vascular	O
and	O
bleeding	O
events	O
.	O

This	O
is	O
a	O
retrospective	O
analysis	O
of	O
transfemoral	O
TAVI	O
patients	O
included	O
in	O
a	O
prospective	O
institutional	O
database	O
.	O

The	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
DSA	B-P
-derived	O
road	O
mapping	O
guidance	O
was	O
introduced	O
in	O
October	O
2012	O
.	O

Before	O
the	O
introduction	O
of	O
this	O
technique	O
,	O
vascular	O
puncture	O
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-P
data	O
,	O
the	O
bony	O
iliofemoral	O
landmarks	O
and	O
a	O
radiopaque	O
object	O
.	O

Consecutive	O
patients	O
who	O
underwent	O
TAVI	O
with	O
the	O
road	O
mapping	O
technique	O
(	O
RM	O
group	O
,	O
n=160	O
)	O
were	O
compared	O
with	O
consecutive	O
patients	O
who	O
underwent	O
TAVI	O
without	O
road	O
mapping	O
(	O
control	O
group	O
,	O
n=160	O
)	O
prior	O
to	O
its	O
introduction	O
.	O

A	O
standardised	O
strategy	O
of	O
periprocedural	O
anticoagulation	O
was	O
adopted	O
in	O
both	O
groups	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	O
suture-based	O
closure	O
device	O
.	O

All	O
endpoints	O
were	O
defined	O
according	O
to	O
the	O
VARC-2	O
criteria	O
for	O
event	O
definition	O
.	O

The	O
mean	O
age	O
in	O
the	O
RM	O
group	O
was	O
80±7.7	O
years	O
compared	O
to	O
81±5.9	O
years	O
in	O
the	O
control	O
group	O
(	O
p=0.19	O
)	O
,	O
and	O
females	O
were	O
equally	O
distributed	O
between	O
both	O
groups	O
(	O
63.1	O
%	O
vs.	O
58.1	O
%	O
,	O
p=0.36	O
)	O
.	O

The	O
baseline	O
logistic	O
EuroSCORE	O
was	O
20.7±14.4	O
%	O
vs.	O
24.9±15.2	O
%	O
in	O
the	O
RM	O
and	O
control	O
group	O
,	O
respectively	O
(	O
p=0.01	O
)	O
.	O

Notably	O
,	O
sheath	O
size	O
was	O
significantly	O
larger	O
in	O
the	O
RM	O
compared	O
to	O
the	O
control	O
group	O
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(	O
23.8	O
%	O
vs.	O
1.8	O
%	O
,	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
associated	O
with	O
the	O
more	O
frequent	O
implantation	O
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM	O
group	O
(	O
43.8	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	O
complications	O
and	O
major	O
bleeding	O
at	O
30	O
days	O
were	O
significantly	O
lower	O
in	O
the	O
RM	O
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
4.3	O
%	O
vs.	O
11.8	O
%	O
,	O
p=0.01	O
,	O
and	O
14.4	O
%	O
vs.	O
25.6	O
%	O
,	O
p=0.01	O
)	O
.	O

An	O
analysis	O
limited	O
to	O
access	O
site-related	O
complications	O
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	O
map	O
group	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
8.1	O
%	O
vs.	O
13.8	O
%	O
,	O
p=0.1	O
)	O
.	O

Other	O
forms	O
of	O
vascular	O
and	O
bleeding	O
complications	O
as	O
well	O
as	O
all-cause	O
mortality	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

A	O
modified	O
femoral	O
artery	O
puncture	O
technique	O
using	O
DSA	B-P
and	O
road	O
mapping	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
major	O
vascular	O
and	O
bleeding	O
complications	O
after	O
transfemoral	O
TAVI	O
,	O
and	O
provides	O
a	O
simple	O
and	O
effective	O
strategy	O
for	O
potentially	O
improving	O
patient	O
outcomes	O
.	O

Pulmonary	O
homograft	O
stenosis	O
in	O
the	O
Ross	O
procedure	O
:	O
Incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
in	O
long-term	O
follow-up	O
.	O

The	O
Ross	O
procedure	O
is	O
used	O
in	O
the	O
treatment	O
of	O
selected	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

Pulmonary	O
graft	O
stenosis	O
can	O
appear	O
in	O
the	O
long-term	O
follow-up	O
after	O
the	O
Ross	O
intervention	O
,	O
but	O
the	O
factors	O
involved	O
and	O
its	O
clinical	O
implications	O
are	O
not	O
fully	O
known	O
.	O

To	O
describe	O
the	O
incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
after	O
the	O
Ross	O
procedure	O
in	O
a	O
prospective	O
series	O
in	O
a	O
tertiary	O
referral	O
hospital	O
.	O

From	O
1997	O
to	O
2009	O
,	O
107	O
patients	O
underwent	O
the	O
Ross	O
procedure	O
(	O
mean	O
age	O
:	O
30±11	O
years	O
;	O
69	O
%	O
men	O
;	O
21	O
aged	O
<	O
18	O
years	O
)	O
,	O
and	O
were	O
followed	O
for	O
echocardiographic	B-P
homograft	O
stenosis	O
(	O
peak	O
gradient	O
>	O
36mmHg	O
)	O
and	O
surgical	O
or	O
percutaneous	O
homograft	O
reintervention	O
.	O

After	O
15	O
years	O
of	O
follow-up	O
(	O
median	O
:	O
11	O
years	O
)	O
,	O
echocardiographic	B-P
and	O
clinical	O
data	O
were	O
available	O
in	O
91	O
(	O
85	O
%	O
)	O
and	O
104	O
(	O
98	O
%	O
)	O
patients	O
,	O
respectively	O
:	O
26/91	O
(	O
29	O
%	O
)	O
patients	O
developed	O
homograft	O
stenosis	O
;	O
10/104	O
(	O
10	O
%	O
)	O
patients	O
underwent	O
13	O
homograft	O
reintervention	O
procedures	O
(	O
three	O
patients	O
underwent	O
surgical	O
replacement	O
,	O
three	O
received	O
a	O
percutaneous	O
pulmonary	O
valve	O
and	O
one	O
needed	O
stent	O
implantation	O
)	O
.	O

The	O
other	O
three	O
patients	O
underwent	O
two	O
consecutive	O
procedures	O
in	O
follow-up	O
;	O
one	O
died	O
because	O
of	O
a	O
procedure-related	O
myocardial	O
infarction	O
.	O

Rates	O
of	O
survival	O
free	O
from	O
homograft	O
stenosis	O
and	O
reintervention	O
at	O
1	O
,	O
5	O
and	O
10	O
years	O
were	O
96	O
%	O
,	O
82	O
%	O
and	O
75	O
%	O
and	O
99	O
%	O
,	O
94	O
%	O
and	O
91	O
%	O
,	O
respectively	O
.	O

Paediatric	O
patients	O
had	O
worse	O
survival	O
free	O
from	O
homograft	O
stenosis	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
3.50	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.56-7.90	O
;	O
P=0.002	O
)	O
,	O
although	O
there	O
were	O
no	O
significant	O
differences	O
regarding	O
reintervention	O
(	O
HR	O
:	O
2.01	O
,	O
95	O
%	O
CI	O
:	O
0.52-7.78	O
;	O
P=0.31	O
)	O
.	O

Younger	O
age	O
of	O
homograft	O
donor	O
was	O
also	O
a	O
stenosis	O
predictor	O
(	O
HR	O
:	O
0.97	O
,	O
95	O
%	O
CI	O
:	O
0.94-0.99	O
;	O
P=0.046	O
)	O
.	O

The	O
probabilities	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
10	O
years	O
after	O
the	O
Ross	O
procedure	O
were	O
29	O
%	O
and	O
10	O
%	O
,	O
respectively	O
;	O
only	O
one	O
patient	O
had	O
a	O
reintervention	O
-related	O
death	O
.	O

Younger	O
donor	O
and	O
recipient	O
age	O
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
stenosis	O
.	O

Cerebrospinal	O
fluid	O
biomarkers	O
as	O
a	O
measure	O
of	O
disease	O
activity	O
and	O
treatment	O
efficacy	O
in	O
relapsing-remitting	O
multiple	O
sclerosis	O
.	O

Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
biomarkers	O
can	O
reflect	O
different	O
aspects	O
of	O
the	O
pathophysiology	O
of	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
RRMS	O
)	O
.	O

Understanding	O
the	O
impact	O
of	O
different	O
disease	O
modifying	O
therapies	O
on	O
the	O
CSF	O
biomarker	O
profile	O
may	O
increase	O
their	O
implementation	O
in	O
clinical	O
practice	O
and	O
their	O
appropriateness	O
for	O
monitoring	O
treatment	O
efficacy	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
first-line	O
(	O
interferon	O
beta	O
)	O
and	O
second-line	O
(	O
natalizumab	O
)	O
therapies	O
on	O
seven	O
CSF	O
biomarkers	O
in	O
RRMS	O
and	O
their	O
correlation	O
with	O
clinical	O
and	O
radiological	O
outcomes	O
.	O

We	O
included	O
59	O
RRMS	O
patients	O
and	O
39	O
healthy	O
controls	O
.	O

The	O
concentrations	O
of	O
C-X-C	O
motif	O
chemokine	O
13	O
(	O
CXCL13	O
)	O
,	O
C-C	O
motif	O
chemokine	O
ligand	O
2	O
(	O
CCL2	O
)	O
,	O
chitinase-3-like	O
protein	O
1	O
(	O
CHI3L1	O
)	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
neurofilament	O
light	O
protein	O
(	O
NFL	O
)	O
,	O
and	O
neurogranin	O
were	O
determined	O
by	O
ELISA	O
,	O
and	O
chitotriosidase	O
(	O
CHIT1	O
)	O
was	O
analyzed	O
by	O
spectrofluorometry	O
.	O

RRMS	O
patients	O
had	O
higher	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
than	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Subgroup	O
analysis	O
revealed	O
higher	O
NFL	O
,	O
CXCL13	O
and	O
CHIT1	O
levels	O
in	O
patients	O
treated	O
with	O
first-line	O
therapy	O
compared	O
to	O
second-line	O
therapy	O
(	O
p	O
=	O
0.008	O
,	O
p	O
=	O
0.001	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O

NFL	O
and	O
CHIT1	O
levels	O
correlated	O
with	O
relapse	O
status	O
,	O
and	O
NFL	O
and	O
CXCL13	O
levels	O
correlated	O
with	O
the	O
formation	O
of	O
new	O
magnetic	B-P
resonance	I-P
imaging	I-P
lesions	O
.	O

Furthermore	O
,	O
we	O
found	O
an	O
association	O
between	O
inflammatory	O
and	O
degenerative	O
biomarkers	O
.	O

The	O
results	O
indicate	O
that	O
CSF	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
correlate	O
with	O
the	O
clinical	O
and/or	O
radiological	O
disease	O
activity	O
,	O
providing	O
additional	O
dimensions	O
in	O
the	O
assessment	O
of	O
treatment	O
efficacy	O
.	O

Budd-Chiari	O
syndrome	O
secondary	O
to	O
catheter	O
-associated	O
inferior	O
vena	O
cava	O
thrombosis	O
.	O

Patients	O
with	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
are	O
at	O
increased	O
risk	O
for	O
thrombotic	O
complications	O
.	O

The	O
use	O
of	O
central	O
venous	O
catheters	O
as	O
dialysis	O
vascular	O
access	O
additionally	O
increases	O
this	O
risk	O
.	O

We	O
describe	O
the	O
first	O
case	O
of	O
Budd-Chiari	O
syndrome	O
(	O
BCS	O
)	O
secondary	O
to	O
central	O
venous	O
catheter	O
misplacement	O
in	O
a	O
patient	O
with	O
CKD	O
.	O

A	O
30-year-old	O
female	O
patient	O
with	O
HIV/AIDS	O
and	O
CKD	O
on	O
hemodialysis	O
was	O
admitted	O
to	O
the	O
emergency	O
room	O
for	O
complaints	O
of	O
fever	O
,	O
prostration	O
,	O
and	O
headache	O
in	O
the	O
last	O
six	O
days	O
.	O

She	O
had	O
a	O
tunneled	O
dialysis	O
catheter	O
placed	O
at	O
the	O
left	O
jugular	O
vein	O
.	O

The	O
diagnosis	O
of	O
BCS	O
was	O
established	O
by	O
abdominal	B-P
computed	I-P
tomography	I-P
that	O
showed	O
a	O
partial	O
thrombus	O
within	O
the	O
inferior	O
vena	O
cava	O
which	O
extended	O
from	O
the	O
right	O
atrium	O
to	O
medium	O
hepatic	O
vein	O
,	O
and	O
continuing	O
along	O
the	O
left	O
hepatic	O
vein	O
.	O

Patient	O
was	O
treated	O
with	O
anticoagulants	O
and	O
discharged	O
asymptomatic	O
.	O

Budd-Chiari	O
syndrome	O
is	O
a	O
rare	O
medical	O
condition	O
caused	O
by	O
hepatic	O
veins	O
thrombosis	O
.	O

It	O
can	O
involve	O
one	O
,	O
two	O
,	O
or	O
all	O
three	O
of	O
the	O
major	O
hepatic	O
veins	O
.	O

It	O
is	O
usually	O
related	O
to	O
myeloproliferative	O
disorders	O
,	O
malignancy	O
and	O
hypercoagulable	O
states	O
.	O

This	O
case	O
calls	O
attention	O
for	O
inadvertent	O
catheter	O
tip	O
placement	O
into	O
hepatic	O
vein	O
leading	O
to	O
this	O
rare	O
complication	O
.	O

Assessment	O
of	O
catheter	O
dialysis	O
tip	O
location	O
with	O
radiological	O
image	O
seems	O
to	O
be	O
a	O
prudent	O
measure	O
after	O
each	O
procedure	O
even	O
if	O
the	O
tunneled	O
dialysis	O
catheter	O
has	O
been	O
introduced	O
with	O
fluoroscopy	O
image	O
.	O

Association	O
between	O
OCT	B-P
-based	O
microangiography	B-P
perfusion	O
indices	O
and	O
diabetic	O
retinopathy	O
severity	O
.	O

To	O
evaluate	O
the	O
association	O
between	O
retinal	O
capillary	O
non-perfusion	O
and	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
severity	O
using	O
optical	B-P
coherence	I-P
tomography-based	I-P
microangiography	I-P
(	O
OMAG	B-P
)	O
.	O

33	O
patients	O
(	O
51	O
eyes	O
)	O
with	O
a	O
history	O
of	O
diabetes	O
underwent	O
imaging	B-P
with	O
a	O
68	O
kHz	O
Cirrus-5000	O
spectral	O
domain	O
OMAG	O
prototype	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
collected	O
.	O

The	O
perfusion	O
index	O
(	O
PI	O
)	O
was	O
defined	O
as	O
per	O
cent	O
coverage	O
of	O
area	O
by	O
retinal	O
vessels	O
with	O
flow	O
,	O
measured	O
within	O
a	O
minimum	O
of	O
6.8×6.8	O
mm	O
(	O
2	O
)	O
OMAG	B-P
scan	I-P
.	O

The	O
PI	O
in	O
each	O
ETDRS	O
zone	O
was	O
analysed	O
using	O
an	O
automated	O
algorithm	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
degree	O
of	O
association	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

51	O
eyes	O
with	O
different	O
DR	O
severities	O
were	O
imaged	B-P
.	O

More	O
severe	O
DR	O
was	O
significantly	O
associated	O
with	O
lower	O
PI	O
after	O
adjusting	O
for	O
logarithm	O
of	O
the	O
minimum	O
angle	O
of	O
resolution	O
best-corrected	O
visual	O
acuity	O
,	O
hyperlipidaemia	O
,	O
diabetes	O
type	O
and	O
ETDRS	O
ring	O
in	O
a	O
multivariate	O
mixed	O
linear	O
model	O
.	O

Compared	O
with	O
the	O
none-	O
mild	O
non-proliferative	O
diabetic	O
retinopathy	O
(	O
NPDR	O
)	O
group	O
,	O
the	O
moderate-severe	O
NPDR	O
group	O
had	O
2.7	O
lower	O
PI	O
(	O
p=0.03	O
)	O
and	O
proliferative	O
DR	O
group	O
had	O
4.3	O
lower	O
PI	O
(	O
p=0.003	O
)	O
.	O

All	O
ETDRS	O
zones	O
except	O
for	O
the	O
foveal	O
centre	O
showed	O
inverse	O
associations	O
between	O
PI	O
and	O
DR	O
severity	O
(	O
p	O
values	O
<	O
0.001	O
to	O
0.862	O
)	O
.	O

A	O
statistically	O
significant	O
inverse	O
association	O
exists	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

Our	O
study	O
suggests	O
that	O
PI	O
may	O
become	O
a	O
useful	O
biomarker	O
in	O
evaluating	O
and	O
following	O
the	O
progression	O
of	O
DR	O
.	O

A	O
Case	O
Presenting	O
with	O
Splenic	O
Infarct	O
Diagnosed	O
as	O
Primary	O
Bone	O
Marrow	O
CD5	O
Positive	O
DLBCL	O
:	O
A	O
Clinicopathological	O
Correlation	O
.	O

De	O
novo	O
CD5+	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
a	O
rare	O
and	O
aggressive	O
subtype	O
of	O
DLBCL	O
.	O

It	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
with	O
complex	O
molecular	O
profile	O
and	O
poor	O
prognosis	O
.	O

A	O
59	O
year	O
old	O
female	O
presented	O
with	O
pyrexia	O
of	O
unknown	O
origin	O
since	O
1	O
month	O
.	O

On	O
examination	O
,	O
there	O
was	O
severe	O
pallor	O
,	O
hepatosplenomegaly	O
and	O
no	O
palpable	O
lymphadenopathy	O
.	O

Complete	O
blood	O
count	O
revealed	O
bicytopenia	O
with	O
normal	O
total	O
leucocyte	O
count	O
.	O

Liver	O
and	O
renal	O
function	O
tests	O
were	O
normal	O
.	O

Ultrasonography	B-P
abdomen	I-P
revealed	O
splenic	O
enlargement	O
with	O
two	O
focal	O
lesions	O
attributed	O
to	O
either	O
splenic	O
abscess	O
or	O
infarcts	O
.	O

Patient	O
was	O
being	O
managed	O
as	O
splenic	O
infarct	O
but	O
continued	O
to	O
have	O
bicytopenia	O
.	O

Further	O
investigation	O
showed	O
elevated	O
serum	O
ferritin	O
,	O
triglycerides	O
and	O
LDH	O
.	O

With	O
a	O
clinical	O
suspicion	O
of	O
infection	O
and	O
haemophagocytic	O
lymphohistiocytosis	O
bone	B-P
bone	B-P
marrow	I-P
aspiration	I-P
(	I-P
BMA	B-P
)	I-P
and	I-P
biopsy	B-P
(	I-P
BMBx	I-P
)	I-P
was	O
done	O
.	O

BMA	O
showed	O
extensive	O
haemophagocytosis	O
and	O
~7.4	O
%	O
large	O
lymphoma-like	O
cells	O
.	O

On	O
this	O
basis	O
PET-CT	B-P
was	O
suggested	O
which	O
showed	O
enlarged	O
spleen	O
with	O
diffuse	O
uptake	O
.	O

BMBx	B-P
showed	O
nodular	O
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O

On	O
immunohistochemistry	B-P
,	O
these	O
cells	O
were	O
positive	O
for	O
CD20	O
,	O
CD5	O
,	O
MUM1	O
,	O
BCL-2	O
,	O
BCL-6	O
and	O
negative	O
for	O
CD3	O
,	O
CD10	O
and	O
CD23	O
.	O

CD34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O

The	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	O
of	O
de	O
novo	O
CD5+	O
DLBCL	O
,	O
with	O
primary	O
hepatosplenic	O
pattern	O
of	O
involvement	O
.	O

CD5+	O
DLBCL	O
presenting	O
as	O
splenic	O
infarct	O
is	O
very	O
rare	O
.	O

This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	O
of	O
a	O
primary	O
aggressive	O
lymphoma	O
with	O
haemophagocytosis	O
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	O
and	O
splenic	O
infarct	O
without	O
lymphadenopathy	O
.	O

This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	O
marrow	O
aspirate	O
and	O
biopsy	B-P
to	O
make	O
a	O
correct	O
diagnosis	O
.	O

Risk	O
stratification	O
of	O
prostate	O
cancer	O
utilizing	O
apparent	O
diffusion	O
coefficient	O
value	O
and	O
lesion	O
volume	O
on	O
multiparametric	B-P
MRI	I-P
.	O

To	O
evaluate	O
the	O
performance	O
of	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
and	O
lesion	O
volume	O
in	O
potentially	O
risk	O
-	O
stratifying	O
patients	O
with	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

Men	O
with	O
elevated	O
prostate-specific	O
antigen	O
or	O
abnormal	B-P
digital	I-P
rectal	I-P
exam	I-P
underwent	O
a	O
3T	B-P
multiparametric	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
mpMRI	B-P
)	O
with	O
endorectal	O
coil	O
.	O

ADC	O
maps	O
were	O
calculated	O
using	O
b	O
values	O
of	O
0	O
,	O
500	O
,	O
1000	O
,	O
and	O
1500	O
;	O
additional	O
images	O
were	O
obtained	O
with	O
b	O
value	O
of	O
2000	O
.	O

We	O
prospectively	O
enrolled	O
312	O
men	O
with	O
lesions	O
suspicious	O
for	O
cancer	O
(	O
suspicion	O
score	O
2-5	O
)	O
on	O
mpMRI	B-P
.	O

MRI/ultrasound	B-P
fusion-guided	I-P
prostate	I-P
biopsies	I-P
were	O
performed	O
.	O

Mean	O
ADC	O
of	O
suspicious	O
lesions	O
were	O
correlated	O
against	O
lesion	O
volume	O
,	O
Gleason	O
and	O
D'Amico	O
risk	O
.	O

The	O
cancer	O
detection	O
rate	O
of	O
fusion	B-P
biopsy	I-P
per	O
lesion	O
was	O
45.6	O
%	O
(	O
206/452	O
)	O
.	O

Cancerous	O
lesions	O
were	O
larger	O
(	O
median	O
volume	O
:	O
0.40	O
vs.	O
0.30	O
cm	O
(	O
3	O
)	O
;	O
P	O
=	O
0.016	O
)	O
.	O

The	O
median	O
ADC	O
(	O
×10	O
(	O
-6	O
)	O
mm	O
(	O
2	O
)	O
/sec	O
)	O
for	O
lesions	O
negative	O
and	O
positive	O
for	O
PCa	O
were	O
984.5	O
and	O
666.5	O
,	O
respectively	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

The	O
AUC	O
of	O
ADC	O
in	O
predicting	O
PCa	O
was	O
0.79	O
.	O

Larger	O
lesions	O
were	O
associated	O
with	O
higher	O
risk	O
PCa	O
(	O
Gleason	O
and	O
D'Amico	O
)	O
and	O
lower	O
ADC	O
(	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

The	O
mean	O
ADC	O
of	O
suspicious	O
lesions	O
on	O
mpMRI	B-P
was	O
inversely	O
correlated	O
,	O
while	O
lesion	O
volume	O
had	O
a	O
direct	O
correlation	O
with	O
PCa	O
detection	O
.	O

Future	O
follow-up	O
studies	O
are	O
needed	O
to	O
assess	O
longitudinal	O
cancer	O
risks	O
of	O
suspicious	O
mpMRI	B-P
lesions	O
.	O

2	O
J.	O
Magn	O
.	O

Reson	O
.	O

Imaging	O
2017	O
;	O
45:610-616	O
.	O

Do	O
post-trauma	O
symptoms	O
mediate	O
the	O
relation	O
between	O
neurobiological	O
stress	O
parameters	O
and	O
conduct	O
problems	O
in	O
girls	O
?	O
.	O

Attenuated	O
activity	O
of	O
stress-regulating	O
systems	O
has	O
consistently	O
been	O
reported	O
in	O
boys	O
with	O
conduct	O
problems	O
.	O

Results	O
in	O
studies	O
of	O
girls	O
are	O
inconsistent	O
,	O
which	O
may	O
result	O
from	O
the	O
high	O
prevalence	O
of	O
comorbid	O
post-trauma	O
symptoms	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
post-trauma	O
symptoms	O
as	O
a	O
potential	O
mediator	O
in	O
the	O
relation	O
between	O
stress-regulation	O
systems	O
functioning	O
and	O
conduct	O
problems	O
in	O
female	O
adolescents	O
.	O

The	O
sample	O
consisted	O
of	O
78	O
female	O
adolescents	O
(	O
mean	O
age	O
15.4	O
;	O
SD	O
1.1	O
)	O
admitted	O
to	O
a	O
closed	O
treatment	O
institution	O
.	O

The	O
diagnosis	B-P
of	O
disruptive	O
behaviour	O
disorder	O
(	O
DBD	O
)	O
was	O
assessed	O
by	O
a	O
structured	O
interview-	O
the	O
diagnostic	O
interview	O
schedule	O
for	O
children	O
version	O
IV	O
(	O
DISC-IV	O
)	O
.	O

To	O
assess	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
,	O
self-report	O
questionnaires	O
,	O
youth	O
self	O
report	O
(	O
YSR	O
)	O
and	O
the	O
trauma	O
symptom	O
checklist	O
for	O
Children	O
(	O
TSCC	O
)	O
were	O
used	O
.	O

The	O
cortisol	O
awakenings	O
response	O
(	O
CAR	O
)	O
measured	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
activity	O
,	O
whereas	O
autonomous	O
nervous	O
system	O
(	O
ANS	O
)	O
activity	O
was	O
assessed	O
by	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
pre-ejection	O
period	O
(	O
PEP	O
)	O
and	O
respiratory	O
sinus	O
arrhythmia	O
(	O
RSA	O
)	O
.	O

Independent	O
t-tests	O
were	O
used	O
to	O
compare	O
girls	O
with	O
and	O
without	O
DBD	O
,	O
while	O
path	O
analyses	O
tested	O
for	O
the	O
mediating	O
role	O
of	O
post-	O
trauma	O
symptoms	O
in	O
the	O
relation	O
between	O
stress	O
regulating	O
systems	O
and	O
externalizing	O
behaviour	O
.	O

Females	O
with	O
DBD	O
(	O
n	O
=	O
37	O
)	O
reported	O
significantly	O
higher	O
rates	O
of	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
than	O
girls	O
without	O
DBD	O
(	O
n	O
=	O
39	O
)	O
.	O

Path	O
analysis	O
found	O
no	O
relation	O
between	O
CAR	O
and	O
externalizing	O
behaviour	O
problems	O
.	O

With	O
regard	O
to	O
ANS	O
activity	O
,	O
positive	O
direct	O
effects	O
on	O
externalizing	O
behaviour	O
problems	O
were	O
present	O
for	O
HR	O
(	O
standardized	O
β	O
=	O
0.306	O
,	O
p	O
=	O
0.020	O
)	O
and	O
PEP	O
(	O
standardized	O
β	O
=	O
-0.323	O
,	O
p	O
=	O
0.031	O
)	O
,	O
though	O
not	O
for	O
RSA	O
.	O

Furthermore	O
,	O
no	O
relation-whether	O
direct	O
or	O
indirect-could	O
be	O
determined	O
from	O
post-trauma	O
symptoms	O
.	O

Present	O
findings	O
demonstrate	O
that	O
the	O
neurobiological	O
characteristics	O
of	O
female	O
externalizing	O
behaviour	O
differ	O
from	O
males	O
,	O
since	O
girls	O
showed	O
heightened	O
instead	O
of	O
attenuated	O
ANS	O
activity	O
.	O

While	O
the	O
prevalence	O
of	O
post-trauma	O
symptoms	O
was	O
high	O
in	O
girls	O
with	O
DBD	O
,	O
it	O
did	O
not	O
mediate	O
the	O
relation	O
between	O
stress	O
parameters	O
and	O
externalizing	O
behaviour	O
.	O

Clinical	O
implications	O
and	O
future	O
directions	O
are	O
discussed	O
.	O

Usefulness	O
of	O
Embolization	O
for	O
Iatrogenic	O
Dural	O
Arteriovenous	O
Fistula	O
Associated	O
with	O
Recurrent	O
Chronic	O
Subdural	O
Hematoma	O
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

Refractory	O
chronic	O
subdural	O
hematomas	O
due	O
to	O
iatrogenic	O
dural	O
arteriovenous	O
fistulas	O
(	O
dAVFs	O
)	O
are	O
difficult	O
to	O
treat	O
.	O

We	O
report	O
our	O
experience	O
and	O
propose	O
a	O
guideline	O
on	O
basis	O
of	O
a	O
literature	O
review	O
for	O
the	O
usefulness	O
of	O
embolization	O
of	O
middle	O
meningeal	O
artery	O
(	O
MMA	O
)	O
for	O
the	O
treatment	O
of	O
the	O
same	O
.	O

We	O
report	O
a	O
case	O
with	O
right	O
hemiparesis	O
and	O
aphasia	O
1	O
month	O
after	O
a	O
fall	O
from	O
a	O
bicycle	O
.	O

Computed	B-P
tomography	I-P
scan	I-P
of	O
the	O
head	O
showed	O
left	O
chronic	O
subdural	O
hematoma	O
,	O
which	O
was	O
evacuated	O
by	O
burr-hole	O
drainage	O
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
by	O
reaccumulation	O
within	O
short	O
period	O
of	O
time	O
.	O

On	O
superselective	B-P
digital	I-P
subtraction	I-P
angiography	I-P
of	O
MMA	O
,	O
iatrogenic	O
dAVF	O
was	O
found	O
on	O
left	O
side	O
.	O

We	O
embolized	O
successfully	O
it	O
using	O
n-butyl	O
cyanoacrylate	O
after	O
a	O
third	O
irrigation	O
.	O

No	O
reaccumulation	O
found	O
in	O
the	O
postoperative	O
period	O
or	O
at	O
last	O
follow-up	O
.	O

We	O
propose	O
treatment	O
protocol	O
based	O
on	O
our	O
experience	O
and	O
literature	O
review	O
.	O

Refractory	O
chronic	O
subdural	O
hematoma	O
with	O
reaccumulation	O
within	O
a	O
short	O
interval	O
should	O
be	O
subjected	O
to	O
digital	B-P
subtraction	I-P
angiography	I-P
of	O
the	O
MMA	O
.	O

Embolization	O
of	O
ipsilateral	O
MMA	O
is	O
safe	O
,	O
effective	O
,	O
and	O
a	O
useful	O
option	O
for	O
the	O
treatment	O
of	O
iatrogenic	O
dAVF	O
and	O
resolution	O
of	O
hematoma	O
.	O

Radiation	O
risk	O
of	O
breast	O
screening	O
in	O
England	O
with	O
digital	B-P
mammography	I-P
.	O

To	O
estimate	O
the	O
risks	O
and	O
benefits	O
of	O
breast	O
screening	O
in	O
terms	O
of	O
number	O
of	O
deaths	O
due	O
to	O
radiation-induced	O
cancers	O
and	O
the	O
number	O
of	O
lives	O
saved	O
owing	O
to	O
modern	O
screening	O
in	O
the	O
National	O
Health	O
Service	O
Breast	O
Screening	O
Programme	O
(	O
NHSBSP	O
)	O
in	O
England	O
.	O

Radiation	O
risk	O
model	O
,	O
patient	O
dose	O
data	O
and	O
data	O
from	O
national	O
screening	O
statistics	O
were	O
used	O
to	O
estimate	O
the	O
number	O
of	O
deaths	O
due	O
to	O
radiation-induced	O
breast	O
cancers	O
in	O
the	O
NHSBSP	O
in	O
England	O
.	O

Dose	O
and	O
dose	O
effectiveness	O
factors	O
(	O
DDREFs	O
)	O
equal	O
to	O
one	O
and	O
two	O
were	O
assumed	O
.	O

The	O
breast	O
cancer	O
mortality	O
reduction	O
in	O
the	O
invited	O
population	O
due	O
to	O
screening	O
and	O
the	O
percentage	O
of	O
females	O
diagnosed	O
with	O
symptomatic	O
breast	O
cancer	O
,	O
who	O
die	O
from	O
breast	O
cancer	O
,	O
were	O
collated	O
from	O
the	O
literature	O
.	O

The	O
number	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
was	O
calculated	O
.	O

Assuming	O
,	O
a	O
total	O
of	O
1,770,436	O
females	O
between	O
the	O
ages	O
of	O
50-70	O
years	O
were	O
screened	O
each	O
year	O
,	O
and	O
a	O
breast	O
cancer	O
mortality	O
reduction	O
of	O
20	O
%	O
due	O
to	O
screening	O
in	O
the	O
invited	O
population	O
,	O
the	O
number	O
of	O
screen-detected	O
cancers	O
were	O
14,872	O
annually	O
,	O
resulting	O
in	O
1071	O
lives	O
saved	O
.	O

Conversely	O
,	O
for	O
the	O
same	O
mortality	O
reduction	O
,	O
the	O
number	O
of	O
radiation-induced	O
cancer	O
s	O
was	O
36	O
and	O
18	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
,	O
respectively	O
.	O

This	O
resulted	O
in	O
seven	O
and	O
three	O
deaths	O
due	O
to	O
radiation-induced	O
cancers	O
annually	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
,	O
respectively	O
.	O

The	O
ratios	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
to	O
radiation-induced	O
cancers	O
were	O
30	O
:	O
1	O
and	O
60	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

The	O
ratios	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
to	O
deaths	O
due	O
to	O
radiation-induced	O
cancer	O
s	O
were	O
156	O
:	O
1	O
and	O
312	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

For	O
the	O
1.8	O
%	O
of	O
the	O
screening	O
population	O
with	O
very	O
thick	O
breasts	O
,	O
the	O
latter	O
ratios	O
decrease	O
to	O
94	O
:	O
1	O
and	O
187	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

The	O
breast	O
cancer	O
mortality	O
reduction	O
due	O
to	O
screening	O
greatly	O
outweighs	O
the	O
risk	O
of	O
death	O
due	O
to	O
radiation-induced	O
cancer	O
s.	O
Advances	O
in	O
knowledge	O
:	O
Estimation	O
of	O
the	O
radiation	O
risk	O
for	O
modern	O
breast	O
screening	O
in	O
England	O
using	O
digital	B-P
mammography	I-P
.	O

ACR	O
Appropriateness	O
Criteria	O
(	O
®	O
)	O
Radiologic	O
Management	O
of	O
Mesenteric	O
Ischemia	O
.	O

Mesenteric	O
vascular	O
insufficiency	O
is	O
a	O
serious	O
medical	O
condition	O
that	O
may	O
lead	O
to	O
bowel	O
infarction	O
,	O
morbidity	O
,	O
and	O
mortality	O
that	O
may	O
approach	O
50	O
%	O
.	O

Recommended	O
therapy	O
for	O
acute	O
mesenteric	O
ischemia	O
includes	O
aspiration	O
embolectomy	O
,	O
transcatheter	O
thrombolysis	O
,	O
and	O
angioplasty	O
with	O
or	O
without	O
stenting	O
for	O
the	O
treatment	O
of	O
underlying	O
arterial	O
stenosis	O
.	O

Nonocclusive	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
transarterial	O
infusion	O
of	O
vasodilators	O
such	O
as	O
nitroglycerin	O
,	O
papaverine	O
,	O
glucagon	O
,	O
and	O
prostaglandin	O
E1	O
.	O

Recommended	O
therapy	O
for	O
chronic	O
mesenteric	O
ischemia	O
includes	O
angioplasty	O
with	O
or	O
without	O
stent	O
placement	O
and	O
,	O
if	O
an	O
endovascular	O
approach	O
is	O
not	O
possible	O
,	O
surgical	O
bypass	O
or	O
endarterectomy	O
.	O

The	O
diagnosis	O
of	O
median	O
arcuate	O
ligament	O
syndrome	O
is	O
controversial	O
,	O
but	O
surgical	O
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	O
situation	O
.	O

Venous	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
systemic	O
anticoagulation	O
alone	O
.	O

Transhepatic	O
or	O
transjugular	O
superior	O
mesenteric	O
vein	O
catheterization	B-P
and	I-P
thrombolytic	I-P
infusion	I-P
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	O
,	O
condition	O
of	O
the	O
patient	O
,	O
and	O
response	O
to	O
systemic	O
anticoagulation	O
.	O

Adjunct	O
transjugular	O
intrahepatic	O
portosystemic	O
shunt	O
creation	O
can	O
be	O
considered	O
for	O
outflow	O
improvement	O
.	O

The	O
American	O
College	O
of	O
Radiology	O
Appropriateness	O
Criteria	O
are	O
evidence-based	O
guidelines	O
for	O
specific	O
clinical	O
conditions	O
that	O
are	O
reviewed	O
annually	O
by	O
a	O
multidisciplinary	O
expert	O
panel	O
.	O

The	O
guideline	O
development	O
and	O
revision	O
include	O
an	O
extensive	O
analysis	O
of	O
current	O
medical	O
literature	O
from	O
peer-reviewed	O
journals	O
and	O
the	O
application	O
of	O
well-established	O
methodologies	O
(	O
RAND	O
/	O
UCLA	O
Appropriateness	O
Method	O
and	O
Grading	O
of	O
Recommendations	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
or	O
GRADE	O
)	O
to	O
rate	O
the	O
appropriateness	O
of	O
imaging	B-P
and	O
treatment	O
procedures	O
for	O
specific	O
clinical	O
scenarios	O
.	O

In	O
those	O
instances	O
where	O
evidence	O
is	O
lacking	O
or	O
equivocal	O
,	O
expert	O
opinion	O
may	O
supplement	O
the	O
available	O
evidence	O
to	O
recommend	O
imaging	B-P
or	O
treatment	O
.	O

Development	O
of	O
(	O
111	O
)	O
In	O
-labeled	O
exendin	O
(	O
9-39	O
)	O
derivatives	O
for	O
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
imaging	I-P
of	O
insulinoma	O
.	O

Insulinoma	O
is	O
a	O
tumor	O
derived	O
from	O
pancreatic	O
β-cells	O
,	O
and	O
the	O
resulting	O
hyperinsulinemia	O
leads	O
to	O
characteristic	O
hypoglycemia	O
.	O

Recent	O
studies	O
have	O
reported	O
the	O
frequent	O
overexpression	O
of	O
glucagon-like	O
peptide-1	O
receptor	O
(	O
GLP-1R	O
)	O
in	O
human	O
insulinomas	O
,	O
suggesting	O
that	O
the	O
binding	O
of	O
a	O
radiolabeled	O
compound	O
to	O
GLP-1R	O
is	O
useful	O
for	O
the	O
imaging	B-P
of	O
such	O
tumors	O
.	O

Exendin	O
(	O
9-39	O
)	O
,	O
a	O
fragment	O
peptide	O
of	O
exendin-3	O
and	O
-4	O
,	O
binds	O
GLP-1R	O
with	O
high	O
affinity	O
and	O
acts	O
as	O
an	O
antagonist	O
.	O

Accordingly	O
,	O
radiolabeled	O
exendin	O
(	O
9-39	O
)	O
derivatives	O
have	O
also	O
been	O
investigated	O
as	O
insulinoma	O
imaging	O
probes	O
that	O
might	O
be	O
less	O
likely	O
to	O
induce	O
hypoglycemia	O
.	O

In	O
this	O
study	O
,	O
we	O
synthesized	O
a	O
novel	O
indium-111	O
(	O
(	O
111	O
)	O
In	O
)	O
-benzyl-diethylenetriaminepentaacetic	O
acid	O
(	O
(	O
111	O
)	O
In-BnDTPA	O
)	O
-conjugated	O
exendin	O
(	O
9-39	O
)	O
,	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
,	O
and	O
evaluated	O
its	O
utility	O
as	O
a	O
probe	O
for	O
the	O
SPECT	B-P
imaging	I-P
of	O
insulinoma	O
.	O

natIn-BnDTPA-exendin	O
(	O
9-39	O
)	O
exhibited	O
a	O
high	O
affinity	O
for	O
GLP-1R	O
(	O
IC50=2.5nM	O
)	O
,	O
stability	O
in	O
plasma	O
,	O
and	O
a	O
specific	O
activity	O
that	O
improved	O
following	O
reactions	O
with	O
a	O
solvent	O
and	O
solubilizer	O
.	O

Regarding	O
the	O
in	O
vivo	O
biodistribution	O
of	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
in	O
INS-1	O
tumor	O
-bearing	O
mice	O
,	O
high	O
uptake	O
levels	O
were	O
observed	O
in	O
tumors	O
(	O
14.6	O
%	O
ID/g	O
at	O
15min	O
)	O
,	O
with	O
corresponding	O
high	O
tumor	O
-to-	O
blood	O
(	O
T/B	O
)	O
,	O
tumor	O
-to-	O
muscle	O
(	O
T/M	O
)	O
,	O
and	O
tumor	O
-to-	O
pancreas	O
(	O
T/P	O
)	O
ratios	O
(	O
T/B	O
=2.55	O
,	O
T/M	O
=22.7	O
,	O
T/P	O
=2.7	O
at	O
1h	O
)	O
.	O

The	O
pre-administration	O
of	O
excess	O
nonradioactive	O
exendin	O
(	O
9-39	O
)	O
significantly	O
reduced	O
accumulation	O
in	O
both	O
the	O
tumor	O
and	O
pancreas	O
(	O
76	O
%	O
and	O
68	O
%	O
inhibition	O
,	O
respectively	O
)	O
at	O
1h	O
after	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
injection	O
,	O
indicating	O
that	O
the	O
GLP-1R	O
mediated	O
a	O
majority	O
of	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
uptake	O
in	O
the	O
tumor	O
and	O
pancreas	O
.	O

Finally	O
,	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
SPECT/CT	B-P
studies	I-P
in	O
mice	O
yielded	O
clear	O
images	O
of	O
tumors	O
at	O
30min	O
post-injection	O
.	O

These	O
results	O
suggest	O
that	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
could	O
be	O
a	O
useful	O
SPECT	B-P
molecular	O
imaging	O
probe	O
for	O
the	O
detection	O
and	O
exact	O
localization	O
of	O
insulinomas	O
.	O

Quantitative	O
phase	B-P
imaging	I-P
by	O
single-shot	O
Hilbert-Huang	O
phase	O
microscopy	O
.	O

We	O
propose	O
a	O
novel	O
single-shot	O
Hilbert-Huang	O
transform-based	O
algorithm	O
applied	O
to	O
digital	B-P
holographic	I-P
microscopy	I-P
(	O
DHM	B-P
)	O
for	O
robust	O
,	O
fast	O
,	O
and	O
accurate	O
single-shot	O
quantitative	O
phase	B-P
imaging	I-P
in	O
on-axis	O
and	O
off-axis	O
configurations	O
.	O

Fringe	O
pattern	O
with	O
possible	O
defects	O
and	O
closed	O
fringes	O
are	O
adaptively	O
filtered	O
and	O
accurately	O
phase	O
demodulated	O
using	O
local	O
fringe	O
direction	O
estimation	O
.	O

Experimental	O
validation	O
of	O
the	O
proposed	O
techniques	O
is	O
presented	O
as	O
the	O
DHM	B-P
study	O
of	O
microbeads	O
and	O
red	O
blood	O
cells	O
phase	O
samples	O
.	O

Obtained	O
results	O
compare	O
very	O
favorably	O
with	O
the	O
Fourier	O
approach	O
(	O
off-axis	O
)	O
and	O
temporal	O
phase	O
shifting	O
(	O
on-axis	O
)	O
.	O

Prevalence	O
of	O
Coronary	O
Artery	O
to	O
Pulmonary	O
Artery	O
Collaterals	O
in	O
Patients	O
with	O
Chronic	O
Thromboembolic	O
Pulmonary	O
Hypertension	O
:	O
Retrospective	O
Analysis	O
from	O
a	O
Single	O
Center	O
.	O

Background	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
in	O
patients	O
with	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
(	O
CTEPH	O
)	O
by	O
retrospectively	O
evaluating	O
coronary	B-P
angiograms	I-P
of	O
eligible	O
consecutive	O
patients	O
who	O
had	O
undergone	O
pulmonary	O
endarterectomy	O
(	O
PEA	O
)	O
.	O

We	O
also	O
aimed	O
to	O
evaluate	O
predictors	O
and	O
potential	O
clinical	O
associates	O
of	O
these	O
collaterals	O
.	O

Methods	O
Coronary	B-P
angiograms	I-P
of	O
83	O
consecutive	O
CTEPH	O
patients	O
who	O
had	O
undergone	O
coronary	B-P
angiography	I-P
before	O
PEA	O
operation	O
between	O
January	O
1	O
,	O
2012	O
and	O
June	O
1	O
,	O
2015	O
were	O
retrospectively	O
evaluated	O
for	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
.	O

Medical	O
records	O
of	O
all	O
patients	O
were	O
also	O
retrospectively	O
reviewed	O
for	O
demographic	O
information	O
,	O
cardiovascular	O
risk	O
factors	O
,	O
preoperative	O
right	O
heart	O
catheterization	O
reports	O
,	O
operation	O
reports	O
,	O
and	O
follow-up	O
data	O
.	O

Data	O
of	O
CTEPH	O
patients	O
with	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
were	O
compared	O
with	O
data	O
of	O
CTEPH	O
patients	O
without	O
such	O
collaterals	O
.	O

Results	O
There	O
were	O
15	O
patients	O
(	O
18.1	O
%	O
)	O
with	O
definite	O
and	O
4	O
patients	O
(	O
4.8	O
%	O
)	O
with	O
probable	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
among	O
the	O
study	O
population	O
.	O

CTEPH	O
patients	O
with	O
collaterals	O
had	O
higher	O
preoperative	O
pulmonary	O
artery	O
pressures	O
,	O
higher	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
and	O
lower	O
cardiac	O
index	O
values	O
compared	O
with	O
CTEPH	O
patients	O
without	O
collaterals	O
.	O

However	O
,	O
CTEPH	O
patients	O
with	O
collaterals	O
displayed	O
higher	O
amount	O
of	O
reduction	O
in	O
PVR	O
after	O
PEA	O
compared	O
with	O
patients	O
without	O
collaterals	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
regarding	O
incidence	O
of	O
reperfusion	O
injury	O
or	O
mortality	O
.	O

Conclusion	O
Prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
seems	O
to	O
be	O
increased	O
in	O
our	O
CTEPH	O
patients	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
is	O
often	O
combined	O
with	O
proximal	O
disease	O
with	O
the	O
possibility	O
of	O
increased	O
reduction	O
of	O
PVR	O
after	O
PEA	O
operation	O
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose-Escalated	O
Chemoradiation	O
for	O
Locally	O
Advanced	O
Unresectable	O
Non-Small	O
Cell	O
Lung	O
Cancer	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
patients	O
treated	O
with	O
dose-escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

The	O
records	O
of	O
170	O
stage	O
III	O
NSCLC	O
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
patients	O
received	O
four-dimensional	B-P
CT	I-P
simulation	I-P
scan	I-P
and	O
had	O
respiratory	O
gating	O
if	O
tumor	O
movement	O
exceeded	O
5	O
mm	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	O
distant	O
metastasis	O
(	O
FFDM	O
)	O
were	O
calculated	O
using	O
log-rank	O
and	O
Cox	O
regression	O
analysis	O
.	O

For	O
the	O
present	O
series	O
of	O
patients	O
,	O
median	O
follow-up	O
was	O
36.6	O
months	O
,	O
median	O
survival	O
27.4	O
months	O
,	O
and	O
the	O
2-	O
and	O
4-	O
year	O
OS	O
was	O
56.0	O
and	O
30.7	O
%	O
,	O
respectively	O
.	O

The	O
4-	O
year	O
LRC	O
and	O
FFDM	O
were	O
43.9	O
and	O
40.7	O
%	O
,	O
respectively	O
.	O

No	O
benefit	O
was	O
associated	O
with	O
irradiation	O
doses	O
above	O
66	O
Gy	O
in	O
OS	O
(	O
p	O
=	O
0.586	O
)	O
,	O
LRC	O
(	O
p	O
=	O
0.440	O
)	O
,	O
or	O
FFDM	O
(	O
p	O
=	O
0.230	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	O
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-0.011	O
)	O
.	O

On	O
multivariable	O
analysis	O
,	O
PTV	O
above	O
450	O
cc	O
(	O
52.2	O
vs.	O
25.3	O
months	O
,	O
p	O
<	O
0.001	O
)	O
and	O
esophageal	O
V60	O
>	O
20	O
%	O
(	O
43.8	O
vs.	O
21.3	O
months	O
,	O
p	O
=	O
-0.01	O
)	O
were	O
associated	O
with	O
lower	O
survival	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	O
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
was	O
reduced	O
if	O
lung	O
V5	O
was	O
≤65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
esophagitis	O
was	O
reduced	O
if	O
V60	O
≤	O
20	O
%	O
(	O
62	O
vs.	O
81.3	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

The	O
use	O
of	O
intensity-modulated	O
radiation	O
therapy	O
was	O
more	O
frequent	O
in	O
stage	O
IIIB	O
compared	O
to	O
stage	O
IIIA	O
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose-escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	O
and	O
IIIB	O
NSCLC	O
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy	O
.	O

Furthermore	O
,	O
maintaining	O
low	O
esophageal	O
V60	O
and	O
lung	O
V5	O
were	O
associated	O
with	O
lower	O
morbidity	O
and	O
mortality	O
.	O

Interbacterial	O
Adhesion	O
Networks	O
within	O
Early	O
Oral	O
Biofilms	O
of	O
Single	O
Human	O
Hosts	O
.	O

Specific	O
interbacterial	O
adhesion	O
,	O
termed	O
coaggregation	O
,	O
is	O
well	O
established	O
for	O
three	O
early	O
colonizers	O
of	O
the	O
plaque	O
biofilm	O
:	O
streptococci	O
,	O
actinomyces	O
,	O
and	O
veillonellae	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
interactions	O
of	O
other	O
early	O
colonizers	O
and	O
about	O
the	O
extent	O
of	O
interactions	O
within	O
the	O
bacterial	O
community	O
from	O
a	O
single	O
host	O
.	O

To	O
address	O
these	O
gaps	O
,	O
subject	O
-	O
specific	O
culture	B-P
collections	I-P
from	O
two	O
individuals	O
were	O
established	O
using	O
an	O
intraoral	O
biofilm	O
retrieval	O
device	O
.	O

Molecular	O
taxonomy	O
(	O
Human	O
Oral	O
Microbe	O
Identification	O
Microarray	O
[	O
HOMIM	O
]	O
)	O
analysis	O
of	O
biofilm	O
samples	O
confirmed	O
the	O
integrity	O
and	O
completeness	O
of	O
the	O
collections	B-P
.	O

HOMIM	O
analysis	O
verified	O
the	O
isolation	O
of	O
Streptococcus	O
gordonii	O
and	O
S.	O
anginosus	O
from	O
only	O
one	O
subject	O
,	O
as	O
well	O
as	O
isolation	O
of	O
a	O
previously	O
uncultivated	O
streptococcal	O
phylotype	O
from	O
the	O
other	O
subject	O
.	O

Strains	O
representative	O
of	O
clonal	O
diversity	O
within	O
each	O
collection	O
were	O
further	O
characterized	O
.	O

Greater	O
than	O
70	O
%	O
of	O
these	O
streptococcal	O
strains	O
from	O
each	O
subject	O
coaggregated	O
with	O
at	O
least	O
one	O
other	O
coisolate	O
.	O

One-third	O
of	O
the	O
strains	O
carry	O
a	O
known	O
coaggregation	O
mediator	O
:	O
receptor	O
polysaccharide	O
(	O
RPS	O
)	O
.	O

Almost	O
all	O
nonstreptococcal	O
isolates	O
coaggregated	O
with	O
other	O
coisolates	O
.	O

Importantly	O
,	O
certain	O
Rothia	O
strains	O
demonstrated	O
more	O
coaggregations	O
with	O
their	O
coisolated	O
bacteria	O
than	O
did	O
any	O
Streptococcus	O
or	O
Actinomyces	O
strain	O
,	O
and	O
certain	O
Haemophilus	O
isolates	O
participated	O
in	O
twice	O
as	O
many	O
.	O

Confocal	O
microscopy	O
of	O
undisturbed	O
biofilms	O
showed	O
that	O
Rothia	O
and	O
Haemophilus	O
each	O
occur	O
in	O
small	O
multispecies	O
microcolonies	O
.	O

However	O
,	O
in	O
confluent	O
high	O
-	O
biomass	O
regions	O
,	O
Rothia	O
occurred	O
in	O
islands	O
whereas	O
Haemophilus	O
was	O
distributed	O
throughout	O
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
that	O
coaggregation	O
networks	O
within	O
an	O
individual	O
's	O
oral	O
microflora	O
are	O
extensive	O
and	O
that	O
Rothia	O
and	O
Haemophilus	O
can	O
be	O
important	O
initiators	O
of	O
cell-cell	O
interactions	O
in	O
the	O
early	O
biofilm	O
.IMPORTANCE	O
Extensive	O
involvement	O
of	O
specific	O
interbacterial	O
adhesion	O
in	O
dental	O
plaque	O
biofilm	O
formation	O
has	O
been	O
postulated	O
based	O
on	O
in	O
vitro	O
coaggregation	O
between	O
oral	O
bacteria	O
from	O
culture	O
collections	O
that	O
are	O
not	O
subject	O
specific	O
.	O

In	O
the	O
present	O
study	O
,	O
subject	O
-	O
specific	O
culture	O
collections	O
were	O
obtained	O
from	O
early	O
plaque	O
biofilm	O
of	O
two	O
volunteers	O
,	O
and	O
coaggregations	O
within	O
each	O
culture	O
collection	O
were	O
assayed	O
.	O

Coaggregations	O
,	O
several	O
of	O
which	O
involved	O
a	O
coaggregation	O
-mediating	O
cell	O
surface	O
molecule	O
known	O
from	O
well-studied	O
streptococci	O
,	O
were	O
widespread	O
.	O

Unexpectedly	O
,	O
the	O
little-studied	O
organisms	O
Haemophilus	O
and	O
Rothia	O
participated	O
in	O
the	O
greatest	O
numbers	O
of	O
interactions	O
with	O
community	O
members	O
;	O
these	O
two	O
organisms	O
showed	O
different	O
distributions	O
within	O
the	O
undisturbed	O
biofilm	O
.	O

The	O
data	O
show	O
that	O
coaggregation	O
networks	O
encompass	O
most	O
organisms	O
within	O
the	O
biofilm	O
community	O
of	O
each	O
individual	O
,	O
and	O
they	O
indicate	O
prominent	O
participation	O
of	O
organisms	O
such	O
as	O
Haemophilus	O
and	O
Rothia	O
in	O
early	O
plaque	O
biofilm	O
formation	O
.	O

Beneficial	O
effects	O
of	O
dark	O
chocolate	O
on	O
exercise	O
capacity	O
in	O
sedentary	O
subjects	O
:	O
underlying	O
mechanisms	O
.	O

A	O
double	O
blind	O
,	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
.	O

In	O
heart	O
failure	O
patients	O
the	O
consumption	O
of	O
(	O
-	O
)	O
-epicatechin	O
(	O
(	O
-	O
)	O
-Epi	O
)	O
-rich	O
cocoa	O
can	O
restore	O
skeletal	O
muscle	O
(	O
SkM	O
)	O
mitochondrial	O
structure	O
and	O
decrease	O
biomarkers	O
of	O
oxidative	O
stress	O
.	O

However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	O
on	O
exercise	O
capacity	O
and	O
underlying	O
mechanisms	O
in	O
normal	O
,	O
sedentary	O
subjects	O
.	O

Twenty	O
normal	O
,	O
sedentary	O
subjects	O
(	O
∼50	O
years	O
old	O
)	O
were	O
randomized	O
to	O
placebo	O
or	O
dark	O
chocolate	O
(	O
DC	O
)	O
groups	O
and	O
consumed	O
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	O
.	O

Subjects	O
underwent	O
before	O
and	O
after	O
treatment	O
,	O
bicycle	B-P
ergometry	I-P
to	O
assess	O
VO2	O
max	O
and	O
work	O
,	O
SkM	B-P
biopsy	I-P
to	O
assess	O
changes	O
in	O
mitochondrial	O
density	O
,	O
function	O
and	O
oxidative	O
stress	O
and	O
blood	B-P
sampling	I-P
to	O
assess	O
metabolic	O
endpoints	O
.	O

Seventeen	O
subjects	O
completed	O
the	O
trial	O
.	O

In	O
the	O
DC	O
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	O
max	O
increased	O
(	O
17	O
%	O
increase	O
,	O
p	O
=	O
0.056	O
)	O
as	O
well	O
as	O
maximum	O
work	O
(	O
watts	O
)	O
achieved	O
(	O
p	O
=	O
0.026	O
)	O
with	O
no	O
changes	O
with	O
placebo	O
(	O
n	O
=	O
8	O
)	O
.	O

The	O
DC	O
group	O
evidenced	O
increases	O
in	O
HDL	O
levels	O
(	O
p	O
=	O
0.005	O
)	O
and	O
decreased	O
triglycerides	O
(	O
p	O
=	O
0.07	O
)	O
.	O

With	O
DC	O
,	O
SkM	O
evidenced	O
significant	O
increases	O
in	O
protein	O
levels	O
for	O
LKB1	O
,	O
AMPK	O
and	O
PGC1α	O
and	O
in	O
their	O
active	O
forms	O
(	O
phosphorylated	O
AMPK	O
and	O
LKB1	O
)	O
as	O
well	O
as	O
in	O
citrate	O
synthase	O
activity	O
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	O
density	O
.	O

With	O
DC	O
,	O
significant	O
increases	O
in	O
SkM	O
reduced	O
glutathione	O
levels	O
and	O
decreases	O
in	O
protein	O
carbonylation	O
were	O
observed	O
.	O

Improvements	O
in	O
maximum	O
work	O
achieved	O
and	O
VO2	O
max	O
may	O
be	O
due	O
to	O
DC	O
activation	O
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	O
mitochondria	O
efficiency	O
.	O

Larger	O
clinical	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
observations	O
.	O

Clinical	O
outcomes	O
of	O
ERCP	B-P
-related	O
retroperitoneal	O
perforations	O
.	O

Endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
-related	O
perforations	O
represent	O
rare	O
but	O
often	O
severe	O
conditions	O
.	O

While	O
lesions	O
with	O
intraperitoneal	O
perforation	O
have	O
an	O
almost	O
imperative	O
indication	O
to	O
surgery	O
,	O
whether	O
or	O
not	O
to	O
manage	O
retroperitoneal	O
perforations	O
surgically	O
is	O
still	O
an	O
area	O
of	O
debate	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
review	O
the	O
available	O
clinical	O
evidence	O
on	O
the	O
operatively	O
and	O
medically	O
treated	O
ERCP	B-P
-related	O
retroperitoneal	O
perforations	O
.	O

From	O
MEDLINE	O
/	O
PubMed	O
databases	O
137	O
patients	O
with	O
retroperitoneal	O
perforation	O
were	O
included	O
from	O
12	O
studies	O
that	O
met	O
the	O
selection	O
criteria	O
for	O
data	O
investigation	O
and	O
analysis	O
.	O

Twenty-four	O
patients	O
were	O
treated	O
by	O
prompt	O
surgery	O
;	O
113	O
were	O
primarily	O
managed	O
conservatively	O
and	O
about	O
20	O
%	O
of	O
these	O
patients	O
required	O
surgery	O
subsequently	O
.	O

Overall	O
,	O
the	O
morbidity	O
and	O
mortality	O
were	O
15.4	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
.	O

Although	O
most	O
patients	O
with	O
retroperitoneal	O
perforation	O
may	O
benefit	O
from	O
a	O
non-operative	O
management	O
,	O
a	O
considerable	O
number	O
of	O
patients	O
fail	O
to	O
respond	O
to	O
medical	O
treatment	O
and	O
require	O
surgery	O
afterwards	O
.	O

Identifying	O
those	O
patients	O
who	O
are	O
at	O
highest	O
risk	O
of	O
poor	O
outcome	O
after	O
conservative	O
treatment	O
should	O
be	O
considered	O
a	O
research	O
priority	O
.	O

Diagnostic	O
Yield	O
of	O
Routine	O
Stress	B-P
Testing	I-P
in	O
Low	O
and	O
Intermediate	O
Risk	O
Chest	O
Pain	O
Patients	O
Under	O
40	O
Years	O
:	O
A	O
Systematic	O
Review	O
.	O

Chest	O
pain	O
is	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
for	O
presentation	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
.	O

The	O
majority	O
of	O
patients	O
will	O
undergo	O
diagnostic	B-P
workup	I-P
including	O
stress	B-P
testing	I-P
to	O
rule	O
out	O
an	O
acute	O
coronary	O
syndrome	O
,	O
but	O
very	O
few	O
patients	O
will	O
be	O
diagnosed	O
with	O
a	O
cardiac	O
cause	O
for	O
their	O
pain	O
.	O

Patients	O
under	O
40	O
years	O
represent	O
a	O
lower	O
risk	O
group	O
in	O
which	O
routine	O
stress	B-P
testing	I-P
may	O
be	O
of	O
little	O
benefit	O
.	O

This	O
systematic	O
review	O
sought	O
to	O
determine	O
the	O
diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
chest	O
pain	O
patients	O
under	O
40	O
years	O
.	O

Electronic	O
databases	O
were	O
searched	O
for	O
relevant	O
studies	O
.	O

The	O
quality	O
of	O
the	O
included	O
primary	O
studies	O
was	O
assessed	O
using	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
evidence	O
hierarchy	O
and	O
the	O
McMaster	O
Critical	O
Appraisal	O
Tool	O
for	O
Quantitative	O
Studies	O
.	O

Descriptive	O
statistics	O
summarized	O
the	O
findings	O
.	O

Five	O
primary	O
studies	O
were	O
included	O
in	O
the	O
review	O
(	O
all	O
level	O
III-3	O
evidence	O
)	O
;	O
7	O
additional	O
sources	O
of	O
relevant	O
data	O
were	O
also	O
included	O
.	O

Diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
patients	O
under	O
40	O
years	O
is	O
reported	O
between	O
0	O
%	O
and	O
1.1	O
%	O
.	O

Combined	O
data	O
from	O
included	O
primary	O
studies	O
demonstrated	O
just	O
4	O
out	O
of	O
1683	O
true	O
positive	O
stress	B-P
tests	I-P
(	O
0.24	O
%	O
)	O
,	O
only	O
one	O
of	O
which	O
was	O
definitively	O
confirmed	O
by	O
coronary	B-P
angiogram	I-P
;	O
additional	O
data	O
sources	O
identified	O
just	O
1	O
out	O
of	O
310	O
true	O
positive	O
stress	B-P
tests	I-P
(	O
0.32	O
%	O
)	O
.	O

Diagnostic	O
yield	O
of	O
routine	O
stress	B-P
testing	I-P
in	O
low	O
-	O
and	O
intermediate-risk	O
chest	O
pain	O
patients	O
under	O
40	O
years	O
is	O
low	O
.	O

However	O
,	O
better	O
quality	O
studies	O
are	O
required	O
to	O
be	O
able	O
to	O
draw	O
definitive	O
conclusions	O
.	O

Effects	O
of	O
obesity	O
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	O
,	O
adipose	O
tissue	O
and	O
liver	O
:	O
study	O
in	O
the	O
experimental	O
model	O
of	O
Zucker	O
rats	O
.	O

Suppression	O
of	O
tumorigenicity	O
2	O
(	O
ST2	O
)	O
mediates	O
the	O
effect	O
of	O
Interleukin-33	O
(	O
IL-33	O
)	O
.	O

Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	O
between	O
IL-33	O
/	O
ST2	O
and	O
obesity	O
.	O

We	O
aimed	O
to	O
investigate	O
effects	O
of	O
obesity	O
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	O
,	O
adipose	O
tissue	O
and	O
liver	O
in	O
a	O
rodent	O
model	O
of	O
obesity	O
.	O

The	O
relationship	O
of	O
cardiac	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
with	O
natriuretic	O
peptides	O
(	O
NPs	O
)	O
system	O
and	O
inflammatory	O
mediators	O
was	O
also	O
studied	O
.	O

mRNA	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
was	O
evaluated	O
in	O
cardiac	B-P
,	O
adipose	O
and	O
hepatic	B-P
biopsies	I-P
from	O
obese	O
Zucker	O
rats	O
(	O
O	O
)	O
and	O
controls	O
(	O
CO	O
)	O
.	O

Expression	O
levels	O
of	O
sST2	O
was	O
significantly	O
lower	O
in	O
O	O
rats	O
compared	O
with	O
CO	O
(	O
p	O
<	O
0.05	O
)	O
in	O
all	O
tissues	O
.	O

Besides	O
,	O
the	O
mRNA	O
levels	O
of	O
IL-33	O
decreased	O
significant	O
in	O
fat	O
of	O
O	O
respect	O
to	O
CO	O
,	O
while	O
,	O
expression	O
levels	O
of	O
ST2L	O
was	O
significantly	O
higher	O
in	O
liver	O
of	O
CO	O
than	O
in	O
O	O
.	O

A	O
strong	O
relationship	O
of	O
IL-33	O
/	O
ST2	O
with	O
NPs	O
and	O
classical	O
inflammatory	O
mediators	O
was	O
observed	O
in	O
cardiac	O
tissue	O
.	O

Expression	O
of	O
sST2	O
in	O
cardiac	O
,	O
adipose	O
and	O
liver	O
tissue	O
decreased	O
in	O
O	O
compared	O
with	O
controls	O
,	O
suggesting	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
system	O
in	O
molecular	O
mechanisms	O
of	O
obesity	O
.	O

The	O
strong	O
relationships	O
with	O
NP	O
systems	O
and	O
inflammatory	O
mediators	O
could	O
suggest	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
in	O
molecular	O
pathways	O
leading	O
to	O
cardiac	O
dysfunction	O
and	O
inflammation	O
associated	O
with	O
obesity	O
.	O

Changes	O
in	O
the	O
Dermal	O
Structure	O
during	O
Cultured	O
Epidermal	O
Autograft	O
Engraftment	O
Process	O
.	O

The	O
use	O
of	O
cultured	O
epithelial	O
autografts	O
for	O
the	O
treatment	O
of	O
extensive	O
burn	O
wounds	O
has	O
become	O
popular	O
in	O
recent	O
years	O
.	O

We	O
examined	O
extensive	O
burn	O
wounds	O
in	O
14	O
patients	O
by	O
using	O
a	O
combination	O
of	O
autograft	O
and	O
cultured	O
epithelial	O
autografts	O
developed	O
in	O
Japan	O
(	O
JACE	O
)	O
.	O

We	O
undertook	O
a	O
skin	B-P
biopsy	I-P
at	O
2	O
,	O
4	O
,	O
and	O
6	O
weeks	O
after	O
transplantation	O
with	O
JACE	O
.	O

By	O
using	O
electron	O
microscopy	O
we	O
observed	O
the	O
engraftment	O
process	O
.	O

In	O
transmission	O
electron	O
microscope	O
findings	O
,	O
we	O
recognized	O
the	O
engraftment	O
process	O
of	O
JACE	O
.	O

Keratinocytes	O
matured	O
gradually	O
.	O

Collagen	O
fibers	O
formed	O
thick	O
bundles	O
in	O
the	O
dermis	O
layer	O
.	O

In	O
scanning	O
electron	O
microscope	O
findings	O
,	O
we	O
observed	O
papillary	O
dermis	O
development	O
on	O
the	O
artificial	O
dermis	O
.	O

After	O
managing	O
wound	O
bed	O
preparation	O
by	O
using	O
artificial	O
dermis	O
,	O
we	O
were	O
able	O
to	O
recognize	O
the	O
good	O
result	O
of	O
grafting	O
JACE	O
on	O
meshed	O
6:1	O
split	O
thickness	O
autografts	O
.	O

This	O
is	O
because	O
the	O
auto	O
dermis	O
from	O
autograft	O
extended	O
under	O
the	O
JACE	O
,	O
binding	O
between	O
JACE	O
,	O
and	O
the	O
dermis	O
became	O
strong	O
.	O

Effect	O
of	O
Low	O
-	O
Dose	O
MDCT	B-P
and	O
Iterative	B-P
Reconstruction	I-P
on	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
dose	O
multi	B-P
detector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
combination	O
with	O
statistical	B-P
iterative	I-P
reconstruction	I-P
algorithms	O
on	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O

Twelve	O
donated	O
vertebrae	O
were	O
scanned	B-P
with	O
the	O
routine	O
radiation	B-P
exposure	I-P
used	O
in	O
our	O
department	O
(	O
standard-dose	O
)	O
and	O
a	O
low	O
-	O
dose	O
protocol	O
.	O

Reconstructions	O
were	O
performed	O
with	O
filtered	B-P
backprojection	I-P
(	O
FBP	B-P
)	O
and	O
maximum-likelihood	O
based	O
statistical	B-P
iterative	I-P
reconstruction	I-P
(	O
SIR	B-P
)	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O
assessed	O
and	O
statistically	O
compared	O
for	O
each	O
reconstruction	O
.	O

Moreover	O
,	O
fracture	O
loads	O
of	O
the	O
vertebrae	O
were	O
biomechanically	B-P
determined	O
and	O
correlated	O
to	O
the	O
assessed	O
microstructure	O
parameters	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O
on	O
low	O
-	O
dose	O
MDCT	B-P
and	O
SIR	B-P
significantly	O
correlated	O
with	O
vertebral	O
bone	O
strength	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
microstructure	O
parameters	O
calculated	O
on	O
low	O
-	O
dose	O
SIR	B-P
and	O
standard	O
-	O
dose	O
FBP	B-P
images	O
.	O

However	O
,	O
the	O
results	O
revealed	O
a	O
strong	O
dependency	O
on	O
the	O
regularization	O
strength	O
applied	O
during	O
SIR	B-P
.	O

It	O
was	O
observed	O
that	O
stronger	O
regularization	O
might	O
corrupt	O
the	O
microstructure	O
analysis	O
,	O
because	O
the	O
trabecular	O
structure	O
is	O
a	O
very	O
small	O
detail	O
that	O
might	O
get	O
lost	O
during	O
the	O
regularization	O
process	O
.	O

As	O
a	O
consequence	O
,	O
the	O
introduction	O
of	O
SIR	B-P
for	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O
a	O
specific	O
optimization	O
of	O
the	O
regularization	O
parameters	O
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
approaches	O
,	O
superior	O
noise	O
-	O
resolution	O
trade-offs	O
can	O
be	O
found	O
with	O
the	O
proposed	O
methods	O
.	O

Assessment	O
of	O
transient	B-P
elastography	I-P
in	O
Japanese	O
patients	O
with	O
non-alcoholic	O
fatty	O
liver	O
disease	O
.	O

Transient	B-P
elastography	I-P
(	O
TE	B-P
)	O
is	O
a	O
non-invasive	O
method	O
for	O
predicting	O
liver	O
fibrosis	O
.	O

However	O
,	O
there	O
are	O
limited	O
data	O
regarding	O
the	O
performance	O
of	O
TE	B-P
in	O
Japanese	O
patients	O
with	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
association	O
between	O
liver	O
stiffness	O
measurement	O
(	O
LSM	O
)	O
by	O
TE	B-P
and	O
liver	O
fibrosis	O
stage	O
,	O
and	O
define	O
a	O
cut-off	O
value	O
for	O
predicting	O
liver	O
fibrosis	O
.	O

A	O
total	O
of	O
171	O
Japanese	O
patients	O
with	O
biopsy	B-P
-	O
proven	O
NAFLD	O
underwent	O
LSM	O
using	O
TE	B-P
with	O
FibroScan	B-P
.	O

The	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
LSM	O
and	O
other	O
non-invasive	O
markers	O
of	O
liver	O
fibrosis	O
were	O
compared	O
to	O
determine	O
the	O
most	O
accurate	O
method	O
of	O
predicting	O
liver	O
fibrosis	O
.	O

Liver	O
stiffness	O
measurement	O
significantly	O
correlated	O
with	O
fibrosis	O
stage	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
areas	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
LSM	O
for	O
fibrosis	O
stage	O
≥1	O
and	O
≥3	O
was	O
0.85	O
and	O
0.91	O
,	O
respectively	O
and	O
were	O
higher	O
than	O
those	O
of	O
the	O
aspartate	O
aminotransferase	O
/	O
alanine	O
aminotransferase	O
ratio	O
,	O
aspartate	O
aminotransferase	O
to	O
platelet	O
ratio	O
index	O
,	O
fibrosis-4	O
index	O
,	O
and	O
NAFLD	O
fibrosis	O
score	O
.	O

The	O
best	O
cut-off	O
values	O
of	O
LSM	O
fibrosis	O
stage	O
≥1	O
and	O
≥3	O
were	O
7.2	O
kPa	O
(	O
sensitivity	O
78.5	O
%	O
,	O
specificity	O
78.3	O
%	O
)	O
and	O
10.0	O
kPa	O
(	O
sensitivity	O
89.5	O
%	O
,	O
specificity	O
87.6	O
%	O
)	O
,	O
respectively	O
.	O

The	O
combination	O
of	O
LSM	O
(	O
≥10	O
kPa	O
)	O
and	O
type	O
IV	O
collagen	O
7	O
s	O
(	O
≥6.0	O
ng/mL	O
)	O
had	O
a	O
specificity	O
of	O
97.6	O
%	O
for	O
advanced	O
fibrosis	O
.	O

The	O
LSM	O
in	O
patients	O
with	O
high	O
alanine	O
aminotransferase	O
levels	O
or	O
high	O
body	O
mass	O
index	O
was	O
associated	O
with	O
false	O
positive	O
results	O
regarding	O
advanced	O
fibrosis	O
.	O

In	O
NAFLD	O
patients	O
,	O
TE	B-P
has	O
excellent	O
utility	O
for	O
the	O
assessment	O
of	O
liver	O
fibrosis	O
,	O
particularly	O
for	O
advanced	O
stage	O
cases	O
.	O

The	O
cut-off	O
value	O
of	O
LSM	O
by	O
TE	B-P
for	O
predicting	O
liver	O
fibrosis	O
stage	O
≥3	O
is	O
10.0	O
kPa	O
in	O
Japanese	O
NAFLD	O
patients	O
.	O

Nontoxic	O
Formulations	O
of	O
Scintillation	O
Nanocrystals	O
for	O
Use	O
as	O
X-ray	B-P
Computed	I-P
Tomography	I-P
Contrast	O
Agents	O
.	O

X-ray	B-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	O
imaging	B-P
techniques	I-P
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X-ray	O
device	O
and	O
contrast	O
enhancement	O
technologies	O
.	O

The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	O
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	O
for	O
X-ray	B-P
,	O
radiation	O
,	O
and	O
CT	B-P
imaging	I-P
,	O
because	O
of	O
the	O
high	O
X-ray	B-P
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O

We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	O
(	O
CWO	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly	O
(	O
ethylene	O
glycol-b-d	O
,	O
l-lactic	O
acid	O
)	O
(	O
PEG-PLA	O
)	O
block	O
copolymer	O
(	O
BCP	O
)	O
capsule	O
.	O

We	O
show	O
that	O
these	O
PEG-PLA	O
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
CT	B-P
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	O
-based	O
radiocontrast	O
agents	O
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	O
atoms	O
.	O

PEG-PLA	O
-	O
coated	O
CWO	O
NPs	O
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
administration	O
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	O
-	O
coated	O
iron	O
oxide	O
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	B-P
contrast	O
agents	O
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg/kg	O
per	O
dose	O
IV	O
)	O
.	O

IV-	O
injected	O
PEG-PLA	O
/	O
CWO	O
NPs	O
caused	O
no	O
histopathologic	O
damage	O
in	O
major	O
excretory	O
organs	O
(	O
heart	O
,	O
liver	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
kidney	O
)	O
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg/kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	O
circulation	O
half-life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	O
and	O
hepatobiliary	O
systems	O
.	O

When	O
intratumorally	O
administered	O
,	O
PEG-PLA	O
-	O
coated	O
CWO	O
NPs	O
showed	O
complete	O
retention	O
in	O
a	O
tumor-bearing	O
mouse	O
model	O
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PEG-PLA	O
-	O
coated	O
CWO	O
NPs	O
are	O
promising	O
materials	O
for	O
use	O
in	O
CT	B-P
contrast	O
.	O

Prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
in	O
Southwest	O
China	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
patients	O
have	O
high	O
risk	O
for	O
anxiety	O
and	O
depression	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
SLE	O
patients	O
in	O
Southwest	O
China	O
.	O

Participants	O
were	O
recruited	O
by	O
convenience	O
sampling	B-P
from	O
Rheumatic	O
Outpatient	O
Clinic	O
of	O
West	O
China	O
Hospital	O
Sichuan	O
University	O
between	O
August	O
and	O
October	O
2014	O
.	O

The	O
prevalence	O
of	O
anxiety	O
and	O
depression	O
was	O
evaluated	O
using	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(	O
HADS	O
)	O
.	O

Risk	O
factors	O
were	O
explored	O
by	O
multiple	O
logistic	O
regression	O
analyses	O
.	O

A	O
total	O
of	O
352	O
participants	O
were	O
enrolled	O
,	O
of	O
who	O
64	O
(	O
18.2	O
%	O
)	O
met	O
the	O
HADS	O
criteria	O
for	O
anxiety	O
and	O
82	O
(	O
23.3	O
%	O
)	O
for	O
depression	O
.	O

In	O
multivariable	O
analysis	O
,	O
higher	O
levels	O
of	O
pain	O
(	O
OR	O
=	O
1.17	O
,	O
P	O
=	O
0.02	O
)	O
and	O
fatigue	O
(	O
OR	O
=	O
1.19	O
,	O
P	O
<	O
0.01	O
)	O
predicted	O
a	O
higher	O
risk	O
of	O
anxiety	O
.	O

Similarly	O
,	O
a	O
higher	O
level	O
of	O
fatigue	O
(	O
OR	O
=	O
1.2	O
,	O
P	O
<	O
0.01	O
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
depression	O
.	O

The	O
results	O
suggest	O
that	O
anxiety	O
and	O
depression	O
are	O
common	O
in	O
patients	O
with	O
SLE	O
in	O
Southwest	O
China	O
.	O

Health	O
care	O
providers	O
and	O
SLE	O
patients	O
should	O
take	O
some	O
measures	O
to	O
cope	O
with	O
them	O
as	O
early	O
as	O
possible	O
.	O

Strengthening	O
management	O
of	O
pain	O
and	O
fatigue	O
may	O
be	O
useful	O
.	O

But	O
further	O
studies	O
are	O
needed	O
to	O
verify	O
these	O
findings	O
.	O

Pupillary	O
response	O
abnormalities	O
in	O
depressive	O
disorders	O
.	O

Depressive	O
disorders	O
lack	O
objective	O
physiological	O
measurements	O
to	O
characterize	O
the	O
affected	O
population	O
and	O
facilitate	O
study	O
of	O
relevant	O
mechanisms	O
.	O

The	O
melanopsin	O
-	O
mediated	O
light	O
signaling	O
pathway	O
may	O
contribute	O
to	O
seasonal	O
variation	O
and	O
can	O
be	O
measured	O
non-invasively	O
by	O
pupillometry	B-P
.	O

We	O
prospectively	O
studied	O
changes	O
in	O
melanopsin	O
-	O
mediated	O
pupillary	O
constriction	O
in	O
19	O
participants	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
10	O
control	O
across	O
the	O
summer	O
and	O
winter	O
solstices	O
.	O

The	O
melanopsin	O
-	O
mediated	O
response	O
,	O
as	O
measured	O
by	O
the	O
pupil	O
's	O
sustained	O
constriction	O
six	O
s	O
after	O
a	O
high	O
intensity	O
blue	O
light	O
stimulus	O
,	O
was	O
marginally	O
attenuated	O
in	O
those	O
with	O
MDD	O
relative	O
to	O
controls	O
(	O
p	O
=0.071	O
)	O
.	O

The	O
participants	O
with	O
MDD	O
unexpectedly	O
showed	O
a	O
significantly	O
reduced	O
transient	O
pupillary	O
response	O
to	O
low	O
intensity	O
red	O
(	O
p	O
=0.011	O
)	O
and	O
blue	O
light	O
(	O
p	O
=0.013	O
)	O
,	O
but	O
not	O
high	O
intensity	O
red	O
and	O
blue	O
light	O
.	O

Sustained	O
pupillary	O
constriction	O
in	O
response	O
to	O
high	O
intensity	O
blue	O
light	O
was	O
more	O
pronounced	O
with	O
increasing	O
daylight	O
hours	O
(	O
p	O
=0.037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	O
measured	O
versus	O
estimated	O
light	O
exposure	O
.	O

Melanopsin	O
-	O
mediated	O
impairments	O
in	O
pupil	O
response	O
may	O
serve	O
as	O
a	O
biological	O
marker	O
for	O
vulnerability	O
to	O
depression	O
in	O
low	O
light	O
conditions	O
.	O

Assessment	O
of	O
these	O
and	O
other	O
responses	O
to	O
light	O
stimuli	O
,	O
such	O
as	O
response	O
to	O
low	O
intensity	O
light	O
,	O
may	O
be	O
useful	O
for	O
the	O
study	O
of	O
the	O
neurobiology	O
of	O
MDD	O
and	O
related	O
mood	O
disorders	O
.	O

The	O
feasibility	O
of	O
Forward-projected	B-P
model-based	I-P
Iterative	I-P
Reconstruction	I-P
SoluTion	I-P
(	O
FIRST	B-P
)	O
for	O
coronary	O
320-row	B-P
computed	I-P
tomography	I-P
angiography	I-P
:	O
A	O
pilot	O
study	O
.	O

We	O
aimed	O
to	O
assess	O
and	O
compare	O
the	O
influence	O
of	O
Forward	B-P
projected	I-P
model-based	I-P
Iterative	I-P
Reconstruction	I-P
SoluTion	I-P
(	O
FIRST	B-P
)	O
,	O
a	O
recently	O
introduced	O
full	O
iterative	B-P
reconstruction	I-P
method	I-P
,	O
on	O
radiation	O
doses	O
and	O
image	O
quality	O
with	O
that	O
of	O
Adaptive	O
Iterative	O
Dose	O
Reduction	O
(	O
AIDR	O
)	O
3D	O
for	O
320-row	B-P
cardiac	I-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

A	O
total	O
of	O
184	O
patients	O
subjected	O
to	O
single-beat	B-P
reconstruction	I-P
cardiac	I-P
CT	I-P
were	O
retrospectively	O
included	O
.	O

The	O
first	O
89	O
patients	O
received	O
standard	O
radiation	O
doses	O
;	O
their	O
data	O
were	O
reconstructed	O
using	O
AIDR	O
3D	O
,	O
whereas	O
the	O
last	O
95	O
patients	O
received	O
in	O
average	O
20	O
%	O
reduction	O
in	O
tube	O
current	O
;	O
their	O
data	O
were	O
reconstructed	O
using	O
FIRST	B-P
.	O

Subjective	O
image	O
quality	O
(	O
blooming	O
,	O
image	O
sharpness	O
,	O
image	O
noise	O
,	O
and	O
overall	O
subjective	O
image	O
quality	O
)	O
were	O
graded	O
using	O
3-	O
,	O
5-	O
,	O
4-	O
,	O
and	O
4-point	O
scales	O
(	O
0-2	O
,	O
1-5	O
,	O
1-4	O
,	O
and	O
1-4	O
)	O
,	O
respectively	O
;	O
for	O
all	O
items	O
,	O
the	O
highest	O
score	O
indicated	O
excellent	O
image	O
quality	O
.	O

Image	O
noise	O
and	O
signal-to-noise	O
ratios	O
at	O
proximal	O
segments	O
were	O
analyzed	O
as	O
objective	O
measures	O
of	O
image	O
quality	O
.	O

FIRST	B-P
reconstruction	I-P
allowed	O
28	O
%	O
dose	O
reduction	O
compared	O
with	O
AIDR	O
3D	O
(	O
1.88	O
vs.	O
2.61	O
mSv	O
,	O
p	O
=	O
0.012	O
)	O
and	O
yielded	O
better	O
subjective	O
image	O
quality	O
in	O
terms	O
of	O
blooming	O
,	O
image	O
sharpness	O
,	O
image	O
noise	O
,	O
and	O
overall	O
image	O
quality	O
(	O
1.10	O
vs.	O
1.01	O
,	O
p	O
=	O
0.0007	O
;	O
3.02	O
vs.	O
2.74	O
,	O
p	O
<	O
0.0001	O
;	O
3.61	O
vs.	O
3.17	O
,	O
p	O
<	O
0.0001	O
;	O
and	O
3.30	O
vs.	O
2.98	O
,	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

Although	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
image	O
noise	O
,	O
the	O
signal-to-noise	O
ratio	O
was	O
significantly	O
higher	O
with	O
FIRST	B-P
(	O
18.4	O
vs.	O
16.6	O
,	O
p	O
=	O
0.0066	O
)	O
.	O

FIRST	B-P
allowed	O
28	O
%	O
dose	O
reduction	O
while	O
improving	O
image	O
quality	O
.	O

Reference	O
data	O
for	O
jumping	B-P
mechanography	I-P
in	O
Canadian	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

To	O
provide	O
age	O
-	O
and	O
sex	O
-	O
specific	O
reference	O
data	O
for	O
mechanography	B-P
-derived	O
parameters	O
of	O
muscle	O
function	O
in	O
Canadian	O
children	O
and	O
youth	O
using	O
the	O
single	O
two-legged	O
jump	O
(	O
S2LJ	O
)	O
with	O
hands-on-waist	O
.	O

Our	O
sample	O
included	O
2017	O
observations	O
from	O
715	O
participants	O
(	O
9-21	O
years	O
;	O
338	O
girls	O
)	O
.	O

Participants	O
performed	O
three	O
S2LJ	O
with	O
hands-on-waist	O
on	O
a	O
force	O
platform	O
(	O
Leonardo	O
Mechanograph	O
,	O
Novotec	O
)	O
.	O

Outcomes	O
were	O
maximum	O
peak	O
power	O
(	O
Pmax	O
)	O
,	O
Pmax	O
/	O
mass	O
,	O
peak	O
force	O
/	O
body	O
weight	O
(	O
Fmax	O
/	O
BW	O
)	O
,	O
force	O
efficiency	O
,	O
maximum	O
jump	O
height	O
(	O
Hmax	O
)	O
,	O
and	O
velocity	O
(	O
Vmax	O
)	O
.	O

We	O
used	O
the	O
LMS	O
method	O
to	O
construct	O
age	O
-	O
and	O
sex	O
-	O
specific	O
percentile	O
curves	O
and	O
mixed	O
effects	O
models	O
to	O
examine	O
sex	O
and	O
ethnic	O
differences	O
.	O

With	O
the	O
exception	O
of	O
Efficiency	O
,	O
mechanography	B-P
outcomes	O
were	O
greater	O
in	O
girls	O
(	O
4-40	O
%	O
,	O
p	O
<	O
0.05	O
)	O
than	O
boys	O
at	O
age	O
9	O
.	O

Boys	O
'	O
advantage	O
in	O
mechanography	B-P
parameters	O
emerged	O
in	O
adolescence	O
(	O
age	O
11-13	O
years	O
;	O
3-65	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
persisted	O
into	O
young	O
adulthood	O
,	O
except	O
for	O
Fmax	O
/	O
BW	O
which	O
was	O
not	O
greater	O
in	O
boys	O
until	O
age	O
17	O
(	O
4-10	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Mechanography	B-P
outcomes	O
were	O
3-9	O
%	O
(	O
p	O
<	O
0.05	O
)	O
greater	O
in	O
Asian	O
compared	O
with	O
white	O
participants	O
.	O

We	O
provide	O
the	O
first	O
reference	O
data	O
for	O
the	O
S2LJ	O
using	O
the	O
hands-on-waist	O
protocol	O
in	O
children	O
,	O
youth	O
and	O
young	O
adults	O
.	O

These	O
data	O
support	O
previous	O
findings	O
using	O
freely	O
moving	O
arms	O
and	O
can	O
be	O
used	O
when	O
evaluating	O
muscle	O
function	O
in	O
pediatric	O
studies	O
.	O

Analyzing	O
Endosomal	O
Docking	O
,	O
Fusion	O
,	O
Sorting	O
,	O
and	O
Budding	O
Mechanisms	O
in	O
Isolated	O
Organelles	O
.	O

Due	O
to	O
their	O
central	O
role	O
in	O
the	O
reception	O
and	O
sorting	O
of	O
newly	O
internalized	O
material	O
,	O
early	O
endosomes	O
undergo	O
extensive	O
membrane	O
remodeling	O
.	O

They	O
dock	O
and	O
fuse	O
with	O
endocytic	O
carrier	O
vesicles	O
originating	O
from	O
the	O
plasma	O
membrane	O
,	O
sort	O
the	O
internalized	O
material	O
in	O
internal	O
microdomains	O
,	O
and	O
allow	O
the	O
budding	O
of	O
new	O
carrier	O
vesicles	O
from	O
their	O
membrane	O
,	O
destined	O
to	O
fuse	O
with	O
the	O
plasma	O
membrane	O
(	O
recycling	O
)	O
or	O
other	O
organelles	O
.	O

Early	O
endosomal	O
compartments	O
might	O
also	O
be	O
involved	O
in	O
the	O
recycling	O
of	O
synaptic	O
vesicles	O
in	O
nerve	O
terminals	O
.	O

The	O
present	O
protocol	O
describes	O
a	O
technique	O
allowing	O
to	O
assess	O
the	O
mechanistic	O
and	O
molecular	O
aspects	O
of	O
the	O
membrane	O
remodeling	O
processes	O
of	O
docking	O
,	O
fusion	O
,	O
sorting	O
,	O
and	O
budding	O
in	O
early	O
endosomes	O
of	O
neuron	O
-like	O
(	O
and	O
other	O
)	O
cells	O
.	O

It	O
involves	O
the	O
fluorescent	B-P
labeling	I-P
and	O
isolation	O
of	O
endosomal	O
organelles	O
,	O
the	O
setup	O
of	O
assays	O
allowing	O
for	O
docking	O
/	O
fusion	O
or	O
sorting	O
/	O
budding	O
in	O
vitro	O
,	O
and	O
finally	O
the	O
assessment	O
and	O
quantification	O
of	O
the	O
membrane	O
remodeling	O
events	O
by	O
fluorescent	O
microscopy	O
.	O

The	O
technique	O
can	O
be	O
easily	O
manipulated	O
by	O
the	O
addition	O
of	O
inhibitors	O
or	O
activators	O
,	O
and	O
can	O
be	O
combined	O
with	O
other	O
techniques	O
,	O
such	O
as	O
immunostaining	O
and	O
high-resolution	O
microscopy	O
,	O
expanding	O
the	O
experimental	O
possibilities	O
in	O
the	O
investigation	O
of	O
early	O
endosomal	O
characteristics	O
.	O

Addressing	O
the	O
Crisis	O
in	O
the	O
Treatment	O
of	O
Osteoporosis	O
:	O
A	O
Path	O
Forward	O
.	O

Considerable	O
data	O
and	O
media	O
attention	O
have	O
highlighted	O
a	O
potential	O
``	O
crisis	O
``	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	O
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
``	O
gap	O
''	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	O
,	O
especially	O
atypical	O
femur	O
fractures	O
(	O
AFFs	O
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	O
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	O
risk	O
and	O
suggest	O
possible	O
short-	O
,	O
intermediate-	O
,	O
and	O
long-term	O
approaches	O
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	O
risk	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	O
,	O
extended	O
femur	O
scans	B-P
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
to	O
monitor	O
patients	O
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
DXA	B-P
and	O
other	O
risk	O
factors	O
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
AFFs	O
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

©	O
2017	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Visualization	B-P
of	O
the	O
Intimal	O
Flap	O
in	O
Intracranial	O
Arterial	O
Dissection	O
Using	O
High-Resolution	O
3T	B-P
MRI	I-P
.	O

Presence	O
of	O
an	O
intimal	O
flap	O
is	O
a	O
critical	O
imaging	O
finding	O
in	O
diagnosing	O
intracranial	O
artery	O
dissection	O
(	O
ICAD	O
)	O
.	O

Recent	O
reports	O
showed	O
that	O
high-resolution	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
was	O
better	O
at	O
identifying	O
intimal	O
flaps	O
as	O
compared	O
with	O
routine	O
MRI	B-P
techniques	I-P
used	O
in	O
clinical	O
settings	O
.	O

However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high-resolution	O
MRI	B-P
without	O
gadolinium	O
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-P
times	O
.	O

This	O
study	O
evaluated	O
a	O
nonenhanced	B-P
high-resolution	I-P
fast	I-P
spin	I-P
echo	I-P
(	I-P
HR-FSE	I-P
)	I-P
MRI	I-P
sequence	O
for	O
visualizing	O
intimal	O
flaps	O
in	O
patients	O
with	O
ICAD	O
.	O

Three	O
patients	O
with	O
ICAD	O
underwent	O
plain	O
MRI	B-P
examination	O
using	O
a	O
2-dimensional	O
T2-weighted	B-P
FSE	I-P
imaging	I-P
sequence	O
optimized	O
for	O
our	O
3T	O
system	O
(	O
in-plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-P
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-P
angiography	I-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
,	O
and	O
digital	B-P
subtraction	I-P
angiography	I-P
.	O

We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	O
flap	O
and/or	O
double	O
lumen	O
sign	O
in	O
the	O
participants	O
and	O
compared	O
the	O
results	O
between	O
HR-FSE	B-P
and	O
the	O
other	O
modalities	O
.	O

HR-FSE	B-P
images	O
clearly	O
showed	O
intimal	O
flaps	O
and	O
double	O
lumen	O
signs	O
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	O
lumen	O
sign	O
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O

The	O
present	O
method	O
of	O
optimized	O
HR-FSE	B-P
imaging	I-P
with	O
a	O
3T	O
system	O
improved	O
visualization	B-P
of	O
intimal	O
flaps	O
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	O
that	O
can	O
not	O
be	O
definitively	O
diagnosed	O
by	O
conventional	O
imaging	O
modalities	O
.	O

Visualization	B-P
for	O
Understanding	O
Uncertainty	O
in	O
Activation	O
Volumes	O
for	O
Deep	O
Brain	O
Stimulation	O
.	O

We	O
have	O
created	O
the	O
Neurostimulation	O
Uncertainty	O
Viewer	O
(	O
nuView	O
or	O
νView	O
)	O
tool	O
for	O
exploring	O
data	O
arising	O
from	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
.	O

Simulated	O
volume	O
of	O
tissue	O
activated	O
(	O
VTA	O
)	O
,	O
using	O
clinical	B-P
electrode	I-P
placements	I-P
,	O
are	O
recorded	O
along	O
with	O
patient	O
outcomes	O
in	O
the	O
Unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
.	O

The	O
data	O
is	O
volumetric	O
and	O
sparse	O
,	O
with	O
multi-value	O
patient	O
results	O
for	O
each	O
activated	O
voxel	O
in	O
the	O
simulation	O
.	O

νView	O
provides	O
a	O
collection	O
of	O
visual	O
methods	O
to	O
explore	O
the	O
activated	O
tissue	O
to	O
enhance	O
understanding	O
of	O
electrode	O
usage	O
for	O
improved	O
therapy	O
with	O
DBS	O
.	O

Individual	O
differences	O
in	O
behavioral	O
activation	O
and	O
cardiac	O
vagal	O
control	O
influence	O
affective	O
startle	O
modification	O
.	O

The	O
startle	O
response	O
(	O
SR	O
)	O
has	O
a	O
close	O
relationship	O
with	O
stress	O
responses	O
.	O

Startle	O
modification	O
(	O
SRM	O
)	O
has	O
been	O
widely	O
used	O
to	O
study	O
stress	O
disorders	O
(	O
e.g.	O
,	O
posttraumatic	O
stress	O
disorder	O
)	O
.	O

The	O
framework	O
of	O
the	O
behavioral	O
inhibition	O
and	O
activation	O
systems	O
(	O
BIS	O
/	O
BAS	O
)	O
has	O
been	O
thought	O
to	O
correspond	O
with	O
withdrawal	O
and	O
approach	O
motivational	O
processes	O
underlying	O
affective	O
SRM	O
and	O
can	O
influence	O
stress	O
reactivity	O
.	O

Vagally-mediated	O
cardiac	O
activity	O
as	O
indexed	O
by	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
has	O
been	O
associated	O
with	O
SRM	O
and	O
regulatory	O
processes	O
during	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
individual	O
differences	O
in	O
the	O
BIS	O
/	O
BAS	O
and	O
resting	O
HRV	O
on	O
affective	O
SRM	O
were	O
examined	O
.	O

Eighty-six	O
subjects	O
viewed	O
affective	O
pictures	O
while	O
acoustic	O
SR	O
stimuli	O
were	O
delivered	O
.	O

Individual	O
differences	O
in	O
motivation	O
were	O
measured	O
by	O
the	O
BIS/BAS	O
scales	O
.	O

The	O
magnitude	O
of	O
SR	O
was	O
assessed	O
as	O
electromyographic	B-P
activity	O
of	O
the	O
SR	O
eyeblink	O
during	O
pictures	O
of	O
different	O
valences	O
.	O

Resting	O
HRV	O
was	O
derived	O
from	O
electrocardiography	B-P
.	O

In	O
contrast	O
to	O
previous	O
studies	O
,	O
the	O
present	O
results	O
showed	O
that	O
startle	O
inhibition	O
and	O
potentiation	O
were	O
related	O
to	O
BAS	O
and	O
HRV	O
,	O
but	O
not	O
to	O
BIS	O
.	O

There	O
was	O
also	O
an	O
interaction	O
of	O
BAS	O
and	O
HRV	O
,	O
indicating	O
that	O
the	O
relationship	O
between	O
HRV	O
and	O
SRM	O
strengthened	O
as	O
BAS	O
scores	O
decreased	O
.	O

The	O
present	O
findings	O
suggest	O
that	O
BAS	O
may	O
relate	O
to	O
both	O
withdrawal	O
and	O
approach	O
,	O
and	O
trait	O
stress	O
reactivity	O
is	O
influence	O
d	O
by	O
BAS	O
and	O
cardiac	O
vagal	O
activity	O
.	O

In	O
addition	O
,	O
BAS	O
moderates	O
the	O
relationship	O
between	O
cardiac	O
vagal	O
activity	O
and	O
SRM	O
.	O

These	O
findings	O
have	O
both	O
theoretical	O
and	O
practical	O
implications	O
for	O
the	O
study	O
of	O
SRM	O
,	O
stress	O
disorders	O
,	O
and	O
health	O
.	O

Management	O
of	O
precipitated	O
opiate	O
withdrawal	O
syndrome	O
induced	O
by	O
nalmefene	O
mistakenly	O
prescribed	O
in	O
opiate	O
-	O
dependent	O
patients	O
:	O
a	O
review	O
for	O
clinicians	O
.	O

Nalmefene	O
,	O
a	O
long-acting	O
µ-opioid	O
antagonist	O
approved	O
to	O
treat	O
alcohol	O
use	O
disorder	O
,	O
is	O
occasionally	O
mistakenly	O
prescribed	O
to	O
opiate	O
-	O
dependent	O
or	O
opioid	O
-	O
treated	O
patients	O
.	O

We	O
review	O
recent	O
literature	O
on	O
drug-drug	O
interactions	O
between	O
nalmefene	O
and	O
opioids	O
that	O
lead	O
to	O
precipitated	O
opioid	O
withdrawal	O
,	O
and	O
focus	O
on	O
its	O
management	O
and	O
planning	O
for	O
care	O
at	O
discharge	O
.	O

Areas	O
covered	O
:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	O
review	O
of	O
management	O
of	O
precipitated	O
opioid	O
withdrawal	O
syndrome	O
when	O
nalmefene	O
is	O
associated	O
with	O
an	O
opioid	O
,	O
whether	O
misused	O
or	O
legally	O
prescribed	O
.	O

Expert	O
opinion	O
:	O
When	O
treating	O
an	O
opiate	O
-	O
dependent	O
patient	O
with	O
co-occurring	O
alcohol	O
use	O
disorder	O
,	O
both	O
conditions	O
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	O
attention	O
.	O

New	O
drugs	O
for	O
alcohol	O
use	O
disorder	O
have	O
been	O
approved	O
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	O
drug-drug	O
interactions	O
with	O
opioid	O
medications	O
.	O

Opiate	O
-	O
dependent	O
patients	O
should	O
be	O
intensively	O
monitored	O
for	O
risk	O
factors	O
of	O
alcohol	O
use	O
disorder	O
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	O
maintenance	O
.	O

When	O
nalmefene	O
is	O
administered	O
to	O
opiate	O
-	O
dependent	O
patients	O
,	O
acute	O
opioid	O
withdrawal	O
syndrome	O
may	O
occur	O
.	O

Management	O
of	O
precipitated	O
acute	O
opioid	O
withdrawal	O
may	O
include	O
short	O
or	O
long-acting	O
µ-opioid	O
agonists	O
during	O
hospitalization	O
,	O
in	O
addition	O
to	O
supportive	O
treatment	O
.	O

The	O
best	O
management	O
of	O
polydrug	O
abusers	O
is	O
based	O
on	O
a	O
multidisciplinary	B-P
approach	I-P
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	O
through	O
continuing	O
medical	O
education	O
.	O

Nonamplification	O
ERBB2	O
genomic	O
alterations	O
in	O
5605	O
cases	O
of	O
recurrent	O
and	O
metastatic	O
breast	O
cancer	O
:	O
An	O
emerging	O
opportunity	O
for	O
anti-HER2	O
targeted	O
therapies	O
.	O

Activating	O
,	O
nonamplification	O
ERBB2	O
mutations	O
(	O
ERBB2mut	O
)	O
are	O
not	O
detected	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
or	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
but	O
are	O
detected	O
by	O
DNA	O
sequencing	O
and	O
may	O
predict	O
clinical	O
responses	O
to	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER2	O
)	O
-	O
targeted	O
therapy	O
.	O

The	O
authors	O
queried	O
5605	O
advanced/metastatic	O
breast	O
cancers	O
(	O
mBC	O
)	O
to	O
uncover	O
the	O
frequency	O
of	O
ERBB2mut	O
genomic	O
alterations	O
.	O

Clinical	O
responses	O
to	O
anti-HER2	O
therapeutics	O
were	O
identified	O
.	O

DNA	O
was	O
extracted	O
from	O
40	O
µm	O
of	O
formalin-fixed	O
paraffin-embedded	O
(	O
FFPE	O
)	O
sections	O
.	O

Comprehensive	O
genomic	O
profiling	O
(	O
CGP	O
)	O
was	O
used	O
to	O
evaluate	O
up	O
to	O
315	O
genes	O
(	O
592×	O
mean	O
coverage	O
depth	O
)	O
.	O

Results	O
were	O
analyzed	O
for	O
base	O
substitutions	O
,	O
short	O
indels	O
,	O
copy	O
number	O
changes	O
,	O
and	O
selected	O
rearrangements	O
.	O

Of	O
5605	O
cases	O
,	O
698	O
(	O
12.5	O
%	O
)	O
featured	O
ERBB2	O
alterations	O
,	O
including	O
596	O
(	O
10.6	O
%	O
)	O
ERBB2	O
amplifications	O
(	O
ERBB2amp	O
)	O
and	O
138	O
(	O
2.4	O
%	O
)	O
ERBB2mut	O
;	O
38	O
cases	O
(	O
0.7	O
%	O
)	O
had	O
co-occurring	O
ERBB2amp	O
and	O
ERBB2mut	O
.	O

ERBB2mut	O
predominantly	O
affected	O
the	O
kinase	O
(	O
124	O
cases	O
;	O
90	O
%	O
)	O
or	O
extracellular	O
(	O
15	O
cases	O
;	O
11	O
%	O
)	O
domains	O
.	O

Both	O
primary	O
BC	O
(	O
52	O
cases	O
;	O
38	O
%	O
)	O
and	O
metastatic	O
site	O
biopsies	B-P
(	O
86	O
cases	O
;	O
62	O
%	O
)	O
were	O
found	O
to	O
harbor	O
ERBB2mut	O
,	O
which	O
were	O
distributed	O
across	O
carcinoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
(	O
69	O
cases	O
;	O
50	O
%	O
)	O
,	O
invasive	O
ductal	O
carcinoma	O
(	O
IDC	O
)	O
(	O
40	O
cases	O
;	O
29	O
%	O
)	O
,	O
invasive	O
lobular	O
carcinoma	O
(	O
ILC	O
)	O
(	O
27	O
cases	O
;	O
20	O
%	O
)	O
,	O
and	O
mucinous	O
mBC	O
(	O
2	O
cases	O
;	O
1	O
%	O
)	O
.	O

Genes	O
commonly	O
coaltered	O
with	O
ERBB2	O
were	O
tumor	O
protein	O
53	O
(	O
TP53	O
)	O
(	O
49	O
%	O
)	O
;	O
phosphatidylinositol	O
3-kinase	O
catalytic	O
subunit	O
alpha	O
(	O
PIK3CA	O
)	O
(	O
42	O
%	O
)	O
;	O
cadherin	O
1	O
,	O
type	O
1	O
(	O
CDH1	O
)	O
(	O
37	O
%	O
)	O
;	O
MYC	O
(	O
17	O
%	O
)	O
;	O
and	O
cyclin	O
D1	O
protein	O
(	O
CCND1	O
)	O
(	O
16	O
%	O
)	O
.	O

CDH1	O
mutations	O
were	O
enriched	O
in	O
ERBB2mut	O
mBC	O
(	O
P	O
<	O
0.0006	O
)	O
and	O
associated	O
with	O
recurrent	O
mBC	O
.	O

Selected	O
patients	O
with	O
ERBB2mut	O
,	O
without	O
ERBB2amp	O
,	O
who	O
responded	O
to	O
anti-HER2	O
targeted	O
therapies	O
are	O
presented	O
herein	O
.	O

Within	O
this	O
large	O
series	O
,	O
1.8	O
%	O
of	O
cases	O
harbored	O
ERBB2mut	O
,	O
which	O
are	O
undetectable	O
by	O
standard-of-care	O
IHC	B-P
or	O
FISH	O
tests	O
.	O

Metastatic	O
BC	O
driven	O
by	O
ERBB2mut	O
respond	O
to	O
anti-HER2	O
targeted	O
therapies	O
,	O
and	O
expanding	O
clinical	O
trials	O
designed	O
to	O
detect	O
ERBB2mut	O
by	O
CGP	O
and	O
optimize	O
targeted	O
treatments	O
are	O
warranted	O
.	O

Cancer	O
2016	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

Cancer	O
2016	O
;	O
122:2654-2662	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

Abnormal	O
metabolic	O
brain	O
network	O
associated	O
with	O
Parkinson	O
's	O
disease	O
:	O
replication	O
on	O
a	O
new	O
European	O
sample	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
specific	O
metabolic	O
brain	O
pattern	O
characteristic	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
:	O
Parkinson	O
's	O
disease-related	O
pattern	O
(	O
PDRP	O
)	O
,	O
using	O
network	O
analysis	O
of	O
[	B-P
18F	I-P
]	I-P
-fluorodeoxyglucose	I-P
positron	I-P
emission	I-P
tomography	I-P
(	O
FDG-PET	B-P
)	O
brain	O
images	O
in	O
a	O
cohort	O
of	O
Slovenian	O
PD	O
patients	O
.	O

Twenty	O
PD	O
patients	O
(	O
age	O
70.1	O
±	O
7.8	O
years	O
,	O
Movement	O
Disorder	O
Society	O
Unified	O
Parkinson	O
's	O
Disease	O
Motor	O
Rating	O
Scale	O
(	O
MDS-UPDRS-III	O
)	O
38.3	O
±	O
12.2	O
;	O
disease	O
duration	O
4.3	O
±	O
4.1	O
years	O
)	O
and	O
20	O
age	O
-	O
matched	O
normal	O
controls	O
(	O
NCs	O
)	O
underwent	O
FDG-PET	B-P
brain	B-P
imaging	I-P
.	O

An	O
automatic	O
voxel-based	O
scaled	O
subprofile	O
model	O
/	O
principal	O
component	O
analysis	O
(	O
SSM	O
/	O
PCA	O
)	O
was	O
applied	O
to	O
these	O
scans	B-P
for	O
PDRP	O
-	O
Slovenia	O
identification	O
.	O

The	O
pattern	O
was	O
characterized	O
by	O
relative	O
hypermetabolism	O
in	O
pallidum	O
,	O
putamen	O
,	O
thalamus	O
,	O
brain	O
stem	O
,	O
and	O
cerebellum	O
associated	O
with	O
hypometabolism	O
in	O
sensorimotor	O
cortex	O
,	O
posterior	O
parietal	O
,	O
occipital	O
,	O
and	O
frontal	O
cortices	O
.	O

The	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
discriminated	O
PD	O
patients	O
from	O
NCs	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
correlated	O
positively	O
with	O
patients	O
'	O
clinical	O
score	O
(	O
MDS-UPDRS-III	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Additionally	O
,	O
its	O
topography	O
agrees	O
well	O
with	O
the	O
original	O
PDRP	O
(	O
p	O
<	O
0.001	O
)	O
identified	O
in	O
American	O
cohort	O
of	O
PD	O
patients	O
.	O

We	O
validated	O
the	O
PDRP	O
-	O
Slovenia	O
expression	O
on	O
additional	O
FDG-PET	B-P
scans	B-P
of	O
20	O
PD	O
patients	O
,	O
20	O
NCs	O
,	O
and	O
25	O
patients	O
with	O
atypical	O
parkinsonism	O
(	O
AP	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
manifests	O
good	O
diagnostic	O
accuracy	O
with	O
specificity	O
and	O
sensitivity	O
of	O
85-90	O
%	O
at	O
optimal	O
pattern	O
expression	O
cutoff	O
for	O
discrimination	O
of	O
PD	O
patients	O
and	O
NCs	O
and	O
is	O
not	O
expressed	O
in	O
AP	O
.	O

PDRP	O
-	O
Slovenia	O
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-P
imaging	I-P
biomarker	O
independent	O
of	O
patient	O
population	O
.	O

It	O
accurately	O
differentiates	O
PD	O
patients	O
from	O
NCs	O
and	O
AP	O
and	O
correlates	O
well	O
with	O
the	O
clinical	O
measure	O
of	O
PD	O
progression	O
.	O

Anterolateral	O
entorhinal	O
cortex	O
volume	O
predicted	O
by	O
altered	O
intra-item	O
configural	O
processing	O
.	O

Recent	O
functional	O
imaging	B-P
studies	I-P
have	O
proposed	O
that	O
the	O
human	O
entorhinal	O
cortex	O
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	O
(	O
alERC	O
)	O
and	O
posteromedial	O
(	O
pmERC	O
)	O
subregions	O
.	O

The	O
alERC	O
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer	O
's	O
disease	O
pathology	O
,	O
yet	O
its	O
cognitive	O
function	O
remains	O
poorly	O
understood	O
.	O

Previous	O
human	O
fMRI	B-P
studies	I-P
have	O
focused	O
on	O
its	O
role	O
in	O
object	O
memory	O
,	O
but	O
rodent	O
studies	O
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	O
cortex	O
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	O
properties	O
of	O
objects	O
.	O

In	O
order	O
to	O
investigate	O
the	O
cognitive	O
effects	O
of	O
human	O
alERC	O
volume	O
differences	O
,	O
we	O
developed	O
an	O
eyetracking-based	O
task	O
to	O
evaluate	O
intra-item	O
configural	O
processing	O
(	O
i.e.	O
,	O
processing	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
features	O
)	O
,	O
and	O
used	O
manual	O
segmentation	O
based	O
on	O
a	O
recently-	O
developed	O
protocol	O
to	O
delineate	O
the	O
alERC	O
/	O
pmERC	O
as	O
well	O
as	O
other	O
medial	O
temporal	O
lobe	O
(	O
MTL	O
)	O
subregions	O
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
men	O
and	O
women	O
at	O
varying	O
stages	O
of	O
brain	O
atrophy	O
and	O
cognitive	O
decline	O
,	O
we	O
found	O
that	O
intra-item	O
configural	O
processing	O
-	O
regardless	O
of	O
an	O
object	O
's	O
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	O
volume	O
,	O
but	O
not	O
by	O
the	O
volume	O
of	O
any	O
other	O
MTL	O
subregion	O
.	O

These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	O
alERC	O
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	O
processing	O
,	O
namely	O
attending	O
to	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
component	O
features.SIGNIFICANCE	O
STATEMENT	O
Alzheimer	O
's	O
disease	O
pathology	O
appears	O
earliest	O
in	O
brain	O
regions	O
that	O
overlap	O
with	O
the	O
anterolateral	O
entorhinal	O
cortex	O
(	O
alERC	O
)	O
.	O

However	O
,	O
the	O
cognitive	O
role	O
of	O
the	O
alERC	O
is	O
poorly	O
understood	O
.	O

Previous	O
human	O
studies	O
treat	O
the	O
alERC	O
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	O
cortex	O
,	O
supporting	O
object	O
memory	O
.	O

Animal	O
studies	O
suggest	O
that	O
the	O
alERC	O
may	O
support	O
the	O
spatial	O
properties	O
of	O
objects	O
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
humans	O
at	O
the	O
earliest	O
stages	O
of	O
cognitive	O
decline	O
,	O
we	O
show	O
that	O
alERC	O
volume	O
selectively	O
predicted	O
configural	O
processing	O
(	O
attention	O
to	O
the	O
spatial	O
arrangement	O
of	O
an	O
object	O
's	O
parts	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	O
role	O
related	O
to	O
alERC	O
volume	O
in	O
humans	O
.	O

This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	O
detection	O
method	O
for	O
Alzheimer	O
's	O
disease	O
pathology	O
.	O

Retroperitoneal	O
hemorrhage	O
after	O
ureteroscopy	B-P
without	O
laser	O
lithotripsy	O
:	O
an	O
extreme	O
example	O
of	O
an	O
underreported	O
event	O
?	O
.	O

Retroperitoneal	O
hemorrhage	O
and	O
an	O
associated	O
hematoma	O
are	O
uncommon	O
but	O
potentially	O
serious	O
complications	O
following	O
ureteroscopy	B-P
with	O
laser	O
lithotripsy	O
.	O

However	O
,	O
no	O
reports	O
of	O
serious	O
bleeding	O
complications	O
have	O
been	O
published	O
regarding	O
ureteroscopy	B-P
without	O
laser	O
lithotripsy	O
in	O
the	O
management	O
of	O
stone	O
disease	O
.	O

We	O
report	O
of	O
such	O
a	O
case	O
here	O
and	O
then	O
review	O
the	O
current	O
literature	O
in	O
order	O
to	O
discuss	O
the	O
incidence	O
,	O
risk	O
factors	O
,	O
and	O
management	O
of	O
such	O
events	O
.	O

Short-term	O
effects	O
of	O
a	O
vibrotactile	O
neck	O
-based	O
treatment	O
device	O
for	O
positional	O
obstructive	O
sleep	O
apnea	O
:	O
preliminary	O
data	O
on	O
tolerability	O
and	O
efficacy	O
.	O

Positional	O
supine	O
obstructive	O
sleep	O
apnea	O
syndrome	O
(	O
OSAS	O
)	O
characterizes	O
a	O
subgroup	O
of	O
patients	O
suffering	O
from	O
OSAS	O
.	O

Several	O
devices	O
designed	O
to	O
limit	O
supine	O
position	O
have	O
been	O
developed	O
,	O
but	O
evidences	O
of	O
their	O
efficacy	O
and	O
safety	O
are	O
lacking	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
neck-worn	O
vibrating	O
device	O
could	O
induce	O
positional	O
change	O
in	O
patients	O
with	O
positional	O
OSAS	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
a	O
neck	O
-worn	O
device	O
to	O
induce	O
supine	O
avoidance	O
positional	O
feedback	O
over	O
a	O
short-term	O
trial	O
in	O
OSAS	O
patients	O
and	O
its	O
impact	O
on	O
sleep	O
quality	O
and	O
polysomnographyc	B-P
indexes	I-P
.	O

Twenty	O
patients	O
with	O
positional	O
apneas	O
/	O
hypopneas	O
were	O
prospectively	O
studied	O
.	O

Baseline	O
characteristics	O
of	O
daytime	O
somnolence	O
and	O
risk	O
of	O
sleep	O
apnea	O
were	O
screened	B-P
and	O
the	O
efficacy	O
of	O
a	O
3-day	O
trial	O
of	O
supine	O
-	O
avoidance	O
therapy	O
by	O
vibrotactile	O
neck	O
worn	O
device	O
assessed	O
by	O
reporting	O
the	O
self-perceived	O
change	O
in	O
quality	O
of	O
sleep	O
and	O
performing	O
cardio-respiratory	B-P
polysomnography	I-P
.	O

Comparison	O
between	O
baseline	O
and	O
treatment	O
results	O
was	O
performed	O
.	O

The	O
neck	O
device	O
produced	O
a	O
reduction	O
in	O
overall	O
apnea-hypopnea	O
index	O
(	O
AHI	O
)	O
(	O
mean	O
AHI	O
pre	O
=16.8/h	O
and	O
post	O
=4.4/h	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
oxygen	O
desaturation	O
(	O
pre	O
=13.7/h	O
and	O
post	O
=3.8/h	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
Respiratory	O
Disturbance	O
Indexes	O
(	O
RDI	O
)	O
(	O
20.0/h	O
vs.	O
5.2/h	O
;	O
P	O
<	O
0.0001	O
)	O
.The	O
time	O
spent	O
in	O
supine	O
position	O
decreased	O
from	O
62.1	O
%	O
to	O
33.7	O
%	O
of	O
the	O
total	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
the	O
impact	O
on	O
the	O
perceived	O
quality	O
of	O
sleep	O
was	O
unpredictable	O
.	O

The	O
neck	O
position	O
therapy	O
device	O
is	O
effective	O
in	O
restricting	O
supine	O
sleep	O
,	O
improving	O
AHI	O
and	O
related	O
polysomnographic	B-P
indexes	I-P
.	O

However	O
,	O
at	O
least	O
in	O
a	O
short-term	O
trial	O
,	O
it	O
seems	O
unable	O
to	O
improve	O
the	O
patient	O
's	O
sleep	O
quality	O
.	O

The	O
AGES-Reykjavik	O
study	O
atlases	O
:	O
Non-linear	O
multi-spectral	O
template	O
and	O
atlases	O
for	O
studies	O
of	O
the	O
ageing	O
brain	O
.	O

Quantitative	O
analyses	O
of	O
brain	O
structures	O
from	O
Magnetic	B-P
Resonance	I-P
(	O
MR	B-P
)	O
image	B-P
data	O
are	O
often	O
performed	O
using	O
automatic	O
segmentation	O
algorithms	O
.	O

Many	O
of	O
these	O
algorithms	O
rely	O
on	O
templates	O
and	O
atlases	O
in	O
a	O
common	O
coordinate	O
space	O
.	O

Most	O
freely	O
available	O
brain	O
atlases	O
are	O
generated	O
from	O
relatively	O
young	O
individuals	O
and	O
not	O
always	O
derived	O
from	O
well-defined	O
cohort	O
studies	O
.	O

In	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	O
available	O
multi-spectral	O
template	O
with	O
corresponding	O
tissue	O
probability	O
atlases	O
and	O
regional	O
atlases	O
,	O
optimised	O
to	O
use	O
in	O
studies	O
of	O
ageing	O
cohorts	O
(	O
mean	O
age	O
75	O
±	O
5	O
years	O
)	O
.	O

Furthermore	O
,	O
we	O
provide	O
validation	O
data	O
from	O
a	O
regional	O
segmentation	O
pipeline	O
to	O
assure	O
the	O
integrity	O
of	O
the	O
dataset	O
.	O

Utility	O
of	O
Post-Mortem	B-P
Genetic	O
Testing	O
in	O
Cases	O
of	O
Sudden	O
Arrhythmic	O
Death	O
Syndrome	O
.	O

Sudden	O
arrhythmic	O
death	O
syndrome	O
(	O
SADS	O
)	O
describes	O
a	O
sudden	O
death	O
with	O
negative	O
autopsy	B-P
and	O
toxicological	O
analysis	O
.	O

Cardiac	O
genetic	O
disease	O
is	O
a	O
likely	O
etiology	O
.	O

This	O
study	O
investigated	O
the	O
clinical	O
utility	O
and	O
combined	O
yield	O
of	O
post-mortem	B-P
genetic	O
testing	O
(	O
molecular	B-P
autopsy	I-P
)	O
in	O
cases	O
of	O
SADS	O
and	O
comprehensive	O
clinical	O
evaluation	O
of	O
surviving	O
relatives	O
.	O

We	O
evaluated	O
302	O
expertly	O
validated	O
SADS	O
cases	O
with	O
suitable	O
DNA	O
(	O
median	O
age	O
:	O
24	O
years	O
;	O
65	O
%	O
males	O
)	O
who	O
underwent	O
next-generation	O
sequencing	O
using	O
an	O
extended	O
panel	O
of	O
77	O
primary	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
.	O

Pathogenic	O
and	O
likely	O
pathogenic	O
variants	O
were	O
classified	O
using	O
American	O
College	O
of	O
Medical	O
Genetics	O
(	O
ACMG	O
)	O
consensus	O
guidelines	O
.	O

The	O
yield	O
of	O
combined	O
molecular	B-P
autopsy	I-P
and	O
clinical	O
evaluation	O
in	O
82	O
surviving	O
families	O
was	O
evaluated	O
.	O

A	O
gene-level	O
rare	O
variant	O
association	O
analysis	O
was	O
conducted	O
in	O
SADS	O
cases	O
versus	O
controls	O
.	O

A	O
clinically	O
actionable	O
pathogenic	O
or	O
likely	O
pathogenic	O
variant	O
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O

The	O
main	O
etiologies	O
established	O
were	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Gene-based	O
rare	O
variants	O
association	O
analysis	O
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	O
variants	O
in	O
RYR2	O
(	O
p	O
=	O
5	O
×	O
10	O
(	O
-5	O
)	O
)	O
.	O

Combining	O
molecular	B-P
autopsy	I-P
with	O
clinical	O
evaluation	O
in	O
surviving	O
families	O
increased	O
diagnostic	O
yield	O
from	O
26	O
%	O
to	O
39	O
%	O
.	O

Molecular	B-P
autopsy	I-P
for	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
,	O
using	O
ACMG	O
guidelines	O
for	O
variant	O
classification	O
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	O
.	O

Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
,	O
especially	O
the	O
RYR2	O
gene	O
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	O
.	O

Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	O
and	O
genetic	O
evaluation	O
.	O

Maturational	O
Patterns	O
of	O
Systolic	O
Ventricular	O
Deformation	O
Mechanics	O
by	O
Two-Dimensional	B-P
Speckle-Tracking	I-P
Echocardiography	I-P
in	O
Preterm	O
Infants	O
over	O
the	O
First	O
Year	O
of	O
Age	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maturational	O
changes	O
in	O
systolic	O
ventricular	O
strain	O
mechanics	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
neonates	O
from	O
birth	O
to	O
1	O
year	O
of	O
age	O
and	O
discern	O
the	O
impact	O
of	O
common	O
cardiopulmonary	O
abnormalities	O
on	O
the	O
deformation	O
measures	O
.	O

In	O
a	O
prospective	O
multicenter	O
study	O
of	O
239	O
extremely	O
preterm	O
infants	O
(	O
<	O
29	O
weeks	O
gestation	O
at	O
birth	O
)	O
,	O
left	O
ventricular	O
(	O
LV	O
)	O
global	O
longitudinal	O
strain	O
(	O
GLS	O
)	O
and	O
global	O
longitudinal	O
systolic	O
strain	O
rate	O
(	O
GLSRs	O
)	O
,	O
interventricular	O
septal	O
wall	O
(	O
IVS	O
)	O
GLS	O
and	O
GLSRs	O
,	O
(	O
RV	O
)	O
free	O
wall	O
longitudinal	O
strain	O
and	O
strain	O
rate	O
,	O
and	O
segmental	O
longitudinal	O
strain	O
in	O
the	O
RV	O
free	O
wall	O
,	O
LV	O
free	O
wall	O
,	O
and	O
IVS	O
were	O
serially	O
measured	O
on	O
days	O
1	O
,	O
2	O
,	O
and	O
5	O
to	O
7	O
,	O
at	O
32	O
and	O
36	O
weeks	O
postmenstrual	O
age	O
,	O
and	O
at	O
1	O
year	O
corrected	O
age	O
(	O
CA	O
)	O
.	O

Premature	O
infants	O
who	O
developed	O
bronchopulmonary	O
dysplasia	O
or	O
had	O
echocardiographic	B-P
findings	O
of	O
pulmonary	O
hypertension	O
were	O
analyzed	O
separately	O
.	O

In	O
uncomplicated	O
preterm	O
infants	O
(	O
n	O
=	O
103	O
[	O
48	O
%	O
]	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
remained	O
unchanged	O
from	O
days	O
5	O
to	O
7	O
to	O
1	O
year	O
CA	O
(	O
P	O
=	O
.60	O
and	O
P	O
=	O
.59	O
)	O
.	O

RV	O
free	O
wall	O
longitudinal	O
strain	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
rate	O
,	O
and	O
IVS	O
GLS	O
and	O
GLSRs	O
significantly	O
increased	O
over	O
the	O
same	O
time	O
period	O
(	O
P	O
<	O
.01	O
for	O
all	O
measures	O
)	O
.	O

A	O
significant	O
base-to-apex	O
(	O
highest	O
to	O
lowest	O
)	O
segmental	O
longitudinal	O
strain	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
was	O
seen	O
in	O
the	O
RV	O
free	O
wall	O
and	O
a	O
reverse	O
apex-to-base	O
gradient	O
(	O
P	O
<	O
.01	O
)	O
in	O
the	O
LV	O
free	O
wall	O
.	O

In	O
infants	O
with	O
bronchopulmonary	O
dysplasia	O
and/or	O
pulmonary	O
hypertension	O
(	O
n	O
=	O
119	O
[	O
51	O
%	O
]	O
)	O
,	O
RV	O
free	O
wall	O
longitudinal	O
strain	O
and	O
IVS	O
GLS	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
.01	O
)	O
,	O
LV	O
GLS	O
and	O
GLSRs	O
were	O
similar	O
(	O
P	O
=	O
.56	O
)	O
,	O
and	O
IVS	O
segmental	O
longitudinal	O
strain	O
persisted	O
as	O
an	O
RV	O
-	O
dominant	O
base-to-apex	O
gradient	O
from	O
32	O
weeks	O
postmenstrual	O
age	O
to	O
1	O
year	O
CA	O
.	O

This	O
study	O
tracks	O
the	O
maturational	O
patterns	O
of	O
global	O
and	O
regional	O
deformation	O
by	O
two-dimensional	B-P
speckle-tracking	I-P
echocardiography	I-P
in	O
extremely	O
preterm	O
infants	O
from	O
birth	O
to	O
1	O
year	O
CA	O
.	O

The	O
maturational	O
patterns	O
are	O
ventricular	O
specific	O
.	O

Bronchopulmonary	O
dysplasia	O
and	O
pulmonary	O
hypertension	O
leave	O
a	O
negative	O
impact	O
on	O
RV	O
and	O
IVS	O
strain	O
,	O
while	O
LV	O
strain	O
remains	O
stable	O
.	O

Effect	O
of	O
Successive	O
Administration	O
of	O
Vancomycin	O
and	O
Amikacin	O
on	O
Auditory	O
Function	O
of	O
Immature	O
Animals	O
.	O

Effect	O
of	O
successive	O
administration	O
vancomycin	O
and	O
amikacin	O
in	O
therapeutic	O
doses	O
on	O
immature	O
auditory	O
organ	O
was	O
compared	O
to	O
single	O
administration	O
of	O
the	O
same	O
drugs	O
in	O
chronic	O
experiments	O
on	O
immature	O
rabbits	O
by	O
recording	O
of	O
short-latency	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
and	O
distortion	B-P
product	I-P
otoacoustic	I-P
emission	I-P
(	O
DPOAE	B-P
)	O
.	O

Drug	O
administration	O
always	O
increased	O
significantly	O
the	O
ABR	O
peak	O
I	O
threshold	O
.	O

Ototoxic	O
antibiotics	O
did	O
not	O
change	O
DPOAE	B-P
,	O
but	O
selectively	O
affected	O
activity	O
of	O
outer	O
hair	O
cells	O
.	O

No	O
enhancement	O
of	O
the	O
ototoxic	O
effects	O
was	O
observed	O
after	O
successive	O
administration	O
of	O
the	O
two	O
antibiotics	O
.	O

Comparison	O
of	O
non-invasive	B-P
blood	I-P
pressure	I-P
monitoring	I-P
using	O
modified	O
arterial	O
applanation	B-P
tonometry	I-P
with	O
intra-arterial	B-P
measurement	I-P
.	O

Intermittent	O
non-invasive	O
blood	O
pressure	O
measurement	O
with	O
tourniquets	O
is	O
slow	O
,	O
can	O
cause	O
nerve	O
and	O
skin	O
damage	O
,	O
and	O
interferes	O
with	O
other	O
measurements	O
.	O

Invasive	B-P
measurement	I-P
can	O
not	O
be	O
safely	O
used	O
in	O
all	O
conditions	O
.	O

Modified	O
arterial	O
tonometry	B-P
may	O
be	O
an	O
alternative	O
for	O
fast	O
and	O
continuous	O
measurement	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
arterial	O
tonometry	O
sensor	O
(	O
BPro	O
(	O
®	O
)	O
)	O
with	O
invasive	B-P
blood	I-P
pressure	I-P
measurement	O
to	O
clarify	O
whether	O
it	O
could	O
be	O
utilized	O
in	O
the	O
postoperative	O
setting	O
.	O

28	O
patients	O
who	O
underwent	O
elective	O
surgery	O
requiring	O
arterial	O
cannulation	O
were	O
analyzed	O
.	O

Patients	O
were	O
monitored	O
post-operatively	O
for	O
2	O
h	O
with	O
standard	O
invasive	B-P
monitoring	I-P
and	O
with	O
a	O
study	O
device	O
comprising	O
an	O
arterial	O
tonometry	O
sensor	O
(	O
BPro	O
(	O
®	O
)	O
)	O
added	O
with	O
a	O
three-dimensional	O
accelerometer	O
to	O
investigate	O
the	O
potential	O
impact	O
of	O
movement	O
.	O

Recordings	O
were	O
collected	O
electronically	O
.	O

The	O
results	O
revealed	O
inaccurate	O
readings	O
in	O
method	O
comparison	O
between	O
the	O
devices	O
based	O
on	O
recommendations	O
by	O
Association	O
for	O
the	O
Advancement	O
of	O
Medical	O
Instrumentation	O
(	O
AAMI	O
)	O
.	O

On	O
a	O
Bland-Altman	O
plot	O
,	O
the	O
bias	O
and	O
precision	O
between	O
these	O
two	O
methods	O
was	O
19.8	O
±	O
16.7	O
(	O
Limits	O
of	O
agreement	O
-	O
20.1	O
to	O
59.6	O
)	O
mmHg	O
,	O
Spearman	O
correlation	O
coefficient	O
r	O
=	O
0.61	O
.	O

For	O
diastolic	O
pressure	O
,	O
the	O
difference	O
was	O
4.8	O
±	O
7.7	O
(	O
LoA	O
-	O
14.1	O
to	O
23.6	O
)	O
mmHg	O
(	O
r	O
=	O
0.72	O
)	O
,	O
and	O
for	O
mean	O
arterial	O
pressure	O
it	O
was	O
11.18	O
±	O
11.1	O
(	O
LoA	O
-	O
12.1	O
to	O
34.2	O
)	O
mmHg	O
(	O
r	O
=	O
0.642	O
)	O
.	O

Our	O
study	O
revealed	O
inaccurate	O
agreement	O
(	O
AAMI	O
)	O
between	O
the	O
two	O
methods	O
when	O
measuring	O
systolic	O
and	O
mean	O
blood	O
pressures	O
during	O
post-operative	O
care	O
.	O

The	O
readings	O
for	O
diastolic	O
pressures	O
were	O
inside	O
the	O
limits	O
recommended	O
by	O
AAMI	O
.	O

Movement	O
increased	O
the	O
failure	O
rate	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Thus	O
,	O
arterial	O
tonometry	B-P
is	O
not	O
an	O
appropriate	O
replacement	O
for	O
invasive	B-P
blood	I-P
pressure	I-P
measurement	I-P
in	O
these	O
patients	O
.	O

Carbon	O
nanotube	O
-based	O
self-adhesive	O
polymer	O
electrodes	O
for	O
wireless	O
long-term	O
recording	O
of	O
electrocardiogram	O
signals	O
.	O

In	O
this	O
study	O
,	O
the	O
concept	O
of	O
polymer	O
electrodes	O
integrated	O
with	O
a	O
wireless	O
electrocardiogram	O
(	O
ECG	O
)	O
system	O
was	O
described	O
.	O

Polymer	O
electrodes	O
for	O
long-term	O
ECG	O
measurements	O
were	O
fabricated	O
by	O
loading	O
high	O
content	O
of	O
carbon	O
nanotubes	O
(	O
CNTs	O
)	O
in	O
polydimethylsiloxane	O
.	O

Silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
were	O
added	O
to	O
increase	O
the	O
flexibility	O
of	O
the	O
polymer	O
and	O
the	O
conductivity	O
of	O
the	O
electrode	O
.	O

An	O
ECG	O
electrode	O
patch	O
was	O
fabricated	O
by	O
integrating	O
the	O
electrodes	O
with	O
an	O
adhesive	O
polydimethylsiloxane	O
(	O
aPDMS	O
)	O
layer	O
.	O

Holes	O
in	O
the	O
electrode	O
filled	O
with	O
aPDMS	O
can	O
enable	O
robust	O
contact	O
between	O
the	O
electrode	O
and	O
skin	O
,	O
reducing	O
motion	O
artifacts	O
.	O

A	O
wireless	O
ECG	O
measurement	O
system	O
was	O
developed	O
and	O
adapted	O
to	O
the	O
polymer	O
electrodes	O
.	O

The	O
polymer	O
electrodes	O
combined	O
with	O
the	O
measurement	O
system	O
were	O
successfully	O
applied	O
in	O
wireless	O
,	O
long-term	O
recording	O
of	O
ECG	B-P
signals	I-P
.	O

An	O
eleven-	O
day	O
continuous	O
test	O
showed	O
that	O
the	O
ECG	B-P
signal	I-P
did	O
not	O
degrade	O
over	O
time	O
.	O

The	O
results	O
of	O
attach/detach	O
tests	O
demonstrated	O
that	O
the	O
ECG	B-P
signal	I-P
was	O
affected	O
by	O
motion	O
artifacts	O
after	O
six	O
attach/detach	O
cycles	O
.	O

The	O
electrodes	O
produced	O
are	O
flexible	O
and	O
exhibit	O
good	O
ECG	O
performance	O
,	O
and	O
therefore	O
can	O
be	O
used	O
in	O
wearable	O
medical	O
monitoring	O
systems	O
.	O

The	O
approach	O
proposed	O
in	O
this	O
study	O
holds	O
significant	O
promise	O
for	O
commercial	O
application	O
in	O
medical	O
fields	O
.	O

An	O
Anatomic	O
Investigation	O
Into	O
the	O
Relationship	O
Between	O
Posterior	O
Condylar	O
Offset	O
and	O
Posterior	O
Tibial	O
Slope	O
of	O
One	O
Thousand	O
One	O
Hundred	O
Thirty-Eight	O
Cadaveric	O
Knees	O
.	O

Posterior	O
condylar	O
offset	O
(	O
PCO	O
)	O
and	O
posterior	O
tibial	O
slope	O
(	O
PTS	O
)	O
have	O
critical	O
consequences	O
in	O
total	O
knee	O
arthroplasty	O
,	O
especially	O
with	O
regards	O
to	O
sagittal	O
plane	O
balancing	O
.	O

However	O
,	O
there	O
has	O
only	O
been	O
limited	O
investigation	O
into	O
the	O
functional	O
consequences	O
of	O
each	O
,	O
and	O
there	O
have	O
only	O
been	O
anecdotal	O
observations	O
regarding	O
any	O
associations	O
between	O
PCO	O
and	O
PTS	O
.	O

In	O
a	O
large	O
osteological	O
study	O
of	O
1138	O
knees	O
,	O
standardized	O
measurements	O
of	O
PCO	O
and	O
PTS	O
were	O
taken	O
using	O
previously	O
described	O
techniques	O
on	O
specimens	O
of	O
different	O
age	O
,	O
race	O
,	O
and	O
gender	O
.	O

Multiple	O
linear	O
regression	O
was	O
performed	O
to	O
determine	O
the	O
independent	O
predictors	O
of	O
medial	O
and	O
lateral	O
PTS	O
.	O

Mean	O
standardized	O
medial	O
PCO	O
was	O
greater	O
than	O
lateral	O
PCO	O
(	O
1.22	O
±	O
0.16	O
vs	O
1.15	O
±	O
0.19	O
mm	O
,	O
P	O
<	O
.001	O
)	O
and	O
medial	O
PTS	O
was	O
greater	O
than	O
lateral	O
PTS	O
(	O
7.3	O
±	O
3.8°	O
vs	O
5.7	O
±	O
3.7°	O
,	O
P	O
<	O
.001	O
)	O
.	O

Decreasing	O
PCO	O
,	O
female	O
gender	O
,	O
and	O
African-American	O
race	O
were	O
associated	O
with	O
both	O
increased	O
medial	O
and	O
lateral	O
PTS	O
.	O

Neither	O
age	O
nor	O
femoral	O
length	O
correlated	O
with	O
medial	O
or	O
lateral	O
PTS	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
quantify	O
that	O
an	O
inverse	O
correlation	O
between	O
PCO	O
and	O
PTS	O
exists	O
.	O

This	O
relationship	O
represents	O
an	O
important	O
area	O
for	O
future	O
biomechanical	B-P
and	O
clinical	O
studies	O
.	O

Low-dose	B-P
dynamic	I-P
myocardial	I-P
perfusion	I-P
CT	I-P
image	I-P
reconstruction	O
using	O
pre-contrast	B-P
normal-dose	I-P
CT	I-P
scan	I-P
induced	O
structure	B-P
tensor	I-P
total	I-P
variation	I-P
regularization	I-P
.	O

Dynamic	B-P
myocardial	I-P
perfusion	I-P
CT	I-P
(	O
DMP-CT	B-P
)	O
imaging	O
provides	O
quantitative	O
functional	O
information	O
for	O
diagnosis	O
and	O
risk	O
stratification	O
of	O
coronary	O
artery	O
disease	O
by	O
calculating	O
myocardial	O
perfusion	O
hemodynamic	O
parameter	O
(	O
MPHP	O
)	O
maps	O
.	O

However	O
,	O
the	O
level	O
of	O
radiation	O
delivered	O
by	O
dynamic	B-P
sequential	I-P
scan	I-P
protocol	I-P
can	O
be	O
potentially	O
high	O
.	O

The	O
purpose	O
of	O
this	O
work	O
is	O
to	O
develop	O
a	O
pre-contrast	O
normal-dose	O
scan	O
induced	O
structure	O
tensor	O
total	O
variation	O
regularization	O
based	O
on	O
the	O
penalized	O
weighted	O
least-squares	O
(	O
PWLS	O
)	O
criteria	O
to	O
improve	O
the	O
image	O
quality	O
of	O
DMP-CT	B-P
with	O
a	O
low-mAs	B-P
CT	I-P
acquisition	I-P
.	O

For	O
simplicity	O
,	O
the	O
present	O
approach	O
was	O
termed	O
as	O
'	O
PWLS-ndiSTV	O
'	O
.	O

Specifically	O
,	O
the	O
ndiSTV	O
regularization	O
takes	O
into	O
account	O
the	O
spatial-temporal	O
structure	O
information	O
of	O
DMP-CT	B-P
data	O
and	O
further	O
exploits	O
the	O
higher	O
order	O
derivatives	O
of	O
the	O
objective	O
images	O
to	O
enhance	O
denoising	O
performance	O
.	O

Subsequently	O
,	O
an	O
effective	O
optimization	O
algorithm	O
based	O
on	O
the	O
split-Bregman	O
approach	O
was	O
adopted	O
to	O
minimize	O
the	O
associative	O
objective	O
function	O
.	O

Evaluations	O
with	O
modified	O
dynamic	O
XCAT	O
phantom	O
and	O
preclinical	O
porcine	O
datasets	O
have	O
demonstrated	O
that	O
the	O
proposed	O
PWLS-ndiSTV	O
approach	O
can	O
achieve	O
promising	O
gains	O
over	O
other	O
existing	O
approaches	O
in	O
terms	O
of	O
noise-induced	O
artifacts	O
mitigation	O
,	O
edge	O
details	O
preservation	O
,	O
and	O
accurate	O
MPHP	O
maps	O
calculation	O
.	O

The	O
SmartOR	O
:	O
a	O
distributed	O
sensor	O
network	O
to	O
improve	O
operating	O
room	O
efficiency	O
.	O

Despite	O
the	O
significant	O
expense	O
of	O
OR	O
time	O
,	O
best	O
practice	O
achieves	O
only	O
70	O
%	O
efficiency	O
.	O

Compounding	O
this	O
problem	O
is	O
a	O
lack	O
of	O
real-time	O
data	O
.	O

Most	O
current	O
OR	O
utilization	O
programs	O
require	O
manual	O
data	O
entry	O
.	O

Automated	O
systems	O
require	O
installation	O
and	O
maintenance	O
of	O
expensive	O
tracking	O
hardware	O
throughout	O
the	O
institution	O
.	O

This	O
study	O
developed	O
an	O
inexpensive	O
,	O
automated	O
OR	O
utilization	O
system	O
and	O
analyzed	O
data	O
from	O
multiple	O
operating	O
rooms	O
.	O

OR	O
activity	O
was	O
deconstructed	O
into	O
four	O
room	O
states	O
.	O

A	O
sensor	O
network	O
was	O
then	O
developed	O
to	O
automatically	O
capture	O
these	O
states	O
using	O
only	O
three	O
sensors	O
,	O
a	O
local	O
wireless	O
network	O
,	O
and	O
a	O
data	O
capture	O
computer	O
.	O

Two	O
systems	O
were	O
then	O
installed	O
into	O
two	O
ORs	O
,	O
recordings	O
captured	O
24/7	O
.	O

The	O
SmartOR	O
recorded	O
the	O
following	O
events	O
:	O
any	O
room	O
activity	O
,	O
patient	O
entry/exit	O
time	O
,	O
anesthesia	O
time	O
,	O
laparoscopy	B-P
time	O
,	O
room	O
turnover	O
time	O
,	O
and	O
time	O
of	O
preoperative	O
patient	O
identification	O
by	O
the	O
surgeon	O
.	O

From	O
November	O
2014	O
to	O
December	O
2015	O
,	O
data	O
on	O
1003	O
cases	O
were	O
collected	O
.	O

The	O
mean	O
turnover	O
time	O
was	O
36	O
min	O
,	O
and	O
38	O
%	O
of	O
cases	O
met	O
the	O
institutional	O
goal	O
of	O
≤30	O
min	O
.	O

Data	O
analysis	O
also	O
identified	O
outlier	O
cases	O
(	O
>	O
1	O
SD	O
from	O
mean	O
)	O
in	O
the	O
domains	O
of	O
time	O
from	O
patient	O
entry	O
into	O
the	O
OR	O
to	O
intubation	O
(	O
11	O
%	O
of	O
cases	O
)	O
and	O
time	O
from	O
extubation	O
to	O
patient	O
exiting	O
the	O
OR	O
(	O
11	O
%	O
of	O
cases	O
)	O
.	O

Time	O
from	O
surgeon	O
identification	O
of	O
patient	O
to	O
scheduled	O
procedure	O
start	O
time	O
was	O
11	O
min	O
(	O
institution	O
bylaws	O
require	O
20	O
min	O
before	O
scheduled	O
start	O
time	O
)	O
,	O
yet	O
OR	O
teams	O
required	O
22	O
min	O
on	O
average	O
to	O
bring	O
a	O
patient	O
into	O
the	O
room	O
after	O
surgeon	O
identification	O
.	O

The	O
SmartOR	O
automatically	O
and	O
reliably	O
captures	O
data	O
on	O
OR	O
room	O
state	O
and	O
,	O
in	O
real	O
time	O
,	O
identifies	O
outlier	O
cases	O
that	O
may	O
be	O
examined	O
closer	O
to	O
improve	O
efficiency	O
.	O

As	O
no	O
manual	O
entry	O
is	O
required	O
,	O
the	O
data	O
are	O
indisputable	O
and	O
allow	O
OR	O
teams	O
to	O
maintain	O
a	O
patient	O
-centric	O
focus	O
.	O

Laparoscopic	B-P
radical	O
lymph	O
node	O
dissection	O
for	O
advanced	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

Complete	O
mesocolic	O
excision	O
is	O
currently	O
recognized	O
as	O
a	O
standard	O
procedure	O
for	O
colon	O
cancer	O
.	O

Gastroepiploic	O
,	O
infrapyloric	O
,	O
and	O
superficial	O
pancreatic	O
head	O
lymph	O
node	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
have	O
been	O
reported	O
for	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

We	O
sought	O
to	O
investigate	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
in	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

This	O
was	O
a	O
single-center	O
retrospective	O
study	O
.	O

All	O
patients	O
with	O
T2	O
or	O
deeper	O
invasive	O
colon	O
cancer	O
in	O
the	O
relevant	O
tumor	O
location	O
who	O
underwent	O
laparoscopic	O
right	O
hemicolectomy	O
or	O
extended	O
right	O
hemicolectomy	O
at	O
our	O
institution	O
between	O
1	O
April	O
2011	O
and	O
31	O
March	O
2015	O
were	O
included	O
.	O

Lymph	O
node	O
dissection	O
in	O
the	O
gastrocolic	O
ligament	O
was	O
performed	O
in	O
35	O
cases	O
.	O

Complications	O
occurred	O
in	O
11	O
patients	O
(	O
31	O
%	O
)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien-Dindo	O
classification	O
.	O

Lymph	O
node	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
were	O
found	O
in	O
only	O
three	O
patients	O
(	O
9	O
%	O
)	O
.	O

Each	O
metastasis	O
was	O
larger	O
than	O
9	O
mm	O
.	O

Metastases	O
in	O
the	O
gastrocolic	O
ligament	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
with	O
T2	O
or	O
deeper	O
invasive	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

Laparoscopy	O
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	O
ligament	O
resection	O
.	O

This	O
study	O
included	O
a	O
small	O
sample	O
and	O
lacked	O
an	O
extended	O
follow-up	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
clinical	O
relevance	O
of	O
this	O
finding	O
,	O
particularly	O
in	O
terms	O
of	O
recurrence	O
and	O
long-term	O
survival	O
.	O

Pancreatic	O
Cystic	O
Lesions	O
:	O
Diagnostic	O
,	O
Management	O
and	O
Indications	O
for	O
Operation	O
.	O

Part	O
I	O
.	O

We	O
notice	O
an	O
increasing	O
frequency	O
in	O
the	O
detection	O
and	O
evaluation	O
of	O
pancreatic	O
cystic	O
lesions	O
(	O
PCLs	O
)	O
over	O
the	O
last	O
three	O
decades	O
.	O

They	O
show	O
awide	O
spectrum	O
of	O
imaging	B-P
and	O
clinical	O
features	O
.	O

The	O
diagnosis	O
and	O
discrimination	O
of	O
these	O
lesions	O
are	O
very	O
important	O
because	O
of	O
the	O
risk	O
for	O
concurrent	O
or	O
later	O
development	O
of	O
malignancy	O
.	O

The	O
main	O
reason	O
is	O
the	O
increased	O
awareness	O
of	O
these	O
lesions	O
and	O
the	O
extensive	O
use	O
of	O
cross-sectional	O
imaging	O
,	O
an	O
always	O
improving	O
technique	O
(	O
1	O
)	O
.	O

Commonly	O
,	O
PCLs	O
are	O
diagnosed	O
incidentally	O
during	O
investigation	O
for	O
often	O
unrelated	O
and	O
nonspecific	O
abdominal	O
complaints	O
using	O
state-of-the	O
art	O
abdominal	O
imaging	B-P
(	O
CT	B-P
,	O
MRT	B-P
)	O
.	O

The	O
term	O
PCN	O
denotes	O
a	O
histologically	O
heterogeneous	O
collection	O
of	O
neoplasms	O
showing	O
a	O
wide	O
spectrum	O
of	O
diagnoses	O
,	O
ranging	O
from	O
completely	O
benign	O
to	O
potentially	O
malignant	O
,	O
to	O
carcinoma	O
in	O
situ	O
,	O
to	O
frankly	O
invasive	O
and	O
malignant	O
(	O
2,3	O
)	O
.	O

In	O
1978	O
,	O
Compagno	O
and	O
Oertel	O
were	O
the	O
first	O
to	O
recognize	O
the	O
crucial	O
distinction	O
between	O
the	O
serous	O
and	O
the	O
mucinous	O
cystic	O
neoplasms	O
of	O
the	O
pancreas	O
by	O
explaining	O
the	O
importance	O
of	O
identifying	O
the	O
mucinous	O
neoplasms	O
because	O
of	O
their	O
overt	O
or	O
latent	O
malignant	O
potential	O
(	O
4,5	O
)	O
.	O

Since	O
then	O
,	O
the	O
interest	O
in	O
PCLs	O
increased	O
markedly	O
,	O
especially	O
so	O
with	O
the	O
recognition	O
of	O
the	O
importance	O
and	O
prevalence	O
of	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
(	O
IPMNs	O
)	O
.	O

Nowadays	O
,	O
PCLs	O
represent	O
a	O
common	O
and	O
often	O
difficult	O
challenge	O
in	O
clinical	O
practice	O
,	O
because	O
of	O
the	O
increase	O
in	O
their	O
detection	O
in	O
asymptomatic	O
patients	O
and	O
our	O
still	O
immature	O
understanding	O
of	O
some	O
aspects	O
of	O
their	O
biologic	O
behavior	O
.	O

Their	O
important	O
differences	O
regarding	O
their	O
outcome	O
and	O
the	O
fact	O
of	O
being	O
increasingly	O
often	O
identified	O
has	O
put	O
a	O
special	O
focus	O
on	O
these	O
neoplasms	O
by	O
surgeons	O
,	O
pathologists	O
,	O
gastroenterologists	O
,	O
radiologists	O
,	O
and	O
oncologists	O
alike	O
.	O

Management	O
of	O
patients	O
with	O
PCNs	O
can	O
be	O
challenging	O
and	O
varies	O
considerably	O
among	O
the	O
various	O
subtypes	O
of	O
PCNs	O
.	O

Their	O
treatment	O
ranges	O
from	O
resection	O
of	O
malignant	O
lesions	O
,	O
to	O
resection	O
and/or	O
surveillance	O
in	O
the	O
case	O
of	O
premalignant	O
lesions	O
,	O
to	O
simple	O
observation	O
in	O
the	O
case	O
of	O
benign	O
or	O
indolent	O
lesions	O
.	O

Under	O
these	O
circumstances	O
,	O
the	O
accurate	O
classification	O
of	O
PCNs	O
becomes	O
crucial	O
.	O

Therapeutic	O
decision	O
making	O
and	O
classification	O
rely	O
mainly	O
on	O
the	O
presenting	O
symptoms	O
and	O
radiologic	O
findings	O
,	O
often	O
without	O
actual	O
histologic	O
tissue	O
.	O

It	O
is	O
of	O
extreme	O
importance	O
to	O
identify	O
suspicious	O
features	O
indicating	O
potential	O
or	O
certain	O
malignancy	O
in	O
order	O
to	O
select	O
the	O
appropriate	O
treatment	O
.	O

The	O
risk	O
of	O
overtreatment	O
(	O
unnecessary	O
pancreatectomy	O
)	O
should	O
he	O
balanced	O
carefully	O
with	O
the	O
risk	O
of	O
under	O
treatment	O
(	O
missing	O
the	O
opportunity	O
to	O
cure	O
a	O
potentially	O
curable	O
malignant	O
or	O
premalignant	O
disease	O
)	O
.	O

Utility	O
of	O
Ward-Based	O
Retinal	B-P
Photography	I-P
in	O
Stroke	O
Patients	O
.	O

Improvements	O
in	O
acute	O
care	O
of	O
stroke	O
patients	O
have	O
decreased	O
mortality	O
,	O
but	O
survivors	O
are	O
still	O
at	O
increased	O
risk	O
of	O
future	O
vascular	O
events	O
and	O
mitigation	O
of	O
this	O
risk	O
requires	O
thorough	O
assessment	O
of	O
the	O
underlying	O
factors	O
leading	O
to	O
the	O
stroke	O
.	O

The	O
brain	O
and	O
eye	O
share	O
a	O
common	O
embryological	O
origin	O
and	O
numerous	O
similarities	O
exist	O
between	O
the	O
small	O
vessels	O
of	O
the	O
retina	O
and	O
brain	O
.	O

Recent	O
population-based	O
studies	O
have	O
demonstrated	O
a	O
close	O
link	O
between	O
retina	O
l	O
vascular	O
changes	O
and	O
stroke	O
,	O
suggesting	O
that	O
retinal	B-P
photography	I-P
could	O
have	O
utility	O
in	O
assessing	O
underlying	O
stroke	O
risk	O
factors	O
and	O
prognosis	O
after	O
stroke	O
.	O

Modern	O
imaging	O
equipment	O
can	O
facilitate	O
precise	O
measurement	O
and	O
monitoring	O
of	O
vascular	O
features	O
.	O

However	O
,	O
use	O
of	O
this	O
equipment	O
is	O
a	O
challenge	O
in	O
the	O
stroke	O
ward	O
setting	O
as	O
patients	O
are	O
frequently	O
unable	O
to	O
maintain	O
the	O
required	O
seated	O
position	O
,	O
and	O
pupil	B-P
dilatation	I-P
is	O
often	O
not	O
feasible	O
as	O
it	O
could	O
potentially	O
obscure	O
important	O
neurological	O
signs	O
of	O
stroke	O
progression	O
.	O

This	O
small	O
study	O
investigated	O
the	O
utility	O
of	O
a	O
novel	O
handheld	O
,	O
nonmydriatic	O
retinal	O
camera	O
in	O
the	O
stroke	O
ward	O
and	O
explored	O
associations	O
between	O
retinal	O
vascular	O
features	O
and	O
stroke	O
risk	O
factors	O
.	O

This	O
camera	O
circumvented	O
the	O
practical	O
limitations	O
of	O
conducting	O
retinal	B-P
photography	I-P
in	O
the	O
stroke	O
ward	O
setting	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
carotid	O
disease	O
and	O
both	O
mean	O
width	O
of	O
arterioles	O
(	O
r	O
=	O
.40	O
,	O
P	O
=	O
.00571	O
)	O
and	O
venules	O
(	O
r	O
=	O
.30	O
,	O
P	O
=	O
.0381	O
)	O
.	O

The	O
results	O
provide	O
further	O
evidence	O
that	O
retinal	O
vascular	O
features	O
are	O
clinically	O
informative	O
about	O
underlying	O
stroke	O
risk	O
factors	O
and	O
demonstrate	O
the	O
utility	O
of	O
handheld	O
retinal	B-P
photography	I-P
in	O
the	O
stroke	O
ward	O
.	O

Serum	O
ferritin	O
levels	O
as	O
a	O
useful	O
diagnostic	O
marker	O
for	O
the	O
distinction	O
of	O
systemic	O
juvenile	O
idiopathic	O
arthritis	O
and	O
Kawasaki	O
disease	O
.	O

The	O
clinical	O
features	O
and	O
laboratory	B-P
parameters	I-P
of	O
patients	O
with	O
Kawasaki	O
disease	O
(	O
KD	O
)	O
and	O
systemic	O
juvenile	O
idiopathic	O
arthritis	O
(	O
s-JIA	O
)	O
tend	O
to	O
overlap	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
no	O
definitive	O
biomarkers	O
for	O
these	O
disease	O
s	O
,	O
making	O
clinical	B-P
diagnosis	I-P
difficult	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
diagnostic	O
value	O
of	O
serum	O
ferritin	O
levels	O
for	O
differentiating	O
KD	O
from	O
s-JIA	O
and	O
predicting	O
the	O
disease	O
severity	O
of	O
KD	O
.	O

We	O
analyzed	O
228	O
patients	O
with	O
KD	O
and	O
81	O
patients	O
with	O
s-JIA	O
.	O

Serum	O
ferritin	O
levels	O
were	O
compared	O
between	O
patients	O
with	O
s-JIA	O
and	O
KD	O
.	O

Furthermore	O
,	O
serum	O
ferritin	O
levels	O
in	O
patients	O
with	O
KD	O
were	O
compared	O
with	O
respect	O
to	O
clinical	O
features	O
such	O
as	O
responsiveness	O
to	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
therapy	O
.	O

Serum	O
ferritin	O
levels	O
in	O
KD	O
patients	O
with	O
no	O
response	O
to	O
IVIG	O
therapy	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
KD	O
patients	O
with	O
a	O
good	O
response	O
to	O
IVIG	O
therapy	O
.	O

Serum	O
ferritin	O
levels	O
in	O
patients	O
with	O
KD	O
needing	O
plasma	O
exchange	O
(	O
PE	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
patients	O
not	O
needing	O
PE	O
.	O

However	O
,	O
serum	O
ferritin	O
levels	O
overlapped	O
between	O
severe	O
KD	O
patients	O
with	O
nonresponsiveness	O
to	O
IVIG	O
therapy	O
or	O
needing	O
PE	O
and	O
other	O
patients	O
with	O
mild	O
KD	O
.	O

Furthermore	O
,	O
patients	O
with	O
s-JIA	O
showed	O
a	O
distinct	O
elevation	O
of	O
serum	O
ferritin	O
levels	O
compared	O
with	O
KD	O
patients	O
.	O

The	O
cutoff	O
value	O
of	O
serum	O
ferritin	O
levels	O
for	O
differentiating	O
KD	O
from	O
s-JIA	O
was	O
369.6	O
ng/ml	O
.	O

Serum	O
ferritin	O
levels	O
were	O
significantly	O
elevated	O
in	O
s-JIA	O
patients	O
compared	O
with	O
KD	O
patients	O
.	O

Measurement	O
of	O
serum	O
ferritin	O
levels	O
can	O
be	O
useful	O
for	O
differentiating	O
s-JIA	O
from	O
KD	O
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
.	O

However	O
,	O
they	O
have	O
been	O
poorly	O
investigated	O
despite	O
their	O
significant	O
impact	O
on	O
quality	O
of	O
life	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
MG	O
symptoms	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
MG	O
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
MG	O
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	O
antibodies	O
)	O
and	O
24	O
age-matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	B-P
(	O
EGG	B-P
)	O
and	O
speech	O
acoustics	O
.	O

For	O
the	O
analysis	O
of	O
voice	O
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
MG	O
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	O
vocal	O
folds	O
(	O
P	O
<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P	O
<	O
0.005	O
)	O
.	O

The	O
analysis	O
of	O
diadochokinesis	O
showed	O
that	O
MG	O
patients	O
had	O
a	O
higher	O
mean	O
duration	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/pa/	O
syllables	O
(	O
P	O
<	O
0.05	O
)	O
,	O
of	O
the	O
sound	O
/t/	O
(	O
P=0.05	O
)	O
and	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/ka/syllables	O
(	O
P	O
<	O
0.05	O
)	O
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
MG	O
subgroups	O
with	O
anti-AchR	O
or	O
anti-MuSK	O
antibodies	O
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
EGG	B-P
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
MG	O
patients	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
-	O
and	O
transrectal	B-P
ultrasonography	I-P
-	O
guided	B-P
biopsy	I-P
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
-	O
guided	B-P
prostate	I-P
biopsy	I-P
approach	O
.	O

A	O
total	O
of	O
960	O
biopsy	B-P
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI-guided	B-P
and	O
659	O
transrectal	B-P
ultrasonography	I-P
(	O
TRUS	B-P
)	O
-	O
guided	B-P
biopsies	I-P
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	O
cancers	O
were	O
significantly	O
higher	O
in	O
MRI-guided	B-P
than	O
in	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
.	O

Of	O
301	O
MRI-guided	B-P
biopsies	I-P
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
TRUS	B-P
biopsies	B-P
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI-guided	B-P
and	O
in	O
36.1	O
%	O
of	O
377	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
also	O
a	O
markedly	O
higher	O
quantity	O
of	O
cancer	O
tissue	O
in	O
MRI-guided	B-P
biopsies	I-P
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	O
surface	O
area	O
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI-guided	B-P
biopsies	I-P
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI-guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI-guided	B-P
biopsy	I-P
was	O
highest	O
in	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	O
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Comparison	O
of	O
biopsy	B-P
Gleason	O
grades	O
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI-guided	B-P
and	O
in	O
170	O
patients	O
with	O
non-MRI-guided	O
biopsies	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
TRUS	B-P
-	O
and	O
MRI-guided	B-P
biopsies	I-P
with	O
the	O
prostatectomy	O
specimen	O
findings	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high-risk	O
cancers	O
were	O
present	O
in	O
~10	O
%	O
of	O
patients	O
with	O
low-risk	O
biopsy	B-P
results	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	O
cancers	O
and	O
who	O
underwent	O
surgery	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
TRUS	B-P
biopsy	B-P
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	B-P
biopsy	I-P
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

MRI-guided	B-P
transgluteal	O
prostate	B-P
biopsy	I-P
has	O
a	O
high	O
detection	O
rate	O
for	O
high-risk	O
carcinomas	O
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

This	O
may	O
by	O
itself	O
lead	O
to	O
a	O
reduction	O
of	O
unnecessary	O
prostatectomies	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	O
to	O
MRI-guided	B-P
biopsies	I-P
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low-risk	O
carcinomas	O
.	O

Individual	O
Leg	O
Muscle	O
Contributions	O
to	O
the	O
Cost	O
of	O
Walking	O
:	O
Effects	O
of	O
Age	O
and	O
Walking	O
Speed	O
.	O

This	O
study	O
examined	O
the	O
contributions	O
of	O
individual	O
muscles	O
to	O
changes	O
in	O
energetic	O
cost	O
of	O
transport	O
(	O
COT	O
)	O
over	O
seven	O
walking	O
speeds	O
,	O
and	O
compared	O
results	O
between	O
healthy	O
young	O
and	O
elderly	O
subjects	O
.	O

Twenty	O
six	O
participants	O
(	O
13	O
young	O
aged	O
18-30	O
;	O
13	O
old	O
aged	O
70-80	O
)	O
were	O
recruited	O
.	O

COT	O
(	O
O2/kg	O
body	O
mass/km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	O
oxygen	O
consumption	O
recorded	O
during	O
steady	O
state	O
walking	O
.	O

Electromyography	B-P
signals	O
from	O
10	O
leg	O
muscles	O
were	O
used	O
to	O
calculate	O
the	O
cumulative	O
activity	O
required	O
to	O
traverse	O
a	O
unit	O
of	O
distance	O
(	O
CMAPD	O
)	O
for	O
each	O
muscle	O
at	O
each	O
speed	O
.	O

In	O
the	O
old	O
group	O
CMAPD	O
was	O
correlated	O
with	O
COT	O
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	O
speed	O
for	O
all	O
studied	O
muscles	O
.	O

Soleus	O
CMAPD	O
was	O
independent	O
of	O
speed	O
in	O
the	O
young	O
group	O
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	O
.	O

Greater	O
energy	O
cost	O
of	O
walking	O
in	O
older	O
individuals	O
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	O
cost	O
of	O
all	O
lower	O
limb	O
muscles	O
.	O

The	O
correlation	O
of	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
of	O
objective	O
studies	O
of	O
nasal	O
obstruction	O
and	O
the	O
geometry	O
of	O
the	O
nasal	O
cavities	O
.	O

In	O
this	O
paper	O
were	O
verified	O
the	O
correlation	O
between	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
and	O
the	O
results	O
of	O
the	O
objective	O
tests	O
of	O
nasal	O
obstruction	O
which	O
are	O
rhinomanometry	B-P
and	O
acoustic	B-P
rhinometry	I-P
before	O
and	O
after	O
surgical	O
treatment	O
,	O
such	O
as	O
septoplasty	O
,	O
septoconchoplasty	B-P
,	O
ethmoidectomy	O
and	O
septoethmoidectomy	B-P
.	O

The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	O
diagnosed	O
routinely	O
in	O
the	O
Rhinomanometry	B-P
Laboratory	O
of	O
the	O
Department	O
of	O
Otolaryngology	O
at	O
the	O
Medical	O
University	O
of	O
Warsaw	O
,	O
reporting	O
rhinological	O
problems	O
.	O

Data	O
were	O
obtained	O
from	O
70	O
women	O
(	O
31,4	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	O
(	O
68,6	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O

The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics	O
SRE	O
2100	O
which	O
combines	O
the	O
Rhinomanometer	O
(	O
RhinoStream	O
)	O
and	O
Acoustic	O
Rhinometer	O
(	O
RhinoScan	O
)	O
Interacoustics	O
AS	O
(	O
Denmark	O
)	O
.	O

Survey	O
SNOT-20	O
(	O
Sino-Nasal	O
Outcome	O
Test-20	O
)	O
in	O
Polish	O
was	O
completed	O
by	O
patients	O
before	O
surgery	O
and	O
during	O
the	O
postoperative	O
control	O
visits	O
.	O

The	O
calculated	O
correlations	O
between	O
the	O
objective	O
parameter	O
,	O
which	O
was	O
the	O
resistance	O
to	O
the	O
flow	O
of	O
air	O
through	O
the	O
nasal	O
cavity	O
,	O
and	O
the	O
subjective	O
feelings	O
of	O
respondents	O
expressed	O
in	O
the	O
survey	O
SNOT-20	O
were	O
generally	O
weak	O
,	O
and	O
statistical	O
significance	O
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	O
question	O
survey	O
(	O
the	O
severity	O
of	O
the	O
nose	O
obstruction	O
)	O
for	O
all	O
components	O
of	O
resistance	O
flow	O
.	O

The	O
feeling	O
of	O
nasal	O
obstruction	O
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	O
with	O
rhinological	O
problems	O
.	O

A	O
Necrotizing	O
Fasciitis	O
Fake	O
Out	O
on	O
Point-of-Care	O
Ultrasound	O
-Watch	O
the	O
Shadow	O
.	O

Point-of-care	O
ultrasound	O
has	O
an	O
increasing	O
role	O
in	O
characterizing	O
soft-tissue	O
infections	O
and	O
has	O
been	O
described	O
previously	O
in	O
the	O
evaluation	O
of	O
necrotizing	O
fasciitis	O
(	O
NF	O
)	O
.	O

The	O
identification	O
of	O
air	O
within	O
the	O
soft	O
tissues	O
can	O
be	O
very	O
suggestive	O
of	O
NF	O
in	O
the	O
correct	O
clinical	O
context	O
.	O

A	O
78-year-old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
extensive	O
lower-extremity	O
redness	O
and	O
edema	O
.	O

A	O
point-of-care	O
ultrasound	O
revealed	O
hyperechoic	O
areas	O
within	O
the	O
soft	O
tissues	O
consistent	O
with	O
air	O
,	O
and	O
the	O
patient	O
was	O
taken	O
to	O
surgery	O
and	O
found	O
to	O
have	O
NF	O
.	O

A	O
60-year-old	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
physical	O
examination	O
findings	O
consistent	O
with	O
severe	O
cellulitis	O
and	O
associated	O
sepsis	O
.	O

A	O
point-of-care	O
ultrasound	O
revealed	O
hyperechoic	O
areas	O
within	O
the	O
soft	O
tissue	O
that	O
were	O
very	O
similar	O
to	O
the	O
prior	O
case	O
.	O

An	O
emergent	O
surgical	O
consultation	O
was	O
placed	O
due	O
to	O
concern	O
for	O
soft-tissue	O
air	O
and	O
NF	O
.	O

However	O
,	O
these	O
hyperechoic	O
areas	O
were	O
found	O
to	O
be	O
subcutaneous	O
calcifications	O
on	O
subsequent	O
imaging	B-P
.	O

WHY	O
SHOULD	O
AN	O
EMERGENCY	O
PHYSICIAN	O
BE	O
AWARE	O
OF	O
THIS	O
?	O

:	O
Air	O
within	O
the	O
soft	O
tissue	O
is	O
easy	O
to	O
identify	O
on	O
point-of-care	O
ultrasound	O
and	O
can	O
expedite	O
surgical	O
evaluation	O
in	O
cases	O
of	O
suspected	O
NF	O
.	O

Calcifications	O
can	O
mimic	O
the	O
appearance	O
of	O
air	O
on	O
ultrasound	O
and	O
the	O
distinction	O
between	O
these	O
objects	O
can	O
often	O
be	O
made	O
based	O
on	O
the	O
echotexture	O
of	O
the	O
posterior	O
acoustic	O
shadow	O
.	O

Attention	O
to	O
the	O
posterior	O
acoustic	O
shadow	O
can	O
facilitate	O
correct	O
identification	O
of	O
various	O
structures	O
and	O
pathologies	O
in	O
a	O
variety	O
of	O
clinical	O
settings	O
.	O

Sedation	O
of	O
Patients	O
With	O
Disorders	O
of	O
Consciousness	O
During	O
Neuroimaging	B-P
:	O
Effects	O
on	O
Resting	B-P
State	I-P
Functional	I-P
Brain	I-P
Connectivity	I-P
.	O

To	O
reduce	O
head	O
movement	O
during	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
,	O
post-coma	O
patients	O
with	O
disorders	O
of	O
consciousness	O
(	O
DOC	O
)	O
are	O
frequently	O
sedated	O
with	O
propofol	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	O
on	O
the	O
brain	O
connectivity	O
patterns	O
in	O
the	O
damaged	O
brain	O
essential	O
for	O
differential	B-P
diagnosis	I-P
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
assess	O
these	O
effects	O
.	O

Using	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
3T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-P
patients	O
for	O
diagnostic	O
and	O
research	O
purposes	O
,	O
we	O
employed	O
a	O
seed-based	O
approach	O
to	O
examine	O
resting	O
state	O
connectivity	O
in	O
higher-order	O
(	O
default	O
mode	O
,	O
bilateral	O
external	O
control	O
,	O
and	O
salience	O
)	O
and	O
lower-order	O
(	O
auditory	O
,	O
sensorimotor	O
,	O
and	O
visual	O
)	O
resting	O
state	O
networks	O
and	O
connectivity	O
with	O
the	O
thalamus	O
,	O
in	O
20	O
healthy	O
unsedated	O
controls	O
,	O
8	O
unsedated	O
patients	O
with	O
DOC	O
,	O
and	O
8	O
patients	O
with	O
DOC	O
sedated	O
with	O
propofol	O
.	O

The	O
DOC	O
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
,	O
etiology	O
,	O
time	O
spent	O
in	O
DOC	O
,	O
diagnosis	O
,	O
standardized	O
behavioral	O
assessment	O
scores	O
,	O
movement	O
intensities	O
,	O
and	O
pattern	O
of	O
structural	O
brain	O
injury	O
(	O
as	O
assessed	O
with	O
T1-based	O
voxel-based	O
morphometry	O
)	O
.	O

DOC	O
were	O
associated	O
with	O
severely	O
impaired	O
resting	O
state	O
network	O
connectivity	O
in	O
all	O
but	O
the	O
visual	O
network	O
.	O

Thalamic	O
connectivity	O
to	O
higher-order	O
network	O
regions	O
was	O
also	O
reduced	O
.	O

Propofol	O
administration	O
to	O
patients	O
was	O
associated	O
with	O
minor	O
further	O
decreases	O
in	O
thalamic	O
and	O
insular	O
connectivity	O
.	O

Our	O
findings	O
indicate	O
that	O
connectivity	O
decreases	O
associated	O
with	O
propofol	O
sedation	O
,	O
involving	O
the	O
thalamus	O
and	O
insula	O
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	O
-associated	O
structural	O
brain	O
injury	O
.	O

Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	O
in	O
brain	O
arousal	O
,	O
its	O
disruption	O
could	O
well	O
reflect	O
the	O
diminished	O
movement	O
obtained	O
in	O
these	O
patients	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	O
question	O
.	O

Macular	O
Ganglion	O
Cell	O
-	O
Inner	O
Plexiform	O
Layer	O
Thickness	O
Is	O
Associated	O
with	O
Clinical	O
Progression	O
in	O
Mild	O
Cognitive	O
Impairment	O
and	O
Alzheimers	O
Disease	O
.	O

We	O
investigated	O
the	O
association	O
of	O
the	O
macular	O
ganglion	O
cell	O
-	O
inner	O
plexiform	O
layer	O
(	O
GCIPL	O
)	O
and	O
peripapillary	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
thicknesses	O
with	O
disease	O
progression	O
in	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
and	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

We	O
recruited	O
42	O
patients	O
with	O
AD	O
,	O
26	O
with	O
MCI	O
,	O
and	O
66	O
normal	O
elderly	O
controls	O
.	O

The	O
thicknesses	O
of	O
the	O
RNFL	O
and	O
GCIPL	O
were	O
measured	O
via	O
spectral-domain	O
optic	O
coherent	O
tomography	O
in	O
all	O
participants	O
at	O
baseline	O
.	O

The	O
patients	O
with	O
MCI	O
or	O
AD	O
underwent	O
clinical	O
and	O
neuropsychological	B-P
tests	I-P
at	O
baseline	O
and	O
once	O
every	O
year	O
thereafter	O
for	O
2	O
years	O
.	O

The	O
Clinical	O
Dementia	O
Rating	O
scale-Sum	O
of	O
Boxes	O
(	O
CDR-SB	O
)	O
score	O
exhibited	O
significant	O
negative	O
relationships	O
with	O
the	O
average	O
GCIPL	O
thickness	O
(	O
β	O
=	O
-0.15	O
,	O
p	O
<	O
0.05	O
)	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
.	O

The	O
composite	O
memory	O
score	O
exhibited	O
significant	O
positive	O
associations	O
with	O
the	O
average	O
GCIPL	O
thickness	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
inferonasal	O
,	O
and	O
inferotemporal	O
sectors	O
.	O

The	O
temporal	O
RNFL	O
thickness	O
,	O
the	O
average	O
and	O
minimum	O
GCIPL	O
thicknesses	O
,	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
inferonasal	O
,	O
inferior	O
,	O
and	O
inferotemporal	O
sectors	O
at	O
baseline	O
were	O
significantly	O
reduced	O
in	O
MCI	O
patients	O
who	O
were	O
converted	O
to	O
AD	O
compared	O
to	O
stable	O
MCI	O
patients	O
.	O

The	O
change	O
of	O
CDR-SB	O
from	O
baseline	O
to	O
2	O
years	O
exhibited	O
significant	O
negative	O
associations	O
with	O
the	O
average	O
(	O
β	O
=	O
-0.150	O
,	O
p	O
=	O
0.006	O
)	O
and	O
minimum	O
GCIPL	O
thicknesses	O
as	O
well	O
as	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
superior	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
at	O
baseline	O
.	O

Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	O
thickness	O
represents	O
a	O
promising	O
biomarker	O
for	O
monitoring	O
the	O
progression	O
of	O
MCI	O
and	O
AD	O
.	O

Systemic	O
and	O
microcirculatory	O
effects	O
of	O
blood	O
transfusion	O
in	O
experimental	O
hemorrhagic	O
shock	O
.	O

The	O
microvascular	O
reperfusion	O
injury	O
after	O
retransfusion	O
has	O
not	O
been	O
completely	O
characterized	O
.	O

Specifically	O
,	O
the	O
question	O
of	O
heterogeneity	O
among	O
different	O
microvascular	O
beds	O
needs	O
to	O
be	O
addressed	O
.	O

In	O
addition	O
,	O
the	O
identification	O
of	O
anaerobic	O
metabolism	O
is	O
elusive	O
.	O

The	O
venoarterial	O
PCO2	O
to	O
arteriovenous	O
oxygen	O
content	O
difference	O
ratio	O
(	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
)	O
might	O
be	O
a	O
surrogate	O
for	O
respiratory	O
quotient	O
,	O
but	O
this	O
has	O
not	O
been	O
validated	O
.	O

Therefore	O
,	O
our	O
goal	O
was	O
to	O
characterize	O
sublingual	O
and	O
intestinal	O
(	O
mucosal	O
and	O
serosal	O
)	O
microvascular	O
injury	O
after	O
blood	O
resuscitation	O
in	O
hemorrhagic	O
shock	O
and	O
its	O
relation	O
with	O
O2	O
and	O
CO2	O
metabolism	O
.	O

Anesthetized	O
and	O
mechanically	O
ventilated	O
sheep	O
were	O
assigned	O
to	O
stepwise	O
bleeding	O
and	O
blood	O
retransfusion	O
(	O
n	O
=	O
10	O
)	O
and	O
sham	O
(	O
n	O
=	O
7	O
)	O
groups	O
.	O

We	O
performed	O
analysis	O
of	O
expired	O
gases	O
,	O
arterial	O
and	O
mixed	B-P
venous	I-P
blood	I-P
gases	I-P
,	O
and	O
intestinal	O
and	O
sublingual	O
videomicroscopy	O
.	O

In	O
the	O
bleeding	O
group	O
during	O
the	O
last	O
step	O
of	O
hemorrhage	O
,	O
and	O
compared	O
to	O
the	O
sham	O
group	O
,	O
there	O
were	O
decreases	O
in	O
oxygen	O
consumption	O
(	O
3.7	O
[	O
2.8-4.6	O
]	O
vs.	O
6.8	O
[	O
5.8-8.0	O
]	O
mL	O
min	O
(	O
-1	O
)	O
kg	O
(	O
-1	O
)	O
,	O
P	O
<	O
0.001	O
)	O
and	O
increases	O
in	O
respiratory	O
quotient	O
(	O
0.96	O
[	O
0.91-1.06	O
]	O
vs.	O
0.72	O
[	O
0.69-0.77	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Retransfusion	O
normalized	O
these	O
variables	O
.	O

The	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
increased	O
in	O
the	O
last	O
step	O
of	O
bleeding	O
(	O
2.4	O
[	O
2.0-2.8	O
]	O
vs.	O
1.1	O
[	O
1.0-1.3	O
]	O
,	O
P	O
<	O
0.001	O
)	O
and	O
remained	O
elevated	O
after	O
retransfusion	O
,	O
compared	O
to	O
the	O
sham	O
group	O
(	O
1.8	O
[	O
1.5-2.0	O
]	O
vs.	O
1.1	O
[	O
0.9-1.3	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Pv-a	O
CO2	O
/Ca-v	O
O2	O
had	O
a	O
weak	O
correlation	O
with	O
respiratory	O
quotient	O
(	O
Spearman	O
R	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
.	O

All	O
the	O
intestinal	O
and	O
sublingual	O
microcirculatory	O
variables	O
were	O
affected	O
during	O
hemorrhage	O
and	O
improved	O
after	O
retransfusion	O
.	O

The	O
recovery	O
was	O
only	O
complete	O
for	O
intestinal	O
red	O
blood	O
cell	O
velocity	O
and	O
sublingual	O
total	O
and	O
perfused	O
vascular	O
densities	O
.	O

Although	O
there	O
were	O
some	O
minor	O
differences	O
,	O
intestinal	O
and	O
sublingual	O
microcirculation	O
behaved	O
similarly	O
.	O

Therefore	O
,	O
sublingual	O
mucosa	O
might	O
be	O
an	O
adequate	O
window	O
to	O
track	O
intestinal	O
microvascular	O
reperfusion	O
injury	O
.	O

Additionally	O
,	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
was	O
poorly	O
correlated	O
with	O
respiratory	O
quotient	O
,	O
and	O
its	O
physiologic	O
behavior	O
was	O
different	O
.	O

Thus	O
,	O
it	O
might	O
be	O
a	O
misleading	O
surrogate	O
for	O
anaerobic	O
metabolism	O
.	O

Comparative	O
kinematic	B-P
gait	I-P
analysis	I-P
in	O
young	O
and	O
old	O
Beagle	O
dogs	O
.	O

Age-related	O
involution	O
in	O
dogs	O
involves	O
loss	O
of	O
muscle	O
mass	O
and	O
changes	O
in	O
connective	O
tissue	O
and	O
articular	O
cartilage	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
an	O
age-related	O
influence	O
on	O
joint	O
mobility	O
can	O
be	O
detected	O
in	O
the	O
absence	O
of	O
diseases	O
.	O

Five	O
young	O
(	O
Ø	O
2.0	O
years	O
)	O
and	O
five	O
old	O
(	O
Ø	O
10.4	O
years	O
)	O
healthy	O
and	O
sound	O
Beagle	O
dogs	O
were	O
measured	O
during	O
locomotion	O
on	O
a	O
treadmill	O
by	O
computer-assisted	O
gait	B-P
analysis	I-P
.	O

Angles	O
of	O
the	O
shoulder	O
,	O
elbow	O
,	O
carpal	O
,	O
hip	O
,	O
stifle	O
and	O
tarsal	O
joints	O
were	O
analyzed	O
,	O
including	O
joint	O
angle	O
progression	O
curves	O
,	O
minimum	O
and	O
maximum	O
joint	O
angles	O
and	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
.	O

The	O
old	O
group	O
showed	O
a	O
smaller	O
maximum	O
joint	O
angle	O
(	O
p	O
=	O
0.037	O
)	O
and	O
ROM	O
(	O
p	O
=	O
0.037	O
)	O
of	O
the	O
carpal	O
joint	O
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	O
,	O
elbow	O
and	O
carpal	O
joint	O
.	O

The	O
descriptive	O
analysis	O
of	O
the	O
progression	O
curves	O
revealed	O
less	O
flexion	O
and	O
extension	O
of	O
the	O
joints	O
of	O
the	O
forelimb	O
.	O

This	O
indicates	O
restricted	O
joint	O
mobility	O
of	O
the	O
forelimb	O
but	O
primarily	O
of	O
the	O
carpal	O
joint	O
.	O

Findings	O
in	O
the	O
joints	O
of	O
the	O
hindlimb	O
were	O
not	O
consistent	O
;	O
contrasting	O
alterations	O
may	O
be	O
due	O
to	O
a	O
compensatory	O
mechanism	O
.	O

As	O
most	O
alterations	O
were	O
found	O
in	O
the	O
distal	O
joints	O
,	O
these	O
should	O
receive	O
particular	O
attention	O
when	O
examining	O
elderly	O
dogs	O
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
hyperpolarized	O
(	O
13	O
)	O
C	O
CSI	O
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
(	O
13	O
)	O
C-labeled	O
metabolites	O
using	O
T2	O
and	O
T2	O
*	O
information	O
of	O
water	O
protons	O
obtained	O
a	O
priori	O
is	O
proposed	O
.	O

The	O
T2	O
values	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
are	O
inferred	O
using	O
the	O
relationship	O
to	O
T2	O
'	O
of	O
coexisting	O
(	O
1	O
)	O
H	O
and	O
the	O
T2	O
*	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
,	O
which	O
is	O
measured	O
using	O
routine	O
hyperpolarized	O
(	O
13	O
)	O
C	O
CSI	O
data	O
.	O

The	O
concept	O
is	O
verified	O
with	O
phantom	O
studies	O
.	O

Simulations	O
were	O
performed	O
to	O
evaluate	O
the	O
extent	O
of	O
T2	O
estimation	O
accuracy	O
due	O
to	O
errors	O
in	O
the	O
other	O
measurements	O
.	O

Also	O
,	O
bias	O
in	O
the	O
(	O
13	O
)	O
C	O
T2	O
*	O
estimation	O
from	O
the	O
(	O
13	O
)	O
C	O
CSI	O
data	O
was	O
studied	O
.	O

In	O
vivo	O
experiments	O
were	O
performed	O
from	O
the	O
brains	O
of	O
normal	O
rats	O
and	O
a	O
rat	O
with	O
C6	O
glioma	O
.	O

Simulation	O
results	O
indicate	O
that	O
the	O
proposed	O
method	O
provides	O
accurate	O
and	O
unbiased	O
(	O
13	O
)	O
C	O
T2	O
values	O
within	O
typical	O
experimental	O
settings	O
.	O

The	O
in	O
vivo	O
studies	O
found	O
that	O
the	O
estimated	O
T2	O
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
the	O
indirect	O
method	O
was	O
longer	O
in	O
tumor	O
than	O
in	O
normal	O
tissues	O
and	O
gave	O
values	O
similar	O
to	O
previous	O
reports	O
.	O

This	O
method	O
can	O
estimate	O
localized	O
T2	O
relaxation	O
times	O
from	O
multiple	O
voxels	O
using	O
conventional	O
hyperpolarized	O
(	O
13	O
)	O
C	O
CSI	O
and	O
can	O
potentially	O
be	O
used	O
with	O
time	O
resolved	O
fast	O
CSI	O
.	O

In	O
vitro	O
affinity	O
of	O
Deinococcus	O
radiodurans	O
MutS	O
towards	O
mismatched	O
DNA	O
exceeds	O
that	O
of	O
its	O
orthologues	O
from	O
Escherichia	O
coli	O
and	O
Thermus	O
thermophilus	O
.	O

The	O
mismatch	O
binding	O
protein	O
MutS	O
is	O
responsible	O
for	O
the	O
recognition	O
of	O
mispaired	O
and	O
unpaired	O
bases	O
,	O
which	O
is	O
the	O
initial	O
step	O
in	O
DNA	O
repair	O
.	O

Among	O
the	O
MutS	O
proteins	O
most	O
extensively	O
studied	O
in	O
vitro	O
are	O
those	O
derived	O
from	O
Thermus	O
thermophilus	O
,	O
Thermus	O
aquaticus	O
and	O
Escherichia	O
coli	O
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
report	O
on	O
the	O
in	O
vitro	O
examination	O
of	O
DNA	O
mismatch	O
binding	O
activity	O
of	O
MutS	O
protein	O
from	O
Deinococcus	O
radiodurans	O
and	O
confront	O
this	O
with	O
the	O
properties	O
of	O
those	O
from	O
E.	O
coli	O
and	O
T.	O
thermophilus	O
.	O

The	O
analyses	O
which	O
included	O
mobility	B-P
gel-shift	I-P
assay	I-P
,	O
colorimetric	O
and	O
qPCR	O
estimation	O
of	O
MutS	O
-bound	O
DNA	O
clearly	O
showed	O
that	O
D.	O
radiodurans	O
MutS	O
exhibited	O
much	O
higher	O
affinity	O
towards	O
mismatched	O
DNA	O
in	O
vitro	O
than	O
its	O
counterparts	O
from	O
E.	O
coli	O
and	O
T.	O
thermophilus	O
.	O

In	O
addition	O
,	O
D.	O
radiodurans	O
MutS	O
displayed	O
a	O
significantly	O
higher	O
specificity	O
of	O
DNA	O
mismatch	O
binding	O
than	O
the	O
two	O
other	O
orthologues	O
.	O

The	O
specificity	O
expressed	O
as	O
the	O
ratio	O
of	O
mismatched	O
to	O
fully	O
complementary	O
DNA	O
bound	O
reached	O
over	O
4	O
and	O
20-fold	O
higher	O
values	O
for	O
D.	O
radiodurans	O
than	O
for	O
T.	O
thermophilus	O
and	O
E.	O
coli	O
MutS	O
,	O
respectively	O
.	O

The	O
results	O
demonstrate	O
mainly	O
the	O
biotechnological	O
potential	O
of	O
D.	O
radiodurans	O
MutS	O
but	O
the	O
in	O
vitro	O
characteristics	O
of	O
the	O
MutS	O
orthologues	O
could	O
reflect	O
substantial	O
differences	O
in	O
DNA	O
mismatch	O
binding	O
activities	O
existing	O
in	O
vivo	O
.	O

Case	O
report	O
:	O
imaging	O
the	O
clinical	O
course	O
of	O
FOPE	O
-a	O
cause	O
of	O
adolescent	O
knee	O
pain	O
.	O

Focal	O
periphyseal	O
oedema	O
(	O
FOPE	O
)	O
is	O
a	O
rare	O
MRI	B-P
finding	O
associated	O
with	O
pain	O
in	O
adolescent	O
patients	O
with	O
very	O
few	O
reported	O
cases	O
.	O

We	O
present	O
a	O
case	O
of	O
FOPE	O
in	O
a	O
13-year-old	O
girl	O
and	O
the	O
only	O
follow-up	O
imaging	B-P
available	O
for	O
an	O
isolated	O
presentation	O
of	O
this	O
condition	O
.This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

Prenatal	B-P
Diagnosis	I-P
of	O
Lysosomal	O
Storage	O
Disorders	O
Using	O
Chorionic	O
Villi	O
.	O

Prenatal	B-P
enzymatic	I-P
diagnosis	I-P
for	O
an	O
array	O
of	O
lysosomal	O
storage	O
disorders	O
(	O
LSDs	O
)	O
can	O
be	O
performed	O
accurately	O
,	O
provided	O
that	O
a	O
confirmed	O
diagnosis	O
by	O
biochemical/molecular	O
study	O
in	O
the	O
index	O
case	O
is	O
available	O
and	O
a	O
strict	O
defined	O
protocol	O
,	O
specific	O
to	O
each	O
individual	O
disorder	O
is	O
followed	O
.	O

The	O
present	O
chapter	O
describes	O
the	O
protocols	O
for	O
reliable	O
and	O
accurate	O
prenatal	B-P
enzymatic	I-P
diagnoses	I-P
by	O
fluorometric	O
and	O
spectrophotometric	O
methods	O
of	O
lysosomal	O
storage	O
disorders	O
:	O
Gaucher	O
,	O
Fabry	O
,	O
Pompe	O
,	O
Niemann	O
Pick	O
A/B	O
,	O
Tay	O
Sach	O
,	O
Sandhoff	O
,	O
GM1	O
,	O
Mucoplysaccharidoses	O
,	O
Wolman	O
,	O
Krabbe	O
,	O
Metachromatic	O
leukodystrophy	O
,	O
and	O
Batten	O
diseases	O
using	O
uncultured	O
chorionic	O
villi	O
samples	O
.	O

The	O
biological	O
reference	O
intervals	O
for	O
enzyme	O
levels	O
in	O
normal	O
and	O
affected	O
fetuses	O
are	O
given	O
for	O
interpretation	O
of	O
prenatal	O
results	O
.	O

It	O
is	O
imperative	O
to	O
establish	O
normal	O
reference	O
interval	O
in	O
each	O
laboratory	O
to	O
take	O
into	O
account	O
the	O
local	O
environment	O
,	O
technical	O
variations	O
,	O
and	O
different	O
ethnicities	O
.	O

Besides	O
,	O
enzyme	O
activity	O
in	O
the	O
fetus	O
should	O
be	O
represented	O
as	O
percentage	O
of	O
the	O
mean	O
activity	O
of	O
enzyme	O
of	O
normal	O
fetuses	O
.	O

The	O
pitfalls	O
and	O
challenges	O
in	O
prenatal	B-P
diagnosis	I-P
as	O
well	O
as	O
technical	O
problems	O
in	O
performing	O
enzyme	O
assays	O
are	O
also	O
discussed	O
to	O
help	O
the	O
reader	O
in	O
standardization	O
and	O
performing	O
the	O
assays	O
for	O
correct	O
diagnosis	O
.	O

Relationship	O
Between	O
Femur	O
and	O
Femoral	O
Arteries	O
for	O
Identifying	O
Risk	O
Factors	O
for	O
Vascular	O
Injury	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
identify	O
risk	O
factors	O
for	O
vascular	O
injury	O
in	O
proximal	O
femoral	O
fracture	O
through	O
identifying	O
frequency	O
and	O
distances	O
between	O
femur	O
and	O
femoral	O
arteries	O
with	O
computed	B-P
tomography	I-P
angiography	I-P
and	O
3-dimensional	B-P
reconstruction	I-P
.	O

MATERIAL	O
AND	O
METHODS	O
In	O
a	O
series	O
of	O
400	O
participants	O
,	O
based	O
on	O
measurement	O
results	O
regarding	O
the	O
distribution	O
of	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
,	O
the	O
femoral	O
portion	O
covering	O
that	O
part	O
was	O
divided	O
into	O
levels	O
A-E	O
.	O

The	O
center	O
region	O
,	O
margin	O
region	O
,	O
and	O
risky	O
area	O
in	O
the	O
medial	O
femur	O
were	O
defined	O
.	O

The	O
frequency	O
of	O
femoral	O
arteries	O
and	O
interested	O
shortest	O
distance	O
between	O
the	O
outer	O
femur	O
and	O
superficial	O
,	O
deep	O
,	O
and	O
perforating	O
femoral	O
arteries	O
(	O
SFAs	O
,	O
DFAs	O
,	O
and	O
PFAs	O
)	O
in	O
the	O
center	O
region	O
,	O
margin	O
region	O
,	O
and	O
risky	O
area	O
at	O
each	O
level	O
were	O
recorded	O
.	O

RESULTS	O
There	O
were	O
173	O
males	O
and	O
227	O
females	O
(	O
average	O
age	O
:	O
63.61±19.18	O
years	O
)	O
in	O
this	O
study	O
.	O

The	O
starting	O
point	O
and	O
end	O
point	O
for	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
were	O
from	O
22.55±4.23	O
%	O
to	O
54.56±8.39	O
%	O
of	O
the	O
whole	O
femur	O
.	O

The	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
mainly	O
were	O
distributed	O
at	O
levels	O
B	O
(	O
88.2	O
%	O
)	O
,	O
C	O
(	O
65.9	O
%	O
)	O
,	O
and	O
D	O
(	O
40.6	O
%	O
)	O
.	O

The	O
femoral	O
arteries	O
in	O
center	O
regions	O
in	O
the	O
risky	O
area	O
,	O
most	O
of	O
which	O
were	O
DFAs	O
and	O
PFAs	O
,	O
were	O
mainly	O
concentrated	O
at	O
levels	O
B	O
(	O
26.93	O
%	O
)	O
and	O
C	O
(	O
11.81	O
%	O
)	O
.	O

CONCLUSIONS	O
The	O
mid-shaft	O
level	O
was	O
the	O
most	O
risky	O
level	O
,	O
and	O
the	O
DFAs	O
and	O
PFAs	O
were	O
easier	O
to	O
injure	O
than	O
the	O
SFAs	O
when	O
performing	O
internal	O
fixation	O
of	O
proximal	O
femoral	O
fracture	O
.	O

We	O
recommended	O
that	O
great	O
attention	O
be	O
paid	O
to	O
drill	O
and	O
screw	O
insertion	O
around	O
the	O
mid-shaft	O
level	O
for	O
prevention	O
of	O
iatrogenic	O
vascular	O
injury	O
.	O

Correlation	O
of	O
cardiopulmonary	B-P
exercise	I-P
testing	I-P
parameters	O
with	O
quality	O
of	O
life	O
in	O
stable	O
COPD	O
patients	O
.	O

The	O
precise	O
head	O
to	O
head	O
relationships	O
between	O
Cardio-pulmonary	B-P
exercise	I-P
testing	I-P
(	O
CPET	B-P
)	O
parameters	O
and	O
patients	O
'	O
daily	O
symptoms	O
/	O
activities	O
and	O
the	O
disease	O
social	O
/	O
emotional	O
impact	O
are	O
less	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
the	O
correlation	O
of	O
COPD	O
daily	O
symptoms	O
and	O
quality	O
of	O
life	O
[	O
assessed	O
by	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
)	O
]	O
and	O
COPD	O
severity	O
index	O
(	O
BODE-index	O
)	O
with	O
CPET	B-P
parameters	O
were	O
investigated	O
.	O

Symptom	O
-limited	O
CPET	B-P
was	O
performed	O
in	O
37	O
consecutive	O
COPD	O
(	O
GOLD	B-P
I-III	I-P
)	O
subjects	O
during	O
non-	O
exacerbation	O
phase	O
.	O

The	O
SGRQ	O
was	O
also	O
completed	O
by	O
each	O
patient	O
.	O

SGRQ-score	O
correlated	O
negatively	O
with	O
FEV1	B-P
(	O
r=-0.49	O
,	O
P	O
<	O
0.01	O
)	O
,	O
predicted	O
maximal	O
work-rate	O
(	O
%	O
WR-max	O
)	O
(	O
r=-0.44	O
,	O
P	O
<	O
0.01	O
)	O
,	O
V'O2	O
/	O
WR	O
(	O
r=-0.52	O
,	O
P	O
<	O
0.01	O
)	O
and	O
breathing	O
reserve	O
(	O
r=-0.50	O
,	O
P	O
<	O
0.01	O
)	O
.	O

However	O
it	O
did	O
not	O
correlate	O
with	O
Peak-V'O2	O
%	O
predicted	O
(	O
r=-0.27	O
,	O
P=0.10	O
)	O
.	O

In	O
20	O
(	O
54.1	O
%	O
)	O
subjects	O
in	O
which	O
leg	O
fatigue	O
was	O
the	O
main	O
cause	O
for	O
stopping	O
the	O
test	O
,	O
Peak-V'O2	O
,	O
%	O
WR-max	O
,	O
HR-Reserve	O
and	O
Breathing	O
reserve	O
were	O
higher	O
(	O
P=0.04	O
,	O
<	O
0.01	O
,	O
0.04	O
and	O
<	O
0.01	O
respectively	O
)	O
than	O
the	O
others	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
BODE-index	O
and	O
∆VO2	O
/	O
∆WR	O
(	O
r=-0.64	O
,	O
P	O
<	O
0.001	O
)	O
and	O
breathing-reserve	O
(	O
r=-0.38	O
,	O
P=0.018	O
)	O
.	O

The	O
observed	O
relationships	O
between	O
CPET	B-P
parameter	O
and	O
daily	O
subjective	O
complaints	O
in	O
COPD	O
were	O
not	O
strong	O
.	O

Those	O
who	O
discontinued	O
the	O
CPET	B-P
because	O
of	O
leg	O
fatigue	O
were	O
in	O
the	O
earlier	O
stages	O
of	O
COPD	O
.	O

Significant	O
negative	O
correlation	O
between	O
∆VO2	O
/	O
∆WR	O
and	O
BODE-index	O
suggests	O
that	O
along	O
with	O
COPD	O
progression	O
,	O
regardless	O
of	O
negative	O
past	O
history	O
,	O
other	O
comorbidities	O
such	O
as	O
cardiac	O
/	O
musculoskeletal	O
problems	O
should	O
be	O
sought	O
.	O

EEG	B-P
Monitoring	O
Technique	O
Influences	O
the	O
Management	O
of	O
Hypoxic-Ischemic	O
Seizures	O
in	O
Neonates	O
Undergoing	O
Therapeutic	O
Hypothermia	O
.	O

Electroencephalogram	O
(	O
EEG	O
)	O
monitoring	O
techniques	O
for	O
neonatal	O
hypoxia-ischemia	O
(	O
HI	O
)	O
are	O
evolving	O
over	O
time	O
,	O
and	O
the	O
specific	O
type	O
of	O
EEG	O
utilized	O
could	O
influence	O
seizure	O
diagnosis	O
and	O
management	O
.	O

We	O
examined	O
whether	O
the	O
type	O
of	O
EEG	B-P
performed	O
affected	O
seizure	O
treatment	O
decisions	O
(	O
e.g.	O
,	O
the	O
choice	O
and	O
number	O
of	O
antiseizure	O
drugs	O
[	O
ASDs	O
]	O
)	O
in	O
therapeutic	O
hypothermia-treated	O
neonates	O
with	O
HI	O
from	O
2007	O
to	O
2015	O
in	O
the	O
Johns	O
Hopkins	O
Hospital	O
Neonatal	O
Intensive	O
Care	O
Unit	O
.	O

During	O
this	O
period	O
,	O
3	O
different	O
EEG	O
monitoring	O
protocols	O
were	O
utilized	O
:	O
Period	O
1	O
(	O
2007-2009	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
(	O
1	O
h	O
duration	O
)	O
at	O
a	O
variable	O
time	O
during	O
therapeutic	O
hypothermia	O
treatment	O
,	O
i.e.	O
,	O
ordered	O
when	O
a	O
seizure	O
was	O
suspected	O
;	O
Period	O
2	O
(	O
2009-2013	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
followed	O
by	O
amplitude-integrated	B-P
EEG	I-P
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
and	O
another	O
brief	O
conventional	O
EEG	B-P
after	O
rewarming	O
;	O
and	O
Period	O
3	O
(	O
2014-2015	O
)	O
,	O
continuous	B-P
video-EEG	I-P
(	O
cEEG	B-P
)	O
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
(	O
72	O
h	O
)	O
plus	O
for	O
an	O
additional	O
12	O
h	O
during	O
and	O
after	O
rewarming	O
.	O

One	O
hundred	O
and	O
sixty-two	O
newborns	O
were	O
included	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

As	O
a	O
function	O
of	O
the	O
type	O
and	O
duration	O
of	O
EEG	O
monitoring	O
,	O
we	O
assessed	O
the	O
risk	O
(	O
likelihood	O
)	O
of	O
receiving	O
no	O
ASD	O
,	O
at	O
least	O
1	O
ASD	O
,	O
or	O
≥2	O
ASDs	O
.	O

We	O
found	O
that	O
the	O
risk	O
of	O
a	O
neonate	O
being	O
prescribed	O
an	O
ASD	O
was	O
46	O
%	O
less	O
during	O
Period	O
3	O
(	O
cEEG	B-P
)	O
than	O
during	O
Period	O
1	O
(	O
brief	O
conventional	O
EEG	B-P
only	O
)	O
(	O
95	O
%	O
CI	O
6-69	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

After	O
adjusting	O
for	O
initial	O
EEG	B-P
and	O
MRI	B-P
results	O
,	O
compared	O
with	O
Period	O
1	O
,	O
there	O
was	O
a	O
38	O
%	O
lower	O
risk	O
of	O
receiving	O
an	O
ASD	O
during	O
Period	O
2	O
(	O
95	O
%	O
CI	O
:	O
9-58	O
%	O
,	O
p	O
=	O
0.02	O
)	O
and	O
a	O
67	O
%	O
lower	O
risk	O
during	O
Period	O
3	O
(	O
95	O
%	O
CI	O
:	O
23-86	O
%	O
,	O
p	O
=	O
0.01	O
)	O
.	O

The	O
risk	O
ratio	O
of	O
receiving	O
≥2	O
ASDs	O
was	O
not	O
significantly	O
different	O
across	O
the	O
3	O
periods	O
.	O

In	O
conclusion	O
,	O
in	O
addition	O
to	O
the	O
higher	O
sensitivity	O
and	O
specificity	O
of	O
continuous	B-P
video-EEG	I-P
monitoring	O
,	O
fewer	O
infants	O
are	O
prescribed	O
an	O
ASD	O
when	O
undergoing	O
continuous	O
forms	O
of	O
EEG	O
monitoring	O
(	O
aEEG	B-P
or	O
cEEG	B-P
)	O
than	O
those	O
receiving	O
conventional	O
EEG	B-P
.	O

We	O
recommend	O
that	O
use	O
of	O
continuous	B-P
video-EEG	I-P
be	O
considered	O
whenever	O
possible	O
,	O
both	O
to	O
treat	O
seizures	O
more	O
specifically	O
and	O
to	O
avoid	O
overtreatment	O
.	O

Netarsudil	O
Increases	O
Outflow	B-P
Facility	I-P
in	O
Human	O
Eyes	O
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	O
is	O
a	O
Rho	O
kinase/norepinephrine	O
transporter	O
inhibitor	O
currently	O
in	O
phase	O
3	O
clinical	O
development	O
for	O
glaucoma	O
treatment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil-M1	O
,	O
on	O
outflow	B-P
facility	I-P
(	O
C	B-P
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

Paired	O
human	O
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil-M1	O
or	O
vehicle	O
solution	O
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	O
were	O
added	O
to	O
perfusion	O
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	O
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
,	O
episcleral	O
veins	O
(	O
ESVs	O
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	O
canal	O
after	O
global	O
and	O
confocal	O
imaging	O
.	O

Morphologic	O
changes	O
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	O
,	O
light	O
,	O
and	O
electron	O
microscopy	O
.	O

Perfusion	O
with	O
netarsudil-M1	O
significantly	O
increased	O
C	B-P
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
ESVs	O
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	O
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
ESVs	O
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	O
area	O
of	O
ESVs	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Percentage	O
effective	O
filtration	O
length	O
in	O
ESVs	O
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-P
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	O
connective	O
tissue	O
(	O
JCT	O
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	O
compared	O
to	O
controls	O
.	O

Netarsudil	O
acutely	O
increased	O
C	B-P
by	O
expansion	O
of	O
the	O
JCT	O
and	O
dilating	O
the	O
ESVs	O
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	O
of	O
the	O
IW	O
and	O
ESVs	O
.	O

Autonomous	O
assembly	O
of	O
ordered	O
metastable	O
DNA	O
nanoarchitecture	O
and	O
in	O
situ	O
visualizing	O
of	O
intracellular	O
microRNAs	O
.	O

Facile	O
assembly	O
of	O
intelligent	O
DNA	O
nanoobjects	O
with	O
the	O
ability	O
to	O
exert	O
in	O
situ	O
visualization	O
of	O
intracellular	O
microRNAs	O
(	O
miRNAs	O
)	O
has	O
long	O
been	O
concerned	O
in	O
the	O
fields	O
of	O
DNA	O
nanotechnology	O
and	O
basic	O
medical	O
study	O
.	O

Here	O
,	O
we	O
present	O
a	O
driving	O
primer	O
(	O
DP	O
)	O
-triggered	O
polymerization	O
-mediated	O
metastable	O
assembly	O
(	O
PMA	O
)	O
strategy	O
to	O
prepare	O
a	O
well-ordered	O
metastable	O
DNA	O
nanoarchitecture	O
composed	O
of	O
only	O
two	O
hairpin	O
probes	O
(	O
HAPs	O
)	O
,	O
which	O
has	O
never	O
been	O
explored	O
by	O
assembly	O
methods	O
.	O

Its	O
structural	O
features	O
and	O
functions	O
are	O
characterized	O
by	O
atomic	O
force	O
microscope	O
(	O
AFM	O
)	O
and	O
gel	O
electrophoresis	O
.	O

Even	O
if	O
with	O
a	O
metastable	O
molecular	O
structure	O
,	O
this	O
nanoarchitecture	O
is	O
relatively	O
stable	O
at	O
physiological	O
temperature	O
.	O

The	O
assembly	O
strategy	O
can	O
be	O
expanded	O
to	O
execute	O
microRNA-21	O
(	O
miRNA-21	O
)	O
in	O
situ	O
imaging	B-P
inside	O
cancer	O
cells	O
by	O
labelling	O
one	O
of	O
the	O
HAPs	O
with	O
fluorophore	O
and	O
quencher	O
.	O

Compared	O
with	O
the	O
conventional	O
fluorescence	O
probe	O
-based	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
,	O
confocal	O
images	O
revealed	O
that	O
the	O
proposed	O
DNA	O
nanoassembly	O
can	O
not	O
only	O
achieve	O
greatly	O
enhanced	O
imaging	B-P
effect	I-P
within	O
cancer	O
cells	O
,	O
but	O
also	O
reflect	O
the	O
miRNA-21	O
expression	O
level	O
sensitively	O
.	O

We	O
believe	O
that	O
the	O
easily	O
constructed	O
DNA	O
nanoarchitecture	O
and	O
in	O
situ	O
profiling	O
strategy	O
are	O
significant	O
progresses	O
in	O
DNA	O
assembly	O
and	O
molecule	O
imaging	O
in	O
cells	O
.	O

Breaking	O
sitting	O
with	O
light	O
activities	O
vs	O
structured	O
exercise	O
:	O
a	O
randomised	O
crossover	O
study	O
demonstrating	O
benefits	O
for	O
glycaemic	O
control	O
and	O
insulin	O
sensitivity	O
in	O
type	O
2	O
diabetes	O
.	O

We	O
aimed	O
to	O
examine	O
the	O
effects	O
of	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
vs	O
an	O
energy	O
-matched	O
bout	O
of	O
structured	O
exercise	O
on	O
24	O
h	O
glucose	O
levels	O
and	O
insulin	O
resistance	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

In	O
a	O
randomised	O
crossover	O
study	O
,	O
19	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
13	O
men	O
/6	O
women	O
,	O
63	O
±	O
9	O
years	O
old	O
)	O
who	O
were	O
not	O
using	O
insulin	O
each	O
followed	O
three	O
regimens	O
under	O
free-living	O
condition	O
s	O
,	O
each	O
lasting	O
4	O
days	O
:	O
(	O
1	O
)	O
Sitting	O
:	O
4415	O
steps	O
/	O
day	O
with	O
14	O
h	O
sitting	O
/	O
day	O
;	O
(	O
2	O
)	O
Exercise	O
:	O
4823	O
steps	O
/	O
day	O
with	O
1.1	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
moderate	O
-	O
to	O
vigorous-intensity	O
cycling	O
(	O
at	O
an	O
intensity	O
of	O
5.9	O
metabolic	O
equivalents	O
[	O
METs	O
]	O
)	O
;	O
and	O
(	O
3	O
)	O
Sit	O
Less	O
:	O
17,502	O
steps	O
/	O
day	O
with	O
4.7	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
standing	O
and	O
light-intensity	O
walking	O
(	O
an	O
additional	O
2.5	O
h	O
and	O
2.2	O
h	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
hours	O
spent	O
doing	O
these	O
activities	O
in	O
the	O
Sitting	O
regimen	O
)	O
.	O

Blocked	O
randomisation	O
was	O
performed	O
using	O
a	O
block	O
size	O
of	O
six	O
regimen	O
orders	O
using	O
sealed	O
,	O
non-translucent	O
envelopes	O
.	O

Individuals	O
who	O
assessed	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O

Meals	O
were	O
standardised	O
during	O
each	O
intervention	O
.	O

Physical	O
activity	O
and	O
glucose	O
levels	O
were	O
assessed	O
for	O
24	O
h/	O
day	O
by	O
accelerometry	B-P
(	O
activPAL	B-P
)	O
and	O
a	O
glucose	O
monitor	O
(	O
iPro2	O
)	O
,	O
respectively	O
.	O

The	O
incremental	O
AUC	O
(	O
iAUC	O
)	O
for	O
24	O
h	O
glucose	O
(	O
primary	O
outcome	O
)	O
and	O
insulin	O
resistance	O
(	O
HOMA2-IR	O
)	O
were	O
assessed	O
on	O
days	O
4	O
and	O
5	O
,	O
respectively	O
.	O

The	O
iAUC	O
for	O
24	O
h	O
glucose	O
(	O
mean	O
±	O
SEM	O
)	O
was	O
significantly	O
lower	O
during	O
the	O
Sit	O
Less	O
intervention	O
than	O
in	O
Sitting	O
(	O
1263	O
±	O
189	O
min	O
×	O
mmol/l	O
vs	O
1974	O
±	O
324	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.002	O
)	O
,	O
and	O
was	O
similar	O
between	O
Sit	O
Less	O
and	O
Exercise	O
(	O
Exercise	O
:	O
1383	O
±	O
194	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.499	O
)	O
.	O

Exercise	O
failed	O
to	O
improve	O
HOMA2-IR	O
compared	O
with	O
Sitting	O
(	O
2.06	O
±	O
0.28	O
vs	O
2.16	O
±	O
0.26	O
;	O
p	O
=	O
0.177	O
)	O
.	O

In	O
contrast	O
,	O
Sit	O
Less	O
(	O
1.89	O
±	O
0.26	O
)	O
significantly	O
reduced	O
HOMA2-IR	O
compared	O
with	O
Exercise	O
(	O
p	O
=	O
0.015	O
)	O
as	O
well	O
as	O
Sitting	O
(	O
p	O
=	O
0.001	O
)	O
.	O

Breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
effectively	O
improved	O
24	O
h	O
glucose	O
levels	O
and	O
improved	O
insulin	O
sensitivity	O
in	O
individuals	O
with	O
type	O
2	O
diabetes	O
to	O
a	O
greater	O
extent	O
than	O
structured	O
exercise	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
may	O
be	O
an	O
alternative	O
to	O
structured	O
exercise	O
to	O
promote	O
glycaemic	O
control	O
in	O
patients	O
type	O
2	O
diabetes	O
.	O

Clinicaltrials.gov	O
NCT02371239	O
FUNDING	O
:	O
:	O
The	O
study	O
was	O
supported	O
by	O
a	O
Kootstra	O
grant	O
from	O
Maastricht	O
University	O
Medical	O
Centre	O
(	O
+	O
)	O
,	O
and	O
the	O
Dutch	O
Heart	O
Foundation	O
.	O

Financial	O
support	O
was	O
also	O
provided	O
by	O
Novo	O
Nordisk	O
BV	O
,	O
and	O
Medtronic	O
and	O
Roche	O
made	O
the	O
equipment	O
available	O
for	O
continuous	O
glucose	O
monitoring	O
.	O

Impending	O
Atypical	O
Femoral	O
Fracture	O
in	O
Patients	O
With	O
Medullary	O
Thyroid	O
Cancer	O
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Atypical	O
femoral	O
fractures	O
(	O
AFFs	O
)	O
occur	O
in	O
osteoporosis	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
.	O

Atypical	O
femoral	O
fractures	O
also	O
occur	O
in	O
cancer	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
or	O
denosumab	O
,	O
but	O
the	O
prevalence	O
is	O
low	O
.	O

We	O
describe	O
a	O
53-	O
year	O
-old	O
woman	O
with	O
a	O
history	O
of	O
medullary	O
thyroid	O
cancer	O
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	O
for	O
6	O
years	O
and	O
denosumab	O
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

Bone	B-P
scintigraphy	I-P
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	O
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	O
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

In	O
oncological	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	B-P
diagnosis	I-P
with	O
focal	O
femoral	O
findings	O
.	O

T1	O
and	O
T2	O
Mapping	O
in	O
Recognition	O
of	O
Early	O
Cardiac	O
Involvement	O
in	O
Systemic	O
Sarcoidosis	O
.	O

Purpose	O
To	O
determine	O
whether	O
quantitative	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
supports	O
recognition	O
of	O
myocardial	O
involvement	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Materials	O
and	O
Methods	O
Fifty-three	O
consecutive	O
patients	O
with	O
a	O
biopsy-proven	B-P
extracardiac	O
diagnosis	O
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	B-P
resonance	I-P
imaging	I-P
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	O
and	O
late	B-P
gadolinium	I-P
enhancement	I-P
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

A	O
follow-up	O
substudy	O
was	O
performed	O
in	O
40	O
patients	O
(	O
mean	O
follow-up	O
interval	O
,	O
144	O
days	O
±	O
35	O
[	O
standard	O
deviation	O
]	O
)	O
;	O
of	O
these	O
40	O
patients	O
,	O
18	O
underwent	O
anti-inflammatory	O
treatment	O
for	O
systemic	O
symptoms	O
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	O
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	O
;	O
Wilcoxon	O
signed	O
rank	O
test	O
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
.	O

Results	O
When	O
compared	O
with	O
control	O
subjects	O
,	O
patients	O
had	O
higher	O
ventricular	O
volume	O
,	O
higher	O
myocardial	O
native	O
T1	O
and	O
T2	O
,	O
and	O
lower	O
longitudinal	O
strain	O
and	O
ejection	O
fraction	O
(	O
P	O
<	O
.05	O
for	O
all	O
)	O
.	O

Myocardial	O
native	O
T1	O
and	O
T2	O
had	O
higher	O
discriminatory	O
accuracy	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AUC	O
]	O
:	O
0.96	O
and	O
0.89	O
,	O
respectively	O
)	O
for	O
separation	O
between	O
control	O
subjects	O
and	O
patients	O
when	O
compared	O
with	O
the	O
standard	O
diagnostic	O
criteria	O
(	O
AUC	O
<	O
0.67	O
)	O
.	O

Native	O
T1	O
was	O
the	O
independent	O
discriminator	O
between	O
health	O
and	O
disease	O
(	O
specificity	O
,	O
90	O
%	O
;	O
sensitivity	O
,	O
96	O
%	O
;	O
accuracy	O
,	O
94	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	O
(	O
z	O
score	O
:	O
-3.72	O
and	O
-2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	O
in	O
the	O
patients	O
who	O
did	O
not	O
(	O
z	O
score	O
,	O
-1.42	O
and	O
-1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

Conclusion	O
Quantitative	O
myocardial	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	O
recognition	O
of	O
cardiac	O
involvement	O
and	O
activity	O
of	O
myocardial	O
inflammation	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Future	O
studies	O
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	O
and	O
guidance	O
of	O
clinical	O
management	O
.	O

(	O
©	O
)	O
RSNA	O
,	O
2017	O
Online	O
supplemental	O
material	O
is	O
available	O
for	O
this	O
article	O
.	O

Validating	O
Signs	O
and	O
Symptoms	O
From	O
An	O
Actual	O
Mass	O
Casualty	O
Incident	O
to	O
Characterize	O
An	O
Irritant	O
Gas	O
Syndrome	O
Agent	O
(	O
IGSA	O
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	O
of	O
a	O
Novel	O
IGSA	O
Triage	O
Algorithm	O
.	O

Chemical	O
exposures	O
can	O
pose	O
a	O
significant	O
threat	O
to	O
life	O
.	O

Rapid	O
assessment	O
by	O
first	O
responders	O
/	O
emergency	O
nurses	O
is	O
required	O
to	O
reduce	O
death	O
and	O
disability	O
.	O

Currently	O
,	O
no	O
informatics	O
tools	O
for	O
irritant	O
gas	O
syndrome	O
agent	O
s	O
(	O
IGSA	O
)	O
exposures	O
exist	O
to	O
process	O
victims	O
efficiently	O
,	O
continuously	O
monitor	O
for	O
latent	O
signs/symptoms	O
,	O
or	O
make	O
triage	O
recommendations	O
.	O

This	O
study	O
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	O
informatics	O
tools	O
for	O
chemical	O
incidents	O
:	O
validation	O
of	O
signs/symptoms	O
that	O
characterize	O
an	O
IGSA	O
syndrome	O
.	O

Data	O
abstracted	O
from	O
146	O
patients	O
treated	O
for	O
chlorine	O
exposure	O
in	O
one	O
emergency	O
department	O
during	O
a	O
2005	O
train	O
derailment	O
and	O
152	O
patients	O
not	O
exposed	O
to	O
chlorine	O
(	O
a	O
comparison	O
group	O
)	O
were	O
mapped	O
to	O
93	O
possible	O
signs/symptoms	O
within	O
2	O
tools	O
(	O
WISER	O
and	O
CHEMM-IST	O
)	O
designed	O
to	O
assist	O
emergency	O
responders	O
/	O
emergency	O
nurses	O
with	O
managing	O
hazardous	O
material	O
exposures	O
.	O

Inferential	O
statistics	O
(	O
χ	O
(	O
2	O
)	O
/	O
Fisher	O
's	O
exact	O
test	O
)	O
and	O
diagnostics	B-P
tests	I-P
were	O
used	O
to	O
examine	O
mapped	O
signs/symptoms	O
of	O
persons	O
who	O
were	O
and	O
were	O
not	O
exposed	O
to	O
chlorine	O
.	O

Three	O
clusters	O
of	O
signs/symptoms	O
are	O
statistically	O
associated	O
with	O
an	O
IGSA	O
syndrome	O
(	O
P	O
<	O
.01	O
)	O
:	O
respiratory	O
(	O
shortness	O
of	O
breath	O
,	O
wheezing	O
,	O
coughing	O
,	O
and	O
choking	O
)	O
;	O
chest	O
discomfort	O
(	O
tightness	O
,	O
pain	O
,	O
and	O
burning	O
)	O
,	O
and	O
eye	O
,	O
nose	O
and/or	O
throat	O
(	O
pain	O
,	O
irritation	O
,	O
and	O
burning	O
)	O
.	O

The	O
syndrome	O
requires	O
the	O
presence	O
of	O
signs/symptoms	O
from	O
at	O
least	O
2	O
of	O
these	O
clusters	O
.	O

The	O
latency	O
period	O
must	O
also	O
be	O
considered	O
for	O
exposed	O
/	O
potentially	O
exposed	O
persons	O
.	O

This	O
study	O
uses	O
actual	O
patient	O
data	O
from	O
a	O
chemical	O
incident	O
to	O
characterize	O
and	O
validate	O
signs/symptoms	O
of	O
an	O
IGSA	O
syndrome	O
.	O

Validating	O
signs/symptoms	O
is	O
the	O
first	O
step	O
in	O
developing	O
new	O
ED	O
informatics	O
tools	O
with	O
the	O
potential	O
to	O
revolutionize	O
the	O
process	O
by	O
which	O
emergency	O
nurses	O
manage	O
triage	O
victims	O
of	O
chemical	O
incidents	O
.	O

Neonatal	O
diffusion	B-P
tensor	I-P
brain	I-P
imaging	I-P
predicts	O
later	O
motor	O
outcome	O
in	O
preterm	O
neonates	O
with	O
white	O
matter	O
abnormalities	O
.	O

White	O
matter	O
(	O
WM	O
)	O
abnormalities	O
associated	O
with	O
prematurity	O
are	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
neurological	O
disability	O
that	O
involves	O
spastic	O
motor	O
deficits	O
in	O
preterm	O
newborns	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
regional	O
microstructural	O
changes	O
in	O
diffusion	B-P
tensor	I-P
imaging	I-P
(	O
DTI	B-P
)	O
associated	O
with	O
WM	O
abnormalities	O
.	O

We	O
prospectively	O
studied	O
extremely	O
low	O
birth	O
weight	O
(	O
ELBW	O
;	O
<	O
1000	O
g	O
)	O
preterm	O
infants	O
who	O
were	O
admitted	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
of	O
Hanyang	O
University	O
Hospital	O
between	O
February	O
2011	O
and	O
February	O
2014	O
.	O

WM	O
abnormalities	O
were	O
assessed	O
with	O
conventional	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
and	O
DTI	B-P
near	O
term-equivalent	O
age	O
before	O
discharge	O
.	O

Region-of-interests	O
(	O
ROIs	O
)	O
measurements	O
were	O
performed	O
to	O
examine	O
the	O
regional	O
distribution	O
of	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
values	O
.	O

Thirty-two	O
out	O
of	O
72	O
ELBW	O
infants	O
underwent	O
conventional	O
MR	B-P
imaging	I-P
and	O
DTI	B-P
at	O
term-equivalent	O
age	O
.	O

Ten	O
of	O
these	O
infants	O
developed	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
.	O

Five	O
of	O
ten	O
of	O
those	O
with	O
WM	O
abnormalities	O
developed	O
cerebral	O
palsy	O
(	O
CP	O
)	O
.	O

DTI	B-P
in	O
the	O
WM	O
abnormalities	O
with	O
CP	O
showed	O
a	O
significant	O
reduction	O
of	O
mean	O
FA	O
in	O
the	O
genu	O
of	O
the	O
corpus	O
callosum	O
(	O
p	O
=	O
0.022	O
)	O
,	O
the	O
ipsilateral	O
posterior	O
limb	O
of	O
the	O
internal	O
capsule	O
(	O
p	O
=	O
0.019	O
)	O
,	O
and	O
the	O
ipsilateral	O
centrum	O
semiovale	O
(	O
p	O
=	O
0.012	O
)	O
compared	O
to	O
normal	O
WM	O
and	O
WM	O
abnormalities	O
without	O
CP	O
.	O

In	O
infants	O
having	O
WM	O
abnormalities	O
with	O
CP	O
,	O
early	O
FA	O
values	O
in	O
neonatal	O
DTI	B-P
revealed	O
abnormalities	O
of	O
the	O
WM	O
regions	O
prior	O
to	O
the	O
manifestation	O
of	O
hemiparesis	O
.	O

DTI	B-P
performed	O
at	O
term	O
equivalent	O
age	O
shows	O
different	O
FA	O
values	O
in	O
WM	O
regions	O
among	O
infants	O
with	O
or	O
without	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
and/or	O
CP	O
.	O

Low	O
FA	O
values	O
of	O
ROIs	O
in	O
DTI	B-P
are	O
related	O
with	O
later	O
development	O
of	O
spastic	O
CP	O
in	O
preterm	O
infants	O
with	O
WM	O
abnormalities	O
.	O

Development	O
of	O
a	O
Robotic	O
Colonoscopic	O
Manipulation	O
System	O
,	O
Using	O
Haptic	O
Feedback	O
Algorithm	O
.	O

Colonoscopy	B-P
is	O
one	O
of	O
the	O
most	O
effective	O
diagnostic	O
and	O
therapeutic	O
tools	O
for	O
colorectal	O
diseases	O
.	O

We	O
aim	O
to	O
propose	O
a	O
master-slave	O
robotic	O
colonoscopy	B-P
that	O
is	O
controllable	O
in	O
remote	O
site	O
using	O
conventional	O
colonoscopy	B-P
.	O

The	O
master	O
and	O
slave	O
robot	O
were	O
developed	O
to	O
use	O
conventional	O
flexible	O
colonoscopy	B-P
.	O

The	O
robotic	O
colonoscopic	O
procedure	O
was	O
performed	O
using	O
a	O
colonoscope	O
training	O
model	O
by	O
one	O
expert	O
endoscopist	O
and	O
two	O
unexperienced	O
engineers	O
.	O

To	O
provide	O
the	O
haptic	O
sensation	O
,	O
the	O
insertion	O
force	O
and	O
the	O
rotating	O
torque	O
were	O
measured	O
and	O
sent	O
to	O
the	O
master	O
robot	O
.	O

A	O
slave	O
robot	O
was	O
developed	O
to	O
hold	O
the	O
colonoscopy	B-P
and	O
its	O
knob	O
,	O
and	O
perform	O
insertion	O
,	O
rotation	O
,	O
and	O
two	O
tilting	O
motions	O
of	O
colonoscope	O
.	O

A	O
master	O
robot	O
was	O
designed	O
to	O
teach	O
motions	O
of	O
the	O
slave	O
robot	O
.	O

These	O
measured	O
force	O
and	O
torque	O
were	O
scaled	O
down	O
by	O
one	O
tenth	O
to	O
provide	O
the	O
operator	O
with	O
some	O
reflection	O
force	O
and	O
torque	O
at	O
the	O
haptic	O
device	O
.	O

The	O
haptic	O
sensation	O
and	O
feedback	O
system	O
was	O
successful	O
and	O
helpful	O
to	O
feel	O
the	O
constrained	O
force	O
or	O
torque	O
in	O
colon	O
.	O

The	O
insertion	O
time	O
using	O
robotic	O
system	O
decreased	O
with	O
repeated	O
procedures	O
.	O

This	O
work	O
proposed	O
a	O
robotic	O
approach	O
for	O
colonoscopy	B-P
using	O
haptic	O
feedback	O
algorithm	O
,	O
and	O
this	O
robotic	O
device	O
would	O
effectively	O
perform	O
colonoscopy	B-P
with	O
reduced	O
burden	O
and	O
comparable	O
safety	O
for	O
patients	O
in	O
remote	O
site	O
.	O

Physical	O
Exercise	O
for	O
Late-Life	O
Depression	O
:	O
Effects	O
on	O
Heart	O
Rate	O
Variability	O
.	O

Late-life	O
major	O
depression	O
is	O
associated	O
with	O
increased	O
cardiovascular	O
risk	O
and	O
impaired	O
autonomic	O
control	O
of	O
the	O
heart	O
,	O
as	O
evident	O
from	O
reduced	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
.	O

Moreover	O
,	O
antidepressant	O
drug	O
therapy	O
also	O
might	O
be	O
associated	O
with	O
further	O
reductions	O
of	O
HRV	O
.	O

In	O
the	O
SEEDS	O
study	O
,	O
we	O
investigated	O
whether	O
sertraline	O
associated	O
with	O
physical	O
exercise	O
protocols	O
led	O
to	O
improvements	O
of	O
HRV	O
,	O
compared	O
with	O
antidepressant	O
drug	O
therapy	O
alone	O
.	O

Single-blind	O
randomized	O
controlled	O
trial	O
.	O

Psychiatric	O
consultation	O
-liaison	O
program	O
for	O
primary	O
care	O
.	O

Patients	O
aged	O
65-85	O
years	O
with	O
major	O
depression	O
,	O
recruited	O
from	O
primary	O
care	O
.	O

Sertraline	O
plus	O
structured	O
,	O
tailored	O
group	O
physical	O
exercise	O
(	O
S	O
+	O
EX	O
)	O
versus	O
sertraline	O
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	O
.	O

HRV	O
indices	O
(	O
RR	O
,	O
percentage	O
of	O
NN	O
intervals	O
greater	O
than	O
50	O
msec	O
[	O
pNN50	O
]	O
,	O
square	O
root	O
of	O
the	O
mean	O
squared	O
differences	O
of	O
successive	O
NN	O
intervals	O
[	O
RMSSD	O
]	O
,	O
standard	O
deviation	O
of	O
heart	O
rate	O
[	O
SDHR	O
]	O
,	O
standard	O
deviation	O
of	O
the	O
NN	O
interval	O
[	O
SDNN	O
]	O
,	O
high-frequency	O
band	O
[	O
HF	O
]	O
,	O
low-frequency	O
band	O
[	O
LF	O
]	O
,	O
and	O
their	O
ratio	O
[	O
LF/HF	O
]	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
.	O

Psychiatric	B-P
and	O
medical	O
assessments	O
.	O

Participants	O
displayed	O
significant	O
improvements	O
of	O
most	O
HRV	O
indices	O
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
LF	O
,	O
and	O
LF/HF	O
)	O
.	O

Moreover	O
,	O
patients	O
in	O
the	O
S	O
+	O
EX	O
group	O
displayed	O
greater	O
increases	O
of	O
different	O
HRV	O
indices	O
(	O
RR	O
,	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
and	O
LF	O
)	O
compared	O
with	O
those	O
in	O
the	O
S	O
group	O
.	O

The	O
combination	O
of	O
structured	O
physical	O
exercise	O
and	O
sertraline	O
might	O
exert	O
positive	O
effects	O
on	O
the	O
autonomic	O
control	O
of	O
the	O
heart	O
among	O
older	O
patients	O
with	O
major	O
depression	O
.	O

JS	O
ISH-ECCR-3	O
A	O
NOVEL	O
ALGORITHM	O
FOR	O
THE	O
CASE	O
DETECTION	O
OF	O
THE	O
MOST	O
COMMON	O
FORM	O
OF	O
ENDOCRINE	O
HYPERTENSION	O
.	O

Primary	O
aldosteronism	O
(	O
PA	O
)	O
involves	O
more	O
than	O
11	O
%	O
of	O
patients	O
referred	O
to	O
specialized	O
hypertension	O
centers	O
and	O
,	O
therefore	O
,	O
is	O
much	O
more	O
common	O
than	O
commonly	O
held	O
.	O

Moreover	O
,	O
it	O
causes	O
a	O
damage	O
to	O
the	O
heart	O
,	O
blood	O
vessels	O
and	O
kidneys	O
,	O
which	O
translates	O
into	O
a	O
high	O
rate	O
of	O
cardiovascular	O
events	O
,	O
in	O
excess	O
to	O
the	O
degree	O
of	O
blood	O
pressure	O
raise	O
.	O

Along	O
with	O
the	O
notion	O
that	O
a	O
timely	O
diagnosis	B-P
entails	O
a	O
fundamental	O
step	O
for	O
the	O
choice	O
of	O
an	O
appropriate	O
therapy	O
,	O
which	O
can	O
correct	O
the	O
arterial	O
hypertension	O
and	O
the	O
hypokalemia	O
,	O
this	O
justifies	O
efforts	O
to	O
search	O
for	O
PA	O
in	O
the	O
majority	O
of	O
the	O
patients	O
with	O
hypertension	O
.	O

Unfortunately	O
,	O
because	O
of	O
the	O
lack	O
of	O
the	O
classical	O
signs	O
,	O
as	O
spontaneous	O
or	O
drug-induced	O
hypokalemia	O
and	O
related	O
symptoms	O
,	O
PA	O
deceives	O
diagnosis	B-P
in	O
the	O
majority	O
of	O
the	O
cases	O
.The	O
identification	O
of	O
a	O
curable	O
form	O
of	O
primary	O
aldosteronism	O
can	O
be	O
beneficial	O
particularly	O
in	O
some	O
subgroups	O
of	O
patients	O
,	O
namely	O
those	O
with	O
drug	O
-	O
resistant	O
hypertension	O
,	O
who	O
are	O
at	O
high	O
risk	O
of	O
primary	O
aldosteronism	O
.	O

An	O
aggressive	O
diagnostic	B-P
approach	I-P
is	O
necessary	O
in	O
these	O
patients	O
,	O
who	O
can	O
benefit	O
most	O
from	O
an	O
accurate	O
diagnosis	B-P
.	O

Knowledge	O
of	O
the	O
sodium	O
intake	O
and	O
drug	O
effects	O
on	O
the	O
aldosterone-renin	O
ratio	O
is	O
a	O
key	O
element	O
for	O
the	O
diagnosis	B-P
in	O
these	O
challenging	O
cases	O
.With	O
the	O
latest	O
work-up	B-P
endorsed	O
by	O
the	O
Endocrine	O
Society	O
Guidelines	O
and	O
supported	O
by	O
the	O
results	O
of	O
the	O
AQUARR	O
Study	O
,	O
the	O
diagnostic	O
algorithm	O
for	O
PA	O
can	O
be	O
substantially	O
simplified	O
.	O

This	O
means	O
skipping	O
the	O
so-called	O
confirmatory	O
tests	B-P
in	O
most	O
cases	O
and	O
thus	O
rendering	O
the	O
screening	B-P
of	O
PA	O
feasible	O
and	O
affordable	O
.	O

Hence	O
,	O
most	O
centers	O
can	O
nowadays	O
exploit	O
use	O
of	O
a	O
cost	O
-	O
effective	O
strategy	O
to	O
screen	O
for	O
patients	O
with	O
primary	O
aldosteronism	O
.	O

At	O
variance	O
,	O
the	O
identification	O
of	O
primary	O
aldosteronism	O
subtypes	O
,	O
which	O
involves	O
adrenal	B-P
vein	I-P
sampling	I-P
(	O
AVS	B-P
)	O
,	O
should	O
only	O
be	O
undertaken	O
at	O
tertiary	O
referral	O
centers	O
that	O
have	O
experience	O
in	O
performing	O
and	O
interpreting	O
this	O
minimally	B-P
invasive	I-P
test	I-P
.Overall	O
,	O
long-term	O
cure	O
biochemical	O
cure	O
can	O
be	O
consistently	O
achieved	O
when	O
adrenalectomy	O
is	O
based	O
on	O
AVS	B-P
-	O
based	O
identification	O
of	O
lateralized	O
aldosterone	O
excess	O
.	O

Moreover	O
,	O
long-term	O
cure	O
of	O
hypertension	O
,	O
defined	O
as	O
no	O
need	O
for	O
antihypertensive	O
drug	O
treatment	O
,	O
can	O
be	O
achieved	O
in	O
about	O
45	O
%	O
of	O
the	O
cases	O
,	O
with	O
an	O
additional	O
40	O
%	O
showing	O
a	O
marked	O
improvement	O
in	O
blood	O
pressure	O
control	O
.	O

Lack	O
of	O
blood	O
pressure	O
normalization	O
can	O
be	O
explained	O
by	O
misdiagnosis	O
and/or	O
concomitant	O
essential	O
hypertension	O
.	O

The	O
Use	O
of	O
a	O
Software	O
-	O
Assisted	O
Method	O
to	O
Estimate	O
Fetal	O
Weight	O
at	O
and	O
Near	O
Term	O
Using	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
apply	O
a	O
semi-automated	O
calculation	O
method	O
of	O
fetal	O
body	O
volume	O
and	O
,	O
thus	O
,	O
of	O
magnetic	O
resonance-estimated	O
fetal	O
weight	O
(	O
MR-EFW	O
)	O
prior	O
to	O
planned	O
delivery	O
and	O
to	O
evaluate	O
whether	O
the	O
technique	O
of	O
measurement	O
could	O
be	O
simplified	O
while	O
remaining	O
accurate	O
.	O

MR-EFW	O
was	O
calculated	O
using	O
a	O
semi-automated	O
method	O
at	O
38.6	O
weeks	O
of	O
gestation	O
in	O
36	O
patients	O
and	O
compared	O
to	O
the	O
picture	O
archiving	O
and	O
communication	O
system	O
(	O
PACS	O
)	O
.	O

Per	O
patient	O
,	O
8	O
sequences	O
were	O
acquired	O
with	O
a	O
slice	O
thickness	O
of	O
4-8	O
mm	O
and	O
an	O
intersection	O
gap	O
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O

The	O
median	O
absolute	O
relative	O
errors	O
for	O
MR-EFW	O
and	O
the	O
time	O
of	O
planimetric	O
measurements	O
were	O
calculated	O
for	O
all	O
8	O
sequences	O
and	O
for	O
each	O
method	O
(	O
assisted	O
vs.	O
PACS	O
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	O
was	O
calculated	O
.	O

The	O
median	O
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	O
relative	O
error	O
for	O
all	O
288	O
MR-EFW	O
calculations	O
was	O
2.4	O
%	O
using	O
the	O
semi-automated	O
method	O
and	O
2.2	O
%	O
for	O
the	O
PACS	O
method	O
.	O

Measurements	O
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	O
using	O
the	O
assisted	O
method	O
(	O
p	O
=	O
0.313	O
)	O
or	O
the	O
PACS	O
(	O
p	O
=	O
0.118	O
)	O
,	O
while	O
the	O
time	O
of	O
planimetric	O
measurement	O
decreased	O
significantly	O
with	O
a	O
larger	O
gap	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
assisted	O
method	O
compared	O
to	O
the	O
PACS	O
method	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Our	O
simplified	O
MR-EFW	O
measurement	O
showed	O
a	O
dramatic	O
decrease	O
in	O
time	O
of	O
planimetric	O
measurement	O
without	O
a	O
decrease	O
in	O
the	O
accuracy	O
of	O
weight	O
estimates	O
.	O

Toe	O
Pressure	O
and	O
Toe	B-P
Brachial	I-P
Index	I-P
are	O
Predictive	O
of	O
Cardiovascular	O
Mortality	O
,	O
Overall	O
Mortality	O
,	O
and	O
Amputation	O
Free	O
Survival	O
in	O
Patients	O
with	O
Peripheral	O
Artery	O
Disease	O
.	O

Peripheral	O
haemodynamic	O
parameters	O
are	O
used	O
to	O
assess	O
the	O
presence	O
and	O
severity	O
of	O
peripheral	O
artery	O
disease	O
(	O
PAD	O
)	O
.	O

The	O
prognostic	O
value	O
of	O
ankle	B-P
brachial	I-P
index	I-P
(	O
ABI	B-P
)	O
has	O
been	O
thoroughly	O
delineated	O
.	O

Nonetheless	O
,	O
the	O
relative	O
usefulness	O
of	O
ankle	O
pressure	O
(	O
AP	O
)	O
,	O
ABI	B-P
,	O
toe	O
pressure	O
(	O
TP	O
)	O
,	O
and	O
toe	B-P
brachial	I-P
index	I-P
(	O
TBI	B-P
)	O
in	O
assessing	O
patient	O
outcome	O
has	O
not	O
been	O
investigated	O
in	O
a	O
concurrent	O
study	O
setting	O
.	O

This	O
study	O
aimed	O
to	O
resolve	O
the	O
association	O
of	O
all	O
four	O
non-invasive	O
haemodynamic	O
parameters	O
in	O
clinically	O
symptomatic	O
patients	O
with	O
PAD	O
with	O
cardiovascular	O
mortality	O
,	O
overall	O
mortality	O
,	O
and	O
amputation	O
free	O
survival	O
(	O
AFS	O
)	O
.	O

In	O
total	O
,	O
732	O
symptomatic	O
patients	O
with	O
PAD	O
admitted	O
to	O
the	O
Department	O
of	O
Vascular	O
Surgery	O
for	O
conventional	B-P
angiography	I-P
at	O
Turku	O
University	O
Hospital	O
,	O
Turku	O
,	O
Finland	O
,	O
between	O
January	O
2009	O
and	O
August	O
2011	O
were	O
reviewed	O
retrospectively	O
.	O

Demographic	O
factors	O
,	O
cardiovascular	O
mortality	O
,	O
all-cause	O
mortality	O
,	O
and	O
above	O
foot	O
level	O
amputations	O
were	O
obtained	O
and	O
assessed	O
in	O
relation	O
to	O
AP	O
,	O
ABI	B-P
,	O
TP	O
,	O
and	O
TBI	B-P
by	O
means	O
of	O
Kaplan-Meier	O
life	O
tables	O
and	O
a	O
multivariate	O
Cox	O
regression	O
model	O
.	O

The	O
haemodynamic	O
parameter	O
that	O
was	O
associated	O
with	O
poor	O
36	O
month	O
general	O
outcome	O
was	O
TP	O
<	O
30	O
mmHg	O
.	O

Univariate	O
Cox	O
regression	O
analysis	O
of	O
stratified	O
values	O
showed	O
that	O
TP	O
and	O
TBI	B-P
associated	O
significantly	O
with	O
mortality	O
.	O

In	O
multivariate	O
analysis	O
both	O
TP	O
and	O
TBI	B-P
were	O
associated	O
with	O
a	O
significant	O
risk	O
of	O
death	O
.	O

For	O
TP	O
<	O
30	O
mmHg	O
and	O
TBI	B-P
<	O
0.25	O
the	O
risk	O
of	O
cardiovascular	O
mortality	O
was	O
hazard	O
ratio	O
[	O
HR	O
]	O
2.84	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.75-4.61	O
[	O
p	O
<	O
.001	O
]	O
;	O
HR	O
3.68	O
,	O
95	O
%	O
CI	O
1.48-9.19	O
[	O
p=.050	O
]	O
,	O
respectively	O
;	O
all-cause	O
mortality	O
(	O
HR	O
2.05	O
,	O
95	O
%	O
CI	O
1.44-2.92	O
[	O
p	O
<	O
.001	O
]	O
;	O
HR	O
2.53	O
,	O
95	O
%	O
CI	O
1.35-4.74	O
[	O
p=.040	O
]	O
,	O
respectively	O
)	O
;	O
and	O
amputation	O
or	O
death	O
(	O
HR	O
2.13	O
,	O
95	O
%	O
CI	O
1.52-2.98	O
[	O
p	O
<	O
.001	O
]	O
;	O
HR	O
2.46	O
,	O
95	O
%	O
CI	O
1.38-4.40	O
[	O
p=.050	O
]	O
,	O
respectively	O
)	O
...	O

Among	O
non-invasive	O
haemodynamic	O
measurements	O
and	O
pressure	O
indices	O
both	O
TP	O
and	O
TBI	B-P
appear	O
to	O
be	O
associated	O
with	O
cardiovascular	O
and	O
overall	O
mortality	O
and	O
AFS	O
for	O
patients	O
with	O
PAD	O
presenting	O
symptoms	O
of	O
the	O
disease	O
.	O

Laparascopic	O
Splenectomy	O
Due	O
to	O
Splenic	O
Injury	O
after	O
Colonoscopy	B-P
.	O

Colonoscopy	B-P
,	O
which	O
is	O
routinely	O
performed	O
in	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	O
disorders	O
,	O
is	O
a	O
reliable	O
procedure	O
.	O

Its	O
most	O
frequent	O
complications	O
are	O
bleeding	O
and	O
perforation	O
.	O

Splenic	O
rupture	O
is	O
a	O
very	O
rarely	O
met	O
complication	O
of	O
colonoscopy	B-P
,	O
and	O
delay	O
in	O
its	O
diagnosis	O
leads	O
to	O
increased	O
morbidity	O
and	O
mortality	O
.	O

We	O
presented	O
a	O
69	O
years	O
old	O
female	O
patient	O
,	O
who	O
was	O
diagnosed	O
by	O
computerized	B-P
abdominal	I-P
tomography	I-P
,	O
performed	O
for	O
her	O
abdominal	O
pain	O
,	O
which	O
started	O
following	O
the	O
colonoscopy	B-P
.	O

After	O
15	O
days	O
of	O
medical	O
treatment	O
and	O
follow-up	O
,	O
laparoscopic	O
splenectomy	O
was	O
performed	O
one	O
month	O
after	O
her	O
colonoscopy	B-P
.	O

The	O
patient	O
was	O
discharged	O
on	O
her	O
4	O
(	O
th	O
)	O
postoperative	O
day	O
,	O
with	O
uneventful	O
recovery	O
.	O

In	O
patients	O
who	O
have	O
complaint	O
of	O
abdominal	O
pain	O
following	O
colonoscopy	B-P
,	O
an	O
intraabdominal	O
pathological	O
condition	O
should	O
be	O
considered	O
and	O
computerized	B-P
abdominal	I-P
tomography	I-P
should	O
be	O
performed	O
.	O

If	O
there	O
is	O
no	O
detected	O
intraperitoneal	O
bleeding	O
,	O
in	O
other	O
words	O
,	O
if	O
there	O
is	O
a	O
sub-capsular	O
hematoma	O
of	O
the	O
spleen	O
,	O
medical	O
management	O
by	O
monitoring	O
the	O
vital	O
signs	O
may	O
be	O
preferred	O
.	O

Then	O
,	O
splenectomy	O
should	O
be	O
performed	O
at	O
an	O
appropriate	O
time	O
.	O

Bone	O
Marrow	O
-Derived	O
Mesenchymal	O
Stem	O
Cells	O
-Derived	O
Exosomes	O
Promote	O
Survival	O
of	O
Retinal	O
Ganglion	O
Cells	O
Through	O
miRNA	O
-Dependent	O
Mechanisms	O
.	O

The	O
loss	O
of	O
retinal	O
ganglion	O
cells	O
(	O
RGC	O
)	O
and	O
their	O
axons	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
blindness	O
and	O
includes	O
traumatic	O
(	O
optic	O
neuropathy	O
)	O
and	O
degenerative	O
(	O
glaucoma	O
)	O
eye	O
diseases	O
.	O

Although	O
no	O
clinical	O
therapies	O
are	O
in	O
use	O
,	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
have	O
demonstrated	O
significant	O
neuroprotective	O
and	O
axogenic	O
effects	O
on	O
RGC	O
in	O
both	O
of	O
the	O
aforementioned	O
models	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
MSC	O
secrete	O
exosomes	O
,	O
membrane	O
enclosed	O
vesicles	O
(	O
30-100	O
nm	O
)	O
containing	O
proteins	O
,	O
mRNA	O
and	O
miRNA	O
which	O
can	O
be	O
delivered	O
to	O
nearby	O
cells	O
.	O

The	O
present	O
study	O
aimed	O
to	O
isolate	O
exosomes	O
from	O
bone	O
marrow	O
-derived	O
MSC	O
(	O
BMSC	O
)	O
and	O
test	O
them	O
in	O
a	O
rat	O
optic	O
nerve	O
crush	O
(	O
ONC	O
)	O
model	O
.	O

Treatment	O
of	O
primary	O
retinal	O
cultures	O
with	O
BMSC	O
-	O
exosomes	O
demonstrated	O
significant	O
neuroprotective	O
and	O
neuritogenic	O
effects	O
.	O

Twenty-one	O
days	O
after	O
ONC	O
and	O
weekly	O
intravitreal	O
exosome	O
injections	O
;	O
optical	B-P
coherence	I-P
tomography	I-P
,	O
electroretinography	B-P
,	O
and	O
immunohistochemistry	B-P
was	O
performed	O
.	O

BMSC	O
-derived	O
exosomes	O
promoted	O
statistically	O
significant	O
survival	O
of	O
RGC	O
and	O
regeneration	O
of	O
their	O
axons	O
while	O
partially	O
preventing	O
RGC	O
axonal	O
loss	O
and	O
RGC	O
dysfunction	O
.	O

Exosomes	O
successfully	O
delivered	O
their	O
cargo	O
into	O
inner	O
retinal	O
layers	O
and	O
the	O
effects	O
were	O
reliant	O
on	O
miRNA	O
,	O
demonstrated	O
by	O
the	O
diminished	O
therapeutic	O
effects	O
of	O
exosomes	O
derived	O
from	O
BMSC	O
after	O
knockdown	O
of	O
Argonaute-2	O
,	O
a	O
key	O
miRNA	O
effector	O
molecule	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
BMSC	O
-derived	O
exosomes	O
as	O
a	O
cell-free	O
therapy	O
for	O
traumatic	O
and	O
degenerative	O
ocular	O
disease	O
.	O

Stem	O
Cells	O
Translational	O
Medicine	O
2017	O
;	O
6:1273-1285	O
.	O

Impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
in	O
laparoscopic	O
cholecystectomy	O
:	O
Experience	O
of	O
an	O
academic	O
Surgical	O
Department	O
in	O
a	O
developing	O
country	O
.	O

Resident	O
participation	O
in	O
laparoscopic	O
cholecystectomy	O
(	O
LC	O
)	O
is	O
one	O
of	O
the	O
first	O
steps	O
of	O
laparoscopic	O
training	O
.	O

The	O
impact	O
of	O
this	O
training	O
is	O
not	O
well-defined	O
,	O
especially	O
in	O
developing	O
countries	O
.	O

However	O
,	O
this	O
training	O
is	O
of	O
critical	O
importance	O
to	O
monitor	O
surgical	O
teaching	O
programmes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
of	O
LC	O
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
all	O
consecutive	O
laparoscopic	O
cholecystectomies	O
for	O
gallbladder	O
lithiasis	O
performed	O
over	O
2	O
academic	O
years	O
in	O
an	O
academic	O
Surgical	O
Department	O
in	O
Morocco	O
.	O

These	O
operations	O
were	O
performed	O
by	O
junior	O
residents	O
(	O
post-graduate	O
year	O
[	O
PGY	O
]	O
4-5	O
)	O
or	O
senior	O
residents	O
(	O
PGY	O
6	O
)	O
,	O
or	O
attending	O
surgeons	O
assisted	O
by	O
junior	O
residents	O
,	O
none	O
of	O
whom	O
had	O
any	O
advanced	O
training	O
in	O
laparoscopy	B-P
.	O

All	O
data	O
concerning	O
demographics	O
(	O
American	O
Society	O
of	O
Anesthesiologists	O
,	O
body	O
mass	O
index	O
and	O
indications	O
)	O
,	O
surgeons	O
,	O
operative	O
time	O
(	O
from	O
skin	O
incision	O
to	O
closure	O
)	O
,	O
conversion	O
rate	O
and	O
operative	O
complications	O
(	O
Clavien-Dindo	O
classification	O
)	O
were	O
recorded	O
and	O
analysed	O
.	O

One-way	O
analysis	O
of	O
variance	O
,	O
Student	O
's	O
t-test	O
and	O
Chi-square	O
tests	O
were	O
used	O
as	O
appropriate	O
with	O
statistical	O
significance	O
attributed	O
to	O
P	O
<	O
0.05	O
.	O

One	O
hundred	O
thirty-eight	O
LC	O
were	O
performed	O
.	O

No	O
differences	O
were	O
found	O
on	O
univariate	O
analysis	O
between	O
groups	O
in	O
demographics	O
or	O
diagnosis	O
category	O
.	O

The	O
overall	O
rate	O
of	O
operative	O
complications	O
or	O
conversions	O
and	O
hospital	O
stay	O
were	O
not	O
significantly	O
different	O
between	O
the	O
three	O
groups	O
.	O

However	O
,	O
mean	O
operative	O
time	O
was	O
significantly	O
longer	O
for	O
junior	O
residents	O
(	O
n	O
=	O
27	O
;	O
115	O
±	O
24	O
min	O
)	O
compared	O
to	O
senior	O
residents	O
(	O
n	O
=	O
37	O
;	O
77	O
±	O
35	O
min	O
)	O
and	O
attending	O
surgeons	O
(	O
n	O
=	O
66	O
;	O
55	O
±	O
17	O
min	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

LC	O
performed	O
by	O
residents	O
appears	O
to	O
be	O
safe	O
without	O
a	O
significant	O
difference	O
in	O
complication	O
rate	O
;	O
however	O
,	O
seniority	O
influences	O
operative	O
time	O
.	O

This	O
information	O
supports	O
early	O
resident	O
involvement	O
in	O
laparoscopic	O
procedures	O
and	O
also	O
the	O
need	O
to	O
develop	O
cost-effective	O
laboratory	O
training	O
programmes	O
.	O

Ocular	O
Argyrosis	O
Mimicking	O
Conjunctival	O
Melanoma	O
.	O

To	O
present	O
a	O
novel	O
case	O
of	O
ocular	O
argyrosis	O
mimicking	O
conjunctival	O
melanoma	O
.	O

A	O
48-year-old	O
man	O
who	O
is	O
a	O
jewelry	O
manufacturer	O
presented	O
with	O
raised	O
pigmented	O
lesions	O
in	O
the	O
inferior	O
fornices	O
of	O
both	O
eyes	O
.	O

Brown	O
-	O
black	O
colored	O
,	O
follicle-like	O
,	O
masses	O
were	O
observed	O
in	O
both	O
fornices	O
.	O

An	O
incisional	B-P
biopsy	I-P
confirmed	O
the	O
presence	O
of	O
silver	O
and	O
the	O
diagnosis	O
of	O
ocular	O
argyrosis	O
.	O

Despite	O
its	O
limited	O
negative	O
health	O
effects	O
,	O
ocular	O
argyrosis	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
conjunctival	O
pigmented	O
lesions	O
because	O
of	O
the	O
potential	O
for	O
misidentification	O
of	O
neoplastic	O
growth	O
.	O

Accelerated	O
intestinal	O
epithelial	O
cell	O
turnover	O
after	O
bowel	O
resection	O
in	O
a	O
rat	O
is	O
correlated	O
with	O
inhibited	O
hedgehog	O
signaling	O
cascade	O
.	O

The	O
hedgehog	O
(	O
Hh	O
)	O
signaling	O
pathway	O
is	O
one	O
of	O
the	O
key	O
regulators	O
of	O
gastrointestinal	O
tract	O
development	O
.	O

Recent	O
studies	O
point	O
to	O
the	O
role	O
of	O
hedgehog	O
signaling	O
in	O
regulating	O
adult	O
stem	O
cells	O
involved	O
in	O
maintenance	O
and	O
regeneration	O
of	O
intestinal	O
stem	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
Hh	O
signaling	O
during	O
intestinal	O
adaptation	O
in	O
a	O
rat	O
model	O
of	O
short	O
bowel	O
syndrome	O
(	O
SBS	O
)	O
.	O

Male	O
rats	O
were	O
divided	O
into	O
two	O
groups	O
:	O
Sham	O
rats	O
underwent	O
bowel	O
transection	O
and	O
SBS	O
rats	O
underwent	O
a	O
75	O
%	O
bowel	O
resection	O
.	O

Parameters	O
of	O
intestinal	O
adaptation	O
,	O
enterocyte	O
proliferation	O
,	O
and	O
apoptosis	O
were	O
determined	O
2	O
weeks	O
after	O
operation	O
.	O

Illumina	O
's	O
Digital	O
Gene	O
Expression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
Hh	O
signaling	O
gene	O
expression	O
profiling	O
.	O

Hh-related	O
genes	O
and	O
protein	O
expression	O
were	O
determined	O
using	O
Real-Time	O
PCR	O
,	O
Western	O
blotting	O
,	O
and	O
immunohistochemistry	B-P
.	O

Massive	O
small	O
bowel	O
resection	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
enterocyte	O
proliferation	O
and	O
concomitant	O
increase	O
in	O
cell	O
apoptosis	O
.	O

From	O
the	O
total	O
number	O
of	O
20,000	O
probes	O
,	O
13	O
genes	O
related	O
to	O
Hh	O
signaling	O
were	O
investigated	O
.	O

In	O
jejunum	O
,	O
eight	O
genes	O
were	O
down-regulated	O
,	O
three	O
genes	O
up-regulated	O
,	O
and	O
two	O
genes	O
remained	O
unchanged	O
.	O

In	O
ileum	O
,	O
five	O
genes	O
were	O
down-regulated	O
and	O
six	O
genes	O
were	O
unchanged	O
in	O
SBS	O
vs	O
sham	O
animals	O
.	O

SBS	O
rats	O
also	O
demonstrated	O
a	O
significant	O
three-	O
to	O
fourfold	O
decrease	O
in	O
SMO	O
,	O
GIL	O
,	O
and	O
PTCH	O
mRNA	O
,	O
and	O
protein	O
levels	O
(	O
determined	O
by	O
Real-Time	O
PCR	O
and	O
Western	O
blot	O
)	O
compared	O
to	O
control	O
animals	O
.	O

Two	O
weeks	O
following	O
massive	O
bowel	O
resection	O
in	O
rats	O
,	O
the	O
accelerated	O
cell	O
turnover	O
was	O
accompanied	O
by	O
an	O
inhibited	O
Hh	O
signaling	O
pathway	O
.	O

Hh	O
signaling	O
may	O
serve	O
as	O
an	O
important	O
mediator	O
of	O
reciprocal	O
interactions	O
between	O
the	O
epithelium	O
and	O
the	O
underlying	O
mesenchymal	O
stroma	O
during	O
intestinal	O
adaptation	O
following	O
massive	O
bowel	O
resection	O
in	O
a	O
rat	O
.	O

When	O
and	O
how	O
should	O
we	O
manage	O
thoracic	O
aortic	O
injuries	O
in	O
the	O
modern	O
era	O
?	O
.	O

A	O
best	O
evidence	O
topic	O
in	O
cardiovascular	O
surgery	O
was	O
written	O
according	O
to	O
a	O
structured	O
protocol	O
.	O

The	O
question	O
addressed	O
was	O
what	O
are	O
the	O
optimum	O
treatment	O
modality	O
and	O
timing	O
of	O
intervention	O
for	O
blunt	O
thoracic	O
aortic	O
injury	O
(	O
BTAI	O
)	O
in	O
the	O
modern	O
era	O
?	O

Of	O
the	O
697	O
papers	O
found	O
using	O
the	O
reported	O
search	O
,	O
14	O
(	O
5	O
meta-analyses	O
,	O
2	O
prospective	O
and	O
7	O
retrospective	O
studies	O
)	O
represented	O
the	O
best	O
evidence	O
to	O
answer	O
the	O
clinical	O
question	O
.	O

The	O
author	O
,	O
journal	O
,	O
country	O
,	O
date	O
of	O
publication	O
,	O
patient	O
group	O
studied	O
,	O
study	O
type	O
,	O
relevant	O
outcomes	O
,	O
results	O
and	O
weakness	O
of	O
these	O
papers	O
are	O
tabulated	O
.	O

All	O
five	O
meta-analyses	O
reported	O
a	O
reduction	O
in	O
mortality	O
with	O
thoracic	O
endovascular	O
aortic	O
repair	O
(	O
TEVAR	O
)	O
compared	O
with	O
open	O
repair	O
(	O
OR	O
)	O
,	O
but	O
only	O
four	O
found	O
the	O
same	O
benefit	O
on	O
paraplegia	O
rate	O
.	O

Similarly	O
,	O
the	O
two	O
prospective	O
and	O
four	O
retrospective	O
studies	O
showed	O
significantly	O
lower	O
mortality	O
with	O
TEVAR	O
than	O
with	O
OR	O
.	O

Only	O
one	O
study	O
(	O
a	O
meta-analysis	O
)	O
reported	O
a	O
significantly	O
lower	O
stroke	O
rate	O
with	O
TEVAR	O
than	O
with	O
OR	O
,	O
whereas	O
the	O
13	O
others	O
reported	O
a	O
similar	O
or	O
even	O
higher	O
stroke	O
rate	O
.	O

Other	O
complication	O
rates	O
were	O
identical	O
.	O

Four	O
studies	O
demonstrated	O
that	O
non-operative	O
management	O
(	O
NOM	O
)	O
as	O
a	O
treatment	O
option	O
for	O
BTAI	O
was	O
associated	O
with	O
increased	O
mortality	O
,	O
even	O
if	O
it	O
has	O
declined	O
in	O
recent	O
years	O
.	O

One	O
study	O
emphasized	O
that	O
some	O
cases	O
with	O
minimal	O
aortic	O
injuries	O
(	O
Grade	O
I	O
and	O
II	O
on	O
CT	B-P
scan	I-P
)	O
could	O
benefit	O
from	O
NOM	O
.	O

Regarding	O
the	O
timing	O
of	O
repair	O
,	O
only	O
three	O
studies	O
analysed	O
outcomes	O
of	O
delayed	O
repair	O
and	O
reported	O
significantly	O
lower	O
mortality	O
than	O
for	O
early	O
repair	O
.	O

We	O
conclude	O
that	O
with	O
lower	O
mortality	O
and	O
similar	O
overall	O
complications	O
including	O
paraplegia	O
but	O
higher	O
stroke	O
rate	O
,	O
TEVAR	O
is	O
the	O
most	O
suitable	O
treatment	O
for	O
BTAI	O
in	O
the	O
modern	O
era	O
,	O
where	O
expertise	O
exists	O
,	O
especially	O
for	O
cases	O
of	O
multiple	O
associated	O
injuries	O
and	O
in	O
the	O
older	O
age	O
group	O
.	O

Delayed	O
aortic	O
repair	O
can	O
be	O
proposed	O
based	O
on	O
CT	B-P
scan	I-P
analysis	I-P
,	O
but	O
emergent	O
repair	O
should	O
still	O
be	O
advocated	O
for	O
imminent	O
free	O
aortic	O
rupture	O
.	O

NOM	O
remains	O
a	O
therapeutic	O
option	O
but	O
only	O
with	O
selected	O
patients	O
.	O

Adequacy	O
of	O
initial	O
evaluation	O
of	O
fever	O
in	O
long-term	O
care	O
facilities	O
.	O

Febrile	O
residents	O
in	O
long-term	O
care	O
facilities	O
(	O
LTCF	O
)	O
might	O
be	O
inadequately	O
evaluated	O
by	O
caregivers	O
.	O

The	O
present	O
study	O
aimed	O
to	O
examine	O
the	O
factors	O
associated	O
with	O
inadequacy	O
of	O
initial	O
fever	O
evaluations	O
by	O
caregivers	O
at	O
night	O
in	O
LTCF	O
.	O

We	O
carried	O
out	O
a	O
cross-sectional	O
study	O
among	O
a	O
convenience	O
sample	O
of	O
caregivers	O
employed	O
at	O
11	O
LTCF	O
in	O
Japan	O
using	O
a	O
vignette-based	O
questionnaire	O
.	O

The	O
respondents	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
scenarios	O
describing	O
a	O
mild	O
or	O
severe	O
febrile	O
episode	O
in	O
an	O
LTCF	O
resident	O
at	O
night	O
.	O

The	O
respondents	O
'	O
thinking	O
patterns	O
were	O
classified	O
based	O
on	O
influential	O
factors	O
in	O
their	O
fever	O
evaluation	O
.	O

Associations	O
between	O
adequacy	O
of	O
evaluation	O
and	O
respondents	O
'	O
characteristics	O
were	O
evaluated	O
using	O
generalized	O
linear	O
mixed	O
models	O
.	O

A	O
total	O
of	O
34	O
%	O
of	O
fever	O
evaluations	O
among	O
caregivers	O
were	O
considered	O
to	O
be	O
inadequate	O
regarding	O
the	O
necessity	O
for	O
examination	O
by	O
a	O
physician	O
,	O
due	O
in	O
most	O
cases	O
to	O
underestimating	O
the	O
severity	O
of	O
the	O
fever	O
.	O

Respondents	O
'	O
thinking	O
patterns	O
in	O
fever	O
evaluation	O
were	O
significantly	O
associated	O
with	O
the	O
adequacy	O
of	O
the	O
evaluation	O
.	O

Caregivers	O
who	O
placed	O
particular	O
importance	O
on	O
the	O
preferences	O
of	O
residents	O
and	O
families	O
versus	O
other	O
factors	O
including	O
the	O
resident	O
's	O
febrile	O
condition	O
,	O
were	O
more	O
likely	O
to	O
make	O
an	O
inadequate	O
evaluation	O
than	O
those	O
who	O
did	O
not	O
.	O

Our	O
findings	O
here	O
suggest	O
that	O
eagerness	O
to	O
comply	O
with	O
residents	O
'	O
preference	O
in	O
fever	O
evaluation	O
could	O
prompt	O
caregivers	O
not	O
to	O
call	O
for	O
an	O
appropriate	O
diagnostic	B-P
procedure	I-P
.	O

Geriatr	O
Gerontol	O
Int	O
2016	O
;	O
••	O
:	O
••-••	O
.	O

Comparative	O
evaluation	O
of	O
iodine-131	O
metaiodobenzylguanidine	O
and	O
18-fluorodeoxyglucose	O
positron	B-P
emission	I-P
tomography	I-P
in	O
assessing	O
neural	O
crest	O
tumors	O
:	O
Will	O
they	O
play	O
a	O
complementary	O
role	O
?	O
.	O

18-Fluorodeoxyglucose	O
positron	B-P
emission	I-P
tomography	I-P
(	O
FDG-PET	B-P
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	O
.	O

However	O
,	O
its	O
precise	O
clinical	O
role	O
in	O
the	O
neural	O
crest	O
cell	O
tumors	O
continues	O
to	O
evolve	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131	O
metaiodobenzylguanidine	O
(	O
(	O
131	O
)	O
I-MIBG	O
)	O
and	O
FDG-PET	B-P
of	O
head	O
to	O
head	O
in	O
patients	O
with	O
neural	O
crest	O
tumors	O
both	O
qualitatively	O
and	O
semiquantitatively	O
and	O
to	O
determine	O
their	O
clinical	O
utility	O
in	O
disease	O
status	O
evaluation	O
and	O
further	O
management	O
.	O

A	O
total	O
of	O
32	O
patients	O
who	O
had	O
undergone	O
(	O
131	O
)	O
I-MIBG	O
and	O
FDG-PET	B-P
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	O
grouped	O
into	O
three	O
categories	O
:	O
neuroblastoma	O
,	O
pheochromocytoma	O
,	O
and	O
medullary	O
carcinoma	O
thyroid	O
.	O

In	O
18	O
patients	O
of	O
neuroblastoma	O
,	O
FDG	B-P
PET	I-P
and	O
(	O
131	O
)	O
I-MIBG	O
showed	O
patient-specific	O
sensitivity	O
of	O
84	O
%	O
and	O
72	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
maximum	O
standardized	O
uptake	O
value	O
(	O
SUVmax	O
)	O
of	O
primary	O
lesions	O
in	O
patients	O
with	O
unfavorable	O
histology	O
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	O
histology	O
(	O
5.18	O
±	O
2.38	O
vs.	O
3.21	O
±	O
1.69	O
)	O
.	O

The	O
mean	O
SUVmax	O
of	O
two	O
common	O
sites	O
(	O
posterior	O
superior	O
iliac	O
spine	O
[	O
PSIS	O
]	O
and	O
greater	O
trochanter	O
)	O
was	O
higher	O
in	O
patients	O
with	O
involved	O
marrow	O
than	O
those	O
with	O
uninvolved	O
one	O
(	O
2.36	O
and	O
2.75	O
vs.	O
1.26	O
and	O
1.34	O
,	O
respectively	O
)	O
.	O

The	O
ratio	O
of	O
SUVmax	O
of	O
the	O
involved/	O
contralateral	O
normal	O
sites	O
was	O
2.16	O
±	O
1.9	O
.	O

In	O
equivocal	O
bone	O
marrow	O
results	O
,	O
the	O
uptake	O
pattern	O
with	O
SUV	O
estimation	O
can	O
depict	O
metastatic	O
involvement	O
and	O
help	O
in	O
redirecting	O
the	O
biopsy	O
site	O
.	O

Among	O
seven	O
patients	O
of	O
pheochromocytoma	O
,	O
FDG-PET	B-P
revealed	O
100	O
%	O
patient-specific	O
sensitivity	O
.	O

FDG-PET	B-P
detected	O
more	O
metastatic	O
foci	O
than	O
(	O
131	O
)	O
I-MIBG	O
(	O
18	O
vs.	O
13	O
sites	O
)	O
.	O

In	O
seven	O
patients	O
of	O
medullary	O
carcinoma	O
thyroid	O
,	O
FDG-PET	B-P
localized	O
residual	O
,	O
recurrent	O
,	O
or	O
metastatic	O
disease	O
with	O
much	O
higher	O
sensitivity	O
(	O
32	O
metastatic	O
foci	O
with	O
72	O
%	O
patient	O
specific	O
sensitivity	O
)	O
than	O
(	O
131	O
)	O
I-MIBG	O
,	O
trending	O
along	O
the	O
higher	O
serum	O
calcitonin	O
levels	O
.	O

FDG-PET	B-P
is	O
not	O
only	O
a	O
good	O
complementary	O
modality	O
in	O
the	O
management	O
of	O
neural	O
crest	O
cell	O
tumors	O
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
(	O
131	O
)	O
I-MIBG	O
nonavid	O
tumors	O
.	O

NIR	B-P
upconversion	O
fluorescence	O
glucose	O
sensing	O
and	O
glucose	O
-	O
responsive	O
insulin	O
release	O
of	O
carbon	O
dot	O
-	O
immobilized	O
hybrid	O
microgels	O
at	O
physiological	O
pH	O
.	O

This	O
work	O
reports	O
the	O
preparation	O
of	O
multifunctional	O
hybrid	O
microgels	O
based	O
on	O
the	O
one-pot	O
free	O
radical	O
dispersion	O
polymerization	O
of	O
hydrogen-bonding	O
complexes	O
in	O
water	O
,	O
formed	O
from	O
hydroxyl	O
/	O
carboxyl	O
bearing	O
carbon	O
dots	O
with	O
4-vinylphenylboronic	O
acid	O
and	O
acrylamide	O
comonomers	O
,	O
which	O
can	O
realize	O
the	O
simultaneous	O
optical	O
detection	O
of	O
glucose	O
using	O
near	O
infrared	O
light	O
and	O
glucose	O
-	O
responsive	O
insulin	O
delivery	O
.	O

Large-scale	O
synthesis	O
and	O
structural	O
analysis	O
of	O
a	O
synthetic	O
glycopeptide	O
dendrimer	O
as	O
an	O
anti-cancer	O
vaccine	O
candidate	O
.	O

Herein	O
,	O
we	O
report	O
a	O
new	O
process	O
that	O
enables	O
the	O
gram-scale	O
production	O
of	O
a	O
fully	O
synthetic	O
anti-cancer	O
vaccine	O
for	O
human	O
use	O
.	O

This	O
therapeutic	O
vaccine	O
candidate	O
,	O
named	O
MAG-Tn3	O
,	O
is	O
a	O
high-molecular-weight	O
tetrameric	O
glycopeptide	O
encompassing	O
carbohydrate	O
tumor-associated	O
Tn	O
antigen	O
clusters	O
and	O
peptidic	O
CD4	O
(	O
+	O
)	O
T-cell	O
epitopes	O
.	O

The	O
synthetic	O
process	O
involves	O
(	O
i	O
)	O
the	O
stepwise	O
solid-phase	O
assembly	O
of	O
protected	O
amino	O
acids	O
,	O
including	O
the	O
high	O
value-added	O
Tn	O
building	O
blocks	O
with	O
only	O
1.5	O
equivalents	O
,	O
(	O
ii	O
)	O
a	O
single	O
isolated	O
intermediate	O
,	O
and	O
(	O
iii	O
)	O
the	O
simultaneous	O
deprotection	O
of	O
36	O
hindered	O
protective	O
groups	O
.	O

The	O
resulting	O
MAG-Tn3	O
was	O
unambiguously	O
characterized	O
using	O
a	O
combination	O
of	O
techniques	O
,	O
including	O
a	O
structural	O
analysis	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
.	O

The	O
four	O
peptidic	O
chains	O
are	O
flexible	O
in	O
solution	O
,	O
with	O
a	O
more	O
constrained	O
but	O
extended	O
conformation	O
at	O
the	O
Tn3	O
antigen	O
motif	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
,	O
when	O
injected	O
into	O
HLA-DR1	O
-	O
expressing	O
transgenic	O
mice	O
,	O
this	O
vaccine	O
induces	O
Tn-specific	O
antibodies	O
that	O
mediate	O
the	O
killing	O
of	O
human	O
Tn-positive	O
tumor	O
cells	O
.	O

These	O
studies	O
led	O
to	O
a	O
clinical	O
batch	O
of	O
the	O
MAG-Tn3	O
,	O
currently	O
investigated	O
in	O
breast	O
cancer	O
patients	O
(	O
phase	O
I	O
clinical	O
trial	O
)	O
.	O

The	O
current	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
the	O
multigram-scale	O
synthesis	O
of	O
a	O
highly	O
pure	O
complex	O
glycopeptide	O
,	O
and	O
it	O
opens	O
new	O
avenues	O
for	O
the	O
use	O
of	O
synthetic	O
glycopeptides	O
as	O
drugs	O
in	O
humans	O
.	O

International	O
validation	O
of	O
a	O
urinary	O
biomarker	O
panel	O
for	O
identification	O
of	O
active	O
lupus	O
nephritis	O
in	O
children	O
.	O

Conventional	O
markers	O
of	O
juvenile-onset	O
systemic	O
lupus	O
erythematosus	O
(	O
JSLE	O
)	O
disease	B-P
activity	I-P
fail	O
to	O
adequately	O
identify	O
lupus	O
nephritis	O
(	O
LN	O
)	O
.	O

While	O
individual	O
novel	O
urine	O
biomarkers	O
are	O
good	O
at	O
detecting	O
LN	O
flares	O
,	O
biomarker	O
panels	O
may	O
improve	O
diagnostic	O
accuracy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
a	O
biomarker	O
panel	O
to	O
identify	O
active	O
LN	O
in	O
two	O
international	O
JSLE	O
cohorts	O
.	O

Novel	O
urinary	O
biomarkers	O
,	O
namely	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
,	O
lipocalin-like	O
prostaglandin	O
D	O
synthase	O
(	O
LPGDS	O
)	O
,	O
transferrin	O
(	O
TF	O
)	O
,	O
ceruloplasmin	O
,	O
alpha-1-acid	O
glycoprotein	O
(	O
AGP	O
)	O
and	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
,	O
were	O
quantified	O
in	O
a	O
cross-sectional	O
study	O
that	O
included	O
participants	O
of	O
the	O
UK	O
JSLE	O
Cohort	O
Study	O
(	O
Cohort	O
1	O
)	O
and	O
validated	O
within	O
the	O
Einstein	O
Lupus	O
Cohort	O
(	O
Cohort	O
2	O
)	O
.	O

Binary	O
logistic	O
regression	O
modelling	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
[	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	O
combinations	O
of	O
biomarkers	O
for	O
diagnostic	O
accuracy	O
.	O

A	O
total	O
of	O
91	O
JSLE	O
patients	O
were	O
recruited	O
across	O
both	O
cohorts	O
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	O
LN	O
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	O
.	O

Urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
VCAM-1	O
,	O
MCP-1	O
and	O
LPGDS	O
levels	O
were	O
significantly	O
higher	O
in	O
those	O
patients	O
with	O
active	O
LN	O
than	O
in	O
non	O
-	O
LN	O
patients	O
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0.05	O
]	O
across	O
both	O
cohorts	O
.	O

Urinary	O
TF	O
also	O
differed	O
between	O
patient	O
groups	O
in	O
Cohort	O
2	O
(	O
p	O
c	O
=	O
0.001	O
)	O
.	O

Within	O
Cohort	O
1	O
,	O
the	O
optimal	O
biomarker	O
panel	O
included	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
(	O
AUC	O
0.920	O
for	O
active	O
LN	O
identification	O
)	O
.	O

These	O
results	O
were	O
validated	O
in	O
Cohort	O
2	O
,	O
with	O
the	O
same	O
markers	O
resulting	O
in	O
the	O
optimal	O
urine	O
biomarker	O
panel	O
(	O
AUC	O
0.991	O
)	O
.	O

In	O
two	O
international	O
JSLE	O
cohorts	O
,	O
urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
demonstrate	O
an	O
'excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	O
LN	O
in	O
children	O
.	O

Neural	O
Correlates	O
of	O
Belief	O
and	O
Emotion	O
Attribution	O
in	O
Schizophrenia	O
.	O

Impaired	O
mental	O
state	O
attribution	O
is	O
a	O
core	O
social	O
cognitive	O
deficit	O
in	O
schizophrenia	O
.	O

With	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
,	O
this	O
study	O
examined	O
the	O
extent	O
to	O
which	O
the	O
core	O
neural	O
system	O
of	O
mental	O
state	O
attribution	O
is	O
involved	O
in	O
mental	O
state	O
attribution	O
,	O
focusing	O
on	O
belief	O
attribution	O
and	O
emotion	O
attribution	O
.	O

Fifteen	O
schizophrenia	O
outpatients	O
and	O
14	O
healthy	O
controls	O
performed	O
two	O
mental	O
state	O
attribution	O
tasks	O
in	O
the	O
scanner	O
.	O

In	O
a	O
Belief	O
Attribution	O
Task	O
,	O
after	O
reading	O
a	O
short	O
vignette	O
,	O
participants	O
were	O
asked	O
infer	O
either	O
the	O
belief	O
of	O
a	O
character	O
(	O
a	O
false	O
belief	O
condition	O
)	O
or	O
a	O
physical	O
state	O
of	O
an	O
affair	O
(	O
a	O
false	O
photograph	O
condition	O
)	O
.	O

In	O
an	O
Emotion	O
Attribution	O
Task	O
,	O
participants	O
were	O
asked	O
either	O
to	O
judge	O
whether	O
character	O
(	O
s	O
)	O
in	O
pictures	O
felt	O
unpleasant	O
,	O
pleasant	O
,	O
or	O
neutral	O
emotion	O
(	O
other	O
condition	O
)	O
or	O
to	O
look	O
at	O
pictures	O
that	O
did	O
not	O
have	O
any	O
human	O
characters	O
(	O
view	O
condition	O
)	O
.	O

fMRI	B-P
data	O
were	O
analyzing	O
focusing	O
on	O
a	O
priori	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
of	O
the	O
core	O
neural	O
systems	O
of	O
mental	O
state	O
attribution	O
:	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
,	O
temporoparietal	O
junction	O
(	O
TPJ	O
)	O
and	O
precuneus	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
was	O
also	O
performed	O
.	O

Both	O
patients	O
and	O
controls	O
showed	O
greater	O
activation	O
in	O
all	O
four	O
ROIs	O
during	O
the	O
Belief	O
Attribution	O
Task	O
than	O
the	O
Emotion	O
Attribution	O
Task	O
.	O

Patients	O
also	O
showed	O
less	O
activation	O
in	O
the	O
precuneus	O
and	O
left	O
TPJ	O
compared	O
to	O
controls	O
during	O
the	O
Belief	O
Attribution	O
Task	O
.	O

No	O
significant	O
group	O
difference	O
was	O
found	O
during	O
the	O
Emotion	O
Attribution	O
Task	O
in	O
any	O
of	O
ROIs	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
showed	O
a	O
similar	O
pattern	O
of	O
neural	O
activation	O
s.	O
These	O
findings	O
suggest	O
that	O
while	O
schizophrenia	O
patients	O
rely	O
on	O
the	O
same	O
neural	O
network	O
as	O
controls	O
do	O
when	O
attributing	O
beliefs	O
of	O
others	O
,	O
patients	O
did	O
not	O
show	O
reduced	O
activation	O
in	O
the	O
key	O
regions	O
such	O
as	O
the	O
TPJ	O
.	O

Further	O
,	O
this	O
study	O
did	O
not	O
find	O
evidence	O
for	O
aberrant	O
neural	O
activation	O
during	O
emotion	O
attribution	O
or	O
recruitment	O
of	O
compensatory	O
brain	O
regions	O
in	O
schizophrenia	O
.	O

Semi-preparative	O
HPLC	O
separation	O
followed	O
by	O
HPLC/UV	O
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
phorbol	O
esters	O
in	O
Jatropha	O
seed	O
.	O

Phorbol	O
esters	O
(	O
PEs	O
)	O
are	O
well	O
known	O
as	O
the	O
main	O
toxic	O
compounds	O
in	O
Jatropha	O
curcas	O
Linnaeus	O
(	O
JCL	O
)	O
,	O
the	O
seed	O
oil	O
of	O
which	O
has	O
been	O
considered	O
as	O
a	O
major	O
feedstock	O
for	O
the	O
production	O
of	O
biodiesel	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
series	O
of	O
PEs	O
extracted	O
from	O
JCL	O
seed	O
kernels	O
with	O
methanol	O
(	O
MeOH	O
)	O
,	O
and	O
identified	O
more	O
than	O
seven	O
components	O
contained	O
in	O
the	O
PEs	O
.	O

The	O
isolation	O
of	O
main	O
five	O
components	O
of	O
a	O
series	O
of	O
PEs	O
was	O
revised	O
using	O
a	O
semi-preparative	O
reversed	O
phase	O
HPLC	O
analysis	O
of	O
ODS-3	O
column	O
.	O

The	O
five	O
peaks	O
of	O
components	O
were	O
successfully	O
isolated	O
,	O
and	O
peaks	O
of	O
J2	O
,	O
J3	O
,	O
J5	O
,	O
and	O
J7	O
were	O
assigned	O
to	O
be	O
Jatropha	O
factors	O
C1	O
,	O
C2	O
,	O
C3	O
,	O
and	O
C4/5	O
,	O
but	O
J6	O
was	O
a	O
mixture	O
of	O
Jatropha	O
factor	O
C6	O
and	O
its	O
isomer	O
based	O
on	O
the	O
data	O
of	O
UV	O
and	O
LC-MS	O
/	O
MS	O
,	O
and	O
J2	O
was	O
identified	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
analysis	I-P
.	O

By	O
characterization	O
using	O
LC-MS	O
/	O
MS	O
analysis	O
,	O
all	O
components	O
of	O
a	O
series	O
of	O
PEs	O
were	O
elucidated	O
to	O
be	O
the	O
12-deoxy-16-hydroxyphorbol	O
esters	O
composed	O
of	O
isomeric	O
form	O
of	O
dicarboxylic	O
groups	O
with	O
same	O
m/z	O
value	O
of	O
380	O
.	O

Hydroxysafflor	O
yellow	O
A	O
attenuates	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
acute	O
soft	O
tissue	O
injury	O
.	O

We	O
examined	O
the	O
effect	O
of	O
hydroxysafflor	O
yellow	O
A	O
(	O
HSYA	O
)	O
on	O
the	O
inflammatory	O
response	O
to	O
strike	O
-	O
induced	O
acute	O
soft	O
tissue	O
injury	O
in	O
rats	O
.	O

Soft	O
tissue	O
injury	O
was	O
induced	O
in	O
rat	O
leg	O
muscles	O
using	O
a	O
strike	O
hammer	O
,	O
followed	O
by	O
intraperitoneal	O
administration	O
of	O
HSYA	O
at	O
16	O
,	O
32	O
,	O
or	O
64	O
mg/kg	O
.	O

After	O
24	O
h	O
,	O
the	O
rats	O
were	O
anaesthetized	O
,	O
blood	O
and	O
muscle	O
samples	O
were	O
taken	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)	O
-6	O
,	O
IL-1β	O
,	O
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-α	O
were	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

Total	O
RNA	O
and	O
protein	O
were	O
isolated	O
from	O
muscle	O
tissue	O
to	O
determine	O
the	O
mRNA	O
levels	O
of	O
IL-6	O
,	O
IL-1β	O
,	O
TNF-α	O
,	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-1	O
,	O
and	O
intercellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
-1	O
,	O
and	O
the	O
protein	O
level	O
of	O
phosphorylated	O
p38	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-κB	O
expression	O
was	O
determined	O
by	O
muscle	O
histopathology	O
and	O
immunohistochemistry	B-P
.	O

HSYA	O
attenuated	O
pathologic	O
changes	O
in	O
strike	O
-	O
induced	O
soft	O
tissue	O
inflammation	O
.	O

Treatment	O
with	O
HSYA	O
also	O
alleviated	O
strike	O
-	O
induced	O
increases	O
in	O
TNF-α	O
,	O
IL-1β	O
,	O
IL-6	O
,	O
VCAM-1	O
,	O
and	O
ICAM-1	O
mRNA	O
levels	O
and	O
inhibited	O
the	O
increased	O
activation	O
of	O
NF-κB	O
and	O
phosphorylation	O
of	O
p38	O
MAPK	O
in	O
muscle	O
tissue	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	O
effectively	O
inhibits	O
strike	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
rats	O
.	O

Direct	O
Repair	O
of	O
Lumbar	O
Pars	O
Interarticularis	O
Defects	O
by	O
Utilizing	O
Intraoperative	O
O-Arm-Based	O
Navigation	O
and	O
Microendoscopic	B-P
Techniques	I-P
.	O

A	O
retrospective	O
analysis	O
of	O
the	O
clinical	O
outcomes	O
of	O
eight	O
patients	O
with	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
treated	O
by	O
direct	O
repair	O
with	O
the	O
aid	O
of	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
direct	O
screw	O
repair	O
by	O
using	O
minimally	O
invasive	O
surgery	O
for	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
in	O
a	O
pilot	O
study	O
.	O

Direct	O
repair	O
of	O
pars	O
interarticulars	O
defects	O
has	O
been	O
used	O
to	O
treat	O
young	O
adult	O
patients	O
.	O

Reports	O
concerning	O
direct	O
repair	O
by	O
minimally	O
invasive	O
techniques	O
for	O
pars	O
interarticulars	O
defects	O
are	O
quite	O
rare	O
.	O

Review	O
of	O
medical	O
records	O
identified	O
eight	O
consecutive	O
patients	O
treated	O
with	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

Debridement	O
and	O
autograft	O
of	O
pars	O
interarticularis	O
defects	O
was	O
performed	O
under	O
microendoscopic	B-P
procedure	I-P
.	O

Then	O
,	O
percutaneous	O
bilateral	O
intralaminar	O
screws	O
were	O
inserted	O
by	O
utilizing	O
intraoperative	O
navigation	O
.	O

The	O
clinical	O
and	O
radiological	O
data	O
were	O
collected	O
and	O
analyzed	O
retrospectively	O
.	O

Eight	O
patients	O
had	O
a	O
mean	O
age	O
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	O
.	O

Symptoms	O
included	O
axial	O
back	O
pain	O
in	O
100	O
%	O
of	O
patients	O
without	O
concomitant	O
radiculopathy	O
.	O

Autograft	O
was	O
used	O
in	O
all	O
cases	O
.	O

The	O
average	O
follow-up	O
duration	O
was	O
27.4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O

Symptoms	O
resolved	O
completely	O
or	O
partially	O
in	O
all	O
patients	O
.	O

Low	O
back	O
pain	O
visual	O
analog	O
scores	O
decrease	O
from	O
preoperative	O
6.8	O
to	O
postoperative	O
1.4	O
of	O
eight	O
cases	O
.	O

Of	O
16	O
pars	O
defects	O
,	O
healing	O
was	O
observed	O
in	O
13	O
(	O
81.3	O
%	O
)	O
at	O
last	O
radiological	O
follow-up	O
.	O

One	O
patient	O
with	O
bilateral	O
fusion	O
failure	O
refused	O
revision	O
surgery	O
because	O
of	O
mild	O
complaint	O
.	O

No	O
complications	O
such	O
as	O
dural	O
tear	O
,	O
nerve	O
root	O
injury	O
,	O
and	O
infection	O
occurred	O
.	O

Minimally	O
invasive	O
direct	O
repair	O
of	O
the	O
pars	O
interarticularis	O
defects	O
with	O
intralaminar	O
screws	O
by	O
using	O
microendoscopic	B-P
system	I-P
and	O
navigation	O
procedure	O
can	O
provide	O
safe	O
and	O
effective	O
treatment	O
of	O
spondylolysis	O
with	O
satisfactory	O
clinical	O
and	O
radiological	O
outcomes	O
,	O
which	O
need	O
some	O
special	O
tools	O
with	O
steep	O
learning	O
curve	O
.	O

4	O
.	O

Moberg	O
Picking-Up	O
Test	O
in	O
patients	O
with	O
hand	O
osteoarthritis	O
.	O

Clinical	O
measurement	O
.	O

The	O
Moberg	O
Pick-up	O
Test	O
(	O
MPUT	O
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	O
performance	O
in	O
patients	O
with	O
hand	O
inflammatory	O
disease	O
.	O

This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	O
in	O
hand	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Compare	O
the	O
functional	O
performance	O
(	O
MPUT	O
)	O
in	O
hand	O
OA	O
patients	O
and	O
healthy	O
controls	O
.	O

Fifty	O
hand	O
OA	O
patients	O
and	O
50	O
controls	O
were	O
assessed	O
using	O
the	O
MPUT	O
,	O
AUSCAN	O
and	O
Cochin	O
questionnaires	O
,	O
grip	O
and	O
pinch	B-P
strength	I-P
,	O
pain	O
using	O
a	O
visual	B-P
analog	I-P
scale	I-P
and	O
a	O
Likert	O
scale	O
regarding	O
difficulty	O
to	O
perform	O
MPUT	O
.	O

In	O
the	O
MPUT	O
evaluation	O
,	O
the	O
OA	O
group	O
presented	O
a	O
statistically	O
significant	O
difference	O
from	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
spent	O
more	O
time	O
executing	O
test	O
.	O

The	O
grip	O
and	O
pinch	B-P
strength	I-P
measurements	I-P
showed	O
higher	O
values	O
for	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
reported	O
a	O
greater	O
difficulty	O
than	O
the	O
control	O
group	O
in	O
performing	O
the	O
test	O
.	O

The	O
MPUT	O
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	O
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	O
performance	O
of	O
the	O
hand	O
OA	O
.	O

II	O
.	O

Epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
analysis	O
of	O
patients	O
in	O
Taiwan	O
with	O
Beckwith-Wiedemann	O
syndrome	O
.	O

Beckwith-Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
is	O
a	O
congenital	O
overgrowth	O
disorder	O
predisposing	O
to	O
tumorigenesis	O
that	O
results	O
from	O
abnormal	O
expression	O
or	O
function	O
of	O
imprinted	O
genes	O
of	O
chromosome	O
11p15.5	O
.	O

Forty-seven	O
patients	O
in	O
Taiwan	O
with	O
clinical	O
suspicion	O
of	O
BWS	O
were	O
referred	O
for	O
diagnostic	O
testing	O
based	O
on	O
methylation	O
profiling	O
of	O
H19	O
-associated	O
imprinting	O
center	O
(	O
IC	O
)	O
1	O
and	O
KCNQ1OT1	O
-associated	O
IC2	O
using	O
high-resolution	O
melting	O
analysis	O
,	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
,	O
or	O
high-resolution	O
quantitative	O
methylation	O
profiling	O
.	O

Twenty-eight	O
patients	O
received	O
a	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
the	O
presence	O
of	O
3	O
major	O
features	O
or	O
2	O
major	O
features	O
and	O
at	O
least	O
1	O
minor	O
feature	O
)	O
,	O
18	O
had	O
suspected	O
BWS	O
(	O
the	O
presence	O
of	O
at	O
least	O
1	O
major	O
feature	O
)	O
,	O
and	O
1	O
had	O
isolated	O
Wilms	O
'	O
tumor	O
.	O

Nineteen	O
patients	O
were	O
identified	O
with	O
IC2	O
hypomethylation	O
(	O
including	O
1	O
with	O
isolated	O
Wilms	O
'	O
tumor	O
)	O
,	O
1	O
with	O
IC1	O
hypermethylation	O
,	O
2	O
with	O
paternal	O
uniparental	O
disomy	O
,	O
and	O
1	O
with	O
CDKN1C	O
mutation	O
.	O

Several	O
clinical	O
features	O
were	O
found	O
to	O
be	O
statistically	O
different	O
(	O
P	O
<	O
0.05	O
)	O
between	O
the	O
2	O
groups-	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
n=28	O
)	O
or	O
suspected	O
BWS	O
(	O
n=18	O
)	O
-including	O
macroglossia	O
,	O
pre-	O
or	O
postnatal	O
gigantism	O
,	O
abdominal	O
wall	O
defect	O
,	O
ear	O
creases	O
,	O
facial	O
nevus	O
flammeus	O
,	O
BWS	O
score	O
,	O
and	O
the	O
molecular	O
diagnosis	O
rate	O
.	O

Molecular	O
lesion	O
was	O
detected	O
in	O
81	O
%	O
of	O
patients	O
with	O
the	O
presence	O
of	O
three	O
major	O
features	O
,	O
compared	O
with	O
33	O
%	O
and	O
28	O
%	O
of	O
those	O
with	O
two	O
or	O
one	O
major	O
feature	O
,	O
respectively	O
.	O

The	O
mean	O
BWS	O
score	O
was	O
5.6	O
for	O
19	O
subjects	O
with	O
``	O
IC2	O
hypomethylation	O
``	O
,	O
compared	O
with	O
3.8	O
for	O
2	O
subjects	O
with	O
pUPD	O
.	O

The	O
BWS	O
score	O
of	O
one	O
subject	O
with	O
CDKN1C	O
mutation	O
and	O
one	O
with	O
IC1	O
hypermethylation	O
was	O
6	O
and	O
7	O
,	O
respectively	O
.	O

The	O
BWS	O
score	O
was	O
positively	O
correlated	O
with	O
the	O
molecular	O
diagnosis	O
rate	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
BWS	O
database	O
of	O
epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
is	O
expected	O
to	O
promote	O
better	O
genetic	O
counseling	O
and	O
medical	O
care	O
of	O
these	O
patients	O
.	O

The	O
effects	O
of	O
captopril	O
on	O
lipopolysaccharide	O
induced	O
learning	O
and	O
memory	O
impairments	O
and	O
the	O
brain	O
cytokine	O
levels	O
and	O
oxidative	O
damage	O
in	O
rats	O
.	O

Renin-angiotensin	O
system	O
has	O
a	O
role	O
in	O
inflammation	O
and	O
also	O
involves	O
in	O
learning	O
and	O
memory	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
captopril	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induced	O
learning	O
and	O
memory	O
impairments	O
,	O
hippocampal	O
cytokine	O
levels	O
and	O
brain	O
tissues	O
oxidative	O
damage	O
was	O
investigated	O
.	O

The	O
rats	O
were	O
divided	O
and	O
treated	O
:	O
[	O
1	O
]	O
saline	O
(	O
Control	O
)	O
,	O
[	O
2	O
]	O
LPS	O
(	O
1mg/kg	O
)	O
,	O
[	O
3-5	O
]	O
10	O
,	O
50	O
or	O
100mg/kg	O
captopril	O
30min	O
before	O
LPS	O
.	O

The	O
treatment	O
was	O
started	O
since	O
six	O
days	O
before	O
the	O
behavioral	B-P
experiments	I-P
and	O
continued	O
during	O
the	O
behavioral	B-P
tests	I-P
(	O
LPS	O
injection	O
two	O
h	O
before	O
each	O
behavioral	B-P
experiment	I-P
)	O
.	O

Administration	O
of	O
LPS	O
prolonged	O
the	O
escape	O
latency	O
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris	B-P
water	I-P
maze	I-P
(	I-P
MWM	I-P
)	I-P
test	I-P
(	O
P	O
<	O
0.01-P	O
<	O
0.001	O
)	O
while	O
,	O
shortened	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
compartment	O
in	O
passive	O
avoidance	O
(	O
PA	O
)	O
test	B-P
(	O
P	O
<	O
0.001	O
)	O
.	O

Pretreatment	O
by	O
all	O
doses	O
of	O
captopril	O
improved	O
performances	O
of	O
the	O
rats	O
in	O
MWM	B-P
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
and	O
also	O
prolonged	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
in	O
PA	O
test	B-P
(	O
P	O
<	O
0.001	O
)	O
.	O

LPS	O
also	O
increased	O
IL-6	O
,	O
TNF-α	O
,	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
metabolites	O
in	O
the	O
hippocampal	O
tissues	O
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
which	O
were	O
prevented	O
by	O
captopril	O
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
.	O

The	O
thiol	O
,	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
in	O
the	O
hippocampus	O
of	O
LPS	O
group	O
were	O
lower	O
than	O
the	O
control	O
(	O
P	O
<	O
0.001	O
)	O
while	O
,	O
they	O
were	O
enhanced	O
when	O
the	O
aniamls	O
were	O
pretreated	O
by	O
captopril	O
(	O
P	O
<	O
0.01-P	O
<	O
0.001	O
)	O
.	O

The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	O
improved	O
the	O
LPS	O
-	O
induced	O
learning	O
and	O
memory	O
impairments	O
in	O
rats	O
which	O
were	O
accompanied	O
with	O
attenuating	O
hippocampal	O
cytokine	O
levels	O
and	O
improving	O
the	O
brain	O
tissues	O
oxidative	O
damage	O
criteria	O
.	O

Antidepressant	O
-like	O
effects	O
of	O
scopolamine	O
in	O
mice	O
are	O
enhanced	O
by	O
the	O
group	O
II	O
mGlu	O
receptor	O
antagonist	O
LY341495	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
the	O
muscarinic	O
receptor	O
antagonist	O
scopolamine	O
induces	O
a	O
potent	O
and	O
rapid	O
antidepressant	O
effect	O
relative	O
to	O
conventional	O
antidepressants	O
.	O

However	O
,	O
potential	O
undesirable	O
effects	O
,	O
including	O
memory	O
impairment	O
,	O
partially	O
limit	O
the	O
use	O
of	O
scopolamine	O
in	O
psychiatry	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
propose	O
to	O
overcome	O
these	O
limitations	O
and	O
enhance	O
the	O
therapeutic	O
effects	O
of	O
scopolamine	O
via	O
administration	O
in	O
combination	O
with	O
the	O
group	O
II	O
metabotropic	O
glutamate	O
(	O
mGlu	O
)	O
receptor	O
antagonist	O
,	O
LY341495	O
.	O

Joint	O
administration	O
of	O
sub-effective	O
doses	O
of	O
scopolamine	O
(	O
0.03	O
or	O
0.1	O
mg/kg	O
,	O
i.p	O
.	O
)	O

with	O
a	O
sub-effective	O
dose	O
of	O
LY341495	O
(	O
0.1	O
mg/kg	O
,	O
i.p	O
.	O
)	O

induced	O
a	O
profound	O
antidepressant	O
effect	O
in	O
the	O
tail	B-P
suspension	I-P
test	I-P
(	O
TST	B-P
)	O
and	O
in	O
the	O
forced	B-P
swim	I-P
test	I-P
(	O
FST	B-P
)	O
in	O
mice	O
.	O

This	O
drug	O
combination	O
did	O
not	O
impair	O
memory	O
,	O
as	O
measured	O
using	O
the	O
Morris	B-P
water	I-P
maze	I-P
(	O
MWM	B-P
)	O
,	O
and	O
did	O
not	O
influence	O
the	O
locomotor	O
activity	O
of	O
mice	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
an	O
AMPA	O
receptor	O
antagonist	O
,	O
NBQX	O
(	O
10	O
mg/kg	O
)	O
,	O
completely	O
reversed	O
the	O
antidepressant-like	O
activity	O
of	O
a	O
mixture	O
of	O
scopolamine	O
and	O
LY341495	O
in	O
the	O
TST	B-P
.	O

However	O
,	O
this	O
effect	O
was	O
not	O
influenced	O
by	O
para-chlorophenylalanine	O
(	O
PCPA	O
)	O
pre-treatment	O
,	O
indicating	O
a	O
lack	O
of	O
involvement	O
of	O
serotonergic	O
system	O
activation	O
in	O
the	O
antidepressant-like	O
effects	O
of	O
jointly	O
given	O
scopolamine	O
and	O
LY341495	O
.	O

Therefore	O
,	O
the	O
combined	O
administration	O
of	O
low	O
doses	O
of	O
the	O
antimuscarinic	O
drug	O
scopolamine	O
and	O
the	O
group	O
II	O
mGlu	O
receptor	O
antagonist	O
LY341495	O
might	O
be	O
a	O
new	O
,	O
effective	O
and	O
safe	O
strategy	O
in	O
the	O
therapy	O
of	O
depression	O
.	O

Albumin	O
-Bioinspired	O
Gd	O
:	O
CuS	O
Nanotheranostic	O
Agent	O
for	O
In	O
Vivo	O
Photoacoustic	B-P
/	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
-Guided	O
Tumor	O
-Targeted	O
Photothermal	O
Therapy	O
.	O

Photothermal	O
therapy	O
(	O
PTT	O
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	O
cancer	O
therapy	O
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O

However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
PTT	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	B-P
,	O
monitoring	O
,	O
and	O
diagnosis	O
.	O

Herein	O
,	O
a	O
biocompatible	O
Gd	O
-integrated	O
CuS	O
nanotheranostic	O
agent	O
(	O
Gd	O
:	O
CuS	O
@	O
BSA	O
)	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O

The	O
as-prepared	O
Gd	O
:	O
CuS	O
@	O
BSA	O
nanoparticles	O
(	O
NPs	O
)	O
with	O
ultrasmall	O
sizes	O
(	O
ca	O
.	O

9	O
nm	O
)	O
exhibited	O
high	O
photothermal	O
conversion	O
efficiency	O
and	O
good	O
photostability	O
under	O
near-infrared	O
(	O
NIR	O
)	O
laser	O
irradiation	O
.	O

With	O
doped	O
Gd	O
species	O
and	O
strong	O
tunable	O
NIR	O
absorbance	O
,	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
demonstrate	O
prominent	O
tumor-contrasted	B-P
imaging	I-P
performance	O
both	O
on	O
the	O
photoacoustic	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
modalities	O
.	O

The	O
subsequent	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
result	O
shows	O
high	O
therapy	O
efficacy	O
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	O
absorption	O
and	O
high	O
photothermal	O
conversion	O
efficiency	O
.	O

The	O
immune	O
response	O
triggered	O
by	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
is	O
preliminarily	O
explored	O
.	O

In	O
addition	O
,	O
toxicity	B-P
studies	I-P
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
qualify	O
as	O
biocompatible	O
agents	O
.	O

A	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
NPs	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O

This	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
possess	O
promising	O
imaging	O
guidance	O
and	O
effective	O
tumor	O
ablation	O
properties	O
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	O
.	O

An	O
Inhibitory	O
Septum	O
to	O
Lateral	O
Hypothalamus	O
Circuit	O
That	O
Suppresses	O
Feeding	O
.	O

Feeding	O
behavior	O
is	O
orchestrated	O
by	O
neural	O
circuits	O
primarily	O
residing	O
in	O
the	O
hypothalamus	O
and	O
hindbrain	O
.	O

However	O
,	O
the	O
relative	O
influence	O
of	O
cognitive	O
and	O
emotional	O
brain	O
circuits	O
to	O
the	O
feeding	O
circuitry	O
in	O
the	O
hypothalamus	O
and	O
hindbrain	O
remains	O
unclear	O
.	O

Here	O
,	O
using	O
the	O
cell-type	O
selectivity	O
of	O
genetic	O
methods	O
,	O
circuit	B-P
mapping	I-P
,	O
and	O
behavior	O
assays	O
,	O
we	O
sought	O
to	O
decipher	O
neural	O
circuits	O
emanating	O
from	O
the	O
septal	O
nucleus	O
to	O
the	O
lateral	O
hypothalamus	O
(	O
LH	O
)	O
that	O
contribute	O
to	O
neural	O
regulation	O
of	O
food	O
intake	O
in	O
mice	O
.	O

We	O
found	O
that	O
chemogenetic	O
and	O
optogenetic	O
activation	O
of	O
septal	O
vesicular	O
GABA	O
transporter	O
(	O
vGAT	O
)	O
-	O
containing	O
neurons	O
or	O
their	O
projections	O
in	O
the	O
LH	O
reduced	O
food	O
intake	O
in	O
mice	O
.	O

Consistently	O
,	O
chemogenetic	O
inhibition	O
of	O
septal	O
vGAT	O
neurons	O
increased	O
food	O
intake	O
.	O

Furthermore	O
,	O
we	O
investigated	O
a	O
previously	O
unknown	O
neural	O
circuit	O
originating	O
from	O
septal	O
vGAT	O
neurons	O
to	O
a	O
subset	O
of	O
vGAT	O
neurons	O
in	O
the	O
LH	O
,	O
an	O
area	O
involved	O
in	O
homeostatic	O
and	O
hedonic	O
control	O
of	O
energy	O
states	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
an	O
inhibitory	O
septohypothalamic	O
feeding	O
circuit	O
that	O
might	O
serve	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
eating	O
disorders	O
such	O
as	O
anorexia	O
nervosa	O
.	O

Our	O
results	O
demonstrate	O
that	O
top-down	O
projections	O
from	O
the	O
septum	O
to	O
the	O
hypothalamus	O
control	O
food	O
intake	O
negatively	O
.	O

Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	O
regions	O
in	O
the	O
control	O
of	O
feeding	O
and	O
emotion	O
-	O
related	O
behaviors	O
,	O
these	O
findings	O
reveal	O
previously	O
unknown	O
neural	O
circuitry	O
that	O
is	O
likely	O
implicated	O
in	O
emotional	O
aspects	O
of	O
food	O
intake	O
and	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
eating	O
disorders	O
.	O

Okanin	O
,	O
effective	O
constituent	O
of	O
the	O
flower	O
tea	O
Coreopsis	O
tinctoria	O
,	O
attenuates	O
LPS	O
-induced	O
microglial	O
activation	O
through	O
inhibition	O
of	O
the	O
TLR4	O
/	O
NF-κB	O
signaling	O
pathways	O
.	O

The	O
EtOAc	O
extract	O
of	O
Coreopsis	O
tinctoria	O
Nutt	O
.	O

significantly	O
inhibited	O
LPS	O
-induced	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
,	O
as	O
judged	O
by	O
the	O
Griess	O
reaction	O
,	O
and	O
attenuated	O
the	O
LPS	O
-induced	O
elevation	O
in	O
iNOS	O
,	O
COX-2	O
,	O
IL-1β	O
,	O
IL-6	O
and	O
TNF-α	O
mRNA	O
levels	O
,	O
as	O
determined	O
by	O
quantitative	O
real-time	O
PCR	O
,	O
when	O
incubated	O
with	O
BV-2	O
microglial	O
cells	O
.	O

Immunohistochemical	B-P
results	I-P
showed	O
that	O
the	O
EtOAc	O
extract	O
significantly	O
decreased	O
the	O
number	O
of	O
Iba-1-positive	O
cells	O
in	O
the	O
hippocampal	O
region	O
of	O
LPS	O
-	O
treated	O
mouse	O
brains	O
.	O

The	O
major	O
effective	O
constituent	O
of	O
the	O
EtOAc	O
extract	O
,	O
okanin	O
,	O
was	O
further	O
investigated	O
.	O

Okanin	O
significantly	O
suppressed	O
LPS	O
-induced	O
iNOS	O
expression	O
and	O
also	O
inhibited	O
IL-6	O
and	O
TNF-α	O
production	O
and	O
mRNA	O
expression	O
in	O
LPS	O
-	O
stimulated	O
BV-2	O
cells	O
.	O

Western	O
blot	O
analysis	O
indicated	O
that	O
okanin	O
suppressed	O
LPS	O
-induced	O
activation	O
of	O
the	O
NF-κB	O
signaling	O
pathway	O
by	O
inhibiting	O
the	O
phosphorylation	O
of	O
IκBα	O
and	O
decreasing	O
the	O
level	O
of	O
nuclear	O
NF-κB	O
p65	O
after	O
LPS	O
treatment	O
.	O

Immunofluorescence	O
staining	O
results	O
showed	O
that	O
okanin	O
inhibited	O
the	O
translocation	O
of	O
the	O
NF-κB	O
p65	O
subunit	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
.	O

Moreover	O
,	O
okanin	O
significantly	O
inhibited	O
LPS	O
-induced	O
TLR4	O
expression	O
in	O
BV-2	O
cells	O
.	O

In	O
summary	O
,	O
okanin	O
attenuates	O
LPS	O
-induced	O
activation	O
of	O
microglia	O
.	O

This	O
effect	O
may	O
be	O
associated	O
with	O
its	O
capacity	O
to	O
inhibit	O
the	O
TLR4	O
/	O
NF-κB	O
signaling	O
pathways	O
.	O

These	O
results	O
suggest	O
that	O
okanin	O
may	O
have	O
potential	O
as	O
a	O
nutritional	O
preventive	O
strategy	O
for	O
neurodegenerative	O
disorders	O
.	O

Expression	O
and	O
Purification	O
of	O
E2	O
Glycoprotein	O
from	O
Insect	O
Cells	O
(	O
Sf9	O
)	O
for	O
Use	O
in	O
Serology	O
.	O

Chikungunya	O
virus	O
(	O
CHIKV	O
)	O
is	O
a	O
mosquito	O
-	O
borne	O
arbovirus	O
which	O
poses	O
a	O
major	O
threat	O
to	O
global	O
public	O
health	O
.	O

Definitive	O
CHIKV	O
diagnosis	O
is	O
crucial	O
,	O
especially	O
in	O
distinguishing	O
the	O
disease	O
from	O
dengue	O
virus	O
,	O
which	O
co-circulates	O
in	O
endemic	O
areas	O
and	O
shares	O
the	O
same	O
mosquito	O
vectors	O
.	O

Laboratory	B-P
diagnosis	I-P
is	O
mainly	O
based	O
on	O
serological	O
or	O
molecular	O
approaches	O
.	O

The	O
E2	O
glycoprotein	O
is	O
a	O
good	O
candidate	O
for	O
serological	O
diagnosis	O
since	O
it	O
is	O
the	O
immunodominant	O
antigen	O
during	O
the	O
course	O
of	O
infection	O
,	O
and	O
reacts	O
with	O
seropositive	O
CHIKV	O
sera	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
generation	O
of	O
stable	O
clone	O
Sf9	O
(	O
Spodoptera	O
frugiperda	O
)	O
cells	O
expressing	O
secreted	O
,	O
soluble	O
,	O
and	O
native	O
recombinant	O
CHIKV	O
E2	O
glycoprotein	O
.	O

We	O
use	O
direct	O
plasmid	O
expression	O
in	O
insect	O
cells	O
,	O
rather	O
than	O
the	O
traditional	O
technique	O
of	O
generating	O
recombinant	O
baculovirus	O
.	O

This	O
recombinant	O
protein	O
is	O
useful	O
for	O
serological	O
diagnosis	O
of	O
CHIKV	O
infection	O
.	O

Addressing	O
reverse	O
inference	O
in	O
psychiatric	O
neuroimaging	B-P
:	O
Meta-analyses	O
of	O
task	O
-related	O
brain	O
activation	O
in	O
common	O
mental	O
disorders	O
.	O

Functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	B-P
fMRI	I-P
)	I-P
studies	I-P
in	O
psychiatry	O
use	O
various	O
tasks	O
to	O
identify	O
case-control	O
differences	O
in	O
the	O
patterns	O
of	O
task	O
-related	O
brain	O
activation	O
.	O

Differently	O
activated	O
regions	O
are	O
often	O
ascribed	O
disorder	O
-specific	O
functions	O
in	O
an	O
attempt	O
to	O
link	O
disease	O
expression	O
and	O
brain	O
function	O
.	O

We	O
undertook	O
a	O
systematic	O
meta-analysis	O
of	O
data	O
from	O
task	O
-	O
fMRI	B-P
studies	I-P
to	O
examine	O
the	O
effect	O
of	O
diagnosis	O
and	O
study	O
design	O
on	O
the	O
spatial	O
distribution	O
and	O
direction	O
of	O
case-control	O
differences	O
on	O
brain	O
activation	O
.	O

We	O
mapped	O
to	O
atlas	O
regions	O
coordinates	O
of	O
case-control	O
differences	O
derived	O
from	O
537	O
task	O
-	O
fMRI	B-P
studies	I-P
in	O
schizophrenia	O
,	O
bipolar	O
disorder	O
,	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
disorders	O
,	O
and	O
obsessive	O
compulsive	O
disorder	O
comprising	O
observations	O
derived	O
from	O
21,427	O
participants	O
.	O

The	O
fMRI	B-P
tasks	I-P
were	O
classified	O
according	O
to	O
the	O
Research	O
Domain	O
Criteria	O
(	O
RDoC	O
)	O
.	O

We	O
investigated	O
whether	O
diagnosis	O
,	O
RDoC	O
domain	O
or	O
construct	O
and	O
use	O
of	O
regions-of-interest	O
or	O
whole-brain	O
analyses	O
influenced	O
the	O
neuroanatomical	O
pattern	O
of	O
results	O
.	O

When	O
considering	O
all	O
primary	O
studies	O
,	O
we	O
found	O
an	O
effect	O
of	O
diagnosis	O
for	O
the	O
amygdala	O
and	O
caudate	O
nucleus	O
and	O
an	O
effect	O
of	O
RDoC	O
domains	O
and	O
constructs	O
for	O
the	O
amygdala	O
,	O
hippocampus	O
,	O
putamen	O
and	O
nucleus	O
accumbens	O
.	O

In	O
contrast	O
,	O
whole-brain	O
studies	O
did	O
not	O
identify	O
any	O
significant	O
effect	O
of	O
diagnosis	O
or	O
RDoC	O
domain	O
or	O
construct	O
.	O

These	O
results	O
resonate	O
with	O
prior	O
reports	O
of	O
common	O
brain	O
structural	O
and	O
genetic	O
underpinnings	O
across	O
these	O
disorders	O
and	O
caution	O
against	O
attributing	O
undue	O
specificity	O
to	O
brain	O
functional	O
changes	O
when	O
forming	O
explanatory	O
models	O
of	O
psychiatric	O
disorders	O
.	O

Hum	O
Brain	O
Mapp	O
38:1846-1864	O
,	O
2017	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
:	O
one-year	O
results	O
:	O
Alternative	O
to	O
surgery	O
in	O
high-risk	O
patients	O
.	O

Although	O
rheumatic	O
heart	O
disease	O
is	O
becoming	O
uncommon	O
in	O
industrialized	O
countries	O
,	O
its	O
global	O
burden	O
is	O
still	O
significant	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
male	O
with	O
rheumatic	O
heart	O
disease	O
,	O
who	O
underwent	O
4	O
previous	O
heart	O
valve	O
replacement	O
surgeries	O
,	O
and	O
presented	O
to	O
our	O
hospital	O
with	O
refractory	O
heart	O
failure	O
(	O
NYHA	O
functional	O
class	O
IV	O
)	O
due	O
to	O
severe	O
stenosis	O
of	O
a	O
previously	O
implanted	O
tricuspid	O
bioprosthesis	O
.	O

The	O
Heart	O
Team	O
deemed	O
the	O
patient	O
as	O
inoperable	O
/	O
high-risk	O
for	O
surgery	O
.	O

As	O
an	O
alternative	O
,	O
a	O
transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
was	O
decided	O
upon	O
and	O
later	O
executed	O
through	O
the	O
right	O
femoral	O
vein	O
,	O
with	O
the	O
insertion	O
of	O
an	O
Edwards	O
SAPIEN	O
XT	O
29	O
no	O
.	O

(	O
Edwards	O
Lifesciences	O
,	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
through	O
the	O
inferior	O
vena	O
cava	O
,	O
towards	O
the	O
RV	O
,	O
followed	O
by	O
direct	O
implantation	O
in	O
the	O
tricuspid	O
bioprosthesis	O
(	O
valve-in-valve	O
)	O
,	O
under	O
rapid	O
pacing	O
,	O
without	O
complications	O
.	O

A	O
substantial	O
clinical	O
and	O
echocardiographic	B-P
improvement	O
was	O
noted	O
after	O
the	O
procedure	O
and	O
the	O
patient	O
was	O
subsequently	O
discharged	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O

These	O
favourable	O
outcomes	O
persisted	O
through	O
the	O
1-year	O
follow-up	O
period	O
.	O

This	O
case	O
report	O
adds	O
to	O
the	O
current	O
body	O
of	O
evidence	O
that	O
tricuspid	O
valve	O
implantation	O
stands	O
as	O
a	O
viable	O
and	O
reliable	O
alternative	O
in	O
the	O
treatment	O
of	O
degenerated	O
bioprosthesis	O
in	O
high-surgical-risk	O
patients	O
.	O

Acoustic	O
Analysis	O
Before	O
and	O
After	O
Voice	O
Therapy	O
for	O
Laryngeal	O
Pathology	O
.	O

Background	O
Voice	O
problems	O
caused	O
by	O
pathologies	O
in	O
vocal	O
folds	O
are	O
well	O
known	O
.	O

Some	O
types	O
of	O
laryngeal	O
pathologies	O
have	O
certain	O
acoustic	O
characteristics	O
.	O

Objective	O
evaluation	O
helps	O
characterize	O
the	O
voice	O
and	O
voice	O
problems	O
providing	O
supporting	O
evidences	O
,	O
severity	O
of	O
disorders	O
.	O

It	O
helps	O
assess	O
the	O
response	O
to	O
the	O
treatment	O
and	O
measures	O
the	O
outcomes	O
.	O

Objective	O
The	O
objective	O
of	O
the	O
study	O
is	O
to	O
determine	O
the	O
effectiveness	O
of	O
the	O
voice	O
therapy	O
and	O
quantify	O
the	O
results	O
objectively	O
by	O
voice	O
parameters	O
.	O

Method	O
Study	O
includes	O
61	O
patients	O
who	O
presented	O
with	O
different	O
types	O
of	O
laryngeal	O
pathologies	O
.	O

Acoustic	O
analyses	O
and	O
voice	B-P
assessment	I-P
was	O
done	O
with	O
Dr	O
.	O

Speech	O
ver	O
4	O
(	O
Tiger	O
DRS	O
Inc.	O
)	O
.	O

Acoustic	O
parameters	O
including	O
fundamental	O
frequency	O
,	O
jitters	O
,	O
shimmers	O
,	O
Harmonic	O
to	O
noise	O
ratio	O
(	O
HNR	O
)	O
,	O
Normalized	O
noise	O
energy	O
(	O
NNE	O
)	O
were	O
analyzed	O
before	O
and	O
after	O
voice	O
therapy	O
.	O

Result	O
Bilateral	O
vocal	O
nodules	O
were	O
the	O
most	O
common	O
pathologies	O
comprising	O
44.26	O
%	O
.	O

All	O
acoustic	O
parameters	O
showed	O
a	O
significant	O
difference	O
after	O
the	O
therapy	O
(	O
p	O
<	O
0.05	O
)	O
except	O
for	O
NNE	O
.	O

Dysphonia	O
due	O
to	O
vocal	O
fold	O
polyp	O
showed	O
no	O
improvement	O
even	O
after	O
voice	O
therapy	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Conclusion	O
Acoustic	O
analysis	O
provides	O
an	O
objective	O
,	O
recordable	O
data	O
regarding	O
the	O
voice	O
parameters	O
and	O
its	O
pathologies	O
.	O

Though	O
,	O
few	O
pathology	O
require	O
alternative	O
therapy	O
rather	O
than	O
voice	O
therapy	O
,	O
overall	O
it	O
has	O
a	O
good	O
effect	O
on	O
glottic	O
closure	O
.	O

As	O
the	O
voice	O
therapy	O
can	O
improve	O
the	O
different	O
indices	O
of	O
voice	O
,	O
it	O
can	O
be	O
viewed	O
as	O
imperative	O
part	O
of	O
treatment	O
and	O
to	O
monitor	O
progression	O
.	O

Determination	O
of	O
volatile	O
organic	O
compounds	O
exhaled	O
by	O
cell	O
lines	O
derived	O
from	O
hematological	O
malignancies	O
.	O

Background	O
:	O
The	O
gas	O
human	O
exhaled	O
contains	O
many	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	O
status	O
of	O
body	O
.	O

Analysis	O
of	O
VOCs	O
has	O
been	O
proposed	O
as	O
a	O
noninvasive	O
diagnostic	B-P
tool	I-P
for	O
certain	O
cancers	O
.	O

Detailed	O
research	O
on	O
the	O
VOCs	O
in	O
gas	O
exhaled	O
by	O
cell	O
can	O
characterize	O
cell	O
type	O
specific	O
metabolites	O
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	O
markers	O
in	O
clinical	O
practice	O
.	O

Methods	O
:	O
Solid	O
phase	O
microextraction	O
-	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
was	O
used	O
to	O
detect	O
VOCs	O
in	O
the	O
headspace	O
of	O
tissue	O
culture	O
flask	O
in	O
non-Hodgkin	O
's	O
lymphoma	O
cell	O
line	O
JEKO	O
and	O
acute	O
mononuclear	O
leukemia	O
cell	O
line	O
SHI-1	O
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	O
biomarkers	O
of	O
hematological	O
malignancies	O
.	O

While	O
macrophage	O
cells	O
and	O
lymphocytic	O
cells	O
were	O
acted	O
as	O
control	O
.	O

The	O
blank	O
group	O
was	O
only	O
the	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
that	O
without	O
cells	O
.	O

Results	O
:	O
Comparing	O
to	O
control	O
group	O
,	O
the	O
concentration	O
of	O
dimethyl	O
sulphide	O
,	O
2,4-dimethyl-heptane	O
,	O
methylbenzene	O
,	O
o-xylene	O
,	O
dodecane	O
and	O
1,3-ditert-butylbenzene	O
in	O
JEKO	O
cells	O
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	O
,	O
hexanal	O
and	O
benzaldehyde	O
was	O
lower	O
.	O

In	O
SHI-1	O
cells	O
,	O
the	O
levels	O
of	O
2,4-dimethyl-heptane	O
,	O
benzene	O
,	O
4-methyldecane	O
,	O
chloroform	O
,	O
3,7-dimethyl	O
dodecane	O
and	O
hexadecane	O
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	O
and	O
cyclohexanol	O
were	O
distinctly	O
reduced	O
.	O

Conclusions	O
:	O
This	O
pilot	O
study	O
revealed	O
that	O
the	O
malignant	O
hematological	O
cells	O
could	O
change	O
the	O
components	O
of	O
VOCs	O
in	O
the	O
cell	O
culture	O
flask	O
in	O
a	O
cell	O
type	O
specific	O
pattern	O
.	O

The	O
traits	O
of	O
VOCs	O
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	O
malignancies	O
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	O
in	O
diagnosis	O
of	O
malignant	O
hematological	O
diseases	O
.	O

Ketogenic	O
diets	O
improve	O
behaviors	O
associated	O
with	O
autism	O
spectrum	O
disorder	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
in	O
the	O
EL	O
mouse	O
.	O

The	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorder	O
are	O
poorly	O
treated	O
with	O
current	O
medications	O
.	O

Symptoms	O
of	O
autism	O
spectrum	O
disorder	O
are	O
frequently	O
comorbid	O
with	O
a	O
diagnosis	B-P
of	O
epilepsy	O
and	O
vice	O
versa	O
.	O

Medically	O
-	O
supervised	O
ketogenic	O
diets	O
are	O
remarkably	O
effective	O
nonpharmacological	O
treatments	O
for	O
epilepsy	O
,	O
even	O
in	O
drug	O
-refractory	O
cases	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
supports	O
the	O
efficacy	O
of	O
ketogenic	O
diets	O
in	O
treating	O
the	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorders	O
in	O
animal	O
models	O
as	O
well	O
as	O
limited	O
reports	O
of	O
benefits	O
in	O
patients	O
.	O

This	O
study	O
tests	B-P
the	O
behavioral	O
effects	O
of	O
ketogenic	O
diet	O
feeding	O
in	O
the	O
EL	O
mouse	O
,	O
a	O
model	O
with	O
behavioral	O
characteristics	O
of	O
autism	O
spectrum	O
disorder	O
and	O
comorbid	O
epilepsy	O
.	O

Male	O
and	O
female	O
EL	O
mice	O
were	O
fed	O
control	O
diet	O
or	O
one	O
of	O
two	O
ketogenic	O
diet	O
formulas	O
ad	O
libitum	O
starting	O
at	O
5weeks	O
of	O
age	O
.	O

Beginning	O
at	O
8weeks	O
of	O
age	O
,	O
diet	O
protocols	O
continued	O
and	O
performance	O
of	O
each	O
group	O
on	O
tests	O
of	O
sociability	O
and	O
repetitive	O
behavior	O
was	O
assessed	O
.	O

A	O
ketogenic	O
diet	O
improved	O
behavioral	O
characteristics	O
of	O
autism	O
spectrum	O
disorder	O
in	O
a	O
sex	O
-	O
and	O
test	O
-	O
specific	O
manner	O
;	O
ketogenic	O
diet	O
never	O
worsened	O
relevant	O
behaviors	O
.	O

Ketogenic	O
diet	O
feeding	O
improved	O
multiple	O
measures	O
of	O
sociability	O
and	O
reduced	O
repetitive	O
behavior	O
in	O
female	O
mice	O
,	O
with	O
limited	O
effects	O
in	O
males	O
.	O

Additional	O
experiments	O
in	O
female	O
mice	O
showed	O
that	O
a	O
less	O
strict	O
,	O
more	O
clinically	O
-	O
relevant	O
diet	O
formula	O
was	O
equally	O
effective	O
in	O
improving	O
sociability	O
and	O
reducing	O
repetitive	O
behavior	O
.	O

Taken	O
together	O
these	O
results	O
add	O
to	O
the	O
growing	O
number	O
of	O
studies	O
suggesting	O
that	O
ketogenic	O
and	O
related	O
diets	O
may	O
provide	O
significant	O
relief	O
from	O
the	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorder	O
,	O
and	O
suggest	O
that	O
in	O
some	O
cases	O
there	O
may	O
be	O
increased	O
efficacy	O
in	O
females	O
.	O

Neural	O
activity	O
promotes	O
long-distance	O
,	O
target	O
-	O
specific	O
regeneration	O
of	O
adult	O
retinal	O
axons	O
.	O

Axons	O
in	O
the	O
mammalian	O
CNS	O
fail	O
to	O
regenerate	O
after	O
injury	O
.	O

Here	O
we	O
show	O
that	O
if	O
the	O
activity	O
of	O
mouse	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
is	O
increased	O
by	O
visual	B-P
stimulation	I-P
or	O
using	O
chemogenetics	O
,	O
their	O
axons	O
regenerate	O
.	O

We	O
also	O
show	O
that	O
if	O
enhancement	O
of	O
neural	O
activity	O
is	O
combined	O
with	O
elevation	O
of	O
the	O
cell-growth	O
-promoting	O
pathway	O
involving	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
,	O
RGC	O
axons	O
regenerate	O
long	O
distances	O
and	O
re-innervate	O
the	O
brain	O
.	O

Analysis	O
of	O
genetically	O
labeled	O
RGCs	O
revealed	O
that	O
this	O
regrowth	O
can	O
be	O
target	O
specific	O
:	O
RGC	O
axons	O
navigated	O
back	O
to	O
their	O
correct	O
visual	O
targets	O
and	O
avoided	O
targets	O
incorrect	O
for	O
their	O
function	O
.	O

Moreover	O
,	O
these	O
regenerated	O
connections	O
were	O
successful	O
in	O
partially	O
rescuing	O
a	O
subset	O
of	O
visual	O
behaviors	O
.	O

Our	O
findings	O
indicate	O
that	O
combining	O
neural	O
activity	O
with	O
activation	O
of	O
mTOR	O
can	O
serve	O
as	O
powerful	O
tool	O
for	O
enhancing	O
axon	O
regeneration	O
,	O
and	O
they	O
highlight	O
the	O
remarkable	O
capacity	O
of	O
CNS	O
neurons	O
to	O
re-establish	O
accurate	O
circuit	O
connections	O
in	O
adulthood	O
.	O

12-Lead	B-P
electrocardiogram	I-P
as	O
a	O
predictor	O
of	O
sudden	O
cardiac	O
death	O
:	O
from	O
epidemiology	O
to	O
clinical	O
practice	O
.	O

Sudden	O
cardiac	O
death	O
(	O
SCD	O
)	O
causes	O
a	O
high	O
burden	O
of	O
premature	O
deaths	O
in	O
the	O
population	O
affecting	O
subjects	O
of	O
all	O
ages	O
.	O

The	O
identification	O
of	O
subjects	O
at	O
high	O
risk	O
for	O
SCD	O
is	O
of	O
great	O
importance	O
as	O
the	O
prevention	O
of	O
many	O
of	O
these	O
events	O
would	O
be	O
possible	O
with	O
the	O
treatment	O
of	O
underlying	O
cardiac	O
diseases	O
and	O
the	O
use	O
of	O
implantable	O
cardioverter-defibrillators	O
(	O
ICD	O
)	O
.	O

However	O
,	O
the	O
current	O
selection	O
of	O
patients	O
for	O
ICD	O
therapy	O
is	O
based	O
solely	O
on	O
left	O
ventricular	O
ejection	O
fraction	O
,	O
and	O
thus	O
a	O
substantial	O
portion	O
of	O
patients	O
at	O
high	O
risk	O
does	O
not	O
qualify	O
for	O
the	O
therapy	O
.	O

Role	O
of	O
the	O
standard	B-P
electrocardiogram	I-P
(	O
ECG	B-P
)	O
in	O
SCD	O
risk	O
stratification	O
has	O
been	O
under	O
active	O
research	O
during	O
the	O
last	O
decade	O
and	O
multiple	O
abnormalities	O
of	O
depolarization	O
and	O
repolarization	O
on	O
the	O
ECG	B-P
associated	O
with	O
an	O
increased	O
risk	O
of	O
SCD	O
have	O
been	O
identified	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
basic	O
pathophysiological	O
principles	O
behind	O
these	O
changes	O
.	O

We	O
also	O
review	O
the	O
current	O
knowledge	O
of	O
the	O
prognostic	O
significance	O
of	O
ECG	B-P
predictors	O
of	O
SCD	O
in	O
the	O
general	O
population	O
,	O
and	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
heart	O
failure	O
,	O
cardiomyopathies	O
,	O
and	O
in	O
inheritable	O
arrhythmia	O
syndromes	O
.	O

Also	O
,	O
insights	O
into	O
the	O
novel	O
digital	O
ECG	B-P
signal	O
processing	O
techniques	O
are	O
provided	O
.	O

Pre-existing	O
renal	O
lesions	O
revealed	O
after	O
renal	O
trauma	O
,	O
Difficulties	O
in	O
diagnosis	O
and	O
accountability	O
:	O
About	O
14	O
cases	O
.	O

Pre-existing	O
renal	O
lesions	O
(	O
PERL	O
)	O
may	O
interfere	O
with	O
the	O
patho-physiology	O
of	O
trauma	O
,	O
alter	O
the	O
radiographic	B-P
imaging	I-P
and	O
influence	O
the	O
therapeutic	O
approach	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
record	O
the	O
PERL	O
found	O
incidentally	O
during	O
blunt	O
renal	O
trauma	O
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	O
management	O
and	O
to	O
determin	O
the	O
estimated	O
partial	O
permanent	O
disability	O
(	O
PPD	O
)	O
.	O

The	O
medical	O
records	O
of	O
14	O
patients	O
with	O
PERL	O
and	O
blunt	O
renal	O
trauma	O
were	O
reviewed	O
.	O

In	O
each	O
patient	O
,	O
pre-existing	O
renal	O
abnormalities	O
,	O
clinical	O
symptoms	O
,	O
CT	B-P
scan	I-P
study	O
findings	O
,	O
associated	O
injuries	O
,	O
therapeutic	O
approach	O
,	O
the	O
accountability	O
criteria	O
and	O
the	O
estimated	O
PPD	O
were	O
recorded	O
.	O

There	O
were	O
11	O
men	O
and	O
3	O
women	O
with	O
a	O
mean	O
age	O
of	O
35,6	O
years	O
(	O
range	O
19-66	O
years	O
)	O
.	O

Renal	O
trauma	O
was	O
due	O
to	O
a	O
traffic	O
accident	O
in	O
8	O
patients	O
.	O

Renal	O
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	O
of	O
the	O
trauma	O
(	O
minor	O
trauma	O
)	O
.	O

They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	O
to	O
other	O
abdominal	O
organs	O
(	O
four	O
patients	O
only	O
)	O
.	O

Urinary	O
stones	O
were	O
present	O
in	O
5	O
patients	O
,	O
pelvi-ureteric	O
junction	O
obstruction	O
in	O
3	O
,	O
horseshoe	O
kidny	O
in	O
3	O
,	O
ectopic	O
kidney	O
in	O
2	O
and	O
upper	O
urinary	O
tract	O
carcinoma	O
in	O
one	O
case	O
.	O

Early	O
nephrectomy	O
was	O
required	O
in	O
three	O
cases	O
for	O
hemodynamic	O
instability	O
.	O

Ureteral	O
stenting	O
was	O
indicated	O
in	O
3	O
cases	O
.	O

Six	O
patients	O
were	O
operated	O
later	O
because	O
of	O
their	O
underlying	O
renal	O
pathology	O
.	O

A	O
conservative	O
treatment	O
was	O
possible	O
only	O
in	O
7	O
of	O
cases	O
.	O

The	O
PPD	O
related	O
to	O
renal	O
trauma	O
varide	O
from	O
0	O
to	O
13	O
%	O
in	O
all	O
cases	O
.	O

PERL	O
may	O
complicate	O
a	O
negligible	O
renal	O
trauma	O
while	O
in	O
some	O
cases	O
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient	O
's	O
final	O
outcome	O
.	O

The	O
imaging	O
findings	O
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O

The	O
therapeutic	O
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	O
and	O
the	O
severity	O
of	O
damage	O
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo-dynamically	O
stable	O
patient	O
.	O

Accountability	O
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	O
depends	O
on	O
the	O
PERL	O
and	O
the	O
renal	O
injuries	O
severity	O
.	O

We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case	O
.	O

Ethical	O
approval	O
:	O
Not	O
required	O
Conflicts	O
of	O
interest	O
:	O
None	O
.	O

Relation	O
of	O
Plasma	O
Lipoprotein	O
(	O
a	O
)	O
to	O
Subclinical	O
Coronary	O
Plaque	O
Volumes	O
,	O
Three-Vessel	O
and	O
Left	O
Main	O
Coronary	O
Disease	O
,	O
and	O
Severe	O
Coronary	O
Stenoses	O
in	O
Apparently	O
Healthy	O
African-Americans	O
With	O
a	O
Family	O
History	O
of	O
Early-Onset	O
Coronary	O
Artery	O
Disease	O
.	O

Serum	O
lipoprotein	O
(	O
a	O
)	O
[	O
Lp	O
(	O
a	O
)	O
]	O
is	O
a	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
risk	O
factor	O
in	O
persons	O
of	O
European	O
ancestry	O
.	O

Levels	O
are	O
twofold	O
to	O
threefold	O
higher	O
in	O
African-Americans	O
(	O
AAs	O
)	O
,	O
but	O
reported	O
associations	O
with	O
CAD	O
have	O
been	O
inconsistent	O
.	O

The	O
relation	O
of	O
Lp	O
(	O
a	O
)	O
with	O
the	O
extent	O
and	O
severity	O
of	O
subclinical	O
coronary	O
plaque	O
has	O
not	O
been	O
described	O
in	O
AAs	O
.	O

We	O
screened	O
269	O
apparently	O
healthy	O
AAs	O
for	O
risk	O
factors	O
and	O
coronary	O
plaque	O
using	O
advanced	O
coronary	B-P
computed	I-P
tomographic	I-P
angiography	I-P
.	O

Total	O
coronary	O
plaque	O
(	O
TCP	O
)	O
,	O
noncalcified	O
coronary	O
plaque	O
,	O
and	O
calcified	O
coronary	O
plaque	O
volumes	O
(	O
mm	O
(	O
3	O
)	O
)	O
were	O
quantified	O
using	O
a	O
validated	O
automated	O
method	O
.	O

Lp	O
(	O
a	O
)	O
was	O
measured	O
by	O
ELISA	O
.	O

Multivariable	O
modeling	O
was	O
performed	O
with	O
adjustment	O
for	O
traditional	O
CAD	O
risk	O
factors	O
and	O
intrafamilial	O
correlations	O
.	O

Mean	O
age	O
was	O
51	O
±	O
11	O
years	O
and	O
64	O
%	O
were	O
female	O
.	O

Plaque	O
was	O
present	O
in	O
41	O
%	O
.	O

Lp	O
(	O
a	O
)	O
was	O
independently	O
associated	O
with	O
TCP	O
volume	O
[	O
log	O
(	O
TCP	O
+	O
1	O
)	O
]	O
(	O
p	O
=	O
0.04	O
)	O
,	O
3-vessel	O
and/or	O
left	O
main	O
involvement	O
(	O
p	O
=	O
0.04	O
)	O
,	O
and	O
at	O
least	O
1	O
stenosis	O
>	O
50	O
%	O
(	O
p	O
=	O
0.006	O
)	O
.	O

Best-fit	O
regression	O
analyses	O
showed	O
that	O
subjects	O
with	O
Lp	O
(	O
a	O
)	O
>	O
40	O
mg/dl	O
were	O
threefold	O
more	O
likely	O
to	O
have	O
3-vessel	O
and/or	O
left	O
main	O
disease	O
(	O
95	O
%	O
confidence	O
interval	O
1.4	O
to	O
6.8	O
,	O
p	O
=	O
0.005	O
)	O
and	O
fourfold	O
more	O
likely	O
to	O
have	O
stenosis	O
>	O
50	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
1.3	O
to	O
15.0	O
,	O
p	O
=	O
0.02	O
)	O
.	O

In	O
subjects	O
with	O
plaque	O
(	O
n	O
=	O
110	O
)	O
,	O
multivariable	O
models	O
showed	O
the	O
Lp	O
(	O
a	O
)	O
level	O
was	O
significantly	O
and	O
independently	O
associated	O
with	O
TCP	O
(	O
p	O
=	O
0.009	O
)	O
,	O
noncalcified	O
coronary	O
plaque	O
(	O
p	O
=	O
0.01	O
)	O
,	O
and	O
calcified	O
coronary	O
plaque	O
(	O
p	O
=	O
0.003	O
)	O
and	O
affected	O
vessel	O
length	O
(	O
p	O
=	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
high	O
Lp	O
(	O
a	O
)	O
is	O
strongly	O
associated	O
with	O
coronary	O
plaque	O
volumes	O
,	O
extent	O
,	O
and	O
severity	O
in	O
apparently	O
healthy	O
AAs	O
.	O

High	O
levels	O
of	O
Lp	O
(	O
a	O
)	O
may	O
be	O
particularly	O
important	O
in	O
the	O
pathogenesis	O
of	O
CAD	O
in	O
AAs	O
.	O

Silent	O
strain	O
of	O
caregiving	O
:	O
exploring	O
the	O
best	O
predictors	O
of	O
distress	O
in	O
family	O
carers	O
of	O
geriatric	O
patients	O
.	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	O
predictors	O
of	O
distress	O
suffered	O
by	O
family	O
carers	O
(	O
FCs	O
)	O
of	O
geriatric	O
patients	O
.	O

A	O
cross-sectional	O
study	O
of	O
100	O
FC	O
-	O
geriatric	O
patient	O
dyads	O
was	O
conducted	O
.	O

The	O
negative	O
impact	O
of	O
care	O
(	O
NIoC	O
)	O
subscale	O
of	O
the	O
COPE	O
index	O
was	O
dichotomized	O
to	O
identify	O
lower	O
stress	O
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	O
stress	O
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	O
by	O
the	O
process	O
of	O
providing	O
care	O
.	O

The	O
set	O
of	O
explanatory	O
variables	O
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	O
and	O
care-related	O
attributes	O
,	O
including	O
patient-related	O
results	O
from	O
comprehensive	O
geriatric	O
assessments	O
and	O
disease	O
profiles	O
.	O

The	O
best	O
combination	O
of	O
explanatory	O
variables	O
that	O
provided	O
the	O
highest	O
predictive	O
powe	O
r	O
for	O
distress	O
among	O
FCs	O
in	O
the	O
multiple	O
logistic	O
regression	O
(	O
LR	O
)	O
model	O
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O

The	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross-validation	O
method	O
.	O

The	O
mean	O
age	O
of	O
FCs	O
was	O
57.2	O
(	O
±10.6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
(	O
±6.4	O
)	O
years	O
.	O

Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	O
,	O
only	O
five	O
predictors	O
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O

A	O
higher	O
level	O
of	O
distress	O
was	O
independently	O
predicted	O
by	O
lower	O
self-evaluation	O
of	O
health	O
;	O
worse	O
self-appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
;	O
lower	O
sense	O
of	O
general	O
support	O
;	O
more	O
hours	O
of	O
care	O
per	O
week	O
;	O
and	O
the	O
motor	O
retardation	O
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-P
Up	I-P
and	I-P
Go	I-P
(	I-P
TUG	I-P
)	I-P
test	I-P
.	O

Worse	O
performance	O
on	O
the	O
TUG	B-P
test	I-P
was	O
only	O
the	O
patient	O
-related	O
predictor	O
of	O
distress	O
among	O
the	O
variables	O
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC	O
.	O

Enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	O
methods	O
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	O
.	O

Utility	O
of	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
low-	O
iodine	O
contrast	O
medium	O
in	O
DIEP	O
angiography	B-P
.	O

To	O
evaluate	O
the	O
utility	O
of	O
dual-energy	B-P
spectral	I-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
low-iodine	O
intake	O
in	O
CT	B-P
angiography	I-P
(	O
CTA	B-P
)	O
of	O
deep	O
inferior	O
epigastric	O
perforator	O
(	O
DIEP	O
)	O
flaps	O
.	O

In	O
this	O
prospective	O
study	O
,	O
40	O
patients	O
with	O
a	O
BMI	O
<	O
28.0	O
kg/m	O
(	O
2	O
)	O
underwent	O
CTA	B-P
examination	O
for	O
breast	O
reconstruction	O
and	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
(	O
n=20	O
for	O
each	O
group	O
)	O
as	O
follows	O
:	O
Group	O
A	O
was	O
submitted	O
to	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
iodixanol	O
(	O
270	O
mg	O
I/mL	O
)	O
and	O
Group	O
B	O
was	O
submitted	O
to	O
conventional	O
high	O
iodine	O
contrast	O
agent	O
iohexol	O
(	O
350	O
mg	O
I/mL	O
)	O
.	O

The	O
volume	O
CT	O
dose	O
index	O
(	O
CTDIvol	O
)	O
and	O
dose	O
length	O
product	O
were	O
recorded	O
and	O
the	O
effective	O
dose	O
(	O
ED	O
)	O
was	O
calculated	O
.	O

The	O
best	O
mono-spectrum	O
images	O
of	O
Group	O
A	O
were	O
selected	O
according	O
to	O
the	O
optimal	O
contrast	O
to	O
noise	O
ratio	O
(	O
CNR	O
)	O
.	O

Both	O
mono-spectrum	O
images	O
of	O
Group	O
A	O
and	O
polychromatic	O
images	O
of	O
Group	O
B	O
were	O
used	O
to	O
reconstruct	O
maximum	O
intensity	O
projection	O
(	O
MIP	O
)	O
and	O
volume	O
rendering	O
(	O
VR	O
)	O
images	O
of	O
the	O
perforating	O
artery	O
,	O
respectively	O
.	O

Two	O
radiologists	O
evaluated	O
subjective	O
image	O
quality	O
using	O
a	O
4-point	O
score	O
.	O

The	O
diameter	O
of	O
the	O
perforating	O
artery	O
,	O
CT	B-P
value	O
and	O
SD	O
value	O
for	O
the	O
common	O
femoral	O
artery	O
were	O
measured	O
and	O
the	O
CNR	O
was	O
calculated	O
.	O

The	O
total	O
iodine	O
intake	O
and	O
radiation	O
doses	O
of	O
the	O
two	O
groups	O
were	O
calculated	O
and	O
compared	O
.	O

The	O
best	O
mono-spectrum	O
energy	O
with	O
the	O
optimal	O
CNR	O
of	O
the	O
perforating	O
artery	O
was	O
63	O
keV	O
.	O

The	O
CT	B-P
value	O
of	O
common	O
femoral	O
artery	O
in	O
Group	O
A	O
(	O
380.96±42.75HU	O
)	O
was	O
7.40	O
%	O
higher	O
than	O
in	O
Group	O
B	O
(	O
354.71±42.01	O
HU	O
)	O
but	O
with	O
no	O
statistical	O
significance	O
(	O
P	O
>	O
.05	O
)	O
.	O

The	O
CNR	O
of	O
the	O
common	O
femoral	O
artery	O
in	O
Group	O
A	O
(	O
23.84±6.73	O
)	O
was	O
6.88	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
25.60±6.20	O
)	O
,	O
with	O
no	O
significant	O
difference	O
(	O
P	O
>	O
.05	O
)	O
.	O

The	O
diameters	O
of	O
the	O
perforator	O
vessels	O
were	O
2.44±0.15	O
and	O
2.49±0.14	O
mm	O
,	O
respectively	O
,	O
with	O
no	O
significant	O
difference	O
(	O
P	O
>	O
.05	O
)	O
.	O

Subjective	O
image	O
qualities	O
for	O
the	O
two	O
groups	O
were	O
both	O
good	O
for	O
diagnostics	B-P
,	O
and	O
the	O
scores	O
for	O
Group	O
A	O
and	O
Group	O
B	O
were	O
(	O
3.88±0.28	O
)	O
and	O
(	O
3.93±0.18	O
)	O
,	O
respectively	O
.	O

The	O
scores	O
of	O
the	O
two	O
radiologists	O
were	O
consistent	O
(	O
kappa=0.634	O
)	O
.	O

The	O
effective	O
radiation	O
dose	O
in	O
Group	O
A	O
(	O
9.09±0	O
mSv	O
)	O
was	O
10.62	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
10.17±1.91	O
mSv	O
)	O
.	O

The	O
total	O
iodine	O
intake	O
in	O
Group	O
A	O
(	O
27	O
000	O
mg	O
)	O
was	O
22.86	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
35	O
000	O
mg	O
)	O
.	O

The	O
combination	O
of	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
low-iodine	O
intake	O
in	O
CTA	B-P
of	O
DIEP	O
flap	O
examination	O
with	O
the	O
optimal	O
CNR	O
technology	O
can	O
meet	O
the	O
requirements	O
of	O
clinical	O
diagnostics	O
,	O
with	O
a	O
22.86	O
%	O
reduction	O
in	O
total	O
iodine	O
intake	O
and	O
an	O
11.01	O
%	O
reduction	O
in	O
radiation	O
dose	O
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	O
muscle	O
,	O
and	O
cardiac	O
abnormalities	O
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	O
in	O
mitochondrial	O
disease	O
.	O

Mitochondrial	O
disease	O
(	O
MD	O
)	O
is	O
a	O
genetic	O
disorder	O
affecting	O
skeletal	O
muscles	O
,	O
with	O
possible	O
myocardial	O
disease	O
.	O

The	O
ergoreflex	O
,	O
sensitive	O
to	O
skeletal	O
muscle	O
work	O
,	O
regulates	O
ventilatory	O
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	O
in	O
MD	O
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	O
involvement	O
.	O

Twenty-five	O
MD	O
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	O
but	O
without	O
known	O
cardiac	O
disease	O
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin-3	O
,	O
soluble	O
suppression	O
of	O
tumorigenesis	O
2	O
(	O
sST2	O
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	O
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	O
recording	O
,	O
cardiopulmonary	B-P
exercise	I-P
testing	I-P
,	O
echocardiography	B-P
,	O
cardiac/muscle	B-P
magnetic	I-P
resonance	I-P
(	O
C/MMR	B-P
)	O
,	O
and	O
ergoreflex	O
assessment	O
.	O

Thirteen	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
were	O
chosen	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	O
cardiac	O
damage	O
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	B-P
.	O

Ergoreflex	O
sensitivity	O
was	O
markedly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
64	O
%	O
vs.	O
37	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
correlated	O
with	O
muscle	O
fat	O
to	O
water	O
ratio	O
and	O
extracellular	O
volume	O
at	O
MMR	B-P
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

Among	O
patients	O
,	O
ergoreflex	O
sensitivity	O
was	O
higher	O
in	O
those	O
with	O
cardiac	O
involvement	O
(	O
P	O
=	O
0.034	O
)	O
.	O

Patients	O
showed	O
a	O
lower	O
peak	O
oxygen	O
consumption	O
(	O
VO2	O
/kg	O
)	O
than	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
ventilatory	O
inefficiency	O
(	O
P	O
=	O
0.024	O
)	O
.	O

Ergoreflex	O
sensitivity	O
correlated	O
with	O
reduced	O
workload	O
and	O
peak	O
VO2	O
/kg	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
several	O
indicators	O
of	O
autonomic	O
imbalance	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Plasma	O
norepinephrine	O
was	O
the	O
unique	O
predictor	O
of	O
myocardial	O
fibrosis	O
at	O
univariate	O
analysis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Skeletal	O
myopathy	O
in	O
MD	O
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	O
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	O
,	O
exercise	O
intolerance	O
,	O
and	O
sympathetic	O
activation	O
.	O

Considerations	O
on	O
the	O
Relevance	O
of	O
Cerebral	O
Fusiform	O
Aneurysms	O
Observed	O
During	O
HIV	O
Infection	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-associated	O
ectatic	O
cerebral	O
vasculitis	O
(	O
HIV	O
-	O
AECV	O
)	O
is	O
a	O
rare	O
form	O
of	O
vasculitis	O
with	O
diffuse	O
fusiform	O
aneurysms	O
.	O

Its	O
pathophysiology	O
remains	O
poorly	O
understood	O
.	O

Although	O
extensively	O
described	O
in	O
children	O
,	O
it	O
is	O
still	O
incompletely	O
studied	O
in	O
adults	O
.	O

Our	O
objective	O
was	O
to	O
present	O
five	O
adult	O
cases	O
with	O
emphasis	O
on	O
imaging	O
findings	O
and	O
long-term	O
evolution	O
.	O

From	O
2006	O
to	O
2014	O
,	O
we	O
included	O
5	O
HIV	O
-	O
infected	O
patients	O
presenting	O
with	O
fusiform	O
cerebral	O
aneurysms	O
.	O

Vessels	O
abnormalities	O
were	O
assessed	O
with	O
brain	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
angiography	B-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
(	O
MRA	B-P
)	O
and/or	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
.	O

All	O
patients	O
had	O
MR	B-P
assessment	O
of	O
the	O
brain	O
.	O

Clinical	O
and	O
biological	O
data	O
were	O
analyzed	O
.	O

Fusiform	O
aneurysms	O
of	O
carotid	O
terminations	O
extending	O
to	O
middle	O
and	O
anterior	O
cerebral	O
arteries	O
were	O
bilateral	O
in	O
three	O
patients	O
and	O
unilateral	O
in	O
one	O
.	O

More	O
distal	O
fusiform	O
aneurysms	O
were	O
observed	O
in	O
four	O
patients	O
and	O
saccular	O
aneurysms	O
in	O
two	O
patients	O
,	O
two	O
patients	O
suffered	O
from	O
ischemic	O
lesions	O
while	O
none	O
experienced	O
hemorrhage	O
.	O

Unlike	O
recent	O
reviews	O
,	O
our	O
study	O
underlines	O
the	O
low	O
hemorrhagic	O
potential	O
of	O
HIV	O
-	O
AECV	O
and	O
long-term	O
follow-up	O
suggests	O
a	O
monophasic	O
evolution	O
under	O
antiretroviral	O
medication	O
.	O

Computer-aided	O
Dereplication	O
and	O
Structure	O
Elucidation	O
of	O
Natural	O
Products	O
at	O
the	O
University	O
of	O
Reims	O
.	O

Natural	O
product	O
chemistry	O
began	O
in	O
Reims	O
,	O
France	O
,	O
in	O
a	O
pharmacognosy	O
research	O
laboratory	O
whose	O
main	O
emphasis	O
was	O
the	O
isolation	O
and	O
identification	O
of	O
bioactive	O
molecules	O
,	O
following	O
the	O
guidelines	O
of	O
chemotaxonomy	O
.	O

The	O
structure	O
elucidation	O
of	O
new	O
compounds	O
of	O
steadily	O
increasing	O
complexity	O
favored	O
the	O
emergence	O
of	O
methodological	O
work	O
in	O
nuclear	O
magnetic	O
resonance	O
.	O

As	O
a	O
result	O
,	O
our	O
group	O
was	O
the	O
first	O
to	O
report	O
the	O
use	O
of	O
proton-detected	O
heteronuclear	O
chemical	O
shift	O
correlation	O
spectra	O
for	O
the	O
computer-assisted	O
structure	O
elucidation	O
of	O
small	O
organic	O
molecules	O
driven	O
by	O
atom	O
proximity	O
relationships	O
and	O
without	O
relying	O
on	O
databases	O
.	O

The	O
early	O
detection	O
of	O
known	O
compounds	O
appeared	O
as	O
a	O
necessity	O
in	O
order	O
to	O
deal	O
more	O
efficiently	O
with	O
complex	O
plant	O
extracts	O
.	O

This	O
goal	O
was	O
reached	O
by	O
an	O
original	O
combination	O
of	O
mixture	O
fractionation	O
by	O
centrifugal	O
partition	O
chromatography	O
,	O
analysis	B-P
by	I-P
(	I-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
digital	O
data	O
reduction	O
and	O
alignment	O
,	O
hierarchical	O
data	O
clustering	O
,	O
and	O
computer	O
database	O
search	O
.	O

Entrapment	O
of	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
inferior	O
cluneal	O
branches	O
:	O
anatomical	O
basis	O
of	O
surgery	O
for	O
inferior	O
cluneal	O
neuralgia	O
.	O

The	O
apparent	O
failure	O
of	O
pudendal	O
nerve	O
surgery	O
in	O
some	O
patients	O
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	O
of	O
other	O
adjacent	O
nerve	O
structures	O
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	O
cluneal	O
neuralgia	O
.	O

Via	O
its	O
numerous	O
collateral	O
branches	O
,	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	O
surface	O
of	O
the	O
thigh	O
,	O
the	O
infragluteal	O
fold	O
,	O
the	O
skin	O
over	O
the	O
ischial	O
tuberosity	O
,	O
but	O
also	O
the	O
lateral	O
anal	O
region	O
,	O
scrotum	O
or	O
labium	O
majus	O
via	O
its	O
perineal	O
branch	O
.	O

We	O
described	O
the	O
pathophysiological	O
features	O
of	O
cluneal	O
neuralgia	O
,	O
the	O
surgical	B-P
technique	I-P
and	O
our	O
preliminary	O
results	O
.	O

We	O
performed	O
a	O
transmuscular	O
approach	O
leading	O
to	O
the	O
fat	O
of	O
the	O
deep	O
gluteal	O
region	O
.	O

Exploration	O
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	O
,	O
looking	O
for	O
potential	O
entrapments	O
affecting	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
the	O
sciatic	O
nerve	O
.	O

Nerve	O
decompression	O
on	O
the	O
lateral	O
surface	O
of	O
the	O
ischial	O
tuberosity	O
was	O
then	O
performed	O
.	O

A	O
constant	O
anatomical	O
finding	O
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	O
fibrous	O
expansion	O
from	O
the	O
ischium	O
passing	O
behind	O
the	O
nerves	O
and	O
vessels	O
,	O
especially	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
perineal	O
branches	O
.	O

In	O
our	O
patients	O
,	O
release	O
of	O
this	O
expansion	O
allowed	O
decompression	O
of	O
the	O
nerve	O
trapped	O
by	O
this	O
expansion	O
.	O

Cluneal	O
neuralgia	O
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	O
pain	O
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	O
neuralgia	O
.	O

Surgery	O
should	O
be	O
performed	O
via	O
a	O
transgluteal	O
approach	O
.	O

A	O
lateral	O
ischial	O
obstacle	O
must	O
be	O
investigated	O
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	O
expansion	O
,	O
which	O
,	O
like	O
a	O
retinaculum	O
,	O
can	O
cause	O
nerve	O
entrapment	O
.	O

Minimally	O
invasive	O
treatment	O
of	O
difficult	O
bleeding	O
lesions	O
of	O
the	O
small	O
bowel	O
.	O

Bleeding	O
lesions	O
of	O
the	O
small	O
bowel	O
are	O
often	O
difficult	O
to	O
identify	O
due	O
to	O
the	O
obscure	O
symptomatology	O
.	O

Localizing	O
these	O
lesions	O
requires	O
specific	O
techniques	O
.	O

The	O
Double-balloon	B-P
enteroscopy	I-P
(	O
DBE	B-P
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	O
and	O
mark	O
lesions	O
,	O
so	O
that	O
a	O
minimally	O
invasive	O
surgical	O
treatment	O
could	O
be	O
performed	O
.	O

Twenty	O
robot	O
-	O
assisted	O
small	O
bowel	O
procedures	O
are	O
presented	O
using	O
a	O
combination	O
of	O
DBE	B-P
for	O
localization	O
and	O
robotic	O
resection	O
.	O

There	O
were	O
10	O
jejunal	O
resections	O
and	O
10	O
ileal	O
resections	O
.	O

Mean	O
age	O
was	O
58.7	O
years	O
.	O

Mean	O
operative	O
time	O
was	O
153.4	O
minutes	O
,	O
mean	O
blood	O
loss	O
of	O
46	O
mL	O
.	O

No	O
conversion-to-open	O
and	O
there	O
were	O
4	O
post-operative	O
complications	O
.	O

The	O
90-	O
day	O
mortality	O
was	O
nil	O
and	O
the	O
median	O
length	O
of	O
stay	O
was	O
4.1	O
days	O
.	O

Final	O
pathology	O
was	O
consistent	O
with	O
malignancy	O
in	O
10	O
cases	O
.	O

The	O
combination	O
of	O
double-balloon	B-P
enteroscopy	I-P
and	O
robotic	O
technology	O
allows	O
accurate	O
identification	O
and	O
selective	O
treatment	O
of	O
lesions	O
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	O
in	O
a	O
minimally	O
invasive	O
fashion	O
.	O

Alanine	O
Aminotransferase	O
Is	O
a	O
Marker	O
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	O
with	O
Polycystic	O
Ovary	O
Syndrome	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	O
(	O
ALT	O
)	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
compared	O
with	O
control	O
subjects	O
.	O

Plasma	O
ALT	O
levels	O
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	O
and	O
hepatic	O
insulin	O
resistance	O
.	O

Retrospective	O
chart	O
review	O
aiming	O
to	O
assess	O
,	O
in	O
PCOS	O
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	O
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
PCOS	O
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	O
index	O
of	O
34.1	O
kg/m	O
(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
.	O

ALT	O
levels	O
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	O
assessment	O
for	O
insulin	O
resistance	O
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL-C	O
(	O
r	O
=	O
-0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	O
(	O
-0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	B-P
secretion-sensitivity	I-P
index-2	I-P
(	O
-0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	O
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	O
and	O
triglyceride	O
levels	O
.	O

ALT	O
cutoff	O
≥24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	O
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	O
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
MetS	O
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole-body	O
insulin	O
resistance	O
(	O
Matsuda	O
index	O
<	O
12.3	O
L	O
(	O
2	O
)	O
·10/mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Plasma	O
ALT	O
levels	O
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	O
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
PCOS	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
ALT	O
cutoff	O
of	O
≥24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Rubinstein-Taybi	O
Syndrome	O
Associated	O
with	O
Pituitary	O
Macroadenoma	O
:	O
A	O
Case	O
Report	O
.	O

Rubinstein-Taybi	O
Syndrome	O
(	O
RSTS	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
is	O
classically	O
characterized	O
by	O
prenatal	O
and	O
postnatal	O
growth	O
restriction	O
,	O
microcephaly	O
,	O
dysmorphic	O
craniofacial	O
features	O
,	O
broad	O
thumbs	O
and	O
toes	O
,	O
and	O
intellectual	O
disability	O
.	O

We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	O
macroadenoma	O
associated	O
with	O
RSTS	O
.	O

A	O
39-year-old	O
Caucasian	O
female	O
with	O
a	O
past	O
medical	O
history	O
of	O
RSTS	O
diagnosed	O
at	O
age	O
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	O
-enhancing	O
pituitary	O
mass	O
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
of	O
the	O
brain	O
three	O
years	O
ago	O
during	O
workup	O
for	O
migraine-like	O
headaches	O
.	O

Subsequent	O
serial	O
imaging	B-P
showed	O
radiographic	O
evidence	O
of	O
growth	O
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	O
.	O

The	O
pituitary	O
sellar	O
lesion	O
was	O
resected	O
through	O
an	O
endoscopic	O
transnasal	O
transsphenoidal	O
approach	O
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	O
adenoma	O
.	O

RSTS	O
is	O
a	O
rare	O
,	O
neurodevelopmental	O
genetic	O
disease	O
where	O
most	O
patients	O
with	O
disabilities	O
survive	O
into	O
adulthood	O
.	O

The	O
disorder	O
is	O
associated	O
with	O
an	O
increased	O
predisposition	O
for	O
development	O
of	O
nervous	O
system	O
tumors	O
,	O
including	O
pituitary	O
adenomas	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
polymorphism	O
association	O
with	O
obesity	O
and	O
some	O
related	O
disorders	O
in	O
Egyptian	O
females	O
:	O
a	O
case-control	O
observational	O
study	O
.	O

According	O
to	O
the	O
WHO	O
report	O
in	O
2015	O
,	O
obesity	O
is	O
the	O
fifth	O
leading	O
cause	O
of	O
death	O
worldwide	O
,	O
and	O
the	O
prevalence	O
of	O
Egyptian	O
female	O
obesity	O
is	O
37.5	O
%	O
.	O

Since	O
obesity	O
is	O
highly	O
influenced	O
by	O
genetics	O
,	O
and	O
adipose	O
tissue	O
renin-angiotensin	O
system	O
is	O
over-activated	O
in	O
obesity	O
,	O
the	O
effect	O
of	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
insertion/deletion	O
(	O
I/D	O
)	O
polymorphism	O
on	O
obesity	O
and	O
related	O
disorders	O
was	O
studied	O
in	O
several	O
populations	O
,	O
because	O
of	O
its	O
effect	O
on	O
ACE	O
activity	O
.	O

Our	O
objective	O
was	O
to	O
study	O
the	O
association	O
of	O
ACE	O
I/D	O
polymorphism	O
with	O
obesity	O
and	O
certain	O
related	O
disorders	O
,	O
namely	O
hypertension	O
,	O
insulin	O
resistance	O
and	O
metabolic	O
syndrome	O
,	O
in	O
Egyptian	O
females	O
.	O

Eighty	O
female	O
volunteers	O
were	O
recruited	O
,	O
blood	O
pressure	O
and	O
body	B-P
measurements	I-P
were	O
recorded	O
and	O
a	O
fasting	O
blood	O
sample	O
was	O
obtained	O
for	O
the	O
quantitation	O
of	O
glucose	O
,	O
lipid	O
profile	O
,	O
insulin	O
,	O
leptin	O
and	O
identification	O
of	O
ACE	O
I/D	O
polymorphs	O
.	O

Subjects	O
were	O
grouped	O
based	O
on	O
hypertension	O
and	O
obesity	O
states	O
.	O

Comparisons	O
of	O
continuous	O
parameters	O
were	O
made	O
with	O
independent	O
sample	O
t-test	O
between	O
two	O
groups	O
.	O

The	O
frequencies	O
of	O
ACE	O
genotypes	O
and	O
alleles	O
,	O
and	O
the	O
association	O
between	O
gene	O
polymorphism	O
and	O
metabolic	O
parameters	O
were	O
assessed	O
using	O
chi-square	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

Genotype	O
frequencies	O
were	O
in	O
Hardy-Weinberg	O
equilibrium	O
for	O
all	O
groups	O
.	O

Genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
controls	O
and	O
cases	O
of	O
all	O
the	O
studied	O
disorders	O
.	O

Although	O
DD	O
carriers	O
had	O
apparently	O
higher	O
parameters	O
of	O
blood	O
pressure	O
,	O
lipid	O
profile	O
and	O
insulin	O
resistance	O
,	O
only	O
diastolic	O
blood	O
pressure	O
was	O
almost	O
significant	O
(	O
p	O
=	O
0.057	O
)	O
.	O

I-carriers	O
were	O
significantly	O
less	O
susceptible	O
to	O
hypertension	O
than	O
DD	O
carriers	O
having	O
normal	O
waist/hip	O
ratio	O
(	O
p	O
=	O
0.007	O
,	O
OR	O
=	O
17.29	O
,	O
CI	O
=	O
1.81-164.96	O
)	O
and	O
normal	O
conicity	O
index	O
(	O
p	O
=	O
0.024	O
,	O
OR	O
=	O
7.00	O
,	O
CI	O
=	O
1.36-35.93	O
)	O
.	O

In	O
DD	O
genotype	O
carriers	O
,	O
a	O
significant	O
association	O
was	O
found	O
between	O
insulin	O
resistance	O
and	O
high	O
body	O
mass	O
index	O
(	O
p	O
=	O
0.004	O
,	O
OR	O
=	O
8.89	O
,	O
CI	O
=	O
1.94-40.71	O
)	O
,	O
waist	O
circumference	O
(	O
p	O
=	O
0.003	O
,	O
OR	O
=	O
9.63	O
,	O
CI	O
=	O
2.14-43.36	O
)	O
and	O
waist/height	O
ratio	O
(	O
p	O
=	O
0.034	O
,	O
OR	O
=	O
6.86	O
,	O
CI	O
=	O
1.25-37.61	O
)	O
,	O
although	O
the	O
variations	O
in	O
percentages	O
between	O
DD	O
and	O
I-carriers	O
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	O
of	O
ACE	O
I/D	O
on	O
such	O
an	O
association	O
.	O

In	O
this	O
sample	O
of	O
Egyptian	O
females	O
,	O
ACE	O
I/D	O
polymorphism	O
was	O
not	O
significantly	O
associated	O
with	O
obesity	O
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	O
studied	O
.	O

The	O
I	O
allele	O
seemed	O
protective	O
against	O
hypertension	O
in	O
subjects	O
with	O
normal	O
,	O
not	O
high	O
,	O
waist/hip	O
ratio	O
and	O
conicity	O
index	O
compared	O
to	O
DD	O
genotype	O
carriers	O
.	O

The	O
next	O
frontier	O
of	O
office	O
-based	O
inferior	O
vena	O
cava	O
filter	O
placement	O
.	O

There	O
is	O
an	O
increasing	O
number	O
of	O
procedures	O
that	O
traditionally	O
were	O
performed	O
in	O
the	O
inpatient	O
setting	O
that	O
are	O
now	O
becoming	O
office	O
-based	O
procedures	O
.	O

These	O
include	O
peripheral	O
endovascular	O
procedures	O
such	O
as	O
angiograms	B-P
,	O
angioplasties	O
,	O
dialysis	O
access	O
interventions	O
,	O
and	O
treatment	O
for	O
venous	O
insufficiency	O
.	O

We	O
chose	O
to	O
evaluate	O
the	O
feasibility	O
,	O
safety	O
of	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
filter	O
placement	O
in	O
the	O
office-based	O
setting	O
.	O

All	O
procedures	O
were	O
performed	O
using	O
local	O
anesthesia	O
,	O
and	O
ultrasound	B-P
guidance	I-P
for	O
puncture	O
.	O

All	O
venograms	B-P
were	O
performed	O
with	O
manual	O
injection	O
of	O
iodinated	O
contrast	O
.	O

An	O
IVC	O
filter	O
was	O
placed	O
in	O
the	O
cases	O
(	O
except	O
one	O
failure	O
of	O
placement	O
)	O
using	O
fluoroscopy	B-P
in	O
the	O
infrarenal	O
position	O
.	O

Patients	O
were	O
observed	O
in	O
a	O
recovery	O
area	O
and	O
then	O
discharged	O
.	O

Follow-up	O
data	O
were	O
obtained	O
through	O
an	O
interview	O
,	O
physical	O
examination	O
,	O
and	O
24-hour	O
postoperative	O
phone	O
call	O
.	O

Over	O
the	O
course	O
of	O
27	O
months	O
,	O
29	O
Greenfield	O
filters	O
(	O
Boston	O
Scientific	O
,	O
Marlborough	O
,	O
Mass	O
)	O
and	O
three	O
Celect	O
temporary	O
filters	O
(	O
Cook	O
,	O
Bloomington	O
,	O
Ind	O
)	O
were	O
placed	O
in	O
the	O
infrarenal	O
IVC	O
for	O
18	O
women	O
and	O
14	O
men	O
,	O
with	O
an	O
average	O
age	O
of	O
75.3	O
±	O
15.6	O
years	O
(	O
range	O
,	O
38-97	O
years	O
)	O
.	O

Twenty-four	O
acute	O
,	O
6	O
recent	O
(	O
<	O
6	O
months	O
ago	O
)	O
and	O
three	O
subacute	O
lower	O
extremity	O
deep	O
vein	O
thromboses	O
(	O
DVTs	O
)	O
were	O
identified	O
.	O

The	O
indications	O
for	O
the	O
procedure	O
were	O
patients	O
with	O
:	O
DVT	O
who	O
were	O
to	O
undergo	O
surgery	O
(	O
n	O
=	O
6	O
)	O
,	O
acute	O
large	O
free-floating	O
iliofemoral	O
DVT	O
(	O
deemed	O
high-risk	O
for	O
long-term	O
anticoagulation	O
)	O
(	O
n	O
=	O
7	O
)	O
,	O
new	O
DVT	O
during	O
anticoagulation	O
therapy	O
(	O
n	O
=	O
6	O
)	O
,	O
DVT	O
with	O
gastrointestinal	O
bleeding	O
(	O
n	O
=	O
4	O
)	O
,	O
DVT	O
with	O
hematuria	O
(	O
n	O
=	O
2	O
)	O
,	O
recent	O
DVT	O
(	O
which	O
extended	O
during	O
full	O
dose	O
anticoagulation	O
treatment	O
)	O
while	O
undergoing	O
a	O
long	O
flight	O
(	O
n	O
=	O
1	O
)	O
(	O
temporary	O
filter	O
placement	O
)	O
,	O
DVT	O
with	O
arm	O
hematoma	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
with	O
unsteady	O
gait	O
and	O
history	O
of	O
falls	O
(	O
n	O
=	O
2	O
)	O
,	O
DVT	O
with	O
nose	O
bleeding	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
with	O
dementia	O
and	O
inability	O
to	O
receive	O
anticoagulation	O
treatment	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
and	O
receiving	O
chemotherapy	O
and	O
with	O
thrombocytopenia	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
DVT	O
and	O
refusal	O
to	O
take	O
anticoagulation	O
medication	O
(	O
n	O
=	O
1	O
)	O
.	O

One	O
patient	O
had	O
a	O
failure	O
to	O
place	O
a	O
filter	O
because	O
of	O
chronic	O
IVC	O
occlusion	O
found	O
on	O
venogram	B-P
.	O

One	O
patient	O
with	O
history	O
of	O
gastrointestinal	O
bleeding	O
,	O
acute	O
DVT	O
,	O
and	O
atrial	O
fibrillation	O
suffered	O
IVC	O
filter	O
thrombosis	O
1	O
month	O
after	O
the	O
procedure	O
.	O

We	O
attempted	O
removal	O
of	O
the	O
temporary	O
filters	O
in	O
the	O
hospital	O
in	O
two	O
patients	O
but	O
failed	O
to	O
retrieve	O
the	O
filter	O
in	O
these	O
two	O
cases	O
.	O

We	O
noted	O
no	O
insertion	O
site	O
DVT	O
,	O
extension	O
of	O
DVT	O
,	O
or	O
pulmonary	O
embolism	O
.	O

Our	O
preliminary	O
experience	O
suggests	O
that	O
placement	O
of	O
IVC	O
filters	O
for	O
treatment	O
of	O
venous	O
thrombotic	O
events	O
in	O
an	O
office-based	O
facility	O
is	O
safe	O
and	O
efficacious	O
with	O
basic	O
endovascular	O
equipment	O
.	O

Long-term	O
outcome	O
can	O
not	O
be	O
determined	O
at	O
this	O
point	O
.	O

Plantar	O
fascia	O
segmentation	O
and	O
thickness	O
estimation	O
in	O
ultrasound	O
images	O
.	O

Ultrasound	B-P
(	I-P
US	I-P
)	I-P
imaging	I-P
offers	O
significant	O
potential	O
in	O
diagnosis	O
of	O
plantar	O
fascia	O
(	O
PF	O
)	O
injury	O
and	O
monitoring	O
treatment	O
.	O

In	O
particular	O
US	B-P
imaging	I-P
has	O
been	O
shown	O
to	O
be	O
reliable	O
in	O
foot	O
and	O
ankle	O
assessment	O
and	O
offers	O
a	O
real-time	O
effective	O
imaging	B-P
technique	I-P
that	O
is	O
able	O
to	O
reliably	O
confirm	O
structural	O
changes	O
,	O
such	O
as	O
thickening	O
,	O
and	O
identify	O
changes	O
in	O
the	O
internal	O
echo	O
structure	O
associated	O
with	O
diseased	O
or	O
damaged	O
tissue	O
.	O

Despite	O
the	O
advantages	O
of	O
US	B-P
imaging	I-P
,	O
images	O
are	O
difficult	O
to	O
interpret	O
during	O
medical	O
assessment	O
.	O

This	O
is	O
partly	O
due	O
to	O
the	O
size	O
and	O
position	O
of	O
the	O
PF	O
in	O
relation	O
to	O
the	O
adjacent	O
tissues	O
.	O

It	O
is	O
therefore	O
a	O
requirement	O
to	O
devise	O
a	O
system	O
that	O
allows	O
better	O
and	O
easier	O
interpretation	O
of	O
PF	O
ultrasound	O
images	O
during	O
diagnosis	O
.	O

This	O
study	O
proposes	O
an	O
automatic	O
segmentation	O
approach	O
which	O
for	O
the	O
first	O
time	O
extracts	O
ultrasound	O
data	O
to	O
estimate	O
size	O
across	O
three	O
sections	O
of	O
the	O
PF	O
(	O
rearfoot	O
,	O
midfoot	O
and	O
forefoot	O
)	O
.	O

This	O
segmentation	O
method	O
uses	O
artificial	O
neural	O
network	O
module	O
(	O
ANN	O
)	O
in	O
order	O
to	O
classify	O
small	O
overlapping	O
patches	O
as	O
belonging	O
or	O
not-belonging	O
to	O
the	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
of	O
the	O
PF	O
tissue	O
.	O

Features	O
ranking	O
and	O
selection	O
techniques	O
were	O
performed	O
as	O
a	O
post-processing	O
step	O
for	O
features	O
extraction	O
to	O
reduce	O
the	O
dimension	O
and	O
number	O
of	O
the	O
extracted	O
features	O
.	O

The	O
trained	O
ANN	O
classifies	O
the	O
image	O
overlapping	O
patches	O
into	O
PF	O
and	O
non-	O
PF	O
tissue	O
,	O
and	O
then	O
it	O
is	O
used	O
to	O
segment	O
the	O
desired	O
PF	O
region	O
.	O

The	O
PF	O
thickness	O
was	O
calculated	O
using	O
two	O
different	O
methods	O
:	O
distance	O
transformation	O
and	O
area-length	O
calculation	O
algorithms	O
.	O

This	O
new	O
approach	O
is	O
capable	O
of	O
accurately	O
segmenting	O
the	O
PF	O
region	O
,	O
differentiating	O
it	O
from	O
surrounding	O
tissues	O
and	O
estimating	O
its	O
thickness	O
.	O

Accuracy	O
of	O
FDG-PET/CT	B-P
for	O
Detection	O
of	O
Incidental	O
Pre-Malignant	O
and	O
Malignant	O
Colonic	O
Lesions	O
-	O
Correlation	O
with	O
Colonoscopic	B-P
and	O
Histopathologic	O
Findings	O
.	O

We	O
evaluated	O
all	O
PET/CTs	B-P
acquired	O
for	O
patients	O
without	O
a	O
primary	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
and	O
compared	O
results	O
for	O
those	O
who	O
had	O
subsequent	O
colonoscopy	B-P
within	O
6	O
months	O
,	O
to	O
assess	O
the	O
accuracy	O
of	O
FDG	B-P
PET/CT	I-P
for	O
detection	O
of	O
incidental	O
pre-malignant	O
polyps	O
and	O
malignant	O
colon	O
cancers	O
.	O

Medical	O
records	O
of	O
9,545	O
patients	O
who	O
underwent	O
F-18	O
FDG	O
PET/CT	O
studies	O
over	O
3.5	O
years	O
were	O
retrospectively	O
reviewed	O
.	O

Due	O
to	O
pre-existing	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
818	O
patients	O
were	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
157	O
patients	O
had	O
colonoscopy	B-P
within	O
6	O
months	O
(	O
79	O
males	O
;	O
mean	O
age	O
61	O
)	O
.	O

We	O
divided	O
the	O
colon	O
into	O
4	O
regions	O
and	O
compared	O
PET/CT	B-P
results	O
for	O
each	O
region	O
with	O
colonoscopy	B-P
and	O
histopathologic	O
findings	O
.	O

True	O
positive	O
lesions	O
included	O
colorectal	O
cancer	O
,	O
villous	O
adenoma	O
,	O
tubulovillous	O
adenoma	O
,	O
tubular	O
adenoma	O
and	O
serrated	O
hyperplastic	O
polyp	O
/	O
hyperplastic	O
polyposis	O
.	O

Of	O
157	O
patients	O
,	O
44	O
had	O
incidental	O
colonic	O
uptake	O
on	O
PET/CT	B-P
(	O
28	O
%	O
)	O
.	O

Of	O
those	O
,	O
25	O
had	O
true	O
positive	O
(	O
TP	O
)	O
uptake	O
,	O
yielding	O
a	O
48	O
%	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
;	O
9	O
%	O
(	O
4/44	O
)	O
were	O
adenocarcinoma	O
.	O

There	O
were	O
23	O
false	O
positive	O
(	O
FP	O
)	O
lesions	O
of	O
which	O
4	O
were	O
hyperplastic	O
polyps	O
,	O
one	O
was	O
a	O
juvenile	O
polyp	O
and	O
7	O
were	O
explained	O
by	O
diverticulitis	O
.	O

Fifty	O
eight	O
patients	O
had	O
false	O
negative	O
PET	B-P
scans	I-P
but	O
colonoscopy	B-P
revealed	O
true	O
pre-malignant	O
and	O
malignant	O
pathology	O
,	O
yielding	O
23	O
%	O
sensitivity	O
.	O

The	O
specificity	O
,	O
negative	O
predictive	O
value	O
(	O
NPV	O
)	O
and	O
accuracy	O
were	O
96	O
%	O
,	O
90	O
%	O
and	O
87	O
%	O
,	O
respectively	O
.	O

The	O
average	O
SUVmax	O
values	O
of	O
TP	O
,	O
FP	O
and	O
FN	O
lesions	O
were	O
7.25	O
,	O
6.11	O
and	O
2.76	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
difference	O
between	O
SUVmax	O
of	O
TP	O
lesions	O
and	O
FP	O
lesions	O
(	O
p	O
>	O
0.95	O
)	O
but	O
significantly	O
higher	O
than	O
in	O
FN	O
lesions	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
average	O
size	O
(	O
by	O
histopathology	O
and	O
colonoscopy	B-P
)	O
of	O
TP	O
lesion	O
s	O
was	O
18.1	O
mm	O
,	O
statistically	O
different	O
from	O
that	O
of	O
FN	O
lesions	O
which	O
was	O
5.9	O
mm	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Fifty-one	O
percent	O
of	O
FN	O
lesion	O
s	O
were	O
smaller	O
than	O
5	O
mm	O
(	O
29/57	O
)	O
and	O
88	O
%	O
smaller	O
than	O
10	O
mm	O
(	O
50/57	O
)	O
.	O

The	O
high	O
positive	O
predictive	O
value	O
of	O
incidental	O
focal	O
colonic	O
FDG	O
uptake	O
of	O
48	O
%	O
for	O
colonic	O
neoplasia	O
suggests	O
that	O
colonoscopy	B-P
follow-up	O
is	O
warranted	O
with	O
this	O
finding	O
.	O

We	O
observed	O
a	O
low	O
sensitivity	O
of	O
standardly	O
acquired	O
FDG-PET/CT	B-P
for	O
detecting	O
small	O
polyps	O
,	O
especially	O
those	O
less	O
than	O
5	O
mm	O
.	O

Clinicians	O
and	O
radiologists	O
should	O
be	O
aware	O
of	O
the	O
high	O
PPV	O
of	O
focal	O
colonic	O
uptake	O
reflecting	O
pre-malignant	O
and	O
malignant	O
lesion	O
s	O
,	O
and	O
the	O
need	O
for	O
appropriate	O
follow	O
up	O
.	O

Botulinum	O
Toxin	O
Use	O
in	O
Refractory	O
Pain	O
and	O
Other	O
Symptoms	O
in	O
Parkinsonism	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
other	O
parkinsonian	O
syndromes	O
are	O
chronic	O
,	O
progressive	O
neurodegenerative	O
diseases	O
.	O

With	O
advancing	O
disease	O
,	O
both	O
motor	O
and	O
non-motor	O
symptoms	O
represent	O
a	O
considerable	O
burden	O
and	O
symptom	O
relief	O
and	O
quality	O
of	O
life	O
improvement	O
become	O
the	O
main	O
goal	O
of	O
treatment	O
.	O

Botulinum	O
toxins	O
(	O
BTX	O
)	O
are	O
an	O
effective	O
treatment	O
modality	O
for	O
many	O
neurological	O
conditions	O
.	O

To	O
understand	O
the	O
potential	O
usefulness	O
of	O
BTX	O
in	O
this	O
population	O
,	O
we	O
performed	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
patients	O
with	O
a	O
clinical	B-P
diagnosis	I-P
of	O
idiopathic	O
PD	O
and	O
atypical	O
parkinsonism	O
who	O
received	O
treatment	O
with	O
BTX	O
injections	O
in	O
our	O
center	O
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	O
.	O

Response	O
to	O
BTX	O
was	O
assessed	O
using	O
a	O
subjective	O
Clinical	O
Global	O
Impression	O
.	O

Records	O
of	O
160	O
patients	O
were	O
reviewed	O
.	O

Probable	O
idiopathic	O
PD	O
was	O
the	O
diagnosis	O
in	O
117	O
patients	O
(	O
73.1	O
%	O
)	O
.	O

The	O
main	O
indication	O
for	O
BTX	O
treatment	O
was	O
pain	O
(	O
50.6	O
%	O
of	O
cases	O
)	O
.	O

Other	O
indications	O
were	O
the	O
treatment	O
of	O
functional	O
impairment	O
resulting	O
from	O
dystonia	O
(	O
26.25	O
%	O
)	O
,	O
sialorrhea	O
(	O
18.75	O
%	O
)	O
,	O
freezing	O
of	O
gait	O
,	O
and	O
camptocormia	O
.	O

Considering	O
pain	O
as	O
indication	O
,	O
81	O
%	O
of	O
all	O
patients	O
with	O
PD	O
reported	O
benefits	O
after	O
the	O
first	O
BTX	O
injections	O
.	O

This	O
benefit	O
was	O
maintained	O
after	O
the	O
last	O
recorded	O
visit	O
without	O
significant	O
difference	O
in	O
outcome	O
compared	O
with	O
the	O
first	O
injection	O
(	O
p=0.067	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
patients	O
with	O
atypical	O
parkinsonism	O
.	O

Our	O
results	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
different	O
uses	O
of	O
BTX	O
in	O
the	O
symptomatic	O
treatment	O
of	O
patients	O
with	O
parkinsonism	O
even	O
in	O
advanced	O
stages	O
of	O
the	O
disease	O
,	O
and	O
suggest	O
BTX	O
treatment	O
could	O
have	O
a	O
safe	O
and	O
useful	O
role	O
in	O
the	O
treatment	O
of	O
pain	O
in	O
this	O
population	O
.	O

A	O
helical	O
segment	O
makes	O
potassium	O
channels	O
go-go	O
.	O

More	O
than	O
500	O
variants	O
in	O
the	O
KCNH2	O
gene	O
,	O
which	O
encodes	O
the	O
cardiac	O
human	O
ether-a-go-go	O
(	O
hERG	O
)	O
ion	O
channel	O
,	O
have	O
been	O
associated	O
with	O
sudden	O
cardiac	O
death	O
,	O
but	O
only	O
a	O
subset	O
of	O
these	O
variants	O
have	O
been	O
investigated	O
.	O

Matthew	O
D.	O
Perry	O
and	O
colleagues	O
now	O
combine	O
NMR	B-P
spectroscopy	I-P
and	O
electrophysiological	B-P
experiments	I-P
to	O
explore	O
the	O
functional	O
properties	O
of	O
mutations	O
within	O
an	O
overlooked	O
hERG	O
helix	O
,	O
finding	O
important	O
contributions	O
to	O
channel	O
function	O
.	O

Surgical	O
Guidance	O
via	O
Multiplexed	B-P
Molecular	I-P
Imaging	I-P
of	O
Fresh	O
Tissues	O
Labeled	O
with	O
SERS	O
-Coded	O
Nanoparticles	O
.	O

The	O
imaging	B-P
of	O
dysregulated	O
cell-surface	O
receptors	O
(	O
or	O
biomarkers	O
)	O
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	O
of	O
cancer	O
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O

However	O
,	O
due	O
to	O
heterogeneities	O
in	O
the	O
expression	O
of	O
protein	O
biomarkers	O
in	O
tumors	O
,	O
molecular	B-P
imaging	I-P
technologies	O
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	O
panel	O
of	O
cancer	O
biomarkers	O
.	O

Recently	O
,	O
surface-enhanced	O
Raman-scattering	O
(	O
SERS	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	O
and	O
multiplexed	O
biomarker	O
detection	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	O
imaging	B-P
using	O
SERS	O
-coded	O
NPs	O
.	O

A	O
brief	O
introduction	O
of	O
the	O
structure	O
and	O
optical	O
properties	O
of	O
SERS	O
NPs	O
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-P
issues	O
such	O
as	O
the	O
administration	O
of	O
NPs	O
in	O
tissue	O
(	O
topical	O
versus	O
systemic	O
)	O
,	O
the	O
optical	O
configuration	O
and	O
imaging	B-P
approach	O
of	O
Raman	O
imaging	O
systems	O
,	O
spectral	B-P
demultiplexing	I-P
methods	I-P
for	O
quantifying	O
NP	O
concentrations	O
,	O
and	O
the	O
disambiguation	O
of	O
specific	O
vs.	O
nonspecific	O
sources	O
of	O
contrast	O
through	O
ratiometric	B-P
imaging	I-P
of	O
targeted	O
and	O
untargeted	O
(	O
control	O
)	O
NP	O
pairs	O
.	O

Finally	O
,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined	O
.	O

Design	O
and	O
synthesis	O
of	O
pH	O
-	O
sensitive	O
polymeric	O
micelles	O
for	O
oral	O
delivery	O
of	O
poorly	O
water	O
-	O
soluble	O
drugs	O
.	O

pH	O
-	O
sensitive	O
polymer	O
poly	O
(	O
polylactide-co-methacrylic	O
acid	O
)	O
-b-poly	O
(	O
acrylic	O
acid	O
)	O
was	O
synthesized	O
using	O
atom	O
transfer	O
radical	O
polymerization	O
and	O
ring-opening	O
polymerization	O
and	O
characterized	O
by	O
gel	O
permeation	O
chromatography	O
and	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
.	O

The	O
polymers	O
can	O
self-assemble	O
to	O
form	O
micelles	O
in	O
aqueous	O
medium	O
,	O
which	O
respond	O
rapidly	O
to	O
pH	O
change	O
within	O
the	O
gastrointestinal	O
relevant	O
pH	O
range	O
.	O

Critical	O
micelle	O
concentrations	O
and	O
pH	O
response	O
behavior	O
of	O
the	O
polymeri	O
c	O
micelle	O
were	O
investigated	O
.	O

Water	O
-	O
insoluble	O
drug	O
nifedipine	O
was	O
loaded	O
and	O
the	O
drug	O
-	O
loading	O
content	O
can	O
be	O
controlled	O
by	O
tuning	O
the	O
composition	O
of	O
the	O
polymers	O
.	O

The	O
in	O
vitro	O
release	O
studies	O
indicate	O
pH	O
sensitivity	O
enabled	O
rapid	O
drug	O
release	O
at	O
the	O
environment	O
of	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
7.36	O
)	O
,	O
the	O
cumulative	O
released	O
amount	O
of	O
NFD	O
reached	O
more	O
than	O
80	O
%	O
within	O
24	O
h	O
,	O
while	O
only	O
35	O
%	O
in	O
the	O
simulated	O
gastric	O
fluid	O
(	O
pH	O
1.35	O
)	O
.	O

All	O
the	O
results	O
showed	O
that	O
the	O
pH	O
-	O
sensitive	O
P	O
(	O
PLAMA-co-MAA	O
)	O
-b-PAA	O
micelle	O
may	O
be	O
a	O
prospective	O
candidate	O
as	O
oral	O
drug	O
delivery	O
carrier	O
for	O
hydrophobic	O
drugs	O
with	O
controlled	O
release	O
behavior	O
.	O

Prevalence	O
of	O
high-risk	O
human	O
papillomavirus	O
infection	O
among	O
women	O
in	O
Shaanxi	O
province	O
of	O
China	O
:	O
A	O
hospital	O
-based	O
investigation	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
characteristics	O
of	O
female	O
high-risk	O
human	O
papillomavirus	O
(	O
HR-HPV	O
)	O
infection	O
in	O
Shaanxi	O
province	O
of	O
China	O
.	O

A	O
total	O
of	O
14	O
111	O
women	O
were	O
enrolled	O
for	O
HPV	O
genotyping	O
test	O
,	O
and	O
a	O
cytology	O
,	O
and/or	O
cervix	B-P
biopsy	I-P
were	O
performed	O
in	O
partial	O
women	O
.	O

Of	O
these	O
women	O
,	O
the	O
HPV	O
infection	O
rate	O
was	O
30.21	O
%	O
,	O
and	O
26.73	O
%	O
were	O
caused	O
by	O
HR-HPV	O
.	O

The	O
most	O
common	O
HR-HPV	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
HPV-18	O
,	O
and	O
HPV-31	O
.	O

The	O
prevalence	O
of	O
HR-HPV	O
among	O
women	O
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
main	O
carcinogenic	O
genotypes	O
were	O
HPV-16	O
,	O
HPV-18	O
,	O
HPV-58	O
,	O
HPV-52	O
,	O
and	O
HPV-31	O
.	O

HPV-16	O
and	O
HPV-18	O
combined	O
caused	O
80.79	O
%	O
of	O
cervical	O
cancer	O
cases	O
.	O

The	O
infection	O
with	O
multiple	O
HR-HPVs	O
was	O
not	O
a	O
risk	O
factor	O
for	O
cervical	O
lesions	O
.	O

In	O
conclusion	O
,	O
HPV	O
infection	O
was	O
common	O
among	O
women	O
in	O
Shaanxi	O
province	O
.	O

Women	O
older	O
than	O
50	O
years	O
were	O
a	O
high-risk	O
group	O
for	O
HR-HPV	O
infection	O
and	O
cervical	O
cancer	O
.	O

HPV-16	O
and	O
HPV-18	O
were	O
the	O
main	O
carcinogenic	O
genotypes	O
in	O
this	O
region	O
.	O

A	O
case	O
of	O
bilateral	O
pneumothoraces	O
resulting	O
from	O
tracheostomy	O
for	O
advanced	O
laryngeal	O
cancer	O
.	O

Pneumothorax	O
is	O
a	O
possible	O
complication	O
of	O
tracheostomy	O
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
bilateral	O
pneumothoraces	O
resulting	O
from	O
tracheostomy	O
in	O
an	O
advanced	O
laryngeal	O
cancer	O
patient	O
.	O

A	O
59-year-old	O
man	O
was	O
referred	O
to	O
our	O
clinic	O
for	O
evaluation	O
and	O
treatment	O
of	O
laryngeal	O
tumor	O
.	O

Laryngeal	B-P
endoscopy	I-P
showed	O
limited	O
movement	O
of	O
bilateral	O
vocal	O
cords	O
,	O
and	O
computed	B-P
tomography	I-P
revealed	O
a	O
tumor	O
lesion	O
extending	O
from	O
the	O
vocal	O
cords	O
to	O
the	O
subglottic	O
area	O
.	O

Three	O
days	O
after	O
the	O
first	O
visit	O
,	O
the	O
patient	O
developed	O
respiratory	O
difficulty	O
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	O
tracheostomy	O
for	O
airway	O
management	O
.	O

Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	O
,	O
he	O
began	O
hyperventilating	O
,	O
and	O
complained	O
of	O
respiratory	O
discomfort	O
and	O
chest	O
pain	O
.	O

We	O
then	O
recognized	O
a	O
mediastinal	O
air	O
leak	O
,	O
and	O
we	O
suspected	O
pneumothorax	O
resulting	O
from	O
the	O
tracheostomy	O
.	O

Chest	B-P
X-ray	I-P
showed	O
bilateral	O
pneumothoraces	O
;	O
therefore	O
,	O
we	O
inserted	O
bilateral	O
chest	O
drainage	O
tubes	O
,	O
which	O
stabilized	O
his	O
respiratory	O
condition	O
.	O

We	O
speculated	O
that	O
the	O
pathogenesis	O
of	O
the	O
bilateral	O
pneumothoraces	O
was	O
weakened	O
alveolar	O
walls	O
secondary	O
to	O
long-term	O
smoking	O
,	O
and	O
a	O
significant	O
rise	O
in	O
airway	O
pressure	O
because	O
of	O
airway	O
constriction	O
by	O
the	O
neck-extended	O
position	O
and	O
hyperventilation	O
,	O
during	O
tracheostomy	O
.	O

Right	O
Ventricular	O
Response	O
During	O
Exercise	O
in	O
Patients	O
with	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
.	O

Right	O
ventricular	O
(	O
RV	O
)	O
pump	O
function	O
is	O
of	O
essential	O
clinical	O
and	O
prognostic	O
importance	O
in	O
a	O
variety	O
of	O
heart	O
and	O
lung	O
diseases	O
.	O

While	O
the	O
evaluation	O
of	O
RV	O
performance	O
at	O
rest	O
has	O
been	O
implemented	O
in	O
the	O
clinical	O
setting	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	O
during	O
exercise	O
may	O
provide	O
additional	O
benefit	O
.	O

With	O
this	O
aim	O
,	O
we	O
evaluated	O
the	O
exercise	O
-	O
induced	O
pulmonary	B-P
arterial	I-P
systolic	I-P
pressure	I-P
(	O
PASP	B-P
)	O
increase	O
during	O
exercise	O
in	O
patients	O
with	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
as	O
an	O
expression	O
of	O
RV	O
contractile	O
reserve	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
(	O
CPET	B-P
)	O
with	O
synchronic	B-P
echocardiography	I-P
was	O
performed	O
in	O
81	O
patients	O
.	O

Patients	O
were	O
classified	O
into	O
two	O
groups	O
according	O
to	O
an	O
exercise	O
-	O
induced	O
PASP	B-P
increase	O
above	O
30mmHg	O
(	O
High	O
PSAP	B-P
)	O
or	O
below	O
30mmHg	O
(	O
Low	O
PSAP	B-P
)	O
during	O
maximal	O
exercise	O
.	O

Patients	O
were	O
then	O
followed	O
for	O
three	O
years	O
.	O

Sixteen	O
patients	O
(	O
20	O
%	O
)	O
had	O
low	O
PSAP	B-P
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	O
PSAP	B-P
.	O

These	O
were	O
not	O
significant	O
clinical	O
and	O
functional	O
differences	O
.	O

Low	O
PSAP	B-P
was	O
associated	O
with	O
a	O
significantly	O
lower	O
peak	O
VO2	O
(	O
mean	O
(	O
SD	O
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	O
)	O
compared	O
to	O
high	O
PSAP	B-P
response	O
(	O
peak	O
VO2	O
45	O
(	O
3	O
)	O
%	O
predicted	O
)	O
,	O
p=0.045	O
.	O

Factors	O
associated	O
with	O
mortality	O
were	O
age	O
and	O
exercise	O
-	O
induced	O
PASP	B-P
.	O

Seventeen	O
patients	O
died	O
during	O
the	O
three	O
years	O
of	O
follow-up	O
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	O
PSAP	B-P
group	O
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	O
PSAP	B-P
group	O
,	O
p=0.041	O
)	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
with	O
a	O
synchronic	B-P
echocardiography	I-P
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	O
of	O
RV	O
contractile	O
reserve	O
in	O
severe	O
COPD	O
patients	O
.	O

Exercise	O
-	O
induced	O
PSAP	B-P
emerges	O
as	O
a	O
possible	O
prognostic	O
factor	O
in	O
these	O
patients	O
.	O

Distinct	O
Abnormalities	O
of	O
Small	O
Bowel	O
and	O
Regional	O
Colonic	O
Volumes	O
in	O
Subtypes	O
of	O
Irritable	O
Bowel	O
Syndrome	O
Revealed	O
by	O
MRI	B-P
.	O

Non-invasive	O
biomarkers	O
which	O
identify	O
different	O
mechanisms	O
of	O
disease	O
in	O
subgroups	O
of	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
could	O
be	O
valuable	O
.	O

Our	O
aim	O
was	O
to	O
seek	O
useful	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
parameters	O
that	O
could	O
distinguish	O
each	O
IBS	O
subtypes	O
.	O

34	O
healthy	O
volunteers	O
(	O
HV	O
)	O
,	O
30	O
IBS	O
with	O
diarrhea	O
(	O
IBS-D	O
)	O
,	O
16	O
IBS	O
with	O
constipation	O
(	O
IBS-C	O
)	O
,	O
and	O
11	O
IBS	O
with	O
mixed	O
bowel	O
habit	O
(	O
IBS-M	O
)	O
underwent	O
whole-gut	O
transit	O
and	O
small	O
and	O
large	O
bowel	O
volumes	O
assessment	O
with	O
MRI	B-P
scans	B-P
from	O
t=0	O
to	O
t=360	O
min	O
.	O

Since	O
the	O
bowel	O
frequency	O
for	O
IBS-M	O
were	O
similar	O
to	O
IBS-D	O
,	O
IBS-M	O
and	O
IBS-D	O
were	O
grouped	O
together	O
and	O
labeled	O
as	O
IBS	O
non-constipation	O
group	O
(	O
IBS-nonC	O
)	O
.	O

Median	O
(	O
interquartile	O
range	O
)	O
:	O
fasting	O
small	O
bowel	O
water	O
content	O
in	O
IBS-nonC	O
was	O
21	O
(	O
10-42	O
)	O
,	O
significantly	O
less	O
than	O
HV	O
at	O
44	O
ml	O
(	O
15-70	O
)	O
,	O
P	O
<	O
0.01	O
as	O
was	O
the	O
postprandial	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
P	O
<	O
0.01	O
.	O

The	O
fasting	O
transverse	O
colon	O
volumes	O
in	O
IBS-C	O
were	O
significantly	O
larger	O
at	O
253	O
(	O
200-329	O
)	O
compared	O
with	O
HV	O
,	O
IBS-nonC	O
whose	O
values	O
were	O
165	O
(	O
117-255	O
)	O
and	O
198	O
(	O
106-270	O
)	O
ml	O
,	O
respectively	O
,	O
P=0.02	O
.	O

Whole-gut	O
transit	O
time	O
for	O
IBS-C	O
was	O
prolonged	O
at	O
69	O
(	O
51-111	O
)	O
,	O
compared	O
with	O
HV	O
at	O
34	O
(	O
4-63	O
)	O
and	O
IBS-D	O
at	O
34	O
(	O
17-78	O
)	O
h	O
,	O
P=0.03	O
.	O

Bloating	O
score	O
(	O
VAS	O
0-10	O
cm	O
)	O
correlated	O
with	O
transverse	O
colon	O
volume	O
at	O
t=405	O
min	O
,	O
Spearman	O
r=0.21	O
,	O
P=0.04	O
.	O

The	O
constricted	O
small	O
bowel	O
in	O
IBS-nonC	O
and	O
the	O
dilated	O
transverse	O
colon	O
in	O
IBS-C	O
point	O
to	O
significant	O
differences	O
in	O
underlying	O
mechanisms	O
of	O
disease	O
.	O

Secondary	O
Ossification	O
Center	O
Appearance	O
and	O
Closure	O
in	O
the	O
Pelvis	O
and	O
Proximal	O
Femur	O
.	O

Variable	O
ossification	O
patterns	O
of	O
the	O
pelvis	O
in	O
skeletally	O
immature	O
patients	O
can	O
make	O
the	O
interpretation	O
of	O
pelvic	O
radiographs	B-P
challenging	O
.	O

Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	O
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	O
ossification	O
centers	O
.	O

This	O
study	O
evaluates	O
the	O
chronology	O
and	O
sex	O
differences	O
for	O
appearance	O
and	O
closure	O
of	O
pelvic	O
and	O
proximal	O
femoral	O
secondary	O
ossification	O
centers	O
using	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

Patients	O
who	O
underwent	O
abdominal	B-P
and	O
pelvic	B-P
CT	I-P
scans	I-P
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	O
centers	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
between	O
the	O
ages	O
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-P
of	O
the	O
pelvis	O
and	O
proximal	O
femurs	O
were	O
included	O
.	O

Patients	O
with	O
a	O
history	O
of	O
orthopaedic	O
trauma	O
or	O
pathology	O
affecting	O
ossification	O
were	O
excluded	O
.	O

CT	B-P
scans	I-P
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	O
of	O
the	O
following	O
secondary	O
ossification	O
centers	O
:	O
anterior	O
inferior	O
iliac	O
spine	O
(	O
AIIS	O
)	O
,	O
anterior	O
superior	O
iliac	O
spine	O
(	O
ASIS	O
)	O
,	O
femoral	O
head	O
(	O
FH	O
)	O
,	O
greater	O
trochanter	O
(	O
GT	O
)	O
,	O
iliac	O
crest	O
(	O
IC	O
)	O
,	O
ischial	O
tuberosity	O
(	O
IT	O
)	O
,	O
lesser	O
trochanter	O
(	O
LT	O
)	O
,	O
posterior	O
superior	O
iliac	O
spine	O
(	O
PSIS	O
)	O
,	O
symphysis	O
pubis	O
(	O
SP	O
)	O
,	O
and	O
triradiate	O
cartilage	O
(	O
TRC	O
)	O
.	O

Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O

A	O
total	O
of	O
496	O
CT	B-P
scans	I-P
met	O
inclusion	O
criteria	O
(	O
240	O
males	O
and	O
256	O
females	O
)	O
.	O

The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	O
ossification	O
centers	O
was	O
:	O
(	O
male	O
)	O
GT	O
,	O
LT	O
,	O
AIIS	O
,	O
IT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
GT	O
,	O
LT	O
,	O
IT	O
,	O
AIIS	O
,	O
PSIS	O
,	O
IC	O
,	O
ASIS	O
,	O
and	O
SP	O
.	O

The	O
order	O
of	O
closure	O
was	O
similar	O
:	O
(	O
male	O
)	O
TRC	O
,	O
LT	O
,	O
FH	O
,	O
AIIS	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
LT	O
,	O
TRC	O
,	O
AIIS	O
,	O
FH	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
.	O

Female	O
ossification	O
centers	O
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
.	O

Female	O
ossification	O
centers	O
closed	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
except	O
TRC	O
,	O
IC	O
,	O
and	O
SP	O
.	O

The	O
appearance	O
and	O
closure	O
of	O
the	O
pelvis	O
and	O
proximal	O
femur	O
secondary	O
ossification	O
centers	O
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	O
than	O
males	O
.	O

Knowledge	O
of	O
more	O
precise	O
ages	O
of	O
developmen	O
t	O
and	O
sex	O
differences	O
better	O
characterize	O
this	O
complex	O
skeletal	O
development	O
.	O

Future	O
studies	O
may	O
use	O
secondary	O
ossification	O
centers	O
to	O
further	O
evaluate	O
skeletal	B-P
maturity	I-P
,	O
assess	O
pediatric	O
pathology	O
,	O
and	O
aid	O
surgical	O
management	O
.	O

Level	O
III	O
.	O

Precision	O
Medicine	O
Starts	O
With	O
Preanalytics	O
:	O
Real-Time	O
Assessment	O
of	O
Tissue	O
Fixation	O
Quality	O
by	O
Ultrasound	O
Time-of-Flight	O
Analysis	O
.	O

Personalized	O
medicine	O
promises	O
diagnosis	O
and	O
treatment	O
of	O
disease	O
at	O
the	O
individual	O
level	O
and	O
relies	O
heavily	O
on	O
clinical	O
specimen	O
integrity	O
and	O
diagnostic	O
assay	O
quality	O
.	O

Preanalytics	O
,	O
the	O
collection	O
and	O
handling	O
steps	O
of	O
a	O
clinical	O
specimen	O
before	O
immunohistochemistry	B-P
or	O
other	O
clinical	O
assay	O
,	O
are	O
critically	O
important	O
to	O
enable	O
the	O
correct	O
diagnosis	O
of	O
disease	O
.	O

However	O
,	O
the	O
effects	O
of	O
preanalytics	O
are	O
often	O
overlooked	O
due	O
to	O
a	O
lack	O
of	O
standardization	O
and	O
limited	O
assessment	O
tools	O
to	O
quantify	O
their	O
variation	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
real-time	O
ultrasound	O
time-of-flight	O
instrument	O
that	O
is	O
capable	O
of	O
monitoring	O
and	O
imaging	B-P
the	O
critical	O
step	O
in	O
formalin	O
fixation	O
,	O
diffusion	O
of	O
the	O
fixative	O
into	O
tissue	O
,	O
which	O
provides	O
a	O
quantifiable	O
quality	O
metric	O
for	O
tissue	O
fixation	O
in	O
the	O
clinical	O
laboratory	O
ensuring	O
consistent	O
downstream	O
molecular	O
assay	O
results	O
.	O

We	O
analyzed	O
hundreds	O
of	O
tissue	O
specimens	O
from	O
34	O
distinct	O
human	O
tissue	O
types	O
and	O
12	O
clinically	O
relevant	O
diseased	O
tissues	O
for	O
diffusion	O
and	O
fixation	O
metrics	O
.	O

Our	O
measurements	O
can	O
be	O
converted	O
into	O
tissue	O
diffusivity	O
constants	O
that	O
correlate	O
with	O
the	O
apparent	O
diffusion	O
constant	O
calculated	O
using	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
R=0.83	O
)	O
,	O
despite	O
the	O
differences	O
in	O
the	O
approaches	O
,	O
indicating	O
that	O
our	O
approach	O
is	O
biophysically	O
plausible	O
.	O

Using	O
data	O
collected	O
from	O
time-of-flight	O
analysis	O
of	O
many	O
tissues	O
,	O
we	O
have	O
therefore	O
developed	O
a	O
novel	O
rapid	O
fixation	O
program	O
that	O
could	O
ensure	O
high-quality	O
downstream	O
assay	O
results	O
for	O
a	O
broad	O
range	O
of	O
human	O
tissue	O
types	O
.	O

Asymmetry	O
of	O
lumbopelvic	O
movement	O
patterns	O
during	O
active	O
hip	O
abduction	B-P
is	O
a	O
risk	O
factor	O
for	O
low	O
back	O
pain	O
development	O
during	O
standing	O
.	O

An	O
induced-pain	O
paradigm	O
has	O
been	O
used	O
in	O
back	O
-	O
healthy	O
people	O
to	O
understand	O
risk	O
factors	O
for	O
developing	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
during	O
prolonged	O
standing	O
.	O

We	O
examined	O
asymmetry	O
of	O
lumbopelvic	O
movement	O
timing	O
during	O
a	O
clinical	O
test	O
of	O
active	O
hip	O
abduction	O
in	O
back-healthy	O
people	O
who	O
developed	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Pain	O
Developers	O
;	O
PDs	O
)	O
compared	O
to	O
back-healthy	O
people	O
who	O
did	O
not	O
develop	O
LBP	O
symptoms	O
during	O
standing	O
(	O
Non	O
Pain	O
Developers	O
,	O
NPDs	O
)	O
.	O

Participants	O
completed	O
the	O
hip	O
abduction	B-P
test	I-P
while	O
movement	O
was	O
recorded	O
with	O
a	O
motion	O
capture	O
system	O
.	O

Difference	O
in	O
time	O
between	O
start	O
of	O
hip	O
and	O
lumbopelvic	O
movement	O
was	O
calculated	O
(	O
startdiff	O
)	O
.	O

PDs	O
moved	O
the	O
lumbopelvic	O
region	O
earlier	O
during	O
left	O
hip	O
abduction	O
than	O
right	O
hip	O
abduction	O
.	O

There	O
was	O
no	O
difference	O
between	O
sides	O
in	O
NPDs	O
.	O

In	O
PDs	O
,	O
the	O
amount	O
of	O
asymmetry	O
was	O
related	O
to	O
average	O
symptom	O
intensity	O
during	O
standing	O
.	O

Asymmetric	O
lumbopelvic	O
movement	O
patterns	O
may	O
be	O
a	O
risk	O
factor	O
for	O
LBP	O
development	O
during	O
prolonged	O
standing	O
.	O

Verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
new	O
real-time	O
tumour	O
-tracking	O
radiotherapy	O
system	O
using	O
cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
.	O

A	O
combined	O
system	O
comprising	O
the	O
TrueBeam	O
linear	O
accelerator	O
and	O
a	O
new	O
real-time	O
tumour	O
-tracking	O
radiotherapy	O
system	O
,	O
SyncTraX	O
,	O
was	O
installed	O
at	O
our	O
institution	O
.	O

The	O
objectives	O
of	O
this	O
study	O
are	O
to	O
develop	O
a	O
method	O
for	O
the	O
verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
SyncTraX	O
using	O
cine	O
electronic	O
portal	O
image	O
device	O
(	O
EPID	O
)	O
images	O
and	O
a	O
log	O
file	O
and	O
to	O
verify	O
this	O
treatment	O
in	O
clinical	O
cases	O
.	O

Respiratory-gated	O
radiotherapy	O
was	O
performed	O
using	O
TrueBeam	O
and	O
the	O
SyncTraX	O
system	O
.	O

Cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
were	O
acquired	O
for	O
a	O
phantom	O
and	O
three	O
patients	O
during	O
the	O
course	O
of	O
the	O
treatment	O
.	O

Digitally	O
reconstructed	O
radiographs	O
(	O
DRRs	O
)	O
were	O
created	O
for	O
each	O
treatment	O
beam	O
using	O
a	O
planning	B-P
CT	I-P
set	O
.	O

The	O
cine	O
EPID	O
images	O
,	O
log	O
file	O
,	O
and	O
DRRs	O
were	O
analysed	O
using	O
a	O
developed	O
software	O
.	O

For	O
the	O
phantom	O
case	O
,	O
the	O
accuracy	O
of	O
the	O
proposed	O
method	O
was	O
evaluated	O
to	O
verify	O
the	O
respiratory-gated	O
radiotherapy	O
.	O

For	O
the	O
clinical	O
cases	O
,	O
the	O
intra-	O
and	O
inter-fractional	O
variations	O
of	O
the	O
fiducial	O
marker	O
used	O
as	O
an	O
internal	O
surrogate	O
were	O
calculated	O
to	O
evaluate	O
the	O
gating	O
accuracy	O
and	O
set-up	O
uncertainty	O
in	O
the	O
superior	O
-	O
inferior	O
(	O
SI	O
)	O
,	O
anterior-posterior	O
(	O
AP	O
)	O
,	O
and	O
left-right	O
(	O
LR	O
)	O
directions	O
.	O

The	O
proposed	O
method	O
achieved	O
high	O
accuracy	O
for	O
the	O
phantom	O
verification	O
.	O

For	O
the	O
clinical	O
cases	O
,	O
the	O
intra-	O
and	O
inter-fractional	O
variations	O
of	O
the	O
fiducial	O
marker	O
were	O
⩽3	O
mm	O
and	O
±3	O
mm	O
in	O
the	O
SI	O
,	O
AP	O
,	O
and	O
LR	O
directions	O
.	O

We	O
proposed	O
a	O
method	O
for	O
the	O
verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
SyncTraX	O
using	O
cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
and	O
showed	O
that	O
this	O
treatment	O
is	O
performed	O
with	O
high	O
accuracy	O
in	O
clinical	O
cases	O
.	O

Trans-oral	O
fine	B-P
needle	I-P
aspiration	I-P
cytology	I-P
in	O
cervical	O
(	O
C1	O
and	O
C2	O
)	O
vertebral	O
lesions	O
:	O
a	O
novel	O
diagnostic	B-P
approach	I-P
.	O

Fine	B-P
needle	I-P
aspiration	I-P
(	I-P
FNA	I-P
)	I-P
cytology	I-P
is	O
a	O
relatively	O
non-invasive	O
method	O
for	O
diagnosing	O
both	O
superficial	O
and	O
deep-seated	O
neoplastic	O
and	O
non-neoplastic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
trans-oral	O
FNA	B-P
in	O
cervical	O
(	O
C1	O
and	O
C2	O
)	O
vertebral	O
and	O
paravertebral	O
lesions	O
.	O

Eighteen	O
FNA	B-P
cases	O
of	O
cervical	O
vertebral	O
and	O
paravertebral	O
lesions	O
performed	O
by	O
a	O
trans-oral	O
route	O
without	O
any	O
image-guidance	O
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	O
department	O
at	O
PGIMER	O
,	O
Chandigarh	O
and	O
reviewed	O
.	O

Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	O
was	O
given	O
in	O
15	O
cases	O
(	O
83.3	O
%	O
)	O
.	O

The	O
commonest	O
diagnosis	O
seen	O
was	O
granulomatous	O
inflammation	O
consistent	O
with	O
tuberculosis	O
(	O
33.3	O
%	O
)	O
.	O

Trans-oral	O
FNA	B-P
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	O
procedure	O
for	O
sampling	O
C1	O
and	O
C2	O
vertebral	O
and	O
paravertebral	O
lesions	O
,	O
which	O
are	O
clinically	O
and	O
radiologically	O
difficult	O
to	O
approach	O
.	O

It	O
helps	O
in	O
the	O
early	B-P
diagnosis	I-P
and	O
management	O
of	O
these	O
patients	O
.	O

Sensitivity	O
and	O
Specificity	O
of	O
Metal	O
Ion	O
Levels	O
in	O
Predicting	O
``	O
Pseudotumors	O
``	O
due	O
to	O
Taper	O
Corrosion	O
in	O
Patients	O
With	O
Dual	O
Taper	O
Modular	O
Total	O
Hip	O
Arthroplasty	O
.	O

Currently	O
,	O
no	O
serum	O
metal	O
ion	O
threshold	O
exists	O
to	O
identify	O
adverse	O
tissue	O
reactions	O
in	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
patients	O
with	O
taper	O
corrosion	O
.	O

Our	O
study	O
aims	O
to	O
investigate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
serum	O
metal	O
ions	O
in	O
detecting	O
taper	O
corrosion	O
related	O
pseudotumors	O
in	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
.	O

A	O
total	O
of	O
148	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
were	O
investigated	O
:	O
(	O
1	O
)	O
90	O
patients	O
with	O
pseudotumors	O
detected	O
with	O
metal	B-P
artifact	I-P
reduction	I-P
sequence-magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MARS-MRI	B-P
)	O
and	O
(	O
2	O
)	O
58	O
patients	O
without	O
pseudotumors	O
on	O
MARS-MRI	B-P
.	O

Receiver	O
operating	O
characteristic	O
curves	O
were	O
constructed	O
to	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
using	O
different	O
metal	O
ion	O
thresholds	O
.	O

The	O
severity	O
of	O
intraoperative	O
tissue	O
damage	O
was	O
correlated	O
with	O
preoperative	O
metal	O
ion	O
levels	O
.	O

Pseudotumor	O
was	O
associated	O
with	O
higher	O
cobalt	O
(	O
5.0	O
μg/L	O
vs	O
3.7	O
μg/L	O
,	O
P	O
<	O
.01	O
)	O
and	O
Co	O
/	O
Cr	O
ratio	O
(	O
6.0	O
vs	O
3.7	O
,	O
P	O
<	O
.01	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
for	O
cobalt	O
level	O
of	O
2.8	O
μg/L	O
and	O
Co	O
/	O
Cr	O
ratio	O
of	O
3.8	O
in	O
detecting	O
taper	O
corrosion	O
-related	O
pseudotumors	O
on	O
MARS-MRI	B-P
was	O
88	O
%	O
and	O
32	O
%	O
and	O
70	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Higher	O
intraoperative	O
tissue	O
damage	O
grades	O
demonstrated	O
significantly	O
higher	O
Co	O
/	O
Cr	O
ratios	O
(	O
8.6	O
vs	O
3.4	O
,	O
P	O
=	O
.03	O
)	O
.	O

Although	O
metal	O
ion	O
levels	O
alone	O
should	O
not	O
be	O
relied	O
on	O
as	O
the	O
sole	O
parameter	O
to	O
determine	O
revision	O
surgery	O
,	O
cobalt	O
level	O
>	O
2.8	O
μg/L	O
and	O
the	O
Co	O
/	O
Cr	O
ratio	O
>	O
3.8	O
are	O
useful	O
clinical	O
diagnostic	O
adjuncts	O
in	O
the	O
systematic	O
clinical	O
evaluation	O
for	O
taper	O
corrosion	O
-related	O
adverse	O
tissue	O
reactions	O
in	O
patients	O
with	O
dual	O
modular	O
taper	O
THA	O
.	O

Multidetector	B-P
CT	I-P
of	O
expected	O
findings	O
and	O
complications	O
after	O
contemporary	O
inguinal	O
hernia	O
repair	O
surgery	O
.	O

Inguinal	O
hernia	O
repair	O
(	O
IHR	O
)	O
with	O
prosthetic	O
mesh	O
implantation	O
is	O
the	O
most	O
common	O
procedure	O
in	O
general	O
surgery	O
,	O
and	O
may	O
be	O
performed	O
using	O
either	O
an	O
open	O
or	O
laparoscopic	O
approach	O
.	O

This	O
paper	O
provides	O
an	O
overview	O
of	O
contemporary	O
tension-free	O
IHR	O
techniques	O
and	O
materials	O
,	O
and	O
illustrates	O
the	O
expected	O
postoperative	O
imaging	O
findings	O
and	O
iatrogenic	O
injuries	O
.	O

Emphasis	O
is	O
placed	O
on	O
multidetector	B-P
CT	I-P
,	O
which	O
represents	O
the	O
ideal	O
modality	O
to	O
comprehensively	O
visualize	O
the	O
operated	O
groin	O
region	O
and	O
deeper	O
intra-abdominal	O
structures	O
.	O

CT	B-P
consistently	O
depicts	O
seroma	O
,	O
mesh	O
infections	O
,	O
hemorrhages	O
,	O
bowel	O
complications	O
and	O
urinary	O
bladder	O
injuries	O
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	O
basis	O
for	O
therapeutic	O
choice	O
.	O

Since	O
radiologists	O
are	O
increasingly	O
requested	O
to	O
investigate	O
suspected	O
iatrogenic	O
complications	O
,	O
this	O
paper	O
aims	O
to	O
provide	O
an	O
increased	O
familiarity	O
with	O
early	O
CT	B-P
studies	B-P
after	O
IHR	O
,	O
including	O
complications	O
and	O
normal	O
postoperative	O
appearances	O
such	O
as	O
focal	O
pseudolesions	O
,	O
in	O
order	O
to	O
avoid	O
misinterpretation	O
and	O
inappropriate	O
management	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
drugs	O
-induced-	O
RAW264.7	O
cells	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
and	O
U-HPLC	O
/	O
Q-TOF-MS.	O
Non-destructive	O
proton	O
nuclear	O
magnetic	O
resonance	O
(	O
(	O
1	O
)	O
H	O
NMR	O
)	O
spectroscopy	O
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	O
chromatography	O
quadrupole	O
time-of-flight	O
mass	O
spectrometry	O
(	O
U-HPLC	O
/	O
Q-TOF-MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	O
changes	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
in	O
RAW264.7	O
cells	O
from	O
inflammation	O
to	O
prognosis	O
.	O

Analysis	O
of	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	O
drugs	O
in	O
the	O
metabolic	O
profiling	O
of	O
GPLs	O
.	O

58	O
GPLs	O
were	O
identified	O
by	O
U-HPLC	O
/	O
Q-TOF-MS	O
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	O
compared	O
with	O
our	O
previous	O
results	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	O
(	O
PC	O
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0/18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug-induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O

Compared	O
with	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
U-HPLC	O
/	O
Q-TOF-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time-consuming	O
sample	O
preparation	O
steps	O
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
GPLs	O
during	O
inflammation	O
by	O
combining	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
spectroscopy	I-P
with	O
U-HPLC	O
/	O
Q-TOF-MS	O
.	O

The	O
metabolic	O
profiling	O
of	O
GPLs	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR-70	O
immunoassay	O
as	O
a	O
tumor	O
marker	O
for	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Lung	O
cancer	O
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	O
cancer	O
are	O
usually	O
diagnosed	B-P
at	O
advanced	O
or	O
locally	O
advanced	O
stage	O
,	O
for	O
this	O
reason	O
early	B-P
diagnosis	I-P
of	O
lung	O
cancer	O
is	O
very	O
important	O
.	O

For	O
early	B-P
detection	I-P
of	O
lung	O
cancer	O
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-P
computed	I-P
tomography	I-P
or	O
tumor	O
biomarkers	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR-70	O
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	O
in	O
detection	O
of	O
non-small	O
cell	O
lung	O
cancers	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	O
from	O
88	O
non	O
lung	O
cancer	O
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disesase	O
were	O
obtained	O
.	O

Blood	O
samples	O
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR-70	O
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O

Histopathologically	O
47	O
(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B-P
with	O
squamous	O
cell	O
lung	O
cancer	O
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
mean	O
serum	O
DR-70	O
levels	O
in	O
lung	O
cancer	O
patients	O
(	O
2.43	O
±	O
1.82	O
µg/mL	O
)	O
was	O
significantly	O
higher	O
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O

DR-70	O
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg/mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	O
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	O
level	O
is	O
1.98	O
µg/mL	O
and	O
higher	O
.	O

DR-70	O
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	O
products	O
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	O
lung	O
cancer	O
patients	O
.	O

Dynamic	B-P
Contrast-enhanced	I-P
MR	I-P
Imaging	I-P
in	O
Renal	O
Cell	O
Carcinoma	O
:	O
Reproducibility	O
of	O
Histogram	O
Analysis	O
on	O
Pharmacokinetic	O
Parameters	O
.	O

Pharmacokinetic	O
parameters	O
derived	O
from	O
dynamic	B-P
contrast-enhanced	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
DCE-MRI	B-P
)	O
have	O
been	O
increasingly	O
used	O
to	O
evaluate	O
the	O
permeability	O
of	O
tumor	O
vessel	O
.	O

Histogram	O
metrics	O
are	O
a	O
recognized	O
promising	O
method	O
of	O
quantitative	O
MR	B-P
imaging	I-P
that	O
has	O
been	O
recently	O
introduced	O
in	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
in	O
oncology	O
due	O
to	O
tumor	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
21	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
underwent	O
paired	O
DCE-MRI	B-P
studies	O
on	O
a	O
3.0	O
T	O
MR	O
system	O
.	O

Extended	O
Tofts	O
model	O
and	O
population-based	O
arterial	O
input	O
function	O
were	O
used	O
to	O
calculate	O
kinetic	O
parameters	O
of	O
RCC	O
tumors	O
.	O

Mean	O
value	O
and	O
histogram	O
metrics	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
of	O
each	O
pharmacokinetic	O
parameter	O
were	O
generated	O
automatically	O
using	O
ImageJ	O
software	O
.	O

Intra-	O
and	O
inter-observer	O
reproducibility	O
and	O
scan-rescan	O
reproducibility	O
were	O
evaluated	O
using	O
intra-class	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CoV	O
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
histogram	O
method	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
was	O
not	O
superior	O
to	O
the	O
conventional	O
Mean	O
value	O
method	O
in	O
reproducibility	O
evaluation	O
on	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
(	O
K	O
(	O
trans	O
)	O
&	O
Ve	O
)	O
in	O
renal	O
cell	O
carcinoma	O
,	O
especially	O
for	O
Skewness	O
and	O
Kurtosis	O
which	O
showed	O
lower	O
intra-	O
,	O
inter-observer	O
and	O
scan-rescan	O
reproducibility	O
than	O
Mean	O
value	O
.	O

Our	O
findings	O
suggest	O
that	O
additional	O
studies	O
are	O
necessary	O
before	O
wide	O
incorporation	O
of	O
histogram	O
metrics	O
in	O
quantitative	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
.	O

Lithium	O
silicate	O
endocrown	O
fabricated	O
with	O
a	O
CAD-CAM	O
system	O
:	O
A	O
functional	O
and	O
esthetic	O
protocol	O
.	O

An	O
endocrown	O
restoration	O
is	O
an	O
alternative	O
approach	O
to	O
complete	O
crowns	O
with	O
intraradicular	O
cores	O
or	O
dowels	O
for	O
the	O
restoration	O
of	O
endodontically	O
treated	O
teeth	O
.	O

Endocrowns	O
conserve	O
tooth	O
structure	O
and	O
require	O
fewer	O
dental	O
visits	O
.	O

This	O
approach	O
has	O
been	O
widely	O
used	O
,	O
and	O
various	O
materials	O
and	O
techniques	O
have	O
been	O
reported	O
.	O

Computer-aided	O
design	O
and	O
computer-aided	O
manufacturing	O
(	O
CAD-CAM	O
)	O
systems	O
can	O
generate	O
and	O
store	O
libraries	O
of	O
teeth	O
with	O
various	O
anatomies	O
in	O
their	O
database	O
,	O
and	O
diagnostic	B-P
tooth	I-P
waxing	I-P
may	O
not	O
be	O
required	O
.	O

However	O
,	O
occlusal	O
adjustments	O
after	O
the	O
cementation	O
of	O
indirect	O
restorations	O
are	O
often	O
frustrating	O
.	O

Thus	O
,	O
a	O
rapid	O
and	O
efficient	O
way	O
of	O
addressing	O
this	O
challenge	O
is	O
necessary	O
.	O

This	O
clinical	O
report	O
presents	O
a	O
protocol	O
for	O
the	O
fabrication	O
and	O
delivery	O
of	O
an	O
endocrown	O
by	O
using	O
the	O
biogeneric	O
design	O
mode	O
with	O
lithium	O
silicate-based	O
ceramic	O
adjusted	O
before	O
its	O
complete	O
sintering	O
.	O

Advanced	O
interlocking	O
systems	O
to	O
improve	O
heavy	O
-	O
load-bearing	O
characteristics	O
of	O
flexible	O
intramedullary	O
nailing	O
.	O

Flexible	O
intramedullary	O
nailing	O
(	O
FIN	O
)	O
is	O
a	O
minimally	O
invasive	O
and	O
widespread	O
standard	O
method	O
for	O
osteosynthesis	O
of	O
pediatric	O
long	O
bone	O
fractures	O
.	O

In	O
the	O
case	O
of	O
unstable	O
fractures	O
of	O
the	O
lower	O
extremity	O
,	O
interlocking	O
systems	O
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	O
shortening	O
and	O
subsequent	O
perforation	O
of	O
the	O
nail	O
at	O
its	O
insertion	O
site	O
.	O

In	O
the	O
present	O
study	O
,	O
four	O
different	O
screw	O
-fixed	O
interlocking	O
systems	O
for	O
FINs	O
(	O
Hofer	O
TwinPlug	O
with	O
two	O
3-mm	O
titanium	O
interlocking	O
screws	O
,	O
Hofer	O
FixPlug	O
with	O
3-mm	O
titanium	O
interlocking	O
screw	O
,	O
Hofer	O
Plug	O
with	O
3.5-mm	O
titanium	O
interlocking	O
screw	O
,	O
and	O
Hofer	O
Plug	O
with	O
3-mm	O
titanium	O
interlocking	O
screw	O
)	O
in	O
comparison	O
with	O
the	O
commonly	O
used	O
Ender	O
stainless	O
steel	O
nails	O
(	O
locked	O
with	O
3.5-mm	O
screw	O
)	O
were	O
experimentally	O
investigated	O
in	O
cadaveric	O
lamb	O
tibiae	O
,	O
regarding	O
their	O
load	O
characteristics	O
and	O
failure	O
modes	O
in	O
the	O
case	O
of	O
heavy	O
loading	O
.	O

The	O
specimens	O
were	O
subjected	O
to	O
sequential	O
axial	O
cyclic	O
loading	O
of	O
5000	O
cycles	O
with	O
stepwise	O
increase	O
of	O
the	O
load	O
amplitude	O
until	O
failure	O
.	O

Migration	O
of	O
locking	O
screws	O
and	O
internal	O
damage	O
of	O
bone	O
tissue	O
was	O
quantified	O
by	O
micro-computed	B-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
imaging	I-P
.	O

Ender	O
nails	O
failed	O
on	O
average	O
at	O
a	O
peak	O
load	O
of	O
800	O
N	O
,	O
TwinPlugs	O
at	O
1367	O
N	O
,	O
FixPlugs	O
at	O
1222	O
N	O
,	O
Plugs	O
3.5mm	O
at	O
1225	O
N	O
and	O
Plugs	O
3.0mm	O
at	O
971	O
N.	O
TwinPlugs	O
,	O
FixPlugs	O
,	O
and	O
Plugs	O
3.5mm	O
failed	O
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	O
cycles	O
,	O
whereas	O
Ender	O
nails	O
and	O
Plugs	O
3.0mm	O
exhibited	O
abrupt	O
failure	O
without	O
any	O
prior	O
indication	O
.	O

Our	O
results	O
confirm	O
that	O
axial	O
stability	O
of	O
FIN	O
can	O
be	O
further	O
improved	O
by	O
screw	O
-fixed	O
plugs	O
by	O
simultaneously	O
avoiding	O
shortcomings	O
of	O
an	O
eye-locked	O
system	O
,	O
which	O
the	O
Ender	O
nails	O
are	O
.	O

Considering	O
biomechanical	O
results	O
,	O
plug	O
interlocking	O
systems	O
with	O
3.5-mm	O
screws	O
should	O
be	O
favored	O
over	O
conventional	O
Ender	O
nails	O
and	O
plugs	O
with	O
3-mm	O
screws	O
.	O

Anger	O
and	O
aggression	O
in	O
borderline	O
personality	O
disorder	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
-	O
does	O
stress	O
matter	O
?	O
.	O

The	O
impact	O
of	O
stress	O
on	O
anger	O
and	O
aggression	O
in	O
Borderline	O
Personality	O
Disorder	O
(	O
BPD	O
)	O
and	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
different	O
aspects	O
of	O
anger	O
and	O
aggression	O
in	O
patients	O
with	O
these	O
disorders	O
.	O

Twenty-nine	O
unmedicated	O
female	O
BPD	O
patients	O
,	O
28	O
ADHD	O
patients	O
and	O
30	O
healthy	O
controls	O
(	O
HC	O
)	O
completed	O
self-reports	O
measuring	O
trait	O
anger	O
,	O
aggression	O
and	O
emotion	O
regulation	O
capacities	O
.	O

A	O
modified	O
version	O
of	O
the	O
Point	O
Subtraction	O
Aggression	O
Paradigm	O
and	O
a	O
state	O
anger	O
measurement	O
were	O
applied	O
under	O
resting	O
and	O
stress	O
conditions	O
.	O

Stress	O
was	O
induced	O
by	O
the	O
Mannheim	B-P
Multicomponent	I-P
Stress	I-P
Test	I-P
(	O
MMST	B-P
)	O
.	O

Both	O
patient	O
groups	O
scored	O
significantly	O
higher	O
on	O
all	O
self-report	O
measures	O
compared	O
to	O
HCs	O
.	O

Compared	O
to	O
ADHD	O
patients	O
,	O
BPD	O
patients	O
reported	O
higher	O
trait	O
aggression	O
and	O
hostility	O
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	O
when	O
provoked	O
and	O
to	O
direct	O
anger	O
inwardly	O
.	O

Furthermore	O
,	O
BPD	O
patients	O
exhibited	O
higher	O
state	O
anger	O
than	O
HCs	O
and	O
ADHD	O
patients	O
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	O
anger	O
increase	O
.	O

At	O
the	O
behavioral	O
level	O
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O

In	O
BPD	O
patients	O
,	O
aggression	O
and	O
anger	O
were	O
positively	O
correlated	O
with	O
emotion	O
regulation	O
deficits	O
.	O

Our	O
findings	O
suggest	O
a	O
significant	O
impact	O
of	O
stress	O
on	O
self-perceived	O
state	O
anger	O
in	O
BPD	O
patients	O
but	O
not	O
on	O
aggressive	O
behavior	O
towards	O
others	O
in	O
females	O
with	O
BPD	O
or	O
ADHD	O
.	O

However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	O
which	O
is	O
of	O
clinical	O
importance	O
in	O
BPD	O
patients	O
.	O

Clinical	O
application	O
and	O
outcomes	O
of	O
sentinel	O
node	O
navigation	O
surgery	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
.	O

Sentinel	O
node	O
navigation	O
surgery	O
(	O
SNNS	O
)	O
has	O
been	O
recognized	O
as	O
a	O
minimally	O
invasive	O
tool	O
for	O
individualized	O
lymphadenectomy	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
(	O
EGC	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinicopathological	O
factors	O
,	O
adverse	O
events	O
,	O
and	O
clinical	O
outcomes	O
between	O
sentinel	B-P
node	I-P
mapping	I-P
(	O
SNM	B-P
)	O
and	O
SN	O
dissection	O
(	O
SND	O
)	O
groups	O
and	O
assess	O
the	O
clinical	O
utility	O
of	O
SNNS	O
in	O
patients	O
with	O
EGC	O
.	O

The	O
clinical	O
data	O
of	O
157	O
patients	O
with	O
EGC	O
,	O
diagnosed	O
as	O
clinical	O
T1N0M0	O
with	O
tumors	O
≤	O
40	O
mm	O
,	O
undergoing	O
SNNS	O
between	O
March	O
2004	O
and	O
April	O
2016	O
were	O
retrospectively	O
reviewed	O
.	O

Twenty-seven	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

In	O
the	O
remaining	O
130	O
patients	O
,	O
59	O
and	O
71	O
patients	O
underwent	O
standard	O
lymphadenectomy	O
for	O
SNM	B-P
and	O
SND	O
,	O
respectively	O
.	O

The	O
sentinel	O
node	O
detection	O
rate	O
in	O
the	O
SNM	B-P
and	O
SND	O
groups	O
was	O
98.3	O
%	O
(	O
58/59	O
)	O
and	O
100	O
%	O
(	O
71/71	O
)	O
,	O
respectively	O
.	O

Two	O
(	O
3.5	O
%	O
)	O
,	O
15	O
(	O
25.9	O
%	O
)	O
,	O
and	O
41	O
(	O
70.7	O
%	O
)	O
patients	O
having	O
sentinel	O
nodes	O
underwent	O
total	O
gastrectomy	O
,	O
proximal	O
gastrectomy	O
(	O
PG	O
)	O
,	O
and	O
distal	O
gastrectomy	O
(	O
DG	O
)	O
,	O
respectively	O
,	O
in	O
the	O
SNM	B-P
group	O
.	O

One	O
(	O
1.4	O
%	O
)	O
,	O
5	O
(	O
7.0	O
%	O
)	O
,	O
10	O
(	O
14.1	O
%	O
)	O
,	O
39	O
(	O
54.9	O
%	O
)	O
,	O
and	O
16	O
(	O
22.5	O
%	O
)	O
patients	O
underwent	O
PG	O
,	O
DG	O
,	O
segmental	O
gastrectomy	O
,	O
local	O
resection	O
,	O
and	O
endoscopic	O
submucosal	O
dissection	O
,	O
respectively	O
,	O
in	O
the	O
SND	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
postoperative	O
complications	O
between	O
the	O
SNM	B-P
and	O
SND	O
groups	O
(	O
P	O
=	O
0.781	O
)	O
.	O

Survival	O
did	O
not	O
differ	O
between	O
the	O
both	O
groups	O
(	O
P	O
=	O
0.856	O
)	O
.	O

The	O
present	O
results	O
suggest	O
that	O
personalized	O
surgery	O
with	O
SND	O
provides	O
technical	O
safety	O
and	O
curability	O
related	O
with	O
a	O
favorable	O
survival	O
outcome	O
in	O
patients	O
with	O
EGC	O
.	O

CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-P
Coherence	I-P
Tomography	I-P
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	O
Age-Related	O
Macular	O
Degeneration	O
.	O

To	O
evaluate	O
choroidal	O
structural	O
changes	O
in	O
exudative	O
age-related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-P
domain	I-P
optical	I-P
coherence	I-P
tomography	I-P
with	O
enhanced	O
depth	B-P
imaging	I-P
.	O

This	O
prospective	O
case	O
series	O
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	O
exudative	O
AMD	O
.	O

Choroidal	O
images	B-P
were	O
segmented	O
into	O
luminal	O
area	O
and	O
stromal	O
area	O
.	O

Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	O
area	O
to	O
total	O
choroid	O
area	O
.	O

Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	O
and	O
fellow	O
eyes	O
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	O
were	O
compared	O
using	O
Student	O
's	O
t-test	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	O
with	O
exudative	O
AMD	O
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Luminal	O
area	O
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	O
in	O
eyes	O
with	O
exudative	O
AMD	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
choroid	O
area	O
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	O
and	O
fellow	O
eyes	O
.	O

Eyes	O
with	O
exudative	O
AMD	O
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	O
.	O

Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	O
tool	O
for	O
studying	O
structural	O
changes	O
in	O
choroid	O
and	O
monitoring	O
choroidal	O
disease	O
in	O
exudative	O
AMD	O
.	O

Does	O
Video	O
Laryngoscopy	O
Offer	O
Advantages	O
over	O
Direct	B-P
Laryngoscopy	I-P
during	O
Cardiopulmonary	O
Resuscitation	O
?	O
.	O

Interruption	O
of	O
chest	O
compressions	O
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	O
effects	O
on	O
survival	O
.	O

This	O
randomized	O
,	O
controlled	O
,	O
cross-over	O
study	O
aimed	O
to	O
analyze	O
the	O
effectiveness	O
of	O
Macintosh	O
,	O
Miller	O
,	O
McCoy	O
and	O
McGrath	O
laryngoscopes	O
during	O
with	O
or	O
without	O
chest	O
compressions	O
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	O
resuscitation	O
scenario	O
.	O

The	O
time	O
required	O
for	O
successful	O
tracheal	O
intubation	O
,	O
number	O
of	O
attempts	O
,	O
dental	O
trauma	O
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	O
during	O
cardiopulmonary	O
resuscitation	O
with	O
and	O
without	O
chest	O
compressions	O
.	O

The	O
experience	O
with	O
computer	O
games	O
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	O
and	O
recorded	O
.	O

McCoy	O
laryngoscope	O
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	O
intubation	O
both	O
in	O
the	O
presence	O
of	O
and	O
without	O
chest	O
compressions	O
.	O

During	O
the	O
use	O
of	O
McCoy	O
laryngoscopes	O
,	O
fewer	O
tracheal	O
intubation	O
attempts	O
,	O
lower	O
incidence	O
of	O
dental	O
trauma	O
and	O
lower	O
visual	O
analogue	O
scale	O
scores	O
on	O
the	O
ease	O
of	O
intubation	O
were	O
recorded	O
.	O

Participants	O
who	O
are	O
experienced	O
computer	O
game	O
players	O
using	O
Macintosh	O
,	O
McCoy	O
and	O
McGrath	O
achieved	O
successful	O
tracheal	O
intubation	O
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	O
without	O
chest	O
compressions	O
.	O

Dental	O
trauma	O
incidence	O
and	O
number	O
of	O
tracheal	O
intubation	O
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	O
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	O
games	O
.	O

McGrath	O
video	O
laryngoscopes	O
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-P
laryngoscopes	I-P
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	O
intubation	O
during	O
rhythmic	O
chest	O
compressions	O
.	O

We	O
believe	O
that	O
as	O
McCoy	O
laryngoscope	O
provided	O
tracheal	O
intubation	O
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	O
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	O
.	O

Fluorescence-	O
and	O
magnetic-activated	O
cell	O
sorting	O
strategies	O
to	O
separate	O
spermatozoa	O
involving	O
plural	O
contributors	O
from	O
biological	O
mixtures	O
for	O
human	B-P
identification	I-P
.	O

No	O
effective	O
method	O
has	O
been	O
developed	O
to	O
distinguish	O
sperm	O
cells	O
originating	O
from	O
different	O
men	O
in	O
multi-suspect	O
sexual	O
assault	O
cases	O
.	O

Here	O
we	O
combined	O
MACS	O
and	O
FACS	O
to	O
isolate	O
single	O
donor	O
sperm	O
cells	O
from	O
forensic	O
mixture	O
samples	O
including	O
female	O
vaginal	O
epithelial	O
cells	O
and	O
sperm	O
cells	O
from	O
multiple	O
contributors	O
.	O

Sperms	O
from	O
vaginal	O
swab	O
were	O
isolated	O
by	O
MACS	O
using	O
FITC	O
-conjugated	O
A	O
kinase	O
anchor	O
protein	O
3	O
(	O
AKAP3	O
)	O
antibody	O
;	O
target	O
individual	O
sperm	O
cells	O
involving	O
two	O
or	O
three	O
donors	O
were	O
separated	O
by	O
FACS	O
using	O
FITC	O
-labeled	O
blood	O
group	O
A/B	O
antigen	O
antibody	O
.	O

This	O
procedure	O
was	O
further	O
tested	O
in	O
two	O
mock	O
multi-suspect	O
sexual	O
assault	O
samples	O
and	O
one	O
practical	O
casework	O
sample	O
.	O

Our	O
results	O
showed	O
that	O
complete	O
single	O
donor	O
STR	O
profiles	O
could	O
be	O
successfully	O
obtained	O
from	O
sperm	O
/	O
epithelial	O
cell	O
and	O
sperm	O
mixtures	O
from	O
two	O
contributors	O
.	O

For	O
unbalanced	O
sperm	O
/	O
epithelial	O
cells	O
and	O
sperm	O
cells	O
mixtures	O
,	O
sensitivity	O
results	O
revealed	O
that	O
target	O
cells	O
could	O
be	O
detected	O
at	O
as	O
low	O
as	O
1:32	O
and	O
1:8	O
mixed	O
ratios	O
,	O
respectively	O
.	O

Although	O
highly	O
relies	O
on	O
cell	O
number	O
and	O
blood	O
types	O
or	O
secretor	O
status	O
of	O
the	O
individuals	O
,	O
this	O
procedure	O
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	O
DNA	O
analysis	O
of	O
multi-suspect	O
sexual	O
assault	O
cases	O
by	O
the	O
combined	O
use	O
of	O
FACS	O
and	O
MACS	O
based	O
on	O
sperm	O
-specific	O
AKAP3	O
antigen	O
and	O
human	O
blood	O
type	O
antigen	O
.	O

Analysis	O
of	O
occupant	O
kinematics	O
and	O
dynamics	O
in	O
nearside	O
oblique	O
impacts	O
.	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
analyze	O
the	O
kinematics	O
and	O
dynamics	O
of	O
restrained	O
postmortem	B-P
human	O
surrogates	O
(	O
PMHS	O
)	O
exposed	O
to	O
a	O
nearside	O
oblique	O
impact	O
and	O
the	O
injuries	O
that	O
were	O
found	O
after	O
the	O
tests	O
.	O

Three	O
male	O
PMHS	O
of	O
similar	O
age	O
(	O
64	O
±	O
4	O
years	O
)	O
and	O
anthropometry	O
(	O
weight	O
:	O
61	O
±	O
9.6	O
kg	O
;	O
stature	O
:	O
172	O
±	O
2.7	O
cm	O
)	O
were	O
exposed	O
to	O
a	O
30°	O
nearside	O
oblique	O
impact	O
at	O
34	O
km/h	O
.	O

The	O
test	O
fixture	O
approximated	O
the	O
seating	O
position	O
of	O
a	O
front	O
seat	O
occupant	O
.	O

A	O
rigid	O
seat	O
was	O
designed	O
to	O
match	O
the	O
pelvic	O
displacement	O
in	O
a	O
vehicle	O
seat	O
.	O

Surrogates	O
were	O
restrained	O
by	O
a	O
3-point	O
seat	O
belt	O
consisting	O
of	O
a	O
2	O
kN	O
pretensioner	O
(	O
PT	O
)	O
,	O
4.5	O
kN	O
force-limiting	O
shoulder	O
belt	O
,	O
and	O
a	O
3.5	O
kN	O
PT	O
lap	O
belt	O
.	O

The	O
shoulder	O
belt	O
PT	O
was	O
not	O
fired	O
in	O
one	O
of	O
the	O
tests	O
.	O

Trajectories	O
of	O
the	O
head	O
,	O
shoulder	O
,	O
and	O
hip	O
joint	O
(	O
bilaterally	O
)	O
were	O
recorded	O
at	O
1,000	O
Hz	O
by	O
a	O
3D	O
motion	O
capture	O
system	O
.	O

The	O
3D	O
acceleration	O
and	O
angular	O
rate	O
of	O
the	O
head	O
,	O
T1	O
,	O
and	O
pelvis	O
,	O
and	O
the	O
3D	O
acceleration	O
of	O
selected	O
spinal	O
locations	O
was	O
measured	O
at	O
10,000	O
Hz	O
.	O

Seat	O
belt	O
load	O
cells	O
measured	O
the	O
belt	O
tension	O
at	O
4	O
locations	O
.	O

PMHS	O
donation	O
and	O
handling	O
were	O
performed	O
with	O
the	O
approval	O
of	O
the	O
relevant	O
regional	O
ethics	O
review	O
board	O
.	O

Activation	O
of	O
the	O
shoulder	O
PT	O
reduced	O
substantially	O
the	O
peak	O
forward	O
excursion	O
of	O
the	O
head	O
but	O
did	O
not	O
influence	O
the	O
lateral	O
displacement	O
of	O
the	O
head	O
center	O
of	O
gravity	O
(	O
CG	O
)	O
.	O

In	O
all	O
3	O
subjects	O
,	O
the	O
lateral	O
excursion	O
of	O
the	O
head	O
CG	O
(	O
291.1	O
,	O
290	O
,	O
292.1	O
mm	O
)	O
was	O
greater	O
than	O
the	O
forward	O
displacement	O
(	O
271.4	O
,	O
216.7	O
,	O
171.5	O
mm	O
)	O
.	O

The	O
hip	O
joint	O
excursion	O
of	O
the	O
PMHS	O
that	O
was	O
not	O
exposed	O
to	O
the	O
shoulder	O
PT	O
seat	O
belt	O
was	O
twice	O
the	O
magnitude	O
observed	O
for	O
the	O
other	O
2	O
subjects	O
.	O

The	O
3	O
PMHS	O
sustained	O
clavicle	O
fractures	O
on	O
the	O
shoulder	O
loaded	O
by	O
the	O
seat	O
belt	O
and	O
2	O
of	O
them	O
were	O
diagnosed	O
atlantoaxial	O
subluxation	O
in	O
the	O
radiologist	O
examination	O
.	O

Avulsion	O
fractures	O
of	O
the	O
right	O
lamina	O
of	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
and	O
T4	O
were	O
found	O
when	O
the	O
PT	O
was	O
not	O
used	O
.	O

The	O
3	O
PMHS	O
received	O
multiple	O
fractures	O
spread	O
over	O
both	O
aspects	O
of	O
the	O
rib	O
cage	O
and	O
involving	O
the	O
posterior	O
aspect	O
of	O
it	O
.	O

In	O
this	O
study	O
of	O
nearside	O
oblique	O
impact	O
loading	O
,	O
the	O
PMHS	O
exhibited	O
kinematics	O
characterized	O
by	O
reduced	O
torso	O
pitching	O
and	O
increased	O
lateral	O
head	O
excursion	O
as	O
compared	O
to	O
previous	O
frontal	O
impact	O
results	O
.	O

These	O
kinematics	O
resulted	O
in	O
potential	O
cervical	O
and	O
thoracic	O
spinal	O
injuries	O
and	O
in	O
complete	O
,	O
displaced	O
fractures	O
of	O
the	O
lateral	O
and	O
posterior	O
aspects	O
of	O
the	O
rib	O
cage	O
.	O

Though	O
this	O
is	O
a	O
limited	O
number	O
of	O
subjects	O
,	O
it	O
shows	O
the	O
necessity	O
of	O
further	O
understanding	O
of	O
the	O
kinematics	O
of	O
occupants	O
exposed	O
to	O
this	O
loading	O
mode	O
.	O

Th1	O
and	O
Innate	O
Lymphoid	O
Cells	O
accumulate	O
in	O
Primary	O
Sclerosing	O
Cholangitis	O
-	O
associated	O
Inflammatory	O
Bowel	O
Disease	O
.	O

Primary	O
sclerosing	O
cholangitis	O
(	O
PSC	O
)	O
is	O
an	O
idiopathic	O
chronic	O
disorder	O
of	O
the	O
hepatobiliary	O
system	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
mainly	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Colitis	O
in	O
patients	O
with	O
PSC	O
and	O
UC	O
(	O
PSC	O
-	O
UC	O
)	O
exhibits	O
characteristic	O
features	O
and	O
is	O
linked	O
to	O
increased	O
colon	O
cancer	O
risk	O
.	O

Genetic	O
studies	O
have	O
identified	O
immune	O
-	O
related	O
susceptibility	O
genes	O
that	O
only	O
partially	O
overlap	O
with	O
those	O
involved	O
in	O
IBD	O
.	O

These	O
observations	O
suggest	O
that	O
PSC	O
-	O
UC	O
may	O
represent	O
a	O
distinct	O
form	O
of	O
IBD	O
.	O

It	O
remains	O
to	O
be	O
elucidated	O
whether	O
different	O
immune-mechanisms	O
are	O
involved	O
in	O
colitis	O
in	O
these	O
patients	O
.	O

We	O
aimed	O
to	O
evaluate	O
systemic	O
and	O
intestinal	O
T-cell	O
and	O
innate	O
lymphoid	O
cell	O
(	O
ILC	O
)	O
responses	O
,	O
previously	O
associated	O
to	O
IBD	O
,	O
in	O
patients	O
with	O
PSC	O
-	O
UC	O
compared	O
to	O
patients	O
with	O
UC	O
and	O
healthy	O
controls	O
.	O

Blood	O
samples	O
and	O
colorectal	O
biopsies	B-P
were	O
collected	O
from	O
patients	O
with	O
PSC	O
-	O
UC	O
,	O
patients	O
with	O
UC	O
and	O
healthy	O
controls	O
.	O

T-cell	O
and	O
ILC	O
phenotype	O
was	O
analysed	O
by	O
multicolour	O
flow	O
cytometry	O
.	O

Chemokine	O
receptor	O
(	O
CCR	O
)	O
profiling	O
of	O
circulating	O
T-cell	O
s	O
showed	O
decreased	O
CCR6-CXCR3+	O
Th1	O
cells	O
in	O
PSC	O
-	O
UC	O
,	O
but	O
increased	O
CCR6-CCR4+	O
Th2	O
cells	O
only	O
in	O
UC	O
,	O
while	O
increased	O
CCR6+CCR4+	O
Th17	O
cells	O
were	O
found	O
in	O
both	O
patient	O
groups	O
compared	O
to	O
healthy	O
controls	O
.	O

Increased	O
frequencies	O
of	O
IFN-γ	O
secreting	O
T-cells	O
were	O
found	O
in	O
the	O
colon	O
of	O
patients	O
with	O
PSC	O
-	O
UC	O
compared	O
to	O
UC	O
.	O

Interestingly	O
,	O
we	O
observed	O
accumulation	O
of	O
ILC	O
in	O
the	O
colon	O
in	O
PSC	O
-	O
UC	O
.	O

Our	O
study	O
suggests	O
that	O
PSC	O
-	O
UC	O
represent	O
a	O
different	O
immunological	O
disorder	O
from	O
UC	O
,	O
characterised	O
by	O
increased	O
intestinal	O
Th1	O
and	O
ILC	O
responses	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
that	O
PSC	O
-	O
UC	O
may	O
represent	O
a	O
distinct	O
form	O
of	O
IBD	O
.	O

Magnetic	B-P
Resonance	I-P
Imaging	I-P
Appearance	O
and	O
Mechanism	O
of	O
Action	O
of	O
Five	O
Hemostatic	O
Agents	O
Used	O
in	O
Neurosurgery	O
.	O

To	O
describe	O
the	O
magnetic	O
resonance	O
(	O
MR	O
)	O
image	O
appearance	O
of	O
5	O
hemostatic	O
agents	O
placed	O
in	O
the	O
brain	O
,	O
and	O
to	O
review	O
their	O
clinical	O
application	O
.	O

Descriptive	O
ex	O
vivo	O
and	O
in	O
vivo	O
study	O
.	O

Canine	O
cadavers	O
(	O
n=4	O
)	O
,	O
client-owned	O
dogs	O
(	O
n=4	O
)	O
.	O

Heads	O
from	O
4	O
canine	O
cadavers	O
were	O
used	O
,	O
each	O
with	O
5	O
hemostatic	O
agents	O
placed	O
in	O
specific	O
locations	O
in	O
the	O
brain	O
.	O

Hemostatic	O
agents	O
were	O
used	O
in	O
their	O
native	O
form	O
in	O
2	O
cadaveric	O
brains	O
,	O
and	O
in	O
2	O
others	O
the	O
materials	O
were	O
saturated	O
with	O
fresh	O
whole	O
blood	O
prior	O
to	O
placement	O
to	O
mimic	O
application	O
in	O
a	O
field	O
of	O
active	O
hemorrhage	O
.	O

The	O
heads	O
underwent	O
MR	B-P
imaging	I-P
and	O
the	O
images	O
were	O
reviewed	O
.	O

Postoperative	O
MRI	B-P
images	O
from	O
4	O
dogs	O
undergoing	O
brain	O
tumor	O
resection	O
were	O
retrospectively	O
reviewed	O
and	O
compared	O
to	O
the	O
images	O
from	O
the	O
cadavers	O
.	O

All	O
clinical	O
cases	O
and	O
cadaveric	O
specimens	O
underwent	O
surgical	O
closure	O
prior	O
to	O
MR	B-P
imaging	I-P
including	O
placement	O
of	O
titanium	O
mesh	O
over	O
the	O
craniotomy	O
defect	O
with	O
a	O
dural	O
graft	O
of	O
porcine	O
small	O
intestinal	O
submucosa	O
(	O
SIS	O
)	O
sealed	O
with	O
Tisseel	O
(	O
fibrin	O
sealant	O
)	O
.	O

The	O
SIS	O
and	O
Tisseel	O
used	O
in	O
the	O
dural	O
graft	O
were	O
consistently	O
indistinguishable	O
from	O
the	O
surrounding	O
tissues	O
on	O
MR	O
images	O
.	O

The	O
MR	B-P
imaging	I-P
appearance	O
of	O
the	O
remaining	O
4	O
hemostatic	O
agents	O
(	O
Gelfoam	O
,	O
Avitene	O
,	O
Surgicel	O
,	O
and	O
Floseal	O
)	O
placed	O
on	O
the	O
surface	O
or	O
in	O
the	O
parenchyma	O
of	O
canine	O
brain	O
,	O
varied	O
with	O
MR	O
sequence	O
weighting	O
and	O
blood	O
saturation	O
.	O

Accurate	O
evaluation	O
of	O
the	O
degree	O
of	O
brain	O
tumor	O
resection	O
on	O
postoperative	O
MR	O
images	O
requires	O
careful	O
differentiation	O
between	O
hemorrhage	O
,	O
residual	O
tumor	O
,	O
and	O
hemostatic	O
agents	O
implanted	O
.	O

Metabolomics	O
analysis	O
of	O
anaphylactoid	O
reaction	O
reveals	O
its	O
mechanism	O
in	O
a	O
rat	O
model	O
.	O

Anaphylactoid	O
reactions	O
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune-mediated	O
immediate	O
hypersensitivity	O
reactions	O
,	O
have	O
become	O
a	O
serious	O
threat	O
to	O
public	O
health	O
,	O
but	O
their	O
effect	O
mechanism	O
is	O
not	O
clear	O
and	O
diagnostic	B-P
tests	I-P
are	O
limited	O
.	O

Comprehensive	O
metabolite	O
analysis	O
may	O
reveal	O
the	O
anaphylactoid	O
effect	O
mechanism	O
systematically	O
and	O
provide	O
reference	O
for	O
future	O
diagnostic	O
purposes	O
.	O

Plasma	O
from	O
Brown	O
Norway	O
rats	O
given	O
intravenous	O
injection	O
of	O
saline	O
,	O
compound	O
48/80	O
(	O
2.5	O
mL/kg	O
)	O
or	O
ovalbumin	O
(	O
20	O
mL/kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	O
to	O
study	O
the	O
effect	O
mechanism	O
of	O
anaphylactoid	O
reactions	O
through	O
metabolomics	O
(	O
UPLC-qTOF-MS/MS	O
)	O
.	O

Metabolomics	O
integrated	O
with	O
proteomics	O
data	O
were	O
used	O
to	O
analyze	O
the	O
anaphylactoid	O
pathways	O
by	O
MetaboAnalyst	O
followed	O
by	O
integrated	O
pathway	O
analysis	O
.	O

Thirty	O
metabolites	O
were	O
identified	O
through	O
the	O
METLIN	O
database	O
by	O
MS/MS	O
and	O
18	O
of	O
them	O
were	O
confirmed	O
by	O
authentic	O
standards	O
.	O

The	O
results	O
showed	O
that	O
adenosine	O
,	O
histamine	O
,	O
N-acetylhistamine	O
,	O
N	O
(	O
α	O
)	O
-γ-glutamylhistamine	O
,	O
malate	O
and	O
xanthine	O
are	O
important	O
indices	O
for	O
anaphylactoid	O
reactions	O
.	O

It	O
could	O
be	O
concluded	O
that	O
the	O
effect	O
mechanism	O
is	O
mainly	O
composed	O
of	O
histidine	O
metabolism	O
,	O
arachidonic	O
acid	O
metabolism	O
,	O
energy	O
metabolism	O
,	O
purine	O
metabolism	O
and	O
other	O
small	O
molecules	O
through	O
30	O
metabolites	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
indicated	O
that	O
not	O
only	O
histamine	O
but	O
also	O
N	O
(	O
α	O
)	O
-γ-glutamylhistamine	O
and	O
arachidonic	O
acid	O
could	O
be	O
used	O
to	O
evaluate	O
anaphylactoid	O
symptoms	O
of	O
animals	O
.	O

Furthermore	O
,	O
the	O
citrate	O
cycle	O
,	O
histidine	O
metabolism	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
be	O
the	O
main	O
pathways	O
of	O
anaphylactoid	O
reactions	O
as	O
determined	O
by	O
MetaboAnalyst	O
.	O

The	O
results	O
may	O
provide	O
a	O
reference	O
to	O
improve	O
diagnostic	O
accuracy	O
and	O
predict	O
and	O
monitor	O
treatment	O
efficacy	O
in	O
anaphylactoid	O
reactions	O
in	O
the	O
clinical	O
setting	O
.	O

Experience	O
of	O
Varied	O
Presentation	O
of	O
Chronic	O
Progressive	O
Disseminated	O
Histoplasmosis	O
in	O
Immunocompetent	O
Patients	O
:	O
A	O
Diagnostic	O
Conundrum	O
.	O

We	O
report	O
two	O
cases	O
of	O
chronic	O
progressive	O
disseminated	O
histoplasmosis	O
with	O
unusual	O
and	O
rare	O
clinical	O
picture	O
in	O
a	O
patient	O
with	O
no	O
underlying	O
risk	O
factor	O
.	O

One	O
50-year-old	O
male	O
,	O
presented	O
with	O
hoarseness	O
of	O
voice	O
,	O
chronic	O
cough	O
,	O
with	O
a	O
history	O
of	O
nonresponding	O
anti-tubercular	O
therapy	O
,	O
revealed	O
mucocutaneous	O
lesions	O
on	O
examination	O
.	O

Fungating	O
vocal	O
cord	O
lesions	O
were	O
visualized	O
on	O
bronchoscopy	B-P
,	O
raised	O
suspicion	O
of	O
carcinoma	O
.	O

The	O
second	O
case	O
,	O
a	O
22-year-	O
old	O
female	O
,	O
referred	O
to	O
hospital	O
with	O
suspected	O
vasculitis	O
,	O
with	O
complaints	O
of	O
``	O
off	O
and	O
on	O
''	O
fever	O
with	O
decreased	O
oral	O
intake	O
,	O
arthralgia	O
,	O
who	O
later	O
developed	O
generalized	O
nodular	O
skin	O
eruptions	O
.	O

On	O
investigation	O
,	O
human	O
immunodeficiency	O
virus	O
test	O
was	O
found	O
to	O
be	O
negative	O
in	O
both	O
the	O
cases	O
.	O

Histopathological	O
findings	O
of	O
skin	B-P
biopsy	I-P
,	O
adrenal	O
and	O
bone	O
marrow	O
aspirates	O
raised	O
suspicion	O
,	O
whereas	O
fungal	O
cultures	O
confirmed	O
Histoplasma	O
infection	O
.	O

Although	O
diagnosis	O
was	O
delayed	O
,	O
but	O
both	O
of	O
them	O
were	O
successfully	O
treated	O
with	O
amphotericin	O
B	O
.	O

Disease	O
Activity	O
and	O
Increased	O
Risk	O
of	O
Cardiovascular	O
Death	O
among	O
Patients	O
with	O
Psoriatic	O
Arthritis	O
.	O

Recent	O
studies	O
indicate	O
increased	O
cardiovascular	O
(	O
CV	O
)	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	O
rate	O
,	O
cause	O
of	O
death	O
,	O
and	O
incidence	O
of	O
acute	O
CV	O
events	O
in	O
patients	O
from	O
northern	O
Sweden	O
with	O
PsA	O
.	O

Patients	O
with	O
established	O
PsA	O
(	O
464	O
)	O
were	O
included	O
.	O

To	O
calculate	O
standardized	O
mortality	O
ratio	O
(	O
SMR	O
)	O
and	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
for	O
CV	O
events	O
,	O
data	O
were	O
extracted	O
from	O
the	O
National	O
Causes	O
of	O
Death	O
Register	O
and	O
the	O
National	O
Inpatient	O
Care	O
Register	O
in	O
Sweden	O
,	O
and	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
study	O
period	O
was	O
1995-2011	O
.	O

To	O
study	O
the	O
effect	O
of	O
inflammatory	O
activity	O
,	O
a	O
composite	O
disease	B-P
activity	I-P
index	I-P
(	O
DAI	B-P
)	O
was	O
used	O
.	O

The	O
SMR	O
(	O
95	O
%	O
CI	O
)	O
for	O
overall	O
mortality	O
and	O
diseases	O
of	O
the	O
circulatory	O
system	O
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
10th	O
edition	O
;	O
I00-I99	O
)	O
was	O
1.22	O
(	O
0.89-1.63	O
)	O
and	O
1.64	O
(	O
1.02-2.52	O
)	O
,	O
respectively	O
.	O

In	O
regression	O
analysis	O
,	O
DAI	B-P
was	O
significantly	O
associated	O
with	O
death	O
(	O
OR	O
1.99	O
,	O
95	O
%	O
CI	O
1.41-2.80	O
)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	O
patients	O
into	O
the	O
2	O
major	O
causes	O
of	O
death	O
:	O
diseases	O
of	O
the	O
circulatory	O
system	O
and	O
malignant	O
neoplasms	O
.	O

Peripheral	O
and	O
axial	O
disease	O
was	O
associated	O
with	O
death	O
(	O
OR	O
4.02	O
,	O
95	O
%	O
CI	O
1.84-8.84	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
peripheral	O
disease	O
only	O
.	O

The	O
SIR	O
(	O
95	O
%	O
CI	O
)	O
for	O
a	O
CV	O
event	O
(	O
myocardial	O
infarction	O
or	O
stroke	O
)	O
was	O
0.597	O
(	O
0.40-0.86	O
)	O
;	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	O
.	O

Patients	O
with	O
PsA	O
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	O
for	O
death	O
due	O
to	O
diseases	O
of	O
the	O
circulatory	O
system	O
compared	O
with	O
the	O
general	O
population	O
.	O

Among	O
patients	O
,	O
death	O
was	O
associated	O
with	O
DAI	B-P
,	O
as	O
well	O
as	O
axial	O
involvement	O
in	O
combination	O
with	O
peripheral	O
disease	O
,	O
indicating	O
more	O
aggressive	O
disease	O
phenotypes	O
.	O

Is	O
minimally	O
invasive	O
thoracoscopic	O
surgery	O
the	O
new	O
benchmark	O
for	O
treating	O
mitral	O
valve	O
disease	O
?	O
.	O

The	O
treatment	O
of	O
mitral	O
valve	O
disease	O
remains	O
dynamic	O
;	O
surgeons	O
and	O
patients	O
must	O
now	O
choose	O
between	O
many	O
different	O
surgical	O
options	O
when	O
addressing	O
mitral	O
regurgitation	O
and	O
mitral	O
stenosis	O
.	O

Notably	O
,	O
advances	O
in	O
imaging	B-P
and	O
surgical	O
instrumentation	O
allow	O
surgeons	O
to	O
perform	O
less	O
invasive	O
mitral	O
valve	O
surgery	O
that	O
spares	O
the	O
sternum	O
.	O

With	O
favorable	O
long-term	O
data	O
now	O
emerging	O
,	O
we	O
compare	O
the	O
benefits	O
and	O
risks	O
of	O
thoracoscopic	O
mitral	O
valve	O
surgery	O
with	O
that	O
through	O
conventional	O
sternotomy	O
or	O
surgery	O
that	O
is	O
robot-assisted	O
.	O

Mechanisms	O
of	O
Improved	O
Exercise	O
Performance	O
under	O
Hyperoxia	O
.	O

The	O
impact	O
of	O
hyperoxia	O
on	O
exercise	O
limitation	O
is	O
still	O
incompletely	O
understood	O
.	O

We	O
investigated	O
to	O
which	O
extent	O
breathing	O
hyperoxia	O
enhances	O
the	O
exercise	O
performance	O
of	O
healthy	O
subjects	O
and	O
which	O
physiologic	O
mechanisms	O
are	O
involved	O
.	O

A	O
total	O
of	O
32	O
healthy	O
volunteers	O
(	O
43	O
±	O
15	O
years	O
,	O
12	O
women	O
)	O
performed	O
4	O
bicycle	O
exercise	O
tests	O
to	O
exhaustion	O
with	O
ramp	O
and	O
constant-load	O
protocols	O
(	O
at	O
75	O
%	O
of	O
the	O
maximal	O
workload	O
[	O
Wmax	O
]	O
on	O
FiO2	O
0.21	O
)	O
on	O
separate	O
occasions	O
while	O
breathing	O
ambient	O
(	O
FiO2	O
0.21	O
)	O
or	O
oxygen-enriched	O
air	O
(	O
FiO2	O
0.50	O
)	O
in	O
a	O
random	O
,	O
blinded	O
order	O
.	O

Workload	O
,	O
endurance	O
,	O
gas	O
exchange	O
,	O
pulse	B-P
oximetry	I-P
(	O
SpO2	B-P
)	O
,	O
and	O
cerebral	O
(	O
CTO	O
)	O
and	O
quadriceps	O
muscle	O
tissue	O
oxygenation	O
(	O
QMTO	O
)	O
were	O
measured	O
.	O

During	O
the	O
final	O
15	O
s	O
of	O
ramp	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
Wmax	O
(	O
mean	O
±	O
SD	O
270	O
±	O
80	O
W	O
)	O
,	O
SpO2	B-P
(	O
99	O
±	O
1	O
%	O
)	O
,	O
and	O
CTO	O
(	O
67	O
±	O
9	O
%	O
)	O
were	O
higher	O
and	O
the	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
was	O
lower	O
(	O
4.8	O
±	O
2.2	O
)	O
than	O
the	O
corresponding	O
values	O
with	O
FiO2	O
0.21	O
(	O
Wmax	O
257	O
±	O
76	O
W	O
,	O
SpO2	B-P
96	O
±	O
3	O
%	O
,	O
CTO	O
61	O
±	O
9	O
%	O
,	O
and	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
5.7	O
±	O
2.6	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
constant-load	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
endurance	O
was	O
longer	O
than	O
with	O
FiO2	O
0.21	O
(	O
16	O
min	O
22	O
s	O
±	O
7	O
min	O
39	O
s	O
vs.	O
10	O
min	O
47	O
s	O
±	O
5	O
min	O
58	O
s	O
)	O
.	O

With	O
FiO2	O
0.50	O
,	O
SpO2	B-P
(	O
99	O
±	O
0	O
%	O
)	O
and	O
QMTO	O
(	O
69	O
±	O
8	O
%	O
)	O
were	O
higher	O
than	O
the	O
corresponding	O
isotime	O
values	O
to	O
end-exercise	O
with	O
FiO2	O
0.21	O
(	O
SpO2	B-P
96	O
±	O
4	O
%	O
,	O
QMTO	O
66	O
±	O
9	O
%	O
)	O
,	O
while	O
minute	O
ventilation	O
was	O
lower	O
in	O
hyperoxia	O
(	O
82	O
±	O
18	O
vs.	O
93	O
±	O
23	O
L/min	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
healthy	O
subjects	O
,	O
hyperoxia	O
increased	O
maximal	O
power	O
output	O
and	O
endurance	O
.	O

It	O
improved	O
arterial	O
,	O
cerebral	O
,	O
and	O
muscle	O
tissue	O
oxygenation	O
,	O
while	O
minute	O
ventilation	O
and	O
dyspnea	O
perception	O
were	O
reduced	O
.	O

The	O
findings	O
suggest	O
that	O
hyperoxia	O
enhanced	O
cycling	O
performance	O
through	O
a	O
more	O
efficient	O
pulmonary	O
gas	O
exchange	O
and	O
a	O
greater	O
availability	O
of	O
oxygen	O
to	O
muscles	O
and	O
the	O
brain	O
(	O
cerebral	O
motor	O
and	O
sensory	O
neurons	O
)	O
.	O

In	O
Vivo	O
Visualization	B-P
of	O
Cardiomyocyte	O
Apicobasal	O
Polarity	O
Reveals	O
Epithelial	O
to	O
Mesenchymal-like	O
Transition	O
during	O
Cardiac	O
Trabeculation	O
.	O

Despite	O
great	O
strides	O
in	O
understanding	O
cardiac	O
trabeculation	O
,	O
many	O
mechanistic	O
aspects	O
remain	O
unclear	O
.	O

To	O
elucidate	O
how	O
cardiomyocyte	O
shape	O
changes	O
are	O
regulated	O
during	O
this	O
process	O
,	O
we	O
engineered	O
transgenes	O
to	O
label	O
their	O
apical	O
and	O
basolateral	O
membranes	O
.	O

Using	O
these	O
tools	O
,	O
we	O
observed	O
that	O
compact-layer	O
cardiomyocytes	O
are	O
clearly	O
polarized	O
while	O
delaminating	O
cardiomyocytes	O
have	O
lost	O
their	O
polarity	O
.	O

The	O
apical	O
transgene	O
also	O
enabled	O
the	O
imaging	B-P
of	O
cardiomyocyte	O
apical	O
constriction	O
in	O
real	O
time	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
Neuregulin	O
signaling	O
and	O
blood	O
flow	O
/	O
cardiac	O
contractility	O
are	O
required	O
for	O
cardiomyocyte	O
apical	O
constriction	O
and	O
depolarization	O
.	O

Notably	O
,	O
we	O
observed	O
the	O
activation	O
of	O
Notch	O
signaling	O
in	O
cardiomyocytes	O
adjacent	O
to	O
those	O
undergoing	O
apical	O
constriction	O
,	O
and	O
we	O
showed	O
that	O
this	O
activation	O
is	O
positively	O
regulated	O
by	O
Neuregulin	O
signaling	O
.	O

Inhibition	O
of	O
Notch	O
signaling	O
did	O
not	O
increase	O
the	O
percentage	O
of	O
cardiomyocytes	O
undergoing	O
apical	O
constriction	O
or	O
of	O
trabecular	O
cardiomyocytes	O
.	O

These	O
studies	O
provide	O
information	O
about	O
cardiomyocyte	O
polarization	O
and	O
enhance	O
our	O
understanding	O
of	O
the	O
complex	O
mechanisms	O
underlying	O
ventricular	O
morphogenesis	O
and	O
maturation	O
.	O

Identification	O
and	O
characterization	O
of	O
Dichelobacter	O
nodosus	O
serogroup	O
H	O
from	O
ovine	O
footrot	O
in	O
India	O
.	O

A	O
total	O
of	O
56	O
foot	O
swabs	O
were	O
collected	O
from	O
inter	O
digital	O
spaces	O
of	O
sheep	O
with	O
footrot	O
lesions	O
were	O
screened	B-P
for	O
16	O
rRNA	O
of	O
Dichelobacter	O
nodosus	O
by	O
PCR	O
.	O

Out	O
of	O
the	O
56	O
samples	O
,	O
38	O
(	O
67.85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	O
.	O

All	O
the	O
positive	O
samples	O
were	O
subjected	O
to	O
multiplex	O
PCR	O
targeting	O
fimA	O
gene	O
for	O
identification	O
of	O
serogroups	O
of	O
D.	O
nodosus	O
.	O

Serogroup	O
H	O
was	O
found	O
along	O
with	O
serogroup	O
B	O
in	O
12	O
(	O
55.26	O
%	O
)	O
samples	O
and	O
with	O
serogroup	O
I	O
in	O
8	O
(	O
22.2	O
%	O
)	O
samples	O
.	O

The	O
serogroup	O
H	O
was	O
identified	O
for	O
the	O
first	O
time	O
from	O
the	O
Indian	O
subcontinent	O
.	O

The	O
phylogenetic	O
analysis	O
of	O
the	O
present	O
sequence	O
with	O
the	O
available	O
serogroup	O
H	O
sequences	O
of	O
GenBank	O
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	O
H1	O
.	O

Protocol	O
for	O
intraoperative	O
assessment	O
of	O
the	O
human	O
cerebrovascular	O
glycocalyx	O
.	O

Adequate	O
functioning	O
of	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
is	O
important	O
for	O
brain	O
homoeostasis	O
and	O
normal	O
neuronal	O
function	O
.	O

Disruption	O
of	O
the	O
BBB	O
has	O
been	O
described	O
in	O
several	O
neurological	O
diseases	O
.	O

Recent	O
reports	O
suggest	O
that	O
an	O
increased	O
permeability	O
of	O
the	O
BBB	O
also	O
contributes	O
to	O
increased	O
seizure	O
susceptibility	O
in	O
patients	O
with	O
epilepsy	O
.	O

The	O
endothelial	O
glycocalyx	O
is	O
coating	O
the	O
luminal	O
side	O
of	O
the	O
endothelium	O
and	O
can	O
be	O
considered	O
as	O
the	O
first	O
barrier	O
of	O
the	O
BBB	O
.	O

We	O
hypothesise	O
that	O
an	O
altered	O
glycocalyx	O
thickness	O
plays	O
a	O
role	O
in	O
the	O
aetiology	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
the	O
most	O
common	O
type	O
of	O
epilepsy	O
.	O

Here	O
,	O
we	O
propose	O
a	O
protocol	O
that	O
allows	O
intraoperative	O
assessment	O
of	O
the	O
cerebrovascular	O
glycocalyx	O
thickness	O
in	O
patients	O
with	O
TLE	O
and	O
assess	O
whether	O
its	O
thickness	O
is	O
decreased	O
in	O
patients	O
with	O
TLE	O
when	O
compared	O
with	O
controls	O
.	O

This	O
protocol	O
is	O
designed	O
as	O
a	O
prospective	O
observational	O
case-control	O
study	O
in	O
patients	O
who	O
undergo	O
resective	O
brain	O
surgery	O
as	O
treatment	O
for	O
TLE	O
.	O

Control	O
subjects	O
are	O
patients	O
without	O
a	O
history	O
of	O
epileptic	O
seizures	O
,	O
who	O
undergo	O
a	O
craniotomy	O
or	O
burr	O
hole	O
surgery	O
for	O
other	O
indications	O
.	O

Intraoperative	O
glycocalyx	O
thickness	O
measurements	O
of	O
sublingual	O
,	O
cortical	O
and	O
hippocampal	O
microcirculation	O
are	O
performed	O
by	O
video	O
microscopy	O
using	O
sidestream	B-P
dark-field	I-P
imaging	I-P
.	O

Demographic	O
details	O
,	O
seizure	O
characteristics	O
,	O
epilepsy	O
risk	O
factors	O
,	O
intraoperative	O
haemodynamic	O
parameters	O
and	O
histopathological	O
evaluation	O
are	O
additionally	O
recorded	O
.	O

This	O
protocol	O
has	O
been	O
ethically	O
approved	O
by	O
the	O
local	O
medical	O
ethical	O
committee	O
(	O
ID	O
:	O
NL51594.068.14	O
)	O
and	O
complies	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
principles	O
of	O
Good	O
Clinical	O
Practice	O
.	O

Informed	O
consent	O
is	O
obtained	O
before	O
study	O
enrolment	O
and	O
only	O
coded	O
data	O
will	O
be	O
stored	O
in	O
a	O
secured	O
database	O
,	O
enabling	O
an	O
audit	O
trail	O
.	O

Results	O
will	O
be	O
submitted	O
to	O
international	O
peer-reviewed	O
journals	O
and	O
presented	O
at	O
international	O
conferences	O
.	O

NTR5568	O
.	O

Development	O
of	O
the	O
pediatric	O
quality	O
of	O
life	O
inventory	O
neurofibromatosis	O
type	O
1	O
module	O
items	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
:	O
qualitative	O
methods	O
.	O

Health-related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	O
measures	O
in	O
evaluating	O
effectiveness	O
of	O
clinical	O
treatments	O
.	O

At	O
present	O
,	O
there	O
is	O
no	O
disease	O
-	O
specific	O
outcome	O
measure	O
to	O
assess	O
the	O
HRQOL	O
of	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
with	O
Neurofibromatosis	O
Type	O
1	O
(	O
NF1	O
)	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
the	O
items	O
and	O
support	O
the	O
content	O
validity	O
for	O
the	O
Pediatric	O
Quality	O
of	O
Life	O
Inventory™	O
(	O
PedsQL™	O
)	O
NF1	O
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
iterative	O
process	O
included	O
multiphase	O
qualitative	O
methods	O
including	O
a	O
literature	O
review	O
,	O
survey	O
of	O
expert	O
opinions	O
,	O
semi-structured	O
interviews	O
,	O
cognitive	O
interviews	O
and	O
pilot	O
testing	O
.	O

Fifteen	O
domains	O
were	O
derived	O
from	O
the	O
qualitative	O
methods	O
,	O
with	O
content	O
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	O
.	O

The	O
domains	O
include	O
skin	O
,	O
pain	O
,	O
pain	O
impact	O
,	O
pain	O
management	O
,	O
cognitive	O
functioning	O
,	O
speech	O
,	O
fine	O
motor	O
,	O
balance	O
,	O
vision	O
,	O
perceived	O
physical	O
appearance	O
,	O
communication	O
,	O
worry	O
,	O
treatment	O
,	O
medicines	O
and	O
gastrointestinal	O
symptoms	O
.	O

This	O
study	O
is	O
limited	O
because	O
all	O
participants	O
are	O
recruited	O
from	O
a	O
single	O
-	O
site	O
.	O

Qualitative	O
methods	O
support	O
the	O
content	O
validity	O
for	O
the	O
PedsQL™	O
NF1	O
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
PedsQL™	O
NF1	O
Module	O
is	O
now	O
undergoing	O
national	O
multisite	O
field	O
testing	O
for	O
the	O
psychometric	B-P
validation	O
of	O
the	O
instrument	O
development	O
.	O

Ammonia	O
as	O
an	O
In	O
Situ	O
Sanitizer	O
:	O
Influence	O
of	O
Virus	O
Genome	O
Type	O
on	O
Inactivation	O
.	O

Treatment	O
of	O
human	O
excreta	O
and	O
animal	O
manure	O
(	O
HEAM	O
)	O
is	O
key	O
in	O
controlling	O
the	O
spread	O
of	O
persistent	O
enteric	O
pathogens	O
,	O
such	O
as	O
viruses	O
.	O

The	O
extent	O
of	O
virus	O
inactivation	O
during	O
HEAM	O
storage	O
and	O
treatment	O
appears	O
to	O
vary	O
with	O
virus	O
genome	O
type	O
,	O
although	O
the	O
reasons	O
for	O
this	O
variability	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
inactivation	O
of	O
viruses	O
of	O
different	O
genome	O
types	O
under	O
conditions	O
representative	O
of	O
HEAM	O
storage	O
or	O
mesophilic	O
digestion	O
.	O

The	O
goals	O
were	O
to	O
characterize	O
the	O
influence	O
of	O
HEAM	O
solution	O
conditions	O
on	O
inactivation	O
and	O
to	O
determine	O
the	O
potential	O
mechanisms	O
involved	O
.	O

Specifically	O
,	O
eight	O
viruses	O
representing	O
the	O
four	O
viral	O
genome	O
types	O
(	O
single-stranded	O
RNA	O
[	O
ssRNA	O
]	O
,	O
double-stranded	O
RNA	O
[	O
dsRNA	O
]	O
,	O
single-stranded	O
DNA	O
[	O
ssDNA	O
]	O
,	O
and	O
double-stranded	O
DNA	O
[	O
dsDNA	O
]	O
)	O
were	O
exposed	O
to	O
synthetic	O
solutions	O
with	O
well-controlled	O
temperature	O
(	O
20	O
to	O
35°C	O
)	O
,	O
pH	O
(	O
8	O
to	O
9	O
)	O
,	O
and	O
ammonia	O
(	O
NH3	O
)	O
concentrations	O
(	O
0	O
to	O
40	O
mmol	O
liter	O
(	O
-1	O
)	O
)	O
.	O

DNA	O
and	O
dsRNA	O
viruses	O
were	O
considerably	O
more	O
resistant	O
than	O
ssRNA	O
viruses	O
,	O
resulting	O
in	O
up	O
to	O
1,000-fold-longer	O
treatment	O
times	O
to	O
reach	O
a	O
4-log	O
inactivation	O
.	O

The	O
apparently	O
slower	O
inactivation	O
of	O
DNA	O
viruses	O
was	O
rationalized	O
by	O
the	O
higher	O
stability	B-P
of	O
DNA	O
than	O
that	O
of	O
ssRNA	O
in	O
HEAM	O
.	O

Pushing	O
the	O
system	O
toward	O
harsher	O
pH	O
(	O
>	O
9	O
)	O
and	O
temperature	O
(	O
>	O
35°C	O
)	O
conditions	O
,	O
such	O
as	O
those	O
encountered	O
in	O
thermophilic	O
digestion	O
and	O
alkaline	O
treatments	O
,	O
led	O
to	O
more	O
consistent	O
inactivation	O
kinetics	O
among	O
ssRNA	O
and	O
other	O
viruses	O
.	O

This	O
suggests	O
that	O
the	O
dependence	O
of	O
inactivation	O
on	O
genome	O
type	O
disappeared	O
in	O
favor	O
of	O
protein	O
-mediated	O
inactivation	O
mechanisms	O
common	O
to	O
all	O
viruses	O
.	O

Finally	O
,	O
we	O
recommend	O
the	O
use	O
of	O
MS2	O
as	O
a	O
conservative	O
indicator	O
to	O
assess	O
the	O
inactivation	O
of	O
ssRNA	O
viruses	O
and	O
the	O
stable	O
ΦX174	O
or	O
dsDNA	O
phages	O
as	O
indicators	O
for	O
persistent	O
viruses	O
.	O

Viruses	O
are	O
among	O
the	O
most	O
environmentally	O
persistent	O
pathogens	O
.	O

They	O
can	O
be	O
present	O
in	O
high	O
concentrations	O
in	O
human	O
excreta	O
and	O
animal	O
manure	O
(	O
HEAM	O
)	O
.	O

Therefore	O
,	O
appropriate	O
treatment	O
of	O
HEAM	O
is	O
important	O
prior	O
to	O
its	O
reuse	O
or	O
discharge	O
into	O
the	O
environment	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
factors	O
that	O
determine	O
the	O
persistence	O
of	O
viruses	O
in	O
HEAM	O
,	O
and	O
we	O
determined	O
the	O
main	O
mechanisms	O
that	O
lead	O
to	O
their	O
inactivation	O
.	O

Unlike	O
other	O
organisms	O
,	O
viruses	O
can	O
have	O
four	O
different	O
genome	O
types	O
(	O
double-	O
or	O
single-stranded	O
RNA	O
or	O
DNA	O
)	O
,	O
and	O
the	O
viruses	O
studied	O
herein	O
represent	O
all	O
four	O
types	O
.	O

Genome	O
type	O
appeared	O
to	O
be	O
the	O
major	O
determinant	O
for	O
persistence	O
.	O

Single-stranded	O
RNA	O
viruses	O
are	O
the	O
most	O
labile	O
,	O
because	O
this	O
genome	O
type	O
is	O
susceptible	O
to	O
degradation	O
in	O
HEAM	O
.	O

In	O
contrast	O
,	O
the	O
other	O
genome	O
types	O
are	O
more	O
stable	O
;	O
therefore	O
,	O
inactivation	O
is	O
slower	O
and	O
mainly	O
driven	O
by	O
the	O
degradation	O
of	O
viral	O
proteins	O
.	O

Overall	O
,	O
this	O
study	O
allows	O
us	O
to	O
better	O
understand	O
the	O
behavior	O
of	O
viruses	O
in	O
HEAM	O
.	O

Design	O
considerations	O
for	O
patient-specific	O
surgical	O
templates	O
for	O
total	O
hip	O
arthroplasty	O
with	O
respect	O
to	O
acetabular	O
cartilage	O
.	O

Patient-specific	O
instruments	O
(	O
PSIs	O
)	O
are	O
clinically	O
used	O
to	O
support	O
the	O
surgeon	O
during	O
a	O
planned	O
intervention	O
.	O

The	O
planning	O
is	O
typically	O
done	O
based	O
on	O
volumetric	O
image	O
data	O
from	O
medical	B-P
imaging	I-P
systems	O
,	O
e.g	O
.	O

computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

The	O
PSI	O
uses	O
the	O
known	O
surface	O
structure	O
of	O
a	O
bone	O
for	O
orientation	O
during	O
the	O
intervention	O
.	O

Some	O
surfaces	O
of	O
human	O
bone	O
are	O
covered	O
with	O
a	O
layer	O
of	O
cartilage	O
which	O
is	O
hardly	O
visible	O
in	O
clinically	O
applied	O
CT-imaging	B-P
.	O

This	O
experimental	O
study	O
investigates	O
ten	O
different	O
PSI	O
designs	O
and	O
their	O
effect	O
to	O
the	O
overall	O
accuracy	O
when	O
neglecting	O
the	O
cartilage	O
in	O
the	O
design	O
process	O
.	O

Therefore	O
,	O
a	O
model	O
of	O
an	O
acetabulum	O
is	O
used	O
to	O
simulate	O
the	O
use	O
case	O
of	O
PSI	O
in	O
total	O
hip	O
arthroplasty	O
.	O

The	O
concept	O
of	O
the	O
different	O
designs	O
is	O
to	O
create	O
structural	O
elasticities	O
in	O
the	O
PSI	O
to	O
avoid	O
shifting	O
of	O
the	O
whole	O
instrument	O
and	O
rather	O
have	O
a	O
small	O
part	O
of	O
it	O
deformed	O
by	O
cartilage	O
.	O

A	O
needle	O
array	O
structure	O
,	O
for	O
instance	O
,	O
should	O
also	O
be	O
able	O
to	O
oust	O
or	O
penetrate	O
remaining	O
soft	O
tissue	O
in	O
the	O
acetabulum	O
.	O

Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	O
Progression	O
of	O
Cerebral	O
Contusions	O
in	O
Moderate	O
and	O
Severe	O
Traumatic	O
Brain	O
Injury	O
.	O

After	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
,	O
hemorrhagic	O
progression	O
of	O
contusions	O
(	O
HPCs	O
)	O
occurs	O
frequently	O
.	O

However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high-risk	O
patients	O
for	O
HPC	O
.	O

Consecutive	O
patients	O
who	O
were	O
hospitalized	O
(	O
2008-2013	O
)	O
with	O
non-penetrating	O
moderate	O
or	O
severe	O
TBI	O
were	O
studied	O
.	O

The	O
primary	O
outcome	O
was	O
HPC	O
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	O
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O

Logistic	O
regression	O
models	O
were	O
created	O
to	O
identify	O
independent	O
risk	O
factors	O
for	O
HPC	O
.	O

The	O
HPC	O
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	O
model	O
.	O

Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	O
,	O
61	O
(	O
21	O
%	O
)	O
patients	O
developed	O
HPC	O
.	O

On	O
univariate	O
analyses	O
,	O
HPC	O
was	O
associated	O
with	O
older	O
age	O
,	O
higher	O
initial	O
blood	O
pressure	O
,	O
antiplatelet	O
medications	O
,	O
anticoagulants	O
,	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
subdural	O
hematoma	O
(	O
SDH	O
)	O
,	O
skull	O
fracture	O
,	O
frontal	O
contusion	O
,	O
larger	O
contusion	O
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	O
to	O
initial	B-P
CT	I-P
.	O

In	O
the	O
final	O
model	O
,	O
SAH	O
(	O
OR	O
6.33	O
,	O
95	O
%	O
CI	O
,	O
1.80-22.23	O
)	O
,	O
SDH	O
(	O
OR	O
3.46	O
,	O
95	O
%	O
CI	O
,	O
1.39-8.63	O
)	O
,	O
and	O
skull	O
fracture	O
(	O
OR	O
2.67	O
,	O
95	O
%	O
CI	O
,	O
1.28-5.58	O
)	O
were	O
associated	O
with	O
HPC	O
.	O

Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	O
Score	O
was	O
derived	O
(	O
SAH	O
=	O
2	O
points	O
,	O
SDH	O
=	O
1	O
point	O
,	O
and	O
skull	O
fracture	O
=	O
1	O
point	O
)	O
.	O

This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0.77	O
.	O

Patients	O
with	O
a	O
score	O
of	O
0-2	O
had	O
a	O
4.0	O
%	O
incidence	O
of	O
HPC	O
,	O
while	O
patients	O
with	O
a	O
score	O
of	O
3-4	O
had	O
a	O
34.6	O
%	O
incidence	O
of	O
HPC	O
.	O

A	O
simple	O
HPC	O
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
TBI	O
.	O

Components	O
of	O
treatment	O
delay	O
in	O
rheumatoid	O
arthritis	O
differ	O
according	O
to	O
autoantibody	O
status	O
:	O
validation	O
of	O
a	O
single-centre	O
observation	O
using	O
national	O
audit	O
data	O
.	O

To	O
determine	O
whether	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O
RA	O
patients	O
according	O
to	O
autoantibody	O
status	O
.	O

A	O
single-centre	O
retrospective	O
analysis	O
of	O
a	O
UK	O
early	O
RA	O
inception	O
cohort	O
was	O
first	O
undertaken	O
to	O
identify	O
those	O
components	O
of	O
the	O
patient	O
journey	O
that	O
differed	O
by	O
serological	O
subtype	O
.	O

Data	O
from	O
a	O
UK	O
national	O
audit	O
of	O
early	O
inflammatory	O
arthritis	O
patients	O
was	O
accessed	O
to	O
replicate	O
the	O
key	O
finding	O
.	O

A	O
total	O
of	O
173	O
RA	O
patients	O
were	O
diagnosed	B-P
over	O
a	O
31-	O
month	O
period	O
,	O
of	O
whom	O
80	O
(	O
46	O
%	O
)	O
were	O
ACPA/RF	O
double-seropositive	O
(	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
)	O
,	O
53	O
(	O
31	O
%	O
)	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
,	O
17	O
(	O
10	O
%	O
)	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
-	O
)	O
and	O
23	O
(	O
13	O
%	O
)	O
RF	O
(	O
+	O
)	O
/ACPA	O
(	O
-	O
)	O
Overall	O
,	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
experienced	O
significantly	O
longer	O
symptom	O
duration	O
before	O
DMARD	O
initiation	O
.	O

This	O
was	O
accounted	O
for	O
by	O
delays	O
in	O
their	O
presentation	O
to	O
primary	O
care	O
following	O
symptom	O
onset	O
-a	O
finding	O
that	O
was	O
robustly	O
confirmed	O
in	O
an	O
independent	O
dataset	O
of	O
2192	O
UK	O
early	O
RA	O
patients	O
.	O

In	O
contrast	O
,	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
delays	O
in	O
DMARD	O
initiation	O
after	O
presenting	O
to	O
secondary	O
care	O
.	O

Causes	O
of	O
treatment	O
delays	O
in	O
early	O
RA	O
differ	O
according	O
to	O
patients	O
'	O
autoantibody	O
status	O
.	O

More	O
insidious	O
symptom	O
onset	O
and/or	O
distinct	O
health-seeking	O
behaviours	O
among	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
may	O
contribute	O
to	O
late	O
presentations	O
in	O
primary	O
care	O
,	O
whereas	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
experience	O
delayed	O
diagnosis	O
and	O
treatment	O
in	O
secondary	O
care	O
.	O

These	O
observations	O
inform	O
the	O
research	O
agenda	O
,	O
potentially	O
influencing	O
the	O
design	O
of	O
service	O
delivery	O
for	O
early	O
arthritis	O
patients	O
.	O

When	O
water	O
is	O
thicker	O
than	O
blood	O
:	O
recognising	O
a	O
systemic	O
cause	O
of	O
haemoptysis	O
.	O

The	O
case	O
of	O
an	O
11-	O
year-old	O
child	O
presenting	O
with	O
acute	O
haemoptysis	O
and	O
breathlessness	O
is	O
described	O
.	O

The	O
girl	O
was	O
Malaysian	O
and	O
had	O
recently	O
arrived	O
in	O
the	O
UK	O
.	O

She	O
subsequently	O
deteriorated	O
,	O
developing	O
respiratory	O
failure	O
.	O

The	O
course	O
of	O
the	O
illness	O
is	O
described	O
,	O
with	O
reference	O
to	O
the	O
diagnostic	B-P
process	I-P
at	O
each	O
stage	O
.	O

The	O
case	O
demonstrates	O
the	O
importance	O
of	O
having	O
a	O
broad	O
investigatory	O
approach	O
in	O
acute	O
haemoptysis	O
.	O

A	O
pilot	O
study	O
on	O
transient	O
ischemic	O
stroke	O
induced	O
with	O
endothelin-1	O
in	O
the	O
rhesus	O
monkeys	O
.	O

Endothelin-1	O
(	O
ET-1	O
)	O
,	O
a	O
vasoconstrictor	O
,	O
has	O
recently	O
been	O
used	O
to	O
induce	O
focal	O
ischemia	O
in	O
rodents	O
and	O
marmoset	O
monkeys	O
.	O

The	O
rhesus	O
monkey	O
,	O
however	O
,	O
has	O
numerous	O
advantages	O
to	O
the	O
rodent	O
and	O
marmoset	O
that	O
make	O
it	O
a	O
superior	O
and	O
irreplaceable	O
animal	O
model	O
for	O
studying	O
stroke	O
in	O
the	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
after	O
mapping	O
the	O
preferred	O
hand	O
representation	O
in	O
two	O
healthy	O
male	O
monkeys	O
with	O
intracortical	O
micro-stimulation	O
,	O
ET-1	O
was	O
microinjected	O
into	O
the	O
contralateral	O
motor	O
cortex	O
(	O
M1	O
)	O
to	O
its	O
preferred	O
hand	O
.	O

The	O
monkeys	O
had	O
been	O
trained	O
in	O
three	O
manual	O
dexterity	O
tasks	O
before	O
the	O
microinjection	O
and	O
were	O
tested	O
for	O
these	O
tasks	O
following	O
the	O
ET-1	O
injection	O
.	O

Brain	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
scans	I-P
were	O
performed	O
1	O
,	O
7	O
,	O
14	O
and	O
28	O
days	O
post	O
ischemia	O
.	O

It	O
was	O
found	O
that	O
ET-1	O
impaired	O
the	O
manual	O
dexterity	O
of	O
the	O
monkeys	O
in	O
the	O
vertical	O
slot	O
and	O
rotating	O
Brinkman	O
board	O
tasks	O
3-8	O
days	O
after	O
the	O
injection	O
.	O

Brain	B-P
imaging	I-P
found	O
that	O
severe	O
edema	O
was	O
present	O
7	O
days	O
after	O
the	O
focal	O
ischemia	O
.	O

This	O
data	O
suggest	O
that	O
ET-1	O
can	O
induce	O
transient	O
ischemic	O
stroke	O
in	O
rhesus	O
monkey	O
and	O
that	O
ET-1	O
induced	O
focal	O
ischemia	O
in	O
non-human	O
primates	O
is	O
a	O
potential	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
stroke	O
and	O
brain	O
repair	O
after	O
stroke	O
.	O

Extraskeletal	O
osteosarcoma	O
of	O
the	O
orbit	O
:	O
A	O
clinicopathologic	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

Primary	O
extraskeletal	O
osteosarcoma	O
(	O
EOS	O
)	O
is	O
an	O
extremely	O
rare	O
malignancy	O
.	O

In	O
this	O
report	O
,	O
the	O
clinical	O
course	O
of	O
a	O
32-year-old	O
man	O
presenting	O
with	O
proptoses	O
is	O
described	O
.	O

Medical	O
history	O
included	O
Hirschsprung	O
disease	O
(	O
HD	O
)	O
,	O
horseshoe	O
kidney	O
,	O
azoospermia	O
,	O
and	O
vertebral	O
anomalies	O
.	O

Imaging	O
of	O
the	O
orbit	O
showed	O
an	O
oval	O
,	O
well-defined	O
heterogeneous	O
mass	O
adjacent	O
to	O
the	O
lateral	O
wall	O
of	O
the	O
orbit	O
.	O

The	O
patient	O
underwent	O
a	O
lateral	O
orbit	O
otomy	O
and	O
complete	O
excision	O
of	O
the	O
mass	O
.	O

The	O
mass	O
was	O
not	O
attached	O
to	O
the	O
bone	O
.	O

Histopathologic	O
and	O
immunohistochemical	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
an	O
EOS	O
.	O

The	O
patient	O
received	O
chemotherapy	O
and	O
radiotherapy	O
and	O
is	O
free	O
of	O
the	O
disease	O
3	O
years	O
after	O
the	O
diagnosis	O
.	O

Genetic	B-P
screening	I-P
showed	O
no	O
mutations	O
for	O
both	O
the	O
RET	O
proto-oncogene	O
for	O
HD	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
for	O
osteosarcoma	O
.	O

Methylation	O
Analysis	O
of	O
BRCA1	O
and	O
APC	O
in	O
Breast	O
Cancer	O
and	O
It	O
's	O
Relationship	O
to	O
Clinicopathological	O
Features	O
.	O

Promoter	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
is	O
an	O
important	O
epigenetic	O
alteration	O
that	O
occurs	O
in	O
the	O
primary	O
stages	O
of	O
human	O
tumors	O
,	O
including	O
breast	O
cancer	O
.	O

Identification	O
of	O
methylated	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
features	O
can	O
contribute	O
to	O
the	O
prognosis	O
and	O
early	B-P
detection	I-P
of	O
tumors	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
factors	O
in	O
breast	O
cancer	O
patients	O
.	O

BRCA1	O
and	O
APC	O
promoter	O
methylation	O
was	O
examined	O
by	O
methylation	O
-	O
specific	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
(	O
MS-MLPA	O
)	O
assay	O
in	O
formalin-fixed	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
breast	O
tissue	O
from	O
75	O
patients	O
.	O

APC	O
promoter	O
methylation	O
was	O
detected	O
in	O
30.67	O
%	O
breast	O
cancer	O
tissues	O
and	O
BRCA1	O
was	O
methylated	O
in	O
9.33	O
%	O
of	O
breast	O
tumors	O
.	O

Methylation	O
of	O
APC	O
was	O
associated	O
with	O
low	O
histological	O
grade	O
(	O
p	O
=	O
0.006	O
)	O
and	O
methylation	O
of	O
BRCA1	O
was	O
related	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
=	O
0.017	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
can	O
be	O
a	O
predictive	O
marker	O
for	O
early	B-P
detection	I-P
and	O
better	O
management	O
of	O
breast	O
cancer	O
patients	O
.	O

Reduced	O
Chest	O
and	O
Abdominal	O
Wall	O
Mobility	O
and	O
Their	O
Relationship	O
to	O
Lung	O
Function	O
,	O
Respiratory	O
Muscle	O
Strength	O
,	O
and	O
Exercise	O
Tolerance	O
in	O
Subjects	O
With	O
COPD	O
.	O

Advanced	O
air-flow	O
limitation	O
in	O
patients	O
with	O
COPD	O
leads	O
to	O
a	O
reduction	O
in	O
vital	O
capacity	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O

However	O
,	O
its	O
impact	O
on	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
is	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	O
of	O
patients	O
with	O
COPD	O
with	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
on	O
pulmonary	O
function	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O

In	O
51	O
elderly	O
male	O
subjects	O
with	O
COPD	O
,	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
,	O
FVC	O
,	O
FEV1	B-P
,	O
FEV1/FVC	O
,	O
maximal	B-P
inspiratory	I-P
pressure	I-P
(	O
PImax	B-P
)	O
,	O
maximal	B-P
expiratory	I-P
pressure	I-P
(	O
PEmax	B-P
)	O
,	O
and	O
the	O
6-min	B-P
walk	I-P
distance	I-P
(	O
6MWD	B-P
)	O
were	O
assessed	O
.	O

Chest	O
and	O
abdominal	O
wall	O
mobility	O
were	O
measured	O
using	O
the	O
breathing	O
movement	O
scale	O
(	O
0-8	O
)	O
at	O
the	O
3	O
regions	O
(	O
upper	O
chest	O
,	O
lower	O
chest	O
,	O
and	O
abdomen	O
)	O
.	O

Reduced	O
mobility	O
was	O
defined	O
as	O
a	O
value	O
lower	O
than	O
the	O
lower	O
limit	O
of	O
the	O
normal	O
scale	O
.	O

The	O
unpaired	O
t	O
test	O
,	O
Mann-Whitney	O
test	O
,	O
and	O
multiple	O
regression	O
analysis	O
were	O
performed	O
.	O

The	O
percentages	O
of	O
subjects	O
with	O
reduced	O
mobility	O
were	O
78	O
%	O
for	O
the	O
upper	O
chest	O
,	O
76	O
%	O
for	O
the	O
lower	O
chest	O
,	O
and	O
53	O
%	O
for	O
the	O
abdomen	O
.	O

The	O
subjects	O
with	O
reduced	O
mobility	O
had	O
significantly	O
low	O
FVC	O
,	O
FEV1	B-P
,	O
and	O
6MWD	B-P
in	O
each	O
region	O
and	O
significantly	O
low	O
FEV1/FVC	O
,	O
PImax	B-P
,	O
and	O
PEmax	B-P
in	O
the	O
abdominal	O
region	O
compared	O
with	O
those	O
with	O
nonreduced	O
mobility	O
.	O

FVC	O
and	O
6MWD	B-P
were	O
independently	O
associated	O
with	O
the	O
scale	O
values	O
in	O
each	O
region	O
and	O
with	O
the	O
abdominal	O
scale	O
value	O
,	O
respectively	O
.	O

The	O
majority	O
of	O
subjects	O
with	O
COPD	O
had	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
,	O
which	O
was	O
independently	O
associated	O
with	O
FVC	O
.	O

Even	O
though	O
abdominal	O
wall	O
mobility	O
was	O
relatively	O
preserved	O
compared	O
with	O
chest	O
wall	O
mobility	O
,	O
it	O
was	O
also	O
independently	O
associated	O
with	O
6MWD	B-P
.	O

Metabolic	O
responses	O
of	O
the	O
growing	O
Daphnia	O
similis	O
to	O
chronic	O
AgNPs	O
exposure	O
as	O
revealed	O
by	O
GC-Q-TOF/MS	O
and	O
LC-Q-TOF/MS	O
.	O

Silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	O
.	O

Their	O
fast-growing	O
utilization	O
has	O
increased	O
the	O
occurrence	O
of	O
AgNPs	O
in	O
the	O
environment	O
,	O
posing	O
potential	O
health	O
and	O
ecological	O
risks	O
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-P
toxicity	I-P
tests	I-P
and	O
investigated	O
the	O
metabolic	O
changes	O
of	O
the	O
growing	O
Daphna	O
similis	O
with	O
exposure	O
to	O
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
AgNPs	O
,	O
using	O
non-targeted	O
mass	O
spectrometry	O
-based	O
metabolomics	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	O
metabolite	O
change	O
of	O
a	O
common	O
aquatic	O
organism	O
Daphnia	O
crustacean	O
through	O
its	O
life-cycle	O
.	O

The	O
results	O
show	O
a	O
dynamic	O
kinetic	O
pattern	O
of	O
the	O
growing	O
Daphnia	O
's	O
metabolome	O
underwent	O
a	O
cycle	O
from	O
day	O
0	O
to	O
day	O
21	O
,	O
with	O
the	O
level	O
of	O
metabolites	O
gradually	O
increasing	O
from	O
day	O
0	O
to	O
day	O
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	O
level	O
of	O
day	O
0	O
on	O
day	O
21	O
.	O

As	O
for	O
the	O
samples	O
exposed	O
to	O
environmental	O
concentrations	O
of	O
AgNPs	O
,	O
although	O
without	O
morphological	O
or	O
structural	O
changes	O
,	O
numerous	O
metabolite	O
changes	O
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	O
,	O
and	O
these	O
changes	O
reached	O
steady	O
state	O
by	O
day	O
13	O
.	O

The	O
significant	O
changes	O
in	O
certain	O
metabolites	O
,	O
such	O
as	O
amino	O
acids	O
(	O
serine	O
,	O
threonine	O
and	O
tyrosine	O
)	O
,	O
sugars	O
(	O
d-allose	O
)	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	O
in	O
Daphnia	O
respond	O
to	O
chronic	O
AgNPs	O
stress	O
.	O

These	O
findings	O
highlight	O
the	O
capability	O
of	O
metabolomics	O
to	O
discover	O
early	O
metabolic	O
responses	O
to	O
environmental	O
silver	O
nanoparticles	O
.	O

Delayed	O
Axillary	O
Artery	O
Occlusion	O
after	O
Reverse	O
Total	O
Shoulder	O
Arthroplasty	O
.	O

Axillary	O
artery	O
injury	O
has	O
been	O
associated	O
with	O
shoulder	O
dislocation	O
and	O
surgery	O
.	O

We	O
describe	O
a	O
case	O
of	O
delayed	O
axillary	O
artery	O
occlusion	O
after	O
reverse	O
total	O
shoulder	O
arthroplasty	O
.	O

The	O
injury	O
was	O
confirmed	O
by	O
Doppler	B-P
and	O
angiography	B-P
and	O
was	O
treated	O
with	O
angioplasty	O
and	O
stenting	O
.	O

Early	B-P
recognition	I-P
and	O
treatment	O
of	O
this	O
injury	O
are	O
mandatory	O
for	O
patients	O
'	O
recovery	O
.	O

Update	O
on	O
the	O
Role	O
of	O
Cardiac	B-P
Magnetic	I-P
Resonance	I-P
in	O
Acquired	O
Nonischemic	O
Cardiomyopathies	O
.	O

Cardiomyopathies	O
refer	O
to	O
a	O
variety	O
of	O
myocardial	O
disorders	O
without	O
underlying	O
coronary	O
artery	O
disease	O
,	O
valvular	O
heart	O
disease	O
,	O
hypertension	O
,	O
or	O
congenital	O
heart	O
disease	O
.	O

Several	O
imaging	O
modalities	O
are	O
available	O
,	O
but	O
cardiac	B-P
magnetic	I-P
resonance	I-P
(	O
CMR	B-P
)	O
has	O
now	O
established	O
itself	O
as	O
a	O
crucial	O
imaging	B-P
technique	I-P
in	O
the	O
evaluation	O
of	O
several	O
cardiomyopathies	O
.	O

It	O
not	O
only	O
provides	O
comprehensive	O
information	O
on	O
structure	O
and	O
function	O
,	O
but	O
also	O
can	O
perform	O
tissue	O
characterization	O
,	O
which	O
helps	O
in	O
establishing	O
the	O
etiology	O
of	O
cardiomyopathy	O
.	O

CMR	B-P
is	O
also	O
useful	O
in	O
establishing	O
the	O
diagnosis	O
,	O
providing	O
guidance	O
for	O
endomyocardial	B-P
biopsy	I-P
,	O
accurate	O
quantification	O
of	O
function	O
,	O
volumes	O
,	O
and	O
fibrosis	O
,	O
prognostic	O
determination	O
,	O
risk	O
stratification	O
,	O
and	O
monitoring	O
response	O
to	O
therapy	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
current	O
role	O
of	O
CMR	B-P
in	O
the	O
evaluation	O
of	O
several	O
acquired	O
nonischemic	O
cardiomyopathies	O
,	O
particularly	O
focusing	O
on	O
recent	O
advances	O
in	O
knowledge	O
.	O

We	O
also	O
discuss	O
in	O
detail	O
a	O
select	O
group	O
of	O
common	O
acquired	O
nonischemic	O
cardiomyopathies	O
.	O

The	O
impact	O
of	O
childhood	O
maltreatment	O
on	O
the	O
differential	O
efficacy	O
of	O
CBASP	O
versus	O
escitalopram	O
in	O
patients	O
with	O
chronic	O
depression	O
:	O
A	O
secondary	O
analysis	O
.	O

Childhood	O
maltreatment	O
(	O
CM	O
)	O
has	O
been	O
indicated	O
as	O
a	O
predictor	O
of	O
a	O
differential	O
response	O
to	O
antidepressant	O
treatment	O
with	O
psychotherapy	O
compared	O
to	O
medication	O
.	O

In	O
this	O
secondary	O
analysis	O
,	O
we	O
investigated	O
whether	O
the	O
presence	O
of	O
CM	O
results	O
in	O
a	O
differential	O
indication	O
for	O
the	O
Cognitive	O
Behavioral	O
Analysis	O
System	O
of	O
Psychotherapy	O
(	O
CBASP	O
)	O
or	O
escitalopram	O
plus	O
clinical	O
management	O
(	O
ESC	O
)	O
.	O

Sixty	O
patients	O
with	O
chronic	O
depression	O
were	O
randomized	O
to	O
either	O
22	O
sessions	O
of	O
CBASP	O
or	O
ESC	O
over	O
the	O
course	O
of	O
8	O
weeks	O
of	O
acute	O
and	O
20	O
weeks	O
of	O
extended	O
treatment	O
at	O
2	O
German	O
treatment	O
sites	O
.	O

CM	O
was	O
assessed	O
using	O
the	O
Childhood	O
Trauma	O
Questionnaire	O
and	O
the	O
clinician	O
rated	O
Early	O
Trauma	O
Inventory	O
.	O

Intention-to-treat	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
impact	O
of	O
CM	O
on	O
depression	O
,	O
global	B-P
functioning	I-P
,	O
and	O
quality	O
of	O
life	O
.	O

The	O
presence	O
of	O
CM	O
did	O
not	O
result	O
in	O
significant	O
differences	O
in	O
treatment	O
response	O
to	O
CBASP	O
or	O
ESC	O
on	O
any	O
outcome	O
measure	O
after	O
28	O
weeks	O
of	O
treatment	O
independent	O
of	O
the	O
type	O
of	O
CM	O
assessment	O
.	O

After	O
8	O
weeks	O
,	O
a	O
significant	O
CM	O
×	O
treatment	O
interaction	O
was	O
found	O
for	O
scores	O
on	O
the	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
.	O

Patients	O
with	O
a	O
history	O
of	O
CM	O
receiving	O
CBASP	O
had	O
a	O
significantly	O
lower	O
response	O
rate	O
compared	O
to	O
patients	O
without	O
CM	O
and	O
to	O
those	O
receiving	O
ESC	O
after	O
8	O
weeks	O
.	O

Conclusively	O
,	O
CBASP	O
and	O
ESC	O
are	O
equally	O
effective	O
treatment	O
options	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	O
depression	O
and	O
a	O
history	O
of	O
CM	O
.	O

CM	O
may	O
be	O
a	O
predictor	O
of	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	O
.	O

CBASP	O
and	O
escitalopram	O
are	O
equally	O
effective	O
treatment	O
options	O
for	O
chronic	O
depression	O
.	O

Both	O
treatments	O
are	O
also	O
equally	O
effective	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	O
depression	O
and	O
a	O
history	O
of	O
childhood	O
maltreatment	O
.	O

Childhood	O
maltreatment	O
may	O
result	O
in	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	O
.	O

Weighing	O
Scale	O
-Based	O
Pulse	O
Transit	O
Time	O
is	O
a	O
Superior	O
Marker	O
of	O
Blood	O
Pressure	O
than	O
Conventional	O
Pulse	O
Arrival	O
Time	O
.	O

Pulse	O
transit	O
time	O
(	O
PTT	O
)	O
is	O
being	O
widely	O
pursued	O
for	O
cuff-less	O
blood	O
pressure	O
(	O
BP	O
)	O
monitoring	O
.	O

Most	O
efforts	O
have	O
employed	O
the	O
time	O
delay	O
between	O
ECG	B-P
and	O
finger	O
photoplethysmography	B-P
(	O
PPG	B-P
)	O
waveforms	O
as	O
a	O
convenient	O
surrogate	O
of	O
PTT	O
.	O

However	O
,	O
these	O
conventional	O
pulse	O
arrival	O
time	O
(	O
PAT	O
)	O
measurements	O
include	O
the	O
pre-ejection	O
period	O
(	O
PEP	O
)	O
and	O
the	O
time	O
delay	O
through	O
small	O
,	O
muscular	O
arteries	O
and	O
may	O
thus	O
be	O
an	O
unreliable	O
marker	O
of	O
BP	O
.	O

We	O
assessed	O
a	O
bathroom	O
weighing	O
scale-like	O
system	O
for	O
convenient	O
measurement	O
of	O
ballistocardiography	B-P
and	O
foot	O
PPG	B-P
waveforms	O
-	O
and	O
thus	O
PTT	O
through	O
larger	O
,	O
more	O
elastic	O
arteries	O
-	O
in	O
terms	O
of	O
its	O
ability	O
to	O
improve	O
tracking	O
of	O
BP	O
in	O
individual	O
subjects	O
.	O

We	O
measured	O
``	O
scale	O
PTT	O
``	O
,	O
conventional	O
PAT	O
,	O
and	O
cuff	O
BP	O
in	O
humans	O
during	O
interventions	O
that	O
increased	O
BP	O
but	O
changed	O
PEP	O
and	O
smooth	O
muscle	O
contraction	O
differently	O
.	O

Scale	O
PTT	O
tracked	O
the	O
diastolic	O
BP	O
changes	O
well	O
,	O
with	O
correlation	O
coefficient	O
of	O
-0.80	O
±	O
0.02	O
(	O
mean	O
±	O
SE	O
)	O
and	O
root-mean-squared-error	O
of	O
7.6	O
±	O
0.5	O
mmHg	O
after	O
a	O
best-case	O
calibration	O
.	O

Conventional	O
PAT	O
was	O
significantly	O
inferior	O
in	O
tracking	O
these	O
changes	O
,	O
with	O
correlation	O
coefficien	O
t	O
of	O
-0.60	O
±	O
0.04	O
and	O
root-mean-squared-error	O
of	O
14.6	O
±	O
1.5	O
mmHg	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Scale	O
PTT	O
also	O
tracked	O
the	O
systolic	O
BP	O
changes	O
better	O
than	O
conventional	O
PAT	O
but	O
not	O
to	O
an	O
acceptable	O
level	O
.	O

With	O
further	O
development	O
,	O
scale	O
PTT	O
may	O
permit	O
reliable	O
,	O
convenient	O
measurement	O
of	O
BP	O
.	O

Cognitive	O
impairment	O
in	O
first-episode	O
drug-naïve	O
patients	O
with	O
schizophrenia	O
:	O
Relationships	O
with	O
serum	O
concentrations	O
of	O
brain-derived	O
neurotrophic	O
factor	O
and	O
glial	O
cell	O
line-derived	O
neurotrophic	O
factor	O
.	O

Evidence	O
suggests	O
that	O
brain-derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
and	O
glial	O
cell	O
line	O
-derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
are	O
important	O
in	O
the	O
regulation	O
of	O
synaptic	O
plasticity	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	O
processes	O
in	O
psychiatric	O
disorders	O
.	O

Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	O
between	O
serum	O
BDNF	O
and	O
GDNF	O
levels	O
and	O
cognitive	O
functions	O
in	O
first-episode	O
drug-naïve	O
(	O
FEDN	O
)	O
patients	O
with	O
schizophrenia	O
.	O

The	O
BDNF	O
and	O
GDNF	O
levels	O
of	O
58	O
FEDN	O
patients	O
and	O
55	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
were	O
measured	O
and	O
test	O
subjects	O
were	O
examined	O
using	O
several	O
neurocognitive	B-P
tests	I-P
including	O
the	O
verbal	B-P
fluency	I-P
test	I-P
(	O
VFT	B-P
)	O
,	O
the	O
trail	O
making	O
test	O
(	O
TMT	O
)	O
,	O
the	O
digit	O
span	O
test	O
(	O
DST	O
)	O
,	O
and	O
the	O
Stroop	B-P
test	I-P
.	O

Patients	O
performed	O
significantly	O
worse	O
than	O
controls	O
in	O
nearly	O
all	O
neurocognitive	B-P
performances	I-P
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	O
.	O

BDNF	O
levels	O
were	O
inversely	O
correlated	O
to	O
TMT-part	O
B	O
scores	O
and	O
positively	O
correlated	O
to	O
VFT-action	B-P
in	O
the	O
FEDN	O
group	O
.	O

GDNF	O
levels	O
showed	O
a	O
positive	O
correlation	O
with	O
VFT-action	O
scores	O
and	O
a	O
negative	O
correlation	O
with	O
TMT-part	O
B	O
scores	O
of	O
these	O
patients	O
.	O

Current	O
data	O
suggests	O
that	O
cognitive	O
dysfunction	O
widely	O
exists	O
in	O
the	O
early	O
stages	O
of	O
schizophrenia	O
.	O

BDNF	O
and	O
GDNF	O
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	O
mechanisms	O
involved	O
in	O
cognitive	O
impairment	O
in	O
FEDN	O
patients	O
with	O
schizophrenia	O
.	O

Leonurine	O
Attenuates	O
Hyperalgesia	O
in	O
Mice	O
with	O
Induced	O
Adenomyosis	O
.	O

BACKGROUND	O
Adenomyosis	O
,	O
defined	O
as	O
the	O
invasion	O
of	O
endometrial	O
glands	O
and	O
stroma	O
into	O
the	O
myometrium	O
,	O
is	O
a	O
common	O
gynecological	O
disorder	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
the	O
effect	O
of	O
leonurine	O
on	O
ICR	O
mice	O
with	O
adenomyosis	O
induced	O
by	O
neonatal	O
tamoxifen	O
.	O

MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	O
with	O
tamoxifen	O
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	O
body	O
weight	O
and	O
pain	O
modulation	O
in	O
mice	O
in	O
hotplate	O
tests	O
.	O

The	O
mice	O
were	O
divided	O
into	O
5	O
groups	O
:	O
a	O
low-dose	O
leonurine	O
treatment	O
group	O
,	O
a	O
high-dose	O
leonurine	O
treatment	O
group	O
,	O
a	O
valproic	O
acid	O
(	O
VPA	O
)	O
treatment	O
group	O
,	O
a	O
vehicle	O
only	O
treatment	O
group	O
,	O
and	O
a	O
blank	O
control	O
group	O
.	O

We	O
evaluated	O
body	O
weight	O
,	O
pain	O
modulation	O
in	O
hotplate	O
tests	O
,	O
and	O
the	O
depth	O
of	O
myometrial	O
infiltration	O
.	O

Immunoreactivity	O
staining	O
of	O
progesterone	O
receptor	O
(	O
PR	O
)	O
,	O
nuclear	O
factor-κB	O
phosphorylated-p65	O
(	O
p-p65	O
)	O
,	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
,	O
and	O
oxytocin	O
receptor	O
(	O
OTR	O
)	O
was	O
evaluated	O
by	O
immunohistochemistry	B-P
.	O

RESULTS	O
The	O
measurement	O
of	O
the	O
body	O
weight	O
,	O
myometrial	O
infiltration	O
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	O
tamoxifen	O
treatment	O
led	O
to	O
adenomyosis	O
.	O

Leonurine	O
treatment	O
appeared	O
to	O
decrease	O
hyperalgesia	O
and	O
myometrial	O
infiltration	O
.	O

Immunoreactivity	O
staining	O
showed	O
decreased	O
p-p65	O
,	O
COX-2	O
,	O
and	O
OTR	O
protein	O
expressions	O
.	O

CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	O
attenuates	O
hyperalgesia	O
in	O
mice	O
with	O
induced	O
adenomyosis	O
via	O
down-regulating	O
expressions	O
of	O
p-P65	O
,	O
COX-2	O
,	O
and	O
OTR	O
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	O
adenomyosis	O
.	O

Effects	O
of	O
a	O
novel	O
phosphodiesterase	O
10A	O
inhibitor	O
in	O
non-human	O
primates	O
:	O
A	O
therapeutic	O
approach	O
for	O
schizophrenia	O
with	O
improved	O
side	O
effect	O
profile	O
.	O

Schizophrenia	O
symptoms	O
are	O
associated	O
with	O
alterations	O
in	O
basal	O
ganglia-cortical	O
networks	O
that	O
include	O
the	O
cyclic	O
nucleotides	O
(	O
cAMP	O
/	O
cGMP	O
)	O
signaling	O
pathways	O
.	O

Phosphodiesterase	O
10A	O
(	O
PDE10A	O
)	O
inhibitors	O
have	O
been	O
considered	O
as	O
therapeutic	O
agents	O
for	O
schizophrenia	O
because	O
the	O
regulation	O
of	O
cAMP	O
and	O
cGMP	O
in	O
the	O
striatum	O
by	O
PDE10A	O
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	O
mechanisms	O
of	O
the	O
striatal-cortical	O
network	O
,	O
and	O
thereby	O
in	O
cognitive	O
function	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non-human	O
primates	O
(	O
NHPs	O
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	O
inhibitor	O
(	O
FRM-6308	O
)	O
that	O
has	O
demonstrated	O
high	O
potency	O
and	O
selectivity	O
for	O
human	O
recombinant	O
PDE10A	O
in	O
vitro	O
.	O

The	O
behavioral	O
effects	O
of	O
FRM-6308	O
in	O
a	O
dose	O
range	O
were	O
determined	O
in	O
rhesus	O
monkeys	O
using	O
a	O
standardized	O
motor	O
disability	O
scale	O
for	O
primates	O
,	O
motor	O
tasks	O
,	O
and	O
the	O
``	O
drug	O
effects	O
on	O
the	O
nervous	O
system	O
''	O
(	O
DENS	O
)	O
scale	O
.	O

The	O
neuronal	O
metabolic	O
effects	O
of	O
FRM-6308	O
were	O
determined	O
with	O
[	B-P
(	I-P
18	I-P
)	I-P
F	I-P
]	I-P
-fluorodeoxyglucose	I-P
PET	I-P
imaging	I-P
.	O

Results	O
showed	O
that	O
FRM-6308	O
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	O
system	O
at	O
s.c.	O
doses	O
up	O
to	O
0.32	O
mg/kg	O
in	O
NHPs	O
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	O
-	O
SUV	O
in	O
striatum	O
(	O
F	O
16.069	O
,	O
p	O
<	O
0.05	O
)	O
and	O
cortical	O
(	O
F	O
15.181	O
,	O
p	O
<	O
0.05	O
)	O
regions	O
.	O

Higher	O
doses	O
induced	O
sedation	O
and	O
occasional	O
involuntary	O
movements	O
with	O
clear	O
development	O
of	O
tolerance	O
after	O
repeated	O
exposures	O
.	O

These	O
findings	O
suggest	O
that	O
FRM-6308	O
has	O
the	O
adequate	O
pharmacological	O
profile	O
to	O
advance	O
testing	O
in	O
clinical	O
trials	O
and	O
demonstrate	O
antipsychotic	O
efficacy	O
of	O
PDE10A	O
inhibition	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
patients	O
.	O

A	O
Fast	O
Peak-Searching	O
Algorithm	O
for	O
Ultrasonic	B-P
Elastography	I-P
.	O

Tissue	B-P
axial	I-P
strain	I-P
estimation	I-P
with	I-P
ultrasound	I-P
elastography	I-P
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O

However	O
,	O
for	O
keypoints	O
tracking-based	O
elastography	O
algorithms	O
,	O
locating	O
extrema	O
in	O
multimodal	O
ultrasonic	O
radiofrequency	O
signals	O
is	O
still	O
a	O
challenging	O
problem	O
.	O

In	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	O
to	O
locate	O
the	O
local	O
maxima	O
and	O
minima	O
of	O
the	O
RF	O
signals	O
directly	O
without	O
derivation	O
operation	O
.	O

This	O
algorithm	O
can	O
accurately	O
locate	O
extrema	O
even	O
if	O
disturbed	O
peaks	O
resulting	O
from	O
different	O
noise	O
exist	O
.	O

Furthermore	O
,	O
the	O
new	O
algorithm	O
can	O
speed	O
up	O
approximately	O
79	O
%	O
of	O
the	O
implementation	O
process	O
as	O
compared	O
with	O
the	O
standard	O
cross-correlation	O
method	O
on	O
the	O
same	O
computing	O
platform	O
.	O

In	O
addition	O
,	O
the	O
elastographic	O
signal-to-noise	O
ratio	O
and	O
the	O
contrast-to-noise	O
ratio	O
are	O
also	O
significantly	O
improved	O
with	O
this	O
new	O
method	O
.	O

A	O
standardized	O
approach	O
for	O
the	O
assessment	O
and	O
treatment	O
of	O
internationally	O
adopted	O
children	O
with	O
a	O
previously	O
repaired	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
.	O

A	O
significant	O
number	O
of	O
internationally	O
adopted	O
children	O
have	O
congenital	O
birth	O
defects	O
.	O

As	O
a	O
specialist	O
center	O
for	O
colorectal	O
diagnoses	B-P
,	O
we	O
evaluate	O
such	O
children	O
with	O
an	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	O
.	O

Knowledge	O
of	O
the	O
common	O
complications	O
following	O
ARM	O
surgery	O
has	O
led	O
us	O
to	O
develop	O
treatment	O
algorithms	O
for	O
patients	O
with	O
unknown	O
past	O
medical	O
and	O
surgical	O
history	O
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	O
population	O
.	O

The	O
results	O
of	O
investigations	O
,	O
indications	O
,	O
and	O
rate	O
of	O
reoperation	O
were	O
assessed	O
for	O
adopted	O
children	O
with	O
an	O
ARM	O
evaluated	O
between	O
2014	O
and	O
2016	O
.	O

56	O
patients	O
(	O
28	O
males	O
)	O
were	O
identified	O
.	O

76.8	O
%	O
required	O
reoperative	O
surgery	O
.	O

Mislocation	O
of	O
the	O
anus	O
outside	O
the	O
sphincter	O
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	O
and	O
39.3	O
%	O
of	O
females	O
.	O

Anal	O
stricture	O
,	O
rectal	O
prolapse	O
,	O
retained	O
vaginal	O
septum	O
,	O
and	O
a	O
strictured	O
vaginal	O
introitus	O
were	O
also	O
common	O
.	O

The	O
reoperative	O
surgery	O
rate	O
in	O
the	O
internationally	O
adopted	O
child	O
with	O
an	O
ARM	O
is	O
high	O
.	O

Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	O
is	O
required	O
to	O
identify	O
complications	O
following	O
initial	O
repair	O
.	O

Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	O
care	O
these	O
children	O
receive	O
is	O
needed	O
.	O

Mapping	B-P
how	O
local	O
perturbations	O
influence	O
systems-level	O
brain	O
dynamics	O
.	O

The	O
human	O
brain	O
exhibits	O
a	O
distinct	O
spatiotemporal	O
organization	O
that	O
supports	O
brain	O
function	O
and	O
can	O
be	O
manipulated	O
via	O
local	O
brain	O
stimulation	O
.	O

Such	O
perturbations	O
to	O
local	O
cortical	O
dynamics	O
are	O
globally	O
integrated	O
by	O
distinct	O
neural	O
systems	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
local	O
changes	O
in	O
neural	O
activity	O
affect	O
large-scale	O
system	O
dynamics	O
.	O

Here	O
,	O
we	O
briefly	O
review	O
empirical	O
and	O
computational	O
studies	O
addressing	O
how	O
localized	O
perturbations	O
affect	O
brain	O
activity	O
.	O

We	O
then	O
systematically	O
analyze	O
a	O
model	O
of	O
large-scale	O
brain	O
dynamics	O
,	O
assessing	O
how	O
localized	O
changes	O
in	O
brain	O
activity	O
at	O
the	O
different	O
sites	O
affect	O
whole-brain	O
dynamics	O
.	O

We	O
find	O
that	O
local	O
stimulation	O
induces	O
changes	O
in	O
brain	O
activity	O
that	O
can	O
be	O
summarized	O
by	O
relatively	O
smooth	O
tuning	O
curves	O
,	O
which	O
relate	O
a	O
region	O
's	O
effectiveness	O
as	O
a	O
stimulation	O
site	O
to	O
its	O
position	O
within	O
the	O
cortical	O
hierarchy	O
.	O

Our	O
results	O
also	O
support	O
the	O
notion	O
that	O
brain	O
hubs	O
,	O
operating	O
in	O
a	O
slower	O
regime	O
,	O
are	O
more	O
resilient	O
to	O
focal	O
perturbations	O
and	O
critically	O
contribute	O
to	O
maintain	O
stability	O
in	O
global	O
brain	O
dynamics	O
.	O

In	O
contrast	O
,	O
perturbations	O
of	O
peripheral	O
regions	O
,	O
characterized	O
by	O
faster	O
activity	O
,	O
have	O
greater	O
impact	O
on	O
functional	O
connectivity	O
.	O

As	O
a	O
parallel	O
with	O
this	O
region-level	O
result	O
,	O
we	O
also	O
find	O
that	O
peripheral	O
systems	O
such	O
as	O
the	O
visual	O
and	O
sensorimotor	O
networks	O
were	O
more	O
affected	O
by	O
local	O
perturbations	O
than	O
high-level	O
systems	O
such	O
as	O
the	O
cingulo-opercular	O
network	O
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
a	O
periphery-to-core	O
hierarchy	O
to	O
determine	O
the	O
effect	O
of	O
local	O
stimulation	O
on	O
the	O
brain	O
network	O
.	O

This	O
study	O
also	O
provides	O
novel	O
resources	O
to	O
orient	O
empirical	O
work	O
aiming	O
at	O
manipulating	O
functional	O
connectivity	O
using	O
non-invasive	O
brain	O
stimulation	O
.	O

Simultaneous	O
edited	O
MRS	B-P
of	O
GABA	O
and	O
glutathione	O
.	O

Edited	O
MRS	B-P
allows	O
the	O
detection	O
of	O
low	O
-	O
concentration	O
metabolites	O
,	O
whose	O
signals	O
are	O
not	O
resolved	O
in	O
the	O
MR	B-P
spectrum	I-P
.	O

Tailored	O
acquisitions	O
can	O
be	O
designed	O
to	O
detect	O
,	O
for	O
example	O
,	O
the	O
inhibitory	O
neurotransmitter	O
γ-aminobutyric	O
acid	O
(	O
GABA	O
)	O
,	O
or	O
the	O
reduction-oxidation	O
(	O
redox	O
)	O
compound	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
single	O
-	O
voxel	O
edited	O
experiments	O
are	O
generally	O
acquired	O
at	O
a	O
rate	O
of	O
one	O
metabolite	O
-	O
per-experiment	O
.	O

We	O
demonstrate	O
that	O
simultaneous	O
detection	O
of	O
the	O
overlapping	O
signals	O
of	O
GABA	O
and	O
GSH	O
is	O
possible	O
using	O
Hadamard	O
Encoding	O
and	O
Reconstruction	O
of	O
Mega-Edited	O
Spectroscopy	O
(	O
HERMES	O
)	O
.	O

HERMES	O
applies	O
orthogonal	O
editing	O
encoding	O
(	O
following	O
a	O
Hadamard	O
scheme	O
)	O
,	O
such	O
that	O
GSH-	O
and	O
GABA	O
-	O
edited	O
difference	O
spectra	O
can	O
be	O
reconstructed	O
from	O
a	O
single	O
multiplexed	O
experiment	O
.	O

At	O
a	O
TE	O
of	O
80ms	O
,	O
20-ms	O
editing	O
pulses	O
are	O
applied	O
at	O
4.56ppm	O
(	O
on	O
GSH	O
)	O
,1.9ppm	O
(	O
on	O
GABA	O
)	O
,	O
both	O
offsets	O
(	O
using	O
a	O
dual-lobe	O
cosine-modulated	O
pulse	O
)	O
or	O
neither	O
.	O

Hadamard	O
combinations	O
of	O
the	O
four	O
sub-experiments	O
yield	O
GABA	O
and	O
GSH	O
difference	O
spectra	O
.	O

It	O
is	O
shown	O
that	O
HERMES	O
gives	O
excellent	O
separation	O
of	O
the	O
edited	O
GABA	O
and	O
GSH	O
signals	O
in	O
phantoms	O
,	O
and	O
resulting	O
edited	O
lineshapes	O
agree	O
well	O
with	O
separate	O
Mescher-Garwood	O
Point-resolved	O
Spectroscopy	O
(	O
MEGA-PRESS	O
)	O
acquisitions	O
.	O

In	O
vivo	O
,	O
the	O
quality	O
and	O
signal-to-noise	O
ratio	O
(	O
SNR	O
)	O
of	O
HERMES	O
spectra	O
are	O
similar	O
to	O
those	O
of	O
sequentially	O
acquired	O
MEGA-PRESS	O
spectra	O
,	O
with	O
the	O
benefit	O
of	O
saving	O
half	O
the	O
acquisition	O
time	O
.	O

Extended	O
Release	O
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	O
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo-Controlled	O
Trial	O
.	O

This	O
is	O
a	O
feasibility	O
study	O
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	O
of	O
the	O
α2	O
agonist	O
guanfacine	O
extended-release	O
(	O
GXR	O
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	O
disorder	O
(	O
GAD	O
)	O
,	O
separation	O
anxiety	O
disorder	O
(	O
SAD	O
)	O
,	O
or	O
social	O
phobia	O
/	O
social	O
anxiety	O
disorder	O
.	O

Youth	O
aged	O
6-17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	O
flexibly	O
dosed	O
GXR	O
(	O
1-6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
GXR	O
in	O
youth	O
with	O
anxiety	O
disorders	O
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	O
(	O
TEAEs	O
)	O
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	O
and	O
behaviors	O
,	O
vital	O
signs	O
,	O
and	O
electrocardiographic	B-P
/	O
laboratory	O
parameters	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	O
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	O
Child	O
Anxiety	O
Related	O
Emotional	O
Disorders	O
[	O
SCARED	O
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	O
Impression-Improvement	O
(	O
CGI-I	O
)	O
scale	O
.	O

As	O
this	O
was	O
an	O
exploratory	O
study	O
,	O
no	O
inferential	O
statistical	O
analyses	O
were	O
performed	O
.	O

GXR	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Treatment	O
-related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	O
(	O
GXR	O
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
2.3	O
±	O
11	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

TEAEs	O
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	O
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
GXR	O
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
SCARED	O
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
GXR	O
versus	O
placebo	O
demonstrated	O
CGI-I	O
scores	O
≤2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	O
.	O

GXR	O
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	O
with	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
.	O

ClinicalTrials.gov	O
Identifier	O
:	O
NCT01470469	O
.	O

Multicentric	O
studies	O
of	O
the	O
fetal	O
neurobehavior	O
by	O
KANET	B-P
test	I-P
.	O

Assessment	B-P
of	O
fetal	O
neurobehavior	O
and	O
detection	O
of	O
neurological	O
impairment	O
prenatally	O
has	O
been	O
a	O
great	O
challenge	O
in	O
perinatal	O
medicine	O
.	O

The	O
evolution	B-P
of	O
four-dimensional	B-P
(	I-P
4D	I-P
)	I-P
ultrasound	I-P
not	O
only	O
enabled	O
a	O
better	O
visualization	O
of	O
fetal	B-P
anatomy	I-P
but	O
also	O
allowed	O
the	O
study	O
of	O
fetal	O
behavior	O
in	O
real	O
time	O
.	O

Kurjak	B-P
Antenatal	I-P
Neurodevelopmental	I-P
Test	I-P
(	O
KANET	B-P
)	O
was	O
developed	O
for	O
the	O
assessment	B-P
of	O
fetal	O
neurobehavior	O
and	O
the	O
detection	O
of	O
neurological	O
disorders	O
,	O
based	O
on	O
the	O
assessment	B-P
of	O
the	O
fetus	O
by	O
application	O
of	O
4D	B-P
ultrasound	I-P
in	O
the	O
same	O
way	O
that	O
a	O
neonate	O
is	O
assessed	O
postnatally	O
.	O

KANET	B-P
is	O
a	O
method	B-P
that	O
has	O
been	O
applied	O
for	O
the	O
past	O
10	O
years	O
and	O
studies	O
show	O
that	O
it	O
is	O
a	O
strong	O
diagnostic	B-P
tool	I-P
and	O
can	O
be	O
introduced	O
into	O
everyday	O
clinical	O
practice	O
.	O

We	O
present	O
all	O
data	O
from	O
studies	O
performed	O
up	O
to	O
now	O
on	O
KANET	B-P
.	O

Unaffected	O
twins	O
discordant	O
for	O
affective	O
disorders	O
show	O
changes	O
in	O
anterior	O
callosal	O
white	O
matter	O
microstructure	O
.	O

The	O
neurobiological	O
mechanisms	O
mediating	O
an	O
increased	O
risk	O
to	O
develop	O
affective	O
disorders	O
remain	O
poorly	O
understood	O
.	O

In	O
a	O
group	O
of	O
individuals	O
with	O
a	O
family	O
history	O
of	O
major	O
depressive	O
(	O
MDD	O
)	O
or	O
bipolar	O
disorder	O
(	O
BD	O
)	O
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	O
matter	O
fiber	O
tracts	O
,	O
that	O
is	O
,	O
cingulum	O
bundle	O
,	O
uncinate	O
fasciculus	O
,	O
anterior	O
limb	O
of	O
the	O
internal	O
capsule	O
,	O
and	O
corpus	O
callosum	O
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	O
regions	O
implicated	O
in	O
affective	O
disorders	O
.	O

Eighty-nine	O
healthy	O
mono	O
-	O
or	O
dizygotic	O
twins	O
with	O
a	O
co-twin	O
diagnosed	O
with	O
MDD	O
or	O
BD	O
(	O
high-risk	O
)	O
and	O
57	O
healthy	O
twins	O
with	O
a	O
co-twin	O
with	O
no	O
familial	O
history	O
of	O
affective	O
disorders	O
(	O
low-risk	O
)	O
were	O
included	O
in	O
a	O
diffusion	B-P
tensor	I-P
imaging	I-P
study	I-P
.	O

The	O
high-risk	O
group	O
showed	O
decreased	O
fractional	B-P
anisotropy	I-P
(	O
FA	B-P
)	O
,	O
a	O
measure	O
of	O
water	O
diffusion	O
directionality	O
,	O
and	O
increased	O
radial	O
diffusivity	O
in	O
the	O
anterior	O
region	O
of	O
corpus	O
callosum	O
compared	O
to	O
the	O
low-risk	O
group	O
.	O

This	O
abnormality	O
was	O
not	O
associated	O
with	O
zygosity	O
or	O
type	O
of	O
depressive	O
disorder	O
of	O
co-twin	O
.	O

The	O
observed	O
decreased	O
anterior	O
callosal	O
fiber	O
FA	B-P
in	O
the	O
high-risk	O
group	O
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	O
communication	O
between	O
left	O
and	O
right	O
frontal	O
regions	O
critically	O
involved	O
in	O
mood	O
regulation	O
.	O

Reduced	O
anterior	O
callosal	O
FA	B-P
may	O
act	O
as	O
a	O
vulnerability	O
marker	O
for	O
affective	O
disorders	O
in	O
individuals	O
at	O
familial	O
risk	O
.	O

Tzumin	O
A	O
and	O
B	O
,	O
two	O
new	O
lignan	O
derivatives	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

Two	O
new	O
lignan	O
compounds	O
,	O
5'-allyl-2,2'-dihydroxy-	O
[	O
1,1'-biphenyl	O
]	O
-5-carboxylic	O
acid	O
(	O
1	O
)	O
and	O
4,4'-diallyl-	O
[	O
1,1'-biphenyl	O
]	O
-2,2'-diol	O
(	O
2	O
)	O
,	O
together	O
with	O
four	O
known	O
compounds	O
(	O
3-6	O
)	O
,	O
were	O
isolated	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

The	O
new	O
compounds	O
were	O
determined	O
by	O
NMR	B-P
(	I-P
(	I-P
1	I-P
)	I-P
H	I-P
and	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
HSQC	O
,	O
HMBC	O
,	O
(	B-P
1	I-P
)	I-P
H-	I-P
(	I-P
1	I-P
)	I-P
H	I-P
COSY	I-P
,	O
NOESY	B-P
/	O
ROESY	B-P
)	O
,	O
and	O
MS	O
analysis	O
.	O

Compounds	O
1-3	O
showed	O
potent	O
AChE	O
inhibitory	O
activities	O
,	O
with	O
IC50	O
values	O
of	O
2.00	O
,	O
1.81	O
and	O
1.91	O
μM	O
,	O
respectively	O
.	O

Medial	O
Patellofemoral	O
Ligament	O
Reconstruction	O
Femoral	O
Tunnel	O
Accuracy	O
:	O
Relationship	O
to	O
Disease	O
-	O
Specific	O
Quality	O
of	O
Life	O
.	O

Medial	O
patellofemoral	O
ligament	O
(	O
MPFL	O
)	O
reconstruction	O
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	O
patellar	O
translation	O
in	O
patients	O
with	O
symptomatic	O
patellofemoral	O
instability	O
.	O

Correct	O
femoral	O
tunnel	O
position	O
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	O
reconstruction	O
,	O
but	O
the	O
accuracy	O
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	O
outcomes	O
has	O
not	O
been	O
tested	O
.	O

To	O
assess	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
placement	O
in	O
an	O
MPFL	O
reconstruction	O
cohort	O
and	O
to	O
determine	O
the	O
correlation	O
between	O
tunnel	O
accuracy	O
and	O
a	O
validated	O
disease	O
-	O
specific	O
,	O
patient	O
-reported	O
quality-of-life	O
outcome	O
measure	O
.	O

Case	O
series	O
;	O
Level	O
of	O
evidence	O
,	O
4	O
.	O

Between	O
June	O
2008	O
and	O
February	O
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	O
underwent	O
an	O
MPFL	O
reconstruction	O
.	O

Lateral	O
radiographs	B-P
were	O
measured	O
to	O
determine	O
the	O
accuracy	O
of	O
the	O
femoral	O
tunnel	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	O
tunnel	O
to	O
the	O
Schöttle	O
point	O
.	O

Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
scores	O
were	O
collected	O
a	O
mean	O
24	O
months	O
postoperatively	O
.	O

A	O
total	O
of	O
155	O
(	O
79.5	O
%	O
)	O
subjects	O
had	O
adequate	O
postoperative	O
lateral	O
radiographs	B-P
and	O
complete	O
BPII	O
scores	O
.	O

The	O
mean	O
duration	O
of	O
follow-up	O
(	O
±	O
SD	O
)	O
was	O
24.4	O
±	O
8.2	O
months	O
(	O
range	O
,	O
12-74	O
months	O
)	O
.	O

Measurement	O
from	O
the	O
center	O
of	O
the	O
femoral	O
tunnel	O
to	O
the	O
Schöttle	O
point	O
resulted	O
in	O
143	O
(	O
92.3	O
%	O
)	O
tunnel	O
s	O
being	O
categorized	O
as	O
``	O
good	O
``	O
or	O
``	O
ideal	O
.	O
''	O

There	O
were	O
8	O
failures	O
in	O
the	O
cohort	O
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	O
tunnels	O
.	O

The	O
mean	O
distance	O
from	O
the	O
center	O
of	O
the	O
MPFL	O
tunnel	O
to	O
the	O
center	O
of	O
the	O
Schöttle	O
point	O
was	O
5.9	O
±	O
4.2	O
mm	O
(	O
range	O
,	O
0.5-25.9	O
mm	O
)	O
.	O

The	O
mean	O
postoperative	O
BPII	O
score	O
was	O
65.2	O
±	O
22.5	O
(	O
range	O
,	O
9.2-100	O
)	O
.	O

Pearson	O
r	O
correlation	O
demonstrated	O
no	O
statistically	O
significant	O
relationship	O
between	O
accuracy	O
of	O
femoral	O
tunnel	O
position	O
and	O
BPII	O
score	O
(	O
r	O
=	O
-0.08	O
;	O
95	O
%	O
CI	O
,	O
-0.24	O
to	O
0.08	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
correlation	O
between	O
the	O
accuracy	O
of	O
MPFL	O
reconstruction	O
femoral	O
tunnel	O
in	O
relation	O
to	O
the	O
Schöttle	O
point	O
and	O
disease	O
-	O
specific	O
quality-of-life	O
scores	O
.	O

Graft	O
failure	O
was	O
not	O
related	O
to	O
femoral	O
tunnel	O
placement	O
.	O

The	O
patellofemoral	O
instability	O
population	O
is	O
complex	O
,	O
and	O
patients	O
present	O
with	O
multiple	O
risk	O
factors	O
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
position	O
,	O
contribute	O
to	O
quality	O
of	O
life	O
and	O
warrant	O
further	O
investigation	O
.	O

The	O
FLASHE	O
Study	O
:	O
Survey	O
Development	O
,	O
Dyadic	O
Perspectives	O
,	O
and	O
Participant	O
Characteristics	O
.	O

The	O
National	O
Cancer	O
Institute	O
developed	O
the	O
Family	O
Life	O
,	O
Activity	O
,	O
Sun	O
,	O
Health	O
,	O
and	O
Eating	O
(	O
FLASHE	O
)	O
Study	O
to	O
examine	O
multiple	O
cancer	O
preventive	O
behaviors	O
within	O
parent	O
-	O
adolescent	O
dyads	O
.	O

The	O
purpose	O
of	O
creating	O
FLASHE	O
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	O
activity	O
,	O
diet	O
,	O
and	O
other	O
cancer	O
preventive	O
behaviors	O
and	O
potential	O
correlates	O
among	O
parent	O
-	O
adolescent	O
dyads	O
.	O

FLASHE	O
surveys	O
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	O
reviews	O
,	O
scientific	O
input	O
from	O
experts	O
in	O
the	O
field	O
,	O
cognitive	B-P
testing	I-P
,	O
and	O
usability	O
testing	O
.	O

This	O
cross-sectional	O
,	O
web-based	O
study	O
of	O
parents	O
and	O
their	O
adolescent	O
children	O
(	O
aged	O
12-17	O
years	O
)	O
was	O
administered	O
between	O
April	O
and	O
October	O
2014	O
.	O

The	O
nationwide	O
sample	O
consisted	O
of	O
1,573	O
parent	O
-	O
adolescent	O
dyads	O
(	O
1,699	O
parents	O
and	O
1,581	O
adolescents	O
)	O
who	O
returned	O
all	O
FLASHE	O
surveys	O
.	O

FLASHE	O
assessed	O
parent	O
and	O
adolescent	O
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	O
domains	O
(	O
including	O
psychosocial	O
variables	O
,	O
parenting	O
,	O
and	O
the	O
community	O
and	O
home	O
environments	O
)	O
.	O

On	O
a	O
subset	O
of	O
example	O
FLASHE	O
items	O
across	O
these	O
domains	O
,	O
responses	O
of	O
parents	O
and	O
adolescents	O
within	O
the	O
same	O
dyads	O
were	O
positively	O
and	O
significantly	O
correlated	O
(	O
r	O
=0.32-0.63	O
)	O
.	O

Analyses	O
were	O
run	O
in	O
2015-2016	O
.	O

FLASHE	O
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	O
questions	O
among	O
individuals	O
or	O
dyads	O
,	O
including	O
the	O
ability	O
to	O
examine	O
similarity	O
between	O
parents	O
and	O
adolescents	O
on	O
many	O
constructs	O
relevant	O
to	O
cancer	O
preventive	O
behaviors	O
.	O

FLASHE	O
data	O
are	O
publicly	O
available	O
for	O
researchers	O
and	O
practitioners	O
to	O
help	O
advance	O
research	O
on	O
cancer	O
preventive	O
health	O
behaviors	O
.	O

Simultaneous	O
Bilateral	O
Femur	O
Neck	O
Fracture	O
in	O
A	O
Young	O
Adult	O
with	O
Chronic	O
Renal	O
Failure	O
-	O
A	O
Case	O
Report	O
and	O
Review	O
of	O
Literature	O
.	O

Pathological	O
bilateral	O
femoral	O
neck	O
fracture	O
due	O
to	O
renal	O
osteodystrophy	O
is	O
rare	O
.	O

This	O
is	O
a	O
report	O
of	O
a	O
chronic	O
renal	O
failure	O
patient	O
who	O
had	O
sustained	O
bilateral	O
intra-capsular	O
displaced	O
fracture	O
neck	O
of	O
femur	O
following	O
an	O
episode	O
of	O
convulsion	O
and	O
the	O
difficulties	O
encountered	O
in	O
early	B-P
diagnosis	I-P
and	O
treatment	O
.	O

The	O
pathophysiology	O
of	O
renal	O
osteodystrophy	O
and	O
the	O
treatment	O
of	O
hip	O
fractures	O
in	O
patients	O
with	O
renal	O
failure	O
are	O
also	O
discussed	O
.	O

A	O
23	O
years	O
old	O
male	O
patient	O
admitted	O
with	O
h/o	O
dysuria	O
,	O
pyuria	O
and	O
loss	O
of	O
appetite	O
since	O
3	O
months	O
.	O

He	O
was	O
a	O
known	O
case	O
of	O
chronic	O
renal	O
failure	O
and	O
reflux	O
nephropathy	O
.	O

On	O
investigating	O
,	O
patient	O
's	O
renal	O
parameters	O
were	O
high	O
and	O
he	O
was	O
started	O
with	O
haemodialysis	O
.	O

The	O
next	O
day	O
patient	O
had	O
c/o	O
bilateral	O
hip	O
pain	O
and	O
inability	O
to	O
move	O
bilateral	O
lower	O
limbs	O
following	O
an	O
episode	O
of	O
seizure	O
.	O

Radiograph	B-P
of	I-P
pelvis	I-P
showed	O
vertical	O
sub	O
capital	O
fractures	O
of	O
bilateral	O
neck	O
of	O
femur	O
.	O

In	O
this	O
patient	O
,	O
considering	O
his	O
age	O
,	O
general	O
condition	O
&	O
prognosis	O
,	O
an	O
elective	O
surgery	O
in	O
the	O
form	O
of	O
bilateral	O
uncemented	O
modular	O
bipolar	O
hemiarthroplasty	O
was	O
done	O
.	O

Overall	O
risk	O
of	O
hip	O
fracture	O
among	O
patients	O
with	O
chronic	O
renal	O
failure	O
is	O
considerably	O
higher	O
than	O
in	O
the	O
general	O
population	O
,	O
independent	O
of	O
age	O
and	O
gender	O
.	O

Simultaneous	O
spontaneous	O
bilateral	O
fractures	O
of	O
the	O
femoral	O
neck	O
are	O
rare	O
and	O
a	O
delayed	O
diagnosis	O
is	O
usual	O
.	O

The	O
study	O
of	O
etiological	O
factors	O
of	O
these	O
fractures	O
is	O
essential	O
to	O
guide	O
us	O
in	O
choosing	O
the	O
treatment	O
of	O
choice	O
.	O

Obviously	O
patient	O
's	O
age	O
,	O
life	O
expectancy	O
as	O
well	O
as	O
renal	O
co	O
morbidity	O
has	O
an	O
influence	O
over	O
deciding	O
treatment	O
and	O
outcome	O
.	O

Application	O
of	O
BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
in	O
diagnosis	O
of	O
gastrointestinal	O
stromal	O
tumors	O
.	O

To	O
evaluate	O
the	O
utility	O
of	O
BRAF	O
V600E	O
allele	O
-	O
specific	O
antibody	O
in	O
the	O
diagnosis	O
of	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
.	O

BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
and	O
BRAF	O
sequencing	O
were	O
performed	O
in	O
24	O
consecutive	O
GISTs	O
,	O
including	O
14	O
cases	O
of	O
KIT	O
or	O
PDGFRA	O
mutations	O
and	O
10	O
cases	O
of	O
KIT	O
/	O
PDGFRA	O
wild	O
GISTs	O
.	O

GISTs	O
of	O
11	O
men	O
and	O
13	O
women	O
with	O
a	O
mean	O
age	O
54	O
years	O
(	O
range	O
29-75	O
years	O
)	O
were	O
included	O
with	O
tumors	O
arising	O
from	O
stomach	O
(	O
16	O
cases	O
)	O
,	O
small	O
bowel	O
(	O
7	O
cases	O
)	O
,	O
and	O
peritoneal	O
cavity	O
(	O
1	O
case	O
)	O
.	O

Strong	O
and	O
diffuse	O
cytoplasmic	O
BRAF	O
staining	O
was	O
noted	O
in	O
4	O
of	O
24	O
cases	O
(	O
17	O
%	O
)	O
,	O
while	O
1	O
of	O
24	O
cases	O
(	O
4	O
%	O
)	O
showed	O
weak	O
staining	O
,	O
and	O
19	O
of	O
24	O
cases	O
(	O
79	O
%	O
)	O
had	O
no	O
staining	O
.	O

The	O
four	O
cases	O
with	O
strong	O
BRAF	O
immunostain	O
were	O
confirmed	O
to	O
have	O
BRAF	O
mutations	O
,	O
including	O
3	O
cases	O
in	O
the	O
stomach	O
and	O
1	O
case	O
in	O
the	O
small	O
intestine	O
.	O

All	O
tumors	O
showed	O
spindle	O
cell	O
morphology	O
.	O

Only	O
one	O
case	O
had	O
progressive	O
disease	O
.	O

No	O
BRAF	O
mutations	O
were	O
detected	O
in	O
cases	O
with	O
weak	O
or	O
negative	O
BRAF	O
immunostain	O
.	O

BRAF	O
V600E	O
mutation	O
-	O
specific	O
immunohistochemistry	B-P
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	O
for	O
detecting	O
BRAF-mutated	O
GISTs	O
.	O

The	O
early	B-P
diagnosis	I-P
of	O
testicular	O
natural	O
killer	O
/	O
t-cell	O
lymphoma	O
.	O

Testicular	O
natural	O
killer	O
/	O
T-cell	O
lymphoma	O
is	O
a	O
rare	O
aggressive	O
extranodal	O
lymphoma	O
associated	O
with	O
Epstein-Barr	O
virus	O
infection	O
.	O

Time	O
to	O
diagnose	O
is	O
crucial	O
as	O
the	O
disease	O
is	O
rapidly	O
progressive	O
and	O
fatal	O
.	O

Early	O
suspicion	O
is	O
documented	O
by	O
imaging	B-P
studies	I-P
and	O
testicular	B-P
biopsies	I-P
which	O
are	O
key	O
factors	O
for	O
diagnosing	O
testicular	O
natural	O
killer	O
/	O
T-cell	O
lymphoma	O
.	O

However	O
,	O
no	O
reports	O
have	O
described	O
the	O
results	O
of	O
imaging	B-P
studies	I-P
.	O

In	O
this	O
paper	O
,	O
contrast-enhanced	B-P
ultrasonography	I-P
(	O
CEUS	B-P
)	O
,	O
fluorine-18-fuorodexoyglucose-positron	B-P
emission	I-P
tomography	I-P
/	O
computed	B-P
tomography	I-P
(	O
(	B-P
18	I-P
)	I-P
F-FDG	I-P
PET	I-P
/	O
CT	B-P
)	O
and	O
tumor	B-P
biopsies	I-P
were	O
all	O
diagnostic	O
of	O
testicular	O
natural	O
killer	O
/	O
T-cell	O
lymphoma	O
.	O

The	O
CEUS	B-P
showed	O
a	O
clear	O
hyperenhancement	O
which	O
strongly	O
indicted	O
malignant	O
tumor	O
.	O

In	O
conclusion	O
,	O
in	O
our	O
study	O
,	O
CEUS	B-P
as	O
a	O
first	O
line	O
easy	O
test	O
,	O
may	O
help	O
physicians	O
to	O
make	O
an	O
early	B-P
diagnosis	I-P
of	O
the	O
very	O
rare	O
case	O
of	O
testicular	O
T-lymphoma	O
.	O

Correlations	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
domain	O
functions	O
in	O
patients	O
with	O
schizophrenia	O
:	O
a	O
cross-sectional	O
study	O
.	O

Neurocognitive	O
dysfunction	O
is	O
a	O
critical	O
target	O
symptom	O
of	O
schizophrenia	O
treatment	O
.	O

A	O
positive	O
correlation	O
between	O
physical	O
activity	O
level	O
and	O
neurocognitive	O
function	O
has	O
been	O
reported	O
in	O
healthy	O
individuals	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	O
exists	O
in	O
patients	O
with	O
schizophrenia	O
and	O
whether	O
the	O
relationship	O
is	O
different	O
according	O
to	O
inpatients	O
or	O
outpatients	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
differences	O
in	O
the	O
correlations	O
between	O
physical	O
activity	O
and	O
multiple	O
neurocognitive	O
domains	O
in	O
inpatients	O
and	O
outpatients	O
with	O
schizophrenia	O
and	O
obtain	O
suggestions	O
for	O
further	O
study	O
to	O
facilitate	O
this	O
field	O
.	O

Twenty-nine	O
patients	O
with	O
schizophrenia	O
were	O
examined	O
(	O
16	O
inpatients	O
and	O
13	O
outpatients	O
,	O
56.0	O
±	O
11.4	O
years	O
of	O
age	O
)	O
.	O

Current	O
symptoms	O
were	O
assessed	O
using	O
the	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
and	O
neurocognitive	O
functions	O
using	O
Cognitrax	O
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-P
index	I-P
(	O
NCI	B-P
)	O
and	O
11	O
domain	O
scores	O
.	O

After	O
testing	O
,	O
participants	O
wore	O
an	O
HJA-750C	O
accelerometer	O
for	O
one	O
week	O
to	O
measure	O
physical	O
activity	O
levels	O
and	O
durations	O
.	O

Partial	O
correlation	O
analyses	O
were	O
performed	O
between	O
exercise	O
and	O
cognitive	O
parameters	O
.	O

In	O
the	O
outpatient	O
group	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
faster	O
Motor	O
and	O
Psychomotor	O
Speeds	O
in	O
outpatients	O
.	O

However	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
lower	O
overall	O
NCI	B-P
,	O
Attention	O
score	O
,	O
and	O
Memory	O
scores	O
in	O
inpatients	O
.	O

Although	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
better	O
neurocognitive	O
functions	O
of	O
outpatients	O
,	O
in	O
inpatients	O
with	O
non-remitted	O
schizophrenia	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
worsening	O
of	O
several	O
cognitive	O
domains	O
.	O

In	O
a	O
future	O
study	O
examining	O
the	O
relationship	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
function	O
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	O
and	O
outpatients	O
are	O
needed	O
because	O
the	O
relationship	O
is	O
different	O
between	O
inpatients	O
and	O
outpatients	O
.	O

Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
images	O
of	O
the	O
thorax	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
.	O

A	O
comprehensive	O
artefact	O
correction	O
method	O
for	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
(	O
CBCT	B-P
)	O
images	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
(	O
IGRT	O
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O

The	O
method	O
is	O
demonstrated	O
to	O
reduce	O
artefacts	O
and	O
recover	O
CT	B-P
-like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Projection	O
image	O
based	O
artefact	O
corrections	O
of	O
image	O
lag	O
,	O
detector	O
scatter	O
,	O
body	O
scatter	O
and	O
beam	O
hardening	O
are	O
described	O
and	O
applied	O
to	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Image	O
quality	O
is	O
evaluated	O
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-correspondence	O
with	O
the	O
planning	O
CT	B-P
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O

Artefacts	O
are	O
reduced	O
and	O
CT	B-P
-like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	O
corrected	O
CBCT	B-P
images	O
.	O

Visual	O
inspection	O
confirms	O
that	O
artefacts	O
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	O
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-P
and	O
the	O
reference	O
CT	B-P
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	O
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-P
reconstruction	O
.	O

A	O
versatile	O
artefact	O
correction	O
method	O
for	O
clinical	O
CBCT	B-P
images	O
acquired	O
for	O
IGRT	O
has	O
been	O
developed	O
.	O

HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-P
images	O
.	O

The	O
proposed	O
method	O
relies	O
on	O
post	O
processing	O
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	O
specific	O
optimisation	O
.	O

It	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-P
images	O
.	O

Perfusion	O
deconvolution	O
in	O
DSC-MRI	B-P
with	O
dispersion-compliant	O
bases	O
.	O

Perfusion	B-P
imaging	I-P
of	O
the	O
brain	O
via	O
Dynamic	B-P
Susceptibility	I-P
Contrast	I-P
MRI	I-P
(	O
DSC-MRI	B-P
)	O
allows	O
tissue	O
perfusion	O
characterization	O
by	O
recovering	O
the	O
tissue	O
impulse	O
response	O
function	O
and	O
scalar	O
parameters	O
such	O
as	O
the	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
blood	O
volume	O
(	O
CBV	O
)	O
,	O
and	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
bolus	O
dispersion	O
causes	O
the	O
data	O
to	O
reflect	O
macrovascular	O
properties	O
,	O
in	O
addition	O
to	O
tissue	O
perfusion	O
.	O

In	O
this	O
case	O
,	O
when	O
performing	O
deconvolution	O
of	O
the	O
measured	O
arterial	O
and	O
tissue	O
concentration	O
time-curves	O
it	O
is	O
only	O
possible	O
to	O
recover	O
the	O
effective	O
,	O
i.e	O
.	O

dispersed	O
,	O
response	O
function	O
and	O
parameters	O
.	O

We	O
introduce	O
Dispersion-Compliant	O
Bases	O
(	O
DCB	O
)	O
to	O
represent	O
the	O
response	O
function	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dispersion	O
.	O

We	O
perform	O
in	O
silico	O
and	O
in	O
vivo	O
experiments	O
,	O
and	O
show	O
that	O
DCB	O
deconvolution	O
outperforms	O
oSVD	O
and	O
the	O
state-of-the-art	O
CPI+VTF	O
techniques	O
in	O
the	O
estimation	O
of	O
effective	O
perfusion	O
parameters	O
,	O
regardless	O
of	O
the	O
presence	O
and	O
amount	O
of	O
dispersion	O
.	O

We	O
also	O
show	O
that	O
DCB	O
deconvolution	O
can	O
be	O
used	O
as	O
a	O
pre-processing	O
step	O
to	O
improve	O
the	O
estimation	O
of	O
dispersion	O
-free	O
parameters	O
computed	O
with	O
CPI+VTF	O
,	O
which	O
employs	O
a	O
model	O
of	O
the	O
vascular	O
transport	O
function	O
to	O
characterize	O
dispersion	O
.	O

Indeed	O
,	O
in	O
silico	O
results	O
show	O
a	O
reduction	O
of	O
relative	O
errors	O
up	O
to	O
50	O
%	O
for	O
dispersion	O
-free	O
CBF	O
and	O
MTT	O
.	O

Moreover	O
,	O
the	O
DCB	O
method	O
recovers	O
effective	O
response	O
functions	O
that	O
comply	O
with	O
healthy	O
and	O
pathological	O
scenarios	O
,	O
and	O
offers	O
the	O
advantage	O
of	O
making	O
no	O
assumptions	O
about	O
the	O
presence	O
,	O
amount	O
,	O
and	O
nature	O
of	O
dispersion	O
.	O

Muscle	O
synergies	O
after	O
stroke	O
are	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Movements	O
can	O
be	O
factored	O
into	O
modules	O
termed	O
``	O
muscle	O
synergies	O
``	O
.	O

After	O
stroke	O
,	O
abnormal	O
synergies	O
are	O
linked	O
to	O
impaired	O
movements	O
;	O
however	O
,	O
their	O
neural	O
basis	O
is	O
not	O
understood	O
.	O

In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-P
signals	I-P
from	O
the	O
perilesional	O
cortex	O
were	O
associated	O
with	O
synergies	O
.	O

The	O
measured	O
synergies	O
contained	O
a	O
mix	O
of	O
both	O
normal	O
and	O
abnormal	O
patterns	O
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	O
and	O
abnormal	O
synergies	O
were	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Given	O
the	O
link	O
between	O
high	O
gamma	O
and	O
cortical	O
spiking	O
,	O
our	O
results	O
suggest	O
that	O
perilesional	O
spiking	O
may	O
organize	O
synergies	O
after	O
stroke	O
.	O

Osteomyelitis	O
of	O
Humerus	O
and	O
Intramuscular	O
Abscess	O
Due	O
to	O
Melioidosis	O
.	O

Melioidosis	O
is	O
a	O
clinically	O
diverse	O
disease	O
caused	O
by	O
gram	O
negative	O
bacterium	O
Burkholderia	O
pseudomallei	O
.	O

It	O
is	O
a	O
potential	O
bioterrorism	O
agent	O
.	O

The	O
high	O
risk	O
group	O
includes	O
the	O
agricultural	O
and	O
construction	O
workers	O
whose	O
contact	O
with	O
contaminated	O
soil	O
and	O
water	O
may	O
expose	O
them	O
to	O
bacteria	O
.	O

The	O
clinical	O
manifestations	O
varies	O
from	O
asymptomatic	O
infection	O
to	O
overwhelming	O
sepsis	O
.	O

To	O
diagnose	O
melioidosis	O
a	O
high	O
index	O
of	O
suspicion	O
along	O
with	O
isolation	O
and	O
identification	O
of	O
the	O
organism	O
from	O
the	O
clinical	O
samples	O
is	O
needed	O
.	O

Early	B-P
diagnosis	I-P
and	O
treatment	O
is	O
essential	O
for	O
better	O
outcome	O
.	O

We	O
are	O
reporting	O
a	O
case	O
of	O
melioidosis	O
which	O
presented	O
as	O
osteomyelitis	O
of	O
humerus	O
with	O
intramuscular	O
abscess	O
.	O

An	O
efficient	O
approach	O
to	O
identify	O
different	O
chemical	O
markers	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
by	O
ultra	O
high-performance	O
liquid	O
chromatography	O
quadrupole	O
time-of-flight	O
tandem	O
mass	O
spectrometry	O
with	O
multivariate	O
statistical	O
analysis	O
.	O

An	O
ultra	O
high-performance	O
liquid	O
chromatography	O
quadrupole	O
time-of-flight	O
tandem	O
mass	O
spectrometry	O
approach	O
coupled	O
with	O
multivariate	O
statistical	O
analysis	O
was	O
established	O
and	O
applied	O
to	O
rapidly	O
distinguish	O
the	O
chemical	O
differences	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
.	O

The	O
datasets	O
of	O
tR-m/z	O
pairs	O
,	O
ion	O
intensity	O
and	O
sample	O
code	O
were	O
processed	O
by	O
principal	O
component	O
analysis	O
and	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
.	O

Chemical	O
markers	O
could	O
be	O
identified	O
based	O
on	O
their	O
exact	O
mass	O
data	O
,	O
fragmentation	O
characteristics	O
,	O
and	O
retention	O
times	O
.	O

And	O
the	O
new	O
compounds	O
among	O
chemical	O
markers	O
could	O
be	O
isolated	O
rapidly	O
guided	O
by	O
the	O
ultra	O
high-performance	O
liquid	O
chromatography	O
quadrupole	O
time-of-flight	O
tandem	O
mass	O
spectrometry	O
and	O
their	O
definitive	O
structures	O
would	O
be	O
further	O
elucidated	O
by	O
NMR	B-P
spectra	I-P
.	O

Using	O
this	O
approach	O
,	O
twenty-four	O
markers	O
were	O
identified	O
on	O
line	O
including	O
nine	O
new	O
saponins	O
and	O
five	O
new	O
steroidal	O
saponins	O
of	O
them	O
were	O
obtained	O
in	O
pure	O
form	O
.	O

The	O
study	O
validated	O
this	O
proposed	O
approach	O
as	O
a	O
suitable	O
method	O
for	O
identification	O
of	O
the	O
chemical	O
differences	O
between	O
various	O
medicinal	O
parts	O
in	O
order	O
to	O
expand	O
medicinal	O
parts	O
and	O
increase	O
the	O
utilization	O
rate	O
of	O
resources	O
.	O

Interobserver	O
and	O
Intraobserver	O
Reliability	O
of	O
Clinical	O
Assessments	O
in	O
Knee	O
Osteoarthritis	O
.	O

Clinical	O
examination	O
of	O
the	O
knee	O
is	O
subject	O
to	O
measurement	O
error	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
reliability	O
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

We	O
studied	O
subjects	O
with	O
symptomatic	O
knee	O
OA	O
who	O
were	O
participants	O
in	O
an	O
open-label	O
clinical	O
trial	O
of	O
intraarticular	O
steroid	O
therapy	O
.	O

Following	O
standardization	O
of	O
the	O
clinical	O
test	O
procedures	O
,	O
2	O
clinicians	O
assessed	O
25	O
subjects	O
independently	O
at	O
the	O
same	O
visit	O
,	O
and	O
the	O
same	O
clinician	O
assessed	O
88	O
subjects	O
over	O
an	O
interval	O
period	O
of	O
2-10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	O
intervention	O
.	O

Clinical	O
examination	O
included	O
assessment	O
of	O
bony	O
enlargement	O
,	O
crepitus	O
,	O
quadriceps	O
wasting	O
,	O
knee	O
effusion	O
,	O
joint-line	O
and	O
anserine	O
tenderness	O
,	O
and	O
knee	O
range	O
of	O
movement	O
(	O
ROM	O
)	O
.	O

Intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
,	O
estimated	O
kappa	O
(	O
κ	O
)	O
,	O
weighted	O
kappa	O
(	O
κω	O
)	O
,	O
and	O
Bland-Altman	O
plots	O
were	O
used	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
levels	O
of	O
agreement	O
.	O

Using	O
Landis	O
and	O
Koch	O
criteria	O
,	O
interobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.53	O
)	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.48	O
)	O
;	O
good	O
for	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.76	O
)	O
,	O
and	O
effusion	O
assessed	O
by	O
ballottement	O
(	O
κ	O
=	O
0.73	O
)	O
and	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.78	O
)	O
;	O
and	O
excellent	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
1.00	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.97	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.87	O
)	O
ROM	O
.	O

Intraobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
effusion	O
assessed	O
by	O
ballottement	O
test	O
(	O
κ	O
=	O
0.77	O
)	O
,	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
(	O
κ	O
=	O
0.64	O
)	O
,	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.73	O
)	O
;	O
and	O
excellent	O
for	O
effusion	O
assessed	O
by	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.83	O
)	O
,	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.98	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.83	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.99	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.96	O
)	O
ROM	O
.	O

Among	O
individuals	O
with	O
symptomatic	O
knee	O
OA	O
,	O
the	O
reliability	O
of	O
clinical	O
examination	O
of	O
the	O
knee	O
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	O
signs	O
of	O
knee	O
OA	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	O
acid	O
and	O
doxorubicin	O
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	O
.	O

Since	O
the	O
discovery	O
that	O
nano-scaled	O
particulates	O
can	O
easily	O
be	O
incorporated	O
into	O
tumors	O
via	O
the	O
enhanced	O
permeability	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
,	O
such	O
nanostructures	O
have	O
been	O
exploited	O
as	O
therapeutic	O
small	O
molecule	O
delivery	O
systems	O
.	O

However	O
,	O
the	O
convoluted	O
synthetic	O
process	O
of	O
conventional	O
nanostructures	O
has	O
impeded	O
their	O
feasibility	O
and	O
reproducibility	O
in	O
clinical	O
applications	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	O
of	O
the	O
anti-cancer	O
drug	O
doxorubicin	O
(	O
DOX	O
)	O
.	O

Phenylboronic	O
acid	O
(	O
PBA	O
)	O
was	O
grafted	O
onto	O
the	O
polymeric	O
backbone	O
of	O
poly	O
(	O
maleic	O
anhydride	O
)	O
.	O

pPBA-DOX	O
nanocomplexes	O
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3-diol	O
of	O
DOX	O
and	O
the	O
PBA	O
moiety	O
on	O
pPBA	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
PBA	O
]	O
:	O
[	O
DOX	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	O
as	O
a	O
targeting	O
ligand	O
.	O

An	O
acid-labile	O
drug	O
release	O
profile	O
was	O
observed	O
,	O
owing	O
to	O
the	O
intrinsic	O
properties	O
of	O
the	O
phenylboronic	O
ester	O
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	O
and	O
in	O
vivo	O
by	O
fluorescence	B-P
imaging	I-P
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
PBA	O
.	O

Ligand	O
competition	O
assays	O
with	O
free	O
PBA	O
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
PBA	O
from	O
the	O
nanocomplexes	O
2	O
and	O
4	O
.	O

Finally	O
,	O
the	O
nanocomplexes	O
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	O
DOX	O
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	O
effects	O
in	O
vitro	O
and	O
even	O
in	O
vivo	O
.	O

Our	O
pPBA-DOX	O
nanocomplex	O
enables	O
a	O
new	O
paradigm	O
for	O
self	O
-	O
assembled	O
nanostructures	O
with	O
potential	O
biomedical	O
applications	O
.	O

FGF21	O
is	O
a	O
biomarker	O
for	O
mitochondrial	O
translation	O
and	O
mtDNA	O
maintenance	O
disorders	O
.	O

To	O
validate	O
new	O
mitochondrial	O
myopathy	O
serum	O
biomarkers	O
for	O
diagnostic	B-P
use	I-P
.	O

We	O
analyzed	O
serum	O
FGF21	O
(	O
S-FGF21	O
)	O
and	O
GDF15	O
from	O
patients	O
with	O
(	O
1	O
)	O
mitochondrial	O
diseases	O
and	O
(	O
2	O
)	O
nonmitochondrial	O
disorders	O
partially	O
overlapping	O
with	O
mitochondrial	O
disorder	O
phenotypes	O
.	O

We	O
(	O
3	O
)	O
did	O
a	O
meta-analysis	O
of	O
S-FGF21	O
in	O
mitochondrial	O
disease	O
and	O
(	O
4	O
)	O
analyzed	O
S-Fgf21	O
and	O
skeletal	O
muscle	O
Fgf21	O
expression	O
in	O
6	O
mouse	O
models	O
with	O
different	O
muscle	O
-	O
manifesting	O
mitochondrial	O
dysfunctions	O
.	O

We	O
report	O
that	O
S-FGF21	O
consistently	O
increases	O
in	O
primary	O
mitochondrial	O
myopathy	O
,	O
especially	O
in	O
patients	O
with	O
mitochondrial	O
translation	O
defects	O
or	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
deletions	O
(	O
675	O
and	O
347	O
pg/mL	O
,	O
respectively	O
;	O
controls	O
:	O
66	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
)	O
.	O

This	O
is	O
corroborated	O
in	O
mice	O
(	O
mtDNA	O
deletions	O
1,163	O
vs	O
379	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

However	O
,	O
patients	O
and	O
mice	O
with	O
structural	O
respiratory	O
chain	O
subunit	O
or	O
assembly	O
factor	O
defects	O
showed	O
low	O
induction	O
(	O
human	O
335	O
pg/mL	O
,	O
p	O
<	O
0.05	O
;	O
mice	O
335	O
pg/mL	O
,	O
not	O
significant	O
)	O
.	O

Overall	O
specificities	O
of	O
FGF21	O
and	O
GDF15	O
to	O
find	O
patients	O
with	O
mitochondrial	O
myopathy	O
were	O
89.3	O
%	O
vs	O
86.4	O
%	O
,	O
and	O
sensitivities	O
67.3	O
%	O
and	O
76.0	O
%	O
,	O
respectively	O
.	O

However	O
,	O
GDF15	O
was	O
increased	O
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	O
conditions	O
.	O

S-FGF21	O
is	O
a	O
specific	O
biomarker	O
for	O
muscle	O
-	O
manifesting	O
defects	O
of	O
mitochondrial	O
translation	O
,	O
including	O
mitochondrial	O
transfer-RNA	O
mutations	O
and	O
primary	O
and	O
secondary	O
mtDNA	O
deletions	O
,	O
the	O
most	O
common	O
causes	O
of	O
mitochondrial	O
disease	O
.	O

However	O
,	O
normal	O
S-FGF21	O
does	O
not	O
exclude	O
structural	O
respiratory	O
chain	O
complex	O
or	O
assembly	O
factor	O
defects	O
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-P
.	O

This	O
study	O
provides	O
Class	O
III	O
evidence	O
that	O
elevated	O
S-FGF21	O
accurately	O
distinguishes	O
patients	O
with	O
mitochondrial	O
myopathies	O
from	O
patients	O
with	O
other	O
conditions	O
,	O
and	O
FGF21	O
and	O
GDF15	O
mitochondrial	O
myopathy	O
from	O
other	O
myopathies	O
.	O

Investigation	O
of	O
the	O
mycobacterial	O
enzyme	O
HsaD	O
as	O
a	O
potential	O
novel	O
target	O
for	O
anti-tubercular	O
agents	O
using	O
a	O
fragment	O
-based	O
drug	O
design	O
approach	O
.	O

With	O
the	O
emergence	O
of	O
extensively	O
drug-resistant	O
tuberculosis	O
,	O
there	O
is	O
a	O
need	O
for	O
new	O
anti-tubercular	O
drugs	O
that	O
work	O
through	O
novel	O
mechanisms	O
of	O
action	O
.	O

The	O
meta	O
cleavage	O
product	O
hydrolase	O
,	O
HsaD	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
critical	O
for	O
the	O
survival	O
of	O
Mycobacterium	O
tuberculosis	O
in	O
macrophages	O
and	O
is	O
encoded	O
in	O
an	O
operon	O
involved	O
in	O
cholesterol	O
catabolism	O
,	O
which	O
is	O
identical	O
in	O
M.	O
tuberculosis	O
and	O
M.	O
bovis	O
BCG	O
.	O

We	O
generated	O
a	O
mutant	O
strain	O
of	O
M.	O
bovis	O
BCG	O
with	O
a	O
deletion	O
of	O
hsaD	O
and	O
tested	O
its	O
growth	O
on	O
cholesterol	O
.	O

Using	O
a	O
fragment	O
based	O
approach	O
,	O
over	O
1000	O
compounds	O
were	O
screened	O
by	O
a	O
combination	O
of	O
differential	O
scanning	O
fluorimetry	O
,	O
NMR	B-P
spectroscopy	I-P
and	O
enzymatic	O
assay	O
with	O
pure	O
recombinant	O
HsaD	O
to	O
identify	O
potential	O
inhibitors	O
.	O

We	O
used	O
enzymological	O
and	O
structural	O
studies	O
to	O
investigate	O
derivatives	O
of	O
the	O
inhibitors	O
identified	O
and	O
to	O
test	O
their	O
effects	O
on	O
growth	O
of	O
M.	O
bovis	O
BCG	O
and	O
M.	O
tuberculosis	O
.	O

The	O
hsaD	O
deleted	O
strain	O
was	O
unable	O
to	O
grow	O
on	O
cholesterol	O
as	O
sole	O
carbon	O
source	O
but	O
did	O
grow	O
on	O
glucose	O
.	O

Of	O
seven	O
chemically	O
distinct	O
'hits	O
'	O
from	O
the	O
library	O
,	O
two	O
chemical	O
classes	O
of	O
fragments	O
were	O
found	O
to	O
bind	O
in	O
the	O
vicinity	O
of	O
the	O
active	O
site	O
of	O
HsaD	O
by	O
X-ray	O
crystallography	O
.	O

The	O
compounds	O
also	O
inhibited	O
growth	O
of	O
M.	O
tuberculosis	O
on	O
cholesterol	O
.	O

The	O
most	O
potent	O
inhibitor	O
of	O
HsaD	O
was	O
also	O
found	O
to	O
be	O
the	O
best	O
inhibitor	O
of	O
mycobacterial	O
growth	O
on	O
cholesterol	O
-supplemented	O
minimal	O
medium	O
.	O

We	O
propose	O
that	O
HsaD	O
is	O
a	O
novel	O
therapeutic	O
target	O
,	O
which	O
should	O
be	O
fully	O
exploited	O
in	O
order	O
to	O
design	O
and	O
discover	O
new	O
anti-tubercular	O
drugs	O
.	O

Comparison	O
of	O
the	O
Effects	O
of	O
Subcutaneous	O
Versus	O
Continuous	O
Infusion	O
of	O
Heparin	O
on	O
Key	O
Inflammatory	O
Parameters	O
Following	O
Sepsis	O
.	O

Sepsis	O
is	O
the	O
result	O
of	O
the	O
interaction	O
between	O
inflammatory	O
mediators	O
and	O
coagulation	O
pathway	O
.	O

Unfractionated	O
heparin	O
may	O
play	O
a	O
role	O
as	O
an	O
anti-inflammatory	O
agent	O
beyond	O
its	O
anticoagulatory	O
effect	O
in	O
sepsis	O
.	O

As	O
a	O
result	O
,	O
it	O
may	O
cause	O
reduction	O
in	O
organ	O
failure	O
rate	O
in	O
patients	O
with	O
sepsis	O
due	O
to	O
its	O
impact	O
on	O
both	O
inflammatory	O
and	O
coagulation	O
process	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
anti-inflammatory	O
effects	O
of	O
heparin	O
in	O
sepsis	O
.	O

Plasma	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
as	O
an	O
inflammatory	O
mediator	O
and	O
urinary	O
necoutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
as	O
a	O
marker	O
of	O
kidney	O
injury	O
were	O
investigated	O
.	O

This	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
32-	O
bed	O
intensive	O
care	O
unit	O
.	O

Thirty	O
patients	O
with	O
sepsis	O
were	O
randomized	O
to	O
receive	O
heparin	O
infusion	O
of	O
500	O
units/hour	O
or	O
5000	O
units	O
of	O
heparin	O
three	O
times	O
a	O
day	O
,	O
subcutaneously	O
.	O

The	O
plasma	O
level	O
of	O
PAI-1	O
and	O
urinary	O
level	O
of	O
NGAL	O
were	O
determined	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

The	O
infusion	O
group	O
had	O
a	O
lower	O
plasma	O
PAI-1	O
level	O
compared	O
to	O
the	O
subcutaneous	O
group	O
at	O
day	O
7	O
(	O
11.3	O
±	O
1.6	O
vs.	O
16.5	O
±	O
4.2	O
;	O
P	O
=	O
0.003	O
)	O
.	O

The	O
urinary	O
NGAL	O
level	O
was	O
lower	O
in	O
the	O
infusion	O
group	O
at	O
day	O
2	O
(	O
131.3	O
±	O
11.9	O
vs.	O
151.2	O
±	O
20.6	O
;	O
P	O
=	O
0.014	O
)	O
;	O
however	O
,	O
at	O
day	O
7	O
the	O
NGAL	O
level	O
was	O
decreased	O
in	O
the	O
subcutaneous	O
group	O
as	O
much	O
as	O
the	O
infusion	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
acute	B-P
physiology	I-P
and	I-P
chronic	I-P
health	I-P
evaluation	I-P
(	I-P
APACHE	I-P
)	I-P
II	I-P
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
scores	O
between	O
the	O
two	O
groups	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

Low-dose	O
heparin	O
infusion	O
compared	O
to	O
subcutaneous	O
heparin	O
can	O
decrease	O
the	O
plasma	O
PAI-1	O
and	O
urinary	O
NGAL	O
levels	O
more	O
rapidly	O
.	O

It	O
can	O
be	O
related	O
to	O
anti-inflammatory	O
effects	O
of	O
heparin	O
,	O
which	O
may	O
be	O
more	O
prominent	O
in	O
infusion	O
route	O
.	O

Engineering	O
monolayer	O
poration	O
for	O
rapid	O
exfoliation	O
of	O
microbial	O
membranes	O
.	O

The	O
spread	O
of	O
bacterial	O
resistance	O
to	O
traditional	O
antibiotics	O
continues	O
to	O
stimulate	O
the	O
search	O
for	O
alternative	O
antimicrobial	O
strategies	O
.	O

All	O
forms	O
of	O
life	O
,	O
from	O
bacteria	O
to	O
humans	O
,	O
are	O
postulated	O
to	O
rely	O
on	O
a	O
fundamental	O
host	O
defense	O
mechanism	O
,	O
which	O
exploits	O
the	O
formation	O
of	O
open	O
pores	O
in	O
microbial	O
phospholipid	O
bilayers	O
.	O

Here	O
we	O
predict	O
that	O
transmembrane	O
poration	O
is	O
not	O
necessary	O
for	O
antimicrobial	O
activity	O
and	O
reveal	O
a	O
distinct	O
poration	O
mechanism	O
that	O
targets	O
the	O
outer	O
leaflet	O
of	O
phospholipid	O
bilayers	O
.	O

Using	O
a	O
combination	O
of	O
molecular	O
-	O
scale	O
and	O
real-time	B-P
imaging	I-P
,	O
spectroscopy	O
and	O
spectrometry	O
approaches	O
,	O
we	O
introduce	O
a	O
structural	O
motif	O
with	O
a	O
universal	O
insertion	O
mode	O
in	O
reconstituted	O
membranes	O
and	O
live	O
bacteria	O
.	O

We	O
demonstrate	O
that	O
this	O
motif	O
rapidly	O
assembles	O
into	O
monolayer	O
pits	O
that	O
coalesce	O
during	O
progressive	O
membrane	O
exfoliation	O
,	O
leading	O
to	O
bacterial	O
cell	O
death	O
within	O
minutes	O
.	O

The	O
findings	O
offer	O
a	O
new	O
physical	O
basis	O
for	O
designing	O
effective	O
antibiotics	O
.	O

Remitting	O
Seronegative	O
Symmetrical	O
Synovitis	O
With	O
Pitting	O
Edema	O
:	O
Appearance	O
on	O
FDG	B-P
PET/CT	I-P
.	O

Remitting	O
seronegative	O
symmetrical	O
synovitis	O
with	O
pitting	O
edema	O
(	O
RS3PE	O
)	O
is	O
a	O
rare	O
condition	O
in	O
the	O
elderly	O
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	O
of	O
rheumatic	O
and	O
malignant	O
diseases	O
.	O

We	O
presented	O
a	O
62-	O
year	O
-old	O
man	O
with	O
the	O
diagnosis	O
of	O
RS3PE	O
based	O
on	O
the	O
clinical	O
sign	O
and	O
laboratory	O
data	O
.	O

Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	O
in	O
RS3PE	O
,	O
FDG	B-P
PET/CT	I-P
was	O
performed	O
to	O
exclude	O
occult	O
tumors	O
.	O

The	O
images	O
showed	O
multiple	O
,	O
symmetrically	O
,	O
diffusely	O
increased	O
F-FDG	O
uptake	O
in	O
the	O
soft	O
tissue	O
around	O
joints	O
and	O
bones	O
in	O
the	O
shoulders	O
,	O
hips	O
,	O
knees	O
,	O
and	O
ankles	O
.	O

Ulnar	O
Osteotomy	O
with	O
2-Pin	O
Unilateral	O
Gradual	O
Distraction	O
for	O
Treatment	O
of	O
Chronic	O
Monteggia	O
Fracture	O
:	O
A	O
Case	O
Report	O
.	O

Missed	O
Monteggia	O
fracture	O
leading	O
to	O
chronic	O
radial	O
head	O
dislocation	O
is	O
a	O
known	O
complication	O
.	O

The	O
surgical	O
treatment	O
options	O
remain	O
challenging	O
.	O

The	O
aim	O
of	O
treatment	O
is	O
to	O
reduce	O
the	O
radial	O
head	O
and	O
to	O
maintain	O
the	O
stability	O
of	O
the	O
elbow	O
in	O
all	O
ranges	O
of	O
motion	O
.	O

A	O
few	O
surgical	B-P
techniques	I-P
have	O
been	O
described	O
with	O
complications	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
13	O
years	O
old	O
boy	O
with	O
chronic	O
radial	O
head	O
dislocation	O
as	O
a	O
result	O
of	O
an	O
unrecognised	O
Monteggia	O
fracture	O
-	O
dislocation	O
for	O
eight	O
years	O
.	O

We	O
successfully	O
reduced	O
the	O
radial	O
head	O
and	O
corrected	O
the	O
cubital	O
valgus	O
from	O
45	O
degrees	O
to	O
10	O
degrees	O
with	O
a	O
proximal	O
ulna	O
osteotomy	O
and	O
gradual	O
distraction	O
with	O
2-pin	O
Monotube	O
external	O
fixator	O
.	O

The	O
correction	O
was	O
uneventful	O
with	O
good	O
functional	O
outcome	O
.	O

Preoperative	O
ultrasonographic	B-P
findings	O
of	O
internal	O
jugular	O
veins	O
and	O
carotid	O
arteries	O
in	O
kidney	O
transplant	O
recipients	O
.	O

Hemodialysis	O
via	O
the	O
internal	O
jugular	O
vein	O
(	O
IJV	O
)	O
has	O
been	O
widely	O
used	O
for	O
patients	O
with	O
end	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
,	O
as	O
they	O
have	O
a	O
higher	O
risk	O
of	O
arterial	O
diseases	O
.	O

We	O
investigated	O
the	O
ultrasonographic	B-P
findings	O
of	O
the	O
IJV	O
and	O
carotid	O
artery	O
(	O
CA	O
)	O
in	O
recipients	O
of	O
kidney	O
transplantation	O
(	O
KT	O
)	O
and	O
identified	O
factors	O
influencing	O
IJV	O
/	O
CA	O
abnormalities	O
.	O

We	O
enrolled	O
120	O
adult	O
KT	O
recipients	O
.	O

Patients	O
in	O
group	O
A	O
(	O
n	O
=	O
57	O
)	O
had	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
,	O
while	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
63	O
)	O
were	O
not	O
yet	O
on	O
dialysis	O
or	O
undergoing	O
dialysis	O
methods	O
not	O
involving	O
the	O
IJV	O
.	O

The	O
day	O
before	O
surgery	O
,	O
we	O
evaluated	O
the	O
state	O
of	O
the	O
IJV	O
and	O
CA	O
using	O
ultrasonography	B-P
.	O

We	O
followed	O
patients	O
with	O
IJV	O
stenosis	O
for	O
six	O
months	O
after	O
KT	O
.	O

Ultrasonography	B-P
revealed	O
that	O
four	O
patients	O
(	O
7	O
%	O
)	O
in	O
group	O
A	O
had	O
IJV	O
abnormalities	O
,	O
while	O
no	O
patients	O
in	O
group	O
B	O
had	O
abnormalities	O
(	O
P	O
=	O
0.118	O
)	O
.	O

Of	O
the	O
four	O
patients	O
with	O
abnormalities	O
,	O
one	O
with	O
57.4	O
%	O
stenosis	O
normalized	O
during	O
follow-	O
up	O
.	O

However	O
,	O
another	O
patient	O
with	O
90.1	O
%	O
stenosis	O
progressed	O
to	O
occlusion	O
,	O
while	O
the	O
two	O
patients	O
with	O
total	O
occlusion	O
remained	O
the	O
same	O
.	O

Twenty	O
patients	O
in	O
group	O
A	O
(	O
n	O
=	O
11	O
)	O
and	O
B	O
(	O
n	O
=	O
9	O
)	O
had	O
several	O
CA	O
abnormalities	O
(	O
P	O
=	O
0.462	O
)	O
.	O

Upon	O
multivariate	O
analysis	O
with	O
stepwise	O
selection	O
,	O
height	O
and	O
age	O
were	O
significantly	O
correlated	O
with	O
IJV	O
stenosis	O
(	O
P	O
=	O
0.043	O
,	O
odds	O
ratio	O
=	O
0.9	O
)	O
and	O
CA	O
abnormality	O
(	O
P	O
=	O
0.012	O
,	O
odds	O
ratio	O
=	O
1.1	O
)	O
,	O
respectively	O
.	O

IJV	O
abnormalities	O
(	O
especially	O
with	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
)	O
and	O
CA	O
abnormalities	O
may	O
be	O
present	O
in	O
ESRD	O
patients	O
.	O

Therefore	O
,	O
we	O
recommend	O
ultrasonographic	B-P
evaluation	O
before	O
catheterization	O
.	O

Cardiovascular	B-P
magnetic	I-P
resonance	I-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
left	O
bundle	O
branch	O
block	O
.	O

Patients	O
with	O
left	O
bundle	O
branch	O
block	O
(	O
LBBB	O
)	O
can	O
exhibit	O
mechanical	O
dyssynchrony	O
which	O
may	O
contribute	O
to	O
heart	O
failure	O
;	O
such	O
patients	O
may	O
benefit	O
from	O
cardiac	O
resynchronization	O
treatment	O
(	O
CRT	O
)	O
.	O

While	O
cardiac	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
CMR	B-P
)	O
has	O
become	O
a	O
common	O
part	O
of	O
heart	O
failure	O
work-up	B-P
,	O
CMR	B-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
have	O
not	O
been	O
well	O
characterized	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
potential	O
of	O
CMR	B-P
to	O
characterize	O
mechanical	O
features	O
of	O
LBBB	O
.	O

CMR	B-P
examinations	O
from	O
43	O
patients	O
with	O
LBBB	O
on	O
their	O
electrocardiogram	O
,	O
but	O
without	O
significant	O
focal	O
structural	O
abnormalities	O
,	O
and	O
from	O
43	O
age-	O
and	O
gender	O
-matched	O
normal	O
controls	O
were	O
retrospectively	O
reviewed	O
.	O

The	O
following	O
mechanical	O
features	O
of	O
LBBB	O
were	O
evaluated	O
:	O
septal	O
flash	O
(	O
SF	O
)	O
,	O
apical	O
rocking	O
(	O
AR	O
)	O
,	O
delayed	O
aortic	O
valve	O
opening	O
measured	O
relative	O
to	O
both	O
end-diastole	O
(	O
AVOED	O
)	O
and	O
pulmonic	O
valve	O
opening	O
(	O
AVOPVO	O
)	O
,	O
delayed	O
left-ventricular	O
(	O
LV	O
)	O
free-wall	O
contraction	O
,	O
and	O
curvatures	O
of	O
the	O
septum	O
and	O
LV	O
free-wall	O
.	O

Septal	O
displacement	O
curves	O
were	O
also	O
generated	O
,	O
using	O
feature	O
-tracking	O
techniques	O
.	O

The	O
echocardiographic	B-P
findings	O
of	O
LBBB	O
were	O
also	O
reviewed	O
in	O
those	O
subjects	O
for	O
whom	O
they	O
were	O
available	O
.	O

LBBB	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
SF	O
and	O
AR	O
;	O
within	O
the	O
LBBB	O
group	O
,	O
79	O
%	O
had	O
SF	O
and	O
65	O
%	O
had	O
AR	O
.	O

Delayed	O
AVOED	O
,	O
AVOPVO	O
,	O
and	O
delayed	O
LV	O
free-wall	O
contraction	O
were	O
significantly	O
associated	O
with	O
LBBB	O
.	O

AVOED	O
and	O
AVOPVO	O
positively	O
correlated	O
with	O
QRS	O
duration	O
and	O
negatively	O
correlated	O
with	O
ejection	B-P
fraction	I-P
.	O

Hearts	O
with	O
electrocardiographic	B-P
evidence	O
of	O
LBBB	O
showed	O
lower	O
septal-to-LV	O
free-wall	O
curvature	O
ratios	O
at	O
end-diastole	O
compared	O
to	O
normal	O
controls	O
.	O

CMR	B-P
can	O
be	O
used	O
to	O
identify	O
and	O
evaluate	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
.	O

None	O
of	O
the	O
normal	O
controls	O
showed	O
the	O
mechanical	O
features	O
associated	O
with	O
LBBB	O
.	O

Moreover	O
,	O
not	O
all	O
patients	O
with	O
LBBB	O
showed	O
the	O
same	O
degree	O
of	O
mechanical	O
dyssynchrony	O
,	O
which	O
could	O
have	O
implications	O
for	O
CRT	O
.	O

Clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
for	O
degenerative	O
lumbar	O
spondylolisthesis	O
with	O
stenosis	O
.	O

Laminectomy	O
with	O
posterior	O
lumbar	O
interbody	O
fusion	O
(	O
PLIF	O
)	O
has	O
been	O
shown	O
to	O
achieve	O
satisfactory	O
clinical	O
outcomes	O
,	O
but	O
it	O
leads	O
to	O
potential	O
adverse	O
consequences	O
associated	O
with	O
extensive	O
disruption	O
of	O
posterior	O
bony	O
and	O
soft	O
tissue	O
structures	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
the	O
clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
(	O
BDUA	O
)	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
(	O
TLIF	O
)	O
and	O
laminectomy	O
with	O
PLIF	O
in	O
the	O
treatment	O
of	O
degenerative	O
lumbar	O
spondylolisthesis	O
(	O
DLS	O
)	O
with	O
stenosis	O
.	O

This	O
is	O
a	O
prospective	O
cohort	O
study	O
.	O

This	O
study	O
compared	O
43	O
patients	O
undergoing	O
BDUA	O
+	O
TLIF	O
and	O
40	O
patients	O
undergoing	O
laminectomy	O
+	O
PLIF	O
.	O

Visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
low	O
back	O
pain	O
and	O
leg	O
pain	O
,	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
and	O
Zurich	O
Claudication	O
Questionnaire	O
(	O
ZCQ	O
)	O
score	O
.	O

The	O
clinical	O
outcomes	O
were	O
assessed	O
,	O
and	O
intraoperative	O
data	O
and	O
complications	O
were	O
collected	O
.	O

Radiographic	O
outcomes	O
included	O
slippage	O
of	O
the	O
vertebra	O
,	O
disc	O
space	O
height	O
,	O
segmental	O
lordosis	O
,	O
and	O
final	O
fusion	O
rate	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
The	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
81572168	O
)	O
.	O

There	O
were	O
significant	O
improvements	O
in	O
clinical	O
and	O
radiographic	O
outcomes	O
from	O
before	O
surgery	O
to	O
3	O
months	O
and	O
2	O
years	O
after	O
surgery	O
within	O
each	O
group	O
.	O

Analysis	O
of	O
leg	O
pain	O
VAS	O
and	O
ZCQ	O
scores	O
showed	O
no	O
significant	O
differences	O
in	O
improvement	O
between	O
groups	O
at	O
either	O
follow-up	O
.	O

The	O
mean	O
improvements	O
in	O
low	O
back	O
pain	O
VAS	B-P
and	O
ODI	O
scores	O
were	O
significantly	O
greater	O
in	O
the	O
BDUA	O
+	O
TLIF	O
group	O
than	O
in	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
final	O
fusion	O
rate	O
at	O
2-year	O
follow-up	O
.	O

The	O
BDUA	O
+	O
TLIF	O
group	O
had	O
significantly	O
less	O
blood	O
loss	O
,	O
shorter	O
length	O
of	O
postoperative	O
hospital	O
stay	O
,	O
and	O
lower	O
complication	O
rate	O
compared	O
with	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

When	O
compared	O
with	O
the	O
conventional	O
laminectomy	O
+	O
PLIF	O
procedure	O
,	O
the	O
BDUA	O
+	O
TLIF	O
procedure	O
achieves	O
similar	O
and	O
satisfactory	O
effects	O
of	O
decompression	O
and	O
fusion	O
for	O
DLS	O
with	O
stenosis	O
.	O

The	O
BDUA	O
+	O
TLIF	O
procedure	O
appears	O
to	O
be	O
associated	O
with	O
less	O
postoperative	O
low	O
back	O
discomfort	O
and	O
quicker	O
recovery	O
.	O

Inter-observer	O
agreement	O
for	O
clinical	O
examinations	O
of	O
foot	O
lesions	O
of	O
sheep	O
.	O

In	O
sheep	O
,	O
the	O
diagnosis	O
of	O
foot	O
lesions	O
is	O
routinely	O
based	O
on	O
physical	O
examination	O
of	O
the	O
hoof	O
.	O

Correct	O
diagnosis	O
is	O
important	O
for	O
the	O
effective	O
treatment	O
,	O
prevention	O
and	O
control	O
of	O
both	O
infectious	O
and	O
non-infectious	O
causes	O
of	O
lameness	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
inter-observer	O
agreement	O
for	O
clinical	O
examination	O
of	O
ovine	O
foot	O
lesions	O
.	O

Eight	O
observers	O
of	O
varying	O
experience	O
,	O
training	O
and	O
occupation	O
performed	O
foot	B-P
examinations	I-P
on	O
a	O
total	O
of	O
1158	O
sheep	O
from	O
38	O
farms	O
across	O
North	O
England	O
and	O
Wales	O
.	O

On	O
each	O
farm	O
,	O
a	O
group	O
of	O
two	O
to	O
four	O
observers	O
independently	O
examined	O
a	O
sample	O
of	O
24	O
to	O
30	O
sheep	O
to	O
diagnose	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
foot	O
lesions	O
including	O
white	O
line	O
lesions	O
(	O
WL	O
)	O
,	O
contagious	O
ovine	O
digital	O
dermatitis	O
(	O
CODD	O
)	O
,	O
footrot	O
(	O
FR	O
)	O
,	O
inter-digital	O
dermatitis	O
(	O
ID	O
)	O
and	O
toe	O
granuloma	O
(	O
TG	O
)	O
.	O

The	O
inter-observer	O
agreement	O
of	O
foot	O
lesion	O
assessments	O
was	O
examined	O
using	O
Fleiss	O
kappa	O
(	O
κ	O
)	O
,	O
and	O
Cohen	O
's	O
κ	O
examined	O
the	O
paired	O
agreement	O
between	O
the	O
test	O
standard	O
observer	O
(	O
TSO	O
)	O
and	O
each	O
observer	O
.	O

Scoring	O
differences	O
with	O
the	O
TSO	O
were	O
examined	O
as	O
the	O
percentage	O
of	O
scoring	O
errors	O
and	O
assessed	O
for	O
evidence	O
of	O
systematic	O
scoring	O
bias	O
.	O

With	O
the	O
exception	O
of	O
WL	O
(	O
maximum	O
error	O
rate	O
33.3	O
%	O
)	O
,	O
few	O
scoring	O
differences	O
with	O
the	O
TSO	O
occurred	O
(	O
maximum	O
error	O
rate	O
3.3	O
%	O
)	O
.	O

This	O
suggests	O
that	O
observers	O
can	O
achieve	O
good	O
levels	O
of	O
reliability	O
when	O
diagnosing	O
most	O
of	O
the	O
commonly	O
observed	O
foot	O
conditions	O
associated	O
with	O
lameness	O
in	O
sheep	O
.	O

Cerebromicrovascular	O
dysfunction	O
predicts	O
cognitive	O
decline	O
and	O
gait	O
abnormalities	O
in	O
a	O
mouse	O
model	O
of	O
whole	O
brain	O
irradiation	O
-induced	O
accelerated	O
brain	O
senescence	O
.	O

Whole	O
brain	O
irradiation	O
(	O
WBI	O
)	O
is	O
a	O
mainstream	O
therapy	O
for	O
patients	O
with	O
both	O
identifiable	O
brain	O
metastases	O
and	O
prophylaxis	O
for	O
microscopic	O
malignancies	O
.	O

However	O
,	O
it	O
also	O
promotes	O
accelerated	O
senescence	O
in	O
healthy	O
tissues	O
and	O
leads	O
to	O
progressive	O
cognitive	O
dysfunction	O
in	O
up	O
to	O
50	O
%	O
of	O
tumor	O
patients	O
surviving	O
long	O
term	O
after	O
treatment	O
,	O
due	O
to	O
γ-irradiation	O
-induced	O
cerebromicrovascular	O
injury	O
.	O

Moment-to-moment	O
adjustment	O
of	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
via	O
neuronal	O
activity	O
-dependent	O
cerebromicrovascular	O
dilation	O
(	O
functional	O
hyperemia	O
)	O
has	O
a	O
critical	O
role	O
in	O
maintenance	O
of	O
healthy	O
cognitive	O
function	O
.	O

To	O
determine	O
whether	O
cognitive	O
decline	O
induced	O
by	O
WBI	O
associates	O
with	O
impaired	O
cerebromicrovascular	O
function	O
,	O
C56BL/6	O
mice	O
(	O
3	O
months	O
)	O
subjected	O
to	O
a	O
clinically	O
relevant	O
protocol	O
of	O
fractionated	O
WBI	O
(	O
5	O
Gy	O
twice	O
weekly	O
for	O
4	O
weeks	O
)	O
and	O
control	O
mice	O
were	O
compared	O
.	O

Mice	O
were	O
tested	O
for	O
spatial	O
memory	O
performance	O
(	O
radial	O
arm	O
water	O
maze	O
)	O
,	O
sensorimotor	O
coordination	O
(	O
computerized	B-P
gait	I-P
analysis	I-P
,	O
CatWalk	O
)	O
,	O
and	O
cerebromicrovascular	O
function	O
(	O
whisker	O
-	O
stimulation	O
-induced	O
increases	O
in	O
CBF	O
,	O
measured	O
by	O
laser	B-P
Doppler	I-P
flowmetry	I-P
)	O
at	O
3	O
to	O
6	O
months	O
post	O
-	O
irradiation	O
.	O

We	O
found	O
that	O
mice	O
with	O
WBI	O
exhibited	O
impaired	O
cerebromicrovascular	O
function	O
at	O
3	O
months	O
post	O
-	O
irradiation	O
,	O
which	O
was	O
associated	O
with	O
impaired	O
performance	O
in	O
the	O
radial	O
arm	O
water	O
maze	O
.	O

At	O
6	O
months	O
,	O
post	O
-	O
irradiation	O
progressive	O
impairment	O
in	O
gait	O
coordination	O
(	O
including	O
changes	O
in	O
the	O
regularity	O
index	O
and	O
phase	O
dispersion	O
)	O
was	O
also	O
evident	O
.	O

Collectively	O
,	O
our	O
findings	O
provide	O
evidence	O
for	O
early	O
and	O
persisting	O
neurovascular	O
impairment	O
after	O
a	O
clinically	O
relevant	O
protocol	O
of	O
fractionated	O
WBI	O
,	O
which	O
predict	O
early	O
manifestations	O
of	O
cognitive	O
impairment	O
.	O

Successful	O
treatment	O
with	O
hyperbaric	O
oxygen	O
therapy	O
for	O
severe	O
brain	O
edema	O
characterized	O
by	O
radiological	O
appearance	O
of	O
pseudosubarachnoid	O
hemorrhage	O
in	O
a	O
child	O
.	O

Pseudosubarachnoid	O
hemorrhage	O
(	O
PSAH	O
)	O
is	O
a	O
rare	O
neuroradiological	O
finding	O
,	O
particularly	O
in	O
pediatric	O
patients	O
.	O

The	O
appearance	O
of	O
PSAH	O
is	O
commonly	O
associated	O
with	O
poor	O
clinical	O
outcome	O
due	O
to	O
refractory	O
cerebral	O
edema	O
.	O

Recent	O
clinical	O
trials	O
have	O
favored	O
hyperbaric	O
oxygen	O
therapy	O
(	O
HBOT	O
)	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
adult	O
patients	O
with	O
severe	O
head	O
injuries	O
.	O

The	O
present	O
report	O
describes	O
a	O
pediatric	O
case	O
of	O
diffuse	O
brain	O
edema	O
characterized	O
by	O
the	O
radiological	O
appearance	O
of	O
PSAH	O
successfully	O
treated	O
with	O
HBOT	O
.	O

An	O
adolescent	O
boy	O
collapsed	O
unconscious	O
following	O
convulsion	O
for	O
3-5	O
min	O
with	O
fever	O
and	O
headache	O
for	O
2	O
days	O
.	O

A	O
brain	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scan	I-P
provided	O
an	O
image	O
compatible	O
with	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
.	O

Lumbar	O
puncture	O
was	O
conducted	O
on	O
admission	O
to	O
hospital	O
and	O
showed	O
no	O
evidence	O
of	O
SAH	O
.	O

The	O
CT	B-P
scan	I-P
was	O
again	O
considered	O
and	O
eventually	O
interpreted	O
as	O
PSAH	O
.	O

The	O
patient	O
received	O
drug	O
treatment	O
including	O
acyclovir	O
and	O
mannitol	O
,	O
but	O
the	O
condition	O
deteriorated	O
rapidly	O
.	O

HBOT	O
was	O
administered	O
at	O
72	O
h	O
post	O
admission	O
and	O
the	O
condition	O
was	O
clearly	O
improved	O
following	O
the	O
initial	O
therapy	O
.	O

The	O
patient	O
was	O
discharged	O
with	O
20	O
sessions	O
of	O
HBOT	O
and	O
recovered	O
completely	O
after	O
1	O
year	O
.	O

The	O
appearance	O
of	O
PSAH	O
indicates	O
severe	O
cerebral	O
edema	O
refractory	O
to	O
treatment	O
with	O
conventional	O
internal	O
medicine	O
.	O

HBOT	O
maybe	O
an	O
effective	O
therapeutic	O
strategy	O
for	O
this	O
condition	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
ultrasound	O
device	O
:	O
reliability	O
of	O
cortical	O
bone	O
thickness	O
measures	O
and	O
their	O
relationship	O
to	O
regional	O
bone	O
mineral	O
density	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
device	O
is	O
currently	O
available	O
and	O
this	O
study	O
analyzed	O
(	O
I	O
)	O
its	O
relative	O
and	O
absolute	O
intra-	O
and	O
inter-session	O
reliability	O
and	O
(	O
II	O
)	O
the	O
relationship	O
between	O
the	O
data	O
provided	O
by	O
Bindex	O
(	O
®	O
)	O
-QUS	O
and	O
the	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
measured	O
by	O
dual-energy	B-P
x-ray	I-P
absorptiometry	I-P
at	O
corresponding	O
skeletal	O
sites	O
in	O
young	O
and	O
healthy	O
subjects	O
(	O
age	O
:	O
25.0	O
±	O
3.6	O
years	O
)	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
calculates	O
a	O
density	O
index	O
on	O
the	O
basis	O
of	O
the	O
thickness	O
of	O
cortical	O
bone	O
measured	O
at	O
the	O
distal	O
radius	O
and	O
the	O
distal	O
plus	O
proximal	O
tibia	O
.	O

The	O
data	O
show	O
a	O
very	O
good	O
relative	O
and	O
absolute	O
intra-	O
(	O
ICC	O
=	O
0.977	O
,	O
CV	O
=	O
1.5	O
%	O
)	O
and	O
inter-session	O
reliability	O
(	O
ICC	O
=	O
0.978	O
,	O
CV	O
=	O
1.4	O
%	O
)	O
for	O
the	O
density	O
index	O
.	O

The	O
highest	O
positive	O
correlations	O
were	O
found	O
between	O
cortical	O
thickness	O
and	O
BMD	O
for	O
the	O
distal	O
radius	O
and	O
distal	O
tibia	O
(	O
r	O
⩾	O
0.71	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
data	O
indicate	O
that	O
the	O
Bindex	O
(	O
®	O
)	O
-QUS	O
parameters	O
are	O
repeatable	O
within	O
and	O
between	O
measurement	O
sessions	O
.	O

Furthermore	O
,	O
the	O
measurements	O
reflect	O
the	O
BMD	O
at	O
specific	O
skeletal	O
sites	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	O
of	O
skeletal	O
adaptations	O
.	O

Supramolecular	O
Recognition	O
of	O
Amino	O
Acids	O
by	O
Twisted	O
Cucurbit	O
[	O
14	O
]	O
uril	O
.	O

Binding	O
interactions	O
between	O
twisted	O
cucurbit	O
[	O
14	O
]	O
uril	O
(	O
tQ	O
[	O
14	O
]	O
)	O
and	O
twenty	O
standard	O
amino	O
acids	O
(	O
AAs	O
)	O
have	O
been	O
investigated	O
by	O
NMR	B-P
spectroscopy	I-P
and	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
in	O
aqueous	O
HCl	O
solutions	O
and	O
in	O
DMSO	O
.	O

The	O
results	O
showed	O
that	O
tQ	O
[	O
14	O
]	O
displays	O
clear	O
binding	O
affinity	O
for	O
AAs	O
with	O
a	O
positively	O
charged	O
side	O
chain	O
or	O
containing	O
an	O
aromatic	O
ring	O
,	O
but	O
weaker	O
binding	O
affinity	O
for	O
AAs	O
with	O
hydrophobic	O
or	O
polar	O
side	O
chains	O
,	O
with	O
the	O
binding	O
mode	O
depending	O
on	O
the	O
type	O
of	O
side	O
chain	O
present	O
in	O
the	O
AAs	O
.	O

Options	O
in	O
treating	O
trigeminal	O
neuralgia	O
:	O
Experience	O
with	O
195	O
patients	O
.	O

For	O
patients	O
with	O
medically	O
unresponsive	O
trigeminal	O
neuralgia	O
(	O
TN	O
)	O
,	O
surgical	O
options	O
include	O
microvascular	O
decompression	O
(	O
MVD	O
)	O
,	O
radiofrequency	O
rhizotomy	O
(	O
RF	O
)	O
,	O
and	O
stereotactic	O
radiosurgery	O
(	O
SRS	O
)	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
the	O
risks	O
and	O
benefits	O
and	O
cost	O
inherent	O
with	O
each	O
of	O
the	O
three	O
modalities	O
,	O
we	O
performed	O
a	O
retrospective	O
review	O
of	O
our	O
experience	O
with	O
195	O
cases	O
of	O
TN	O
treated	O
over	O
the	O
past	O
15	O
years	O
.	O

Since	O
2001	O
,	O
195	O
patients	O
with	O
previously	O
untreated	O
TN	O
were	O
managed	O
:	O
with	O
MVD	O
in	O
79	O
,	O
RF	O
in	O
36	O
,	O
and	O
SRS	O
in	O
80	O
.	O

All	O
patients	O
reported	O
herein	O
underwent	O
preoperative	O
MRI	B-P
.	O

Women	O
outnumbered	O
men	O
122/73	O
(	O
p=0.045	O
)	O
.	O

Follow-up	O
after	O
surgery	O
was	O
32±46	O
months	O
.	O

The	O
patients	O
qualifying	O
for	O
MVD	O
were	O
generally	O
healthier	O
and	O
younger	O
,	O
with	O
a	O
mean	O
age	O
±	O
SD	O
of	O
57±14	O
,	O
compared	O
to	O
those	O
undergoing	O
RF	O
(	O
75±15	O
)	O
or	O
SRS	O
(	O
73±13	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
case	O
of	O
relapse	O
,	O
medical	O
treatment	O
was	O
always	O
tried	O
and	O
failed	O
prior	O
to	O
consideration	O
of	O
surgical	O
intervention	O
.	O

A	O
second	O
surgical	O
procedure	O
was	O
necessary	O
in	O
2	O
,	O
23	O
,	O
and	O
18	O
patients	O
initially	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
respectively	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
the	O
patients	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
,	O
the	O
average	O
number	O
of	O
procedures	O
per	O
patient	O
necessary	O
to	O
achieve	O
pain	O
control	O
was	O
1.1	O
,	O
2.0	O
,	O
and	O
1.3	O
respectively	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
7	O
complications	O
in	O
the	O
patients	O
treated	O
with	O
MVD	O
but	O
no	O
deaths	O
.	O

Numbness	O
was	O
present	O
in	O
13	O
,	O
18	O
,	O
and	O
29	O
patients	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
respectively	O
(	O
p=0.008	O
)	O
.	O

MVD	O
for	O
TN	O
is	O
the	O
treatment	O
least	O
likely	O
to	O
fail	O
or	O
require	O
additional	O
treatment	O
.	O

Patients	O
who	O
underwent	O
MVD	O
were	O
younger	O
than	O
those	O
undergoing	O
RF	O
or	O
SRS	O
.	O

The	O
highest	O
rate	O
of	O
recurrence	O
of	O
TN	O
was	O
encountered	O
in	O
patients	O
undergoing	O
RF	O
(	O
64	O
%	O
)	O
.	O

Facial	O
numbness	O
was	O
least	O
likely	O
to	O
occur	O
with	O
MVD	O
(	O
16	O
%	O
)	O
compared	O
to	O
RF	O
and	O
SRS	O
(	O
50	O
%	O
and	O
36	O
%	O
respectively	O
)	O
.	O

Body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

Overweight	O
and	O
obesity	O
is	O
associated	O
with	O
lower	O
rates	O
of	O
suicide	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
with	O
different	O
suicide	O
methods	O
.	O

We	O
studied	O
the	O
association	O
between	O
groups	O
of	O
body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

We	O
identified	O
all	O
medicolegal	O
autopsy	B-P
cases	O
with	O
a	O
cause	O
of	O
death	O
due	O
to	O
external	O
causes	O
in	O
Sweden	O
during	O
1999-2013	O
(	O
N	O
=	O
39,368	O
)	O
and	O
included	O
11,715	O
suicides	O
and	O
13,316	O
accidents	O
or	O
homicides	O
as	O
controls	O
.	O

We	O
applied	O
multinomial	O
regression	O
models	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
year	O
and	O
season	O
of	O
death	O
.	O

Obesity	O
was	O
associated	O
with	O
suicidal	O
intoxication	O
,	O
OR	O
1.15	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.02	O
,	O
1.30	O
]	O
and	O
negatively	O
associated	O
with	O
all	O
other	O
suicide	O
methods	O
studied	O
.	O

Underweight	O
showed	O
a	O
negative	O
association	O
with	O
suicidal	O
drowning	O
and	O
there	O
was	O
an	O
indication	O
towards	O
a	O
negative	O
association	O
with	O
hanging	O
in	O
men	O
OR	O
0.81	O
(	O
95	O
%	O
CI	O
0.65	O
,	O
1.01	O
)	O
.	O

We	O
conclude	O
that	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
is	O
associated	O
with	O
the	O
choice	O
of	O
suicide	O
method	O
.	O

This	O
may	O
be	O
of	O
importance	O
in	O
a	O
public	O
health	O
perspective	O
,	O
e.g	O
.	O

potential	O
for	O
prevention	O
of	O
intoxications	O
.	O

In	O
the	O
practice	O
of	O
forensic	O
medicine	O
,	O
the	O
physician	O
's	O
level	O
of	O
suspicion	O
may	O
rise	O
if	O
the	O
apparent	O
suicidal	O
method	O
is	O
less	O
common	O
for	O
the	O
individual	O
characteristics	O
of	O
the	O
deceased	O
,	O
such	O
as	O
BMI	O
.	O

Assessment	O
of	O
cerebral	O
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	O
using	O
3D	B-P
spiral	I-P
ASL	I-P
MRI	I-P
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
a	O
new	O
non-Cartesian	B-P
cylindrically-distributed	I-P
spiral	I-P
3D	I-P
pseudo-continuous	I-P
arterial	I-P
spin	I-P
labeling	I-P
(	I-P
pCASL	I-P
)	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
pulse	O
sequence	O
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
response	O
to	O
an	O
acetazolamide	O
(	O
ACZ	O
)	O
vasodilator	O
challenge	O
.	O

MRI	B-P
exams	I-P
were	O
performed	O
on	O
two	O
3	O
Tesla	O
Philips	O
Ingenia	O
systems	O
using	O
32	O
channel	O
head	O
coil	O
arrays	O
.	O

After	O
local	O
institutional	O
review	O
board	O
approval	O
,	O
the	O
3D	B-P
spiral-based	I-P
pCASL	I-P
technique	I-P
was	O
added	O
to	O
a	O
standard	O
brain	B-P
MRI	I-P
exam	I-P
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4-22.2years	O
)	O
.	O

All	O
patients	O
were	O
administered	O
ACZ	O
for	O
clinically	O
indicated	O
reasons	O
.	O

Quantitative	O
whole-brain	B-P
CBF	I-P
measurements	I-P
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
ACZ	O
to	O
assess	O
cerebrovascular	O
reserve	O
.	O

3D	B-P
spiral	I-P
pCASL	I-P
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	O
.	O

In	O
11	O
patients	O
,	O
CBF	O
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	O
of	O
ACZ	O
.	O

In	O
the	O
two	O
remaining	O
patients	O
,	O
CBF	O
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
ACZ	O
.	O

The	O
group	O
average	O
change	O
in	O
CBF	O
due	O
to	O
ACZ	O
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p	O
<	O
0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t-test	O
analysis	O
.	O

CBF	O
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B-P
angiography	I-P
and	O
clinical	O
findings	O
.	O

3D	B-P
cylindrically-distributed	I-P
spiral	I-P
pCASL	I-P
MRI	I-P
provides	O
a	O
robust	O
approach	O
to	O
assess	O
cerebral	O
blood	O
flow	O
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O

Dynamic	O
and	O
steady-state	O
oxygen	O
-	O
dependent	O
lung	B-P
relaxometry	I-P
using	O
inversion	B-P
recovery	I-P
ultra-fast	I-P
steady-state	I-P
free	I-P
precession	I-P
imaging	I-P
at	O
1.5	O
T.	O
To	O
demonstrate	O
the	O
feasibility	O
of	O
oxygen	O
-	O
dependent	O
relaxometry	O
in	O
human	O
lung	O
using	O
an	O
inversion	O
recovery	O
ultra-fast	O
steady-state	O
free	O
precession	O
(	O
IR-ufSSFP	O
)	O
technique	O
.	O

Electrocardiogram-triggered	B-P
pulmonary	I-P
relaxometry	I-P
with	O
IR-ufSSFP	B-P
was	O
performed	O
in	O
7	O
healthy	O
human	O
subjects	O
at	O
1.5	O
T.	O
The	O
data	O
were	O
acquired	O
under	O
both	O
normoxic	O
and	O
hyperoxic	O
conditions	O
.	O

In	O
a	O
single	O
breath	O
-	O
hold	O
of	O
less	O
than	O
9	O
seconds	O
,	O
30	O
transient	O
state	O
IR-ufSSFP	O
images	O
were	O
acquired	O
,	O
yielding	O
longitudinal	B-P
(	I-P
T1	I-P
)	I-P
and	O
transversal	B-P
(	I-P
T2	I-P
)	I-P
relaxometry	I-P
parameter	O
maps	O
using	O
voxel	O
-wise	O
nonlinear	O
fitting	O
.	O

Possible	O
spatial	O
misalignments	O
between	O
consecutive	O
IR-ufSSFP	B-P
parameter	O
maps	O
were	O
corrected	O
using	O
elastic	O
image	O
registration	O
.	O

Furthermore	O
,	O
dynamic	O
relaxometry	B-P
oxygen	O
wash-in	B-P
and	O
wash-out	B-P
scans	I-P
were	O
performed	O
in	O
one	O
volunteer	O
.	O

From	O
this	O
,	O
T1	O
-related	O
wash-in	O
and	O
wash-out	O
time	O
constants	O
(	O
τwi	O
,	O
τwo	O
)	O
were	O
calculated	O
voxel	O
-wise	O
on	O
registered	O
maps	O
using	O
an	O
exponential	O
fitting	O
model	O
.	O

For	O
healthy	O
lung	O
,	O
observed	O
T1	O
values	O
were	O
1399	O
±	O
77	O
and	O
1290	O
±	O
76	O
ms	O
under	O
normoxic	O
and	O
hyperoxic	O
conditions	O
,	O
respectively	O
.	O

Oxygen	O
-related	O
reduction	O
of	O
T1	O
was	O
statistically	O
significant	O
in	O
every	O
volunteer	O
.	O

No	O
statistically	O
significant	O
change	O
,	O
however	O
,	O
was	O
observed	O
in	O
T2	O
,	O
with	O
normoxic	O
and	O
hyperoxic	O
T2	O
values	O
of	O
55	O
±	O
16	O
and	O
56	O
±	O
17	O
ms	O
,	O
respectively	O
.	O

The	O
observed	O
average	O
τwi	O
was	O
87.0	O
±	O
28.7	O
seconds	O
,	O
whereas	O
the	O
average	O
τwo	O
was	O
73.5	O
±	O
21.6	O
seconds	O
.	O

IR-ufSSFP	B-P
allows	O
fast	O
,	O
steady-state	O
,	O
and	O
dynamic	O
oxygen	O
-	O
dependent	O
relaxometry	B-P
of	O
the	O
human	O
lung	O
.	O

Magn	O
Reson	O
Med	O
,	O
2017	O
.	O

©	O
2017	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O

Interleukin-15	O
as	O
a	O
potential	O
new	O
target	O
in	O
Sjögren	O
's	O
syndrome	O
-	O
associated	O
inflammation	O
.	O

IL-15	O
is	O
a	O
key	O
regulatory	O
cytokine	O
that	O
shares	O
many	O
biological	O
properties	O
with	O
IL-2	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
IL-15	O
could	O
be	O
up-regulated	O
in	O
T	O
cell	O
-mediated	O
inflammatory	O
disorders	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
inflammatory	O
bowel	O
diseases	O
.	O

However	O
,	O
the	O
role	O
and	O
expression	O
of	O
IL-15	O
in	O
the	O
inflammatory	O
autoimmune	O
disease	O
Sjögren	O
's	O
syndrome	O
(	O
SS	O
)	O
has	O
not	O
been	O
investigated	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
expression	O
of	O
IL-15	O
mRNA	O
and	O
protein	O
in	O
minor	O
salivary	O
gland	O
(	O
MSG	O
)	O
biopsy	O
specimens	O
and	O
in	O
human	O
salivary	O
gland	O
epithelial	O
cell	O
(	O
SGEC	O
)	O
cultures	O
obtained	O
from	O
patients	O
with	O
primary	O
SS	O
(	O
pSS	O
)	O
and	O
compared	O
their	O
expression	O
with	O
that	O
seen	O
in	O
normal	O
healthy	O
control	O
subjects	O
.	O

IL-15	O
gene	O
and	O
protein	O
analysis	O
revealed	O
that	O
SGEC	O
are	O
able	O
to	O
produce	O
IL-15	O
.	O

Results	O
obtained	O
demonstrated	O
that	O
the	O
number	O
of	O
IL-15	O
(	O
+	O
)	O
cultured	O
SGEC	O
was	O
significantly	O
higher	O
in	O
cells	O
derived	O
from	O
patients	O
with	O
pSS	O
in	O
comparison	O
with	O
SGEC	O
from	O
healthy	O
subjects	O
;	O
similar	O
results	O
were	O
obtained	O
for	O
IL-15	O
immunoreactivity	O
by	O
using	O
immunohistochemistry	B-P
that	O
revealed	O
a	O
strong	O
expression	O
both	O
in	O
acinar	O
and	O
in	O
ductal	O
cells	O
from	O
pSS	O
MSG	O
.	O

These	O
studies	O
could	O
provide	O
a	O
rational	O
basis	O
to	O
determine	O
whether	O
IL-15	O
could	O
be	O
a	O
good	O
candidate	O
for	O
anti-cytokine	O
therapy	O
in	O
chronic	O
inflammatory	O
pSS	O
diseases	O
.	O

Anatomical	O
subgroup	O
analysis	O
of	O
the	O
MERIDIAN	O
cohort	O
:	O
Posterior	O
fossa	O
abnormalities	O
.	O

To	O
assess	O
the	O
diagnostic	O
and	O
clinical	O
contribution	O
of	O
in	B-P
utero	I-P
magnetic	I-P
resonance	I-P
(	I-P
iuMR	I-P
)	I-P
imaging	I-P
in	O
fetuses	O
diagnosed	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
as	O
the	O
only	O
intracranial	O
abnormality	O
recognised	O
on	O
antenatal	B-P
ultrasonography	I-P
(	O
USS	B-P
)	O
.	O

We	O
report	O
a	O
sub-group	O
analysis	O
of	O
fetuses	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
diagnosed	O
on	O
antenatal	B-P
USS	I-P
(	O
with	O
or	O
without	O
ventriculomegaly	O
)	O
from	O
the	O
MERIDIAN	O
cohort	O
who	O
had	O
iuMR	B-P
imaging	I-P
within	O
2	O
weeks	O
of	O
USS	B-P
and	O
outcome	O
reference	O
data	O
were	O
available	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
USS	B-P
and	O
iuMR	B-P
are	O
reported	O
as	O
well	O
as	O
indicators	O
of	O
diagnostic	O
confidence	O
and	O
effects	O
on	O
prognosis	O
and	O
clinical	O
management	O
.	O

Abnormalities	O
confined	O
to	O
the	O
posterior	O
fossa	O
according	O
to	O
USS	B-P
were	O
found	O
in	O
81	O
fetuses	O
(	O
67	O
with	O
parenchymal	O
and	O
14	O
with	O
CSF	O
-containing	O
lesions	O
)	O
.	O

The	O
overall	O
diagnostic	O
accuracy	O
for	O
detecting	O
an	O
isolated	O
posterior	O
fossa	O
abnormality	O
was	O
65	O
%	O
for	O
USS	B-P
and	O
88	O
%	O
for	O
iuMR	B-P
(	O
difference	O
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14.0	O
to	O
30.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

There	O
was	O
an	O
improvement	O
in	O
'	O
appropriate	O
'	O
diagnostic	O
confidence	O
as	O
assessed	O
by	O
a	O
score	O
-	O
based	O
weighted	O
average	O
'	O
method	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
a	O
three-fold	O
reduction	O
in	O
'high	O
confidence	O
but	O
incorrect	O
diagnoses	O
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-P
imaging	I-P
.	O

The	O
prognostic	O
information	O
given	O
to	O
the	O
women	O
after	O
iuMR	B-P
imaging	I-P
changed	O
in	O
44	O
%	O
of	O
cases	O
and	O
the	O
overall	O
effect	O
of	O
iuMR	B-P
on	O
clinical	O
management	O
was	O
considered	O
to	O
be	O
'	O
significant	O
'	O
,	O
'	O
major	O
'	O
or	O
'	O
decisive	O
'	O
in	O
35	O
%	O
of	O
cases	O
.	O

Our	O
data	O
suggests	O
that	O
any	O
woman	O
whose	O
fetus	O
has	O
a	O
posterior	O
fossa	O
abnormality	O
as	O
the	O
only	O
intracranial	O
finding	O
on	O
USS	B-P
should	O
have	O
iuMR	B-P
imaging	I-P
for	O
further	O
evaluation	O
.	O

This	O
is	O
on	O
the	O
basis	O
of	O
improved	O
diagnostic	O
accuracy	O
and	O
confidence	O
which	O
has	O
substantial	O
effects	O
on	O
the	O
prognostic	O
information	O
given	O
to	O
women	O
and	O
changes	O
in	O
clinical	O
management	O
.	O

Endoscopic	O
Fundoplication	O
:	O
Effectiveness	O
for	O
Controlling	O
Symptoms	O
of	O
Gastroesophageal	O
Reflux	O
Disease	O
.	O

Transoral	O
incisionless	O
fundoplication	O
(	O
TIF	O
)	O
is	O
a	O
completely	O
endoscopic	B-P
approach	I-P
to	O
treat	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

We	O
previously	O
reported	O
our	O
initial	O
results	O
demonstrating	O
safety	O
and	O
early	O
effectiveness	O
.	O

We	O
now	O
present	O
an	O
updated	O
experience	O
describing	O
outcomes	O
with	O
longer	O
follow-up	O
.	O

For	O
a	O
three-year	O
period	O
,	O
TIF	O
procedures	O
were	O
performed	O
on	O
80	O
patients	O
.	O

Preoperative	O
workup	O
routinely	O
consisted	O
of	O
contrast	B-P
esophagram	I-P
and	O
manometry	B-P
.	O

PH	O
testing	O
was	O
reserved	O
for	O
patients	O
with	O
either	O
atypical	O
symptoms	O
or	O
typical	O
symptoms	O
unresponsive	O
to	O
proton-pump	O
inhibitors	O
(	O
PPIs	O
)	O
.	O

Heartburn	O
severity	O
was	O
longitudinally	O
assessed	O
using	O
the	O
GERD	O
health-related	O
quality	O
of	O
life	O
index	O
.	O

Safety	O
analysis	O
was	O
performed	O
on	O
all	O
80	O
patients	O
,	O
and	O
an	O
effectiveness	O
analysis	O
was	O
performed	O
on	O
patients	O
with	O
at	O
least	O
6-month	O
follow-up	O
.	O

Mean	O
procedure	O
time	O
was	O
75	O
minutes	O
.	O

There	O
were	O
seven	O
(	O
8.75	O
%	O
)	O
grade	O
2	O
complications	O
and	O
one	O
(	O
1.25	O
%	O
)	O
grade	O
3	O
complication	O
(	O
aspiration	O
pneumonia	O
)	O
.	O

The	O
median	O
length	O
of	O
stay	O
was	O
1	O
day	O
(	O
mean	O
,	O
1.4	O
)	O
.	O

Forty-one	O
patients	O
had	O
a	O
minimum	O
of	O
6-month	O
of	O
follow-up	O
(	O
mean	O
,	O
24	O
months	O
;	O
range	O
,	O
6-68	O
months	O
)	O
.	O

The	O
mean	O
satisfaction	O
scores	O
at	O
follow-up	O
improved	O
significantly	O
from	O
baseline	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Sixty-three	O
percent	O
of	O
patients	O
had	O
completely	O
stopped	O
or	O
reduced	O
their	O
PPI	O
dose	O
.	O

Results	O
were	O
not	O
impacted	O
by	O
impaired	O
motility	O
;	O
however	O
,	O
the	O
presence	O
of	O
a	O
small	O
hiatal	O
hernia	O
or	O
a	O
Hill	O
grade	O
2/4	O
valve	O
was	O
associated	O
with	O
reduced	O
GERD	O
health-related	O
quality	O
of	O
life	O
scores	O
postoperatively	O
.	O

At	O
a	O
mean	O
follow-up	O
of	O
24	O
months	O
,	O
TIF	O
is	O
effective	O
.	O

Although	O
symptoms	O
and	O
satisfaction	O
improved	O
significantly	O
,	O
many	O
patients	O
continued	O
to	O
take	O
PPIs	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
longer-term	O
durability	O
and	O
comparisons	O
with	O
laparoscopic	O
techniques	O
.	O

Role	O
of	O
endoscopy	B-P
in	O
primary	O
sclerosing	O
cholangitis	O
:	O
European	O
Society	O
of	O
Gastrointestinal	O
Endoscopy	O
(	O
ESGE	O
)	O
and	O
European	O
Association	O
for	O
the	O
Study	O
of	O
the	O
Liver	O
(	O
EASL	O
)	O
Clinical	O
Guideline	O
.	O

1	O
ESGE	O
/	O
EASL	O
recommend	O
that	O
,	O
as	O
the	O
primary	O
diagnostic	B-P
modality	O
for	O
PSC	O
,	O
magnetic	B-P
resonance	I-P
cholangiography	I-P
(	O
MRC	B-P
)	O
should	O
be	O
preferred	O
over	O
endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
.	O

Moderate	O
quality	O
evidence	O
,	O
strong	O
recommendation	O
.	O

2	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
ERCP	B-P
can	O
be	O
considered	O
if	O
MRC	B-P
plus	O
liver	B-P
biopsy	I-P
is	O
equivocal	O
or	O
contraindicated	O
in	O
patients	O
with	O
persisting	O
clinical	O
suspicion	O
of	O
PSC	O
.	O

The	O
risks	O
of	O
ERCP	B-P
have	O
to	O
be	O
weighed	O
against	O
the	O
potential	O
benefit	O
with	O
regard	O
to	O
surveillance	O
and	O
treatment	O
recommendations	O
.	O

Low	O
quality	O
evidence	O
,	O
weak	O
recommendation	O
.	O

6	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
,	O
in	O
patients	O
with	O
an	O
established	O
diagnosis	O
of	O
PSC	O
,	O
MRC	B-P
should	O
be	O
considered	O
before	O
therapeutic	O
ERCP	B-P
.	O

Weak	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

7	O
ESGE	O
/	O
EASL	O
suggest	O
performing	O
endoscopic	B-P
treatment	O
with	O
concomitant	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
of	O
suspected	O
significant	O
strictures	O
identified	O
at	O
MRC	B-P
in	O
PSC	O
patients	O
who	O
present	O
with	O
symptoms	O
likely	O
to	O
improve	O
following	O
endoscopic	B-P
treatment	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

9	O
ESGE	O
/	O
EASL	O
recommend	O
weighing	O
the	O
anticipated	O
benefits	O
of	O
biliary	O
papillotomy	O
/	O
sphincterotomy	O
against	O
its	O
risks	O
on	O
a	O
case-by-case	O
basis	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

Biliary	O
papillotomy	O
/	O
sphincterotomy	O
should	O
be	O
considered	O
especially	O
after	O
difficult	O
cannulation	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

16	O
ESGE	O
/	O
EASL	O
suggest	O
routine	O
administration	O
of	O
prophylactic	O
antibiotics	O
before	O
ERCP	B-P
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

17	O
EASL	O
/	O
ESGE	O
recommend	O
that	O
cholangiocarcinoma	O
(	O
CCA	O
)	O
should	O
be	O
suspected	O
in	O
any	O
patient	O
with	O
worsening	O
cholestasis	O
,	O
weight	O
loss	O
,	O
raised	O
serum	O
CA19-9	O
,	O
and/or	O
new	O
or	O
progressive	O
dominant	O
stricture	O
,	O
particularly	O
with	O
an	O
associated	O
enhancing	O
mass	O
lesion	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

19	O
ESGE	O
/	O
EASL	O
recommend	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
as	O
part	O
of	O
the	O
initial	O
investigation	O
for	O
the	O
diagnosis	O
and	O
staging	B-P
of	O
suspected	O
CCA	O
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
high	O
quality	O
evidence	O
.	O

Implementation	O
of	O
infrared	O
and	O
Raman	O
modalities	O
for	O
glycosaminoglycan	O
characterization	O
in	O
complex	O
systems	O
.	O

Glycosaminoglycans	O
(	O
GAGs	O
)	O
are	O
natural	O
,	O
linear	O
and	O
negatively	O
charged	O
heteropolysaccharides	O
which	O
are	O
incident	O
in	O
every	O
mammalian	O
tissue	O
.	O

They	O
consist	O
of	O
repeating	O
disaccharide	O
units	O
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	O
or	O
non-sulfated	O
monosaccharides	O
.	O

Depending	O
on	O
tissue	O
types	O
,	O
GAGs	O
exhibit	O
structural	O
heterogeneity	O
such	O
as	O
the	O
position	O
and	O
degree	O
of	O
sulfation	O
or	O
within	O
their	O
disaccharide	O
units	O
composition	O
being	O
heparin	O
,	O
heparan	O
sulfate	O
,	O
chondroitine	O
sulfate	O
,	O
dermatan	O
sulfate	O
,	O
keratan	O
sulfate	O
,	O
and	O
hyaluronic	O
acid	O
.	O

They	O
are	O
covalently	O
linked	O
to	O
a	O
core	O
protein	O
(	O
proteoglycans	O
)	O
or	O
as	O
free	O
chains	O
(	O
hyaluronan	O
)	O
.	O

GAGs	O
affect	O
cell	O
properties	O
and	O
functions	O
either	O
by	O
direct	O
interaction	O
with	O
cell	O
receptors	O
or	O
by	O
sequestration	O
of	O
growth	O
factors	O
.	O

These	O
evidences	O
of	O
divert	O
biological	O
roles	O
of	O
GAGs	O
make	O
their	O
characterization	O
at	O
cell	O
and	O
tissue	O
levels	O
of	O
importance	O
.	O

Thus	O
,	O
non-invasive	O
techniques	O
are	O
interesting	O
to	O
investigate	O
,	O
to	O
qualitatively	O
and	O
quantitatively	O
characterize	O
GAGs	O
in	O
vitro	O
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	O
biomarkers	O
and/or	O
as	O
therapeutic	O
targets	O
in	O
several	O
human	O
diseases	O
including	O
cancer	O
.	O

Infrared	O
and	O
Raman	O
microspectroscopies	O
and	O
imaging	B-P
are	O
sensitive	O
enough	O
to	O
differentiate	O
and	O
classify	O
GAG	O
types	O
and	O
subtypes	O
in	O
spite	O
of	O
their	O
close	O
molecular	O
structures	O
.	O

Spectroscopic	O
markers	O
characteristic	O
of	O
reference	O
GAG	O
molecules	O
were	O
identified	O
.	O

Beyond	O
these	O
investigations	O
of	O
the	O
standard	O
GAG	O
spectral	O
signature	O
,	O
infrared	O
and	O
Raman	O
spectral	O
signatures	O
of	O
GAG	O
were	O
searched	O
in	O
complex	O
biological	O
systems	O
like	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	O
of	O
these	O
complementary	O
vibrational	O
spectroscopy	O
techniques	O
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	O
analysis	O
.	O

In	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	O
infrared	O
and	O
Raman	O
spectral	O
signatures	O
from	O
conditioned	O
media	O
and	O
live	O
cells	O
,	O
respectively	O
.	O

Severe	O
respiratory	O
depression	O
and	O
bradycardia	O
before	O
induction	O
of	O
anesthesia	O
and	O
onset	O
of	O
Takotsubo	O
cardiomyopathy	O
after	O
cardiopulmonary	O
resuscitation	O
.	O

A	O
69-	O
year	O
-old	O
woman	O
undergoing	O
treatment	O
for	O
hypertension	O
and	O
epilepsy	O
was	O
scheduled	O
to	O
undergo	O
cataract	O
surgery	O
.	O

All	O
preoperative	O
examination	O
results	O
were	O
within	O
normal	O
limits	O
.	O

Despite	O
being	O
tense	O
,	O
she	O
walked	O
to	O
the	O
operating	O
room	O
.	O

Approximately	O
2	O
minutes	O
after	O
an	O
intravenous	O
line	O
was	O
established	O
by	O
an	O
anesthesia	O
resident	O
,	O
severe	O
hypoxia	O
and	O
bradycardia	O
developed	O
,	O
and	O
she	O
lost	O
consciousness	O
.	O

Cardiopulmonary	O
resuscitation	O
was	O
initiated	O
immediately	O
,	O
and	O
after	O
1	O
minute	O
,	O
she	O
regained	O
consciousness	O
,	O
and	O
her	O
breathing	O
and	O
circulation	O
recovered	O
.	O

After	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
emergency	O
coronary	B-P
angiography	I-P
was	O
performed	O
.	O

The	O
blood	O
flow	O
in	O
all	O
the	O
coronary	O
arteries	O
was	O
normal	O
.	O

However	O
,	O
a	O
decrease	O
in	O
the	O
apical	O
left	O
ventricular	O
wall	O
motion	O
and	O
an	O
increase	O
in	O
the	O
basal	O
wall	O
motion	O
were	O
observed	O
.	O

Based	O
on	O
these	O
findings	O
,	O
Takotsubo	O
cardiomyopathy	O
was	O
diagnosed	O
.	O

The	O
wall	O
motion	O
gradually	O
improved	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
on	O
postoperative	O
day	O
15	O
.	O

The	O
respiratory	O
depression	O
and	O
bradycardia	O
were	O
thought	O
to	O
be	O
due	O
to	O
an	O
inadvertent	O
bolus	O
of	O
remifentanil	O
.	O

We	O
surmised	O
that	O
the	O
patient	O
had	O
received	O
a	O
slight	O
amount	O
of	O
retained	O
medication	O
when	O
the	O
anesthesia	O
resident	O
established	O
the	O
intravenous	O
line	O
,	O
which	O
caused	O
severe	O
respiratory	O
depression	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
adverse	O
effects	O
such	O
as	O
severe	O
respiratory	O
depression	O
and	O
bradycardia	O
can	O
be	O
caused	O
by	O
even	O
small	O
doses	O
of	O
remifentanil	O
.	O

A	O
Concurrent	O
Case	O
of	O
Ménétrier	O
's	O
Disease	O
and	O
Signet	O
Ring	O
Carcinoma	O
.	O

Ménétrier	O
's	O
disease	O
,	O
also	O
known	O
as	O
hyperplastic	O
protein-losing	O
gastropathy	O
,	O
is	O
a	O
rare	O
,	O
idiopathic	O
,	O
acquired	O
,	O
premalignant	O
condition	O
associated	O
with	O
gastric	O
carcinoma	O
.	O

Its	O
association	O
with	O
signet	O
ring	O
cell	O
cancer	O
of	O
the	O
stomach	O
has	O
been	O
previously	O
reported	O
only	O
twice	O
.	O

We	O
present	O
the	O
third	O
case	O
of	O
histologically	O
confirmed	O
concurrent	O
Ménétrier	O
's	O
disease	O
with	O
signet	O
ring	O
carcinoma	O
of	O
the	O
stomach	O
,	O
interrogated	O
by	O
esophagogastroduodenoscopy	B-P
and	O
endoscopic	B-P
ultrasound	I-P
.	O

Entropy-driven	O
reactions	O
in	O
living	O
cells	O
for	O
assay	O
let-7a	O
microRNA	O
.	O

Imaging	B-P
of	O
microRNA	O
(	O
miRNA	O
)	O
in	O
living	O
cells	O
could	O
facilitate	O
the	O
monitoring	O
of	O
the	O
expression	O
and	O
distribution	O
of	O
miRNA	O
and	O
research	O
on	O
miRNA	O
-related	O
diseases	O
.	O

Given	O
the	O
low	O
expression	O
levels	O
and	O
even	O
down-regulation	O
of	O
cellular	O
miRNA	O
that	O
is	O
associated	O
with	O
some	O
diseases	O
,	O
enzyme	O
-	O
free	O
amplification	O
strategies	O
are	O
imperative	O
for	O
intracellular	O
miRNA	O
assay	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy-driven	O
reaction	O
for	O
amplification	O
assay	O
miRNA	O
with	O
a	O
detection	O
limit	O
of	O
0.27	O
pM	O
.	O

The	O
resulting	O
signal	O
amplification	O
provides	O
excellent	O
recognition	O
and	O
signal	O
enhancement	O
of	O
specific	O
miRNA	O
s	O
in	O
living	O
cells	O
.	O

This	O
method	O
supplies	O
accurate	O
information	O
regarding	O
cellular	O
miRNA	O
-related	O
biological	O
events	O
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	O
sensitive	O
and	O
simultaneous	O
imaging	B-P
of	O
multiple	O
low-level	O
biomarkers	O
,	O
thereby	O
improving	O
the	O
accuracy	O
of	O
early	B-P
disease	I-P
diagnosis	I-P
.	O

Three-dimensional	O
morphological	O
characterization	O
of	O
malocclusions	O
with	O
mandibular	O
lateral	O
displacement	O
using	O
cone-beam	B-P
computed	I-P
tomography	I-P
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
morphologic	O
characteristics	O
of	O
MLD	O
malocclusions	O
using	O
3D	B-P
imaging	I-P
.	O

MLD	O
characteristics	O
were	O
examined	O
using	O
CBCT	B-P
data	O
in	O
40	O
subjects	O
.	O

A	O
3D	O
Cephalometric	B-P
analysis	I-P
was	O
developed	O
to	O
describe	O
the	O
spatial	O
position	O
of	O
the	O
mandible	O
and	O
temporal	O
bones	O
.	O

Vertical	O
dental	O
heights	O
were	O
shorter	O
and	O
the	O
posterior	O
occlusal	O
plane	O
(	O
POP	O
)	O
presented	O
a	O
steeper	O
sagittal	O
inclination	O
on	O
the	O
shifted	O
side	O
(	O
the	O
side	O
of	O
the	O
laterally	O
displaced	O
bony	O
chin	O
)	O
than	O
on	O
the	O
contralateral	O
side	O
.	O

(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
MLD	O
was	O
related	O
to	O
a	O
superiorly	O
inclined	O
POP	O
Cant	O
in	O
the	O
same	O
direction	O
(	O
r	O
=	O
0.82	O
;	O
p	O
<	O
0.01	O
)	O
.	O

The	O
shifted	O
side	O
condyle	O
was	O
dislocated	O
medially	O
and	O
was	O
smaller	O
.	O

Temporal	O
bone	O
sagittal	O
inclination	O
showed	O
a	O
more	O
forward	O
and	O
medial	O
inclination	O
on	O
the	O
contralateral	O
side	O
(	O
p	O
<	O
0.01	O
)	O
.	O

A	O
unilateral	O
decrease	O
in	O
the	O
vertical	O
height	O
of	O
the	O
dentition	O
and	O
the	O
subsequent	O
steeper	O
occlusal	O
plane	O
inclinations	O
correlated	O
with	O
(	O
1	O
)	O
mandibular	O
rotational	O
displacement	O
and	O
condylar	O
lateral	O
displacement	O
,	O
(	O
2	O
)	O
mandibular	O
and	O
condylar	O
morphologic	O
changes	O
(	O
3	O
)	O
changes	O
in	O
temporal	O
bone	O
position	O
.	O

Generalized	O
Weakness	O
in	O
a	O
Transplant	O
Patient	O
:	O
A	O
Case	O
Presentation	O
.	O

Generalized	O
weakness	O
in	O
transplant	O
patients	O
is	O
a	O
major	O
complaint	O
in	O
tertiary	O
rehabilitation	O
hospitals	O
.	O

The	O
diagnosis	O
and	O
management	O
of	O
generalized	O
weakness	O
in	O
this	O
population	O
pose	O
challenges	O
for	O
physicians	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
transplant	O
patient	O
with	O
generalized	O
weakness	O
who	O
was	O
eventually	O
diagnosed	O
with	O
calciphylaxis	O
using	O
a	O
multidisciplinary	B-P
diagnostic	I-P
approach	I-P
of	O
electrodiagnostics	B-P
,	O
vascular	O
study	B-P
,	O
and	O
skin	B-P
biopsy	I-P
.	O

Calciphylaxis	O
is	O
a	O
rare	O
cutaneous	O
disorder	O
that	O
mimics	O
other	O
collagen	O
vascular	O
diseases	O
in	O
its	O
presentation	O
and	O
fulminant	O
course	O
.	O

Physiatrists	O
should	O
be	O
cognizant	O
of	O
calciphylaxis	O
,	O
as	O
it	O
signals	O
a	O
poor	O
prognosis	O
if	O
not	O
correctly	O
diagnosed	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
,	O
with	O
high	O
incidence	O
of	O
sepsis	O
,	O
wound	O
pain	O
,	O
and	O
disability	O
.	O

V	O
.	O

Digital	O
Myopericytoma	O
:	O
A	O
Case	O
Report	O
and	O
Systematic	O
Literature	O
Review	O
.	O

A	O
myopericytoma	O
(	O
MP	O
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular	O
tumor	O
of	O
unknown	O
etiology	O
.	O

Given	O
their	O
potential	O
for	O
mimicry	O
and	O
malignancy	O
,	O
MP	O
tumors	O
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	O
and	O
may	O
be	O
overlooked	O
on	O
differential	B-P
diagnosis	I-P
.	O

We	O
present	O
a	O
case	O
report	O
of	O
an	O
otherwise	O
healthy	O
33-year-old	O
right-hand	O
dominant	O
male	O
who	O
presented	O
to	O
our	O
outpatient	O
clinic	O
with	O
a	O
2-month	O
history	O
of	O
painless	O
swelling	O
and	O
erythema	O
of	O
the	O
pulp	O
of	O
his	O
left	O
index	O
finger	O
.	O

Subsequent	O
plain	B-P
film	I-P
X-ray	I-P
showed	O
near-complete	O
bony	O
destruction	O
of	O
his	O
distal	O
phalanx	O
.	O

Pathological	O
evaluation	O
of	O
an	O
incisional	B-P
biopsy	I-P
showed	O
a	O
benign	O
variant	O
of	O
MP	O
.	O

The	O
lesion	O
was	O
treated	O
by	O
excision	O
with	O
tumor	O
shelling	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
recurrence	O
81	O
days	O
postoperatively	O
.	O

A	O
systematic	O
literature	O
review	O
of	O
the	O
management	O
and	O
outcome	O
of	O
all	O
known	O
cases	O
of	O
hand	O
and	O
wrist	O
MP	O
is	O
presented	O
.	O

Myometrial	O
relaxation	O
of	O
mice	O
via	O
expression	O
of	O
two	O
pore	O
domain	O
acid	O
sensitive	O
K	O
(	O
+	O
)	O
(	O
TASK-2	O
)	O
channels	O
.	O

Myometrial	O
relaxation	O
of	O
mouse	O
via	O
expression	O
of	O
two-pore	O
domain	O
acid	O
sensitive	O
(	O
TASK	O
)	O
channels	O
was	O
studied	O
.	O

In	O
our	O
previous	O
report	O
,	O
we	O
suggested	O
that	O
two-pore	O
domain	O
acid-sensing	O
K	O
(	O
+	O
)	O
channels	O
(	O
TASK-2	O
)	O
might	O
be	O
one	O
of	O
the	O
candidates	O
for	O
the	O
regulation	O
of	O
uterine	O
circular	O
smooth	O
muscles	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
tried	O
to	O
show	O
the	O
mechanisms	O
of	O
relaxation	O
via	O
TASK-2	O
channels	O
in	O
marine	O
myometrium	O
.	O

Isometric	O
contraction	O
measurements	O
and	O
patch	O
clamp	O
technique	O
were	O
used	O
to	O
verify	O
TASK	O
conductance	O
in	O
murine	O
myometrium	O
.	O

Western	O
blot	O
and	O
immunehistochemical	B-P
study	I-P
under	O
confocal	O
microscopy	O
were	O
used	O
to	O
investigate	O
molecular	O
identity	O
of	O
TASK	O
channel	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
TEA	O
and	O
4-AP	O
insensitive	O
non-inactivating	O
outward	O
K	O
(	O
+	O
)	O
current	O
(	O
NIOK	O
)	O
may	O
be	O
responsible	O
for	O
the	O
quiescence	O
of	O
murine	O
pregnant	O
longitudinal	O
myometrium	O
.	O

The	O
characteristics	O
of	O
NIOK	O
coincided	O
with	O
two-pore	O
domain	O
acid-sensing	O
K	O
(	O
+	O
)	O
channels	O
(	O
TASK-2	O
)	O
.	O

NIOK	O
in	O
the	O
presence	O
of	O
K	O
(	O
+	O
)	O
channel	O
blockers	O
was	O
inhibited	O
further	O
by	O
TASK	O
inhibitors	O
such	O
as	O
quinidine	O
,	O
bupivacaine	O
,	O
lidocaine	O
,	O
and	O
extracellular	O
acidosis	O
.	O

Furthermore	O
,	O
oxytocin	O
and	O
estrogen	O
inhibited	O
NIOK	O
in	O
pregnant	O
myometrium	O
.	O

When	O
compared	O
to	O
non-pregnant	O
myometrium	O
,	O
pregnant	O
myometrium	O
showed	O
stronger	O
inhibition	O
of	O
NIOK	O
by	O
quinidine	O
and	O
increased	O
immunohistochemical	O
expression	O
of	O
TASK-2	O
.	O

Finally	O
,	O
TASK-2	O
inhibitors	O
induced	O
strong	O
myometrial	O
contraction	O
even	O
in	O
the	O
presence	O
of	O
L-methionine	O
,	O
a	O
known	O
inhibitor	O
of	O
stretch-activated	O
channels	O
in	O
the	O
longitudinal	O
myometrium	O
of	O
mouse	O
.	O

Activation	O
of	O
TASK-2	O
channels	O
seems	O
to	O
play	O
an	O
essential	O
role	O
for	O
relaxing	O
uterus	O
during	O
pregnancy	O
and	O
it	O
might	O
be	O
one	O
of	O
the	O
alternatives	O
for	O
preventing	O
preterm	O
delivery	O
.	O

Phosphodiesterase	O
Type	O
5	O
Inhibitors	O
and	O
Risk	O
of	O
Malignant	O
Melanoma	O
:	O
Matched	O
Cohort	O
Study	O
Using	O
Primary	O
Care	O
Data	O
from	O
the	O
UK	O
Clinical	O
Practice	O
Research	O
Datalink	O
.	O

Laboratory	O
evidence	O
suggests	O
that	O
reduced	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
expression	O
increases	O
the	O
invasiveness	O
of	O
melanoma	O
cells	O
;	O
hence	O
,	O
pharmacological	O
inhibition	O
of	O
PDE5	O
could	O
affect	O
melanoma	O
risk	O
.	O

Two	O
major	O
epidemiological	O
studies	O
have	O
investigated	O
this	O
and	O
come	O
to	O
differing	O
conclusions	O
.	O

We	O
therefore	O
aimed	O
to	O
investigate	O
whether	O
PDE5	O
inhibitor	O
use	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	O
melanoma	O
,	O
and	O
whether	O
any	O
increase	O
in	O
risk	O
is	O
likely	O
to	O
represent	O
a	O
causal	O
relationship	O
.	O

We	O
conducted	O
a	O
matched	O
cohort	O
study	O
using	O
primary	O
care	O
data	O
from	O
the	O
UK	O
Clinical	O
Practice	O
Research	O
Datalink	O
.	O

All	O
men	O
initiating	O
a	O
PDE5	O
inhibitor	O
and	O
with	O
no	O
prior	O
cancer	B-P
diagnosis	I-P
were	O
identified	O
and	O
matched	O
on	O
age	O
,	O
diabetes	O
status	O
,	O
and	O
general	O
practice	O
to	O
up	O
to	O
four	O
unexposed	O
controls	O
.	O

Ever	O
use	O
of	O
a	O
PDE5	O
inhibitor	O
and	O
time-updated	O
cumulative	O
number	O
of	O
PDE5	O
inhibitor	O
prescriptions	O
were	O
investigated	O
as	O
exposures	O
,	O
and	O
the	O
primary	O
outcome	O
was	O
malignant	O
melanoma	O
.	O

Basal	O
cell	O
carcinoma	O
,	O
solar	O
keratosis	O
,	O
and	O
colorectal	O
cancer	O
were	O
investigated	O
as	O
negative	O
control	O
outcomes	O
to	O
exclude	O
bias	O
.	O

Hazard	O
ratios	O
(	O
HRs	O
)	O
were	O
estimated	O
from	O
Cox	O
models	O
stratified	O
by	O
matched	O
set	O
and	O
adjusted	O
for	O
potential	O
confounders	O
.	O

145,104	O
men	O
with	O
≥1	O
PDE5	O
inhibitor	O
prescription	O
,	O
and	O
560,933	O
unexposed	O
matched	O
controls	O
were	O
included	O
.	O

In	O
total	O
,	O
1,315	O
incident	O
malignant	O
melanoma	O
diagnoses	O
were	O
observed	O
during	O
3.44	O
million	O
person-years	O
of	O
follow-up	O
(	O
mean	O
4.9	O
y	O
per	O
person	O
)	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
there	O
was	O
weak	O
evidence	O
of	O
a	O
small	O
positive	O
association	O
between	O
PDE5	O
inhibitor	O
use	O
and	O
melanoma	O
risk	O
(	O
HR	O
=	O
1.14	O
,	O
95	O
%	O
CI	O
1.01-1.29	O
,	O
p	O
=	O
0.04	O
)	O
.	O

A	O
similar	O
increase	O
in	O
risk	O
was	O
seen	O
for	O
the	O
two	O
negative	O
control	O
outcomes	O
related	O
to	O
sun	O
exposure	O
(	O
HR	O
=	O
1.15	O
,	O
95	O
%	O
CI	O
1.11-1.19	O
,	O
p	O
<	O
0.001	O
,	O
for	O
basal	O
cell	O
carcinoma	O
;	O
HR	O
=	O
1.21	O
,	O
95	O
%	O
CI	O
1.17-1.25	O
,	O
p	O
<	O
0.001	O
,	O
for	O
solar	O
keratosis	O
)	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
colorectal	O
cancer	O
(	O
HR	O
=	O
0.91	O
,	O
95	O
%	O
CI	O
0.85-0.98	O
,	O
p	O
=	O
0.01	O
)	O
.	O

There	O
was	O
no	O
evidence	O
that	O
risk	O
increased	O
with	O
number	O
of	O
prescriptions	O
received	O
(	O
p-trend	O
=	O
0.83	O
)	O
.	O

In	O
a	O
post	O
hoc	O
analysis	O
,	O
there	O
was	O
strong	O
evidence	O
that	O
solar	O
keratosis	O
was	O
associated	O
with	O
future	O
PDE5	O
inhibitor	O
use	O
(	O
odds	O
ratio	O
=	O
1.28	O
,	O
95	O
%	O
CI	O
1.23-1.34	O
,	O
p	O
<	O
0.001	O
)	O
,	O
suggesting	O
that	O
men	O
with	O
higher	O
sun	O
exposure	O
were	O
more	O
likely	O
to	O
become	O
PDE5	O
inhibitor	O
users	O
.	O

However	O
,	O
a	O
limitation	O
of	O
our	O
study	O
was	O
that	O
we	O
did	O
not	O
have	O
individual-level	O
data	O
on	O
sun	O
exposure	O
,	O
so	O
we	O
could	O
not	O
directly	O
control	O
for	O
this	O
in	O
the	O
primary	O
analysis	O
.	O

Our	O
results	O
were	O
not	O
consistent	O
with	O
PDE5	O
inhibitors	O
being	O
causally	O
associated	O
with	O
melanoma	O
risk	O
,	O
and	O
strongly	O
suggest	O
that	O
observed	O
risk	O
increases	O
are	O
driven	O
by	O
greater	O
sun	O
exposure	O
among	O
patients	O
exposed	O
to	O
a	O
PDE5	O
inhibitor	O
.	O

Metacarpophalangeal	O
Joint	O
Arthrodesis	O
of	O
the	O
Thumb	O
-	O
Minimum	O
of	O
Eight	O
Months	O
Follow-up	O
.	O

Disorders	O
of	O
the	O
thumb	O
metacarpophalangeal	O
(	O
MCP	O
)	O
joint	O
can	O
lead	O
to	O
significant	O
loss	O
of	O
function	O
and	O
pain	O
.	O

Thumb	O
MCP	O
arthrodesis	O
following	O
traumatic	O
injuries	O
is	O
inadequately	O
described	O
and	O
recent	O
studies	O
have	O
questioned	O
the	O
outcome	O
of	O
this	O
treatment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
report	O
outcome	O
and	O
disability	O
following	O
thumb	O
MCP	O
joint	O
arthrodesis	O
in	O
the	O
treatment	O
of	O
chronic	O
instability	O
after	O
traumatic	O
injuries	O
.	O

A	O
retrospective	O
review	O
of	O
26	O
patients	O
operated	O
on	O
with	O
MCP	O
joint	O
arthrodesis	O
,	O
median	O
follow-up	O
42	O
months	O
(	O
8-104	O
months	O
)	O
.	O

Subjective	O
outcome	O
was	O
assessed	O
using	O
the	O
disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
,	O
and	O
Hand-questionnaire	O
(	O
DASH	O
)	O
.	O

In	O
addition	O
,	O
patient	O
satisfaction	O
,	O
pain	O
,	O
stiffness	O
,	O
and	O
impairment	O
of	O
activities	O
of	O
daily	O
living	O
were	O
assessed	O
on	O
a	O
Visual	B-P
Analogue	I-P
Scale	I-P
(	O
VAS	B-P
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Two	O
patients	O
(	O
7.7	O
%	O
)	O
needed	O
re-operation	O
due	O
to	O
nonunion	O
.	O

Four	O
patients	O
(	O
15.4	O
%	O
)	O
needed	O
hardware	O
removal	O
.	O

Median	O
DASH	O
-	O
score	O
was	O
18	O
(	O
25-75	O
%	O
range	O
6-47	O
)	O
,	O
with	O
lower	O
DASH	O
score	O
s	O
being	O
better	O
.	O

Score	O
s	O
were	O
significantly	O
worse	O
in	O
gender	O
and	O
age	O
matched	O
individuals	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Median	O
VAS	B-P
for	O
pain	O
was	O
3.7	O
(	O
range	O
0-8	O
)	O
.	O

More	O
than	O
50	O
%	O
of	O
patients	O
reported	O
mild	O
,	O
moderate	O
or	O
severe	O
pain	O
,	O
but	O
all	O
patients	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
patients	O
with	O
post-traumatic	O
thumb	O
injuries	O
managed	O
with	O
thumb	O
MCP	O
joint	O
arthrodesis	O
perform	O
worse	O
than	O
gender	O
and	O
age	O
matched	O
individuals	O
.	O

Many	O
lived	O
with	O
pain	O
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

We	O
suggest	O
that	O
the	O
disability	O
scale	O
by	O
the	O
National	O
Board	O
of	O
Industrial	O
Injuries	O
should	O
be	O
reconsidered	O
for	O
patients	O
operated	O
on	O
with	O
thumb	O
MCP	O
arthrodesis	O
.	O

Computed	B-P
Tomography	I-P
Imaging	I-P
Features	O
and	O
Changes	O
in	O
Hemostatic	O
Agents	O
After	O
Laparoscopic	O
Partial	O
Nephrectomy	O
.	O

Urologists	O
and	O
radiologists	O
should	O
be	O
aware	O
of	O
the	O
CT	B-P
scan	I-P
appearance	O
of	O
laparoscopic	O
partial	O
nephrectomy	O
(	O
LPN	O
)	O
with	O
the	O
various	O
hemostatic	O
agents	O
since	O
they	O
may	O
confound	O
the	O
interpretation	O
of	O
these	O
radiographic	O
findings	O
.	O

We	O
report	O
the	O
various	O
postoperative	O
CT	B-P
scan	I-P
appearance	O
and	O
changes	O
after	O
LPN	O
.	O

We	O
reviewed	O
CT	B-P
scans	I-P
retrospectively	O
(	O
within	O
3	O
months	O
)	O
of	O
86	O
patients	O
who	O
underwent	O
LPN	O
using	O
various	O
hemostatic	O
agents	O
between	O
March	O
2008	O
and	O
July	O
2014	O
.	O

We	O
analyzed	O
the	O
CT	B-P
findings	O
after	O
LPN	O
,	O
including	O
postoperative	O
changes	O
,	O
tumor	O
recurrence	O
,	O
and	O
complications	O
.	O

We	O
also	O
discuss	O
changes	O
in	O
abnormal	O
features	O
,	O
such	O
as	O
mass-like	O
lesions	O
and	O
gas	O
formation	O
,	O
on	O
follow-up	O
CT	B-P
scans	I-P
.	O

To	O
categorize	O
the	O
postoperative	O
changes	O
,	O
we	O
classified	O
them	O
according	O
to	O
their	O
specific	O
CT	B-P
findings	O
:	O
(	O
1	O
)	O
a	O
combination	O
of	O
perinephric	O
stranding	O
and	O
postsurgical	O
fluid	O
collection	O
(	O
n	O
=	O
46	O
)	O
,	O
(	O
2	O
)	O
mass-like	O
lesions	O
(	O
n	O
=	O
35	O
)	O
,	O
(	O
3	O
)	O
a	O
parenchymal	O
defect	O
(	O
n	O
=	O
2	O
)	O
,	O
(	O
4	O
)	O
local	O
recurrence	O
at	O
the	O
surgical	O
site	O
(	O
n	O
=	O
1	O
)	O
,	O
(	O
5	O
)	O
a	O
large	O
hematoma	O
as	O
a	O
complication	O
after	O
LPN	O
(	O
n	O
=	O
2	O
)	O
,	O
(	O
6	O
)	O
gas	O
pockets	O
,	O
which	O
may	O
be	O
a	O
response	O
to	O
postsurgical	O
fluid	O
collection	O
around	O
soft	O
tissue	O
(	O
n	O
=	O
35	O
)	O
,	O
(	O
7	O
)	O
fat	O
at	O
the	O
excision	O
site	O
(	O
n	O
=	O
2	O
;	O
Fig	O
.	O

7	O
)	O
,	O
and	O
(	O
8	O
)	O
contrast	O
extravasation	O
in	O
the	O
delayed	O
phase	O
(	O
n	O
=	O
1	O
)	O
.	O

Mass-like	O
lesions	O
were	O
visible	O
in	O
35	O
cases	O
.	O

The	O
average	O
change	O
in	O
size	O
of	O
bolster	O
masses	O
was	O
-1.19	O
mm/month	O
.	O

However	O
,	O
the	O
overall	O
change	O
in	O
enhancement	O
of	O
mass-like	O
lesions	O
was	O
not	O
significant	O
over	O
time	O
.	O

Foci	O
of	O
gas	O
were	O
noted	O
in	O
16	O
patients	O
at	O
the	O
resection	O
site	O
in	O
the	O
first	O
follow-up	O
period	O
(	O
<	O
3	O
months	O
)	O
,	O
as	O
late	O
as	O
40	O
days	O
after	O
the	O
procedure	O
.	O

Knowledge	O
of	O
CT	B-P
imaging	I-P
features	O
and	O
changes	O
in	O
hemostatic	O
agents	O
following	O
LPN	O
is	O
important	O
in	O
interpreting	O
postoperative	O
CT	B-P
scans	I-P
,	O
as	O
postoperative	O
changes	O
can	O
be	O
confused	O
with	O
tumor	O
recurrence	O
and	O
can	O
mimic	O
abscesses	O
.	O

Smooth	O
versus	O
Textured	O
Surfaces	O
:	O
Feature	O
-Based	O
Category	O
Selectivity	O
in	O
Human	O
Visual	O
Cortex	O
.	O

In	O
fMRI	B-P
studies	I-P
,	O
human	O
lateral	O
occipital	O
(	O
LO	O
)	O
cortex	O
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	O
of	O
objects	O
,	O
compared	O
with	O
nonobjects	O
.	O

However	O
,	O
it	O
remains	O
unresolved	O
whether	O
all	O
objects	O
evoke	O
equivalent	O
levels	O
of	O
activity	O
in	O
LO	O
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	O
features	O
produce	O
stronger	O
activation	O
.	O

Here	O
,	O
we	O
used	O
an	O
unbiased	O
parametric	O
texture	O
model	O
to	O
predict	O
preferred	O
versus	O
nonpreferred	O
stimuli	O
in	O
LO	O
.	O

Observation	O
and	O
psychophysical	O
results	O
showed	O
that	O
predicted	O
preferred	O
stimuli	O
(	O
both	O
objects	O
and	O
nonobjects	O
)	O
had	O
smooth	O
(	O
rather	O
than	O
textured	O
)	O
surfaces	O
.	O

These	O
predictions	O
were	O
confirmed	O
using	O
fMRI	B-P
,	O
for	O
objects	O
and	O
nonobjects	O
.	O

Similar	O
preferences	O
were	O
also	O
found	O
in	O
the	O
fusiform	O
face	O
area	O
(	O
FFA	O
)	O
.	O

Consistent	O
with	O
this	O
:	O
(	O
1	O
)	O
FFA	O
and	O
LO	O
responded	O
more	O
strongly	O
to	O
nonfreckled	O
(	O
smooth	O
)	O
faces	O
,	O
compared	O
with	O
otherwise	O
identical	O
freckled	O
(	O
textured	O
)	O
faces	O
;	O
and	O
(	O
2	O
)	O
strong	O
functional	O
connections	O
were	O
found	O
between	O
LO	O
and	O
FFA	O
.	O

Thus	O
,	O
LO	O
and	O
FFA	O
may	O
be	O
part	O
of	O
an	O
information	O
-	O
processing	O
stream	O
distinguished	O
by	O
feature	O
-based	O
category	O
selectivity	O
(	O
smooth	O
>	O
textured	O
)	O
.	O

Endoscopic	B-P
endonasal	O
surgery	O
for	O
remission	O
of	O
Cushing	O
's	O
Disease	O
caused	O
by	O
ectopic	O
intracavernous	O
macroadenoma	O
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

Complete	O
surgical	O
resection	O
of	O
an	O
ACTH-secreting	O
pituitary	O
adenoma	O
is	O
the	O
gold	O
standard	O
of	O
treatment	O
of	O
Cushing	O
's	O
Disease	O
.	O

Ectopic	O
location	O
of	O
these	O
adenomas	O
is	O
an	O
extremely	O
rare	O
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	O
and	O
surgical	O
success	O
.	O

We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	O
intracavernous	O
ACTH-secreting	O
macroadenoma	O
totally	O
resected	O
with	O
endoscopic	B-P
endonasal	O
surgery	O
(	O
EES	O
)	O
.	O

A	O
36	O
year	O
old	O
female	O
presented	O
with	O
Cushing	O
syndrome	O
.	O

Increased	O
ACTH	O
,	O
serum	O
cortisol	O
and	O
free	O
urine	O
cortisol	O
levels	O
were	O
identified	O
,	O
however	O
the	O
pituitary	B-P
MRI	I-P
failed	O
to	O
reveal	O
a	O
pituitary	O
tumor	O
;	O
instead	O
,	O
a	O
parasellar	O
lesion	O
in	O
the	O
left	O
cavernous	O
sinus	O
(	O
CS	O
)	O
was	O
noticed	O
.	O

Inferior	B-P
petrosal	I-P
sinus	I-P
sampling	I-P
demonstrated	O
a	O
significant	O
central	O
-to-	O
peripheral	O
and	O
lateralized	O
left-sided	O
ACTH	O
gradient	O
.	O

The	O
patient	O
underwent	O
EES	O
.	O

No	O
tumor	O
was	O
found	O
in	O
the	O
sella	O
,	O
however	O
,	O
the	O
left	O
CS	O
was	O
widely	O
explored	O
and	O
a	O
tumor	O
was	O
found	O
lateral	O
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	O
artery	O
.	O

There	O
were	O
no	O
complications	O
following	O
EES	O
.	O

Pathology	O
confirmed	O
the	O
diagnosis	O
of	O
an	O
ACTH-secreting	O
adenoma	O
.	O

During	O
the	O
immediately	O
postoperative	O
course	O
serum	O
cortisol	O
levels	O
dropped	O
below	O
5	O
mcg/dl	O
.	O

Postoperative	O
MRI	B-P
demonstrated	O
complete	O
tumor	O
resection	O
.	O

At	O
20	O
months	O
follow-up	O
,	O
the	O
patient	O
remains	O
in	O
clinical	O
and	O
biochemical	O
remission	O
of	O
Cushing	O
's	O
Disease	O
.	O

Only	O
12	O
cases	O
of	O
ectopic	O
intracavernous	O
ACTH-secreting	O
adenomas	O
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	O
.	O

The	O
presence	O
of	O
an	O
ectopic	O
ACTH-secreting	O
macroadenoma	O
in	O
the	O
CS	O
represents	O
a	O
surgical	O
challenge	O
.	O

EES	O
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	O
of	O
ectopic	O
intracavernous	O
adenomas	O
allowing	O
for	O
a	O
wide	O
exploration	O
of	O
the	O
CS	O
with	O
no	O
surgical	O
complications	O
.	O

Unplanned	O
readmissions	O
within	O
30	O
days	O
after	O
discharge	O
:	O
improving	O
quality	O
through	O
easy	O
prediction	O
.	O

To	O
propose	O
an	O
easy	O
predictive	O
model	O
for	O
the	O
risk	O
of	O
rehospitalization	O
,	O
built	O
from	O
hospital	O
administrative	O
data	O
,	O
in	O
order	O
to	O
prevent	O
repeated	O
admissions	O
and	O
to	O
improve	O
transitional	O
care	O
.	O

Retrospective	O
cohort	O
study	O
.	O

Azienda	O
Ospedaliero	O
Universitaria	O
Pisana	O
(	O
Pisa	O
University	O
Hospital	O
)	O
.	O

Patients	O
residing	O
in	O
the	O
territory	O
of	O
the	O
province	O
of	O
Pisa	O
(	O
Tuscany	O
Region	O
)	O
with	O
at	O
least	O
one	O
unplanned	O
hospital	O
admission	O
leading	O
to	O
a	O
medical	O
Diagnosis-Related	O
Group	O
(	O
DRG	O
)	O
in	O
the	O
calendar	O
year	O
2012	O
.	O

We	O
compared	O
two	O
groups	O
of	O
patients	O
:	O
patients	O
coded	O
as	O
'RA30	O
'	O
(	O
readmitted	O
within	O
30	O
days	O
after	O
the	O
previous	O
discharge	O
)	O
and	O
patients	O
coded	O
as	O
'NRA30	O
'	O
(	O
either	O
admitted	O
only	O
once	O
or	O
readmitted	O
after	O
30	O
days	O
since	O
the	O
latest	O
discharge	O
)	O
.	O

The	O
effect	O
of	O
age	O
,	O
sex	O
,	O
length	O
of	O
stay	O
,	O
number	O
of	O
diagnoses	O
,	O
normalized	O
number	O
of	O
admissions	O
and	O
presence	O
of	O
diseases	O
on	O
the	O
probability	O
of	O
rehospitalization	O
within	O
30	O
days	O
after	O
discharge	O
was	O
evaluated	O
.	O

The	O
significant	O
variables	O
included	O
in	O
the	O
predictive	O
model	O
were	O
:	O
age	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.018	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.011-1.026	O
;	O
normalized	O
number	O
of	O
admissions	O
,	O
OR	O
=	O
1.257	O
,	O
CI	O
=	O
1.225-1.290	O
;	O
number	O
of	O
diagnoses	O
,	O
OR	O
=	O
1.306	O
,	O
CI	O
=	O
1.174-1.452	O
and	O
presence	O
of	O
cancer	B-P
diagnosis	I-P
,	O
OR	O
=	O
1.479	O
,	O
CI	O
=	O
1.088-2.011	O
.	O

The	O
model	O
can	O
be	O
easily	O
applied	O
when	O
discharging	O
patients	O
who	O
have	O
been	O
hospitalized	O
after	O
an	O
access	O
to	O
the	O
Emergency	O
Department	O
to	O
predict	O
the	O
risk	O
of	O
rehospitalization	O
within	O
30	O
days	O
.	O

The	O
prediction	O
can	O
be	O
used	O
to	O
activate	O
focused	O
hospital-primary	O
care	O
transitional	O
interventions	O
.	O

The	O
model	O
has	O
to	O
be	O
validated	O
first	O
in	O
order	O
to	O
be	O
implemented	O
in	O
clinical	O
practice	O
.	O

Intraspinal	O
meningioma	O
with	O
malignant	O
transformation	O
and	O
distant	O
metastasis	O
.	O

Meningioma	O
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	O
tumor	O
.	O

Malignant	O
transformation	O
and	O
metastasis	O
of	O
meningiomas	O
are	O
rare	O
.	O

Moreover	O
,	O
most	O
meningiomas	O
are	O
intracranial	O
,	O
and	O
there	O
are	O
few	O
reports	O
on	O
intraspinal	O
meningiomas	O
.	O

This	O
report	O
aimed	O
to	O
describe	O
the	O
clinical	O
features	O
and	O
pathological	O
findings	O
of	O
a	O
case	O
of	O
malignant	O
transformation	O
and	O
distant	O
metastasis	O
of	O
intraspinal	O
meningioma	O
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O

A	O
44-year-old	O
man	O
with	O
a	O
bilateral	O
lower	O
limb	O
paresis	O
was	O
diagnosed	O
with	O
an	O
intradural	O
extramedullary	O
tumor	O
of	O
the	O
thoracic	O
spine	O
.	O

Primary	O
tumor	O
resection	O
was	O
performed	O
,	O
and	O
the	O
histological	O
findings	O
revealed	O
atypical	O
meningioma	O
.	O

The	O
meningioma	O
recurred	O
2	O
years	O
after	O
the	O
primary	O
surgery	O
,	O
and	O
a	O
second	O
resection	O
was	O
performed	O
,	O
but	O
only	O
partial	O
resection	O
was	O
possible	O
because	O
of	O
decreased	O
motor	O
evoked	O
potential	O
.	O

At	O
age	O
48	O
,	O
the	O
patient	O
's	O
lower	O
limb	O
weakness	O
returned	O
,	O
and	O
a	O
third	O
resection	O
was	O
performed	O
,	O
and	O
the	O
histological	O
finding	O
remained	O
atypical	O
meningioma	O
.	O

At	O
age	O
54	O
,	O
the	O
tumor	O
increased	O
and	O
stereotactic	O
irradiation	O
was	O
performed	O
.	O

At	O
age	O
60	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
metastatic	O
tumors	O
of	O
the	O
rib	O
,	O
lumbar	O
vertebra	O
,	O
cervical	O
spine	O
,	O
and	O
sacrum	O
.	O

Biopsy	B-P
of	O
the	O
rib	O
metastatic	O
tumor	O
was	O
performed	O
,	O
and	O
the	O
histological	O
findings	O
revealed	O
anaplastic	O
meningioma	O
.	O

This	O
case	O
is	O
the	O
first	O
report	O
of	O
an	O
intraspinal	O
meningioma	O
that	O
transformed	O
from	O
atypical	O
to	O
anaplastic	O
meningioma	O
with	O
distant	O
hematogenous	O
metastasis	O
.	O

CD44	O
positive	O
/	O
CD24	O
negative	O
(	O
stem	O
cell	O
like	O
property	O
)	O
breast	O
carcinoma	O
cells	O
as	O
marker	O
of	O
tumor	O
aggression	O
.	O

Cells	O
with	O
stem	O
cell	O
like	O
properties	O
in	O
solid	O
organ	O
malignancies	O
like	O
breast	O
and	O
pancreas	O
have	O
been	O
studied	O
over	O
the	O
last	O
decade	O
and	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
poor	O
prognosis	O
.	O

Presence	O
of	O
CD44	O
positive	O
and	O
CD24	O
negative	O
tumor	O
cells	O
in	O
breast	O
carcinoma	O
(	O
cells	O
with	O
'	O
stem	O
cell	O
'	O
like	O
property	O
)	O
as	O
marker	O
of	O
aggressiveness	O
and	O
poor	O
prognosis	O
was	O
checked	O
for	O
association	O
with	O
various	O
markers	O
of	O
disease	O
aggression	O
like	O
age	O
at	O
presentation	O
,	O
size	O
of	O
tumor	O
,	O
histological	O
grade	O
of	O
tumor	O
,	O
triple	O
negative	O
status	O
,	O
level	O
of	O
micro-vessel	O
density	O
,	O
and	O
nodal	O
status	O
.	O

Single	B-P
and	I-P
double	I-P
staining	I-P
immunohistochemistry	I-P
protocol	I-P
was	O
used	O
for	O
CD24	O
and	O
CD44	O
staining	O
.	O

The	O
staining	O
protocol	O
was	O
repeated	O
with	O
more	O
contemporary	O
techniques	O
using	O
fluorescent	O
chromogen	O
also	O
.	O

52	O
cases	O
,	O
all	O
females	O
who	O
underwent	O
modified	O
radical	O
mastectomy	O
at	O
a	O
tertiary	O
care	O
hospital	O
over	O
a	O
period	O
of	O
3	O
years	O
,	O
were	O
evaluated	O
.	O

No	O
association	O
was	O
found	O
between	O
presence	O
of	O
stem	O
cells	O
and	O
size	O
of	O
lesion	O
,	O
histological	O
grade	O
,	O
triple	O
negative	O
status	O
or	O
micro-vessel	O
density	O
.	O

However	O
,	O
significant	O
association	O
was	O
found	O
with	O
respect	O
to	O
younger	O
age	O
of	O
presentation	O
(	O
p	O
value	O
=	O
0.044	O
)	O
.	O

20	O
out	O
of	O
25	O
cases	O
with	O
nodal	O
metastasis	O
were	O
positive	O
for	O
presence	O
of	O
stem	O
cells	O
(	O
p	O
value	O
is	O
0.0003	O
)	O
.	O

Further	O
,	O
18	O
of	O
these	O
20	O
cases	O
also	O
had	O
stem	O
cells	O
in	O
the	O
metastatic	O
nodule	O
.	O

Fluorescent	O
chromogens	O
(	O
FITC	O
and	O
Cyanine	O
Red	O
)	O
revealed	O
similar	O
results	O
.	O

Cases	O
positive	O
for	O
stem	O
cells	O
showed	O
earlier	O
onset	O
of	O
disease	O
and	O
proneness	O
to	O
nodal	O
metastasis	O
.	O

Targeting	O
accuracy	O
of	O
single-isocenter	O
intensity-modulated	O
radiosurgery	O
for	O
multiple	O
lesions	O
.	O

To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity-modulated	O
SRS	O
(	O
IMRS	O
)	O
plans	O
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	O
metastases	O
with	O
a	O
single	O
isocenter	O
.	O

A	O
home-made	O
acrylic	O
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	O
plane	O
was	O
used	O
.	O

The	O
phantom	O
was	O
CT	B-P
scanned	I-P
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	O
and	O
two	O
peripheral	O
)	O
were	O
outlined	O
in	O
the	O
Eclipse	O
system	O
.	O

Peripheral	O
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	O
one	O
.	O

A	O
reference	O
IMRS	O
plan	O
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	O
isocenter	O
located	O
at	O
the	O
center	O
of	O
the	O
central	O
target	O
was	O
used	O
.	O

After	O
positioning	O
the	O
phantom	O
on	O
the	O
linac	O
using	O
the	O
room	O
lasers	O
,	O
a	O
CBCT	B-P
scan	I-P
was	O
acquired	O
and	O
the	O
reference	O
plan	O
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	O
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	O
isocenter	O
.	O

The	O
mapped	O
plan	O
was	O
then	O
recalculated	O
and	O
delivered	O
.	O

The	O
film	O
dose	O
distribution	O
was	O
derived	O
using	O
a	O
cloud	O
computing	O
application	O
(	O
www.radiochromic.com	O
)	O
that	O
uses	O
a	O
triple-channel	O
dosimetry	O
algorithm	O
.	O

Comparison	O
of	O
dose	O
distributions	O
using	O
the	O
gamma	O
index	O
(	O
5	O
%	O
/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm	O
(	O
2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O

2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	O
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	O
target	O
.	O

The	O
experiment	O
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	O
.	O

Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
,	O
respectively	O
.	O

No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
.	O

The	O
study	O
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off-	O
isocenter	O
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	O
isocenter	O
,	O
when	O
a	O
single-isocenter	O
IMRS	O
plan	O
is	O
designed	O
.	O

Real-time	O
observation	O
of	O
protein	O
aggregates	O
in	O
pharmaceutical	O
formulations	O
using	O
liquid	O
cell	O
electron	O
microscopy	O
.	O

Understanding	O
the	O
properties	O
of	O
protein-based	O
therapeutics	O
is	O
a	O
common	O
goal	O
of	O
biologists	O
and	O
physicians	O
.	O

Technical	O
barriers	O
in	O
the	O
direct	O
observation	O
of	O
small	O
proteins	O
or	O
therapeutic	O
agents	O
can	O
limit	O
our	O
knowledge	O
of	O
how	O
they	O
function	O
in	O
solution	O
and	O
in	O
the	O
body	O
.	O

Electron	O
microscopy	O
(	O
EM	O
)	O
imaging	B-P
performed	O
in	O
a	O
liquid	O
environment	O
permits	O
us	O
to	O
peer	O
into	O
the	O
active	O
world	O
of	O
cells	O
and	O
molecules	O
at	O
the	O
nanoscale	O
.	O

Here	O
,	O
we	O
employ	O
liquid	O
cell	O
EM	O
to	O
directly	O
visualize	O
a	O
protein-based	O
therapeutic	O
in	O
its	O
native	O
conformation	O
and	O
aggregate	O
state	O
in	O
a	O
time-resolved	O
manner	O
.	O

In	O
combination	O
with	O
quantitative	O
analyses	O
,	O
information	O
from	O
this	O
work	O
contributes	O
new	O
molecular	O
insights	O
toward	O
understanding	O
the	O
behaviours	O
of	O
immunotherapies	O
in	O
a	O
solution	O
state	O
that	O
mimics	O
the	O
human	O
body	O
.	O

Redistribution	O
of	O
Cav2.1	O
channels	O
and	O
calcium	O
ions	O
in	O
nerve	O
terminals	O
following	O
end-to-side	O
neurorrhaphy	O
:	O
ionic	B-P
imaging	I-P
analysis	I-P
by	O
TOF-SIMS	O
.	O

The	O
P/Q-type	O
voltage-dependent	O
calcium	O
channel	O
(	O
Cav2.1	O
)	O
in	O
the	O
presynaptic	O
membranes	O
of	O
motor	O
nerve	O
terminals	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
Ca	O
(	O
2+	O
)	O
transport	O
,	O
resulting	O
in	O
transmitter	O
release	O
within	O
the	O
nervous	O
system	O
.	O

The	O
recovery	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
on	O
motor	O
end	O
plates	O
(	O
MEPs	O
)	O
and	O
innervated	O
muscle	O
may	O
directly	O
reflect	O
nerve	O
regeneration	O
following	O
peripheral	O
nerve	O
injury	O
.	O

Although	O
the	O
functional	O
significance	O
of	O
calcium	O
channels	O
and	O
the	O
levels	O
of	O
Ca	O
(	O
2+	O
)	O
signalling	O
in	O
nerve	O
regeneration	O
are	O
well	O
documented	O
,	O
little	O
is	O
known	O
about	O
calcium	O
channel	O
expression	O
and	O
its	O
relation	O
with	O
the	O
dynamic	O
Ca	O
(	O
2+	O
)	O
ion	O
distribution	O
at	O
regenerating	O
MEPs	O
.	O

In	O
the	O
present	O
study	O
,	O
end-to-side	O
neurorrhaphy	O
(	O
ESN	O
)	O
was	O
performed	O
as	O
an	O
in	O
vivo	O
model	O
of	O
peripheral	O
nerve	O
injury	O
.	O

The	O
distribution	O
of	O
Ca	O
(	O
2+	O
)	O
at	O
regenerating	O
MEPs	O
following	O
ESN	O
was	O
first	O
detected	O
by	O
time-of-flight	O
secondary	O
ion	O
mass	O
spectrometry	O
,	O
and	O
the	O
specific	O
localization	O
and	O
expression	O
of	O
Cav2.1	O
channels	O
were	O
examined	O
by	O
confocal	O
microscopy	O
and	O
western	O
blotting	O
.	O

Compared	O
with	O
other	O
fundamental	O
ions	O
,	O
such	O
as	O
Na	O
(	O
+	O
)	O
and	O
K	O
(	O
+	O
)	O
,	O
dramatic	O
changes	O
in	O
the	O
Ca	O
(	O
2+	O
)	O
distribution	O
were	O
detected	O
along	O
with	O
the	O
progression	O
of	O
MEP	O
regeneration	O
.	O

The	O
re-establishment	O
of	O
Ca	O
(	O
2+	O
)	O
distribution	O
and	O
intensity	O
were	O
correlated	O
with	O
the	O
functional	O
recovery	O
of	O
muscle	O
in	O
ESN	O
rats	O
.	O

Furthermore	O
,	O
the	O
re-clustering	O
of	O
Cav2.1	O
channels	O
after	O
ESN	O
at	O
the	O
nerve	O
terminals	O
corresponded	O
with	O
changes	O
in	O
the	O
Ca	O
(	O
2+	O
)	O
distribution	O
.	O

These	O
results	O
indicated	O
that	O
renewal	O
of	O
the	O
Cav2.1	O
distribution	O
within	O
the	O
presynaptic	O
nerve	O
terminals	O
may	O
be	O
necessary	O
for	O
initiating	O
a	O
proper	O
Ca	O
(	O
2+	O
)	O
influx	O
and	O
shortening	O
the	O
latency	O
of	O
muscle	O
contraction	O
during	O
nerve	O
regeneration	O
.	O

High-Throughput	O
Genotyping	O
with	O
TaqMan	O
Allelic	O
Discrimination	O
and	O
Allele-Specific	O
Genotyping	O
Assays	O
.	O

Real-time	O
PCR	O
-based	O
genotyping	O
methods	O
,	O
such	O
as	O
TaqMan	O
allelic	O
discrimination	O
assays	O
and	O
allele-specific	O
genotyping	O
,	O
are	O
particularly	O
useful	O
when	O
screening	B-P
a	O
handful	O
of	O
single	O
nucleotide	O
polymorphisms	O
in	O
hundreds	O
of	O
samples	O
;	O
either	O
derived	O
from	O
different	O
individuals	O
,	O
tissues	O
,	O
or	O
pre	O
-	O
amplified	O
DNA	O
.	O

Although	O
real-time	O
PCR	O
-	O
based	O
methods	O
such	O
as	O
TaqMan	O
are	O
well-established	O
,	O
alternative	O
methods	O
,	O
like	O
allele-specific	O
genotyping	O
,	O
are	O
powerful	O
alternatives	O
,	O
especially	O
for	O
genotyping	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
length	O
polymorphisms	O
.	O

Here	O
,	O
we	O
describe	O
all	O
relevant	O
aspects	O
when	O
developing	O
an	O
assay	O
for	O
a	O
new	O
SNP	O
or	O
STR	O
using	O
either	O
TaqMan	O
or	O
allele-specific	O
genotyping	O
,	O
respectively	O
,	O
such	O
as	O
primer	O
and	O
probe	O
design	O
,	O
optimization	O
of	O
reaction	O
conditions	O
,	O
the	O
experimental	O
procedure	O
for	O
typing	O
hundreds	O
of	O
samples	O
,	O
and	O
finally	O
the	O
data	O
evaluation	O
.	O

Our	O
goal	O
is	O
to	O
provide	O
a	O
guideline	O
for	O
developing	O
genotyping	O
assays	O
using	O
these	O
two	O
approaches	O
that	O
render	O
reliable	O
and	O
reproducible	O
genotype	O
calls	O
involving	O
minimal	O
optimization	O
.	O

Estrogen	O
deficiency	O
accelerates	O
lumbar	O
facet	O
joints	O
arthritis	O
.	O

Dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
lumbar	O
facet	O
joint	O
(	O
LFJ	O
)	O
arthritis	O
in	O
women	O
around	O
the	O
age	O
of	O
menopause	O
indicates	O
a	O
protective	O
role	O
for	O
estrogen	O
in	O
LFJ	O
arthritis	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
evidence	O
for	O
this	O
indication	O
and	O
the	O
mechanism	O
of	O
such	O
an	O
effect	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
ovariectomized	O
(	O
OVX	O
)	O
mice	O
were	O
used	O
to	O
mimic	O
the	O
estrogen	O
-	O
deficient	O
status	O
of	O
post-menopausal	O
women	O
.	O

Micro-CT	B-P
and	O
immunohistochemistry	B-P
was	O
employed	O
to	O
assess	O
the	O
morphological	O
and	O
molecular	O
changes	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

The	O
results	O
show	O
that	O
the	O
LFJ	O
subchondral	O
bone	O
mass	O
was	O
significantly	O
decreased	O
in	O
OVX	O
mice	O
,	O
with	O
increased	O
cavities	O
on	O
the	O
interface	O
of	O
the	O
subchondral	O
bone	O
.	O

Severe	O
cartilage	O
degradation	O
was	O
observed	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

Increased	O
blood	O
vessels	O
and	O
innervations	O
were	O
also	O
found	O
in	O
degenerated	O
LFJ	O
,	O
particularly	O
in	O
the	O
subchondral	O
bone	O
area	O
.	O

17β-Estradiol	O
treatment	O
efficiently	O
suppressed	O
LFJ	O
subchondral	O
bone	O
turnover	O
,	O
markedly	O
inhibited	O
cartilage	O
degradation	O
,	O
and	O
increased	O
blood	O
vessel	O
and	O
nerve	O
ending	O
growth	O
in	O
degenerated	O
LFJ	O
in	O
OVX	O
mice	O
.	O

Our	O
study	O
reveals	O
that	O
estrogen	O
is	O
a	O
key	O
factor	O
in	O
regulating	O
LFJ	O
metabolism	O
.	O

Severe	O
LFJ	O
degeneration	O
occurs	O
when	O
estrogen	O
is	O
absent	O
in	O
vivo	O
.	O

Collapsed	O
subchondral	O
bone	O
may	O
be	O
the	O
initiation	O
of	O
this	O
process	O
,	O
and	O
estrogen	O
replacement	O
therapy	O
can	O
effectively	O
prevent	O
degeneration	O
of	O
LFJ	O
under	O
estrogen	O
-	O
deficient	O
conditions	O
.	O

The	O
relationship	O
between	O
anthropometry	O
and	O
body	O
composition	O
from	O
computed	B-P
tomography	I-P
:	O
The	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
Study	O
.	O

Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	O
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	O
Asians	O
living	O
in	O
the	O
US	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
study	O
of	O
871	O
participants	O
in	O
the	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
(	O
MASALA	O
)	O
Study	O
who	O
had	O
BMI	O
<	O
40	O
kg/m	O
(	O
2	O
)	O
and	O
underwent	O
abdominal	B-P
CT	I-P
scans	I-P
for	O
measurement	O
of	O
visceral	O
and	O
subcutaneous	O
fat	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
model	O
the	O
associations	O
between	O
anthropometric	O
measures	O
and	O
naturally	O
log-transformed	O
body	O
composition	O
measures	O
.	O

All	O
measures	O
of	O
anthropometry	O
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	O
fat	O
and	O
had	O
a	O
significant	O
non-linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
only	O
associations	O
for	O
visceral	O
fat	O
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	O
circumference	O
(	O
%	O
difference	O
in	O
visceral	O
fat	O
slope	O
:	O
women	O
1.92	O
,	O
men	O
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist-to-hip	O
ratio	O
(	O
women	O
25.9	O
,	O
men	O
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O

Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	O
were	O
significantly	O
associated	O
with	O
subcutaneous	O
fat	O
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
)	O
:	O
2.74	O
for	O
women	O
,	O
4.08	O
for	O
men	O
;	O
BMI	O
(	O
kg/m	O
(	O
2	O
)	O
)	O
:	O
10.3	O
,	O
14.0	O
;	O
waist	O
circumference	O
(	O
cm	O
)	O
:	O
1.51	O
,	O
3.36	O
;	O
hip	O
circumference	O
(	O
cm	O
)	O
:	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O

In	O
MASALA	O
participants	O
,	O
the	O
relationships	O
of	O
anthropometric	O
measures	O
with	O
visceral	O
and	O
subcutaneous	O
fat	O
appear	O
similar	O
to	O
other	O
race	O
/	O
ethnic	O
groups	O
,	O
but	O
with	O
weaker	O
non-linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O

Given	O
these	O
results	O
,	O
researchers	O
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	O
Asians	O
when	O
approximating	O
subcutaneous	O
fat	O
or	O
when	O
using	O
waist	O
circumference	O
to	O
approximate	O
visceral	O
fat	O
.	O

Diagnostic	O
Value	O
and	O
Effect	O
of	O
Bedside	O
Ultrasound	B-P
in	O
Acute	O
Appendicitis	O
in	O
the	O
Emergency	O
Department	O
.	O

Early	O
and	O
accurate	O
diagnosis	O
of	O
acute	O
appendicitis	O
(	O
AA	O
)	O
with	O
ultrasound	B-P
(	O
US	B-P
)	O
can	O
minimize	O
the	O
morbidity	O
and	O
mortality	O
of	O
the	O
patients	O
.	O

In	O
this	O
regard	O
,	O
US	B-P
can	O
help	O
emergency	O
physicians	O
(	O
EPs	O
)	O
in	O
the	O
diagnosing	O
process	O
and	O
clinical	B-P
decision	I-P
making	I-P
for	O
AA	O
.	O

Therefore	O
,	O
we	O
primarily	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
point-of-care	O
US	B-P
(	O
POCUS	B-P
)	O
in	O
clinical	B-P
decision	I-P
making	I-P
of	O
EPs	O
for	O
the	O
diagnostic	O
evaluation	O
for	O
AA	O
in	O
the	O
emergency	O
department	O
(	O
ED	O
)	O
.	O

The	O
study	O
sample	O
consisted	O
of	O
patients	O
aged	O
>	O
18	O
years	O
who	O
presented	O
to	O
the	O
ED	O
with	O
abdominal	O
pain	O
and	O
underwent	O
diagnostic	O
evaluation	O
for	O
AA	O
.	O

All	O
patients	O
were	O
examined	O
initially	O
with	O
POCUS	B-P
by	O
EPs	O
and	O
then	O
with	O
radiology	O
-	O
performed	O
US	B-P
(	O
RADUS	B-P
)	O
by	O
radiologists	O
.	O

Pre	O
-	O
and	O
post	O
-	O
POCUS	B-P
median	O
diagnostic	O
certainty	O
values	O
(	O
MDCVs	O
)	O
for	O
AA	O
were	O
determined	O
with	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
scores	O
(	O
0	O
=	O
not	O
present	O
,	O
100	O
=	O
certainly	O
present	O
)	O
by	O
POCUS	B-P
performers	O
.	O

Definitive	O
diagnoses	O
were	O
determined	O
by	O
surgery	O
,	O
pathologic	O
evaluation	O
of	O
appendectomy	O
specimens	O
,	O
or	O
clinical	O
follow-up	O
results	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
likelihood	O
ratio	O
(	O
PLR	O
)	O
,	O
and	O
negative	O
likelihood	O
ratio	O
(	O
NLR	O
)	O
for	O
POCUS	B-P
and	O
RADUS	B-P
together	O
with	O
pre	O
-	O
and	O
post	O
-	O
POCUS	B-P
VAS	O
scores	O
for	O
MDCVs	O
were	O
compared	O
.	O

A	O
total	O
of	O
264	O
patients	O
were	O
included	O
into	O
the	O
final	O
analysis	O
and	O
169	O
(	O
64	O
%	O
)	O
had	O
a	O
diagnosis	O
of	O
AA	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
PLR	O
,	O
and	O
NLR	O
of	O
US	B-P
examinations	O
were	O
92.3	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
87.2	O
%	O
-95.8	O
%	O
)	O
,	O
95.8	O
%	O
(	O
89.5	O
%	O
-98.8	O
%	O
)	O
,	O
21.9	O
(	O
8.4-57.2	O
)	O
,	O
and	O
0.08	O
(	O
0.05-0.1	O
)	O
for	O
POCUS	B-P
and	O
76.9	O
%	O
(	O
69.8-83	O
%	O
)	O
,	O
97.8	O
%	O
(	O
84.9-99.7	O
%	O
)	O
,	O
36.4	O
(	O
9.25-144.3	O
)	O
,	O
and	O
0.24	O
(	O
0.18-0.31	O
)	O
for	O
RADUS	B-P
,	O
respectively	O
.	O

Pre	O
-	O
POCUS	B-P
and	O
post	O
-	O
POCUS	B-P
VAS	O
scores	O
for	O
MDCVs	O
were	O
60	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
=	O
50-65	O
)	O
and	O
95	O
(	O
IQR	O
=	O
20-98	O
)	O
,	O
respectively	O
(	O
p	O
=	O
0.000	O
)	O
.	O

Point-of-care	O
ultrasonography	B-P
,	O
when	O
performed	O
in	O
ED	O
for	O
the	O
diagnosis	O
of	O
AA	O
,	O
has	O
high	O
sensitivity	O
and	O
specificity	O
and	O
had	O
a	O
positive	O
impact	O
on	O
the	O
clinical	B-P
decision	I-P
making	I-P
of	O
EPs	O
.	O

Enhancing	O
Comparative	O
Effectiveness	O
Research	O
With	O
Automated	O
Pediatric	O
Pneumonia	O
Detection	O
in	O
a	O
Multi-Institutional	O
Clinical	O
Repository	O
:	O
A	O
PHIS	O
+	O
Pilot	O
Study	O
.	O

Community-acquired	O
pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
pediatric	O
morbidity	O
.	O

Administrative	O
data	O
are	O
often	O
used	O
to	O
conduct	O
comparative	O
effectiveness	O
research	O
(	O
CER	O
)	O
with	O
sufficient	O
sample	O
sizes	O
to	O
enhance	O
detection	O
of	O
important	O
outcomes	O
.	O

However	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	O
errors	O
because	O
of	O
the	O
variable	O
accuracy	O
of	O
discharge	O
diagnosis	O
codes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	O
,	O
scalable	O
,	O
and	O
accurate	O
method	O
to	O
determine	O
the	O
presence	O
or	O
absence	O
of	O
pneumonia	O
in	O
children	O
using	O
chest	B-P
imaging	I-P
reports	O
.	O

The	O
multi-institutional	O
PHIS	O
+	O
clinical	O
repository	O
was	O
developed	O
to	O
support	O
pediatric	O
CER	O
by	O
expanding	O
an	O
administrative	O
database	O
of	O
children	O
's	O
hospitals	O
with	O
detailed	O
clinical	O
data	O
.	O

To	O
develop	O
a	O
scalable	O
approach	O
to	O
find	O
patients	O
with	O
bacterial	O
pneumonia	O
more	O
accurately	O
,	O
we	O
developed	O
a	O
Natural	O
Language	O
Processing	O
(	O
NLP	O
)	O
application	O
to	O
extract	O
relevant	O
information	O
from	O
chest	B-P
diagnostic	I-P
imaging	I-P
reports	O
.	O

Domain	O
experts	O
established	O
a	O
reference	O
standard	O
by	O
manually	O
annotating	O
282	O
reports	O
to	O
train	O
and	O
then	O
test	O
the	O
NLP	O
application	O
.	O

Findings	O
of	O
pleural	O
effusion	O
,	O
pulmonary	O
infiltrate	O
,	O
and	O
pneumonia	O
were	O
automatically	O
extracted	O
from	O
the	O
reports	O
and	O
then	O
used	O
to	O
automatically	O
classify	O
whether	O
a	O
report	O
was	O
consistent	O
with	O
bacterial	O
pneumonia	O
.	O

Compared	O
with	O
the	O
annotated	O
diagnostic	B-P
imaging	I-P
reports	O
reference	O
standard	O
,	O
the	O
most	O
accurate	O
implementation	O
of	O
machine	O
learning	O
algorithms	O
in	O
our	O
NLP	O
application	O
allowed	O
extracting	O
relevant	O
findings	O
with	O
a	O
sensitivity	O
of	O
.939	O
and	O
a	O
positive	O
predictive	O
value	O
of	O
.925	O
.	O

It	O
allowed	O
classifying	O
reports	O
with	O
a	O
sensitivity	O
of	O
.71	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
.86	O
,	O
and	O
a	O
specificity	O
of	O
.962	O
.	O

When	O
compared	O
with	O
each	O
of	O
the	O
domain	O
experts	O
manually	O
annotating	O
these	O
reports	O
,	O
the	O
NLP	O
application	O
allowed	O
for	O
significantly	O
higher	O
sensitivity	O
(	O
.71	O
vs	O
.527	O
)	O
and	O
similar	O
positive	O
predictive	O
value	O
and	O
specificity	O
.	O

NLP	O
-based	O
pneumonia	O
information	O
extraction	O
of	O
pediatric	O
diagnostic	B-P
imaging	I-P
reports	O
performed	O
better	O
than	O
domain	O
experts	O
in	O
this	O
pilot	O
study	O
.	O

NLP	O
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	O
from	O
a	O
large	O
collection	O
of	O
imaging	O
reports	O
to	O
facilitate	O
CER	O
.	O

Bioresorbable	O
Vascular	O
Scaffolds	O
for	O
the	O
Treatment	O
of	O
Chronic	O
Total	O
Occlusions	O
:	O
An	O
International	O
Multicenter	O
Registry	O
.	O

There	O
are	O
only	O
limited	O
studies	O
reporting	O
clinical	O
outcomes	O
after	O
bioresorbable	O
vascular	O
scaffold	O
(	O
BVS	O
;	O
Absorb	O
;	O
Abbott	O
Vascular	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
implantation	O
for	O
coronary	O
chronic	O
total	O
occlusions	O
(	O
CTO	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
real-world	O
feasibility	O
and	O
safety	O
of	O
BVS	O
implantation	O
for	O
the	O
treatment	O
of	O
CTO	O
.	O

We	O
retrospectively	O
evaluated	O
CTO	O
cases	O
treated	O
with	O
BVS	O
from	O
a	O
multicenter	O
registry	O
.	O

The	O
primary	O
end	O
point	O
was	O
target	O
lesion	O
failure	O
defined	O
as	O
a	O
composite	O
of	O
cardiac	O
death	O
,	O
target	O
vessel	O
myocardial	O
infarction	O
,	O
and	O
clinically	O
driven	O
target	O
lesion	O
revascularization	O
.	O

From	O
September	O
2012	O
to	O
November	O
2015	O
,	O
65	O
patients	O
with	O
CTO	O
were	O
successfully	O
treated	O
with	O
BVS	O
.	O

The	O
mean	O
age	O
of	O
patients	O
was	O
60.8±11.0	O
years	O
;	O
89.2	O
%	O
were	O
male	O
and	O
40.0	O
%	O
diabetic	O
.	O

The	O
mean	O
ejection	O
fraction	O
was	O
57.7±10.8	O
%	O
.	O

The	O
mean	O
reference	O
vessel	O
diameter	O
and	O
CTO	O
lesion	O
length	O
were	O
3.0±0.4	O
and	O
20.2±3.0	O
mm	O
,	O
respectively	O
.	O

The	O
mean	O
number	O
of	O
BVS	O
deployed	O
per	O
patient	O
was	O
1.8±0.7	O
,	O
of	O
which	O
mean	O
diameter	O
and	O
total	O
length	O
were	O
3.0±0.4	O
and	O
47.6±19.9	O
mm	O
,	O
respectively	O
.	O

Postdilatation	O
with	O
noncompliant	O
balloons	O
(	O
mean	O
diameter	O
3.3±0.3	O
mm	O
)	O
was	O
performed	O
at	O
high	O
pressures	O
(	O
18.6±5.3	O
atm	O
)	O
in	O
all	O
cases	O
.	O

Intravascular	B-P
ultrasound	I-P
(	O
n=34	O
)	O
or	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
n=31	O
)	O
was	O
performed	O
in	O
all	O
cases	O
.	O

During	O
the	O
follow-up	O
period	O
(	O
median	O
:	O
453	O
days	O
,	O
25th	O
and	O
75th	O
percentiles	O
:	O
230	O
and	O
703	O
)	O
,	O
there	O
were	O
no	O
occurrences	O
of	O
target	O
lesion	O
failure	O
or	O
scaffold	O
thrombosis	O
.	O

BVS	O
implantation	O
for	O
the	O
treatment	O
of	O
CTO	O
seems	O
feasible	O
and	O
safe	O
.	O

Appropriate	O
lesion	O
preparation	O
,	O
high-pressure	O
postdilatation	O
,	O
and	O
the	O
use	O
of	O
intravascular	B-P
imaging	I-P
are	O
recommended	O
to	O
obtain	O
the	O
best	O
possible	O
final	O
result	O
.	O

Distinct	O
cortical	O
and	O
sub-cortical	O
neurogenic	O
domains	O
for	O
GABAergic	O
interneuron	O
precursor	O
transcription	O
factors	O
NKX2.1	O
,	O
OLIG2	O
and	O
COUP-TFII	O
in	O
early	O
fetal	O
human	O
telencephalon	O
.	O

The	O
extent	O
of	O
similarities	O
and	O
differences	O
between	O
cortical	O
GABAergic	O
interneuron	O
generation	O
in	O
rodent	O
and	O
primate	O
telencephalon	O
remains	O
contentious	O
.	O

We	O
examined	O
expression	O
of	O
three	O
interneuron	O
precursor	O
transcription	O
factors	O
,	O
alongside	O
other	O
markers	O
,	O
using	O
immunohistochemistry	B-P
on	O
8-12	O
post-conceptional	O
weeks	O
(	O
PCW	O
)	O
human	O
telencephalon	O
sections	O
.	O

NKX2.1	O
,	O
OLIG2	O
,	O
and	O
COUP-TFII	O
expression	O
occupied	O
distinct	O
(	O
although	O
overlapping	O
)	O
neurogenic	O
domains	O
which	O
extended	O
into	O
the	O
cortex	O
and	O
revealed	O
three	O
CGE	O
compartments	O
:	O
lateral	O
,	O
medial	O
,	O
and	O
ventral	O
.	O

NKX2.1	O
expression	O
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	O
,	O
medial	O
CGE	O
,	O
and	O
ventral	O
septum	O
confirming	O
that	O
,	O
at	O
this	O
developmental	O
stage	O
,	O
interneuron	O
generation	O
from	O
NKX2.1	O
+	O
precursor	O
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	O
.	O

OLIG2	O
immunoreactivity	O
was	O
observed	O
in	O
GABAergic	O
cells	O
of	O
the	O
proliferative	O
zones	O
of	O
the	O
MGE	O
and	O
septum	O
,	O
but	O
not	O
necessarily	O
co-expressed	O
with	O
NKX2.1	O
,	O
and	O
OLIG2	O
expression	O
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	O
,	O
CGE	O
,	O
and	O
cortex	O
.	O

At	O
8	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
only	O
present	O
in	O
the	O
medial	O
and	O
anterior	O
cortical	O
wall	O
suggesting	O
a	O
migratory	O
pathway	O
for	O
interneuron	O
precursor	O
s	O
via	O
the	O
septum	O
into	O
the	O
medial	O
cortex	O
.	O

By	O
12	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
present	O
throughout	O
the	O
cortex	O
and	O
many	O
were	O
actively	O
dividing	O
but	O
without	O
co-expressing	O
cortical	O
progenitor	O
markers	O
.	O

Dividing	O
COUP-TFII	O
+	O
progenitor	O
cells	O
were	O
localized	O
to	O
ventral	O
CGE	O
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	O
cortex	O
;	O
in	O
both	O
the	O
cases	O
,	O
COUP-TFII	O
was	O
co-expressed	O
with	O
PAX6	O
in	O
proliferative	O
zones	O
and	O
TBR1	O
or	O
calretinin	O
in	O
post-	O
mitotic	O
cortical	O
neurons	O
.	O

Thus	O
COUP-TFII	O
+	O
progenitors	O
gave	O
rise	O
to	O
pyramidal	O
cells	O
,	O
but	O
also	O
interneurons	O
which	O
not	O
only	O
migrated	O
posteriorly	O
into	O
the	O
cortex	O
from	O
ventral	O
CGE	O
but	O
also	O
anteriorly	O
via	O
the	O
LGE	O
.	O

Dural	O
Venous	O
Sinus	O
Diameters	O
in	O
Children	O
with	O
Sickle	O
Cell	O
Disease	O
:	O
Correlation	O
with	O
History	O
of	O
Stroke	O
in	O
a	O
Case-Control	O
Study	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
diameters	O
of	O
the	O
dural	O
venous	O
sinuses	O
(	O
DVSs	O
)	O
in	O
children	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
with	O
healthy	O
controls	O
and	O
determine	O
whether	O
the	O
size	O
has	O
any	O
correlation	O
to	O
history	O
of	O
cerebral	O
infarct	O
among	O
children	O
with	O
SCD	O
.	O

A	O
retrospective	O
review	O
compared	O
demographics	O
,	O
medical	O
history	O
and	O
magnetic	B-P
resonance	I-P
venography	I-P
(	O
MRV	B-P
)	O
findings	O
in	O
children	O
with	O
SCD	O
with	O
those	O
in	O
controls	O
.	O

Venous	O
sinus	O
diameters	O
were	O
measured	O
on	O
MRV	B-P
in	O
all	O
subjects	O
by	O
the	O
authors	O
,	O
who	O
were	O
blinded	O
to	O
the	O
children	O
's	O
clinical	O
history	O
.	O

The	O
study	O
cohort	O
included	O
38	O
MRVs	B-P
in	O
children	O
with	O
SCD	O
and	O
38	O
control	O
subjects	O
.	O

Statistical	O
comparison	O
showed	O
children	O
with	O
SCD	O
had	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
larger	O
DVS	O
diameters	O
than	O
controls	O
.	O

Among	O
children	O
with	O
SCD	O
with	O
a	O
history	O
of	O
stroke	O
or	O
silent	O
infarct	O
,	O
DVS	O
diameters	O
were	O
not	O
significantly	O
different	O
.	O

Children	O
with	O
SCD	O
had	O
larger	O
DVS	O
diameters	O
than	O
did	O
controls	O
,	O
regardless	O
of	O
the	O
former	O
group	O
's	O
history	O
of	O
cerebral	O
infarct	O
.	O

The	O
difference	O
in	O
size	O
of	O
venous	O
sinuses	O
is	O
important	O
to	O
be	O
aware	O
of	O
during	O
the	O
interpretation	O
of	O
neuroimaging	B-P
studies	O
to	O
avoid	O
unneeded	O
additional	O
imaging	B-P
or	O
referral	O
.	O

pH	O
-Dependent	O
Transmembrane	O
Activity	O
of	O
Peptide	O
-Functionalized	O
Gold	O
Nanostars	O
for	O
Computed	B-P
Tomography	I-P
/	O
Photoacoustic	B-P
Imaging	I-P
and	O
Photothermal	O
Therapy	O
.	O

Progress	O
in	O
multifunctional	O
nanomaterials	O
for	O
tumor	O
therapy	O
mostly	O
depends	O
on	O
the	O
development	O
of	O
tumor	O
-	O
targeting	O
delivery	O
strategies	O
.	O

One	O
approach	O
is	O
to	O
explore	O
a	O
pH	O
-responsive	O
strategy	O
to	O
target	O
the	O
slightly	O
acidic	O
solid	O
tumor	O
microenvironment	O
.	O

A	O
novel	O
class	O
of	O
pH	O
(	O
low	O
)	O
insertion	O
peptides	O
(	O
pHLIPs	O
)	O
with	O
pH	O
-dependent	O
transmembrane	O
activity	O
can	O
fold	O
and	O
rapidly	O
insert	O
into	O
the	O
lipid	O
bilayer	O
of	O
tumor	O
cells	O
triggered	O
by	O
acidity	O
,	O
facilitating	O
the	O
cellular	O
internalization	O
of	O
nanomaterials	O
synchronously	O
.	O

Here	O
,	O
we	O
innovatively	O
decorated	O
gold	O
nanostars	O
(	O
GNSs	O
)	O
with	O
pHLIPs	O
(	O
GNS	O
-	O
pHLIP	O
)	O
to	O
improve	O
their	O
targeting	O
ability	O
and	O
photothermal	O
therapeutic	O
(	O
PTT	O
)	O
efficiency	O
.	O

The	O
obtained	O
GNS	O
-	O
pHLIP	O
exhibited	O
the	O
excellent	O
characteristics	O
of	O
uniform	O
size	O
and	O
good	O
biocompatibility	O
.	O

As	O
compared	O
to	O
GNS	O
-	O
mPEG	O
,	O
the	O
cellular	O
internalization	O
of	O
GNS	O
-	O
pHLIP	O
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	O
in	O
media	O
at	O
pH	O
6.4	O
than	O
at	O
pH	O
7.4	O
.	O

Moreover	O
,	O
the	O
tumor	O
accumulation	O
of	O
the	O
GNS	O
-	O
pHLIP	O
was	O
3-fold	O
higher	O
than	O
that	O
of	O
GNS	O
-	O
mPEG	O
after	O
intravenous	O
injection	O
into	O
MCF-7	O
breast	O
tumor	O
animal	O
models	O
for	O
24	O
h.	O
Furthermore	O
,	O
GNS	O
-	O
pHLIP	O
exhibited	O
stronger	O
signals	O
than	O
the	O
GNS	O
-	O
mPEG	O
through	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
photoacoustic	B-P
(	I-P
PA	I-P
)	I-P
imaging	I-P
.	O

Simultaneously	O
,	O
the	O
desirable	O
targeting	O
efficiency	O
significantly	O
improved	O
the	O
PTT	O
efficacy	O
to	O
tumors	O
,	O
with	O
low	O
side	O
effects	O
on	O
normal	O
tissues	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	O
-	O
pHLIP	O
successfully	O
took	O
advantage	O
of	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
pHLIPs	O
and	O
the	O
good	O
characteristics	O
of	O
GNS	O
s	O
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	O
imaging	B-P
and	O
therapy	O
.	O

Dosimetry	O
software	O
Hermes	O
Internal	O
Radiation	O
Dosimetry	O
:	O
from	O
quantitative	O
image	O
reconstruction	O
to	O
voxel	O
-level	O
absorbed	O
dose	O
distribution	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
validate	O
a	O
software	O
package	O
called	O
Hermes	O
Internal	O
Radiation	O
Dosimetry	O
(	O
HIRD	O
)	O
for	O
internal	O
dose	O
assessment	O
tailored	O
for	O
clinical	O
practice	O
.	O

The	O
software	O
includes	O
all	O
the	O
necessary	O
steps	O
to	O
perform	O
voxel	O
-level	O
absorbed	O
dose	O
calculations	O
including	O
quantitative	O
reconstruction	O
,	O
image	O
coregistration	O
and	O
volume	O
of	O
interest	O
tools	O
.	O

The	O
basics	O
of	O
voxel	O
-level	O
dosimetry	O
methods	O
and	O
implementations	O
to	O
HIRD	O
software	O
are	O
reviewed	O
.	O

Then	O
,	O
HIRD	O
is	O
validated	O
using	O
simulated	O
SPECT	B-P
/	O
CT	B-P
data	O
and	O
data	O
from	O
Lu-DOTATATE	O
-	O
treated	O
patients	O
by	O
comparing	O
absorbed	O
kidney	O
doses	O
with	O
OLINDA/EXM	O
-based	O
dosimetry	O
.	O

In	O
addition	O
,	O
electron	O
and	O
photon	O
dose	O
components	O
are	O
studied	O
separately	O
in	O
an	O
example	O
patient	O
case	O
.	O

The	O
simulation	O
study	O
showed	O
that	O
HIRD	O
can	O
reproduce	O
time-activity	O
curves	O
accurately	O
and	O
produce	O
absorbed	O
doses	O
with	O
less	O
than	O
10	O
%	O
error	O
for	O
the	O
kidneys	O
,	O
liver	O
and	O
spleen	O
.	O

From	O
the	O
patient	O
data	O
,	O
the	O
absorbed	O
kidney	O
doses	O
calculated	O
using	O
HIRD	O
and	O
using	O
OLINDA/EXM	O
were	O
highly	O
correlated	O
(	O
Pearson	O
's	O
correlation	O
coefficient	O
,	O
r=0.98	O
)	O
.	O

From	O
Bland-Altman	O
plot	O
analysis	O
,	O
an	O
average	O
absorbed	O
dose	O
difference	O
of	O
-2	O
%	O
was	O
found	O
between	O
the	O
methods	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
in	O
Lu-DOTATATE	O
-	O
treated	O
patients	O
,	O
photons	O
can	O
contribute	O
over	O
10	O
%	O
of	O
the	O
kidney	O
's	O
total	O
dose	O
and	O
is	O
partly	O
because	O
of	O
cross-irradiation	O
from	O
high	O
-	O
uptake	O
lesions	O
close	O
to	O
the	O
kidneys	O
.	O

HIRD	O
is	O
a	O
straightforward	O
voxel	O
-level	O
internal	O
dosimetry	O
software	O
.	O

Its	O
clinical	O
utility	O
was	O
verified	O
with	O
simulated	O
and	O
clinical	O
Lu-DOTATATE	O
-	O
treated	O
patient	O
data	O
.	O

Patient	O
studies	O
also	O
showed	O
that	O
photon	O
contribution	O
towards	O
the	O
total	O
dose	O
can	O
be	O
relatively	O
high	O
and	O
voxel	O
-level	O
dose	O
calculations	O
can	O
be	O
valuable	O
in	O
cases	O
where	O
the	O
target	O
organ	O
is	O
in	O
close	O
proximity	O
to	O
high-	O
uptake	O
organs	O
.	O

Sella	O
turcica	O
bridging	O
and	O
dental	O
anomalies	O
:	O
is	O
there	O
an	O
association	O
?	O
.	O

Sella	O
turcica	O
bridging	O
(	O
STB	O
)	O
,	O
or	O
calcification	O
of	O
the	O
interclinoid	O
ligament	O
of	O
sella	O
turcica	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
some	O
dental	O
anomalies	O
(	O
palatal	O
canine	O
impaction	O
and	O
transposition	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
any	O
association	O
between	O
canine	O
impaction	O
,	O
hyperdontia	O
or	O
hypodontia	O
and	O
sellar	O
dimensions	O
or	O
bridging	O
.	O

Lateral	O
cephalometric	B-P
radiographs	B-P
from	O
78	O
patients	O
with	O
impacted	O
canines	O
,	O
68	O
with	O
dental	O
agenesis	O
and	O
17	O
with	O
hyperdontia	O
were	O
collected	O
.	O

Linear	O
dimensions	O
of	O
sella	O
turcica	O
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	O
group	O
(	O
47	O
individuals	O
)	O
.	O

A	O
standardize	O
scoring	O
scale	O
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	O
from	O
each	O
radiographs	B-P
.	O

The	O
frequency	O
of	O
partial	O
and	O
complete	O
calcifications	O
of	O
sella	O
in	O
patients	O
with	O
dental	O
anomalies	O
is	O
increased	O
when	O
compared	O
to	O
controls	O
.	O

STB	O
can	O
influence	O
the	O
interclinoid	O
distance	O
but	O
does	O
not	O
affect	O
other	O
linear	O
dimensions	O
of	O
sella	O
.	O

No	O
statistically	O
significant	O
difference	O
has	O
been	O
found	O
in	O
sellar	O
dimensions	O
and	O
STB	O
expression	O
when	O
evaluating	O
radiographs	B-P
at	O
different	O
ages	O
.	O

STB	O
is	O
frequently	O
found	O
in	O
patients	O
with	O
dental	O
abnormalities	O
.	O

The	O
Therapeutic	O
Effect	O
of	O
Berberine	O
in	O
the	O
Treatment	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
:	O
A	O
Meta-Analysis	O
.	O

Aim	O
.	O

To	O
assess	O
the	O
efficacy	O
of	O
berberine	O
in	O
the	O
treatment	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
through	O
meta-analysis	O
.	O

Method	O
.	O

We	O
searched	O
Embase	O
,	O
Pubmed	O
,	O
Cochrane	O
Library	O
,	O
and	O
so	O
forth	O
,	O
until	O
March	O
2016	O
for	O
randomized	O
controlled	O
trials	O
using	O
berberine	O
to	O
treat	O
NAFLD	O
.	O

Result	O
.	O

Six	O
randomized	O
controlled	O
trials	O
involving	O
501	O
patients	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
results	O
showed	O
that	O
the	O
efficacy	O
of	O
reducing	O
TC	O
,	O
LDL	O
,	O
ALT	O
,	O
2hPG	O
,	O
and	O
HbA1c	O
in	O
NAFLD	O
patients	O
of	O
the	O
berberine	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

The	O
subgroup	O
analyses	O
on	O
TG	O
,	O
AST	O
,	O
and	O
FBG	O
indicated	O
that	O
treatment	O
combined	O
with	O
berberine	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
berberine	O
alone	O
decreased	O
TG	O
level	O
in	O
NAFLD	O
patients	O
significantly	O
.	O

We	O
also	O
conducted	O
a	O
descriptive	O
analysis	O
on	O
insulin	O
resistance	O
and	O
radiography	B-P
results	O
that	O
berberine	O
can	O
improve	O
NAFLD	O
patients	O
'	O
insulin	O
resistance	O
and	O
fatty	O
liver	O
.	O

Conclusion	O
.	O

According	O
to	O
analysis	O
result	O
,	O
berberine	O
has	O
positive	O
efficacy	O
on	O
blood	O
lipids	O
,	O
blood	O
glucose	O
,	O
liver	O
function	O
,	O
insulin	O
resistance	O
,	O
and	O
fatty	O
liver	O
condition	O
of	O
NAFLD	O
patients	O
.	O

However	O
,	O
due	O
to	O
the	O
limitation	O
of	O
number	O
and	O
quality	O
of	O
trials	O
included	O
,	O
more	O
clinical	O
randomized	O
controlled	O
trials	O
with	O
high	O
quality	O
are	O
needed	O
for	O
further	O
verification	O
of	O
the	O
efficacy	O
of	O
berberine	O
on	O
NAFLD	O
patients	O
.	O

Molecular	O
Mechanisms	O
of	O
Resistance	O
to	O
First-	O
and	O
Second-Generation	O
ALK	O
Inhibitors	O
in	O
ALK	O
-Rearranged	O
Lung	O
Cancer	O
.	O

Advanced	O
,	O
anaplastic	O
lymphoma	O
kinase	O
(	O
ALK	O
)	O
-positive	O
lung	O
cancer	O
is	O
currently	O
treated	O
with	O
the	O
first-generation	O
ALK	O
inhibitor	O
crizotinib	O
followed	O
by	O
more	O
potent	O
,	O
second-generation	O
ALK	O
inhibitors	O
(	O
e.g.	O
,	O
ceritinib	O
and	O
alectinib	O
)	O
upon	O
progression	O
.	O

Second-generation	O
inhibitors	O
are	O
generally	O
effective	O
even	O
in	O
the	O
absence	O
of	O
crizotinib	O
-	O
resistant	O
ALK	O
mutations	O
,	O
likely	O
reflecting	O
incomplete	O
inhibition	O
of	O
ALK	O
by	O
crizotinib	O
in	O
many	O
cases	O
.	O

Herein	O
,	O
we	O
analyzed	O
103	O
repeat	O
biopsies	B-P
from	O
ALK	O
-positive	O
patients	O
progressing	O
on	O
various	O
ALK	O
inhibitors	O
.	O

We	O
find	O
that	O
each	O
ALK	O
inhibitor	O
is	O
associated	O
with	O
a	O
distinct	O
spectrum	O
of	O
ALK	O
resistance	O
mutations	O
and	O
that	O
the	O
frequency	O
of	O
one	O
mutation	O
,	O
ALK	O
(	O
G1202R	O
)	O
,	O
increases	O
significantly	O
after	O
treatment	O
with	O
second-generation	O
agents	O
.	O

To	O
investigate	O
strategies	O
to	O
overcome	O
resistance	O
to	O
second-generation	O
ALK	O
inhibitors	O
,	O
we	O
examine	O
the	O
activity	O
of	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
in	O
a	O
series	O
of	O
ceritinib	O
-	O
resistant	O
,	O
patient	O
-derived	O
cell	O
lines	O
,	O
and	O
observe	O
that	O
the	O
presence	O
of	O
ALK	O
resistance	O
mutations	O
is	O
highly	O
predictive	O
for	O
sensitivity	O
to	O
lorlatinib	O
,	O
whereas	O
those	O
cell	O
lines	O
without	O
ALK	O
mutations	O
are	O
resistant	O
.	O

Secondary	O
ALK	O
mutations	O
are	O
a	O
common	O
resistance	O
mechanism	O
to	O
second-generation	O
ALK	O
inhibitors	O
and	O
predict	O
for	O
sensitivity	O
to	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
repeat	O
biopsies	B-P
and	O
genotyping	O
following	O
disease	O
progression	O
on	O
targeted	O
therapies	O
,	O
particularly	O
second-generation	O
ALK	O
inhibitors	O
.	O

Cancer	O
Discov	O
;	O
6	O
(	O
10	O
)	O
;	O
1118-33	O
.	O

©2016	O
AACRSee	O
related	O
commentary	O
by	O
Qiao	O
and	O
Lovly	O
,	O
p.	O
1084This	O
article	O
is	O
highlighted	O
in	O
the	O
In	O
This	O
Issue	O
feature	O
,	O
p.	O
1069	O
.	O

Combined	O
ultrasound	B-P
and	O
exome	O
sequencing	O
approach	O
recognizes	O
Opitz	O
G/BBB	O
syndrome	O
in	O
two	O
malformed	O
fetuses	O
.	O

Orofacial	O
clefts	O
are	O
the	O
most	O
common	O
congenital	O
craniofacial	O
anomalies	O
and	O
can	O
occur	O
as	O
an	O
isolated	O
defect	O
or	O
be	O
associated	O
with	O
other	O
anomalies	O
such	O
as	O
posterior	O
fossa	O
anomalies	O
as	O
a	O
part	O
of	O
several	O
genetic	O
syndromes	O
.	O

We	O
report	O
two	O
consecutive	O
voluntary	O
pregnancy	O
interruptions	O
in	O
a	O
nonconsanguineous	O
couple	O
following	O
the	O
fetal	B-P
ultrasound	I-P
finding	O
of	O
cleft	O
lip	O
and	O
palate	O
and	O
posterior	O
fossa	O
anomalies	O
confirmed	O
by	O
means	O
of	O
post-termination	O
examination	O
on	O
the	O
second	O
fetus	O
.	O

The	O
quantitative	O
fluorescent	O
PCR	O
,	O
the	O
karyotype	O
,	O
and	O
the	O
comparative	O
genomic	O
hybridization-array	O
analysis	O
after	O
amniocentesis	B-P
were	O
normal	O
.	O

Exome	O
sequencing	O
on	O
abortive	O
material	O
from	O
both	O
fetuses	O
detected	O
a	O
missense	O
mutation	O
in	O
MID1	O
,	O
resulting	O
in	O
a	O
clinical	B-P
diagnosis	I-P
of	O
Opitz	O
G/BBB	O
syndrome	O
.	O

The	O
same	O
mutation	O
was	O
found	O
in	O
the	O
mother	O
and	O
in	O
her	O
brother	O
,	O
who	O
both	O
revealed	O
cerebellar	O
anomalies	O
at	O
an	O
MRI	B-P
examination	O
.	O

Our	O
study	O
supports	O
the	O
efficacy	O
of	O
exome	O
sequencing	O
in	O
the	O
presence	O
of	O
both	O
a	O
family	O
history	O
suggestive	O
of	O
an	O
inherited	O
disorder	O
and	O
well-documented	O
ultrasound	O
findings	O
.	O

It	O
reveals	O
the	O
importance	O
of	O
a	O
synergistic	O
effort	O
between	O
gynecologists	O
and	O
geneticists	O
aimed	O
at	O
the	O
integration	O
of	O
the	O
most	O
sophisticated	O
ultrasound	B-P
techniques	I-P
with	O
the	O
next-generation	O
sequencing	O
tools	O
to	O
provide	O
a	O
definite	O
diagnosis	O
essential	O
to	O
orient	O
the	O
final	O
decision	O
and	O
to	O
estimate	O
a	O
proper	O
recurrence	O
risk	O
.	O

Diabetes	O
mellitus	O
and	O
sensorineural	O
hearing	O
loss	O
:	O
is	O
there	O
an	O
association	O
?	O

Baseline	O
of	O
the	O
Brazilian	O
Longitudinal	O
Study	O
of	O
Adult	O
Health	O
(	O
ELSA-Brasil	O
)	O
.	O

Although	O
several	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
diabetes	O
on	O
hearing	O
loss	O
,	O
the	O
relationship	O
between	O
these	O
two	O
conditions	O
remains	O
unclear	O
.	O

Some	O
studies	O
have	O
suggested	O
that	O
diabetes	O
may	O
cause	O
sensorineural	O
hearing	O
loss	O
,	O
whereas	O
others	O
have	O
failed	O
to	O
find	O
an	O
association	O
.	O

The	O
biggest	O
challenge	O
in	O
investigating	O
the	O
association	O
between	O
diabetes	O
and	O
hearing	O
loss	O
is	O
the	O
presence	O
of	O
confounding	O
variables	O
and	O
the	O
complexity	O
of	O
the	O
auditory	O
system	O
.	O

Our	O
study	O
investigated	O
the	O
association	O
between	O
diabetes	O
and	O
sensorineural	O
hearing	O
loss	O
.	O

We	O
evaluated	O
the	O
influence	O
of	O
time	O
from	O
diabetes	O
diagnosis	O
on	O
this	O
association	O
after	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
and	O
hypertension	O
diagnosis	O
and	O
excluding	O
those	O
subjects	O
with	O
exposure	O
to	O
noise	O
.	O

This	O
cross-sectional	O
study	O
evaluated	O
901	O
adult	O
and	O
elderly	O
Brazilian	O
Longitudinal	O
Study	O
of	O
Adult	O
Health	O
(	O
ELSA-Brasil	O
)	O
participants	O
from	O
São	O
Paulo	O
,	O
Brazil	O
who	O
underwent	O
audiometry	B-P
testing	I-P
as	O
part	O
of	O
ELSA-Brasil	O
's	O
baseline	O
assessment	O
.	O

Hearing	O
thresholds	O
and	O
speech	B-P
test	I-P
results	O
were	O
significantly	O
worse	O
in	O
the	O
group	O
with	O
diabetes	O
than	O
in	O
the	O
group	O
without	O
diabetes	O
.	O

However	O
,	O
no	O
significant	O
differences	O
were	O
found	O
between	O
participants	O
with	O
and	O
without	O
diabetes	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
and	O
the	O
presence	O
of	O
hypertension	O
.	O

Hearing	O
thresholds	O
were	O
not	O
affected	O
by	O
occupational	O
noise	O
exposure	O
in	O
the	O
group	O
s	O
with	O
and	O
without	O
diabetes	O
.	O

In	O
addition	O
,	O
no	O
association	O
between	O
the	O
duration	O
of	O
diabetes	O
and	O
hearing	O
thresholds	O
was	O
observed	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
and	O
hypertension	O
.	O

We	O
found	O
no	O
association	O
between	O
the	O
duration	O
of	O
diabetes	O
and	O
worse	O
hearing	O
thresholds	O
after	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
and	O
the	O
presence	O
of	O
hypertension	O
.	O

Regeneration	O
of	O
mandibular	O
ameloblastoma	O
defect	O
with	O
the	O
help	O
of	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
and	O
buccal	O
pad	O
of	O
fat	O
stromal	O
vascular	O
fraction	O
.	O

Ameloblastoma	O
is	O
benign	O
odontogenic	O
tumor	O
,	O
which	O
is	O
locally	O
aggressive	O
in	O
behavior	O
.	O

Till	O
date	O
,	O
the	O
treatment	O
of	O
choice	O
is	O
resection	O
and	O
reconstruction	O
using	O
a	O
variety	O
of	O
modalities	O
.	O

Inadequate	O
resection	O
may	O
lead	O
to	O
many	O
complications	O
such	O
as	O
bone	O
deformity	O
and	O
dysfunction	O
.	O

This	O
report	O
is	O
about	O
a	O
14-	O
year-old	O
male	O
with	O
ameloblastoma	O
treated	O
with	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
(	O
DPSCs	O
)	O
and	O
stromal	O
vascular	O
fraction	O
(	O
SVF	O
)	O
and	O
evidence	O
of	O
bone	O
regeneration	O
.	O

Marsupialization	O
was	O
performed	O
;	O
tooth	O
was	O
extracted	O
and	O
sent	O
for	O
DPSC	O
cultivation	O
.	O

On	O
the	O
day	O
of	O
surgery	O
,	O
SVF	O
was	O
processed	O
from	O
buccal	O
pad	O
of	O
fat	O
,	O
and	O
platelet-rich	O
fibrin	O
(	O
PRF	O
)	O
was	O
prepared	O
from	O
patient	O
's	O
peripheral	O
blood	O
.	O

During	O
the	O
procedure	O
,	O
labial	O
plate	O
resection	O
and	O
curating	O
of	O
tumor	O
lining	O
were	O
done	O
.	O

After	O
which	O
,	O
a	O
mesh	O
packed	O
with	O
SyboGraft	O
T-plug	O
,	O
prepared	O
SVF	O
,	O
DPSCs	O
,	O
and	O
PRF	O
were	O
placed	O
over	O
lingual	O
cortex	O
and	O
pressure	O
dressing	O
was	O
done	O
.	O

After	O
the	O
1	O
(	O
st	O
)	O
month	O
of	O
surgery	O
the	O
postoperative	O
course	O
was	O
uneventful	O
,	O
the	O
wound	O
shrinkage	O
led	O
to	O
exposure	O
of	O
mesh	O
in	O
the	O
intraoral	O
region	O
.	O

Removal	O
of	O
exposed	O
mesh	O
was	O
done	O
.	O

The	O
correction	O
surgery	O
with	O
removal	O
of	O
part	O
of	O
mesh	O
and	O
primary	O
closure	O
was	O
achieved	O
with	O
SyboGraft	O
plug	O
,	O
SVF	O
and	O
PRF	O
.	O

Enhanced	O
bone	O
formation	O
was	O
seen	O
in	O
post-operative	O
OPG	B-P
and	O
CT	B-P
Scan	I-P
after	O
10	O
(	O
th	O
)	O
month	O
.	O

In	O
this	O
article	O
,	O
we	O
propose	O
an	O
innovative	O
approach	O
to	O
manage	O
these	O
cases	O
by	O
using	O
a	O
combination	O
of	O
autologous	O
DPSC	O
and	O
buccal	O
pad	O
of	O
fat	O
SVF	O
to	O
regenerate	O
a	O
mandibular	O
defect	O
left	O
by	O
the	O
resection	O
of	O
an	O
ameloblastoma	O
with	O
1.5	O
year	O
follow-up	O
.	O

We	O
were	O
able	O
to	O
demonstrate	O
bone	O
regeneration	O
using	O
this	O
technique	O
with	O
no	O
recurrence	O
of	O
tumor	O
.	O

Abstract	O
and	O
Effector-Selective	O
Decision	O
Signals	O
Exhibit	O
Qualitatively	O
Distinct	O
Dynamics	O
before	O
Delayed	O
Perceptual	O
Reports	O
.	O

Electrophysiological	B-P
research	I-P
has	O
isolated	O
neural	O
signatures	O
of	O
decision	O
formation	O
in	O
a	O
variety	O
of	O
brain	O
regions	O
.	O

Studies	O
in	O
rodents	O
and	O
monkeys	O
have	O
focused	O
primarily	O
on	O
effector-selective	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
but	O
,	O
more	O
recently	O
,	O
research	O
on	O
the	O
human	O
brain	O
has	O
identified	O
an	O
abstract	O
signature	O
of	O
evidence	O
accumulation	O
that	O
does	O
not	O
appear	O
to	O
play	O
any	O
direct	O
role	O
in	O
action	O
preparation	O
.	O

The	O
functional	O
dissociations	O
between	O
these	O
distinct	O
signal	O
types	O
have	O
only	O
begun	O
to	O
be	O
characterized	O
,	O
and	O
their	O
dynamics	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
or	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
,	O
a	O
commonly	O
studied	O
task	O
scenario	O
in	O
single-unit	O
and	O
functional	B-P
imaging	I-P
investigations	O
,	O
have	O
not	O
been	O
established	O
.	O

Here	O
we	O
traced	O
the	O
dynamics	O
of	O
distinct	O
abstract	O
and	O
effector-selective	O
decision	O
signals	O
in	O
the	O
form	O
of	O
the	O
broad-band	O
centro-parietal	O
positivity	O
(	O
CPP	O
)	O
and	O
limb-selective	O
β-band	O
(	O
8-16	O
and	O
18-30	O
Hz	O
)	O
EEG	B-P
activity	O
,	O
respectively	O
,	O
during	O
delayed	O
-	O
reported	O
motion	O
direction	O
decisions	O
with	O
and	O
without	O
foreknowledge	O
of	O
direction	O
-	O
response	O
mapping	O
.	O

With	O
foreknowledge	O
,	O
the	O
CPP	O
and	O
β-band	O
signals	O
exhibited	O
a	O
similar	O
gradual	O
build-up	O
following	O
evidence	O
onset	O
,	O
but	O
whereas	O
choice	O
-	O
predictive	O
β-band	O
activity	O
persisted	O
up	O
until	O
the	O
delayed	O
response	O
,	O
the	O
CPP	O
dropped	O
toward	O
baseline	O
after	O
peaking	O
.	O

Without	O
foreknowledge	O
,	O
the	O
CPP	O
exhibited	O
identical	O
dynamics	O
,	O
whereas	O
choice	O
-	O
selective	O
β-band	O
activity	O
was	O
eliminated	O
.	O

These	O
findings	O
highlight	O
qualitative	O
functional	O
distinctions	O
between	O
effector-selective	O
and	O
abstract	O
decision	O
signals	O
and	O
are	O
of	O
relevance	O
to	O
the	O
assumptions	O
founding	O
functional	O
neuroimaging	O
investigations	O
of	O
decision-making	O
.	O

Neural	O
signatures	O
of	O
evidence	O
accumulation	O
have	O
been	O
isolated	O
in	O
numerous	O
brain	O
regions	O
.	O

Although	O
animal	O
neurophysiology	O
has	O
largely	O
concentrated	O
on	O
effector-selective	O
decision	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
recent	O
research	O
on	O
the	O
human	O
brain	O
has	O
isolated	O
abstract	O
neural	O
signatures	O
of	O
decision	O
formation	O
that	O
are	O
independent	O
of	O
specific	O
sensory	O
and	O
motor	O
requirements	O
.	O

Here	O
,	O
we	O
examine	O
the	O
functional	O
distinctions	O
between	O
the	O
two	O
distinct	O
classes	O
of	O
decision	O
variable	O
signal	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
and	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
.	O

We	O
find	O
salient	O
distinctions	O
in	O
the	O
dynamics	O
of	O
abstract	O
versus	O
effector-selective	O
decision	O
signals	O
in	O
the	O
human	O
brain	O
,	O
in	O
terms	O
of	O
sustainment	O
through	O
response	O
delays	O
and	O
contingency	O
on	O
foreknowledge	O
of	O
stimulus-response	O
mapping	O
.	O

Timing	O
of	O
Hormone	O
Withdrawal	O
in	O
Children	O
Undergoing	O
131I	O
Whole-Body	B-P
Scans	I-P
for	O
Thyroid	O
Cancer	O
.	O

Little	O
objective	O
pediatric	O
data	O
exist	O
to	O
guide	O
the	O
optimal	O
time	O
needed	O
to	O
achieve	O
thyroid-stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
≥30	O
μIU/mL	O
prior	O
to	O
performing	O
131I	O
or	O
123I	O
whole-body	B-P
scan	I-P
(	I-P
WBS	I-P
)	I-P
imaging	I-P
in	O
children	O
with	O
thyroid	O
cancer	O
in	O
the	O
post	O
-	O
thyroidectomy	O
period	O
or	O
after	O
hormone	O
discontinuation	O
.	O

Retrospective	O
study	O
of	O
patients	O
aged	O
5-19	O
years	O
who	O
underwent	O
WBS	B-P
.	O

Patient	O
data	O
collection	O
included	O
type	O
and	O
duration	O
of	O
withdrawal	O
(	O
liothyronine	O
[	O
L-T3	O
]	O
,	O
levothyroxine	O
[	O
L-T4	O
]	O
,	O
or	O
post	O
-	O
thyroidectomy	O
status	O
without	O
hormonal	O
replacement	O
)	O
and	O
TSH	O
measured	O
prior	O
to	O
WBS	B-P
(	O
level	O
and	O
timing	O
)	O
.	O

A	O
total	O
of	O
175	O
TSH	O
level	O
measurements	O
were	O
performed	O
in	O
68	O
patients	O
.	O

Thirty-five	O
TSH	O
values	O
were	O
obtained	O
2-7	O
weeks	O
postoperatively	O
and	O
101	O
values	O
were	O
obtained	O
2-8	O
weeks	O
post	O
L-T4	O
withdrawal	O
.	O

One	O
patient	O
in	O
each	O
group	O
had	O
a	O
TSH	O
level	O
<	O
30	O
μIU/mL	O
.	O

There	O
was	O
no	O
difference	O
in	O
TSH	O
levels	O
between	O
3	O
weeks	O
and	O
4	O
weeks	O
postoperatively	O
(	O
p	O
=	O
0.14	O
)	O
or	O
post	O
L-T4	O
cessation	O
(	O
p	O
=	O
0.21	O
)	O
.	O

Thirty-nine	O
TSH	O
measurements	O
were	O
obtained	O
1-28	O
days	O
post	O
L-T3	O
withdrawal	O
.	O

Three	O
patients	O
had	O
to	O
be	O
rescheduled	O
due	O
to	O
inadequate	O
TSH	O
levels	O
,	O
including	O
one	O
after	O
14	O
days	O
L-T3	O
withdrawal	O
.	O

TSH	O
levels	O
≥30	O
μIU/mL	O
were	O
achieved	O
at	O
3	O
weeks	O
post	O
thyroidectomy	O
or	O
after	O
L-T4	O
withdrawal	O
and	O
after	O
at	O
least	O
2	O
weeks	O
following	O
L-T3	O
cessation	O
.	O

Simultaneous	O
Bilateral	O
Cataract	O
Surgery	O
in	O
Outreach	O
Surgical	O
Camps	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
visual	O
outcomes	O
of	O
simultaneous	O
bilateral	O
cataract	O
surgery	O
(	O
SBCS	O
)	O
with	O
intraocular	O
lens	O
implantation	O
performed	O
in	O
outreach	O
surgical	O
eye	O
camps	O
.	O

The	O
medical	O
records	O
of	O
47	O
consecutive	O
patients	O
who	O
underwent	O
simultaneous	O
bilateral	O
small-incision	O
cataract	O
surgery	O
between	O
January	O
2010	O
and	O
December	O
2015	O
in	O
outreach	O
surgical	O
camps	O
in	O
rural	O
Cameroon	O
were	O
reviewed	O
.	O

The	O
measures	O
included	O
postoperative	O
visual	O
outcomes	O
and	O
intraoperative	O
and	O
postoperative	O
complications	O
.	O

Data	O
from	O
94	O
eyes	O
of	O
47	O
participants	O
(	O
30	O
men	O
,	O
17	O
women	O
;	O
mean	O
age	O
:	O
60.93	O
±	O
13.58	O
years	O
,	O
range	O
:	O
45-80	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
presented	O
best	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
less	O
than	O
3/60	O
in	O
100	O
%	O
of	O
the	O
eyes	O
.	O

At	O
the	O
4-	O
week	O
follow-up	O
,	O
84.04	O
%	O
of	O
the	O
eyes	O
showed	O
increased	O
VA	O
of	O
1	O
line	O
or	O
more	O
(	O
P	O
=	O
.001	O
)	O
.	O

Of	O
these	O
,	O
71	O
(	O
75.53	O
%	O
)	O
achieved	O
good	O
VA	O
(	O
greater	O
than	O
6/18	O
)	O
.	O

Intraoperative	O
or	O
postoperative	O
complications	O
occurred	O
in	O
19	O
(	O
20.21	O
%	O
)	O
eyes	O
.	O

The	O
most	O
serious	O
intraoperative	O
complication	O
was	O
a	O
posterior	O
capsule	O
rupture	O
and	O
vitreous	O
loss	O
(	O
2	O
patients	O
,	O
2	O
eyes	O
)	O
.	O

The	O
postoperative	O
complications	O
included	O
a	O
transient	O
elevation	O
in	O
the	O
intraocular	O
pressure	O
(	O
6	O
eyes	O
)	O
,	O
chronic	O
corneal	O
oedema	O
(	O
5	O
eyes	O
)	O
,	O
iris	O
capture	O
(	O
3	O
eyes	O
)	O
,	O
lens	B-P
decentration	I-P
(	O
2	O
eyes	O
)	O
,	O
and	O
hyphema	O
(	O
1	O
eye	O
)	O
.	O

No	O
cases	O
of	O
postoperative	O
endophthalmitis	O
were	O
recorded	O
.	O

Under	O
the	O
strict	O
observation	O
of	O
endophthalmitis	O
prophylaxis	O
,	O
SBCS	O
is	O
an	O
option	O
to	O
reduce	O
the	O
cataract	O
blindness	O
backlog	O
in	O
rural	O
areas	O
of	O
developing	O
countries	O
.	O

Dobutamine	B-P
Stress	I-P
Echocardiography	I-P
:	O
Impact	O
of	O
Abnormal	O
Blood	O
Potassium	O
Levels	O
on	O
Cardiac	O
Arrhythmias	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	O
level	O
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B-P
stress	I-P
echocardiography	I-P
(	O
DSE	B-P
)	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	O
of	O
patients	O
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
DSE	B-P
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	O
over	O
a	O
10-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

Normal	O
potassium	O
range	O
in	O
our	O
laboratory	O
is	O
3.6-5.2	O
mmol/L	O
.	O

Hemolyzed	O
samples	O
were	O
not	O
included	O
.	O

The	O
association	O
of	O
potassium	O
levels	O
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
was	O
assessed	O
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	O
/	O
atrial	O
fibrillation	O
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	O
tachycardia	O
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	O
tachycardia	O
or	O
ventricular	O
fibrillation	O
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
DSE	B-P
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	O
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Patients	O
with	O
hyperkalemia	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01-0.68	O
)	O
supraventricular	O
arrhythmias	O
as	O
well	O
as	O
mild	O
ventricular	O
arrhythmias	O
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40-0.83	O
)	O
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	O
levels	O
≤	O
3.1	O
mmol/L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	O
and	O
ventricular	O
ectopy	O
.	O

DSE	B-P
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	O
concentrations	O
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-P
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

Elevated	O
potassium	O
levels	O
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	O
levels	O
(	O
≤3.1	O
mmol/L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-P
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	O
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	O
prior	O
to	O
DSE	B-P
.	O

Major	O
amyloid-β-degrading	O
enzymes	O
,	O
endothelin-converting	O
enzyme-2	O
and	O
neprilysin	O
,	O
are	O
expressed	O
by	O
distinct	O
populations	O
of	O
GABAergic	O
interneurons	O
in	O
hippocampus	O
and	O
neocortex	O
.	O

Impaired	O
clearance	O
of	O
amyloid-β	O
peptide	O
(	O
Aβ	O
)	O
has	O
been	O
postulated	O
to	O
significantly	O
contribute	O
to	O
the	O
amyloid	O
accumulation	O
typical	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Among	O
the	O
enzymes	O
known	O
to	O
degrade	O
Aβ	O
in	O
vivo	O
are	O
endothelin-converting	O
enzyme	O
(	O
ECE	O
)	O
-1	O
,	O
ECE-2	O
,	O
and	O
neprilysin	O
(	O
NEP	O
)	O
,	O
and	O
evidence	O
suggests	O
that	O
they	O
regulate	O
independent	O
pools	O
of	O
Aβ	O
that	O
may	O
be	O
functionally	O
significant	O
.	O

To	O
better	O
understand	O
the	O
differential	O
regulation	O
of	O
Aβ	O
concentration	O
by	O
its	O
physiological	O
degrading	O
enzymes	O
,	O
we	O
characterized	O
the	O
cell	O
and	O
region-specific	O
expression	O
pattern	O
of	O
ECE-1	O
,	O
ECE-2	O
,	O
and	O
NEP	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	B-P
in	O
brain	O
areas	O
relevant	O
to	O
Alzheimer	O
's	O
disease	O
.	O

In	O
contrast	O
to	O
the	O
broader	O
distribution	O
of	O
ECE-1	O
,	O
ECE-2	O
and	O
NEP	O
were	O
found	O
enriched	O
in	O
GABAergic	O
neurons	O
.	O

ECE-2	O
was	O
majorly	O
expressed	O
by	O
somatostatin	O
-	O
expressing	O
interneurons	O
and	O
was	O
active	O
in	O
isolated	O
synaptosomes	O
.	O

NEP	O
messenger	O
RNA	O
was	O
found	O
mainly	O
in	O
parvalbumin	O
-	O
expressing	O
interneurons	O
,	O
with	O
NEP	O
protein	O
localized	O
to	O
perisomatic	O
parvalbuminergic	O
synapses	O
.	O

The	O
identification	O
of	O
somatostatinergic	O
and	O
parvalbuminergic	O
synapses	O
as	O
hubs	O
for	O
Aβ	O
degradation	O
is	O
consistent	O
with	O
the	O
possibility	O
that	O
Aβ	O
may	O
have	O
a	O
physiological	O
function	O
related	O
to	O
the	O
regulation	O
of	O
inhibitory	O
signaling	O
.	O

Implementing	O
Non-Invasive	O
Prenatal	B-P
Diagnosis	I-P
(	O
NIPD	B-P
)	O
in	O
a	O
National	O
Health	O
Service	O
Laboratory	O
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	O
.	O

Our	O
UK	O
National	O
Health	O
Service	O
regional	O
genetics	O
laboratory	O
offers	O
NIPD	B-P
for	O
autosomal	O
dominant	O
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	O
,	O
Apert	O
syndrome	O
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	O
and	O
a	O
range	O
of	O
bespoke	B-P
tests	I-P
.	O

NIPD	B-P
avoids	O
the	O
risks	O
associated	O
with	O
invasive	B-P
testing	I-P
,	O
making	O
prenatal	B-P
diagnosis	I-P
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	O
diseases	O
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell-free	O
DNA	O
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
NIPD	B-P
of	O
congenital	O
adrenal	O
hyperplasia	O
(	O
CAH	O
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

We	O
have	O
used	O
an	O
assay	O
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	O
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high-risk	O
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
NIPD	B-P
.	O

We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	O
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	O
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
NIPD	B-P
multi-disorder	O
panel	O
for	O
autosomal	O
recessive	O
disease	O
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	O
conditions	O
.	O

Total	O
synthesis	O
and	O
neuroprotective	O
effect	O
of	O
O-methylmurrayamine	O
A	O
and	O
7-methoxymurrayacine	O
.	O

O-Methylmurrayamine	O
A	O
(	O
7	O
)	O
and	O
7-methoxymurrayacine	O
(	O
8	O
)	O
are	O
natural	O
products	O
isolated	O
from	O
Murraya	O
koenigii	O
and	O
Murraya	O
siamensis	O
,	O
respectively	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
7	O
and	O
8	O
which	O
are	O
featured	O
in	O
the	O
key	O
step	O
of	O
cyclization	O
to	O
form	O
carbazole	O
intermediate	O
5	O
with	O
mild	O
conditions	O
.	O

The	O
structures	O
were	O
confirmed	O
by	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
and	O
HR-ESI-MS	O
.	O

In	O
addition	O
,	O
compounds	O
7	O
and	O
8	O
were	O
tested	O
for	O
their	O
neuroprotective	O
effects	O
against	O
H2O2	O
-induced	O
PC12	O
cell	O
damage	O
.	O

The	O
results	O
showed	O
that	O
compounds	O
7	O
and	O
8	O
have	O
neuroprotective	O
effect	O
.	O

Perceived	O
image	O
quality	O
with	O
simulated	O
segmented	O
bifocal	O
corrections	O
.	O

Bifocal	O
contact	O
or	O
intraocular	O
lenses	O
use	O
the	O
principle	O
of	O
simultaneous	O
vision	O
to	O
correct	O
for	O
presbyopia	O
.	O

A	O
modified	O
two-channel	O
simultaneous	O
vision	O
simulator	O
provided	O
with	O
an	O
amplitude	O
transmission	O
spatial	O
light	O
modulator	O
was	O
used	O
to	O
optically	O
simulate	O
14	O
segmented	O
bifocal	O
patterns	O
(	O
+	O
3	O
diopters	O
addition	O
)	O
with	O
different	O
far/near	O
pupillary	O
distributions	O
of	O
equal	O
energy	O
.	O

Five	O
subjects	O
with	O
paralyzed	O
accommodation	O
evaluated	O
image	O
quality	O
and	O
subjective	O
preference	O
through	O
the	O
segmented	O
bifocal	O
corrections	O
.	O

There	O
are	O
strong	O
and	O
systematic	O
perceptual	O
differences	O
across	O
the	O
patterns	O
,	O
subjects	O
and	O
observation	B-P
distances	I-P
:	O
48	O
%	O
of	O
the	O
conditions	O
evaluated	O
were	O
significantly	O
preferred	O
or	O
rejected	O
.	O

Optical	O
simulations	O
(	O
in	O
terms	O
of	O
through-	O
focus	O
Strehl	O
ratio	O
from	O
Hartmann-Shack	O
aberrometry	O
)	O
accurately	O
predicted	O
the	O
pattern	O
producing	O
the	O
highest	O
perceived	O
quality	O
in	O
4	O
out	O
of	O
5	O
patients	O
,	O
both	O
for	O
far	O
and	O
near	O
vision	O
.	O

These	O
perceptual	O
differences	O
found	O
arise	O
primarily	O
from	O
optical	O
grounds	O
,	O
but	O
have	O
an	O
important	O
neural	O
component	O
.	O

Using	O
language	O
for	O
social	O
interaction	O
:	O
Communication	O
mechanisms	O
promote	O
recovery	O
from	O
chronic	O
non-fluent	O
aphasia	O
.	O

Clinical	O
research	O
highlights	O
the	O
importance	O
of	O
massed	O
practice	O
in	O
the	O
rehabilitation	O
of	O
chronic	O
post-stroke	O
aphasia	O
.	O

However	O
,	O
while	O
necessary	O
,	O
massed	O
practice	O
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	O
in	O
speech-language	O
therapy	O
.	O

Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	O
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	O
as	O
a	O
tool	O
for	O
communication	O
and	O
social	O
interaction	O
leads	O
to	O
synergistic	O
effects	O
in	O
left	O
perisylvian	O
eloquent	O
areas	O
.	O

Here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	O
language	O
function	O
on	O
the	O
outcome	O
of	O
intensive	O
aphasia	O
therapy	O
.	O

Eighteen	O
individuals	O
with	O
left-hemisphere	O
lesions	O
and	O
chronic	O
non-fluent	O
aphasia	O
each	O
received	O
two	O
types	O
of	O
training	O
in	O
counterbalanced	O
order	O
:	O
(	O
i	O
)	O
Intensive	O
Language-Action	O
Therapy	O
(	O
ILAT	O
,	O
an	O
extended	O
form	O
of	O
Constraint-Induced	O
Aphasia	O
Therapy	O
)	O
embedding	O
verbal	O
utterances	O
in	O
the	O
context	O
of	O
communication	O
and	O
social	O
interaction	O
,	O
and	O
(	O
ii	O
)	O
Naming	O
Therapy	O
focusing	O
on	O
speech	B-P
production	I-P
per	I-P
se	I-P
.	O

Both	O
types	O
of	O
training	O
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(	O
3.5	O
h	O
per	O
session	O
)	O
and	O
duration	O
(	O
six	O
consecutive	O
working	O
days	O
)	O
,	O
with	O
therapy	O
materials	O
and	O
number	O
of	O
utterances	O
matched	O
between	O
treatment	O
groups	O
.	O

A	O
standardized	O
aphasia	O
test	B-P
battery	I-P
revealed	O
significantly	O
improved	O
language	O
performance	O
with	O
ILAT	O
,	O
independent	O
of	O
when	O
this	O
method	O
was	O
administered	O
.	O

In	O
contrast	O
,	O
Naming	O
Therapy	O
tended	O
to	O
benefit	O
language	O
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	O
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	O
.	O

The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	O
practice	O
alone	O
promotes	O
recovery	O
from	O
chronic	O
post-stroke	O
aphasia	O
.	O

Instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	O
for	O
communication	O
and	O
social	O
interaction	O
increases	O
the	O
efficacy	O
of	O
intensive	O
aphasia	O
therapy	O
.	O

Neuroticism	O
and	O
Fatigue	O
3	O
Months	O
After	O
Ischemic	O
Stroke	O
:	O
A	O
Cross-Sectional	O
Study	O
.	O

To	O
examine	O
the	O
relation	O
between	O
neuroticism	O
and	O
fatigue	O
in	O
Chinese	O
patients	O
with	O
stroke	O
.	O

Cross-sectional	O
study	O
.	O

Acute	O
stroke	O
unit	O
.	O

Survivors	O
of	O
ischemic	O
stroke	O
(	O
N=191	O
)	O
recruited	O
from	O
the	O
acute	O
stroke	O
unit	O
between	O
May	O
1	O
,	O
2010	O
,	O
and	O
September	O
1	O
,	O
2011	O
.	O

Not	O
applicable	O
.	O

The	O
personality	O
trait	O
of	O
neuroticism	O
was	O
measured	O
with	O
the	O
neuroticism	O
subscale	O
of	O
the	O
Chinese	O
version	O
of	O
the	O
NEO	B-P
Five-Factor	I-P
Inventory	I-P
.	O

The	O
level	O
of	O
fatigue	O
was	O
measured	O
with	O
the	O
Fatigue	O
Assessment	O
Scale	O
.	O

The	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
,	O
Geriatric	O
Depression	O
Scale	O
,	O
Barthel	O
Index	O
,	O
and	O
Mini-Mental	B-P
State	I-P
Examination	I-P
were	O
administered	O
to	O
obtain	O
demographic	O
and	O
clinical	O
information	O
.	O

Fatigue	O
severity	O
3	O
months	O
after	O
stroke	O
positively	O
correlated	O
with	O
Geriatric	O
Depression	O
Scale	O
and	O
NEO	B-P
Five-Factor	I-P
Inventory	I-P
neuroticism	O
scores	O
and	O
negatively	O
correlated	O
with	O
the	O
Barthel	O
Index	O
score	O
.	O

Neuroticism	O
,	O
independent	O
of	O
depressive	O
symptoms	O
,	O
is	O
a	O
predictor	O
of	O
fatigue	O
severity	O
3	O
months	O
after	O
stroke	O
.	O

Interventions	O
such	O
as	O
psychological	O
screening	O
programs	O
are	O
warranted	O
for	O
early	O
detection	O
of	O
patients	O
at	O
high	O
risk	O
of	O
poststroke	O
depression	O
.	O

Rare	O
deleterious	O
mutations	O
are	O
associated	O
with	O
disease	O
in	O
bipolar	O
disorder	O
families	O
.	O

Bipolar	O
disorder	O
(	O
BD	O
)	O
is	O
a	O
common	O
,	O
complex	O
and	O
heritable	O
psychiatric	O
disorder	O
characterized	O
by	O
episodes	O
of	O
severe	O
mood	O
swings	O
.	O

The	O
identification	O
of	O
rare	O
,	O
damaging	O
genomic	O
mutations	O
in	O
families	O
with	O
BD	O
could	O
inform	O
about	O
disease	O
mechanisms	O
and	O
lead	O
to	O
new	O
therapeutic	O
interventions	O
.	O

To	O
determine	O
whether	O
rare	O
,	O
damaging	O
mutations	O
shared	O
identity-by-descent	O
in	O
families	O
with	O
BD	O
could	O
be	O
associated	O
with	O
disease	O
,	O
exome	O
sequencing	O
was	O
performed	O
in	O
multigenerational	O
families	O
of	O
the	O
NIMH	O
BD	O
Family	B-P
Study	I-P
followed	O
by	O
in	O
silico	O
functional	O
prediction	O
.	O

Disease	O
association	O
and	O
disease	O
specificity	O
was	O
determined	O
using	O
5090	O
exomes	O
from	O
the	O
Sweden	O
-	O
Schizophrenia	O
(	O
SZ	O
)	O
Population	O
-Based	O
Case-	O
Control	O
Exome	O
Sequencing	O
study	O
.	O

We	O
identified	O
14	O
rare	O
and	O
likely	O
deleterious	O
mutations	O
in	O
14	O
genes	O
that	O
were	O
shared	O
identity-by-descent	O
among	O
affected	O
family	O
members	O
.	O

The	O
variants	O
were	O
associated	O
with	O
BD	O
(	O
P	O
<	O
0.05	O
after	O
Bonferroni	O
's	O
correction	O
)	O
and	O
disease	O
specificity	O
was	O
supported	O
by	O
the	O
absence	O
of	O
the	O
mutations	O
in	O
patients	O
with	O
SZ	O
.	O

In	O
addition	O
,	O
we	O
found	O
rare	O
,	O
functional	O
mutations	O
in	O
known	O
causal	O
genes	O
for	O
neuropsychiatric	O
disorders	O
including	O
holoprosencephaly	O
and	O
epilepsy	O
.	O

Our	O
results	O
demonstrate	O
that	O
exome	O
sequencing	O
in	O
multigenerational	O
families	O
with	O
BD	O
is	O
effective	O
in	O
identifying	O
rare	O
genomic	O
variants	O
of	O
potential	O
clinical	O
relevance	O
and	O
also	O
disease	O
modifiers	O
related	O
to	O
coexisting	O
medical	O
conditions	O
.	O

Replication	O
of	O
our	O
results	O
and	O
experimental	O
validation	O
are	O
required	O
before	O
disease	O
causation	O
could	O
be	O
assumed.Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
11	O
October	O
2016	O
;	O
doi:10.1038/mp.2016.181	O
.	O

A	O
Feasibility	O
Study	O
of	O
Telementoring	O
for	O
Identifying	O
the	O
Appendix	O
Using	O
Smartphone	O
-Based	O
Telesonography	B-P
.	O

We	O
investigated	O
the	O
feasibility	O
of	O
the	O
clinical	O
application	O
of	O
novice	O
-	O
practitioner	O
-	O
performed	O
/	O
offsite	O
-	O
mentor	O
-guided	O
ultrasonography	B-P
for	O
identifying	O
the	O
appendix	O
.	O

A	O
randomized	O
crossover	O
study	O
was	O
conducted	O
using	O
a	O
telesonography	O
system	O
that	O
can	O
transmit	O
the	O
ultrasound	B-P
images	O
displayed	O
on	O
the	O
ultrasound	O
monitor	O
(	O
ultrasound	O
sequence	O
video	O
)	O
and	O
images	O
showing	O
the	O
practitioner	O
's	O
operations	O
(	O
background	O
video	O
)	O
to	O
a	O
smartphone	O
without	O
any	O
interruption	O
in	O
motion	O
over	O
a	O
Long-Term	O
Evolution	O
(	O
LTE	O
)	O
network	O
.	O

Thirty	O
novice	O
practitioners	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
.	O

The	O
subjects	O
in	O
group	O
A	O
(	O
n	O
=	O
15	O
)	O
performed	O
ultrasonography	B-P
for	O
the	O
identification	O
of	O
the	O
appendix	O
under	O
mentoring	O
by	O
an	O
onsite	O
expert	O
,	O
whereas	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
15	O
)	O
performed	O
the	O
same	O
procedure	B-P
under	O
mentoring	O
by	O
an	O
offsite	O
expert	O
.	O

Each	O
subject	O
performed	O
the	O
procedure	B-P
on	O
three	O
simulated	O
patients	O
.	O

After	O
a	O
4-	O
week	O
interval	O
,	O
they	O
performed	O
the	O
procedure	B-P
again	O
under	O
the	O
other	O
type	O
of	O
mentoring	O
.	O

A	O
total	O
of	O
90	O
ultrasound	B-P
examinations	O
were	O
performed	O
in	O
each	O
scenario	O
.	O

The	O
primary	O
outcomes	O
were	O
the	O
success	O
rate	O
for	O
identifying	O
the	O
appendix	O
and	O
the	O
time	O
required	O
to	O
identify	O
the	O
appendix	O
.	O

The	O
success	O
rates	O
for	O
identifying	O
the	O
appendix	O
were	O
91.1	O
%	O
(	O
82/90	O
)	O
in	O
onsite	O
-	O
mentored	O
ultrasonography	B-P
and	O
87.8	O
%	O
(	O
79/90	O
)	O
in	O
offsite	O
-	O
mentored	O
ultrasonography	B-P
;	O
both	O
rates	O
were	O
high	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
(	O
p	O
=	O
0.468	O
)	O
between	O
them	O
.	O

The	O
time	O
required	O
in	O
the	O
case	O
of	O
offsite	O
mentoring	O
(	O
median	O
,	O
242.9	O
s	O
;	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
238.2	O
)	O
was	O
longer	O
than	O
that	O
for	O
onsite	O
mentoring	O
(	O
median	O
,	O
291.4	O
s	O
;	O
IQR	O
,	O
200.9	O
)	O
;	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
p	O
=	O
0.051	O
)	O
.	O

It	O
appears	O
that	O
offsite	O
mentoring	O
can	O
allow	O
novice	O
onsite	O
practitioners	O
to	O
perform	O
ultrasonography	B-P
as	O
effectively	O
as	O
they	O
can	O
under	O
onsite	O
mentoring	O
,	O
even	O
for	O
examinations	O
that	O
require	O
proficiency	O
in	O
rather	O
complex	O
practices	O
,	O
such	O
as	O
identifying	O
the	O
appendix	O
.	O

Association	O
of	O
abdominal	O
fat	O
with	O
serum	O
amylase	O
in	O
an	O
older	O
cohort	O
:	O
The	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
.	O

Abdominal	O
fat	O
is	O
a	O
major	O
determinant	O
of	O
metabolic	O
diseases	O
in	O
older	O
individuals	O
.	O

Obesity	O
and	O
diabetes	O
are	O
associated	O
with	O
low	O
serum	O
amylase	O
(	O
SA	O
)	O
levels	O
,	O
but	O
the	O
association	O
between	O
SA	O
and	O
metabolic	O
disease	O
is	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
association	O
of	O
low	O
SA	O
with	O
diabetes	O
and	O
sex	O
-	O
specific	O
associations	O
of	O
serum	O
amylase	O
with	O
abdominal	O
fat	O
in	O
older	O
adults	O
.	O

In	O
community-dwelling	O
volunteers	O
from	O
the	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
(	O
778	O
participants	O
,	O
age	O
66.8±13.6	O
years	O
)	O
,	O
we	O
assessed	O
abdominal	O
fat	O
by	O
computed	B-P
tomography	I-P
and	O
diabetes	O
status	O
using	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O

Linear	O
regression	O
analyses	O
assessed	O
the	O
cross-sectional	O
associations	O
between	O
abdominal	O
fat	O
and	O
SA	O
,	O
and	O
logistic	O
regression	O
assessed	O
the	O
odds	O
of	O
diabetes	O
,	O
given	O
low	O
SA	O
.	O

In	O
unadjusted	O
analyses	O
,	O
individuals	O
in	O
the	O
lowest	O
SA	O
quartile	O
(	O
<	O
48μ/L	O
)	O
had	O
1.97	O
greater	O
odds	O
of	O
diabetes	O
,	O
(	O
95	O
%	O
CI	O
,	O
1.01-3.83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	O
(	O
⩾80μ/L	O
)	O
.	O

This	O
association	O
was	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
visceral	O
adipose	O
tissue	O
area	O
(	O
VAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
,	O
abdominal	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
or	O
BMI	O
.	O

In	O
adjusted	O
analyses	O
,	O
VAT	O
and	O
SAT	O
were	O
significantly	O
associated	O
with	O
SA	O
in	O
both	O
sexes	O
.	O

Among	O
women	O
,	O
SA	O
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
SAT	O
or	O
BMI	O
;	O
VAT	O
(	O
β=-0.117±0.048	O
,	O
P	O
<	O
0.001	O
)	O
,	O
SAT	O
(	O
β=-0.023±0.025	O
,	O
P=0.346	O
)	O
and	O
BMI	O
(	O
β=-0.0052±0.075	O
,	O
P=0.49	O
)	O
.	O

The	O
association	O
between	O
SA	O
and	O
diabetes	O
was	O
explained	O
mainly	O
by	O
abdominal	O
visceral	O
fat	O
.	O

In	O
women	O
,	O
SA	O
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
BMI	O
or	O
SAT	O
.	O

These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	O
studies	O
on	O
SA	O
's	O
role	O
in	O
metabolic	O
diseases	O
.	O

Mandibular	O
position	O
influence	O
on	O
pilots	O
'	O
postural	O
balance	O
analyzed	O
under	O
dynamic	O
conditions	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
influence	O
of	O
the	O
mandibular	O
position	O
on	O
the	O
postural	O
stability	O
in	O
a	O
sample	O
of	O
civilian	O
and	O
military	O
pilots	O
.	O

Twenty	O
military	O
pilots	O
(	O
males	O
,	O
mean	O
age	O
35.15	O
±	O
3.14	O
years	O
)	O
and	O
17	O
civilian	O
pilots	O
(	O
males	O
,	O
mean	O
34.91	O
±	O
2.15	O
years	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
and	O
underwent	O
a	O
Sensory	B-P
Organization	I-P
Test	I-P
(	O
SOT	B-P
)	O
using	O
the	O
EquiTest	B-P
®	O
(	O
NeuroCom	O
International	O
Inc	O
.	O
,	O
Clackamas	O
,	O
OR	O
,	O
USA	O
)	O
computerized	B-P
dynamic	I-P
posturography	I-P
.	O

The	O
composite	O
parameter	O
was	O
recorded	O
and	O
analyzed	O
.	O

The	O
equilibrium	O
score	O
(	O
ES	O
)	O
recorded	O
in	O
centric	O
occlusion	O
is	O
slightly	O
higher	O
than	O
the	O
ES	O
recorded	O
in	O
mandibular	O
rest	O
position	O
;	O
civilian	O
pilots	O
showed	O
ESs	O
slightly	O
higher	O
than	O
military	O
pilots	O
.	O

The	O
two-way	O
ANOVA	O
analysis	O
shows	O
these	O
differences	O
are	O
not	O
statistically	O
significant	O
.	O

The	O
findings	O
of	O
this	O
study	O
seem	O
to	O
suggest	O
that	O
the	O
composite	O
parameter	O
of	O
the	O
SOT	B-P
is	O
not	O
sensitive	O
in	O
analyzing	O
the	O
influence	O
of	O
the	O
stomatognathic	O
system	O
on	O
the	O
postural	O
balance	O
of	O
civilian	O
and	O
military	O
pilots	O
.	O

Prevalence	O
and	O
presentation	O
of	O
tuberculosis	O
among	O
hemodialysis	O
patients	O
in	O
Khartoum	O
,	O
Sudan	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
is	O
a	O
major	O
health	O
problem	O
in	O
the	O
developing	O
countries	O
.	O

There	O
are	O
limited	O
data	O
about	O
the	O
prevalence	O
of	O
TB	O
patients	O
on	O
maintenance	O
hemodialysis	O
(	O
HD	O
)	O
in	O
Sudan	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
identify	O
the	O
prevalence	O
and	O
presentation	O
of	O
TB	O
among	O
Sudanese	O
maintenance	O
HD	O
patients	O
.	O

This	O
is	O
a	O
hospital	O
-based	O
descriptive	O
study	O
.	O

The	O
participants	O
of	O
the	O
study	O
are	O
all	O
HD	O
patients	O
distributed	O
in	O
13	O
HD	O
centers	O
in	O
Khartoum	O
and	O
Khartoum	O
North	O
Provinces	O
in	O
Sudan	O
.	O

All	O
patients	O
attended	O
the	O
HD	O
centers	O
from	O
November	O
1	O
,	O
2014	O
to	O
February	O
1	O
,	O
2015	O
,	O
were	O
interviewed	O
by	O
a	O
questionnaire	O
focused	O
on	O
personal	O
and	O
clinical	O
data	O
.	O

Those	O
who	O
were	O
diagnosed	O
as	O
having	O
active	O
TB	O
were	O
studied	O
regarding	O
their	O
clinical	O
presentation	O
,	O
presence	O
of	O
comorbidities	O
,	O
site	O
of	O
TB	O
,	O
and	O
methods	O
used	O
on	O
diagnosis	O
.	O

The	O
total	O
number	O
of	O
HD	O
patients	O
during	O
the	O
study	O
period	O
was	O
1328	O
patients	O
.	O

We	O
found	O
19	O
patients	O
who	O
already	O
diagnosed	O
and	O
treated	O
for	O
TB	O
infection	O
.	O

The	O
prevalence	O
rate	O
of	O
TB	O
among	O
HD	O
patients	O
is	O
1.4	O
%	O
.	O

The	O
mean	O
age	O
of	O
patient	O
was	O
44.53±8.69	O
years	O
,	O
89.5	O
%	O
of	O
them	O
were	O
males	O
.	O

The	O
majority	O
of	O
them	O
have	O
comorbidities	O
:	O
31.6	O
%	O
%	O
have	O
hypertension	O
and	O
21.1	O
%	O
have	O
diabetes	O
.	O

Extrapulmonary	O
TB	O
was	O
the	O
major	O
presentation	O
(	O
57.9	O
%	O
)	O
mainly	O
tuberculous	O
lymphadenitis	O
(	O
26.3	O
%	O
)	O
.	O

The	O
pulmonary	O
presentation	O
was	O
found	O
to	O
be	O
42.1	O
%	O
.	O

The	O
diagnosis	O
of	O
TB	O
was	O
supported	O
by	O
microbiological	O
evidence	O
of	O
alcohol	O
acid-fast	O
Bacilli	O
present	O
in	O
sputum	O
smear	O
(	O
21	O
%	O
)	O
,	O
histological	O
diagnosis	O
(	O
31.6	O
%	O
)	O
,	O
polymerase	O
chain	O
reaction	O
(	O
21	O
%	O
)	O
,	O
and	O
imaging	B-P
in	I-P
(	O
26.3	O
%	O
)	O
.	O

Patients	O
on	O
maintenance	O
HD	O
are	O
at	O
an	O
increased	O
risk	O
of	O
TB	O
and	O
diagnosis	O
of	O
TB	O
among	O
HD	O
patients	O
need	O
a	O
high	O
index	O
of	O
suspicion	O
.	O

There	O
is	O
a	O
great	O
need	O
for	O
establishing	O
a	O
screening	O
scheme	O
for	O
TB	O
among	O
HD	O
patients	O
and	O
further	O
epidemiological	O
studies	O
are	O
needed	O
to	O
fully	O
evaluate	O
this	O
problem	O
.	O

Copolymer	O
Brush	O
-Based	O
Ultralow-Fouling	O
Biorecognition	O
Surface	O
Platform	O
for	O
Food	O
Safety	O
.	O

Functional	O
polymer	O
coatings	O
that	O
combine	O
the	O
ability	O
to	O
resist	O
nonspecific	O
fouling	O
from	O
complex	O
media	O
with	O
high	O
biorecognition	O
element	O
(	O
BRE	O
)	O
immobilization	O
capacity	O
represent	O
an	O
emerging	O
class	O
of	O
new	O
functional	O
materials	O
for	O
a	O
number	O
of	O
bioanalytical	O
and	O
biosensor	O
technologies	O
for	O
medical	B-P
diagnostics	I-P
,	O
security	O
,	O
and	O
food	O
safety	O
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
random	O
copolymer	O
brush	O
surface	O
-	O
poly	O
(	O
CBMAA-ran-HPMAA	O
)	O
-	O
providing	O
high	O
BRE	O
immobilization	O
capacity	O
while	O
simultaneously	O
exhibiting	O
ultralow-fouling	O
behavior	O
in	O
complex	O
food	O
media	O
.	O

We	O
demonstrate	O
that	O
both	O
the	O
functionalization	O
and	O
fouling	O
resistance	O
capabilities	O
of	O
such	O
copolymer	O
brushes	O
can	O
be	O
tuned	O
by	O
changing	O
the	O
surface	O
contents	O
of	O
the	O
two	O
monomer	O
units	O
:	O
nonionic	O
N-	O
(	O
2-hydroxypropyl	O
)	O
methacrylamide	O
(	O
HPMAA	O
)	O
and	O
carboxy-functional	O
zwitterionic	O
carboxybetaine	O
methacrylamide	O
(	O
CBMAA	O
)	O
.	O

It	O
is	O
demonstrated	O
that	O
the	O
resistance	O
to	O
fouling	O
decreases	O
with	O
the	O
surface	O
content	O
of	O
CBMAA	O
;	O
poly	O
(	O
CBMAA-ran-HPMAA	O
)	O
brushes	O
with	O
CBMAA	O
molar	O
content	O
up	O
to	O
15	O
mol	O
%	O
maintain	O
excellent	O
resistance	O
to	O
fouling	O
from	O
a	O
variety	O
of	O
homogenized	O
foods	O
(	O
hamburger	O
,	O
cucumber	O
,	O
milk	O
,	O
and	O
lettuce	O
)	O
even	O
after	O
covalent	O
attachment	O
of	O
BREs	O
to	O
carboxy	O
groups	O
of	O
CBMAA	O
.	O

The	O
poly	O
(	O
CBMAA	O
15	O
mol	O
%	O
-ran-HPMAA	O
)	O
brushes	O
functionalized	O
with	O
antibodies	O
are	O
demonstrated	O
to	O
exhibit	O
fouling	O
resistance	O
from	O
food	O
samples	O
by	O
up	O
to	O
3	O
orders	O
of	O
magnitude	O
better	O
when	O
compared	O
with	O
the	O
widely	O
used	O
low-fouling	O
carboxy-functional	O
oligo	O
(	O
ethylene	O
glycol	O
)	O
(	O
OEG	O
)	O
-based	O
alkanethiolate	O
self-assembled	O
monolayers	O
(	O
AT	O
SAMs	O
)	O
and	O
,	O
furthermore	O
,	O
by	O
up	O
to	O
2	O
orders	O
of	O
magnitude	O
better	O
when	O
compared	O
with	O
the	O
most	O
successful	O
ultralow-fouling	O
biorecognition	O
coatings	O
-	O
poly	O
(	O
carboxybetaine	O
acrylamide	O
)	O
,	O
poly	O
(	O
CBAA	O
)	O
.	O

When	O
model	O
SPR	O
detections	O
of	O
food-borne	O
bacterial	O
pathogens	O
in	O
homogenized	O
foods	O
are	O
used	O
,	O
it	O
is	O
also	O
demonstrated	O
that	O
the	O
antibody	O
-	O
functionalized	O
poly	O
(	O
CBMAA	O
15	O
mol	O
%	O
-ran-HPMAA	O
)	O
brush	O
exhibits	O
superior	O
biorecognition	O
properties	O
over	O
the	O
poly	O
(	O
CBAA	O
)	O
.	O

Synaptic	O
NMDA	O
Receptor	O
Activation	O
Induces	O
Ubiquitination	O
and	O
Degradation	O
of	O
STEP61	O
.	O

NMDA	O
receptor	O
signaling	O
is	O
critical	O
for	O
the	O
development	O
of	O
synaptic	O
plasticity	O
,	O
learning	O
,	O
and	O
memory	O
,	O
and	O
dysregulation	O
of	O
NMDAR	O
signaling	O
is	O
implicated	O
in	O
a	O
number	O
of	O
neurological	O
disorders	O
including	O
schizophrenia	O
(	O
SZ	O
)	O
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
the	O
STriatal-Enriched	O
protein	O
tyrosine	O
Phosphatase	O
61	O
kDa	O
(	O
STEP61	O
)	O
is	O
elevated	O
in	O
human	O
SZ	O
postmortem	B-P
cortical	O
samples	O
and	O
after	O
administration	O
of	O
psychotomimetics	O
to	O
cultures	O
or	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
activation	O
of	O
synaptic	O
NMDAR	O
by	O
bicuculline	O
or	O
D-serine	O
results	O
in	O
the	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
STEP61	O
,	O
and	O
increased	O
surface	O
localization	O
of	O
GluN1	O
/	O
GluN2B	O
receptors	O
.	O

Moreover	O
,	O
bicuculline	O
or	O
D-serine	O
treatments	O
rescue	O
the	O
motor	O
and	O
cognitive	O
deficits	O
in	O
MK-801	O
-treated	O
mice	O
and	O
reduce	O
STEP61	O
in	O
mouse	O
frontal	O
cortex	O
.	O

These	O
results	O
suggest	O
that	O
STEP61	O
may	O
contribute	O
to	O
the	O
therapeutic	O
effects	O
of	O
D-serine	O
.	O

Development	O
of	O
delineation	O
for	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
region	O
in	O
left	O
breast	O
cancer	O
radiotherapy	O
:	O
An	O
optimized	O
organ	O
at	O
risk	O
.	O

The	O
left	O
anterior	O
descending	O
coronary	O
artery	O
(	O
LAD	O
)	O
and	O
diagonal	O
branches	O
(	O
DBs	O
)	O
are	O
blurred	O
on	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

We	O
aimed	O
to	O
define	O
the	O
LAD	O
region	O
(	O
LADR	O
)	O
with	O
adequate	O
inclusion	O
of	O
the	O
LAD	O
and	O
DBs	O
and	O
contouring	O
consistency	O
.	O

The	O
LADR	O
was	O
defined	O
using	O
coronary	O
CT	B-P
angiograms	I-P
.	O

The	O
inclusion	O
ratio	O
was	O
used	O
to	O
assess	O
the	O
LAD	O
and	O
DBs	O
inclusion	O
by	O
the	O
LADR	O
.	O

Four	O
radiation	O
oncologists	O
delineated	O
the	O
LAD	O
and	O
LADR	O
,	O
using	O
contrast-enhanced	B-P
CT	I-P
of	O
15	O
patients	O
undergoing	O
left	O
breast	O
radiotherapy	O
.	O

The	O
Sørensen-Dice	O
similarity	O
index	O
(	O
DSI	O
)	O
,	O
Jaccard	O
similarity	O
index	O
(	O
JSI	O
)	O
,	O
and	O
Hausdorff	O
distance	O
(	O
HD	O
)	O
were	O
calculated	O
to	O
assess	O
similarity	O
.	O

The	O
mean	O
dose	O
(	O
Dmean	O
)	O
and	O
maximum	O
dose	O
(	O
Dmax	O
)	O
to	O
the	O
LAD	O
and	O
LADR	O
were	O
calculated	O
to	O
compare	O
consistency	O
.	O

Correlations	O
were	O
evaluated	O
using	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O

The	O
inclusion	O
ratio	O
of	O
the	O
LAD	O
by	O
the	O
LADR	O
was	O
96	O
%	O
.	O

The	O
mean	O
DSI	O
,	O
JSI	O
,	O
and	O
HD	O
values	O
were	O
respectively	O
27.9	O
%	O
,	O
16.7	O
%	O
,	O
and	O
0.42mm	O
for	O
the	O
LAD	O
,	O
and	O
83.1	O
%	O
,	O
73.0	O
%	O
,	O
and	O
0.18mm	O
for	O
the	O
LADR	O
.	O

The	O
Dmean	O
between	O
the	O
LAD	O
and	O
LADR	O
were	O
strongly	O
correlated	O
(	O
r=0.93	O
)	O
.	O

Delineation	O
of	O
the	O
LADR	O
significantly	O
improved	O
contouring	O
similarity	O
and	O
consistency	O
for	O
dose	O
reporting	O
.	O

This	O
could	O
optimize	O
dose	O
estimation	O
for	O
breast	O
radiotherapy	O
.	O

Heterogeneous	O
Mechanisms	O
of	O
Primary	O
and	O
Acquired	O
Resistance	O
to	O
Third-Generation	O
EGFR	O
Inhibitors	O
.	O

To	O
identify	O
novel	O
mechanisms	O
of	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
that	O
progressed	O
under	O
therapy	O
with	O
either	O
AZD9291	O
or	O
rociletinib	O
(	O
CO-1686	O
)	O
.	O

We	O
analyzed	O
tumor	B-P
biopsies	I-P
from	O
seven	O
patients	O
obtained	O
before	O
,	O
during	O
,	O
and/or	O
after	O
treatment	O
with	O
AZD9291	O
or	O
rociletinib	O
(	O
CO-1686	O
)	O
.	O

Targeted	O
sequencing	O
and	O
FISH	O
analyses	O
were	O
performed	O
,	O
and	O
the	O
relevance	O
of	O
candidate	O
genes	O
was	O
functionally	O
assessed	O
in	O
in	O
vitro	O
models	O
.	O

We	O
found	O
recurrent	O
amplification	O
of	O
either	O
MET	O
or	O
ERBB2	O
in	O
tumors	O
that	O
were	O
resistant	O
or	O
developed	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
and	O
show	O
that	O
ERBB2	O
and	O
MET	O
activation	O
can	O
confer	O
resistance	O
to	O
these	O
compounds	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
KRAS	O
(	O
G12S	O
)	O
mutation	O
in	O
a	O
patient	O
with	O
acquired	O
resistance	O
to	O
AZD9291	O
as	O
a	O
potential	O
driver	O
of	O
acquired	O
resistance	O
.	O

Finally	O
,	O
we	O
show	O
that	O
dual	O
inhibition	O
of	O
EGFR	O
/MEK	O
might	O
be	O
a	O
viable	O
strategy	O
to	O
overcome	O
resistance	O
in	O
EGFR-mutant	O
cells	O
expressing	O
mutant	O
KRAS	O
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
heterogeneous	O
mechanisms	O
of	O
resistance	O
can	O
drive	O
primary	O
and	O
acquired	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
and	O
provide	O
a	O
rationale	O
for	O
potential	O
combination	O
strategies	O
.	O

Clin	O
Cancer	O
Res	O
;	O
1-11	O
.	O

©2016	O
AACR	O
.	O

The	O
clinico-	O
radiological	O
paradox	O
of	O
cognitive	O
function	O
and	O
MRI	B-P
burden	O
of	O
white	O
matter	O
lesions	O
in	O
people	O
with	O
multiple	O
sclerosis	O
:	O
A	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

Moderate	O
correlation	O
exists	O
between	O
the	O
imaging	O
quantification	O
of	O
brain	O
white	O
matter	O
lesions	O
and	O
cognitive	O
performance	O
in	O
people	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	O
,	O
including	O
subvisible	O
pathology	O
,	O
or	O
methodological	O
limitations	O
of	O
the	O
primary	O
literature	O
.	O

To	O
summarise	O
the	O
cognitive	O
clinico-	O
radiological	O
paradox	O
and	O
explore	O
the	O
potential	O
methodological	O
factors	O
that	O
could	O
influence	O
the	O
assessment	O
of	O
this	O
relationship	O
.	O

Systematic	O
review	O
and	O
meta-analysis	O
of	O
primary	O
research	O
relating	O
cognitive	O
function	O
to	O
white	O
matter	O
lesion	O
burden	O
.	O

Fifty	O
papers	O
met	O
eligibility	O
criteria	O
for	O
review	O
,	O
and	O
meta-analysis	O
of	O
overall	O
results	O
was	O
possible	O
in	O
thirty-two	O
(	O
2050	O
participants	O
)	O
.	O

Aggregate	O
correlation	O
between	O
cognition	O
and	O
T2	O
lesion	O
burden	O
was	O
r	O
=	O
-0.30	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
-0.34	O
,	O
-0.26	O
)	O
.	O

Wide	O
methodological	O
variability	O
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	O
in	O
the	O
cognitive	O
data	O
capture	O
and	O
image	O
analysis	O
techniques	O
.	O

Resolving	O
the	O
persistent	O
clinico-	O
radiological	O
paradox	O
will	O
likely	O
require	O
simultaneous	O
evaluation	O
of	O
multiple	O
components	O
of	O
the	O
complex	O
pathology	O
using	O
optimum	O
measurement	O
techniques	O
for	O
both	O
cognitive	O
and	O
MRI	B-P
feature	O
quantification	O
.	O

We	O
recommend	O
a	O
consensus	O
initiative	O
to	O
support	O
common	O
standards	O
for	O
image	O
analysis	O
in	O
MS	O
,	O
enabling	O
benchmarking	O
while	O
also	O
supporting	O
ongoing	O
innovation	O
.	O

Outcome	O
of	O
obese	O
and	O
diabetic	O
patients	O
underwent	O
laparoscopic	O
gastric	O
bypass	O
:	O
when	O
the	O
surgery	O
fails	O
.	O

The	O
beneficial	O
effects	O
of	O
bariatric	O
surgery	O
on	O
diabetes	O
and	O
obesity	O
have	O
been	O
widely	O
demonstrated	O
in	O
literature	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
rate	O
of	O
failure	O
of	O
laparoscopic	O
gastric	O
bypass	O
both	O
in	O
terms	O
of	O
weight	O
loss	O
and	O
metabolic	O
remission	O
after	O
one	O
follow-up	O
year	O
.	O

A	O
longitudinal	O
,	O
multicentric	O
prospective	O
study	O
was	O
carried	O
out	O
on	O
771	O
patients	O
affected	O
by	O
pathological	O
obesity	O
.	O

The	O
following	O
parameters	O
were	O
recorded	O
for	O
each	O
patient	O
before	B-P
surgery	I-P
:	O
anthropometric	O
,	O
metabolic	O
,	O
social	O
,	O
smoking	O
habits	O
and	O
previous	O
failure	O
of	O
other	O
bariatric	O
procedures	O
.	O

After	O
1	O
follow-up	O
year	O
,	O
final	O
weight	O
,	O
final	O
BMI	O
,	O
final	O
percentage	O
of	O
lost	O
excess	O
body	O
weight	O
and	O
percentage	O
of	O
lost	O
BMI	O
were	O
evaluated	O
.	O

Statistical	O
analysis	O
showed	O
a	O
correlation	O
between	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
diabetes	O
,	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
and	O
failure	O
of	O
weight	O
loss	O
outcome	O
.	O

Statistical	O
analysis	O
of	O
metabolic	O
failure	O
has	O
recognized	O
a	O
high	O
preoperative	O
HbA1c	O
%	O
value	O
as	O
a	O
statistically	O
significant	O
negative	O
predictive	O
factor	O
.	O

Bariatric	O
Surgery	O
is	O
the	O
most	O
effective	O
treatment	O
for	O
weight	O
loss	O
and	O
metabolic	O
improvement	O
.	O

However	O
,	O
in	O
our	O
study	O
,	O
surgery	O
did	O
not	O
achieve	O
the	O
expected	O
outcome	O
in	O
patients	O
with	O
specific	O
metabolic	O
,	O
anthropometric	O
and	O
surgical	O
characteristics	O
(	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
T2DM	O
with	O
high	O
preoperative	O
HbA1c	O
%	O
level	O
and	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
)	O
.	O

Initial	O
experience	O
with	O
laparoscopic	O
radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
for	O
left-sided	O
pancreatic	O
cancer	O
in	O
a	O
single	O
institution	O
:	O
technical	O
aspects	O
and	O
oncological	O
outcomes	O
.	O

Laparoscopic	O
surgery	O
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	O
cancer	O
due	O
to	O
technical	O
difficulties	O
and	O
concerns	O
about	O
oncological	O
safety	O
.	O

Radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
(	O
RAMPS	O
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	O
margin	O
during	O
radical	O
lymph	O
node	O
dissection	O
.	O

We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	O
as	O
a	O
laparoscopic	O
application	O
due	O
to	O
unique	O
features	O
.	O

Fifteen	O
laparoscopic	B-P
RAMPS	O
for	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O

Five	O
trocars	O
were	O
usually	O
used	O
,	O
and	O
the	O
operative	O
procedures	O
and	O
range	O
of	O
dissection	O
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	O
described	O
by	O
Strasberg	O
.	O

All	O
medical	O
records	O
and	O
follow-up	O
data	O
were	O
reviewed	O
and	O
analyzed	O
.	O

All	O
patients	O
had	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

Mean	O
operative	O
time	O
was	O
219.3	O
±	O
53.8	O
min	O
,	O
and	O
estimated	O
blood	O
loss	O
was	O
250	O
±	O
70	O
ml	O
.	O

The	O
length	O
of	O
postoperative	O
hospital	O
stay	O
was	O
6.1	O
±	O
1.2	O
days	O
,	O
and	O
postoperative	O
morbidities	O
developed	O
in	O
two	O
patients	O
(	O
13.3	O
%	O
)	O
with	O
urinary	O
retention	O
.	O

The	O
median	O
number	O
of	O
retrieved	O
lymph	O
nodes	O
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative	O
margins	O
.	O

Median	O
follow-up	O
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3-year	O
disease	O
free	O
survival	O
and	O
overall	O
survival	O
rates	O
were	O
56.3	O
%	O
and	O
74.1	O
%	O
,	O
respectively	O
.	O

Our	O
early	O
experience	O
with	O
laparoscopic	B-P
RAMPS	O
achieved	O
feasible	O
perioperative	O
results	O
accompanied	O
by	O
acceptable	O
survival	O
outcomes	O
.	O

Laparoscopic	B-P
RAMPS	O
could	O
be	O
a	O
safe	O
and	O
oncologically	O
feasible	O
procedure	O
in	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
.	O

Personalized	O
Medicine	O
applied	O
to	O
Forensic	O
Sciences	O
:	O
new	O
advances	O
and	O
perspectives	O
for	O
a	O
tailored	O
forensic	O
approach	O
.	O

Personalized	O
medicine	O
(	O
PM	O
)	O
,	O
included	O
in	O
P5	O
medicine	O
(	O
Personalized	O
,	O
Predictive	O
,	O
Preventive	O
,	O
Participative	O
and	O
Precision	O
medicine	O
)	O
is	O
an	O
innovative	O
approach	O
to	O
the	O
patient	O
,	O
emerging	O
from	O
the	O
need	O
to	O
tailor	O
and	O
to	O
fit	O
the	O
profile	O
of	O
each	O
individual	O
.	O

PM	O
promises	O
to	O
dramatically	O
impact	O
also	O
on	O
forensic	O
sciences	O
and	O
justice	O
system	O
in	O
ways	O
we	O
are	O
only	O
beginning	O
to	O
understand	O
.	O

The	O
application	O
of	O
omics	O
(	O
genomic	O
,	O
transcriptomics	O
,	O
epigenetics/imprintomics	O
,	O
proteomic	O
and	O
metabolomics	O
)	O
is	O
ever	O
more	O
fundamental	O
in	O
the	O
so	O
called	O
``	O
molecular	B-P
autopsy	I-P
``	O
.	O

Emerging	O
fields	O
of	O
interest	O
in	O
forensic	O
pathology	O
are	O
represented	O
by	O
diagnosis	O
and	O
detection	O
of	O
predisposing	O
conditions	O
to	O
fatal	O
thromboembolic	O
and	O
hypertensive	O
events	O
,	O
determination	O
of	O
genetic	O
variants	O
related	O
to	O
sudden	O
death	O
,	O
such	O
as	O
congenital	O
long	O
QT	O
syndromes	O
,	O
demonstration	O
of	O
lesions	O
vitality	O
,	O
identification	O
of	O
biological	O
matrices	O
and	O
species	O
diagnosis	O
of	O
a	O
forensic	O
trace	O
on	O
crime	O
scenes	O
without	O
destruction	O
of	O
the	O
DNA	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
the	O
state-of-art	O
in	O
the	O
application	O
of	O
personalized	O
medicine	O
in	O
forensic	O
sciences	O
,	O
to	O
understand	O
the	O
possibilities	O
of	O
integration	O
in	O
routine	O
investigation	O
of	O
these	O
procedures	O
with	O
classical	O
post-mortem	B-P
studies	I-P
and	O
to	O
underline	O
the	O
importance	O
of	O
these	O
new	O
updates	O
in	O
medical	O
examiners	O
'	O
armamentarium	O
in	O
determining	O
cause	O
of	O
death	O
or	O
contributing	O
factors	O
to	O
death	O
.	O

Nicotine	O
Suppressed	O
Fetal	O
Adrenal	O
StAR	O
Expression	O
via	O
YY1	O
Mediated-	O
Histone	O
Deacetylation	O
Modification	O
Mechanism	O
.	O

Steroidogenic	O
acute	O
regulatory	O
(	O
StAR	O
)	O
protein	O
plays	O
a	O
pivotal	O
role	O
in	O
steroidogenesis	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
prenatal	O
nicotine	O
exposure	O
suppressed	O
fetal	O
adrenal	O
steroidogenesis	O
via	O
steroidogenic	O
factor	O
1	O
deacetylation	O
.	O

This	O
study	O
further	O
explored	O
the	O
potential	O
role	O
of	O
the	O
transcriptional	O
repressor	O
Yin	O
Yang	O
1	O
(	O
YY1	O
)	O
in	O
nicotine	O
-mediated	O
StAR	O
inhibition	O
.	O

Nicotine	O
was	O
subcutaneously	O
administered	O
(	O
1.0	O
mg/kg	O
)	O
to	O
pregnant	O
rats	O
twice	O
per	O
day	O
and	O
NCI-H295A	O
cells	O
were	O
treated	O
with	O
nicotine	O
.	O

StAR	O
and	O
YY1	O
expression	O
were	O
analyzed	O
by	O
real-time	O
PCR	O
,	O
immunohistochemistry	B-P
,	O
and	O
Western	O
blotting	O
.	O

Histone	O
modifications	O
and	O
the	O
interactions	O
between	O
the	O
YY1	O
and	O
StAR	O
promoter	O
were	O
assessed	O
using	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
.	O

Prenatal	O
nicotine	O
exposure	O
increased	O
YY1	O
expression	O
and	O
suppressed	O
StAR	O
expression	O
.	O

ChIP	O
assay	O
showed	O
that	O
there	O
was	O
a	O
decreasing	O
trend	O
for	O
histone	O
acetylation	O
at	O
the	O
StAR	O
promoter	O
in	O
fetal	O
adrenal	O
glands	O
,	O
whereas	O
H3	O
acetyl-K14	O
at	O
the	O
YY1	O
promoter	O
presented	O
an	O
increasing	O
trend	O
following	O
nicotine	O
exposure	O
.	O

Furthermore	O
,	O
in	O
nicotine	O
-	O
treated	O
NCI-H295A	O
cells	O
,	O
nicotine	O
enhanced	O
YY1	O
expression	O
and	O
inhibited	O
StAR	O
expression	O
.	O

ChIP	O
assay	O
showed	O
that	O
histone	O
acetylation	O
decreased	O
at	O
the	O
StAR	O
promoter	O
in	O
NCI-H295A	O
cells	O
and	O
that	O
the	O
interaction	O
between	O
the	O
YY1	O
and	O
StAR	O
promoter	O
increased	O
.	O

These	O
data	O
indicated	O
that	O
YY1	O
-medicated	O
histone	O
deacetylation	O
modification	O
in	O
StAR	O
promoters	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
inhibitory	O
effect	O
of	O
nicotine	O
on	O
StAR	O
expression	O
.	O

The	O
effect	O
of	O
different	O
decline	O
angles	O
on	O
the	O
biomechanics	O
of	O
double	O
limb	O
squats	O
and	O
the	O
implications	O
to	O
clinical	O
and	O
training	O
practice	O
.	O

Bilateral	O
decline	O
squatting	O
has	O
been	O
well	O
documented	O
as	O
a	O
rehabilitation	O
exercise	O
,	O
however	O
,	O
little	O
information	O
exists	O
on	O
the	O
optimum	O
angle	O
of	O
decline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
ankle	O
and	O
knee	O
angle	O
,	O
moments	O
,	O
the	O
patellofemoral	O
joint	O
load	O
,	O
patellar	O
tendon	O
load	O
and	O
associated	O
muscle	O
activity	O
while	O
performing	O
a	O
double	O
limb	O
squat	O
at	O
different	O
decline	O
angles	O
and	O
the	O
implications	O
to	O
rehabilitation	O
.	O

Eighteen	O
healthy	O
subjects	O
performed	O
double	O
limb	O
squats	O
at	O
6	O
angles	O
of	O
declination	O
:	O
0	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
and	O
25	O
degrees	O
.	O

The	O
range	O
of	O
motion	O
of	O
the	O
knee	O
and	O
ankle	O
joints	O
,	O
external	O
moments	O
,	O
the	O
patellofemoral	O
/	O
patellar	O
tendon	O
load	O
and	O
integrated	O
EMG	B-P
of	O
gastrocnemius	O
,	O
tibialis	O
anterior	O
,	O
rectus	O
femoris	O
and	O
biceps	O
femoris	O
were	O
evaluated	O
.	O

As	O
the	O
decline	O
angle	O
increased	O
up	O
to	O
20	O
degrees	O
,	O
the	O
range	O
of	O
motion	O
possible	O
at	O
the	O
ankle	O
and	O
knee	O
increased	O
.	O

The	O
joint	O
moments	O
showed	O
a	O
decrease	O
at	O
the	O
ankle	O
up	O
to	O
15	O
degrees	O
and	O
an	O
increase	O
at	O
the	O
knee	O
up	O
to	O
25	O
degrees	O
,	O
indicating	O
a	O
progressive	O
reduction	O
in	O
loading	O
around	O
the	O
ankle	O
with	O
a	O
corresponding	O
increase	O
of	O
the	O
load	O
in	O
the	O
patellar	O
tendon	O
and	O
patellofemoral	O
joint	O
.	O

These	O
trends	O
were	O
supported	O
by	O
a	O
decrease	O
in	O
tibialis	O
anterior	O
activity	O
and	O
an	O
increase	O
in	O
the	O
rectus	O
femoris	O
activity	O
up	O
to	O
15	O
degrees	O
declination	O
.	O

However	O
,	O
gastrocnemius	O
and	O
biceps	O
femoris	O
activity	O
increased	O
as	O
the	O
decline	O
angle	O
increased	O
above	O
15	O
degrees	O
.	O

The	O
action	O
of	O
gastrocnemius	O
and	O
biceps	O
femoris	O
stabilises	O
the	O
knee	O
against	O
an	O
anterior	O
displacement	O
of	O
the	O
femur	O
on	O
the	O
tibia	O
.	O

These	O
findings	O
would	O
suggest	O
that	O
there	O
is	O
little	O
benefit	O
in	O
using	O
a	O
decline	O
angle	O
greater	O
than	O
15-20	O
degrees	O
unless	O
the	O
purpose	O
is	O
to	O
offer	O
an	O
additional	O
stability	O
challenge	O
to	O
the	O
knee	O
joint	O
.	O

Quantitative	B-P
Susceptibility	I-P
Mapping	I-P
using	O
Structural	O
Feature	O
based	O
Collaborative	O
Reconstruction	O
(	O
SFCR	O
)	O
in	O
the	O
Human	O
Brain	O
.	O

The	O
reconstruction	O
of	O
MR	O
quantitative	B-P
susceptibility	I-P
mapping	I-P
(	O
QSM	B-P
)	O
from	O
local	O
phase	O
measurements	O
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	O
strategies	O
incorporating	O
a	O
priori	O
information	O
extracted	O
from	O
magnitude	O
and	O
phase	O
images	O
have	O
been	O
proposed	O
.	O

However	O
,	O
the	O
anatomy	O
observed	O
in	O
magnitude	O
and	O
phase	O
images	O
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	O
maps	O
,	O
which	O
could	O
give	O
erroneous	O
estimation	O
in	O
the	O
reconstructed	O
susceptibility	O
map	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	O
feature	O
based	O
collaborative	O
reconstruction	O
(	O
SFCR	O
)	O
method	O
for	O
QSM	B-P
including	O
both	O
magnitude	O
and	O
susceptibility	O
based	O
information	O
.	O

The	O
SFCR	O
algorithm	O
is	O
composed	O
of	O
two	O
consecutive	O
steps	O
corresponding	O
to	O
complementary	O
reconstruction	O
models	O
,	O
each	O
with	O
a	O
structural	O
feature	O
based	O
l1	O
norm	O
constraint	O
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	O
constraint	O
,	O
which	O
allows	O
both	O
the	O
structure	O
edges	O
and	O
tiny	O
features	O
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	O
and	O
artifacts	O
could	O
be	O
reduced	O
.	O

In	O
the	O
M-step	O
,	O
the	O
initial	O
susceptibility	O
map	O
is	O
reconstructed	O
by	O
employing	O
a	O
k-space	O
based	O
compressed	O
sensing	O
model	O
incorporating	O
magnitude	O
prior	O
.	O

In	O
the	O
S-step	O
,	O
the	O
susceptibility	O
map	O
is	O
fitted	O
in	O
spatial	O
domain	O
using	O
weighted	O
constraints	O
derived	O
from	O
the	O
initial	O
susceptibility	O
map	O
from	O
the	O
M-step	O
.	O

Simulations	O
and	O
in	O
vivo	O
human	O
experiments	O
at	O
7T	O
MRI	B-P
show	O
that	O
the	O
SFCR	O
method	O
provides	O
high	O
quality	O
susceptibility	O
maps	O
with	O
improved	O
RMSE	O
and	O
MSSIM	O
.	O

Finally	O
,	O
the	O
susceptibility	O
values	O
of	O
deep	O
gray	O
matter	O
are	O
analyzed	O
in	O
multiple	O
head	O
positions	O
,	O
with	O
the	O
supine	O
position	O
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	O
result	O
.	O

Intrinsic	O
inter-network	O
brain	O
dysfunction	O
correlates	O
with	O
symptom	O
dimensions	O
in	O
late-life	O
depression	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
dysfunctions	O
within	O
the	O
core	O
neurocognitive	O
networks	O
(	O
the	O
executive	O
control	O
[	O
ECN	O
]	O
,	O
default	O
mode	O
[	O
DMN	O
]	O
and	O
salience	O
[	O
SN	O
]	O
networks	O
)	O
in	O
late-life	O
depression	O
(	O
LLD	O
)	O
.	O

Whether	O
inter-network	O
dysfunctional	O
connectivity	O
is	O
present	O
in	O
LLD	O
,	O
and	O
if	O
such	O
disruptions	O
are	O
associated	O
with	O
core	O
symptom	O
dimensions	O
is	O
unknown	O
.	O

A	O
cross-sectional	B-P
resting-state	I-P
functional	I-P
connectivity	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
investigation	O
was	O
conducted	O
of	O
LLD	O
(	O
n	O
=	O
39	O
)	O
and	O
age	O
-	O
and	O
gender	O
-equated	O
healthy	O
comparison	O
(	O
HC	O
)	O
(	O
n	O
=	O
29	O
)	O
participants	O
.	O

Dual	O
regression	O
independent	O
component	O
analysis	O
approach	O
was	O
used	O
to	O
identify	O
components	O
that	O
represented	O
the	O
ECN	O
,	O
DMN	O
and	O
SN	O
.	O

The	O
intrinsic	O
inter-network	O
connectivity	O
was	O
compared	O
between	O
LLD	O
and	O
HC	O
participants	O
and	O
the	O
relationship	O
of	O
inter-network	O
connectivity	O
abnormalities	O
with	O
dimensional	O
measures	O
was	O
examined	O
.	O

Relative	O
to	O
HC	O
participants	O
,	O
LLD	O
subjects	O
showed	O
decreased	O
inter-network	O
connectivity	O
between	O
the	O
bilateral	O
ECN	O
and	O
default	O
mode	O
subcortical	O
(	O
thalamus	O
,	O
basal	O
ganglia	O
and	O
ventral	O
striatum	O
)	O
networks	O
,	O
and	O
the	O
left	O
ECN	O
and	O
SN	O
insula	O
component	O
;	O
and	O
increased	O
inter-network	O
connections	O
between	O
the	O
left	O
ECN	O
and	O
posterior	O
DMN	O
and	O
salience	O
(	O
dorsal	O
anterior	O
cingulate	O
)	O
network	O
components	O
.	O

Distinct	O
inter-network	O
connectivity	O
abnormalities	O
correlated	O
with	O
depression	O
and	O
anxiety	O
severity	O
,	O
and	O
executive	O
dysfunction	O
in	O
LLD	O
participants	O
.	O

LLD	O
subjects	O
also	O
showed	O
pronounced	O
intra-network	O
connectivity	O
differences	O
within	O
the	O
ECN	O
,	O
whereas	O
fewer	O
but	O
significant	O
DMN	O
and	O
SN	O
disruptions	O
were	O
also	O
detected	O
.	O

Investigating	O
the	O
intrinsic	O
inter-network	O
functional	O
connectivity	O
could	O
provide	O
a	O
mechanistic	O
framework	O
to	O
better	O
understand	O
the	O
neural	O
basis	O
that	O
underlies	O
core	O
symptom	O
dimensions	O
in	O
LLD	O
.	O

Inter-network	O
connectivity	O
measures	O
have	O
the	O
potential	O
to	O
be	O
neuroimaging	O
biomarkers	O
of	O
symptom	O
dimensions	O
comprising	O
LLD	O
,	O
and	O
may	O
assist	O
in	O
developing	O
symptom	O
-specific	O
treatment	O
algorithms	O
.	O

Why	O
being	O
an	O
expert	O
-	O
despite	O
xpert	O
-remains	O
crucial	O
for	O
children	O
in	O
high	O
TB	O
burden	O
settings	O
.	O

As	O
access	O
to	O
Xpert	O
expands	O
in	O
high	O
TB-burden	O
settings	O
,	O
its	O
performance	O
against	O
clinically	B-P
diagnosed	I-P
TB	O
as	O
a	O
reference	O
standard	O
provides	O
important	O
insight	O
as	O
the	O
majority	O
of	O
childhood	O
TB	O
is	O
bacteriologically	O
unconfirmed	O
.	O

We	O
aim	O
to	O
describe	O
the	O
characteristics	O
and	O
outcomes	O
of	O
children	O
with	O
presumptive	O
TB	O
and	O
TB	O
disease	O
,	O
and	O
assess	O
performance	O
of	O
Xpert	O
under	O
programmatic	O
conditions	O
against	O
a	O
clinical	B-P
diagnosis	I-P
of	O
TB	O
as	O
a	O
reference	O
standard	O
.	O

Retrospective	O
review	O
of	O
children	O
evaluated	O
for	O
presumptive	O
TB	O
in	O
Mbeya	O
,	O
Tanzania	O
.	O

Baseline	O
characteristics	O
were	O
compared	O
by	O
TB	O
disease	O
status	O
and	O
,	O
for	O
patients	O
diagnosed	B-P
with	O
TB	O
,	O
by	O
TB	O
confirmation	O
status	O
using	O
Wilcoxon	O
rank	O
sum	O
test	O
for	O
continuous	O
variables	O
and	O
the	O
Chi-square	O
test	O
for	O
categorical	O
variables	O
.	O

Sensitivity	O
and	O
specificity	O
were	O
calculated	O
to	O
assess	O
the	O
performance	O
of	O
Xpert	O
,	O
smear	B-P
,	O
and	O
culture	B-P
against	O
clinical	O
TB	O
.	O

Kappa	O
statistics	O
were	O
calculated	O
to	O
assess	O
agreement	O
between	O
Xpert	O
and	O
smear	B-P
to	O
culture	B-P
.	O

Among	O
children	O
(	O
N	O
=	O
455	O
)	O
evaluated	O
for	O
presumptive	O
TB	O
,	O
70.3	O
%	O
(	O
320/455	O
)	O
had	O
Xpert	O
and	O
62.8	O
%	O
(	O
286/455	O
)	O
had	O
culture	B-P
performed	O
on	O
sputa	O
.	O

34.5	O
%	O
(	O
157/455	O
)	O
were	O
diagnosed	B-P
with	O
TB	O
:	O
80.3	O
%	O
(	O
126/157	O
)	O
pulmonary	O
TB	O
,	O
13.4	O
%	O
(	O
21/157	O
)	O
bacteriologically	O
confirmed	O
,	O
53.5	O
%	O
(	O
84/157	O
)	O
HIV	O
positive	O
,	O
and	O
48.4	O
%	O
(	O
76/157	O
)	O
inpatients	O
.	O

Compared	O
to	O
the	O
reference	O
standard	O
of	O
clinical	B-P
diagnosis	I-P
,	O
sensitivity	O
of	O
Xpert	O
was	O
8	O
%	O
(	O
95	O
%	O
CI	O
4-15	O
)	O
,	O
smear	B-P
6	O
%	O
(	O
95	O
%	O
CI	O
3-12	O
)	O
and	O
culture	B-P
16	O
%	O
(	O
95	O
%	O
CI	O
9-24	O
)	O
,	O
and	O
did	O
not	O
differ	O
based	O
on	O
patient	O
disposition	O
,	O
nutrition	O
or	O
HIV	O
status	O
.	O

Despite	O
access	O
to	O
Xpert	O
,	O
the	O
majority	O
of	O
children	O
with	O
presumptive	O
TB	O
were	O
treated	O
based	O
on	O
clinical	B-P
diagnosis	I-P
.	O

Reflecting	O
the	O
reality	O
of	O
clinical	O
practice	O
in	O
resource	O
limited	O
settings	O
,	O
new	O
diagnostics	B-P
such	O
as	O
Xpert	O
serve	O
as	O
important	O
adjunctive	O
tests	O
but	O
will	O
not	O
obviate	O
the	O
need	O
for	O
astute	O
clinicians	O
and	O
comprehensive	O
diagnostic	O
algorithms	O
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Cytotoxic	O
Evaluation	O
of	O
Certain	O
7-Chloro-4-	O
(	O
piperazin-1-yl	O
)	O
quinoline	O
Derivatives	O
as	O
VEGFR-II	O
Inhibitors	O
.	O

Signaling	O
pathway	O
inhibition	O
of	O
VEGFR-II	O
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	O
management	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
synthesis	O
of	O
novel	O
1-4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
-2-	O
(	O
N-substituted-amino	O
)	O
-ethanone	O
derivatives	O
(	O
4a-t	O
)	O
was	O
achieved	O
through	O
the	O
amination	O
of	O
2-chloro-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
3	O
)	O
with	O
different	O
secondary	O
amines	O
.	O

The	O
structures	O
of	O
the	O
target	O
compounds	O
were	O
confirmed	O
by	O
IR	O
,	O
(	B-P
1	I-P
)	I-P
H-NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C-NMR	I-P
,	O
HRMS	O
,	O
and	O
microanalysis	O
.	O

Compounds	O
4a-t	O
were	O
subjected	O
to	O
in	O
vitro	O
anticancer	O
screening	O
against	O
human	O
breast	O
cancer	O
(	O
MCF-7	O
)	O
and	O
prostate	O
cancer	O
(	O
PC3	O
)	O
cell	O
lines	O
.	O

The	O
highest	O
cytotoxicty	O
against	O
both	O
cell	O
lines	O
was	O
displayed	O
by	O
2-	O
(	O
4-	O
(	O
4-bromobenzyl	O
)	O
piperazin-1-yl	O
)	O
-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
4q	O
)	O
,	O
with	O
IC50	O
values	O
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	O
and	O
PC3	O
cells	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
standard	O
drug	O
doxorubicin	O
(	O
MCF-7	O
:	O
6.774	O
μM	O
,	O
PC3	O
:	O
7.7316	O
μM	O
)	O
.	O

Due	O
to	O
its	O
notable	O
activity	O
toward	O
MCF-7	O
cells	O
,	O
4q	O
was	O
further	O
evaluated	O
as	O
VEGFR-II	O
inhibitor	O
,	O
showing	O
an	O
IC50	O
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	O
(	O
0.33	O
μM	O
)	O
.	O

The	O
docking	O
study	O
proved	O
that	O
4q	O
has	O
a	O
binding	O
mode	O
akin	O
to	O
that	O
of	O
VEGFR-II	O
inhibitors	O
.	O

Whole-body	O
strength	O
training	O
with	O
Huber	O
Motion	O
Lab	O
and	O
traditional	O
strength	O
training	O
in	O
cardiac	O
rehabilitation	O
:	O
A	O
randomized	O
controlled	O
study	O
.	O

Isometric	O
strengthening	O
has	O
been	O
rarely	O
studied	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	O
side	O
effects	O
and	O
lack	O
of	O
appropriate	O
and	O
reliable	O
devices	O
.	O

We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	O
of	O
resistance	O
training	O
,	O
an	O
isometric	O
mode	O
with	O
the	O
Huber	O
Motion	O
Lab	O
(	O
HML	O
)	O
and	O
traditional	O
strength	O
training	O
(	O
TST	O
)	O
,	O
in	O
CHD	O
patients	O
undergoing	O
a	O
cardiac	O
rehabilitation	O
program	O
.	O

We	O
randomly	O
assigned	O
50	O
patients	O
to	O
HML	O
or	O
TST	O
.	O

Patients	O
underwent	O
complete	O
blinded	O
evaluation	O
before	O
and	O
after	O
the	O
rehabilitation	O
program	O
,	O
including	O
testing	B-P
for	I-P
cardiopulmonary	I-P
exercise	I-P
,	O
maximal	B-P
isometric	I-P
voluntary	I-P
contraction	I-P
,	O
endothelial	O
function	O
and	O
body	O
composition	O
.	O

After	O
4	O
weeks	O
of	O
training	O
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	O
did	O
not	O
differ	O
in	O
body	O
composition	O
,	O
anthropometric	O
characteristics	O
,	O
or	O
endothelial	O
function	O
.	O

With	O
HML	O
,	O
peak	O
power	O
output	O
(	O
P=0.035	O
)	O
,	O
maximal	O
heart	O
rate	O
(	O
P	O
<	O
0.01	O
)	O
and	O
gain	O
of	O
force	O
measured	O
in	O
the	O
chest	O
press	O
position	O
(	O
P	O
<	O
0.02	O
)	O
were	O
greater	O
after	O
versus	O
before	O
training	O
.	O

Both	O
protocols	O
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	O
patients	O
.	O

A	O
training	O
protocol	O
involving	O
6s	O
phases	O
of	O
isometric	O
contractions	O
with	O
10s	O
of	O
passive	O
recovery	O
on	O
an	O
HML	O
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	O
programs	O
for	O
patients	O
with	O
CHD	O
and	O
improve	O
functional	O
outcomes	O
.	O

Does	O
the	O
Use	O
of	O
Ibuprofen	O
in	O
Children	O
with	O
Extremity	O
Fractures	O
Increase	O
their	O
Risk	O
for	O
Bone	O
Healing	O
Complications	O
?	O
.	O

Despite	O
being	O
an	O
effective	O
analgesic	O
for	O
children	O
with	O
fractures	O
,	O
some	O
clinicians	O
may	O
avoid	O
prescribing	O
ibuprofen	O
due	O
to	O
its	O
potentially	O
harmful	O
effect	O
on	O
bone	O
healing	O
.	O

To	O
determine	O
if	O
exposure	O
to	O
ibuprofen	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bone	O
healing	O
complications	O
in	O
children	O
with	O
fractures	O
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
children	O
aged	O
6	O
months	O
to	O
17	O
years	O
who	O
presented	O
to	O
the	O
pediatric	O
emergency	O
department	O
(	O
PED	O
)	O
with	O
a	O
fracture	O
of	O
the	O
tibia	O
,	O
femur	O
,	O
humerus	O
,	O
scaphoid	O
,	O
or	O
fifth	O
metatarsus	O
and	O
who	O
followed	O
up	O
with	O
the	O
orthopedic	O
service	O
.	O

We	O
chose	O
these	O
fractures	O
due	O
to	O
their	O
higher	O
risk	O
for	O
complications	O
.	O

We	O
classified	O
patients	O
as	O
exposed	O
if	O
they	O
received	O
ibuprofen	O
in	O
the	O
PED	O
or	O
during	O
hospitalization	O
or	O
were	O
prescribed	O
ibuprofen	O
at	O
discharge	O
.	O

The	O
main	O
outcome	O
was	O
a	O
bone	O
healing	O
complication	O
as	O
evidenced	O
by	O
nonunion	O
,	O
delayed	O
union	O
,	O
or	O
re-displacement	O
on	O
follow-up	O
radiographs	B-P
.	O

Of	O
the	O
808	O
patients	O
included	O
in	O
the	O
final	O
analysis	O
,	O
338	O
(	O
42	O
%	O
)	O
were	O
exposed	O
to	O
ibuprofen	O
.	O

Overall	O
,	O
27	O
(	O
3	O
%	O
)	O
patients	O
had	O
a	O
bone	O
healing	O
complication	O
;	O
8	O
(	O
1	O
%	O
)	O
developed	O
nonunion	O
,	O
3	O
(	O
0.4	O
%	O
)	O
developed	O
delayed	O
union	O
,	O
and	O
16	O
(	O
2	O
%	O
)	O
developed	O
re-displacement	O
.	O

Ten	O
(	O
3	O
%	O
)	O
patients	O
who	O
were	O
exposed	O
to	O
ibuprofen	O
,	O
and	O
17	O
(	O
4	O
%	O
)	O
who	O
were	O
not	O
,	O
developed	O
a	O
bone	O
healing	O
complication	O
(	O
odds	O
ratio	O
0.8	O
,	O
95	O
%	O
confidence	O
interval	O
0.4-1.8	O
;	O
p	O
=	O
0.61	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
ibuprofen	O
exposure	O
and	O
the	O
development	O
of	O
a	O
bone	O
healing	O
complication	O
despite	O
adjustment	O
for	O
potential	O
confounders	O
.	O

Children	O
with	O
extremity	O
fractures	O
who	O
are	O
exposed	O
to	O
ibuprofen	O
do	O
not	O
seem	O
to	O
be	O
at	O
increased	O
risk	O
for	O
clinically	O
important	O
bone	O
healing	O
complications	O
.	O

DT	B-P
MRI	I-P
microstructural	O
cortical	O
lesion	O
damage	O
does	O
not	O
explain	O
cognitive	O
impairment	O
in	O
MS.	O
We	O
combined	O
double	O
inversion	O
recovery	O
(	B-P
DIR	I-P
)	O
and	O
diffusion	O
tensor	O
(	O
DT	O
)	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
to	O
quantify	O
the	O
severity	O
of	O
cortical	O
lesion	O
(	O
CL	O
)	O
microstructural	O
tissue	O
abnormalities	O
in	O
a	O
large	O
cohort	O
of	O
relapse	O
-	O
onset	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
patients	O
and	O
its	O
contribution	O
to	O
cognitive	O
dysfunction	O
.	O

DIR	B-P
,	O
DT	B-P
,	O
dual-echo	B-P
,	O
and	O
three-dimensional	O
(	O
3D	O
)	O
T1-weighted	B-P
scans	I-P
were	O
acquired	O
from	O
149	O
MS	O
patients	O
and	O
40	O
controls	O
.	O

Cognitively	O
impaired	O
(	O
CI	O
)	O
patients	O
had	O
⩾2	O
abnormal	O
neuropsychological	B-P
tests	I-P
.	O

Diffusivity	O
values	O
in	O
CLs	O
,	O
cortex	O
,	O
white	O
matter	O
(	O
WM	O
)	O
lesions	O
,	O
and	O
normal-appearing	O
(	O
NA	O
)	O
WM	O
were	O
assessed	O
.	O

Predictors	O
of	O
cognitive	O
impairment	O
were	O
identified	O
using	O
a	O
random	O
forest	O
analysis	O
.	O

Compared	O
to	O
controls	O
,	O
MS	O
patients	O
had	O
lower	O
normalized	O
brain	O
volume	O
(	O
NBV	O
)	O
,	O
gray	O
matter	O
volume	O
(	O
GMV	O
)	O
,	O
WM	O
volume	O
,	O
lower	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
,	O
and	O
higher	O
mean	O
diffusivity	O
in	O
cortex	O
and	O
normal-appearing	O
white	O
matter	O
(	O
NAWM	O
)	O
.	O

A	O
total	O
of	O
44	O
(	O
29.5	O
%	O
)	O
patients	O
were	O
CI	O
.	O

Compared	O
to	O
cognitively	O
preserved	O
(	O
CP	O
)	O
,	O
CI	O
patients	O
had	O
higher	O
T2	O
WM	O
lesion	O
volume	O
(	O
LV	O
)	O
,	O
lower	O
NBV	O
and	O
GMV	O
,	O
and	O
more	O
severe	O
diffusivity	O
abnormalities	O
in	O
WM	O
lesions	O
,	O
cortex	O
,	O
and	O
NAWM	O
.	O

CL	O
measures	O
did	O
not	O
differ	O
between	O
CI	O
and	O
CP	O
patients	O
.	O

Cortex	O
FA	O
,	O
age	O
,	O
disease	O
duration	O
,	O
T2	O
WM	O
LV	O
,	O
and	O
GMV	O
best	O
predicted	O
MS	O
-related	O
cognitive	O
impairment	O
(	O
C-statistic	O
=	O
0.88	O
)	O
.	O
``	O

Diffuse	O
``	O
GM	O
and	O
NAWM	O
damage	O
and	O
WM	O
lesions	O
,	O
rather	O
than	O
intrinsic	O
CL	O
damage	O
,	O
contribute	O
to	O
cognitive	O
impairment	O
in	O
MS	O
.	O

Tooth	O
replacements	O
in	O
young	O
adults	O
with	O
severe	O
hypodontia	O
:	O
Orthodontic	O
space	O
closure	O
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
.	O

A	O
follow-up	O
study	O
.	O

Children	O
with	O
severe	O
hypodontia	O
have	O
a	O
substantial	O
impairment	O
of	O
their	O
dental	O
health	O
starting	O
early	O
in	O
life	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
types	O
and	O
locations	O
of	O
substitutes	O
for	O
missing	O
teeth	O
in	O
patients	O
with	O
severe	O
hypodontia	O
and	O
to	O
compare	O
the	O
crown	O
and	O
soft	O
tissue	O
morphologies	O
of	O
orthodontic	O
space	O
closure	O
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
for	O
replacing	O
teeth	O
in	O
the	O
anterior	O
region	O
.	O

Fifty	O
patients	O
missing	O
6	O
or	O
more	O
teeth	O
and	O
aged	O
18	O
years	O
or	O
older	O
(	O
mean	O
age	O
,	O
25.6	O
years	O
)	O
took	O
part	O
in	O
a	O
follow-up	O
study	O
.	O

The	O
patients	O
were	O
examined	O
clinically	O
with	O
panoramic	B-P
radiographs	I-P
and	O
clinical	B-P
photographs	I-P
.	O

Crown	O
and	O
soft	O
tissue	O
variables	O
(	O
mucosal	O
discoloration	O
,	O
crown	O
morphology	O
,	O
color	O
,	O
and	O
papilla	O
index	O
)	O
were	O
compared	O
for	O
orthodontic	O
space	O
closure	O
,	O
dental	O
implant	O
fixtures	O
,	O
and	O
fixed	O
dental	O
prostheses	O
.	O

Dental	O
implants	O
,	O
orthodontic	O
space	O
closure	O
,	O
and	O
retaining	O
deciduous	O
teeth	O
were	O
the	O
most	O
commonly	O
prescribed	O
treatments	O
.	O

Persisting	O
deciduous	O
teeth	O
showed	O
a	O
good	O
survival	O
rate	O
at	O
the	O
follow-up	O
examination	O
.	O

Mucosal	O
discoloration	O
was	O
seen	O
only	O
for	O
implant	O
fixtures	O
and	O
was	O
evident	O
for	O
almost	O
all	O
fixtures	O
in	O
the	O
anterior	O
mandible	O
and	O
two	O
thirds	O
of	O
those	O
in	O
the	O
anterior	O
maxilla	O
.	O

The	O
papilla	O
index	O
scored	O
poorer	O
for	O
both	O
implant	O
fixtures	O
and	O
fixed	O
dental	O
prostheses	O
compared	O
with	O
orthodontic	O
space	O
closure	O
.	O

Dental	O
implants	O
in	O
the	O
anterior	O
region	O
proved	O
to	O
be	O
an	O
inadequate	O
treatment	O
modality	O
in	O
patients	O
with	O
severe	O
hypodontia	O
because	O
of	O
pronounced	O
mucosal	O
discoloration	O
.	O

Avulsions	O
of	O
Triceps	O
Brachii	O
:	O
associated	O
injuries	O
and	O
surgical	O
treatment	O
;	O
a	O
case	O
series	O
.	O

This	O
study	O
reports	O
the	O
clinical	O
presentations	O
,	O
intra	O
-operative	O
findings	O
,	O
type	O
of	O
the	O
treatments	O
,	O
outcome	O
of	O
the	O
treatment	O
and	O
specially	O
associated	O
injuries	O
in	O
patients	O
with	O
the	O
avulsion	O
of	O
the	O
distal	O
end	O
of	O
the	O
triceps	O
brachii	O
(	O
TB	O
)	O
tendon	O
.	O

We	O
studied	O
6	O
patients	O
with	O
rupture	O
or	O
avulsion	O
of	O
the	O
distal	O
end	O
of	O
the	O
TB	O
tendon	O
.	O

The	O
medical	O
records	O
,	O
imaging	O
files	O
,	O
clinical	O
outcomes	O
at	O
the	O
final	O
follow	O
up	O
visit	O
were	O
reviewed	O
.	O

The	O
clinical	O
outcomes	O
were	O
assessed	O
by	O
Mayo	O
Elbow	O
Score	O
at	O
the	O
final	O
follow-up	O
visit	O
.	O

All	O
patients	O
were	O
male	O
,	O
4	O
of	O
them	O
having	O
injury	O
in	O
the	O
left	O
hand	O
as	O
the	O
non-dominant	O
hand	O
.	O

Mean	O
age	O
of	O
them	O
was	O
34.5	O
years	O
.	O

All	O
cases	O
had	O
small	O
bony	O
fleck	O
in	O
the	O
posterior	O
of	O
elbow	O
in	O
lateral	B-P
radiograph	I-P
.	O

Three	O
patients	O
had	O
associated	O
injuries	O
-including	O
intra-articular	O
fractures	O
and	O
medial	O
collateral	O
ligament	O
rupture	O
.	O

In	O
one	O
case	O
V-Y	O
plasty	O
of	O
the	O
distal	O
TB	O
was	O
done	O
.	O

In	O
4	O
patients	O
the	O
results	O
of	O
surgery	O
were	O
excellent	O
,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair	O
.	O

Although	O
TB	O
tendon	O
rupture	O
is	O
rare	O
,	O
it	O
should	O
be	O
-considered	O
in	O
differential	O
diagnosis	O
of	O
the	O
upper	O
-extremity	O
trauma	O
and	O
its	O
associated	O
injuries	O
should	O
be	O
addressed	O
properly	O
.	O

Atorvastatin	O
-induced	O
dermatomyositis	O
.	O

A	O
49-year-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	O
who	O
had	O
a	O
myocardial	O
infarction	O
(	O
MI	O
)	O
was	O
treated	O
with	O
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	O
intervention	O
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	O
clinic	O
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	O
weakness	O
.	O

In	O
the	O
physical	O
examination	O
,	O
a	O
reddish	O
rash	O
on	O
the	O
face	O
and	O
Gottron	O
's	O
papules	O
on	O
the	O
knuckles	O
were	O
detected	O
.	O

The	O
skin	B-P
biopsy	I-P
performed	O
indicated	O
interface	O
dermatitis	O
with	O
hydropic	O
degeneration	O
of	O
basal	O
keratinocytes	O
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

He	O
was	O
started	O
on	O
prednisolone	O
1	O
mg/kg/day	O
.	O

After	O
30	O
days	O
of	O
prednisolone	O
therapy	O
,	O
all	O
symptoms	O
disappeared	O
.	O

Undisclosed	O
HIV	O
infection	O
and	O
art	O
use	O
in	O
the	O
kenya	O
AIDS	O
indicator	O
survey	O
2012	O
:	O
relevance	O
to	O
targets	O
for	O
HIV	B-P
diagnosis	I-P
and	O
treatment	O
in	O
kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	O
and	O
antiretroviral	O
(	O
ARV	O
)	O
therapy	O
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	O
.	O

HIV-positive	O
dried	O
blood	O
spot	O
samples	O
from	O
Kenya	O
's	O
second	O
AIDS	O
Indicator	O
Survey	O
were	O
tested	O
for	O
an	O
ARV	O
biomarker	O
by	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
use	O
based	O
on	O
self-report	O
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
based	O
on	O
ARV	O
testing	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
among	O
persons	O
on	O
ART	O
.	O

Among	O
559	O
HIV-positive	O
samples	O
,	O
the	O
ARV	O
biomarker	O
was	O
detected	O
in	O
42.5	O
%	O
(	O
CI	O
37.4-47.7	O
)	O
.	O

ARV	O
drugs	O
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1-95.2	O
)	O
reporting	O
HIV-positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9-73.4	O
)	O
reporting	O
HIV-positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4-28.6	O
)	O
reporting	O
HIV-negative	O
status	O
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0-29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	O
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	O
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O

Undisclosed	O
HIV	O
infection	O
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	O
25-39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	O
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Supplementing	O
self-reported	O
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-based	O
sero-surveys	O
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Antimicrobial	O
susceptibility	O
of	O
Pseudomonas	O
aeruginosa	O
before	O
and	O
after	O
initiation	O
of	O
inhaled	O
tobramycin	O
in	O
Bulgaria	O
.	O

In	O
aim	O
to	O
achieve	O
better	O
infection	O
control	O
and	O
possible	O
eradication	O
of	O
the	O
pathogens	O
involved	O
in	O
chronic	O
infections	O
of	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
scientists	O
have	O
developed	O
a	O
new	O
way	O
to	O
administer	O
antimicrobials	O
-	O
inhalation	O
.	O

The	O
first	O
and	O
so	O
far	O
the	O
only	O
available	O
inhalable	O
antimicrobial	O
in	O
Bulgaria	O
is	O
inhaled	O
tobramycin	O
(	O
TOBI	O
)	O
,	O
introduced	O
in	O
2009	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
antimicrobial	O
susceptibility	O
of	O
Pseudomonas	O
aeruginosa	O
isolates	O
from	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
before	O
and	O
after	O
initiation	O
of	O
TOBI	O
in	O
the	O
regular	O
treatment	O
regimen	O
.	O

We	O
have	O
determined	O
the	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
17	O
antimicrobials	O
by	O
the	O
E-test	B-P
(	O
LIOFILCHEM	O
)	O
in	O
sputa	O
samples	O
of	O
118	O
CF	O
patients	O
for	O
the	O
period	O
of	O
2005-2014	O
.	O

The	O
results	O
were	O
interpreted	O
according	O
to	O
the	O
annual	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
guidelines	O
.	O

In	O
the	O
sputa	O
of	O
70	O
patients	O
a	O
total	O
of	O
102	O
P.	O
aeruginosa	O
isolates	O
were	O
found	O
.	O

Sixty-eight	O
out	O
of	O
102	O
(	O
66.7	O
%	O
)	O
were	O
susceptible	O
to	O
all	O
studied	O
antimicrobials	O
.	O

We	O
divided	O
the	O
isolates	O
in	O
two	O
chronological	O
groups	O
:	O
those	O
collected	O
before	O
the	O
introduction	O
of	O
TOBI	O
as	O
a	O
regular	O
treatment	O
in	O
2009	O
and	O
those	O
collected	O
after	O
2009	O
.	O

A	O
significant	O
reduction	O
(	O
p	O
<	O
0,001-0,02	O
)	O
in	O
susceptibility	O
for	O
the	O
strains	O
after	O
2009	O
was	O
noted	O
towards	O
piperacillin	O
(	O
100	O
%	O
vs	O
50	O
%	O
)	O
,	O
ceftazidime	O
(	O
100	O
%	O
/	O
77.3	O
%	O
)	O
,	O
cefepime	O
(	O
97.9	O
%	O
/	O
68.2	O
%	O
)	O
,	O
amikacin	O
(	O
100	O
%	O
/	O
63.6	O
%	O
)	O
,	O
gentamicin	O
(	O
95.7	O
%	O
/	O
40.9	O
%	O
)	O
,	O
tobramycin	O
(	O
93.6	O
%	O
/	O
59.1	O
%	O
)	O
and	O
ciprofloxacin	O
(	O
93.6	O
%	O
/	O
45.5	O
%	O
)	O
.	O

The	O
introduction	O
of	O
inhaled	O
tobramycin	O
as	O
a	O
regular	O
therapy	O
for	O
CF	O
patients	O
in	O
Bulgaria	O
lead	O
to	O
a	O
significant	O
change	O
in	O
antimicrobial	O
susceptibility	O
of	O
CF	O
P.	O
aeruginosa	O
.	O

Clinical	O
Features	O
of	O
Smokers	O
With	O
Radiological	B-P
Emphysema	O
But	O
Without	O
Airway	O
Limitation	O
.	O

The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
emphysema	O
but	O
without	O
airway	O
limitations	O
remain	O
unknown	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
current	O
and	O
former	O
smokers	O
without	O
airflow	O
limitation	O
who	O
have	O
radiologic	B-P
emphysema	O
on	O
chest	B-P
CT	I-P
scans	I-P
vs	O
a	O
control	O
group	O
of	O
current	O
and	O
ex-smokers	O
without	O
emphysema	O
.	O

Subjects	O
enrolled	O
had	O
anthropometric	B-P
characteristics	I-P
recorded	O
,	O
provided	O
a	O
medical	O
history	O
,	O
and	O
underwent	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
.	O

The	O
following	O
parameters	O
were	O
also	O
evaluated	O
:	O
pulmonary	B-P
function	I-P
tests	I-P
including	O
diffusion	B-P
capacity	I-P
for	I-P
carbon	I-P
monoxide	I-P
(	O
Dlco	B-P
)	O
,	O
the	O
modified	O
Medical	O
Research	O
Council	O
dyspnea	O
score	O
,	O
COPD	O
assessment	O
test	O
(	O
CAT	O
)	O
,	O
and	O
6-min	B-P
walk	I-P
test	I-P
(	O
6MWT	B-P
)	O
.	O

A	O
comparison	O
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-P
-	O
confirmed	O
emphysema	O
.	O

Of	O
the	O
203	O
subjects	O
,	O
154	O
had	O
emphysema	O
,	O
and	O
49	O
did	O
not	O
.	O

Adjusted	O
group	O
comparisons	O
revealed	O
that	O
a	O
higher	O
proportion	O
of	O
patients	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
had	O
an	O
abnormal	O
Dlco	O
value	O
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.02	O
)	O
,	O
a	O
decrease	O
in	O
percentage	O
of	O
oxygen	O
saturation	O
>	O
4	O
%	O
during	O
the	O
6MWT	B-P
(	O
8.5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.04	O
)	O
,	O
and	O
an	O
altered	O
quality	O
of	O
life	O
(	O
CAT	O
score	O
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
CAT	O
questionnaire	O
items	O
revealed	O
that	O
more	O
patients	O
with	O
emphysema	O
had	O
a	O
score	O
≥	O
1	O
in	O
the	O
``	O
chest	O
tightness	O
``	O
(	O
P	O
=	O
.05	O
)	O
and	O
``	O
limitation	O
when	O
doing	O
activities	O
at	O
home	O
``	O
(	O
P	O
<	O
.01	O
)	O
items	O
compared	O
with	O
those	O
with	O
no	O
emphysema	O
.	O

They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	O
in	O
the	O
previous	O
year	O
(	O
0.19	O
vs	O
0.04	O
;	O
P	O
=	O
.02	O
)	O
.	O

A	O
significant	O
proportion	O
of	O
smokers	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
but	O
without	O
airway	O
limitation	O
had	O
alterations	O
in	O
their	O
quality	O
of	O
life	O
,	O
number	O
of	O
exacerbations	O
,	O
Dlco	B-P
values	O
,	O
and	O
oxygen	O
saturation	O
during	O
the	O
6MWT	B-P
test	I-P
.	O

Evaluation	O
of	O
Spontaneous	O
Bone	O
Regeneration	O
after	O
Enucleation	O
of	O
Large	O
Cysts	O
of	O
the	O
Jaws	O
using	O
Radiographic	O
Computed	O
Software	O
.	O

Spontaneous	O
regeneration	O
of	O
bone	O
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	O
defects	O
caused	O
by	O
enucleation	O
of	O
cysts	O
.	O

However	O
,	O
in	O
case	O
of	O
large	O
surgical	O
defects	O
caused	O
by	O
the	O
enucleation	O
,	O
spontaneous	O
regeneration	O
of	O
bone	O
is	O
a	O
rare	O
phenomenon	O
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	O
of	O
the	O
patient	O
,	O
intact	O
periosteum	O
,	O
and	O
proper	O
stabilization	O
.	O

The	O
study	O
included	O
16	O
patients	O
,	O
who	O
reported	O
to	O
the	O
department	O
of	O
oral	O
and	O
maxillofacial	O
surgery	O
with	O
the	O
complaint	O
of	O
pain	O
and	O
swelling	O
in	O
the	O
jaws	O
diagnosed	O
as	O
cyst	O
.	O

The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
subjects	O
aged	O
between	O
15	O
and	O
40	O
years	O
.	O

Panoramic	B-P
radiographs	I-P
were	O
taken	O
pre-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	O
.	O

The	O
dimensions	O
of	O
the	O
cyst	O
were	O
evaluated	O
on	O
the	O
radiograph	B-P
according	O
to	O
the	O
proforma	O
.	O

Subsequent	O
radiographs	B-P
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	O
using	O
MCID™	O
analysis	O
software	O
of	O
imaging	B-P
research	I-P
.	O

Mean	O
reduction	O
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	O
size	O
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90.2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O

Spontaneous	O
bone	O
regeneration	O
was	O
seen	O
even	O
after	O
primary	O
closure	O
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	O
of	O
foreign	O
substances	O
or	O
grafts	O
and	O
it	O
also	O
eliminated	O
the	O
complications	O
resulting	O
from	O
placement	O
of	O
foreign	O
substance	O
.	O

Further	O
studies	O
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow-up	O
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	O
.	O

The	O
present	O
study	O
depicted	O
that	O
spontaneous	O
bone	O
regeneration	O
can	O
occur	O
with	O
accepted	O
results	O
after	O
simple	O
enucleation	O
of	O
jaw	O
cyst	O
without	O
the	O
aid	O
of	O
any	O
graft	O
material	O
.	O

Hence	O
,	O
simple	O
enucleation	O
may	O
be	O
considered	O
as	O
a	O
first	O
line	O
of	O
treatment	O
modality	O
for	O
cystic	O
lesion	O
of	O
the	O
jaws	O
.	O

This	O
simplifies	O
the	O
surgical	O
procedure	O
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	O
the	O
risk	O
of	O
postoperative	O
complications	O
.	O

Follow-up	O
is	O
necessary	O
along	O
with	O
patient	O
's	O
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O

Microcapillary	O
sign	O
of	O
flap	O
alignment	O
in	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
.	O

We	O
present	O
an	O
observational	B-P
sign	O
that	O
ensures	O
perfect	O
alignment	O
during	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
(	O
FS	O
LASIK	O
)	O
.	O

Alignment	O
is	O
assured	O
when	O
a	O
microsponge	O
is	O
used	O
to	O
dry	O
the	O
flap	O
and	O
the	O
area	O
of	O
dryness	O
exceeds	O
the	O
area	O
of	O
direct	O
touch	O
of	O
the	O
microsponge	O
.	O

The	O
area	O
might	O
even	O
reach	O
the	O
whole	O
circumference	O
of	O
the	O
flap	O
at	O
the	O
first	O
touch	O
.	O

This	O
sign	O
of	O
alignment	O
can	O
be	O
explained	O
by	O
microcapillary	O
action	O
.	O

This	O
sign	O
was	O
not	O
elicited	O
in	O
flaps	O
created	O
by	O
a	O
microkeratome	O
.	O

Comparison	O
of	O
the	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
third	O
molar	O
surgery	O
:	O
A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Preemptive	O
analgesia	O
is	O
considered	O
an	O
alternative	O
for	O
treating	O
the	O
postsurgical	O
pain	O
of	O
third	O
molar	O
removal	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
preemptive	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
was	O
carried	O
out	O
.	O

Thirty	O
patients	O
were	O
randomized	O
into	O
two	O
treatment	O
groups	O
using	O
a	O
series	O
of	O
random	O
numbers	O
:	O
Group	O
A	O
,	O
oral	O
ketorolac	O
10	O
mg	O
plus	O
intramuscular	O
placebo	O
(	O
1	O
mL	O
saline	O
solution	O
)	O
;	O
or	O
Group	O
B	O
,	O
oral	O
placebo	O
(	O
similar	O
tablet	O
to	O
oral	O
ketorolac	O
)	O
plus	O
intramuscular	O
tramadol	O
50	O
mg	O
diluted	O
in	O
1	O
mL	O
saline	O
solution	O
.	O

These	O
treatments	O
were	O
given	O
30	O
min	O
before	O
the	O
surgery	O
.	O

We	O
evaluated	O
the	O
time	O
of	O
first	O
analgesic	O
rescue	O
medication	O
,	O
pain	O
intensity	O
,	O
total	O
analgesic	O
consumption	O
and	O
adverse	O
effects	O
.	O

Patients	O
taking	O
oral	O
ketorolac	O
had	O
longer	O
time	O
of	O
analgesic	O
covering	O
and	O
less	O
postoperative	O
pain	O
when	O
compared	O
with	O
patients	O
receiving	O
intramuscular	O
tramadol	O
.	O

According	O
to	O
the	O
VAS	B-P
and	O
UAC	O
results	O
,	O
this	O
study	O
suggests	O
that	O
10	O
mg	O
of	O
oral	O
ketorolac	O
had	O
superior	O
analgesic	O
effect	O
than	O
50	O
mg	O
of	O
tramadol	O
when	O
administered	O
before	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

Validity	O
and	O
reliability	O
of	O
fluoroscopy	B-P
for	O
digital	B-P
radiography	I-P
:	O
a	O
new	O
way	O
to	O
evaluate	O
diaphragmatic	O
mobility	O
.	O

Fluoroscopy	B-P
is	O
considered	O
the	O
most	O
accurate	O
method	O
to	O
evaluate	O
the	O
diaphragm	O
,	O
yet	O
most	O
existing	O
methods	O
for	O
measuring	O
diaphragmatic	O
mobility	O
using	O
fluoroscopy	B-P
are	O
complex	O
.	O

To	O
assess	O
the	O
validity	O
and	O
reliability	O
of	O
a	O
new	O
evaluation	O
method	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
of	O
healthy	O
adults	O
.	O

Twenty-six	O
adults	O
were	O
evaluated	O
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	O
and	O
pulmonary	B-P
function	I-P
test	I-P
.	O

The	O
evaluation	O
of	O
diaphragm	O
mobility	O
by	O
means	O
of	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
method	O
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O

The	O
Pearson	O
correlation	O
coefficient	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	O
.	O

The	O
inter-rater	O
and	O
intra-rater	O
reliability	O
of	O
the	O
measurement	O
of	O
diaphragmatic	O
motion	O
was	O
determined	O
using	O
ICC	O
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O

There	O
was	O
a	O
relationship	O
in	O
the	O
assessment	O
of	O
the	O
concurrent	O
validity	O
.	O

There	O
was	O
good	O
inter-rater	O
reliability	O
for	O
right	O
hemidiaphragm	O
mobility	O
and	O
moderate	O
reliability	O
for	O
left	O
hemidiaphragm	O
in	O
the	O
first	O
assessment	O
.	O

In	O
the	O
second	O
assessment	O
,	O
there	O
was	O
good	O
reliability	O
for	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
.	O

There	O
was	O
good	O
intra-rater	O
reliability	O
in	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
for	O
raters	O
A	O
and	O
B	O
.	O

The	O
evaluation	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
proved	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
method	O
of	O
healthy	O
adults	O
.	O

Semimembranosus	O
tenosynovitis	O
:	O
Diagnosis	O
and	O
management	O
of	O
a	O
commonly	O
missed	O
cause	O
of	O
posteromedial	O
knee	O
pain	O
.	O

In	O
orthopedic	O
and	O
sports	O
medicine	O
literature	O
there	O
is	O
minimal	O
information	O
regarding	O
accurate	O
diagnosis	O
and	O
the	O
treatment	O
options	O
for	O
tenosynovitis	O
of	O
the	O
distal	O
semimembranosus	O
tendon	O
.	O

After	O
reviewing	O
the	O
literature	O
,	O
the	O
authors	O
question	O
both	O
the	O
etiology	O
and	O
treatment	O
of	O
this	O
condition	O
.	O

Previous	O
descriptions	O
have	O
associated	O
the	O
condition	O
primarily	O
with	O
the	O
endurance	O
athlete	O
but	O
we	O
have	O
noted	O
multiple	O
cases	O
in	O
which	O
this	O
is	O
a	O
condition	O
common	O
to	O
the	O
'sprinter	O
'	O
as	O
well	O
.	O

There	O
has	O
been	O
very	O
little	O
mention	O
of	O
this	O
condition	O
in	O
recent	O
literature	O
but	O
the	O
most	O
recent	O
complete	O
description	O
of	O
operative	O
treatment	O
for	O
this	O
condition	O
recommends	O
both	O
tendon	O
transfer	O
and	O
concomitant	O
arthroscopy	B-P
.	O

We	O
propose	O
this	O
condition	O
is	O
akin	O
to	O
De	O
Quervain	O
's	O
tenosynovitis	O
of	O
the	O
knee	O
,	O
with	O
sensitive	O
and	O
specific	O
signs	O
on	O
physical	O
examination	O
.	O

We	O
describe	O
a	O
case	O
series	O
of	O
six	O
cases	O
(	O
five	O
patients	O
)	O
,	O
that	O
underwent	O
open	O
surgical	O
release	O
for	O
semimembranosus	O
tenosynovitis	O
.	O

The	O
anatomy	O
and	O
the	O
treatment	O
options	O
for	O
the	O
condition	O
are	O
also	O
discussed	O
.	O

At	O
a	O
follow-up	O
period	O
of	O
18-64months	O
,	O
all	O
cases	O
showed	O
improvement	O
in	O
the	O
Tegner	O
activity	O
score	O
following	O
surgical	O
release	O
.	O

Diagnostic	O
confusion	O
can	O
be	O
decreased	O
with	O
more	O
modern	O
diagnostic	O
imaging	O
modalities	O
than	O
those	O
described	O
in	O
the	O
literature	O
.	O

The	O
authors	O
outline	O
an	O
alternative	O
operative	O
approach	O
significantly	O
decreasing	O
surgical	O
complexity	O
and	O
therefore	O
post-operative	O
morbidity	O
.	O

What	O
is	O
known	O
about	O
this	O
subject	O
:	O
This	O
is	O
a	O
rare	O
condition	O
and	O
the	O
surgical	O
treatment	O
is	O
seldom	O
performed	O
.	O

What	O
this	O
study	O
adds	O
to	O
existing	O
knowledge	O
:	O
We	O
describe	O
the	O
technique	O
for	O
surgical	O
decompression	O
and	O
reveal	O
positive	O
results	O
at	O
medium	O
term	O
follow-up	O
.	O

Effect	O
of	O
Genotype	O
and	O
Previous	O
GH	O
Treatment	O
on	O
Adiposity	O
in	O
Adults	O
With	O
Prader-Willi	O
Syndrome	O
.	O

Adults	O
with	O
Prader-Willi	O
syndrome	O
(	O
PWS	O
)	O
have	O
an	O
increased	O
proportion	O
of	O
sc	O
fat	O
mass	O
compared	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-matched	O
controls	O
,	O
but	O
whether	O
the	O
genotype	O
influences	O
body	O
composition	O
and	O
metabolic	O
profile	O
remains	O
controversial	O
.	O

To	O
assess	O
body	O
composition	O
and	O
metabolic	O
features	O
in	O
adults	O
with	O
PWS	O
,	O
according	O
to	O
genetic	O
subtype	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
previous	O
GH	O
treatment	O
was	O
assessed	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Body	O
composition	O
(	O
Dual	B-P
Energy	I-P
X-ray	I-P
Absorptiometry	I-P
)	O
and	O
metabolic	O
parameters	O
were	O
compared	O
in	O
PWS	O
adults	O
(	O
mean	O
age	O
,	O
25.5	O
±	O
8.9	O
y	O
)	O
with	O
deletion	O
(	O
n	O
=	O
47	O
)	O
or	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
(	O
n	O
=	O
26	O
)	O
,	O
taking	O
into	O
account	O
GH	O
treatment	O
in	O
childhood	O
and/or	O
adolescence	O
.	O

In	O
subgroups	O
,	O
adipocyte	O
size	O
,	O
fasting	O
total	O
ghrelin	O
levels	O
,	O
and	O
resting	O
energy	O
expenditure	O
were	O
measured	O
,	O
and	O
hyperphagia	O
was	O
assessed	O
by	O
the	O
Dykens	O
Hyperphagia	O
Questionnaire	O
.	O

In	O
the	O
whole	O
sample	O
,	O
the	O
deletion	O
group	O
had	O
a	O
higher	O
BMI	O
compared	O
with	O
UPD	O
(	O
40.9	O
±	O
11.5	O
vs	O
34.6	O
±	O
9.6	O
kg/m	O
(	O
2	O
)	O
,	O
P	O
=	O
.02	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
groups	O
in	O
percent	O
body	O
fat	O
,	O
metabolic	O
profile	O
,	O
adipocyte	O
size	O
,	O
resting	O
energy	O
expenditure	O
,	O
hyperphagia	O
score	O
,	O
or	O
ghrelin	O
levels	O
.	O

In	O
subjects	O
previously	O
treated	O
with	O
GH	O
,	O
BMI	O
was	O
not	O
different	O
between	O
UPD	O
and	O
deletion	O
groups	O
(	O
33.0	O
±	O
9.7	O
vs	O
33.5	O
±	O
11.1	O
kg/m	O
(	O
2	O
)	O
)	O
.	O

In	O
addition	O
,	O
previous	O
GH	O
treatment	O
was	O
associated	O
with	O
decreased	O
percent	O
body	O
fat	O
and	O
adipocyte	O
volume	O
only	O
in	O
the	O
deletion	O
group	O
.	O

A	O
deletion	O
genotype	O
in	O
adults	O
with	O
PWS	O
is	O
associated	O
with	O
increased	O
BMI	O
.	O

GH	O
treatment	O
in	O
childhood	O
and/or	O
adolescence	O
limits	O
this	O
deleterious	O
phenotypic	O
effect	O
with	O
improved	O
adiposity	O
markers	O
.	O

This	O
study	O
suggests	O
relationships	O
between	O
the	O
molecular	O
phenotype	O
of	O
PWS	O
and	O
adipose	O
tissue	O
development	O
as	O
well	O
as	O
sensitivity	O
to	O
GH	O
.	O

Gene	O
Expression	O
Profile	O
in	O
the	O
Liver	O
of	O
Sheep	O
Infected	O
with	O
Cystic	O
Echinococcosis	O
.	O

Cystic	O
Echinococcosis	O
(	O
CE	O
)	O
,	O
caused	O
by	O
infection	O
with	O
the	O
Echinococcus	O
granulosus	O
(	O
E.	O
granulosus	O
)	O
,	O
represents	O
considerable	O
health	O
problems	O
in	O
both	O
humans	O
and	O
livestock	O
.	O

Nevertheless	O
,	O
the	O
genetic	O
program	O
that	O
regulates	O
the	O
host	O
response	O
to	O
E.	O
granulosus	O
infection	O
is	O
largely	O
unknown	O
.	O

Previously	O
,	O
using	O
microarray	O
analysis	O
,	O
we	O
found	O
that	O
the	O
innate	O
immunity	O
played	O
a	O
vital	O
role	O
in	O
the	O
E.	O
granulosus	O
defense	O
of	O
the	O
intestine	O
tissue	O
where	O
E.	O
granulosus	O
first	O
invaded	O
.	O

Subsequently	O
,	O
we	O
turned	O
our	O
attention	O
to	O
investigating	O
the	O
molecular	O
immune	O
mechanism	O
in	O
its	O
organ	O
target	O
,	O
the	O
liver	O
,	O
which	O
is	O
where	O
the	O
E.	O
granulosus	O
metacestodes	O
are	O
established	O
and	O
live	O
for	O
very	O
long	O
periods	O
.	O

In	O
this	O
work	O
,	O
the	O
microarray-based	O
methodology	O
was	O
used	O
to	O
study	O
gene	O
expression	O
profiles	O
in	O
the	O
liver	O
of	O
sheep	O
infected	O
with	O
E.	O
granulosus	O
at	O
8	O
weeks	O
post	O
infection	O
,	O
corresponding	O
to	O
the	O
early	O
cystic	O
established	O
phase	O
.	O

A	O
total	O
of	O
6	O
female	O
-1-	O
year	O
-old	O
healthy	O
Kazakh	O
sheep	O
were	O
used	O
for	O
the	O
experiments	O
.	O

Three	O
Kazakh	O
sheep	O
were	O
orally	O
infected	O
with	O
E.	O
granulosus	O
eggs	O
,	O
and	O
the	O
others	O
remained	O
untreated	O
and	O
served	O
as	O
controls	O
.	O

Sheep	O
were	O
humanely	O
euthanized	O
and	O
necropsized	B-P
at	O
8	O
weeks	O
post	O
-	O
infection	O
(	O
the	O
early	O
stage	O
of	O
cyst	O
established	O
)	O
.	O

The	O
microarray	O
was	O
used	O
to	O
detect	O
differential	O
hepatic	O
gene	O
expression	O
between	O
CE	O
infection	O
sheep	O
and	O
healthy	O
controls	O
at	O
this	O
time	O
point	O
.	O

Real-time	O
PCR	O
was	O
used	O
to	O
validate	O
the	O
microarray	O
data	O
.	O

We	O
found	O
that	O
E.	O
granulosus	O
infection	O
induces	O
153	O
differentially	O
expressed	O
genes	O
in	O
the	O
livers	O
of	O
infected	O
sheep	O
compared	O
with	O
healthy	O
controls	O
.	O

Among	O
them	O
,	O
87	O
genes	O
were	O
up-regulated	O
,	O
and	O
66	O
genes	O
were	O
notably	O
down-regulated	O
.	O

Functional	O
analysis	O
showed	O
that	O
these	O
genes	O
were	O
associated	O
with	O
three	O
major	O
functional	O
categories	O
:	O
(	O
a	O
)	O
metabolism	O
,	O
(	O
b	O
)	O
the	O
immune	O
system	O
and	O
(	O
c	O
)	O
signaling	O
and	O
transport	O
.	O

Deeper	O
analysis	O
indicated	O
that	O
complement	O
together	O
with	O
other	O
genes	O
associated	O
with	O
metabolism	O
,	O
played	O
important	O
roles	O
in	O
the	O
defense	O
of	O
E.	O
granulosus	O
infection	O
.	O

The	O
present	O
study	O
identified	O
genes	O
profiling	O
in	O
the	O
liver	O
tissue	O
of	O
E.	O
granulosus	O
infection	O
in	O
sheep	O
.	O

The	O
expression	O
pattern	O
obtained	O
here	O
could	O
be	O
helpful	O
for	O
understanding	O
the	O
molecular	O
immunity	O
mechanisms	O
of	O
host	O
responses	O
to	O
E.	O
granulosus	O
infection	O
.	O

However	O
,	O
it	O
is	O
necessary	O
to	O
carry	O
out	O
further	O
studies	O
to	O
evalute	O
the	O
role	O
of	O
these	O
genes	O
.	O

Parallel-processing	O
continuous-flow	O
device	O
for	O
optimization	O
-	O
free	O
polymerase	O
chain	O
reaction	O
.	O

A	O
parallel-processing	O
four-station	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
device	O
has	O
been	O
developed	O
,	O
which	O
performs	O
continuous-flow	O
PCR	O
without	O
optimization	O
of	O
the	O
annealing	O
temperature	O
.	O

Since	O
the	O
annealing	O
temperature	O
of	O
each	O
station	O
can	O
be	O
controlled	O
independently	O
,	O
the	O
device	O
covers	O
an	O
annealing	O
temperature	O
range	O
of	O
50-68	O
°C	O
,	O
which	O
is	O
wide	O
enough	O
to	O
perform	O
PCR	O
for	O
any	O
DNA	O
fragment	O
regardless	O
of	O
its	O
optimum	O
annealing	O
condition	O
.	O

This	O
arrangement	O
lets	O
us	O
continuously	O
obtain	O
an	O
amplified	O
amount	O
of	O
a	O
DNA	O
fragment	O
at	O
least	O
from	O
one	O
of	O
the	O
stations	O
.	O

The	O
device	O
consists	O
of	O
four	O
identical	O
cylindrical	O
stations	O
(	O
diameter	O
20	O
mm	O
,	O
height	O
55	O
mm	O
)	O
.	O

A	O
polytetrafluoroethylene	O
capillary	O
reactor	O
(	O
length	O
2	O
m	O
,	O
I.D	O
.	O

100	O
μm	O
,	O
O.D	O
.	O

400	O
μm	O
)	O
is	O
wound	O
helically	O
up	O
around	O
each	O
station	O
.	O

The	O
whole	O
assembly	O
is	O
designed	O
to	O
minimize	O
the	O
number	O
of	O
heating	O
blocks	O
(	O
for	O
providing	O
temperatures	O
of	O
denaturation	O
,	O
annealing	O
,	O
and	O
extension	O
)	O
to	O
be	O
seven	O
and	O
to	O
shape	O
a	O
compact	O
cube	O
(	O
height	O
55	O
mm	O
,	O
base	O
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O

The	O
reproducibility	O
for	O
continuous-flow	O
PCR	O
is	O
reasonably	O
high	O
(	O
run	O
-to-	O
run	O
and	O
station	O
-to-	O
station	O
relative	O
standard	O
deviation	O
of	O
their	O
amplification	O
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O

Performance	O
on	O
the	O
optimization	O
-	O
free	O
DNA	O
amplification	O
has	O
been	O
evaluated	O
with	O
four	O
DNA	O
samples	O
with	O
different	O
annealing	O
conditions	O
and	O
product	O
sizes	O
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	O
that	O
in	O
all	O
cases	O
,	O
PCR	O
is	O
successful	O
at	O
least	O
on	O
one	O
station	O
.	O

In	O
addition	O
,	O
three	O
DNA	O
fragment	O
s	O
with	O
different	O
lengths	O
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	O
amplified	O
in	O
a	O
segmented	O
-	O
flow	O
mode	O
without	O
the	O
carry-over	O
contamination	O
between	O
segments	O
.	O

This	O
result	O
suggests	O
that	O
this	O
device	O
could	O
serve	O
as	O
the	O
PCR	O
module	O
of	O
a	O
continuous-flow	O
high-throughput	B-P
on-line	I-P
total	I-P
DNA	I-P
analysis	I-P
system	O
integrating	O
all	O
necessary	O
modules	O
from	O
cell	O
lysis	O
/	O
DNA	O
extraction	O
to	O
PCR	O
product	O
analysis	O
.	O

Rotary	O
and	O
High	O
-	O
Pressure	O
Nozzle	O
Spray	O
Plume	O
Droplet	O
Analysis	O
For	O
Aerially	O
Applied	O
Mosquito	O
Adulticides	O
:	O
Laser	B-P
Diffraction	I-P
Characterization	I-P
.	O

The	O
droplet	O
spectrum	O
of	O
a	O
mosquito	O
adulticide	O
spray	O
plume	O
determines	O
its	O
ability	O
to	O
drift	O
through	O
the	O
target	O
area	O
,	O
impinge	O
on	O
the	O
mosquito	O
,	O
deliver	O
a	O
toxic	O
dose	O
,	O
and	O
the	O
risk	O
of	O
environmental	O
contamination	O
.	O

This	O
paper	O
provides	O
data	O
on	O
droplet	O
spectra	O
produced	O
from	O
6	O
nozzles	O
in	O
a	O
high	O
-	O
pressure	O
nozzle	O
spray	O
system	O
and	O
5	O
rotary	O
nozzle	O
systems	O
for	O
common	O
mosquito	O
adulticides	O
.	O

Spray	O
plume	O
spectra	O
were	O
measured	O
by	O
laser	B-P
diffraction	I-P
.	O

High	O
-	O
pressure	O
nozzles	O
were	O
evaluated	O
at	O
pressure	O
s	O
ranging	O
from	O
500	O
psi	O
to	O
6,000	O
psi	O
.	O

Rotary	O
nozzles	O
were	O
evaluated	O
at	O
rotational	O
speeds	O
ranging	O
from	O
500	O
rpm	O
to	O
24,000	O
rpm	O
.	O

Measurements	O
were	O
made	O
at	O
wind	O
speeds	O
of	O
129	O
km/h	O
(	O
80	O
mph	O
)	O
to	O
225	O
km/h	O
(	O
140	O
mph	O
)	O
.	O

Adulticides	O
included	O
were	O
Fyfanon	O
(	O
®	O
)	O
,	O
Aqua-Reslin	O
(	O
®	O
)	O
,	O
Dibrom	O
(	O
®	O
)	O
,	O
Duet	O
(	O
®	O
)	O
,	O
Permanone	O
(	O
®	O
)	O
,	O
and	O
the	O
inert	O
mineral	O
oil	O
,	O
Orchex	O
(	O
®	O
)	O
796	O
.	O

High-	O
pressure	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
(	O
EPA	O
)	O
label	O
requirements	O
for	O
all	O
configurations	O
tested	O
except	O
for	O
one	O
at	O
a	O
wind	O
speed	O
of	O
225	O
km/h	O
,	O
BETE	O
(	O
®	O
)	O
MW125	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
the	O
spray	O
plume	O
volume	O
median	O
diameter	O
(	O
Dv	O
(	O
0.5	O
)	O
)	O
at	O
the	O
speeds	O
tested	O
with	O
Fyfanon	O
(	O
®	O
)	O
.	O

The	O
spray	O
plume	O
90	O
%	O
drop	O
volume	O
diameter	O
(	O
Dv	O
(	O
0.9	O
)	O
)	O
significantly	O
decreased	O
,	O
13	O
%	O
at	O
the	O
higher	O
wind	O
speed	O
of	O
225	O
km/h	O
.	O

Drop	O
size	O
was	O
inversely	O
related	O
to	O
pressure	O
.	O

Dilution	O
of	O
the	O
product	O
formulations	O
increased	O
the	O
Dv	O
(	O
0.5	O
)	O
of	O
the	O
spray	O
plume	O
but	O
it	O
did	O
not	O
exceed	O
the	O
label	O
requirements	O
.	O

For	O
the	O
PJ15	O
nozzle	O
,	O
orientation	O
of	O
the	O
nozzle	O
into	O
the	O
wind	O
of	O
up	O
to	O
135°	O
showed	O
a	O
significant	O
increase	O
in	O
Dv	O
(	O
0.5	O
)	O
at	O
500	O
psi	O
,	O
750	O
psi	O
,	O
and	O
1,500	O
psi	O
.	O

The	O
Dv	O
(	O
0.5	O
)	O
varied	O
<	O
5	O
μm	O
over	O
the	O
3	O
angles	O
examined	O
for	O
any	O
specific	O
pressure	O
.	O

Rotary	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
EPA	O
label	O
requirements	O
for	O
all	O
test	O
configurations	O
examined	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
Dv	O
(	O
0.5	O
)	O
or	O
Dv	O
(	O
0.9	O
)	O
of	O
the	O
plume	O
at	O
speeds	O
tested	O
with	O
Fyfanon	O
for	O
the	O
ASC	O
A20	O
nozzle	O
.	O

The	O
rotary	O
AU5000	O
nozzle	O
using	O
Orchex	O
796	O
produced	O
plumes	O
of	O
larger	O
drops	O
in	O
all	O
configurations	O
than	O
any	O
of	O
the	O
rotary	O
nozzles	O
of	O
similar	O
configurations	O
using	O
active	O
ingredient	O
formulations	O
and	O
within	O
EPA	O
label	O
requirements	O
.	O

Double	O
strand	O
break	O
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	O
in	O
keratinocytes	O
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	O
.	O

Previously	O
we	O
reported	O
that	O
hyper-radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	O
double	O
strand	O
break	O
(	O
DSB	O
)	O
foci	O
in	O
epidermis	O
biopsies	B-P
collected	O
after	O
delivering	O
radiotherapeutic	O
one	O
and	O
five	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7-	O
week	O
radiotherapy	O
treatment	O
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O

42	O
patients	O
with	O
prostate	O
cancer	O
received	O
7-	O
week	O
fractionated	O
radiotherapy	O
treatment	O
(	O
RT	O
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0.05-1.10Gy	O
to	O
the	O
skin	O
.	O

Before	O
RT	O
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	O
,	O
skin	B-P
biopsies	I-P
(	O
n=452	O
)	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O

DSB-foci	O
markers	O
,	O
γH2AX	O
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

Foci	O
were	O
counted	O
both	O
with	O
digital	B-P
image	I-P
analysis	I-P
and	O
manually	O
.	O

HRS	O
in	O
keratinocytes	O
was	O
evidenced	O
by	O
the	O
dose-response	O
relationships	O
of	O
DSB	O
foci	O
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	B-P
time	O
and	O
quantification	O
method	O
.	O

Foci	O
observed	O
at	O
24h	O
after	O
dose	O
fractions	O
indicated	O
considerable	O
DSB	O
persistence	O
.	O

Accordingly	O
,	O
foci	O
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	O
fractions	O
.	O

For	O
doses	O
below	O
0.3Gy	O
,	O
persistent	O
foci	O
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	O
induction	O
.	O

A	O
comparison	O
of	O
γH2AX	O
and	O
53BP1	O
quantifications	O
in	O
double-staine	O
d	O
biopsies	B-P
showed	O
similar	O
HRS	O
dose-response	O
relationships	O
.	O

These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γH2AX	O
-	O
and	O
53BP1	O
-labelled	O
DSB	O
foci	O
,	O
throughout	O
a	O
7-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O

Stromal	O
alterations	O
in	O
ovarian	O
cancers	O
via	O
wavelength	O
dependent	O
Second	O
Harmonic	O
Generation	O
microscopy	O
and	O
optical	O
scattering	O
.	O

Ovarian	O
cancer	O
remains	O
the	O
most	O
deadly	O
gynecological	O
cancer	O
with	O
a	O
poor	O
aggregate	O
survival	O
rate	O
;	O
however	O
,	O
the	O
specific	O
rates	O
are	O
highly	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
disease	O
upon	O
diagnosis	O
.	O

Current	O
screening	O
and	O
imaging	O
tools	O
are	O
insufficient	O
to	O
detect	O
early	O
lesions	O
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	O
of	O
ovarian	O
cancer	O
that	O
may	O
benefit	O
from	O
specific	O
treatments	O
.	O

As	O
an	O
alternative	O
to	O
current	O
screening	O
and	O
imaging	O
tools	O
,	O
we	O
utilized	O
wavelength	O
dependent	O
collagen	O
-specific	O
Second	O
Harmonic	O
Generation	O
(	O
SHG	O
)	O
imaging	O
microscopy	O
and	O
optical	O
scattering	O
measurements	O
to	O
probe	O
the	O
structural	O
differences	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
normal	O
stroma	O
,	O
benign	O
tumors	O
,	O
endometrioid	O
tumors	O
,	O
and	O
low	O
and	O
high-grade	O
serous	O
tumors	O
.	O

The	O
SHG	O
signatures	O
of	O
the	O
emission	O
directionality	O
and	O
conversion	O
efficiency	O
as	O
well	O
as	O
the	O
optical	O
scattering	O
are	O
related	O
to	O
the	O
organization	O
of	O
collagen	O
on	O
the	O
sub-micron	O
size	O
scale	O
and	O
encode	O
structural	O
information	O
.	O

The	O
wavelength	O
dependence	O
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	O
and	O
distribution	O
of	O
collagen	O
fibrils	O
/	O
fibers	O
relative	O
to	O
the	O
interrogating	O
wavelengths	O
.	O

We	O
found	O
a	O
strong	O
wavelength	O
dependence	O
of	O
these	O
metrics	O
that	O
are	O
related	O
to	O
significant	O
structural	O
differences	O
in	O
the	O
collagen	O
organization	O
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	O
of	O
type	O
I	O
and	O
II	O
serous	O
tumors	O
.	O

Moreover	O
,	O
type	O
I	O
endometrioid	O
tumors	O
have	O
strongly	O
differing	O
ECM	O
architecture	O
than	O
the	O
serous	O
malignancies	O
.	O

The	O
SHG	O
metrics	O
and	O
optical	O
scattering	O
measurements	O
were	O
used	O
to	O
form	O
a	O
linear	O
discriminant	O
model	O
to	O
classify	O
the	O
tissues	O
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high-grade	O
serous	O
tumors	O
from	O
the	O
other	O
tissue	O
types	O
.	O

High-grade	O
serous	O
tumors	O
account	O
for	O
~70	O
%	O
of	O
ovarian	O
cancers	O
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	O
analysis	O
,	O
understanding	O
the	O
etiology	O
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	O
vivo	O
screening	O
tool	O
.	O

SHG	O
and	O
optical	O
scattering	O
measurements	O
provide	O
sub-resolution	O
information	O
and	O
when	O
combined	O
provide	O
superior	B-P
diagnostic	I-P
power	I-P
over	O
clinical	B-P
imaging	I-P
modalities	O
.	O

Additionally	O
the	O
measurements	O
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	O
of	O
ovarian	O
cancer	O
and	O
may	O
potentially	O
assist	O
in	O
treatment	O
protocols	O
.	O

Understanding	O
the	O
altered	O
collagen	O
assembly	O
can	O
supplement	O
histological	O
analysis	O
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	O
.	O

These	O
methods	O
could	O
become	O
an	O
in	O
vivo	O
screening	O
tool	O
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	O
malignancies	O
can	O
metastasize	O
while	O
undetectable	O
by	O
current	O
clinical	B-P
imaging	I-P
resolution	O
.	O

Famous	O
faces	O
and	O
voices	O
:	O
Differential	O
profiles	O
in	O
early	O
right	O
and	O
left	O
semantic	O
dementia	O
and	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Famous	O
face	O
and	O
voice	O
recognition	O
is	O
reported	O
to	O
be	O
impaired	O
both	O
in	O
semantic	O
dementia	O
(	O
SD	O
)	O
and	O
in	O
Alzheimer	O
's	O
Disease	O
(	O
AD	O
)	O
,	O
although	O
more	O
severely	O
in	O
the	O
former	O
.	O

In	O
AD	O
a	O
coexistence	O
of	O
perceptual	O
impairment	O
in	O
face	O
and	O
voice	O
processing	O
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	O
in	O
complex	O
semantic	O
tasks	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
SD	O
both	O
face	O
and	O
voice	O
recognition	O
disorders	O
could	O
be	O
related	O
to	O
the	O
prevalence	O
of	O
atrophy	O
in	O
the	O
right	O
temporal	O
lobe	O
(	O
RTL	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
twofold	O
:	O
(	O
1	O
)	O
to	O
investigate	O
famous	O
faces	O
and	O
voices	O
recognition	O
in	O
SD	O
and	O
AD	O
to	O
verify	O
if	O
the	O
two	O
diseases	O
show	O
a	O
differential	O
pattern	O
of	O
impairment	O
,	O
resulting	O
from	O
disruption	O
of	O
different	O
cognitive	O
mechanisms	O
;	O
(	O
2	O
)	O
to	O
check	O
if	O
face	O
and	O
voice	O
recognition	O
disorders	O
prevail	O
in	O
patients	O
with	O
atrophy	O
mainly	O
affecting	O
the	O
RTL	O
.	O

To	O
avoid	O
the	O
potential	O
influence	O
of	O
primary	O
perceptual	O
problems	O
in	O
face	O
and	O
voice	O
recognition	O
,	O
a	O
pool	O
of	O
patients	O
suffering	O
from	O
early	O
SD	O
and	O
AD	O
were	O
administered	O
a	O
detailed	O
set	O
of	O
tests	O
exploring	O
face	O
and	O
voice	O
perception	O
.	O

Thirteen	O
SD	O
(	O
8	O
with	O
prevalence	O
of	O
right	O
and	O
5	O
with	O
prevalence	O
of	O
left	O
temporal	O
atrophy	O
)	O
and	O
25	O
CE	O
patients	O
,	O
who	O
did	O
not	O
show	O
visual	O
and	O
auditory	O
perceptual	O
impairment	O
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	O
an	O
experimental	O
battery	O
exploring	O
famous	O
face	O
and	O
voice	O
recognition	O
and	O
naming	O
.	O

Twelve	O
SD	O
patients	O
underwent	O
cerebral	O
PET	B-P
imaging	I-P
and	O
were	O
classified	O
in	O
right	O
and	O
left	O
SD	O
according	O
to	O
the	O
onset	O
modality	O
and	O
to	O
the	O
prevalent	O
decrease	O
in	O
FDG	O
uptake	O
in	O
right	O
or	O
left	O
temporal	O
lobe	O
respectively	O
.	O

Correlation	O
of	O
PET	B-P
imaging	I-P
and	O
famous	O
face	O
and	O
voice	O
recognition	O
was	O
performed	O
.	O

Results	O
showed	O
a	O
differential	O
performance	O
profile	O
in	O
the	O
two	O
diseases	O
,	O
because	O
AD	O
patients	O
were	O
significantly	O
impaired	O
in	O
the	O
naming	O
tests	O
,	O
but	O
showed	O
preserved	O
recognition	O
,	O
whereas	O
SD	O
patients	O
were	O
profoundly	O
impaired	O
both	O
in	O
naming	O
and	O
in	O
recognition	O
of	O
famous	O
faces	O
and	O
voices	O
.	O

Furthermore	O
,	O
face	O
and	O
voice	O
recognition	O
disorders	O
prevailed	O
in	O
SD	O
patients	O
with	O
RTL	O
atrophy	O
,	O
who	O
also	O
showed	O
a	O
conceptual	O
impairment	O
on	O
the	O
Pyramids	O
and	O
Palm	O
Trees	O
test	O
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	O
modality	O
.	O

Finally	O
,	O
in	O
12	O
SD	O
patients	O
in	O
whom	O
PET	B-P
was	O
available	O
,	O
a	O
strong	O
correlation	O
between	O
FDG	O
uptake	O
and	O
face-to-name	O
and	O
voice-to-name	O
matching	O
data	O
was	O
found	O
in	O
the	O
right	O
but	O
not	O
in	O
the	O
left	O
temporal	O
lobe	O
.	O

The	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
different	O
cognitive	O
basis	O
for	O
impairment	O
of	O
face	O
and	O
voice	O
recognition	O
in	O
the	O
two	O
dementias	O
and	O
suggest	O
that	O
the	O
pattern	O
of	O
impairment	O
in	O
SD	O
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	O
representations	O
,	O
while	O
a	O
defect	O
of	O
semantic	O
control	O
,	O
with	O
impaired	O
naming	O
and	O
preserved	O
recognition	O
might	O
be	O
hypothesized	O
in	O
AD	O
.	O

Furthermore	O
,	O
the	O
correlation	O
between	O
face	O
and	O
voice	O
recognition	O
disorders	O
and	O
RTL	O
damage	O
are	O
consistent	O
with	O
the	O
hypothesis	O
assuming	O
that	O
in	O
the	O
RTL	O
person	O
-specific	O
knowledge	O
may	O
be	O
mainly	O
based	O
upon	O
non-verbal	O
representations	O
.	O

From	O
chemotherapy	O
to	O
target	O
therapies	O
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
NSCLC	O
:	O
a	O
durable	O
marriage	O
?	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Areas	O
covered	O
:	O
We	O
searched	O
Medline	O
,	O
Google	O
Scholar	O
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	O
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer-related	O
radiotherapy	O
and	O
included	O
patients	O
with	O
NSCLC	O
treated	O
with	O
chemo	O
and/or	O
target	O
therapies	O
.	O

Review	O
articles	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

Expert	O
commentary	O
:	O
Chemo-radiotherapy	O
still	O
represents	O
the	O
standard	O
of	O
choice	O
in	O
locally	O
advanced	O
NSCLC	O
,	O
while	O
to	O
date	O
the	O
addition	O
of	O
target	O
therapies	O
to	O
chemo-radiotherapy	O
did	O
not	O
demonstrate	O
any	O
robust	O
advantage	O
in	O
this	O
stage	B-P
of	I-P
disease	I-P
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	O
trials	O
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
NSCLC	O
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	O
disease	O
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

HERG1	O
potassium	O
channel	O
expression	O
in	O
potentially	O
malignant	O
disorders	O
of	O
the	O
oral	O
mucosa	O
and	O
prognostic	O
relevance	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

HERG1	O
potassium	O
channel	O
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	O
proliferation	O
.	O

HERG1	O
protein	O
expression	O
was	O
analyzed	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
in	O
62	O
patients	O
with	O
oral	O
leukoplakias	O
and	O
100	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinomas	O
(	O
OSCC	O
)	O
.	O

HERG1	O
mRNA	O
levels	O
were	O
assessed	O
by	O
real-time	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
in	O
22	O
patients	O
with	O
primary	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
.	O

Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	O
expression	O
and	O
tobacco	O
consumption	O
,	O
disease	B-P
stage	I-P
,	O
tumor	O
differentiation	O
,	O
tumor	O
recurrence	O
,	O
and	O
reduced	O
survival	O
.	O

There	O
was	O
no	O
association	O
between	O
HERG1	O
expression	O
and	O
the	O
risk	O
of	O
progression	O
from	O
oral	O
leukoplakia	O
to	O
OSCC	O
.	O

In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	O
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	O
mRNA	O
levels	O
compared	O
to	O
normal	O
mucosa	O
from	O
nononcologic	O
patients	O
.	O

Aberrant	O
HERG1	O
expression	O
increases	O
as	O
oral	O
tumorigenesis	O
progresses	O
from	O
oral	O
hyperplasia	O
to	O
OSCC	O
.	O

Increased	O
HERG1	O
mRNA	O
levels	O
were	O
also	O
frequently	O
detected	O
in	O
OSCC	O
and	O
other	O
HNSCC	O
subsites	O
.	O

HERG1	O
expression	O
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	O
progression	O
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	O
for	O
OSCC	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
38	O
:	O
1708-1716	O
,	O
2016	O
.	O

Personalizing	O
lung	O
cancer	O
risk	O
prediction	O
and	O
imaging	B-P
follow-up	O
recommendations	O
using	O
the	O
National	O
Lung	O
Screening	O
Trial	O
dataset	O
.	O

To	O
demonstrate	O
a	O
data-driven	O
method	O
for	O
personalizing	O
lung	O
cancer	O
risk	O
prediction	O
using	O
a	O
large	O
clinical	O
dataset	O
.	O

An	O
algorithm	O
was	O
used	O
to	O
categorize	O
nodules	O
found	O
in	O
the	O
first	O
screening	B-P
year	O
of	O
the	O
National	O
Lung	O
Screening	O
Trial	O
as	O
malignant	O
or	O
nonmalignant	O
.	O

Risk	O
of	O
malignancy	O
for	O
nodules	O
was	O
calculated	O
based	O
on	O
size	O
criteria	O
according	O
to	O
the	O
Fleischner	O
Society	O
recommendations	O
from	O
2005	O
,	O
along	O
with	O
the	O
additional	O
discriminators	O
of	O
pack-years	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
.	O

Imaging	B-P
follow-up	O
recommendations	O
were	O
assigned	O
according	O
to	O
Fleischner	O
size	O
category	O
malignancy	O
risk	O
.	O

Nodule	O
size	O
correlated	O
with	O
malignancy	O
risk	O
as	O
predicted	O
by	O
the	O
Fleischner	O
Society	O
recommendations	O
.	O

With	O
the	O
additional	O
discriminators	O
of	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
,	O
significant	O
risk	O
stratification	O
was	O
observed	O
.	O

For	O
example	O
,	O
men	O
with	O
≥60	O
pack-years	O
smoking	O
history	O
and	O
upper	O
lobe	O
nodules	O
measuring	O
>	O
4	O
and	O
≤6	O
mm	O
demonstrated	O
significantly	O
increased	O
risk	O
of	O
malignancy	O
at	O
12.4	O
%	O
compared	O
to	O
the	O
mean	O
of	O
3.81	O
%	O
for	O
similarly	O
sized	O
nodules	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Based	O
on	O
personalized	O
malignancy	O
risk	O
,	O
54	O
%	O
of	O
nodules	O
>	O
4	O
and	O
≤6	O
mm	O
were	O
reclassified	O
to	O
longer-term	O
follow-up	O
than	O
recommended	O
by	O
Fleischner	O
.	O

Twenty-seven	O
percent	O
of	O
nodules	O
≤4	O
mm	O
were	O
reclassified	O
to	O
shorter-term	O
follow-up	O
.	O

Using	O
available	O
clinical	O
datasets	O
such	O
as	O
the	O
National	O
Lung	O
Screening	O
Trial	O
in	O
conjunction	O
with	O
locally	O
collected	O
datasets	O
can	O
help	O
clinicians	O
provide	O
more	O
personalized	O
malignancy	O
risk	O
prediction	O
s	O
and	O
follow-up	O
recommendations	O
.	O

By	O
incorporating	O
3	O
demographic	O
data	O
points	O
,	O
the	O
risk	O
of	O
lung	O
nodule	O
malignancy	O
within	O
the	O
Fleischner	O
categories	O
can	O
be	O
considerably	O
stratified	O
and	O
more	O
personalized	O
follow-up	O
recommendations	O
can	O
be	O
made	O
.	O

Fluorescence	B-P
hyperspectral	I-P
imaging	I-P
(	O
fHSI	B-P
)	O
using	O
a	O
spectrally	O
resolved	O
detector	O
array	O
.	O

The	O
ability	O
to	O
resolve	O
multiple	O
fluorescent	O
emissions	O
from	O
different	O
biological	O
targets	O
in	O
video	O
rate	O
applications	O
,	O
such	O
as	O
endoscopy	B-P
and	O
intraoperative	B-P
imaging	I-P
,	O
has	O
traditionally	O
been	O
limited	O
by	O
the	O
use	O
of	O
filter-based	O
imaging	O
systems	O
.	O

Hyperspectral	B-P
imaging	I-P
(	O
HSI	B-P
)	O
facilitates	O
the	O
detection	O
of	O
both	O
spatial	O
and	O
spectral	O
information	O
in	O
a	O
single	O
data	O
acquisition	O
,	O
however	O
,	O
instrumentation	O
for	O
HSI	B-P
is	O
typically	O
complex	O
,	O
bulky	O
and	O
expensive	O
.	O

We	O
sought	O
to	O
overcome	O
these	O
limitations	O
using	O
a	O
novel	O
robust	O
and	O
low	O
cost	O
HSI	B-P
camera	O
based	O
on	O
a	O
spectrally	O
resolved	O
detector	O
array	O
(	O
SRDA	O
)	O
.	O

We	O
integrated	O
this	O
HSI	B-P
camera	O
into	O
a	O
wide-field	O
reflectance-based	O
imaging	O
system	O
operating	O
in	O
the	O
near-infrared	O
range	O
to	O
assess	O
the	O
suitability	O
for	O
in	O
vivo	O
imaging	O
of	O
exogenous	O
fluorescent	O
contrast	O
agents	O
.	O

Using	O
this	O
fluorescence	B-P
HSI	I-P
(	O
fHSI	B-P
)	O
system	O
,	O
we	O
were	O
able	O
to	O
accurately	O
resolve	O
the	O
presence	O
and	O
concentration	O
of	O
at	O
least	O
7	O
fluorescent	O
dyes	O
in	O
solution	O
.	O

We	O
also	O
demonstrate	O
high	O
spectral	O
unmixing	O
precision	O
,	O
signal	O
linearity	O
with	O
dye	O
concentration	O
and	O
at	O
depth	O
in	O
tissue	O
mimicking	O
phantoms	O
,	O
and	O
delineate	O
4	O
fluorescent	O
dyes	O
in	O
vivo	O
.	O

Our	O
approach	O
,	O
including	O
statistical	O
background	O
removal	O
,	O
could	O
be	O
directly	O
generalised	O
to	O
broader	O
spectral	O
ranges	O
,	O
for	O
example	O
,	O
to	O
resolve	O
tissue	O
reflectance	O
or	O
autofluorescence	O
and	O
in	O
future	O
be	O
tailored	O
to	O
video	O
rate	O
applications	O
requiring	O
snapshot	O
HSI	B-P
data	O
acquisition	O
.	O

Effects	O
of	O
Ibudilast	O
on	O
the	O
Subjective	O
,	O
Reinforcing	O
,	O
and	O
Analgesic	O
Effects	O
of	O
Oxycodone	O
in	O
Recently	O
Detoxified	O
Adults	O
with	O
Opioid	O
Dependence	O
.	O

Ibudilast	O
,	O
a	O
nonselective	O
phosphodiesterase	O
inhibitor	O
,	O
is	O
used	O
clinically	O
in	O
Asia	O
for	O
the	O
treatment	O
of	O
asthma	O
and	O
poststroke	O
dizziness	O
.	O

Recent	O
preclinical	O
studies	O
have	O
suggested	O
that	O
it	O
also	O
inhibits	O
glial	O
cell	O
activation	O
in	O
rodents	O
,	O
and	O
may	O
alter	O
opioid	O
-	O
mediated	O
effects	O
,	O
including	O
analgesia	O
and	O
withdrawal	O
symptoms	O
.	O

The	O
effects	O
of	O
ibudilast	O
on	O
the	O
abuse	O
potential	O
of	O
opioids	O
in	O
humans	O
are	O
largely	O
unknown	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
influence	O
of	O
ibudilast	O
on	O
subjective	O
(	O
including	O
drug	O
craving	O
)	O
,	O
reinforcing	O
,	O
and	O
analgesic	O
effects	O
of	O
oxycodone	O
in	O
human	O
volunteers	O
diagnosed	O
with	O
opioid	O
dependence	O
(	O
equivalent	O
to	O
moderate-severe	O
opioid	O
use	O
disorder	O
)	O
.	O

Non-treatment-seeking	O
opioid-dependent	O
male	O
volunteers	O
(	O
n=11	O
)	O
underwent	O
an	O
in-patient	O
detoxification	O
with	O
morphine	O
,	O
followed	O
by	O
maintenance	O
on	O
placebo	O
(	O
0	O
mg	O
b.i.d	O
.	O
)	O

and	O
active	O
ibudilast	O
(	O
50	O
mg	O
b.i.d.	O
)	O
.	O

Under	O
each	O
maintenance	O
dose	O
,	O
six	O
experimental	O
sample	O
and	O
choice	O
sessions	O
were	O
completed	O
involving	O
oral	O
oxycodone	O
administration	O
(	O
0	O
,	O
15	O
,	O
and	O
30	O
mg/70	O
kg	O
,	O
p.o.	O
)	O
.	O

Subjective	O
effects	O
of	O
oxycodone	O
and	O
drug	O
craving	O
were	O
measured	O
with	O
visual	B-P
analog	I-P
scales	I-P
(	O
VAS	B-P
)	O
and	O
a	O
Drug	O
Effects	O
Questionnaire	O
.	O

The	O
cold	B-P
pressor	I-P
test	I-P
was	O
used	O
to	O
produce	O
pain	O
,	O
and	O
a	O
modified	O
progressive-ratio	O
choice	O
procedure	O
was	O
used	O
to	O
measure	O
the	O
reinforcing	O
effects	O
of	O
oxycodone	O
.	O

Under	O
the	O
active	O
ibudilast	O
condition	O
compared	O
with	O
the	O
placebo	O
condition	O
,	O
ratings	O
of	O
drug	O
liking	O
following	O
15	O
mg	O
of	O
oxycodone	O
were	O
decreased	O
significantly	O
.	O

The	O
mean	O
drug	O
breakpoint	O
value	O
was	O
also	O
significantly	O
lower	O
in	O
the	O
active	O
vs	O
the	O
placebo	O
ibudilast	O
condition	O
under	O
the	O
15	O
mg	O
oxycodone	O
condition	O
,	O
but	O
not	O
significantly	O
lower	O
under	O
the	O
30	O
mg	O
oxycodone	O
condition	O
.	O

Heroin	O
craving	O
was	O
significantly	O
reduced	O
under	O
active	O
ibudilast	O
vs	O
placebo	O
,	O
and	O
similar	O
effects	O
were	O
observed	O
for	O
tobacco	O
and	O
cocaine	O
craving	O
.	O

Furthermore	O
,	O
mean	O
subjective	O
ratings	O
of	O
pain	O
were	O
lower	O
in	O
the	O
active	O
ibudilast	O
condition	O
.	O

Our	O
data	O
suggest	O
that	O
ibudilast	O
may	O
be	O
useful	O
for	O
treating	O
opioid	O
use	O
disorders	O
and	O
it	O
may	O
enhance	O
the	O
analgesic	O
effects	O
of	O
oxycodone	O
.Neuropsychopharmacology	O
advance	O
online	O
publication	O
,	O
10	O
May	O
2017	O
;	O
doi:10.1038/npp.2017.70	O
.	O

Flexible	O
Coordination	O
of	O
Stationary	O
and	O
Mobile	O
Conversations	O
with	O
Gaze	O
:	O
Resource	O
Allocation	O
among	O
Multiple	O
Joint	O
Activities	O
.	O

Gaze	O
is	O
instrumental	O
in	O
coordinating	O
face-to-face	O
social	O
interactions	O
.	O

But	O
little	O
is	O
known	O
about	O
gaze	O
use	O
when	O
social	O
interactions	O
co-occur	O
with	O
other	O
joint	O
activities	O
.	O

We	O
investigated	O
the	O
case	O
of	O
walking	O
while	O
talking	O
.	O

We	O
assessed	O
how	O
gaze	O
gets	O
allocated	O
among	O
various	O
targets	O
in	O
mobile	O
conversations	O
,	O
whether	O
allocation	O
of	O
gaze	O
to	O
other	O
targets	O
affects	O
conversational	O
coordination	O
,	O
and	O
whether	O
reduced	O
availability	O
of	O
gaze	O
for	O
conversational	O
coordination	O
affects	O
conversational	O
performance	O
and	O
content	O
.	O

In	O
an	O
experimental	O
study	O
,	O
pairs	O
were	O
videotaped	O
in	O
four	O
conditions	O
of	O
mobility	O
(	O
standing	O
still	O
,	O
talking	O
while	O
walking	B-P
along	I-P
a	I-P
straight-line	I-P
itinerary	I-P
,	O
talking	O
while	O
walking	O
along	O
a	O
complex	O
itinerary	O
,	O
or	O
walking	O
along	O
a	O
complex	O
itinerary	O
with	O
no	O
conversational	O
task	O
)	O
.	O

Gaze	O
to	O
partners	O
was	O
substantially	O
reduced	O
in	O
mobile	O
conversations	O
,	O
but	O
gaze	O
was	O
still	O
used	O
to	O
coordinate	O
conversation	O
via	O
displays	O
of	O
mutual	O
orientation	O
,	O
and	O
conversational	O
performance	O
and	O
content	O
was	O
not	O
different	O
between	O
stationary	O
and	O
mobile	O
conditions	O
.	O

Results	O
expand	O
the	O
phenomena	O
of	O
multitasking	O
to	O
joint	O
activities	O
.	O

Magnetic	B-P
resonance	I-P
spectroscopy	I-P
of	O
current	O
hand	O
amputees	O
reveals	O
evidence	O
for	O
neuronal	O
-level	O
changes	O
in	O
former	O
sensorimotor	O
cortex	O
.	O

Deafferentation	O
is	O
accompanied	O
by	O
large-scale	O
functional	O
reorganization	O
of	O
maps	O
in	O
the	O
primary	O
sensory	O
and	O
motor	O
areas	O
of	O
the	O
hemisphere	O
contralateral	O
to	O
injury	O
.	O

Animal	O
models	O
of	O
deafferentation	O
suggest	O
a	O
variety	O
of	O
cellular	O
-level	O
changes	O
including	O
depression	O
of	O
neuronal	O
metabolism	O
and	O
even	O
neuronal	O
death	O
.	O

Whether	O
similar	O
neuronal	O
changes	O
contribute	O
to	O
patterns	O
of	O
reorganization	O
within	O
the	O
contralateral	O
sensorimotor	O
cortex	O
of	O
chronic	O
human	O
amputees	O
is	O
uncertain	O
.	O

We	O
used	O
functional	O
MRI-guided	B-P
proton	I-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
to	O
test	O
the	O
hypothesis	O
that	O
unilateral	O
deafferentation	O
is	O
associated	O
with	O
lower	O
levels	O
of	O
N-acetylaspartate	O
(	O
NAA	O
,	O
a	O
putative	O
marker	O
of	O
neuronal	O
integrity	O
)	O
in	O
the	O
sensorimotor	O
hand	O
territory	O
located	O
contralateral	O
to	O
the	O
missing	O
hand	O
in	O
chronic	O
amputees	O
(	O
n	O
=	O
19	O
)	O
compared	O
with	O
the	O
analogous	O
hand	O
territory	O
of	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
(	O
n	O
=	O
28	O
)	O
.	O

We	O
also	O
tested	O
whether	O
former	O
amputees	O
[	O
i.e.	O
,	O
recipients	O
of	O
replanted	O
(	O
n	O
=	O
3	O
)	O
or	O
transplanted	O
(	O
n	O
=	O
2	O
)	O
hands	O
]	O
exhibit	O
NAA	O
levels	O
that	O
are	O
indistinguishable	O
from	O
controls	O
,	O
possible	O
evidence	O
for	O
reversal	O
of	O
the	O
effects	O
of	O
deafferentation	O
.	O

As	O
predicted	O
,	O
relative	O
to	O
controls	O
,	O
current	O
amputees	O
exhibited	O
lower	O
levels	O
of	O
NAA	O
that	O
were	O
negatively	O
and	O
significantly	O
correlated	O
with	O
the	O
time	O
after	O
amputation	O
.	O

Contrary	O
to	O
our	O
prediction	O
,	O
NAA	O
levels	O
in	O
both	O
replanted	O
and	O
transplanted	O
patients	O
fell	O
within	O
the	O
range	O
of	O
the	O
current	O
amputees	O
.	O

We	O
suggest	O
that	O
lower	O
levels	O
of	O
NAA	O
in	O
current	O
amputees	O
reflects	O
altered	O
neuronal	O
integrity	O
consequent	O
to	O
chronic	O
deafferentation	O
.	O

Thus	O
local	O
changes	O
in	O
NAA	O
levels	O
may	O
provide	O
a	O
means	O
of	O
assessing	O
neuroplastic	O
changes	O
in	O
deafferented	O
cortex	O
.	O

Results	O
from	O
former	O
amputees	O
suggest	O
that	O
these	O
changes	O
may	O
not	O
be	O
readily	O
reversible	O
through	O
reafferentation	O
.NEW	O
&	O
NOTEWORTHY	O
This	O
study	O
is	O
the	O
first	O
to	O
use	O
functional	O
magnetic	B-P
resonance-guided	I-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
to	O
examine	O
neurochemical	O
mechanisms	O
underlying	O
functional	O
reorganization	O
in	O
the	O
primary	O
somatosensory	O
and	O
motor	O
cortices	O
consequent	O
to	O
upper	O
extremity	O
amputation	O
and	O
its	O
potential	O
reversal	O
through	O
hand	O
replantation	O
or	O
transplantation	O
.	O

We	O
provide	O
evidence	O
for	O
selective	O
alteration	O
of	O
cortical	O
neuronal	O
integrity	O
associated	O
with	O
amputation	O
-	O
related	O
deafferentation	O
that	O
may	O
not	O
be	O
reversible	O
.	O

Chronic	O
adiponectin	O
deficiency	O
leads	O
to	O
Alzheimer	O
's	O
disease	O
-like	O
cognitive	O
impairments	O
and	O
pathologies	O
through	O
AMPK	O
inactivation	O
and	O
cerebral	O
insulin	O
resistance	O
in	O
aged	O
mice	O
.	O

Insulin	O
resistance	O
is	O
the	O
major	O
pathogenesis	O
underlying	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
these	O
patients	O
have	O
doubled	O
risk	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
insulin	O
resistance	O
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	O
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	O
activation	O
,	O
causing	O
intra-	O
and	O
extracellular	O
amyloid-beta	O
(	O
Aβ	O
)	O
accumulation	O
.	O

Adiponectin	O
(	O
APN	O
)	O
is	O
an	O
adipokine	O
with	O
insulin-sensitizing	O
and	O
anti-inflammatory	O
effects	O
.	O

Reduced	O
circulatory	O
APN	O
level	O
is	O
associated	O
with	O
insulin	O
resistance	O
and	O
T2DM	O
.	O

The	O
role	O
of	O
APN	O
in	O
AD	O
has	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	O
deficiency	O
would	O
lead	O
to	O
cerebral	O
insulin	O
resistance	O
,	O
cognitive	O
decline	O
and	O
Alzheimer's-like	O
pathology	O
in	O
mice	O
.	O

To	O
study	O
the	O
role	O
of	O
adiponectin	O
in	O
cognitive	O
functions	O
,	O
we	O
employed	O
adiponectin-knockout	O
(	O
APN-KO	O
)	O
mice	O
and	O
demonstrated	O
chronic	O
APN	O
deficiency	O
in	O
their	O
CNS	O
.	O

Behavioral	B-P
tests	I-P
were	O
performed	O
to	O
study	O
the	O
cognitions	O
of	O
male	O
APN-KO	O
mice	O
.	O

Brains	O
and	O
tissue	O
lysates	O
were	O
collected	O
to	O
study	O
the	O
pathophysiological	O
and	O
molecular	O
changes	O
in	O
the	O
brain	O
of	O
APN-KO	O
mice	O
.	O

SH-SY5Y	O
neuroblastoma	O
cell	O
line	O
was	O
used	O
to	O
study	O
the	O
molecular	O
mechanism	O
upon	O
APN	O
and	O
insulin	O
treatment	O
.	O

Aged	O
APN	O
-deficient	O
mice	O
displayed	O
spatial	O
memory	O
and	O
learning	O
impairments	O
,	O
fear-conditioned	O
memory	O
deficit	O
as	O
well	O
as	O
anxiety	O
.	O

These	O
mice	O
also	O
developed	O
AD	O
pathologies	O
including	O
increased	O
cerebral	O
Aβ42	O
level	O
,	O
Aβ	O
deposition	O
,	O
hyperphosphorylated	O
Tau	O
proteins	O
,	O
microgliosis	O
and	O
astrogliosis	O
with	O
increased	O
cerebral	O
IL-1β	O
and	O
TNFα	O
levels	O
that	O
associated	O
with	O
increased	O
neuronal	O
apoptosis	O
and	O
reduced	O
synaptic	O
proteins	O
levels	O
,	O
suggesting	O
APN	O
deficiency	O
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	O
.	O

AD	O
pathologies	O
-associated	O
APN	O
-	O
KO	O
mice	O
displayed	O
attenuated	O
AMPK	O
phosphorylation	O
and	O
impaired	O
insulin	O
signaling	O
including	O
decreased	O
Akt	O
induction	O
and	O
increased	O
GSK3β	O
activation	O
in	O
the	O
hippocampus	O
and	O
frontal	O
cortex	O
.	O

Aged	O
APN	O
-KO	O
mice	O
developed	O
hippocampal	O
insulin	O
resistance	O
with	O
reduced	O
pAkt	O
induction	O
upon	O
intracerebral	O
insulin	O
injection	O
.	O

Consistently	O
,	O
APN	O
treatment	O
in	O
SH-SY5Y	O
cells	O
with	O
insulin	O
resistance	O
and	O
overexpressing	O
Aβ	O
induce	O
higher	O
pAkt	O
levels	O
through	O
AdipoR1	O
upon	O
insulin	O
treatment	O
whereas	O
the	O
induction	O
was	O
blocked	O
by	O
compound	O
C	O
,	O
indicating	O
APN	O
can	O
enhance	O
neuronal	O
insulin	O
sensitivity	O
through	O
AMPK	O
activation	O
.	O

Our	O
results	O
indicated	O
that	O
chronic	O
APN	O
deficiency	O
inactivated	O
AMPK	O
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD-like	O
pathogenesis	O
in	O
aged	O
mice	O
which	O
also	O
developed	O
significant	O
cognitive	O
impairments	O
and	O
psychiatric	O
symptoms	O
.	O

Craving	O
behavioral	O
intervention	O
for	O
internet	O
gaming	O
disorder	O
:	O
remediation	O
of	O
functional	O
connectivity	O
of	O
the	O
ventral	O
striatum	O
.	O

Psychobehavioral	O
intervention	O
is	O
an	O
effective	O
treatment	O
of	O
Internet	O
addiction	O
,	O
including	O
Internet	O
gaming	O
disorder	O
(	O
IGD	O
)	O
.	O

However	O
,	O
the	O
neural	O
mechanisms	O
underlying	O
its	O
efficacy	O
remain	O
unclear	O
.	O

Cortical	O
-	O
ventral	O
striatum	O
(	O
VS	O
)	O
circuitry	O
is	O
a	O
common	O
target	O
of	O
psychobehavioral	O
interventions	O
in	O
drug	O
addiction	O
,	O
and	O
cortical	O
-	O
VS	O
dysfunction	O
has	O
been	O
reported	O
in	O
IGD	O
;	O
hence	O
,	O
the	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
the	O
VS	O
circuitry	O
responds	O
to	O
psychobehavioral	O
interventions	O
in	O
IGD	O
.	O

In	O
a	O
cross-sectional	O
study	O
,	O
we	O
examined	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
in	O
74	O
IGD	O
subjects	O
(	O
IGDs	O
)	O
and	O
41	O
healthy	O
controls	O
(	O
HCs	O
)	O
.	O

In	O
a	O
follow-up	O
craving	O
behavioral	O
intervention	O
(	O
CBI	O
)	O
study	O
,	O
of	O
the	O
74	O
IGD	O
subjects	O
,	O
20	O
IGD	O
subjects	O
received	O
CBI	O
(	O
CBI+	O
)	O
and	O
16	O
IGD	O
subjects	O
did	O
not	O
(	O
CBI-	O
)	O
.	O

All	O
participants	O
were	O
scanned	B-P
twice	O
with	O
similar	O
time	O
interval	O
to	O
assess	O
the	O
effects	O
of	O
CBI	O
.	O

IGD	O
subjects	O
showed	O
greater	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
to	O
left	O
inferior	O
parietal	O
lobule	O
(	O
lIPL	O
)	O
,	O
right	O
inferior	O
frontal	O
gyrus	O
and	O
left	O
middle	O
frontal	O
gyrus	O
,	O
in	O
positive	O
association	O
with	O
the	O
severity	O
of	O
IGD	O
.	O

Moreover	O
,	O
compared	O
with	O
CBI-	O
,	O
CBI+	O
showed	O
significantly	O
greater	O
decrease	O
in	O
VS	O
-	O
lIPL	O
connectivity	O
,	O
along	O
with	O
amelioration	O
in	O
addiction	O
severity	O
following	O
the	O
intervention	O
.	O

These	O
findings	O
demonstrated	O
that	O
functional	O
connectivity	O
between	O
VS	O
and	O
lIPL	O
,	O
each	O
presumably	O
mediating	O
gaming	O
craving	O
and	O
attentional	O
bias	O
,	O
may	O
be	O
a	O
potential	O
biomarker	O
of	O
the	O
efficacy	O
of	O
psychobehavioral	O
intervention	O
.	O

These	O
results	O
also	O
suggested	O
that	O
non-invasive	O
techniques	O
such	O
as	O
transcranial	O
magnetic	O
or	O
direct	O
current	O
stimulation	O
targeting	O
the	O
VS	O
-	O
lIPL	O
circuitry	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
Internet	O
gaming	O
disorders	O
.	O

